0000012208-19-000014.txt : 20190401 0000012208-19-000014.hdr.sgml : 20190401 20190329210723 ACCESSION NUMBER: 0000012208-19-000014 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 102 CONFORMED PERIOD OF REPORT: 20181231 FILED AS OF DATE: 20190401 DATE AS OF CHANGE: 20190329 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-RAD LABORATORIES, INC. CENTRAL INDEX KEY: 0000012208 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 941381833 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-07928 FILM NUMBER: 19718546 BUSINESS ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 BUSINESS PHONE: 5107247000 MAIL ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 FORMER COMPANY: FORMER CONFORMED NAME: BIO RAD LABORATORIES INC DATE OF NAME CHANGE: 19920703 10-K 1 a10k123118.htm 10-K 12.31.18 Document
false--12-31FY20182018-12-3110-K0000012208247078685092404YesfalseLarge Accelerated Filer6181361340BIO-RAD LABORATORIES, INC.falsefalseNoNo25549000267130000.00010.00010.00010.000180000000200000008000000020000000246791275107674248842655096421246785455106757247047725095504.101P8YP7YP12YP12YP8YP0YP6YP1YP1YP1YP1YP1YP0YP1YP7YP6YP10YP11YP7YP0YP6YP1YP1YP1YP7YP7YP0YP2Y00.00010.0001750000075000000000P12YP3Y5600000P5YP5Y00582917179493917 0000012208 2018-01-01 2018-12-31 0000012208 2018-06-30 0000012208 us-gaap:CommonClassAMember 2019-03-26 0000012208 us-gaap:CommonClassBMember 2019-03-26 0000012208 2018-12-31 0000012208 bio:TreasuryClassBMember 2018-12-31 0000012208 2017-12-31 0000012208 us-gaap:CommonClassAMember 2017-12-31 0000012208 bio:TreasuryClassAMember 2018-12-31 0000012208 bio:TreasuryClassAMember 2017-12-31 0000012208 us-gaap:CommonClassBMember 2018-12-31 0000012208 us-gaap:CommonClassAMember 2018-12-31 0000012208 bio:TreasuryClassBMember 2017-12-31 0000012208 us-gaap:CommonClassBMember 2017-12-31 0000012208 2017-01-01 2017-12-31 0000012208 2016-01-01 2016-12-31 0000012208 2016-12-31 0000012208 2015-12-31 0000012208 us-gaap:CommonStockMember 2016-12-31 0000012208 us-gaap:TreasuryStockMember 2017-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0000012208 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000012208 us-gaap:AccountingStandardsUpdate201616Member 2018-01-01 0000012208 us-gaap:RetainedEarningsMember 2017-12-31 0000012208 us-gaap:TreasuryStockMember 2017-01-01 2017-12-31 0000012208 us-gaap:CommonStockMember 2015-12-31 0000012208 us-gaap:TreasuryStockMember 2015-12-31 0000012208 us-gaap:TreasuryStockMember 2018-01-01 2018-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000012208 us-gaap:CommonStockMember 2017-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0000012208 us-gaap:TreasuryStockMember 2016-12-31 0000012208 us-gaap:RetainedEarningsMember 2018-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 0000012208 us-gaap:RetainedEarningsMember 2015-12-31 0000012208 2018-01-01 0000012208 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 0000012208 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000012208 us-gaap:RetainedEarningsMember 2018-01-01 0000012208 us-gaap:TreasuryStockMember 2018-12-31 0000012208 us-gaap:RetainedEarningsMember 2016-12-31 0000012208 us-gaap:CommonStockMember 2018-12-31 0000012208 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2018-01-01 2018-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2018-12-31 0000012208 srt:MinimumMember us-gaap:EquipmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccountingStandardsUpdate201601Member 2018-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2017-01-01 2017-12-31 0000012208 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2018-01-01 2018-12-31 0000012208 naics:ZZ541714 2018-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2016-01-01 2016-12-31 0000012208 srt:MaximumMember us-gaap:EquipmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccountingStandardsUpdate201601Member 2018-01-01 0000012208 us-gaap:NewAccountingPronouncementMember 2018-01-01 0000012208 srt:MaximumMember bio:ReagentRentalEquipmentMember 2018-01-01 2018-12-31 0000012208 srt:MinimumMember bio:ReagentRentalEquipmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2017-12-31 0000012208 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2018-01-01 2018-12-31 0000012208 srt:MaximumMember us-gaap:ComputerSoftwareIntangibleAssetMember 2018-01-01 2018-12-31 0000012208 srt:MinimumMember us-gaap:ComputerSoftwareIntangibleAssetMember 2018-01-01 2018-12-31 0000012208 bio:RainDanceTechnologiesInc.Member 2017-01-01 2017-03-31 0000012208 bio:RainDanceTechnologiesInc.Member 2017-02-15 0000012208 us-gaap:DeferredTaxAssetDomain bio:RainDanceTechnologiesInc.Member 2017-02-15 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2018-01-01 2018-12-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2018-12-31 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2018-12-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2018-01-01 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2017-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2018-01-01 2018-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2018-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2017-12-31 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2018-07-01 2018-09-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoicesMember 2018-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoiceslowMember 2018-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestoneminimumamountMember 2018-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-12-01 2018-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2018-01-01 2018-03-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2018-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:ProjectedVolatilityOfSalesMemberMember 2018-01-01 2018-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:MarketPriceOfRiskMember 2018-01-01 2018-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0000012208 us-gaap:TradeNamesMember 2018-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2018-12-31 0000012208 us-gaap:LicensingAgreementsMember 2018-12-31 0000012208 bio:KnowHowMember 2018-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2018-12-31 0000012208 bio:ClinicalDiagnosticsMember 2018-01-01 2018-03-31 0000012208 bio:DiaMedMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 bio:CellsorterMember us-gaap:NoncompeteAgreementsMember bio:LifeScienceMember 2018-01-01 2018-12-31 0000012208 bio:RainDanceTechnologiesInc.Member us-gaap:TradeNamesMember 2017-02-15 0000012208 bio:RainDanceTechnologiesInc.Member us-gaap:LicensingAgreementsMember 2017-02-15 0000012208 bio:CellsorterMember us-gaap:DevelopedTechnologyRightsMember bio:LifeScienceMember 2018-01-01 2018-12-31 0000012208 bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:LifeScienceMember 2017-01-01 2017-12-31 0000012208 bio:LifeScienceMember 2018-01-01 2018-12-31 0000012208 bio:RainDanceTechnologiesInc.Member us-gaap:DevelopedTechnologyRightsMember 2017-02-15 0000012208 bio:PasteurSanofiDiagnosicsS.A.Member bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 bio:BiotestAGMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 us-gaap:LicensingAgreementsMember 2017-12-31 0000012208 us-gaap:TradeNamesMember 2017-12-31 0000012208 bio:KnowHowMember 2017-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2017-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2017-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2017-12-31 0000012208 bio:ClinicalDiagnosticsMember 2016-12-31 0000012208 bio:ClinicalDiagnosticsMember 2018-12-31 0000012208 bio:ClinicalDiagnosticsMember 2017-12-31 0000012208 bio:LifeScienceMember 2018-12-31 0000012208 bio:LifeScienceMember 2017-12-31 0000012208 bio:LifeScienceMember 2016-12-31 0000012208 bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 srt:MinimumMember us-gaap:LicensingAgreementsMember 2018-01-01 2018-12-31 0000012208 srt:MinimumMember us-gaap:NoncompeteAgreementsMember 2017-01-01 2017-12-31 0000012208 srt:MaximumMember us-gaap:OtherIntangibleAssetsMember 2017-01-01 2017-12-31 0000012208 srt:MaximumMember us-gaap:DevelopedTechnologyRightsMember 2018-01-01 2018-12-31 0000012208 srt:MinimumMember us-gaap:TradeNamesMember 2018-01-01 2018-12-31 0000012208 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-12-31 0000012208 srt:MinimumMember us-gaap:OtherIntangibleAssetsMember 2018-01-01 2018-12-31 0000012208 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-12-31 0000012208 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2017-01-01 2017-12-31 0000012208 srt:MaximumMember us-gaap:OtherIntangibleAssetsMember 2018-01-01 2018-12-31 0000012208 srt:MaximumMember us-gaap:NoncompeteAgreementsMember 2018-01-01 2018-12-31 0000012208 srt:MaximumMember us-gaap:TradeNamesMember 2018-01-01 2018-12-31 0000012208 srt:MaximumMember us-gaap:LicensingAgreementsMember 2017-01-01 2017-12-31 0000012208 srt:MinimumMember bio:KnowHowMember 2018-01-01 2018-12-31 0000012208 srt:MaximumMember bio:KnowHowMember 2017-01-01 2017-12-31 0000012208 srt:MinimumMember us-gaap:TradeNamesMember 2017-01-01 2017-12-31 0000012208 srt:MinimumMember us-gaap:LicensingAgreementsMember 2017-01-01 2017-12-31 0000012208 srt:MinimumMember us-gaap:NoncompeteAgreementsMember 2018-01-01 2018-12-31 0000012208 srt:MaximumMember bio:KnowHowMember 2018-01-01 2018-12-31 0000012208 srt:MinimumMember us-gaap:OtherIntangibleAssetsMember 2017-01-01 2017-12-31 0000012208 srt:MaximumMember us-gaap:NoncompeteAgreementsMember 2017-01-01 2017-12-31 0000012208 srt:MaximumMember us-gaap:LicensingAgreementsMember 2018-01-01 2018-12-31 0000012208 srt:MaximumMember us-gaap:DevelopedTechnologyRightsMember 2017-01-01 2017-12-31 0000012208 srt:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2018-01-01 2018-12-31 0000012208 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2017-01-01 2017-12-31 0000012208 srt:MaximumMember us-gaap:TradeNamesMember 2017-01-01 2017-12-31 0000012208 srt:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2017-01-01 2017-12-31 0000012208 srt:MinimumMember bio:KnowHowMember 2017-01-01 2017-12-31 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2017-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2017-12-31 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2018-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2018-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2010-12-31 0000012208 us-gaap:LineOfCreditMember 2014-06-30 0000012208 us-gaap:PerformanceGuaranteeMember 2018-12-31 0000012208 us-gaap:StandbyLettersOfCreditMember 2018-12-31 0000012208 us-gaap:StandbyLettersOfCreditMember 2017-12-31 0000012208 us-gaap:LineOfCreditMember 2018-12-31 0000012208 us-gaap:ForeignCountryMember 2018-12-31 0000012208 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2018-12-31 0000012208 bio:IncludingaccruedinterestandpenaltiesMember 2018-12-31 0000012208 us-gaap:StateAndLocalJurisdictionMember 2018-12-31 0000012208 bio:NetofprepaidtaxesMember 2018-12-31 0000012208 us-gaap:DomesticCountryMember 2018-01-01 2018-12-31 0000012208 us-gaap:DomesticCountryMember 2017-01-01 2017-12-31 0000012208 us-gaap:AcquisitionRelatedCostsMember 2018-01-01 2018-12-31 0000012208 us-gaap:DomesticCountryMember 2016-01-01 2016-12-31 0000012208 bio:TaxCutsandJobsActMember 2017-01-01 2017-12-31 0000012208 us-gaap:AcquisitionRelatedCostsMember 2017-01-01 2017-12-31 0000012208 bio:TaxCutsandJobsActMember 2016-01-01 2016-12-31 0000012208 bio:TaxCutsandJobsActMember 2018-01-01 2018-12-31 0000012208 us-gaap:AcquisitionRelatedCostsMember 2016-01-01 2016-12-31 0000012208 us-gaap:CommonClassBMember 2016-01-01 2016-12-31 0000012208 us-gaap:CommonClassAMember 2018-01-01 2018-12-31 0000012208 us-gaap:CommonClassAMember 2016-12-31 0000012208 us-gaap:CommonClassAMember 2015-12-31 0000012208 us-gaap:CommonClassAMember 2016-01-01 2016-12-31 0000012208 us-gaap:CommonClassAMember 2017-01-01 2017-12-31 0000012208 us-gaap:CommonClassBMember 2018-01-01 2018-12-31 0000012208 us-gaap:CommonClassBMember 2016-12-31 0000012208 us-gaap:CommonClassBMember 2017-01-01 2017-12-31 0000012208 us-gaap:CommonClassBMember 2015-12-31 0000012208 2018-11-30 0000012208 2017-06-30 0000012208 2017-08-01 2017-08-31 0000012208 2017-06-01 2017-06-30 0000012208 2018-11-01 2018-11-30 0000012208 2017-08-31 0000012208 2017-05-31 0000012208 2017-05-01 2017-05-31 0000012208 bio:TreasuryClassAMember 2017-01-01 2017-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-12-31 0000012208 us-gaap:ParentMember 2017-01-01 2017-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-12-31 0000012208 us-gaap:ParentMember 2018-01-01 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:ParentMember 2016-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000012208 us-gaap:ParentMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000012208 us-gaap:ParentMember 2017-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 0000012208 us-gaap:ParentMember 2018-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000012208 us-gaap:EmployeeStockMember 2018-01-01 2018-12-31 0000012208 us-gaap:EmployeeStockMember 2018-12-31 0000012208 us-gaap:EmployeeStockMember 2017-01-01 2017-12-31 0000012208 us-gaap:EmployeeStockMember 2016-01-01 2016-12-31 0000012208 us-gaap:EmployeeStockMember 2016-12-31 0000012208 us-gaap:EmployeeStockMember 2017-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2018-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2017-12-31 0000012208 bio:StockOptionAndAwardPlansMember bio:IncentiveAwardPlan2017Member 2018-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0000012208 bio:StockAwardPlansMember 2018-01-01 2018-12-31 0000012208 bio:A2011EmployeeStockPurchasePlanMember 2018-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-12-31 0000012208 bio:StockAwardPlansMember bio:IncentiveAwardPlan2017Member 2018-01-01 2018-12-31 0000012208 country:US 2018-12-31 0000012208 us-gaap:SubsequentEventMember 2019-02-26 2019-02-26 0000012208 srt:EuropeMember 2017-01-01 2017-12-31 0000012208 srt:EuropeMember 2016-01-01 2016-12-31 0000012208 country:US 2016-01-01 2016-12-31 0000012208 srt:AmericasMember 2018-01-01 2018-12-31 0000012208 srt:AmericasMember 2017-01-01 2017-12-31 0000012208 srt:AsiaPacificMember 2016-01-01 2016-12-31 0000012208 country:US 2018-01-01 2018-12-31 0000012208 srt:EuropeMember 2018-01-01 2018-12-31 0000012208 srt:AsiaPacificMember 2018-01-01 2018-12-31 0000012208 srt:AsiaPacificMember 2017-01-01 2017-12-31 0000012208 country:US 2017-01-01 2017-12-31 0000012208 srt:AmericasMember 2016-01-01 2016-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherCurrentAssetsMember 2017-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherCurrentAssetsMember 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember bio:PropertyPlantandEquipmentexcludingsegmentspecificMember 2017-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNoncurrentAssetsMember 2017-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:GoodwillMember 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember bio:PropertyPlantandEquipmentexcludingsegmentspecificMember 2018-12-31 0000012208 us-gaap:OperatingSegmentsMember 2017-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:GoodwillMember 2017-12-31 0000012208 us-gaap:OperatingSegmentsMember 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNoncurrentAssetsMember 2018-12-31 0000012208 us-gaap:OperatingSegmentsMember 2016-01-01 2016-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2016-01-01 2016-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2017-01-01 2017-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember 2018-01-01 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2017-01-01 2017-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-12-31 0000012208 us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember 2017-01-01 2017-12-31 0000012208 us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2018-01-01 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-01-01 2016-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember 2016-01-01 2016-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2016-01-01 2016-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2016-01-01 2016-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2018-01-01 2018-12-31 0000012208 bio:ClinicalDiagnosticsMember 2016-01-01 2016-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2018-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2017-01-01 2017-12-31 0000012208 bio:LifeScienceMember 2016-01-01 2016-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2017-12-31 0000012208 srt:EuropeMember 2017-12-31 0000012208 srt:AmericasMember 2017-12-31 0000012208 srt:AmericasMember 2018-12-31 0000012208 country:US 2018-12-31 0000012208 srt:AsiaPacificMember 2017-12-31 0000012208 srt:EuropeMember 2018-12-31 0000012208 country:US 2017-12-31 0000012208 srt:AsiaPacificMember 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2017-01-01 2017-12-31 0000012208 bio:EuropeanReorganizationMember 2017-01-01 2017-12-31 0000012208 bio:EuropeanReorganizationMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2016-12-31 0000012208 bio:EuropeanReorganizationMember 2018-01-01 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2018-01-01 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember 2016-12-31 0000012208 bio:EuropeanReorganizationMember 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2016-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:EuropeanReorganizationMember 2017-01-01 2017-12-31 0000012208 us-gaap:OtherOperatingIncomeExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 us-gaap:EmployeeSeveranceMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 us-gaap:OtherOperatingIncomeExpenseMember us-gaap:FacilityClosingMember bio:ClinicalDiagnosticsMember 2018-10-01 2018-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanReorganizationMember 2017-01-01 2017-12-31 0000012208 us-gaap:EmployeeSeveranceMember us-gaap:FacilityClosingMember bio:ClinicalDiagnosticsMember 2018-10-01 2018-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-12-31 0000012208 bio:GnuBIOMember us-gaap:ResearchAndDevelopmentExpenseMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanReorganizationMember 2018-01-01 2018-12-31 0000012208 bio:EuropeanReorganizationMember 2016-01-01 2016-12-31 0000012208 bio:EuropeanReorganizationMember 2016-05-01 2018-12-31 0000012208 us-gaap:EmployeeSeveranceMember bio:TerminationofanDiagnosticsResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanReorganizationMember 2016-01-01 2016-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember 2017-12-01 2018-12-31 0000012208 us-gaap:AccountsPayableAndAccruedLiabilitiesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-12-31 0000012208 us-gaap:OtherOperatingIncomeExpenseMember bio:TerminationofanDiagnosticsResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:EuropeanReorganizationMember 2018-01-01 2018-12-31 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-12-31 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2017-01-01 2017-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2017-01-01 2017-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:EuropeanReorganizationMember 2016-01-01 2016-12-31 0000012208 bio:GnuBIOMember us-gaap:OtherOperatingIncomeExpenseMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:GnuBIOMember us-gaap:EmployeeSeveranceMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:GnuBIOMember 2017-12-31 0000012208 bio:GnuBIOMember us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2017-01-01 2017-12-31 0000012208 us-gaap:EmployeeSeveranceMember us-gaap:FacilityClosingMember 2018-01-01 2018-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2017-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2017-01-01 2017-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2016-12-31 0000012208 2018-10-01 2018-12-31 0000012208 2018-04-01 2018-06-30 0000012208 2017-01-01 2017-03-31 0000012208 2017-10-01 2017-12-31 0000012208 2017-04-01 2017-06-30 0000012208 2018-07-01 2018-09-30 0000012208 2018-01-01 2018-03-31 0000012208 2017-07-01 2017-09-30 0000012208 us-gaap:SubsequentEventMember 2019-03-04 2019-03-04 0000012208 us-gaap:AllowanceForCreditLossMember 2016-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2018-01-01 2018-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2017-01-01 2017-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2015-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2016-01-01 2016-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2017-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2018-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2016-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-01-01 2018-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-01-01 2017-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2016-01-01 2016-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2015-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:pure xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 10-K
(Mark One)
 
x
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the year ended December 31, 2018
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the transition period from ___________________________ to _________________________________
 
Commission file number 1-7928
 
BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
 
94-1381833
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)
 
 
 
1000 Alfred Nobel Drive, Hercules, California
 
94547
(Address of principal executive offices)
 
(Zip Code)
 
 
Registrant's telephone number, including area code
 
   (510) 724-7000 
Securities registered pursuant to Section 12(b) of the Act:
 
 
 
Title of Each Class
 
Name of Each Exchange on Which Registered
Class A Common Stock Par Value $0.0001 per share
 
New York Stock Exchange
Class B Common Stock Par Value $0.0001 per share
 
New York Stock Exchange
 
Securities registered pursuant to Section 12(g) of the Act:  NONE
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
 
  ¨ Yes
 
 ý No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
 
 ¨ Yes
 
   ý  No
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
 ý Yes
 
¨ No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
 
    ý Yes
 
¨ No
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  ý
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 
 
 
 
 
 
Large accelerated filer
ý
 
 
Accelerated filer
¨
Non-accelerated file
¨
 
 
Smaller reporting company
¨
 
 
 
 
Emerging growth company
¨
 
 
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ¨ Yes x No
As of June 30, 2018, the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value of the Registrant's Class A Common Stock held by non-affiliates was approximately $6,113,695,454 and the aggregate market value of the registrant's Class B Common Stock held by non-affiliates was approximately $67,665,886.
 
As of March 26, 2019, there were 24,707,868 shares of Class A Common Stock and 5,092,404 shares of Class B Common Stock outstanding.
Documents Incorporated by Reference
 
 
 
 
 
 
 
 
 
Document
 
 
Form 10-K Parts 
(1)
Definitive Proxy Statement to be mailed to stockholders in connection with the
 
 
 
 
registrant's 2019 Annual Meeting of Stockholders (specified portions)
 
 III



BIO-RAD LABORATORIES, INC.

FORM 10-K DECEMBER 31, 2018

TABLE OF CONTENTS



2


INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS

Other than statements of historical fact, statements made in this Annual Report include forward-looking statements, such as statements with respect to our future financial performance, operating results, plans and objectives that involve risk and uncertainties.  Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions.  Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements.  We have based these forward-looking statements on our current expectations and projections about future events.  However, actual results may differ materially from those currently anticipated depending on a variety of risk factors including but not limited to those identified under “Item 1A, Risk Factors” of this Annual Report. We caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

PART I.

ITEM 1.  BUSINESS

General

Founded in 1952 and incorporated in 1957, Bio-Rad Laboratories, Inc. (referred to in this report as “Bio-Rad,” “we,” “us,” and “our”) was initially engaged in the development and production of specialty chemicals used in biochemical, pharmaceutical and other life science research applications.  We entered the field of clinical diagnostics with the development of our first test kit based on separation techniques and materials developed for life science research.  Through internal research and development efforts and acquisitions we have expanded into various markets.  Today, Bio-Rad manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a broad range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

As we broadened our product lines, we also expanded our geographical market.  We have direct distribution channels in over 35 countries outside the United States through subsidiaries whose focus is sales, customer service and product distribution. In some locations outside and inside these 35 countries, sales efforts are supplemented by distributors and agents.

Description of Business

Business Segments

Today, Bio-Rad operates in two industry segments designated as Life Science and Clinical Diagnostics.  Both segments operate worldwide.  Our Life Science segment and our Clinical Diagnostics segment generated 37% and 62%, respectively, of our net sales for the year ended December 31, 2018. We generated approximately 38% of our consolidated net sales for the year ended December 31, 2018 from U.S. sales and approximately 62% from sales in our remaining worldwide markets.

For a description of business and financial information on industry and geographic segments, see Note 14 of Item 8 of Part II of this report.

3



Life Science Segment

Our Life Science segment is at the forefront of discovery, creating advanced tools to answer complex biological questions.  We are a leader in the life sciences market and develop, manufacture and market approximately 6,000 reagents, apparatus and laboratory instruments that serve a global customer base. Many of our products are used in established research techniques, biopharmaceutical production processes and food testing regimes. These techniques are typically used to separate, purify and identify biological materials such as proteins, nucleic acids and bacteria within a laboratory or production setting.  We focus on selected segments of the life sciences market in proteomics (the study of proteins), genomics (the study of genes), biopharmaceutical production, cellular biology and food safety.  We estimate that the worldwide market that our portfolios can address for products in these selected segments of our addressable markets is approximately $9 billion. Our principal life science customers include universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers and food testing laboratories.

Clinical Diagnostics Segment

Our Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market.  Our products currently address specific niches within the in vitro diagnostics (IVD) test market, and we seek to focus on the higher margin, higher growth segments of this market.

We supply more than 3,000 different products that cover more than 300 clinical diagnostic tests to the IVD test market. We estimate that the worldwide sales for products in the markets we serve were approximately $12 billion. IVD tests are conducted outside the human body and are used to identify and measure substances in a patient’s tissue, blood or urine. Our products consist of reagents, instruments and software, typically provided to our customers as an integrated package to allow them to generate reproducible test results. Revenue in this business is highly recurring, as laboratories typically standardize test methodologies, which are dependent on a particular supplier’s equipment, reagents and consumable products. An installed base of diagnostic test systems therefore typically creates an ongoing source of revenue through the sale of test kits for each sample analyzed on an installed system.  Our principal clinical diagnostic customers include hospital laboratories, reference laboratories, transfusion laboratories and physician office laboratories.

Raw Materials and Components

We utilize a wide variety of chemicals, biological materials, electronic components, machined metal parts, optical parts, computing and peripheral devices.  Most of these materials and components are available from numerous sources, and generally we have not experienced difficulty in securing adequate supplies. However, in certain instances we acquire components and materials from a sole supplier. Due to the regulatory environment in which we operate, we may be unable to quickly establish additional or replacement sources for some components or materials.

Patents, Trademarks and Licenses

We own over 2,000 U.S. and international patents and numerous trademarks.  We also hold licenses under U.S. and foreign patents owned by third parties and pay royalties on the sales of certain products under the licenses.  We view these patents, trademarks and license agreements as valuable assets; however, we believe that our ability to develop and manufacture our products depends primarily on our knowledge, technology and special skills rather than our patent, trademark and licensing positions.

4



Seasonal Operations and Backlog

Our business is not inherently seasonal.  However, the European custom of concentrating vacation during the summer months usually tempers third quarter sales volume and operating income.

For the most part, we operate in markets characterized by short lead times and the absence of significant backlogs. Management has concluded that backlog information is not material to our business as a whole.

Sales and Marketing

We conduct our worldwide operations through an extensive direct sales force, employing approximately 940 direct sales and sales management personnel around the world. Our sales force typically consists of experienced industry professionals with scientific training, and we maintain a separate specialist sales force for each of our segments. We believe that this direct sales approach allows us to sell a broader range of our products that creates more brand awareness and long-term relationships with our customers.

We also use a range of sales and marketing intermediaries (SMIs) in our international markets. The types of SMIs we utilize are distributors, agents, brokers and resellers. We have programs and policies in place with our SMIs that require compliance with all applicable laws, including adhering to our anti-corruption standards to ensure a transparent sale to our customers.

Our customer base is broad and diversified. Our worldwide customer base includes (1) prominent university and research institutions; (2) hospital, public health and commercial laboratories; (3) other leading diagnostic manufacturers; and (4) leading companies in the biotechnology, pharmaceutical, chemical and food industries. There has been no single customer that accounted for more than three percent of our total net sales.  Our sales are affected by a number of external factors.  For example, a number of our customers, particularly in the Life Science segment, are substantially dependent on government grants and research contracts for their funding.  

Most of our international sales are generated by our wholly-owned international subsidiaries and their branch offices.  Certain of these subsidiaries also have manufacturing facilities.  Bio-Rad’s international operations are subject to certain risks common to foreign operations in general, such as changes in governmental regulations, import restrictions and foreign exchange fluctuations.  

Competition

The markets served by our product groups are highly competitive.  Our competitors range in size from start-ups to large multinational corporations with significant resources and reach.  We seek to compete primarily in market segments where our products and technology offer customers specific advantages over the competition.

Because of the breadth of its product lines, our Life Science segment does not face the same competitors for all of its products.  Major competitors in this market include Becton Dickinson, GE Biosciences, Merck Millipore and Thermo Fisher Scientific. We compete primarily based on meeting performance specifications and offering complete solutions.
Major competitors of our Clinical Diagnostics segment include Roche, Abbott Laboratories, Siemens, Danaher, Thermo Fisher, Becton Dickinson, bioMérieux, Ortho Clinical Diagnostics, Tosoh, Immucor and DiaSorin. We compete in our customer segments by providing high quality products, broad product portfolios and outstanding customer support.

5


Research and Development
We conduct extensive research and development activities in all areas of our business, employing approximately 800 employees worldwide in these activities, including degreed scientists and technical support staff. Research and development has played a major role in Bio-Rad’s growth and is expected to continue to do so in the future. Our research teams are continuously developing new products and new applications for existing products. In our development of new products and applications, we interact with scientific and medical professionals at universities, hospitals and medical schools, and within our industry.

Regulatory Matters

The development, testing, manufacturing, marketing, post-market surveillance, distribution, advertising and labeling of certain of our products (primarily diagnostic products) are subject to regulation in the United States by the Center for Devices and Radiological Health of the U.S. Food and Drug Administration (FDA) and in other jurisdictions by state and foreign government authorities.  FDA regulations require that some new products have pre-marketing clearance or approval by the FDA and require certain products to be manufactured in accordance with FDA’s “good manufacturing practice” regulations, to be extensively tested and to be properly labeled to disclose test results and performance claims and limitations. After a product that is subject to FDA regulation is placed on the market, numerous regulatory requirements apply, including, for example, the requirement that we comply with recordkeeping and reporting requirements, such as the FDA’s medical device reporting regulations and reporting of corrections and removals. The FDA enforces these requirements by inspection and market surveillance. The FDA has authority to take various administrative and legal actions against us for our, or our products’, failure to comply with relevant legal or regulatory requirements, including issuing warning letters, initiating product seizures, requesting or requiring product recalls or withdrawals, and other civil or criminal sanctions, among other things.

We are also subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security and physician sunshine laws and regulations. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs and imprisonment.

Sales of our products will depend, in part, on the extent to which our products or diagnostic tests using our products will be covered by third-party payors, such as government health care programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly reducing reimbursements for certain medical products and services. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost containment programs, including price controls and restrictions on reimbursement. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our products or diagnostic tests using our products, or a decision by a third-party payor to not cover our products could reduce or eliminate utilization of our products and have a material adverse effect on our sales, results of operations and financial condition. In addition, healthcare reform measures have been and will be adopted in the future, any of which could limit the amounts that governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures.

As a multinational manufacturer and distributor of sophisticated instrumentation, we must meet a wide array of electromagnetic compatibility and safety compliance requirements to satisfy regulations in the United States, the European Union and other jurisdictions.  

6



Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, emissions to air and discharges to water, as well as handling and disposal practices for solid, hazardous and medical wastes.  In addition to environmental laws that regulate our operations, we are also subject to environmental laws and regulations that create liabilities and clean-up responsibility for spills, disposals or other releases of hazardous substances into the environment as a result of our operations or otherwise impacting real property that we own or operate.  The environmental laws and regulations could also subject us to claims by third parties for damages resulting from any spills, disposals or releases resulting from our operations or at any of our properties.

These regulatory requirements vary widely among countries.

Employees

At December 31, 2018, Bio-Rad had approximately 8,260 employees.  Approximately eight percent of our approximately 3,265 U.S. employees are covered by a collective bargaining agreement, which will expire on November 7, 2019.  Many of our non-U.S. full-time employees, especially in France, are covered by collective bargaining agreements.  We consider our employee relations to be generally good.

Available Information

Bio-Rad files annual, quarterly, and current reports, proxy statements, and other documents with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, as amended.  The SEC maintains an Internet website that contains reports, proxy and information statements, and other information regarding issuers, including Bio-Rad, that file electronically with the SEC.  The public can obtain any documents that we file with the SEC at http://www.sec.gov.

Bio-Rad’s website address is www.bio-rad.com.  We make available, free of charge through our website, our Form 10-Ks, 10-Qs and 8-Ks, and any amendments to these forms, as soon as reasonably practicable after filing with the SEC. The information on our website is not part of this Annual Report on Form 10-K.

ITEM 1A. RISK FACTORS

In evaluating our business and whether to invest in any of our securities, you should carefully read the following risk factors in addition to the other information contained in this Annual Report.  We believe that any of the following risks could have a material effect on our business, results of operations or financial condition, our industry or the trading price of our common stock.  We operate in a continually changing business environment, and new risks and uncertainties emerge from time to time. We cannot predict these new risks and uncertainties, nor can we assess the extent to which any such new risks and uncertainties or the extent to which the risks and uncertainties set forth below may adversely affect our business, results of operations, financial condition, our industry or the trading price of our common stock.

Our settlement with government agencies in connection with violations by us of the U.S. Foreign Corrupt Practices Act could have a material adverse effect on our business, results of operations and financial condition.

As previously disclosed, we entered into a non-prosecution agreement (NPA) with the U.S. Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) and consented to the entry of an Order by the SEC (SEC Order), effective November 3, 2014, which actions resolved both the DOJ and the SEC investigations into our violations of the U.S. Foreign Corrupt Practices Act (FCPA). Under the terms of the NPA and the SEC Order, we agreed to pay a financial penalty and certain amounts in disgorgement and interest as well as to compliance, reporting and cooperation obligations to be performed for two years. On October 28, 2016, the DOJ and SEC informed Bio-Rad that they did not intend to extend the NPA after it expired November 2, 2016.


7


Whether by virtue of disclosure of the NPA and the SEC Order or otherwise, we may be subject to investigations by foreign governments or further claims by third parties arising from conduct subject to the investigation or our other international operations. Many of our customers in our significant international operations are government agencies or state-owned or state-controlled universities, hospitals and laboratories. The disclosure of the NPA and the SEC Order and any further violations of the FCPA could harm our reputation with these customers, which could materially adversely affect our business, results of operations and financial condition. Any further violations of the FCPA also could result in more punitive actions by the SEC and DOJ, which also could materially adversely affect our business, results of operations and financial condition.

Our international operations expose us to additional costs and legal and regulatory risks, which could have a material adverse effect on our business, results of operations and financial condition.

We have significant international operations. We have direct distribution channels in over 35 countries outside the United States, and in 2018 our foreign subsidiaries generated 62% of our net sales. Compliance with complex foreign and U.S. laws and regulations that apply to our international operations increases our cost of doing business. These numerous and sometimes conflicting laws and regulations include, among others, data privacy requirements (including the requirements for compliance with the EU General Data Protection Regulation, which went into effect May 25, 2018), labor relations laws, tax laws, anti-competition regulations, import and trade restrictions, tariffs, quotas and other trade barriers, export requirements, U.S. laws such as the FCPA and other U.S. federal laws and regulations established by the office of Foreign Asset Control, foreign laws such as the UK Bribery Act 2010 or other foreign laws which prohibit corrupt payments to governmental officials or certain payments or remunerations to customers. In addition, changes in laws or regulations potentially could be disruptive to our operations and business relationships in the affected regions. For example, the United Kingdom's anticipated withdrawal from the European Union (commonly referred to as “Brexit”) could disrupt the free movement of goods, services and people between the United Kingdom and the European Union and result in increased regulatory, legal, labor and tax complexities.

Given the high level of complexity of the foreign and U.S. laws and regulations that apply to our international operations, there is a risk that we may inadvertently breach some provisions, for example, through fraudulent or negligent behavior of individual employees, our failure to comply with certain formal documentation requirements, or otherwise. Our success depends, in part, on our ability to anticipate these risks and manage these challenges through policies, procedures and internal controls. However, we have a dispersed international sales organization, and we use distributors and agents in many of our international operations. This structure makes it more difficult for us to ensure that our international selling operations comply with our global policies and procedures.

Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Violations of laws and regulations also could result in prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, or our business, results of operations and financial condition. See also our risk factors regarding government regulations and regarding global economic conditions below.

The industries and market segments in which we operate are highly competitive, and we may not be able to compete effectively.

The life science and clinical diagnostics markets are each highly competitive. Some of our competitors have merged, and some of our competitors have greater financial resources than we do, making them better equipped to license technologies and intellectual property from third parties or to fund research and development, manufacturing and marketing efforts. Moreover, competitive and regulatory conditions in many markets in which we operate restrict our ability to fully recover, through price increases, higher costs of acquired goods and services resulting from inflation and other drivers of cost increases. Many public tenders have become more competitive due to governments lengthening the commitments of their public tenders to multiple years, which reduce the number of tenders in which we can participate annually. Because the value of these multiple-year tenders is so

8


high, our competitors have been more aggressive with their pricing. Our failure to compete effectively and/or pricing pressures resulting from competition could adversely affect our business, results of operations and financial condition.

We may not be able to grow our business because of our failure to develop new or improved products.

Our future growth depends in part on our ability to continue to improve our product offerings and develop and introduce new product lines and extensions that integrate technological advances. In particular, we may not be able to keep up with changes in the clinical diagnostics industry, such as the trend toward molecular diagnostics or point-of-care tests. If we are unable to integrate technological advances into our product offerings or to design, develop, manufacture and market new product lines and extensions successfully and in a timely manner, our business, results of operations and financial condition will be adversely affected. We have experienced product launch delays in the past, and may do so in the future. We cannot assure you that our product and process development efforts will be successful or that new products we introduce will achieve market acceptance. Failure to launch successful new products or improvements to existing products may cause our products to become obsolete, which could harm our business, results of operations and financial condition.

We are subject to foreign currency exchange fluctuations, which could have a material adverse effect on our results of operations and financial condition.

As stated above, a significant portion of our operations and sales are outside of the United States. When we make purchases and sales in currencies other than the U.S. dollars, we are exposed to fluctuations in foreign currencies relative to the U.S. dollar that may adversely affect our results of operations and financial condition. Our international sales are largely denominated in local currencies. As a result, the strengthening of the U.S. dollar negatively impacts our consolidated net sales expressed in U.S. dollars. Conversely, when the U.S. dollar weakens, our expenses at our international sites increase. In addition, the volatility of other currencies may negatively impact our operations outside of the United States and increase our costs to hedge against currency fluctuations. We cannot assure you that future shifts in currency exchange rates will not have a material adverse effect on our results of operations and financial condition.

We may experience difficulties implementing our new global enterprise resource planning system.

We are engaged in a multi-year implementation of a new global enterprise resource planning system (ERP). The ERP is designed to efficiently maintain our books and records and provide information important to the operation of our business to our management team. The ERP will continue to require significant investment of human and financial resources. In implementing the ERP, we may experience significant delays, increased costs and other difficulties. Any significant disruption or deficiency in the design and implementation of the ERP could adversely affect our ability to process orders, ship product, send invoices and track payments, fulfill contractual obligations or otherwise operate our business. For example, we experienced system implementation issues in our Clinical Diagnostics segment during our first deployment that impacted invoicing and caused an increase in accounts receivable. In our second deployment, we experienced delays in manufacturing and logistics, which adversely impacted our sales. In our third deployment in Western Europe in April 2017 we experienced system implementation issues impacting the timing of payment of vendor invoices and resulting in delays in product availability and shipments. We also experienced lower productivity levels related to the April 2017 go-live of the ERP in Western Europe, which adversely impacted our sales during the second and third quarters of 2017. We expect to implement the remaining smaller phases of the ERP platform over the next few years. In addition, our efforts to centralize various business processes and functions within our organization in connection with our ERP implementation may continue to disrupt our operations and negatively impact our business, results of operations and financial condition.

9



Recent and planned changes to our organizational structure and executive management team could negatively impact our business.

We made significant changes to our organizational structure over the past few years. In 2016, we began implementing the reorganization of the structure of our European organization, and we have continued implementing this reorganization in 2017 and 2018. Our Chief Operating Officer retired on March 30, 2018, and our search for a new Chief Operating Officer is underway. In addition, our Chief Financial Officer will be retiring on April 30, 2019, so we will have a new Chief Financial Officer in 2019. These changes may have unintended consequences, such as distraction of our management and employees, business disruption, attrition of our workforce, inability to attract or retain key employees, and reduced employee morale or productivity.

Our failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial statements, our failure to meet our reporting obligations and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our common stock to decline.

Maintaining effective disclosure controls and procedures and internal controls over financial reporting are necessary for us to produce reliable financial statements.  

As previously discussed in Item 9A "Controls and Procedures" of our Annual Report for the period ended December 31, 2017, and Item 4 "Controls and Procedures" of our 2018 Form 10-Q's, management identified a material weakness in our internal control over financial reporting resulting from our ERP system conversion and European reorganization leading to the internal control deficiencies described below. We determined that we did not maintain a sufficient complement of personnel in certain European countries with appropriate training and expertise in accounting and reporting in the new ERP system following the system conversion and European reorganization that we undertook in April 2017, including the implementation of reporting lines, appropriate authorities and responsibilities within and between our accounting and reporting function, information technology and the business operations in these European countries. We did not conduct continuous risk assessment over changes in our European business operations, IT systems and personnel to identify and assess necessary changes in internal control over financial reporting. As a result, we did not design effective control activities over the accounting for financial statement amounts, including inventory and revenue, reported by entities impacted by the European reorganization, including management review controls with sufficient precision to identify and investigate potential outliers.

During the fourth quarter of 2017 and throughout 2018, management conducted an extensive remediation plan to address its material weakness. The remediation plan involved enhancing the control environment in the entities impacted by the ERP system conversion and European reorganization by (i) increasing resources with sufficient accounting and reporting expertise within our reorganized business and expertise in using our new ERP system, (ii) implementing and monitoring reporting lines and appropriate authorities and responsibilities within the accounting and reporting function, information technology and the business operations, and (iii) providing training to our control owners to effectively perform controls in the new environment including training on reconciliation review controls and certain ERP system enhancements. Management also enhanced its risk assessment process to continuously assess the potential impact on internal control over financial reporting of changes to business operations, including changes relating to similar ERP system conversions and reorganizations that may occur in the future. In addition, management designed and implemented additional control activities over financial statement amounts reported by entities impacted by the European reorganization, including inventory, revenue and cost of goods sold. Implementation of management's remediation plans described above have strengthened our internal control over financial reporting and addressed the material weakness that was identified in 2017. Based on this assessment, management concluded that the material weakness has been remediated as of December 31, 2018. However, we cannot assure you that additional deficiencies or material weaknesses in our internal control over financial reporting will not be identified in the future.


10


Material weaknesses have adversely affected us in the past and could affect us in the future, and the results of our periodic management evaluations and annual auditor attestation reports regarding the effectiveness of our internal control over financial reporting required by Section 404 of the Sarbanes-Oxley Act of 2002.  Any failure to maintain or implement new or improved internal controls, or any difficulties that we may encounter in their maintenance or implementation, could result in additional significant deficiencies or material weaknesses, result in material misstatements in our consolidated financial statements and cause us to fail to meet our reporting obligations.  This could cause us to lose public confidence, and could cause the trading price of our common stock to decline.  For further information regarding our controls and procedures, see Part II, Item 9A of this Annual Report on Form 10-K.

Breaches of our information systems could have material adverse effect on our business and results of operations.

Through our sales and eCommerce channels, we collect and store confidential information that customers provide to, among other things, purchase products or services, enroll in promotional programs and register on our Web site. We also acquire and retain information about suppliers and employees in the normal course of business. We also create and maintain proprietary information that is critical to our business, such as our product designs and manufacturing processes. Despite recent initiatives to improve our technology systems, such as our enterprise resource planning implementation and the centralization of our global information technology organization, we could experience a significant data security breach. Computer hackers may attempt to penetrate our or our vendors’ information systems and, if successful, misappropriate confidential customer, supplier, employee or other business information, such as our intellectual property. Third parties could also gain control of our systems and use them for criminal purposes while appearing to be us. As a result, we could lose existing customers, have difficulty attracting new customers, be exposed to claims from customers, financial institutions, payment card associations, employees and other persons, have regulatory sanctions or penalties imposed, incur additional expenses or lose revenues as a result of a data privacy breach, or suffer other adverse consequences. Our operations and ability to process sales orders, particularly through our eCommerce channels, could also be disrupted. Any significant breakdown, intrusion, interruption, corruption, or destruction of our systems, as well as any data breaches, could have a material adverse effect on our business and results of operations. See also our risk factors regarding our ERP implementation above and our information technology systems below.

Risks relating to intellectual property rights may negatively impact our business.

We rely on a combination of copyright, trade secret, patent and trademark laws and third-party nondisclosure agreements to protect our intellectual property rights and products. However, we cannot assure you that our intellectual property rights will not be challenged, invalidated, circumvented or rendered unenforceable, or that meaningful protection or adequate remedies will be available to us. For instance, unauthorized third parties have attempted to copy our intellectual property, reverse engineer or obtain and use information that we regard as proprietary, or have developed equivalent technologies independently, and may do so in the future. Additionally, third parties have asserted patent, copyright and other intellectual property rights to technologies that are important to us, and may do so in the future. If we are unable to license or otherwise access protected technology used in our products, or if we lose our rights under any existing licenses, we could be prohibited from manufacturing and marketing such products. From time to time, we also must enforce our patents or other intellectual property rights or defend ourselves against claimed infringement of the rights of others through litigation. As a result, we could incur substantial costs, be forced to redesign our products, or be required to pay damages to an infringed party. Any of the foregoing matters could adversely impact our business, results of operations and financial condition.

Global economic conditions could adversely affect our operations.

In recent years, we have been faced with very challenging global economic conditions. A deterioration in the global economic environment may result in decreased demand for our products, increased competition, downward pressure on the prices for our products and longer sales cycles. A weakening of macroeconomic conditions may also adversely affect our suppliers, which could result in interruptions in supply in the future. We have also experienced delays in collecting receivables in certain countries in Western Europe, and we may experience similar

11


delays in these and other countries or regions experiencing liquidity problems. In addition, a slowing of growth in the Chinese economy and in emerging markets, especially those oil-producing countries that would be affected by a decline in oil prices, could adversely affect our business, results of operations or financial condition. There is also uncertainty surrounding the impact that Brexit will have on European and worldwide economic conditions and the stability of global financial markets, and a negative effect from any of these things could adversely affect our business, results of operations or financial condition. Additionally, the United States and other countries recently have imposed tariffs on certain goods. While tariffs imposed by other countries on U.S. goods have not yet had a significant impact on our business, further escalation of tariffs or other trade barriers could adversely impact our profitability and/or our competitiveness. See also our risk factors regarding our international operations above and regarding government regulations below.

Reductions in government funding and the capital spending programs of our customers could have a material adverse effect on our business, results of operations or financial condition.

Our customers include universities, clinical diagnostics laboratories, government agencies, hospitals and pharmaceutical, biotechnology and chemical companies.  The capital spending programs of these institutions and companies have a significant effect on the demand for our products.  Such programs are based on a wide variety of factors, including the resources available to make such purchases, the availability of funding from grants by governments or government agencies, the spending priorities for various types of equipment and the policies regarding capital expenditures during industry downturns or recessionary periods.  If government funding to our customers were to decrease, or if our customers were to decrease or reallocate their budgets in a manner adverse to us, our business, results of operations or financial condition could be materially and adversely affected.

Changes in the healthcare industry could have an adverse effect on our business, results of operations and financial condition.

There have been, and will continue to be, significant changes in the healthcare industry in an effort to reduce costs. These changes include:

•
The trend towards managed care, together with healthcare reform of the delivery system in the United States and efforts to reform in Europe, has resulted in increased pressure on healthcare providers and other participants in the healthcare industry to reduce selling prices.  Consolidation among healthcare providers and consolidation among other participants in the healthcare industry has resulted in fewer, more powerful groups, whose purchasing power gives them cost containment leverage.  In particular, there has been a consolidation of laboratories and a consolidation of blood transfusion centers. These industry trends and competitive forces place constraints on the levels of overall pricing, and thus could have a material adverse effect on our gross margins for products we sell in clinical diagnostic markets.

•
Third party payors, such as Medicare and Medicaid in the United States, have reduced their reimbursements for certain medical products and services. Our Clinical Diagnostics business is impacted by the level of reimbursement available for clinical tests from third party payors. In the United States payment for many diagnostic tests furnished to Medicare fee-for-service beneficiaries is made based on the Medicare Clinical Laboratory Fee Schedule (CLFS), a fee schedule established and adjusted from time to time by the Centers for Medicare and Medicaid Services (CMS). Some commercial payors are guided by the CLFS in establishing their reimbursement rates. Clinicians may decide not to order clinical diagnostic tests if third party payments are inadequate, and we cannot predict whether third party payors will offer adequate reimbursement for tests utilizing our products to make them commercially attractive. Legislation, such as the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (PPACA) and the Middle Class Tax Relief and Job Creation Act of 2012, has reduced the payments for clinical laboratory services paid under the CLFS. In addition, the Protecting Access to Medicare Act of 2014 (PAMA) has made significant changes to the way Medicare will pay for clinical laboratory services, which has further reduced reimbursement rates.


12


•
The PPACA has also imposed a 2.3% excise tax on the sales of certain medical devices in the U.S., which we are required to pay on most of our United States Clinical Diagnostic sales. However, the Consolidated Appropriations Act, 2016 (Pub. L. 114-113), signed into law on December 18, 2015, included a two year moratorium on the medical device excise tax. On January 22, 2018, the moratorium on the medical device excise tax was further extended until January 1, 2020.

To the extent that the healthcare industry seeks to address the need to contain costs stemming from reform measures such as those contained in the PPACA and the PAMA, or in future legislation, by limiting the number of clinical tests being performed or the amount of reimbursement available for such tests, our business, results of operations and financial condition could be adversely affected.  If these changes in the healthcare markets in the United States and Europe continue, we could be forced to alter our approach in selling, marketing, distributing and servicing our products.

We are subject to substantial government regulation, and any changes in regulation or violations of regulations by us could adversely affect our business, prospects, results of operations or financial condition.

Some of our products (primarily our Clinical Diagnostic products), production processes and marketing are subject to U.S. federal, state and local, and foreign regulation, including by the FDA in the United States and its foreign counterparts.  The FDA regulates our Clinical Diagnostic products as medical devices, and we are subject to significant regulatory clearances or approvals to market our Clinical Diagnostic products and other requirements including, for example, recordkeeping and reporting requirements, such as the FDA’s medical device reporting regulations and reporting of corrections and removals. The FDA has broad regulatory and enforcement powers. If the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of enforcement actions ranging from public warning letters, fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals, seizure or recall of our products, total or partial shutdown of production, withdrawal of approvals or clearances already granted, and criminal prosecution.

The FDA can also require us to repair, replace or refund the cost of devices that we manufactured or distributed.
In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of our products or impact our ability to modify our currently approved or cleared products on a timely basis. Changes in the FDA’s review of certain clinical diagnostic products referred to as laboratory developed tests, which are tests developed by a single laboratory for use only in that laboratory, could affect some of our customers who use our Life Science instruments for laboratory developed tests. In the past, the FDA has chosen to not enforce applicable regulations and has not reviewed such tests for approval. However, the FDA has issued draft guidance that it may begin enforcing its medical device requirements, including premarket submission requirements, to such tests. Any delay in, or failure to receive or maintain, clearance or approval for our products could prevent us from generating revenue from these products and adversely affect our business operations and financial results. Additionally, the FDA and other regulatory authorities have broad enforcement powers. Regulatory enforcement or inquiries, or other increased scrutiny on us, could affect the perceived safety and efficacy of our products and dissuade our customers from using our products.

Many foreign governments have similar rules and regulations regarding the importation, registration, labeling, sale and use of our products. Such agencies may also impose new requirements that may require us to modify or re-register products already on the market or otherwise impact our ability to market our products in those countries. For example, in April 2017 the European Parliament voted to enact final regulations that include broad changes regarding in vitro diagnostic devices and medical devices, which will require us to modify or re-register some products and will result in additional costs. In addition, Russia has enacted more stringent medical product registration and labeling regulations, China has enacted stricter labeling requirements, and we expect other countries, such as Brazil and India, to impose more regulations that impact our product registrations. Brexit also will likely result in additional regulatory requirements associated with goods sold in the United Kingdom and will likely result in additional complexities and possible delays with respect to goods, raw materials and personnel moving between the United Kingdom and the European Union. Due to these evolving and diverse requirements, we face uncertain product approval timelines, additional time and effort to comply, as well as the potential for

13


reduced sales and/or fines for noncompliance. Increasing protectionism in such countries also impedes our ability to compete with local companies. For example, we may not be able to participate in certain public tenders in Russia because of increasing measures to restrict access to such tenders for companies without local manufacturing capabilities. Such regulations could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our international operations and regarding global economic conditions above.

We are also subject to government regulation of the use and handling of a number of materials and controlled substances.  The U.S. Drug Enforcement Administration establishes registration, security, recordkeeping, reporting, storage, distribution and other requirements for controlled substances pursuant to the Controlled Substances Act of 1970. Failure to comply with present or future laws and regulations could result in substantial liability to us, suspension or cessation of our operations, restrictions on our ability to expand at our present locations or require us to make significant capital expenditures or incur other significant expenses.

We cannot assure you that we will be able to integrate acquired companies, products or technologies into our company successfully, or we may not be able to realize the anticipated benefits from the acquisitions.

As part of our overall business strategy, we pursue acquisitions of and investments in complementary companies, products and technologies. In order to be successful in these activities, we must, among other things:
•
assimilate the operations and personnel of acquired companies;
•
retain acquired business customers;
•
minimize potential disruption to our ongoing business;
•
retain key technical and management personnel;
•
integrate acquired companies into our strategic and financial plans;
•
accurately assess the value of target companies, products and technologies;
•
comply with new regulatory requirements;
•
harmonize standards, controls, procedures and policies;
•
minimize the impact to our relationships with our employees and customers; and
•
assess, document and remediate any deficiencies in disclosure controls and procedures and internal control over financial reporting.

The benefits of any acquisition may prove to be less than anticipated and may not outweigh the costs reported in our financial statements.  Completing any potential future acquisitions could cause significant diversion of our management’s time and resources.  If we acquire new companies, products or technologies, we may be required to assume contingent liabilities or record impairment charges for goodwill and other intangible assets over time. Goodwill and non-amortizable intangible assets are subject to impairment testing, and potential periodic goodwill impairment charges, amortization expenses related to certain intangible assets, and other write-offs could harm our operating results. Impairment tests are highly sensitive to changes in assumptions and minor changes to assumptions could result in impairment losses. If the results forecast in our impairment tests are not achieved, or business trends vary from the assumptions used in forecasts, or external factors change detrimentally, future impairment losses may occur. For example, as we previously discussed in Item 7 of our Annual Report for the period ended December 31, 2017, one reporting unit, whose goodwill was primarily from the acquisitions of Biotest AG and DiaMed Holding AG, had excess fair value over book value of only 8% at December 31, 2017. The goodwill allocated to this reporting unit as of December 31, 2017 was $263.6 million. We impaired all the goodwill related to this reporting unit for the year ended December 31, 2018 because assumptions utilized in our 2017 forecast did not materialize.

We cannot assure you that we will successfully overcome these risks or any other problems we encounter in connection with any acquisitions, and any such acquisitions could adversely affect our business, results of operations and financial condition.

14



Product quality and liability issues could harm our reputation and negatively impact our business, results of operations and financial condition.

We must adequately address quality issues associated with our products, including defects in our engineering, design and manufacturing processes, as well as defects in third-party components included in our products. Our instruments, reagents and consumables are complex, and identifying the root cause of quality issues, especially those affecting reagents or third-party components, is difficult. We may incur significant costs and expend substantial time in researching and remediating such issues. Quality issues could also delay our launching or manufacturing of new products. In addition, quality issues, unapproved uses of our products, or inadequate disclosure of risks related to our products, could result in product recalls or product liability or other claims being brought against us. These issues could harm our reputation, impair our relationship with existing customers and harm our ability to attract new customers, which could negatively impact our business, results of operations and financial condition.

Lack of key personnel could hurt our business.

Our products are very technical in nature. In general, only highly qualified and well-trained scientists have the necessary skills to develop, market and sell our products, and many of our manufacturing positions require very specialized knowledge and skills.  In addition, the global nature of our business also requires that we have sophisticated and experienced staff to comply with increasingly complex international laws and regulations. We face intense competition for these professionals from our competitors, customers, marketing partners and other companies throughout our industry. In particular, the job market in Northern California, where many of our employees are located, is very competitive. If we do not offer competitive compensation and benefits, we may fail to retain or attract a sufficient number of qualified personnel, which could impair our ability to properly run our business.

In some cases we rely on temporary personnel or consultants, and we may do so in the future. Such temporary personnel or consultants may lack the knowledge and/or specific skills necessary for our business, require time to train without benefiting us through extended employment and increase our costs. In addition, as noted above, our strategic initiatives, such as our internal restructuring and ERP implementation, may be burdensome and disruptive and lead to employee dissatisfaction and attrition.

A reduction or interruption in the supply of components and raw materials could adversely affect our manufacturing operations and related product sales.

The manufacture of many of our products requires the timely delivery of sufficient amounts of quality components and materials. We manufacture our products in numerous manufacturing facilities around the world. We acquire our components and materials from many suppliers in various countries. We work closely with our suppliers to ensure the continuity of supply but we cannot guarantee these efforts will always be successful. Further, while we seek to diversify our sources of components and materials, in certain instances we acquire components and materials from a sole supplier. In addition, due to the regulatory environment in which we operate, we may be unable to quickly establish additional or replacement sources for some components or materials. If our supply is reduced or interrupted or of poor quality, and we are unable to develop alternative sources for such supply, our ability to manufacture our products in a timely or cost-effective manner could be adversely affected, which would adversely affect our ability to sell our products.

15



If our information technology systems are disrupted, or if we fail to successfully implement, manage and integrate our information technology and reporting systems, our business, results of operations and financial condition could be harmed.

Our information technology (IT) systems are an integral part of our business, and a serious disruption of our IT systems could have a material adverse effect on our business, results of operations and financial condition. We depend on our IT systems to process orders, manage inventory and collect accounts receivable.  Our IT systems also allow us to efficiently purchase products from our suppliers and ship products to our customers on a timely basis, maintain cost-effective operations and provide customer service.  We may experience disruption of our IT systems due to redundancy issues with our network servers. We cannot assure you that our contingency plans will allow us to operate at our current level of efficiency.

Our ability to implement our business plan in a rapidly evolving market requires effective planning, reporting and analytical processes.  We expect that we will need to continue to improve and further integrate our IT systems, reporting systems and operating procedures by training and educating our employees with respect to these improvements and integrations on an ongoing basis in order to effectively run our business.  We may suffer interruptions in service, loss of data or reduced functionality when we upgrade or change systems. If we fail to successfully manage and integrate our IT systems, reporting systems and operating procedures, it could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our ERP implementation and data security above and events beyond our control below.

Natural disasters, terrorist attacks, acts of war or other events beyond our control may cause damage or disruption to us and our employees, facilities, information systems, security systems, vendors and customers, which could significantly impact our business, results of operations and financial condition.

We have significant manufacturing and distribution facilities, including in the western United States, France, Switzerland, Germany and Singapore.  In particular, the western United States has experienced a number of earthquakes, wildfires, floods, landslides and other natural disasters in recent years.  These occurrences could damage or destroy our facilities which may result in interruptions to our business and losses that exceed our insurance coverage. In addition, strikes or other labor unrest at any of our sites or surrounding areas could cause disruption to our business.

Acts of terrorism, bioterrorism, violence or war could also affect the markets in which we operate, our business operations and strategic plans. Political unrest may affect our sales in certain regions, such as in Southeast Asia, the Middle East and Eastern Europe. Any of these events could adversely affect our business, results of operations and financial condition.

We may have higher than anticipated tax liabilities.

We are subject to income taxes in the United States and many foreign jurisdictions. We report our results of operations based on our determination of the amount of taxes owed in various tax jurisdictions in which we operate. The determination of our worldwide provision for income taxes and other tax liabilities requires estimation, judgment and calculations where the ultimate tax determination may not be certain. Our determination of tax liability is always subject to review or examination by tax authorities in various tax jurisdictions. Tax authorities have disagreed with our judgment in the past and may disagree with positions we take in the future resulting in assessments of additional taxes. Any adverse outcome of such review or examination could have a negative impact on our operating results and financial condition.

16



Economic and political pressures to increase tax revenues in various jurisdictions may make resolving tax disputes more difficult. For example, in recent years, the tax authorities in Europe have disagreed with our tax positions related to hybrid debt, research and development credits, transfer pricing and indirect taxes, among others. We regularly assess the likelihood of the outcome resulting from these examinations to determine the adequacy of our provision for income taxes. Although we believe our tax estimates are reasonable, the final determination of tax audits and any related litigation could be materially different from our historical income tax provisions and accruals.

The results from various tax examinations, audits and litigation may differ from the liabilities recorded in our financial statements and could materially and adversely affect our financial results and cash flows in the period or periods for which that determination is made.

Changes in tax laws or rates, changes in the interpretation of tax laws or changes in the jurisdictional mix of our earnings could adversely affect our financial position and results of operations.

On December 22, 2017, the U.S. enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act made a number of substantial changes, including the imposition of a one-time mandatory deemed repatriation tax on the 2017 unrepatriated earnings accumulated offshore since 1986, the establishment of global minimum income tax and base erosion tax provisions related to offshore activities and affiliated party payments, and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of deferred taxes to reflect their value at a lower tax rate of 21%. These changes to U.S. tax laws will significantly impact how U.S. multinational corporations are taxed on foreign earnings.

The U.S Treasury, Internal Revenue Service and other standard setting bodies are continuing to issue guidance and interpretation relating to the Tax Act. As future guidance is issued, we may make adjustments to amounts previously reported that could materially impact our financial statements.

Our global operations subject us to income and other taxes in the U.S. and in numerous foreign jurisdictions, each with different tax schemes and tax rates. In addition to the changes in tax laws and the interpretation of tax laws and tax rates in these jurisdictions, the jurisdictional mix of our earnings in countries with differing statutory tax rates can have a significant impact on our effective tax rate from period to period.

The tax effect of our investment in Sartorius AG and the jurisdictional mix of our earnings could continue to materially affect our financial results and cash flow.

In addition, the adoption of some or all of the recommendations set forth in the Organization for Economic Co-operation and Development’s project on “Base Erosion and Profit Shifting” (BEPS) by tax authorities in the countries in which we operate, could negatively impact our effective tax rate. These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in a particular country.

Our reported financial results may be materially affected by changes in accounting principles generally accepted in the United States.
Generally accepted accounting principles in the United States, or U.S. GAAP, are subject to interpretation by the Financial Accounting Standards Board, or FASB, the U.S. Securities and Exchange Commission, or SEC, and various bodies formed to promulgate and interpret appropriate accounting principles. A change in these principles or interpretations could have a significant effect on our reported financial results, and could affect the reporting of transactions completed before the announcement of a change.

17



For example, in January 2016, the FASB issued Accounting Standards Update No. (ASU) 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting), such as our investment in Sartorius AG, will be measured at fair value through earnings. The impact of adoption of ASU 2016-01 in the first quarter of 2018 materially impacted our Consolidated Statement of Income due to our investment in Sartorius AG. In future periods, changes in the market value of our investment in Sartorius AG may continue to materially impact our Consolidated Statement of Income.

Also for example, in February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. We will adopt ASU 2016-02 on a modified retrospective basis effective January 1, 2019 with practical expedients. Where we act as a lessee, the adoption of the standard will result in material additions to the balance sheet for right-of-use assets and the associated liabilities. Where we act as a lessor in reagent rental arrangements, we estimate an insignificant impact to our consolidated financial statements.

We may incur losses in future periods due to write-downs in the value of financial instruments.
We have positions in a variety of financial instruments including asset backed securities and other similar instruments. Financial markets are volatile and the markets for these securities can be illiquid.  The value of these securities will continue to be impacted by external market factors including default rates, changes in the value of the underlying property, such as residential or commercial real estate, rating agency actions, the prices at which observable market transactions occur and the financial strength of various entities, such as financial guarantors who provide insurance for the securities. Should we need to convert these positions to cash, we may not be able to sell these instruments without significant losses due to current debtor financial conditions or other market considerations.

We also have positions in equity securities, including our investment in Sartorius AG. Financial markets are volatile and the markets for these equity securities can be illiquid as well. A decline in the market value of our investment in Sartorius AG or in the market value of the other equity securities that we own could result in significant losses due to write-downs in the value of the equity securities. In addition, if we need to convert these positions to cash, we may not be able to sell these equity securities without significant losses.

Environmental, health and safety regulations and enforcement proceedings may negatively impact our business, results of operations and financial condition.

Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, emissions to air and discharges to water, as well as handling and disposal practices for solid, hazardous and medical wastes.  In addition to environmental laws that regulate our operations, we are also subject to environmental laws and regulations that create liability and clean-up responsibility for spills, disposals or other releases of hazardous substances into the environment as a result of our operations or otherwise impacting real property that we own or operate.  The environmental laws and regulations also subject us to claims by third parties for damages resulting from any spills, disposals or releases resulting from our operations or at any of our properties. We must also comply with various health and safety regulations in the United States and abroad in connection with our operations.

We may in the future incur capital and operating costs to comply with currently existing laws and regulations, and possible new statutory enactments, and these expenditures may be significant.  We have incurred, and may in the future incur, fines related to environmental matters and/or liability for costs or damages related to spills or other releases of hazardous substances into the environment at sites where we have operated, or at off-site locations where we have sent hazardous substances for disposal.  We cannot assure you, however, that such matters or any future obligations to comply with environmental or health and safety laws and regulations will not adversely affect our business, results of operations or financial condition.


18


Our debt may restrict our future operations.

We have substantial debt and have the ability to incur additional debt. As of December 31, 2018, we had approximately $439.4 million of outstanding indebtedness. In addition, we have a revolving credit facility that provides for up to $200.0 million, $0.2 million of which has been utilized for domestic standby letters of credit. Our incurrence of substantial amounts of debt may have important consequences.  For instance, it could:

•
make it more difficult for us to satisfy our financial obligations, including those relating to our outstanding debt;
•
require us to dedicate a substantial portion of our cash flow from operations to the payment of interest and principal due under our debt, which will reduce funds available for other business purposes;
•
increase our vulnerability to general adverse economic and industry conditions;
•
limit our flexibility in planning for, or reacting to, changes in our business and the industries in which we operate;
•
place us at a competitive disadvantage compared with some of our competitors that have less debt; and
•
limit our ability to obtain additional financing required to fund working capital and capital expenditures and for other general corporate purposes.

Our existing credit facility and the terms of our other debt instruments, including agreements we may enter in the future, contain or will contain covenants imposing significant restrictions on our business.  These restrictions may affect our ability to operate our business and may limit our ability to take advantage of potential business opportunities as they arise.  These covenants place restrictions on our ability to, among other things: incur additional debt; acquire other businesses or assets through merger or purchase; create liens; make investments; enter into transactions with affiliates; sell assets; in the case of some of our subsidiaries, guarantee debt; and declare or pay dividends, redeem stock or make other distributions to stockholders. Our existing credit facility also requires that we comply with certain financial ratios, including a maximum consolidated leverage ratio test and a minimum consolidated interest coverage ratio test.

Our ability to comply with these covenants may be affected by events beyond our control, including prevailing economic, financial and industry conditions.  The breach of any of these restrictions could result in a default.  An event of default under our debt agreements would permit some of our lenders to declare all amounts borrowed from them to be due and payable, together with accrued and unpaid interest. In addition, acceleration of our other indebtedness may cause us to be unable to make interest payments on our outstanding notes and repay the principal amount of our outstanding notes or may cause the future subsidiary guarantors, if any, to be unable to make payments under the guarantees.

We are subject to healthcare fraud and abuse laws and regulations and could face substantial penalties if we are unable to fully comply with such laws.

We are subject to healthcare fraud and abuse regulation and enforcement by both the U.S. federal government and the U.S. states and foreign governments in which we conduct our business. These healthcare laws and regulations include, for example:

•
the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from soliciting, receiving, offering or providing remuneration, directly or indirectly, in return for or to induce either the referral of an individual for, or the purchase order or recommendation of, any item or services for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs;

19



•
U.S. federal false claims laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent. In addition, the U.S. federal government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes;

•
the U.S. Physician Payment Sunshine Act, which requires certain manufacturers of drugs, biologics, devices and medical supplies to record any transfers of value to U.S. physicians and U.S. teaching hospitals;

•
the Health Insurance Portability and Accountability Act ("HIPAA"), as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; and

•
state or foreign law equivalents of each of the U.S. federal laws above, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers.

These laws will continue to impose administrative, cost and compliance burdens on us. The shifting compliance environment and the need to build and maintain robust systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may violate one or more of these requirements. In addition, any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business, results of operations and financial condition.

Regulations related to “conflict minerals” could adversely impact our business.
As part of the Dodd-Frank Wall Street Reform and Consumer Protection Act, the SEC adopted disclosure requirements regarding the use of certain minerals, known as conflict minerals, which are mined from the Democratic Republic of Congo (DRC) and adjoining countries, as well as procedures regarding a manufacturer's efforts to identify the sourcing of such minerals and metals produced from those minerals. In March and April 2017, the European Parliament and the European Council formally approved a conflict minerals regulation, and the requirements will become effective starting in January 2021. We have incurred, and will continue to incur, additional costs in order to comply with the SEC’s disclosure requirements. In addition, we might incur further costs due to possible changes to our products, processes, or sources of supply as a consequence of our due diligence activities. As our supply chain is complex, we may not be able to sufficiently verify the origins of the specified minerals used in our products through our due diligence procedures, which may harm our reputation. In addition, we may encounter challenges to satisfy those customers who require that all of the components of our products be certified as “DRC conflict free”, which could place us at a competitive disadvantage if we do not do so. We filed our report for the calendar year 2017 with the SEC on May 4, 2018.

20



Risks related to our common stock
 
A significant majority of our voting stock is held by the Schwartz family, which could lead to conflicts of interest.
We have two classes of voting stock: Class A Common Stock and Class B Common Stock. With a few exceptions, holders of Class A and Class B Common Stock vote as a single class.  When voting as a single class, each share of Class A Common Stock is entitled to one-tenth of a vote, while each share of Class B Common Stock has one vote. In the election or removal of directors, the classes vote separately and the holders of Class A Common Stock are entitled to elect 25% of the Board of Directors, with holders of Class B Common Stock electing the remaining directors.

As a result of the Schwartz family's ownership of our Class A and Class B Common Stock, they are able to elect a majority of our directors, effect fundamental changes in our direction and control matters affecting us, including the determination of business opportunities that may be suitable for our company.  The Schwartz family may exercise its control over us according to interests that are different from other investors’ or debtors’ interests. In particular, this concentration of ownership and voting power may have the effect of delaying or preventing a change in control of our company.



ITEM 1B.  UNRESOLVED STAFF COMMENTS
None.


21



 
ITEM 2.  PROPERTIES

We own our corporate headquarters located in Hercules, California.  The principal manufacturing and research locations for each segment are as follows:

 
 
 
Segment
Location
Owned/Leased
 
 
 
Life Science
Greater San Francisco Bay Area, California
Owned/Leased
 
Singapore, Singapore
Leased
 
Oxford, England
Leased
 
 
 
Clinical
 
 
Diagnostics
Greater San Francisco Bay Area, California
Owned/Leased
 
Irvine, California
Leased
 
Greater Seattle Area, Washington
Leased
 
Lille, France
Owned
 
Greater Paris Area, France
Leased
 
Nazareth-Eke, Belgium
Leased
 
Cressier, Switzerland
Owned/Leased
 
Dreieich, Germany
Owned/Leased

Most manufacturing and research facilities also house administration, sales and distribution activities.  In addition, we lease office and warehouse facilities in a variety of locations around the world.  The facilities are used principally for sales, service, distribution and administration for both segments.

ITEM 3.  LEGAL PROCEEDINGS  

On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015, we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million, plus prejudgment interest of $141,608, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We have provided for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017, we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit. Oral arguments occurred on November 14, 2018. On February 26, 2019, the United States Court of Appeals for the Ninth Circuit issued its decision, reversing in part,

22


vacating in part, and affirming in part. Specifically, the court: (1) reversed the Dodd-Frank claim, which amounts to about $2.96 million plus interest, and directed the district court to enter judgment in Bio-Rad’s favor on that claim; (2) vacated the SOX claim due to instructional error and remanded for further proceedings, including whether a new trial is needed; and (3) affirmed the California public policy claim and the $7.96 million in damages attributable to it. On March 12, 2019 we filed a petition for panel rehearing or rehearing en banc with the United States Court of Appeals for the Ninth Circuit.

We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.

 
ITEM 4.  MINE SAFETY DISCLOSURES  

Not applicable.

PART II.


ITEM 5.   MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER
MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Information Concerning Common Stock

Bio-Rad’s Class A and Class B Common Stock are listed on the New York Stock Exchange with the ticker symbols BIO and BIO.B, respectively.

On March 26, 2019, we had 233 holders of record of Class A Common Stock and 111 holders of record of Class B Common Stock.  Bio-Rad has never paid a cash dividend and has no present plans to pay cash dividends.

In November, 2017, the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to $250.0 million of outstanding shares of our common stock. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. This new authorization superseded the prior authorization of up to $18.0 million of Bio-Rad's common stock and has no expiration.

The following table contains information on the shares of our common stock that we purchased or otherwise acquired during the three months ended December 31, 2018, as required by the Securities and Exchange Commission rules. These were the only repurchases of our shares during 2018.


23


Period
Total Number of Shares Purchased
Average Price Paid per Share
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
Maximum Number (or Approximate Dollar Value) of Shares that May yet be Purchased Under the Plans or Programs (in millions)
October 1 to October 31, 2018
—

 
$
—

—

 
$
250.0

November 1 to November 30, 2018
178,911

Class A
$
273.39

178,911

Class A
$
201.1

December 1 to December 31, 2018
—

 
$
—

—

 
$
201.1



See Item 12 of Part III of this report for the security ownership of certain beneficial owners and management and for securities authorized for issuance under equity compensation plans.

Stock Performance Graph

The following graph compares the cumulative stockholder returns over the past five years for our Class A Common Stock, the S&P 400 MidCap Index and a selected peer group, assuming $100 invested on December 31, 2013, and reinvestment of dividends if paid:             
    
    chart-fb6cb6843e3154ef808.jpg        
(1)  The Peer Group consists of the following public companies: Danaher, Becton Dickinson, Thermo Fisher Scientific, Meridian Bioscience and PerkinElmer. Companies in our peer group reflect our participation in two different markets: life science research products and clinical diagnostics. No single public or private company has a comparable mix of products which serve the same markets. In many cases, only one division of a peer-group company competes in the same market as we do. Collectively, however, our peer group reflects products and markets similar to those of Bio-Rad.

This stock performance graph shall not be deemed incorporated by reference by any general statement incorporating by reference into any filing under the Securities Act or the Exchange Act, and shall not otherwise be deemed filed under these Acts.

24




ITEM 6.  SELECTED FINANCIAL DATA

BIO-RAD LABORATORIES, INC.
 
 
 
 
 
 
Selected Financial Data
 
 
 
 
 
 
(In thousands, except per share data)
 
 
 
 
 
 
 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
 
2015
 
2014
 
 
 
 
 
 
 
 
 
 
 
Net sales
 
$
2,289,415

 
$
2,160,153

 
$
2,068,172

 
$
2,019,441

 
$
2,175,044

Cost of goods sold
 
1,066,264

 
972,450

 
929,744

 
897,771

 
996,527

Gross profit
 
1,223,151

 
1,187,703

 
1,138,428

 
1,121,670

 
1,178,517

Selling, general and administrative expense
 
834,783

 
806,790

 
814,697

 
761,990

 
808,200

Research and development expense
 
199,196

 
250,157

 
205,708

 
192,972

 
220,333

Impairment losses on goodwill and long-lived assets
 
292,513

 
11,506

 
62,305

 
—

 
—

Interest expense
 
23,962

 
23,014

 
23,380

 
21,692

 
22,131

Foreign currency exchange losses, net
 
2,861

 
9,128

 
4,542

 
10,249

 
9,305

Change in fair market value of equity securities
 
(606,230
)
 
—

 
—

 
—

 
—

Other (income) expense, net
 
(36,593
)
 
(10,697
)
 
(13,764
)
 
(11,080
)
 
(13,009
)
Income before income taxes
 
512,659

 
97,805

 
41,560

 
145,847

 
131,557

(Provision for) benefit from income taxes
 
(147,045
)
 
24,444

 
(15,560
)
 
(36,608
)
 
(42,712
)
Net income
 
$
365,614

 
$
122,249

 
$
26,000

 
$
109,239

 
$
88,845

 
 
 
 
 
 
 
 
 
 
 
Basic earnings per share
 
$
12.25

 
$
4.12

 
$
0.88

 
$
3.74

 
$
3.08

Diluted earnings per share
 
$
12.10

 
$
4.07

 
$
0.88

 
$
3.71

 
$
3.05

Cash dividends paid per common share
 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

Total assets
 
$
5,611,068

 
$
4,273,012

 
$
3,850,504

 
$
3,709,718

 
$
3,341,278

Long-term debt, net of current maturities
 
$
438,937

 
$
434,581

 
$
434,186

 
$
433,883

 
$
435,710



25



ITEM 7.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This discussion should be read in conjunction with the information contained in our consolidated financial statements and the accompanying notes which are an integral part of the statements.

Overview.  We are a multinational manufacturer and worldwide distributor of our own life science research and clinical diagnostics products.  Our business is organized into two primary segments, Life Science and Clinical Diagnostics, with the mission to provide scientists with specialized tools needed for biological research and clinical diagnostics.  

We sell more than 9,000 products and services to a diverse client base comprised of scientific research, healthcare, education and government customers worldwide. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.

We manufacture and supply our customers with a range of reagents, apparatus and equipment to separate complex chemical and biological materials and to identify, analyze and purify components.  Because our customers require standardization for their experiments and test results, much of our revenues are recurring.  

We are impacted by the support of many governments for both research and healthcare. The current global economic outlook is still uncertain as the need to control government social spending by many governments limits opportunities for growth. Adding to this uncertainty was the referendum in the United Kingdom to withdraw from the European Union, and a change in the U.S. executive branch of government. Approximately 38% of our 2018 consolidated net sales are derived from the United States and approximately 62% are derived from international locations, with Europe being our largest international region.  The international sales are largely denominated in local currencies such as the Euro, Swiss Franc, Japanese Yen, Chinese Yuan and British Sterling. As a result, our consolidated net sales expressed in dollars benefit when the U.S. dollar weakens and suffer when the dollar strengthens.  When the U.S. dollar strengthens, we benefit from lower cost of sales from our own international manufacturing sites as well as non-U.S. suppliers, and from lower international operating expenses. We regularly discuss our changes in revenue and expense categories in terms of both changing foreign exchange rates and in terms of a currency neutral basis, if notable, to explain the impact currency has on our results.

Impairment losses on goodwill and long-lived assets

In 2018, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A., 2007 through 2012 acquisitions of DiaMed Holding AG, DiaMed Fennica Oy, DiaMed (G.B.) Limited, and DiaMed Benelux (collectively DiaMed), 2010 acquisition of Biotest AG, and 2013 acquisition of AbD Serotec in the amounts of $18.1 million, $247.2 million, $10.8 million and $5.9 million, respectively. Goodwill for DiaMed, Biotest AG and AbD Serotec was fully impaired at December 31, 2018.

In 2018, we impaired developed product technology and fully impaired covenants not to compete in the amounts of $8.8 million and $1.7 million, respectively, associated with our 2012 acquisition of a cell sorting system from Propel Labs, Inc.

In 2017, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A. and with our 2013 acquisition of AbD Serotec in the amounts of $2.8 million and $8.7 million, respectively.

In 2016, we fully impaired goodwill and in-process research and development in the amounts of $13.5 million and $46.4 million, respectively, associated with the 2014 acquisition of GnuBIO, Inc. Also in 2016, we impaired an intellectual property license associated with a research and development project for $2.4 million.


26


Restructuring Costs for Termination of a Diagnostics Research and Development Project and Facility Closures

In December 2018, we announced the closure of a small manufacturing facility outside Paris, France. We recorded restructuring charges related to severance and employee benefits of $3.9 million and exit costs of $0.2 million for the year ended December 31, 2018.

In June 2018, we announced the closure of a small manufacturing operation in Munich, Germany. We recorded $1.7 million of expense in restructuring charges related to severance and employee benefits for the year ended December 31, 2018.

In December 2017, we announced the termination of a diagnostics research and development project in Europe. We recorded restructuring charges and adjustments related to severance and employee benefits of $0.4 million and $11.0 million, and asset write-offs and exit costs of $(0.1) million and $10.1 million for the years ended December 31, 2018 and 2017, respectively.

Restructuring charges for the termination of a diagnostics research and development project and the facility closures are all included in our Clinical Diagnostics segment's results of operations. The facility closures are a natural evolution from the larger consolidations that began with the 2016 European reorganization activities described below. The amounts recorded were reflected in Cost of goods sold of $5.4 million and $2.3 million, in Selling, general and administrative expense of $0.4 million and $3.3 million, and in Research and development expense of $0.3 million and $15.5 million in the Consolidated Statements of Income for the years ended December 31, 2018 and 2017, respectively. The liability of $11.5 million as of December 31, 2018 consisted of $7.3 million recorded in Accrued payroll and employee benefits, and $4.2 million recorded in Other long-term liabilities in the Consolidated Balance Sheets.

Restructuring Costs for GnuBIO, Inc.

In September 2017, we announced that we were closing the GnuBIO research program facilities in Massachusetts. We recorded restructuring charges in September 2017 related to severance and employee benefits of $2.9 million and asset write-offs of $5.5 million. The amounts recorded were reflected in Selling, general and administrative expense of $0.8 million and in Research and development expense of $7.6 million in the Consolidated Statements of Income for the year ended December 31, 2017. The liability balance as of December 31, 2017 was $1.4 million and was recorded in Accrued payroll and employee benefits in the Consolidated Balance Sheets. The liability was paid in early 2018.

Restructuring Costs for European Reorganization

In May 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance enterprise resource planning ("ERP") platform, are expected to be incurred through 2019. We recorded approximately $(0.2) million, $0.5 million and $12.5 million in restructuring charges and adjustments related to severance and other employee benefits for the years ended December 31, 2018, 2017 and 2016, respectively. From May 2016 to December 31, 2018, total expenses were $12.8 million. The liability of $1.6 million as of December 31, 2018 was recorded in Accrued payroll and employee benefits in the Consolidated Balance Sheets. The amounts recorded were reflected in Cost of goods sold of $(0.1) million, $(0.2) million and $2.1 million, and in Selling, general and administrative expense of $(0.1) million, $0.7 million and $10.4 million in the Consolidated Statements of Income for the years ended December 31, 2018, 2017 and 2016, respectively. The amounts adjusted were primarily for additional positions identified for elimination, partially offset by employees finding other positions within Bio-Rad or leaving prematurely.

27



Acquisition of RainDance Technologies, Inc.
In February 2017, we acquired all the issued and outstanding stock of RainDance Technologies, Inc. (RainDance) for approximately $72.7 million. Cash payments at closing were $72.9 million. In addition, we had a cash payment of $10.0 million for a preexisting condition concurrent with the acquisition that was recorded in Cost of goods sold. The acquisition was included in our Life Science segment’s results of operations from the acquisition date and was accounted for as a business combination. RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy. We believe that RainDance's droplet-based solutions will extend our reach into next-generation sequencing applications and strengthen our position in the area of Droplet Digital™ PCR, offering customers solutions for a wide range of nucleic acid detection applications.
The final allocation for the payments of $72.9 million was $37.6 million to definite-lived intangibles, $0.2 million to acquired net assets, $26.2 million to goodwill, a deferred tax liability of $13.6 million primarily related to the purchased intangibles and a deferred tax asset of $22.5 million primarily related to the acquired net operating losses.

Critical Accounting Policies and Estimates

The accompanying discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (GAAP).  The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and contingencies as of the date of the financial statements and reported amounts of revenues and expenses during the reporting periods.  We evaluate our estimates on an on-going basis.  We base our estimates on historical experience and on other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. However, future events may cause us to change our assumptions and estimates, which may require adjustment. Actual results could differ from these estimates. We have determined that for the periods reported in this Annual Report on Form 10-K the following accounting policies and estimates are critical in understanding our financial condition and results of operations.

Accounting for Income Taxes.  Management is required to make estimates related to our income tax provision in each of the jurisdictions in which we operate.  This process involves estimating our current tax exposures, as well as making judgments regarding the recoverability of deferred tax assets in each jurisdiction. Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Management assesses the likelihood that the deferred tax assets will be recovered from future taxable income and to the extent management believes that recovery is not likely, a valuation allowance must be established.  To the extent management establishes a valuation allowance or increases this allowance in a period, an increase to expense within the Provision for income taxes in the Consolidated Statements of Income may result.

As of December 31, 2018 and 2017, we recorded a valuation allowance of $70.8 million and $66.4 million, respectively, due to uncertainties related to our ability to utilize some of the deferred tax assets, primarily consisting of certain foreign net operating losses carried forward and certain state research and development credits.  The valuation allowance is based on management’s current estimates of taxable income for the jurisdictions in which we operate and the period over which the deferred tax assets will be recoverable.  In the event that actual results differ from these estimates, or these estimates are adjusted in future periods, an additional valuation allowance may need to be established, which would increase the tax provision, lowering income and impacting our financial position.

28


Should realization of these deferred tax assets for which a valuation allowance has been provided occur, the provision for income taxes may decrease, raising income and positively impacting Bio-Rad’s financial position.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in income tax expense. Our overall effective tax rate is subject to fluctuations because of changes in the geographic mix of earnings, changes to statutory tax rates and tax laws, and because of the impact of various tax audits and assessments, as well as generation of tax credits.

On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The new legislation contains significant tax provisions that affect us, including a one-time mandatory deemed repatriation tax on certain unrepatriated foreign earnings ("Transition Tax"), a reduction of the corporate income tax rate from 35% to 21% effective January 1, 2018, and a change from a worldwide tax system to a modified territorial system.

We are required to recognize the effect of the tax law changes in the period of enactment, such as the computation of the Transition Tax, remeasurement of our U.S. deferred tax assets and liabilities, as well as reassessment of the net realizability of our deferred tax assets and liabilities.

Subsequent to the enactment of the Tax Act, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act ("SAB 118"), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under Accounting Standards Codification ("ASC") 740, "Income Taxes." We have completed the accounting for the income tax effects of the Tax Act, under SAB 118, as of December 31, 2018. As noted in our 2017 Annual Report, we were able to make reasonable estimates and provisionally recorded an income tax benefit of $70 million related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. The final accounting for the Tax Act resulted in an additional income tax benefit of $49 million for a final income tax benefit of $119 million. This is comprised of $169 million tax benefit related to the remeasurement of U.S. federal deferred tax assets and liabilities, offset by $50 million tax detriment for the Transition Tax. We elected to account for the tax effect of the Global Intangible Low-Taxed Income (“GILTI”) in the period in which it is incurred.

Valuation of Business Acquisitions, Goodwill and Long-lived Assets.  Upon the consummation of a business combination, we use multiple analyses to determine the fair market value of the consideration of assets acquired and liabilities assumed. Once the fair market value of the acquired business is determined, any residual value between fair market value and the consideration is defined as goodwill.

Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses, which could include contingent consideration. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interest to the former owners of an acquiree as part of the exchange for control of the acquiree if specified future events occur or conditions are met. Contingent consideration is reported at fair value each reporting period until the contingency is resolved. Any changes in fair value are recognized in earnings, which could become volatile over time depending on the facts and circumstances.

29



Goodwill amounts are assigned to reporting units at the time of acquisition and are adjusted for any subsequent significant transfers of business between reporting units. We assess the impairment of goodwill annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. We perform the impairment tests of goodwill at our reporting unit level, which is one level below our operating segments. On January 1, 2017, we adopted Accounting Standards Update 2017-04, "Simplifying the Test for Goodwill Impairment," in which a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill.

We use a projected discounted cash flow model to determine the fair value of a reporting unit. This discounted cash flow method for determining goodwill may be different from the fair value that would result from an actual transaction between a willing buyer and a willing seller. Projections such as discounted cash flow models are inherently uncertain and accordingly, actual future cash flows may differ materially from projected cash flows. Management judgment is required in developing the assumptions for the discounted cash flow model. These assumptions include revenue growth rates, profit margins, future capital expenditures, working capital needs, expected foreign currency rates, discount rates and terminal values. We estimate future cash flows using current and longer-term financial forecasts. These forecasts take into account the current economic environment. The discount rates used are compiled using independent sources, current trends in similar businesses and other observable market data. Changes to these rates might result in material changes in the valuation and determination of the recoverability of goodwill. For example, an increase in the discount rate used to discount cash flows will decrease the computed fair value.

Impairment tests are highly sensitive to changes in assumptions and minor changes to assumptions could result in impairment losses. Our forecasts utilized in our 2018 impairment test assumed, among other things, sales growth from executing our sales and marketing programs, new product introductions, successful product development and timely registration of our products when required, while controlling costs to manufacture and service our equipment at the customer site. In addition, external factors, such as competitive pricing in the market, currency, inflation rates, cost of capital, and forecasted tax rates could affect the determination of fair value of our reporting units. Aside from our Pasteur Sanofi Diagnostics S.A., DiaMed Holding AG, Biotest AG, and AbD Serotec reporting units, which reflected a carrying value that exceeded its fair value, our impairment tests resulted in excessive fair value over book value ranging from 13% to more than 400% for our various reporting units. One reporting unit, which consists of our 2001 acquisition of Helix Inc., had excess fair value over book value of only 13% at December 31, 2018. Goodwill in the amount of $1.4 million is allocated to this reporting unit at December 31, 2018. If the initiatives mentioned above do not achieve the desired results, or external factors change detrimentally, future impairment losses may occur.

To validate the reasonableness of the reporting unit fair values, we reconcile the aggregate fair values of the reporting units to the enterprise market capitalization. In performing the reconciliation we may, depending on the volatility of the market value of our stock price, use either the stock price on the valuation date or the average stock price over a range of dates around the valuation date.

For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. We assess the impairment of long-lived assets (including identifiable intangibles) whenever events or changes in circumstances indicate that the carrying value may not be recoverable. In addition to the required quantitative review, we also review quarterly qualitative factors that we consider important, which could trigger an impairment review and include:

30



•
significant reporting unit under-performance relative to expected, historical or projected future operating results;
•
significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;
•
a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of before the end of its previously estimated useful life; and
•
significant negative industry, legal, regulatory or economic trends.

When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method. Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets. We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If this is the case, an impairment loss would be recognized. The impairment loss recognized is the amount by which the carrying amount exceeds the fair value.

In 2018, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A., 2007 through 2012 acquisitions of DiaMed Holding AG, DiaMed Fennica Oy, DiaMed (G.B.) Limited, and DiaMed Benelux (collectively DiaMed), 2010 acquisition of Biotest AG, and 2013 acquisition of AbD Serotec in the amounts of $18.1 million, $247.2 million, $10.8 million and $5.9 million, respectively. Goodwill for DiaMed, Biotest AG and AbD Serotec was fully impaired at December 31, 2018. In 2018, we impaired developed product technology and fully impaired covenants not to compete in the amounts of $8.8 million and $1.7 million, respectively, associated with our 2012 acquisition of a cell sorting system from Propel Labs, Inc.

In 2017, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A. and with our 2013 acquisition of AbD Serotec in the amounts of $2.8 million and $8.7 million, respectively.

In 2016, we fully impaired goodwill and in-process research and development in the amounts of $13.5 million and $46.4 million, respectively, associated with our 2014 acquisition of GnuBIO, Inc.

All the impairments above were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows.

Also in 2016, we impaired intellectual property in the amount of $2.4 million associated with the termination of a research and development project.

Valuation of Inventories.   We value inventory at the lower of the actual cost to purchase and/or manufacture the inventory, or the current estimated net realizable value of the inventory.  We review inventory quantities on hand and reduce the cost basis of excess and obsolete inventory based primarily on an estimated forecast of product demand, production requirements and the quality, efficacy and potency of raw materials.  This review is done on a quarterly basis or, if warranted by the circumstances, more frequently.  In addition, our industry is characterized by technological change, frequent new product development and product obsolescence that could result in an increase in the amount of obsolete inventory quantities on hand.  Our estimates of future product demand may prove to be inaccurate, and if too high, we may have overstated the carrying value of our inventory. In the future, if inventory is determined to be overvalued, we would be required to write down the value of inventory to market and recognize such costs in our cost of goods sold at the time of such determination.  Therefore, although we make efforts to ensure the accuracy of our forecasts of future product demand and perform procedures to safeguard overall inventory quality, any significant unanticipated changes in demand, technological developments, regulations, storage conditions, or other economic or environmental factors affecting biological materials, could have a significant impact on the value of our inventory and reported results of operations.



31





Results of Operations - Sales, Gross Margins and Expenses

The following shows cost of goods sold, gross profit, expense items and net income as a percentage of net sales:

 
Year Ended December 31,
 
 
2018
 
2017
 
2016
 
Net sales
100.0
%
 
100.0
%
 
100.0
%
 
Cost of goods sold
46.6

 
45.0

 
45.0

 
Gross profit
53.4

 
55.0

 
55.0

 
Selling, general and administrative expense
36.5

 
37.3

 
39.4

 
Research and development expense
8.7

 
11.6

 
9.9

 
Net income
16.0

 
5.7

 
1.3

 

Net sales

Net sales (sales) in 2018 were $2.29 billion, an increase of 6.0% compared to $2.16 billion in 2017. Excluding the impact of foreign currency exchange rate fluctuations, 2018 sales increased by approximately 5.0% compared to 2017. Currency neutral sales increased in all regions, with a slight increase in Europe. On January 1, 2018, we adopted FASB Accounting Standards Codification ("ASC") 606, “Revenue from Contracts with Customers,” using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018 (see Note 1 to the consolidated financial statements). The impact to revenue as a result of applying ASC 606 for 2018 was not significant.

The Life Science segment sales in 2018 were $861.7 million, an increase of 9.7% compared to 2017.  On a currency neutral basis, sales increased 8.9% compared to 2017. The currency neutral sales increase was primarily in our Droplet Digital™ PCR, process chromatography, Real Time amplification systems, food science, cell biology, and antibody businesses. The currency neutral sales increase was primarily reflected in North America, Europe, Brazil within Latin America, and all countries within Asia Pacific except Japan.

The Clinical Diagnostics segment sales in 2018 were $1.41 billion, an increase of 3.7% compared to 2017. On a currency neutral basis, sales increased 2.6% compared to 2017. The currency neutral sales increase was primarily attributable to growth across quality control, immunology, blood typing product lines, including the resolution of a claim relating to a licensed patent of $6.0 million in the first quarter of 2018. On a geographic view, currency neutral sales for the year were up in the Americas and Asia Pacific, partially offset by decreased sales in Europe primarily due to pricing pressure on product renewals, loss of a few customers and timing on several Middle Eastern customer orders.
 
Net sales (sales) in 2017 were $2.16 billion, an increase of 4.4% compared to $2.07 billion in 2016. Excluding the impact of foreign currency exchange rate fluctuations, 2017 sales increased by approximately 3.5% compared to 2016. Currency neutral sales growth was reflected in most regions.

The Life Science segment sales in 2017 were $785.2 million, an increase of 7.5% compared to 2016.  On a currency neutral basis, sales increased 6.8% compared to 2016. The currency neutral sales increase was primarily driven by growth in our Droplet Digital™ PCR and gene expression product lines, in addition to sales from our acquisition of RainDance in 2017. The currency neutral sales increase was primarily reflected in all regions except Latin America mostly due to government imposed spend control.

32



The Clinical Diagnostics segment sales in 2017 were $1.36 billion, an increase of 2.8% compared to 2016. On a currency neutral basis, sales increased 1.6% compared to 2016. The currency neutral sales increase was primarily attributable to growth across quality control, immunohematology, diabetes and immunology, partially offset by lower sales in infectious disease. On a geographic view, the currency neutral sales increases for 2017 were primarily reflected in Asia Pacific, excluding Japan, and Latin America, partially offset by lower sales in North America and Japan.

Gross margin

Consolidated gross margins were 53.4% in 2018 compared to 55.0% in 2017. Life Science segment gross margins in 2018 increased when compared to 2017 by approximately 1.2 percentage points primarily due to a $10.0 million one-time expense associated with the RainDance acquisition in 2017 and lower intangible amortization within digital biology that was partially offset by an increase for royalty amortization within gene expression. In addition in 2017, gross margins were impacted by legal matters that reduced 2017 cost of goods sold by approximately $10.4 million. Clinical Diagnostics segment gross margins in 2018 decreased by approximately 2.9 percentage points compared to 2017 and were primarily driven by product mix and competitive pricing pressures, impacting particularly equipment that consumes reagents for diagnostic testing.  Other factors were $18.6 million of higher costs for excess and expired inventory and on-site service, as well as $5.4 million of expenses associated with the closing of a small manufacturing operation in Munich, Germany and a small manufacturing facility outside Paris, France.  The decrease in gross margins was partially offset by $6.0M of royalties generated by a license resolution on a patent owned by Bio-Rad. 

Consolidated gross margins were 55.0% in 2017 compared to 55.0% in 2016. Life Science segment gross margins in 2017 increased from 2016 by approximately 1.2 percentage points primarily due to higher margins in gene expression and digital biology businesses largely due to a decline in royalty expense for license agreements relating to amplification reagents. In addition, gross margins were impacted by legal matters that reduced cost of goods sold by approximately $10.4 million. These gross margin improvements were partially offset by $10.0 million for a preexisting condition and higher acquisition intangible amortization, both associated with the RainDance acquisition. Clinical Diagnostics segment gross margins in 2017 decreased by approximately 0.8 percentage points compared to 2016 primarily due to lower margin sales and the termination of an infectious disease research and development project that effected cost of goods sold at a cost of $2.3 million in 2017, partially offset by lower amortization of intangibles, licenses fees and favorable manufacturing variances as compared to 2016.

Selling, general and administrative expense

Consolidated selling, general and administrative expenses (SG&A) increased to $834.8 million or 36.5% of sales in 2018 compared to $806.8 million or 37.3% of sales in 2017.  Increases to SG&A primarily were related to professional fees of $14.9 million primarily for legal matters to defend our intellectual property, a lower benefit from the reversal of contingent consideration of $11.9 million, normal increases in employee related expenses of $8.6 million (excluding restructuring costs) and increased bad debt that was occasioned by the failure of a certain distributor in the Middle East. These expenses were partially offset by lower restructuring costs in 2018 of approximately $8.5 million, and equipment savings of $2.0 million primarily due to lower information technology maintenance for hardware and software support.

Consolidated SG&A decreased to $806.8 million or 37.3% of sales in 2017 compared to $814.7 million or 39.4% of sales in 2016.  Decreases to SG&A were primarily due to $21.0 million for various legal matters in 2016 that did not occur in 2017, including the Wadler judgment as discussed further in Note 13 to the consolidated financial statements compared to a few legal matters in 2017 that reduced SG&A by approximately $0.7 million, $10.4 million of restructuring costs associated with the European reorganization announced in June 2016 (see Note 15) that did not occur in 2017 compared to the other restructuring costs in 2017 of approximately $8.5 million that are also in Note 15 in addition to a few other reduction in force activities, lower contingent consideration of $19.7 million, lower third party commissions of $2.5 million and other numerous net costs of $12.1 million. Increases to

33


SG&A primarily included employee-related expenses (excluding restructuring costs) of $17.0 million, facilities of $12.2 million, software of $7.7 million, bad debt expense of $5.4 million, advertising of $3.5 million, other taxes of $3.3 million, travel of $3.0 million and purchase accounting amortization of $1.0 million. Some of these increased costs were associated with the transition that took place to a new European operating model supported by the European ERP implementation, the inclusion of RainDance, closure costs for the GnuBIO research program facilities, and the termination of an infectious disease research and development project that all occurred in 2017.

Research and development expense

Research and development expense decreased to $199.2 million or 8.7% of sales in 2018 compared to $250.2 million or 11.6% of sales in 2017.  Life Science segment research and development expense decreased in 2018 from 2017 primarily due to lower development milestone expenses of $11.7 million, as well as the consolidation of the RainDance research and development. The decrease was partially offset by additional spending for new product development within the Droplet Digital business. Clinical Diagnostics segment research and development expense decreased in 2018 from 2017 as a result of reduced research and development activity.

Research and development expense increased to $250.2 million or 11.6% of sales in 2017 compared to $205.7 million or 9.9% of sales in 2016.  Life Science segment research and development expense increased in 2017 from 2016 primarily due to higher milestone expenses of $5.5 million associated with the 2016 Propel platform acquisition, and increased project activities, which included our recent RainDance acquisition. Clinical Diagnostics segment research and development expense increased in 2017 from 2016 primarily driven by a termination of an infectious disease research and development project of $15.5 million (see Note 15 to the consolidated financial statements), an asset purchase for an early stage diagnostic device for $7.5 million, and closure costs of $7.6 million that included severance and the impairment of equipment and leasehold improvements for the GnuBIO research program, which all occurred in 2017, partially offset by lower spending due to the timing of projects.

Impairment losses on goodwill and long-lived assets

In 2018, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A., 2007 through 2012 acquisitions of DiaMed Holding AG, DiaMed Fennica Oy, DiaMed (G.B.) Limited, and DiaMed Benelux (collectively DiaMed), 2010 acquisition of Biotest AG, and 2013 acquisition of AbD Serotec in the amounts of $18.1 million, $247.2 million, $10.8 million and $5.9 million, respectively. Goodwill for DiaMed, Biotest AG and AbD Serotec was fully impaired at December 31, 2018. Impairments for the Pasteur Sanofi Diagnostics S.A., DiaMed and Biotest AG were included in our Clinical Diagnostics segment's results of operations, and the impairment for AbD Serotec was included in our Life Science segment's results of operations.

In 2018, we impaired developed product technology and fully impaired covenants not to compete in the amounts of $8.8 million and $1.7 million, respectively, associated with our 2012 acquisition of a cell sorting system from Propel Labs, Inc. These impairments were included in our Life Science segment's results of operations.

In 2017, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A. and with our 2013 acquisition of AbD Serotec in the amounts of $2.8 million and $8.7 million, respectively. Impairment for the Pasteur Sanofi Diagnostics S.A. was included in our Clinical Diagnostics segment's results of operations, and the impairment for AbD Serotec was included in our Life Science segment's results of operations.

In 2016, we fully impaired goodwill and in-process research and development in the amounts of $13.5 million and $46.4 million, respectively, associated with our 2014 acquisition of GnuBIO, Inc. Also in 2016, we impaired an intellectual property license associated with a research and development project for $2.4 million. These impairments were included in our Clinical Diagnostics segment's results of operations.

34



Results of Operations – Non-operating

Interest expense

Interest expense in 2018 was $24.0 million, a slight increase compared to 2017 of $23.0 million.

Interest expense in 2017 was $23.0 million, a slight decrease from 2016 of $23.4 million.

Foreign currency exchange gains and losses

Foreign currency exchange gains and losses consist primarily of foreign currency transaction gains and losses on intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts used to manage our foreign currency exchange risk.  Net foreign currency exchange losses for 2018, 2017 and 2016 were $2.9 million, $9.1 million and $4.5 million, respectively.  The 2018, 2017 and 2016 net foreign currency exchange losses were attributable to market volatility, the result of the estimating process inherent in the timing of shipments and payments of intercompany debt, and the intercompany movement of assets and capital for the new European operating model in 2017, and the cost of hedging. All years are affected by the economic hedging program we employ to hedge our intercompany receivables and payables denominated in foreign currencies.

Change in fair market value of equity securities

Change in fair market value of equity securities of $606.2 million for 2018 compared to none for 2017 and 2016 was primarily due to the adoption of ASU 2016-01 (see Note 1 to the consolidated financial statements) and mostly consisted of holding gains on our investment in Sartorius AG.

Other (income) expense, net

Other (income) expense, net includes investment and dividend income, generally interest income on our cash and cash equivalents, short-term investments and long term marketable securities.  Other (income) expense, net in 2018 increased to $36.6 million of income compared to $10.7 million of income in 2017. Other income, net increased primarily due higher dividends of $14.0 million in 2018 compared to $10.9 million in 2017 from our investment in Sartorius AG, higher investment income of approximately $11.9 million, and a land sale of $4.1 million and a divestiture of a product line of $5.1 million that both occurred in the first quarter of 2018.

Other (income) expense, net in 2017 decreased to $10.7 million income compared to $13.8 million income in 2016. The decrease was primarily due to $6.4 million of higher other-than-temporary impairment losses on investments in 2017 than in 2016 in light of continuing declines in the investment market prices and investees' financial conditions at that time, partially offset by $1.2 million of higher dividend income in 2017 than in 2016 on the ordinary and preferred shares of our investment in Sartorius AG, and higher investment income.

Effective tax rate

On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code that affect our 2017 financial statements, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities.

Our effective tax rate was 29%, (25)% and 37% in 2018, 2017 and 2016, respectively. The effective tax rate for 2018 was driven by detriments due to non-deductible impairment charges and the taxation of our foreign operations, partially offset by a $49 million benefit recorded as a result of the completion of our accounting for the Tax Act under SAB 118. The effective tax rate for 2017 was driven by a $70 million benefit recorded as a provisional estimate of the accounting for the Tax Act. The effective tax rate for 2016 included additional tax

35


liabilities for unrecognized tax benefits related to the non-deductibility of interest expense in our foreign jurisdictions. Our effective tax rate may be impacted in the future, either favorably or unfavorably, by many factors including, but not limited to, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits.

Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe the resolution of our uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

As of December 31, 2018, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $3.1 million. Substantially all such amounts will impact our effective income tax rate.
 

Liquidity and Capital Resources

Bio-Rad operates and conducts business globally, primarily through subsidiary companies established in the markets in which we trade.  Goods are manufactured in a small number of locations, and are then shipped to local distribution facilities around the world.  Our product mix is diversified, and certain products compete largely on product efficacy, while others compete on price.  Gross margins are generally sufficient to exceed normal operating costs, and funding for research and development of new products, as well as routine outflows of capital expenditures, interest and taxes.  In addition to the annual positive cash flow from operating activities, additional liquidity is readily available via the sale of short-term investments and access to our domestic $200.0 million unsecured Credit Agreement, and to a lesser extent international lines of credit.  Borrowings under the 2014 Credit Agreement are available on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of December 31, 2018, however, $0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability.  The Credit Agreement matures in June 2019. We are currently evaluating our options on renewing the Credit Agreement or similar arrangements. In total under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had approximately $208.2 million available for borrowing and usage as of December 31, 2018, which was reduced by approximately $3.1 million that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations. Management believes that this availability, together with cash flow from operations, will be adequate to meet our current objectives for operations, research and development, capital additions for manufacturing and distribution, plant and equipment, information technology systems and an acquisition of reasonable proportion to our existing total available capital.
 
At December 31, 2018, we had available $844.8 million in cash, cash equivalents and short-term investments, of which approximately 17% was held in our foreign subsidiaries. We believe that our holdings of cash, cash equivalents and short-term investments in the U.S. and in our foreign subsidiaries are sufficient to meet both the current and long-term needs of our global operations. The amount of funds held in the United States can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business-development activities. As part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and foreign cash flows (both inflows and outflows).


36


It is generally our intention to repatriate certain foreign earnings to the extent that such repatriations are not restricted by local laws or accounting rules, and there are no substantial incremental costs.  During the current year, we recorded approximately $6.7 million of deferred tax liability for the earnings of certain foreign jurisdictions that we may repatriate in the future. The determination of the amount of the unrecognized deferred tax liability for foreign earnings that are indefinitely reinvested is not practicable to estimate.

Demand for our products and services could change more dramatically than in previous years based on activity, funding, reimbursement constraints and support levels from government, universities, hospitals and private industry, including diagnostic laboratories.  The need for certain sovereign nations with large annual deficits to curtail spending, and international trade disputes and increased regulation, could lead to slower growth of, or even a decline in, our business. Sovereign nations either delaying payment for goods and services or renegotiating their debts could impact our liquidity.


Cash Flows from Operations

Net cash provided by operations was $285.5 million, $104.1 million and $216.1 million in 2018, 2017, and 2016, respectively.  The net increase between 2018 and 2017 of $181.4 million primarily resulted from:

•
higher cash received from customers in 2018 primarily due to higher sales, in addition to improving collections subsequent to the ERP implementation in 2017,
•
net proceeds in 2018 compared to net payments in 2017 for forward foreign exchange contracts, and
•
higher investment income received, partially offset by
•
higher cash paid to suppliers in 2018 primarily for inventory build, employee related costs and professional fees, and included in 2017 was a $10.0 payment for the RainDance preexisting condition, and
•
higher income tax payments in 2018 compared to 2017.

The net decrease between 2017 and 2016 of $112.0 million primarily resulted from:

•
more cash paid to suppliers primarily related to increased inventory, higher employee related costs, an asset purchase for an early stage diagnostic device for $7.5 million, $10.0 million for the RainDance preexisting condition, and higher value added taxes in part due to the European reorganization,
•
higher net payments in 2017 compared to 2016 for forward foreign exchange contracts primarily associated with the timing of product shipments, intercompany debt payments, and the intercompany movement of assets and capital for the new European operating model, and
•
lower income tax refunds in 2017 compared to 2016, partially offset by
•
higher cash received from customers in 2017 primarily due to higher sales, partially offset by higher accounts receivable balances due in part to implementation matters associated with the European ERP system, and
•
higher investment income received.

Cash flows from operations during the first quarter have historically had larger payments for royalties, fourth quarter sales commissions to third parties and annual employee bonuses, and we expect this pattern to recur in the first quarter of 2019.

Cash Flows from Investing Activities

Net cash used in investing activities was $187.0 million, $175.6 million and $213.9 million for 2018, 2017 and 2016, respectively. Purchases of marketable securities and investments, net of combined proceeds from sales and maturities, were net purchases of $68.7 million in 2018 compared to net proceeds in 2017 of $17.1 million. Improved cash generated from operations in 2018 generated more purchases of marketable securities and investments. Proceeds from sales and maturities, net of purchases of marketable securities and investments combined were net proceeds of$17.1 million in 2017 compared to net purchases of $58.2 million in 2016.


37


Our investment objective is to maintain liquidity to meet anticipated operational and other corporate requirements in which capital is preserved and increased through investing in low risk, high quality securities with commensurate returns, consistent with our risk tolerance level.

During the first quarter of 2018, we received $7.0 million for a divestiture of a product line. Purchases of intangible assets in 2017 were primarily due to a $3.8 million payment for an acquired technology and know-how to expand our product offerings. Payments for acquisitions, net of cash received, and long-term investments in 2017 and 2016 were primarily due to the following:

•
in February 2017, we acquired all the issued and outstanding stock of RainDance for approximately $72.7 million including certain assumed net liabilities. Cash payments at closing were $72.9 million.
•
in January 2016, we acquired a high performance analytical flow cytometer platform from Propel for total consideration of $32.8 million, which included $9.5 million paid in cash at the closing date and $23.3 million in contingent consideration potentially payable to Propel, after the effects of a calculation revision that were reflected in the fourth quarter of 2016.

We continue to review possible acquisitions, including early stage businesses, to expand both our Life Science and Clinical Diagnostics segments. We routinely meet with the principals or brokers of the subject companies.  However, it is not certain at this time that any of these discussions will advance to completion.

Capital expenditures in 2018 totaled $129.8 million, compared to $111.3 million and $141.4 million in 2017 and 2016, respectively. Capital expenditures represent the addition and replacement of production machinery and research equipment, ongoing manufacturing and facility additions for expansion, regulatory, environmental and compliance. Also included in capital expenditures are investments in business systems and data communication upgrades and enhancements.  All periods include equipment placed with Clinical Diagnostics segment customers who then contract to purchase our reagents for use. Capital expenditures were higher in 2018 than 2017 primarily due to an investment in two office buildings and adjacent land in the greater San Francisco Bay Area, California. Capital expenditures were lower in 2017 than in 2016 as implementation costs were higher in 2016 for the third phase of the ERP platform, which was implemented in April 2017. As we implement the remaining smaller phases of the ERP platform, we expect lower levels of information technology capital expenditures as the majority of the ERP platform has been implemented.

Cash Flows from Financing Activities

Net cash used in financing activities was $48.7 million in 2018, and net cash provided by financing activities was $0.3 million and $9.0 million in 2017 and 2016, respectively. In 2018 and 2017, we repurchased our common stock for $48.9 million and $2.9 million, respectively, under our repurchase programs as described below. In 2018, 2017 and 2016, there were payments of $2.1 million, $3.7 million and $3.5 million, respectively, to Propel Labs' shareholders in contingent consideration for sales milestones that were associated with the acquisitions in 2016 and 2012. Income taxes paid from net share settlement for share-based compensation in 2018, 2017 and 2016 was $8.9 million, $7.3 million and zero, respectively. Proceeds from issuance of our common stock in 2018, 2017 and 2016 were $14.1 million, $14.6 million and $11.3 million, respectively.

We have outstanding Senior Notes of $425.0 million, which are not due until December 2020. We believe the current cash is sufficient to meet normal operating costs, and funding for research and development of new products, as well as routine outflows of capital expenditures, interest and taxes.

In November, 2017, the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to $250.0 million of outstanding shares of our common stock. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. This new authorization superseded the prior authorization of up to $18.0 million of Bio-Rad's common stock and has no expiration. See Note 7 to the consolidated financial statements for the share repurchase activity.


38


Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have had or are reasonably likely to have a current or future material effect on our financial condition, results of operations or liquidity.

Contractual Obligations

The following summarizes certain of our contractual obligations as of December 31, 2018 and the effect such obligations are expected to have on our cash flows in future periods (in millions):

 
 
Payments Due by Period
 
 
 
 
Less
Than
 
1-3
 
3-5
 
More
than
Contractual Obligations
 
Total
 
One Year
 
Years
 
Years
 
5 Years
Long-term debt, including current portion (1)
 
$
440.7

 
$
0.5

 
$
428.3

 
$
2.0

 
$
9.9

Interest payments (1)
 
40.2

 
20.7

 
19.5

 
—

 
—

Operating lease obligations (2)
 
168.8

 
44.4

 
65.2

 
33.7

 
25.5

Purchase obligations (3)
 
12.5

 
6.5

 
5.4

 
0.4

 
0.2

Long-term liabilities (4)
 
110.9

 
5.8

 
22.6

 
5.9

 
76.6

 
 
 
 
 
 
 
 
 
 
 
(1) These amounts represent expected cash payments, including capital lease obligations, which are included in our December 31, 2018 Consolidated Balance Sheet. Our debt is fixed and primarily consists of the 4.875% Notes. See Note 5 of the Consolidated Financial Statements for additional information about our debt.
 
 
 
(2) Operating lease obligations are described in Note 12 of the Consolidated Financial Statements.
 
 
 
(3) Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify all significant terms.  Purchase obligations exclude agreements that are cancelable without penalty.
 
 
 
(4) These amounts primarily represent long-term obligations for other post-retirement benefits mostly due in more than 5 years, and long-term deferred revenue. Excluded from this table are tax liabilities for uncertain tax positions and contingencies in the amount of $36.0 million.  We are not able to reasonably estimate the timing of future cash flows of these tax liabilities, therefore, our income tax obligations are excluded from the table above.  See Note 6 of the Consolidated Financial Statements for additional information about our income taxes.
 
 
 

Recent Accounting Pronouncements Adopted and to be Adopted

See Note 1 to the consolidated financial statements for recent accounting pronouncements adopted and to be adopted.


ITEM 7A.  QUANTITIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Financial Risk Management

The main goal of Bio-Rad’s financial risk management program is to reduce the variance in expected cash flows arising from unexpected foreign exchange rate and interest rate changes.  Financial exposures are managed through operational means and by using various financial instruments, including cash and liquid resources, borrowings, and forward and spot foreign exchange contracts.  No derivative financial instruments are entered into for the purpose of trading or speculation.  Company policy requires that all derivative positions are undertaken to manage the risks arising from underlying business activities.  These derivative transactions do not qualify for hedge accounting treatment.  Derivative instruments used in these transactions are valued at fair value and changes in fair value are included in reported earnings.


39


Foreign Exchange Risk.  We operate and conduct business in many countries and are exposed to movements in foreign currency exchange rates.  We face transactional currency exposures that arise when we enter into transactions denominated in currencies other than U.S. dollars.  Additionally, our consolidated net equity is impacted by the conversion of the net assets of our international subsidiaries for which the functional currency is not the U.S. dollar.

Foreign currency exposures are managed on a centralized basis.  This allows for the netting of natural offsets and lowers transaction costs and net exposures.  Where possible, we seek to manage our foreign exchange risk in part through operational means, including matching same-currency revenues to same-currency costs, and same-currency assets to same-currency liabilities.  Moreover, weakening in one currency can often be offset by strengthening in another currency.  Foreign exchange risk is also managed through the use of forward foreign exchange contracts. Positions are primarily in Euro, Swiss Franc, Japanese Yen, Chinese Yuan and British Sterling. The majority of forward contracts are for periods of 90 days or less. We record the change in value of our foreign currency receivables and payables as a Foreign exchange (gain) loss on our Consolidated Statements of Income along with the change in fair market value of the forward exchange contract used as an economic hedge of those assets or liabilities.

Our forward contract holdings at year-end were analyzed to determine their sensitivity to fluctuations in foreign currency exchange rates.  All other variables were held constant.  Market risk associated with derivative holdings is the potential change in fair value of derivative positions arising from an adverse movement in foreign exchange rates.  A decline of 10% on quoted foreign exchange rates would result in an approximate net-present-value loss of $26 million on our derivative position as of December 31, 2018.  This impact of a change in exchange rates excludes the offset derived from the change in value of the underlying assets and liabilities, which could reduce the adverse effect significantly.

Interest Rate Risk of Debt Instruments.  Bio-Rad centrally manages the short-term cash surpluses and shortfalls of its subsidiaries.  Our holdings of variable rate debt instruments at year-end were analyzed to determine their sensitivity to movements in interest rates.  Due to the relatively small amount of short-term variable rate debt we have outstanding, there would not be a material impact to earnings or cash flows if interest rates moved adversely by 10%.  Our long-term debt consists primarily of fixed-rate instruments, and is thus insulated from interest rate changes.  As of December 31, 2018, the overall interest rate risk associated with our debt was not significant.

40






ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 
 
 
Index to Consolidated Financial Statements
 
 
Page
 
 
 
Reports of Independent Registered Public Accounting Firm
 
42-43

Consolidated Balance Sheets at December 31, 2018 and 2017
 
44-45
Consolidated Statements of Income for each of the three years in the period ended
 
 
December 31, 2018
 
46
Consolidated Statements of Comprehensive Income for each of the three years in the period
 
 
December 31, 2018
 
47
Consolidated Statements of Cash Flows for each of the three years in the period ended
 
 
December 31, 2018
 
48
Consolidated Statements of Changes in Stockholders’ Equity for each of the three years
 
 
in the period ended December 31, 2018
 
49
Notes to Consolidated Financial Statements
 
50-90
 
 
 



41


Report of Independent Registered Public Accounting Firm
To the Stockholders and Board of Directors
Bio-Rad Laboratories, Inc.:
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of Bio-Rad Laboratories, Inc. and subsidiaries (the Company) as of December 31, 2018 and 2017, the related consolidated statements of income, comprehensive income, changes in stockholders’ equity, and cash flows for each of the years in the three‑year period ended December 31, 2018, and the related notes and financial statement schedule (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2018, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated March 29, 2019 expressed an unqualified opinion on the effectiveness of the Company's internal control over financial reporting.
 
Changes in Accounting Principle
As discussed in note 1 to the consolidated financial statements, the Company has changed its method of accounting for revenue from contracts with customers effective January 1, 2018, due to the adoption of Accounting Standards Codification 606 (ASC 606), Revenue from Contracts with Customers. The Company has also changed its method of accounting for equity instruments effective January 1, 2018 due to the adoption of Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities.

Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ KPMG LLP
We have served as the Company's auditor since 2013.
 
Santa Clara, California
March 29, 2019

42


Report of Independent Registered Public Accounting Firm
To the Stockholders and Board of Directors
Bio‑Rad Laboratories, Inc.:

Opinion on Internal Control Over Financial Reporting
We have audited Bio-Rad Laboratories, Inc. and subsidiaries' (the Company) internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2018 and 2017, the related consolidated statements of income, comprehensive income, changes in stockholders' equity, and cash flows for each of the years in the three-year period ended December 31, 2018, and the related notes and financial statement schedule (collectively, the consolidated financial statements), and our report dated March 29, 2019 expressed an unqualified opinion on those consolidated financial statements.
Basis for Opinion
The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ KPMG LLP
Santa Clara, California
March 29, 2019

43




BIO-RAD LABORATORIES, INC.
Consolidated Balance Sheets
(In thousands, except share data)
 
December 31,
 
2018
 
2017
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
431,526

 
$
383,824

Short-term investments
413,270

 
371,154

Restricted investments
5,560

 
5,560

Accounts receivable, less allowance for doubtful accounts of $26,713 at 2018 and $25,549 at 2017
392,443

 
464,847

 
 
 
 
Inventories:
 
 
 
Raw materials
108,008

 
113,925

Work in process
145,051

 
142,589

Finished goods
330,756

 
338,290

Total inventories
583,815

 
594,804

 
 
 
 
Prepaid expenses
187,249

 
146,135

Other current assets
9,615

 
10,325

Total current assets
2,023,478

 
1,976,649

 
 
 
 
Property, plant and equipment:
 
 
 
   Land and improvements
25,185

 
18,026

   Buildings and leasehold improvements
331,563

 
315,984

   Equipment
970,081

 
971,140

     Total property, plant and equipment
1,326,829

 
1,305,150

Less: accumulated depreciation and amortization
(818,139
)
 
(811,654
)
Property, plant and equipment, net
508,690

 
493,496

 
 
 
 
Goodwill, net
219,770

 
506,069

Purchased intangibles, net
133,123

 
174,113

Other investments
2,655,709

 
1,027,736

Other assets
70,298

 
94,949

Total assets
$
5,611,068

 
$
4,273,012

 
 
 
 

The accompanying notes are an integral part of these consolidated financial statements.

 44



BIO-RAD LABORATORIES, INC.
Consolidated Balance Sheets
(continued)
(In thousands, except share data)

 
December 31,
 
2018
 
2017
LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
  Accounts payable
$
122,450

 
$
135,182

  Accrued payroll and employee benefits
143,510

 
171,632

  Current maturities of long-term debt
493

 
420

  Income taxes payable
27,513

 
19,802

  Other taxes payable
28,675

 
20,139

  Deferred revenue
26,936

 
28,233

  Other current liabilities
101,218

 
127,288

Total current liabilities
450,795

 
502,696

 
 
 
 
Long-term debt, net of current maturities
438,937

 
434,581

Deferred income taxes
553,239

 
222,209

Other long-term liabilities
147,766

 
183,276

Total liabilities
1,590,737

 
1,342,762

 
 
 
 
Commitments and contingent liabilities


 


 
 
 
 
Stockholders’ equity:
 
 
 
Preferred stock, $0.0001 par value, 7,500,000 shares authorized; issued and outstanding - none
—

 
—

  Class A common stock, $0.0001 par value; 80,000,000 shares authorized; shares issued - 24,884,265 and 24,679,127 at 2018 and 2017, respectively; shares outstanding - 24,704,772 and 24,678,545 at 2018 and 2017, respectively
2

 
2

  Class B common stock, $0.0001 par value; 20,000,000 shares authorized; shares issued - 5,096,421 and 5,107,674 at 2018 and 2017, respectively; shares outstanding - 5,095,504 and 5,106,757 at 2018 and 2017, respectively
1

 
1

Additional paid-in capital
394,342

 
361,231

  Class A treasury stock at cost, 179,493 shares at 2018 and 582 shares at 2017
(49,040
)
 
(128
)
  Class B treasury stock at cost, 917 shares at 2018 and 2017
(89
)
 
(89
)
Retained earnings
3,722,073

 
1,830,439

Accumulated other comprehensive (loss) income
(46,958
)
 
738,794

Total stockholders’ equity
4,020,331

 
2,930,250

Total liabilities and stockholders’ equity
$
5,611,068

 
$
4,273,012

 
 
 
 



The accompanying notes are an integral part of these consolidated financial statements.

 45



BIO-RAD LABORATORIES, INC.
Consolidated Statements of Income
(In thousands, except per share data)


 
Year Ended December 31,
 
 
2018
 
2017
 
2016
 
 
 
 
 
 
 
 
Net sales
$
2,289,415

 
$
2,160,153

 
$
2,068,172

 
Cost of goods sold
1,066,264

 
972,450

 
929,744

 
Gross profit
1,223,151

 
1,187,703

 
1,138,428

 
Selling, general and administrative expense
834,783

 
806,790

 
814,697

 
Research and development expense
199,196

 
250,157

 
205,708

 
Impairment losses on goodwill and long-lived assets
292,513

 
11,506

 
62,305

 
(Loss) income from operations
(103,341
)
 
119,250

 
55,718

 
Interest expense
23,962

 
23,014

 
23,380

 
Foreign currency exchange losses, net
2,861

 
9,128

 
4,542

 
Change in fair market value of equity securities
(606,230
)
 
—

 
—

 
Other (income) expense, net
(36,593
)
 
(10,697
)
 
(13,764
)
 
Income before income taxes
512,659

 
97,805

 
41,560

 
(Provision for) benefit from income taxes
(147,045
)
 
24,444

 
(15,560
)
 
Net income
$
365,614

 
$
122,249

 
$
26,000

 
 
 
 
 
 
 
 
Basic earnings per share:
 
 
 
 
 
 
Net income per basic share
$
12.25

 
$
4.12

 
$
0.88

 
Weighted average common shares - basic
29,836

 
29,655

 
29,440

 
 
 
 
 
 
 
 
Diluted earnings per share:
 
 
 
 
 
 
Net income per diluted share
$
12.10

 
$
4.07

 
$
0.88

 
Weighted average common shares - diluted
30,228

 
30,034

 
29,646

 

The accompanying notes are an integral part of these consolidated financial statements. 


46


BIO-RAD LABORATORIES, INC.
Consolidated Statements of Comprehensive Income
(In thousands)


 
Year Ended December 31,
 
2018
 
2017
 
2016
Net income
$
365,614

 
$
122,249

 
$
26,000

Other comprehensive (loss) income:
 
 
 
 
 
Foreign currency translation adjustments
(112,857
)
 
76,050

 
(32,394
)
Foreign other post-employment benefits adjustments, net of income taxes
7,549

 
(3,767
)
 
2,086

Net unrealized holding (losses) gains on available-for-sale (AFS) investments, net of income taxes and effect of adoption of ASU 2018-02*
(1,187
)
 
248,745

 
65,936

Other comprehensive (loss) income, net of income taxes
(106,495
)
 
321,028

 
35,628

Comprehensive income
$
259,119

 
$
443,277

 
$
61,628


*See Note 8, "Accumulated Other Comprehensive Income (Loss)"
Reclassification adjustments are calculated using the specific identification method.
The accompanying notes are an integral part of these consolidated financial statements.



47


BIO-RAD LABORATORIES, INC.
Consolidated Statements of Cash Flows
(In thousands)
 
Year Ended December 31,
 
2018
 
2017
 
2016
Cash flows from operating activities:
 
 
 
 
 
Cash received from customers
$
2,326,310

 
$
2,093,948

 
$
2,074,024

Cash paid to suppliers and employees
(1,989,685
)
 
(1,916,119
)
 
(1,808,687
)
Interest paid, net
(22,703
)
 
(22,224
)
 
(22,756
)
Income tax payments, net
(62,414
)
 
(52,136
)
 
(38,442
)
Investment proceeds and miscellaneous receipts, net
26,383

 
18,392

 
14,597

Excess tax benefits from share-based compensation
—

 
—

 
(1,506
)
Proceeds from (payments for) forward foreign exchange contracts, net
7,603

 
(17,724
)
 
(1,164
)
Net cash provided by operating activities
285,494

 
104,137

 
216,066

Cash flows from investing activities:
 
 
 
 
 
Capital expenditures
(129,825
)
 
(111,332
)
 
(141,436
)
Proceeds from dispositions of property, plant and equipment
4,315

 
86

 
398

Proceeds from divestiture of a product line
6,964

 
—

 
—

Proceeds from (payments for) acquisitions and long-term investment
266

 
(76,645
)
 
(14,165
)
Payments for purchases of intangible assets
(3
)
 
(3,795
)
 
(135
)
Payments for purchases of restricted investment
—

 
(1,000
)
 
(350
)
Payments for purchases of marketable securities and investments
(371,019
)
 
(282,656
)
 
(278,071
)
Proceeds from sales of marketable securities and investments
77,029

 
97,523

 
76,859

Proceeds from maturities of marketable securities and investments
225,295

 
202,247

 
143,020

Net cash used in investing activities
(186,978
)
 
(175,572
)
 
(213,880
)
Cash flows from financing activities:
 
 
 
 
 
Net (payments) borrowings on line-of-credit arrangements and notes payable
—

 
(36
)
 
37

Payments on long-term borrowings
(2,961
)
 
(316
)
 
(303
)
Proceeds from issuances of common stock for share-based compensation
14,133

 
14,604

 
11,280

Tax payments from net share settlement
(8,862
)
 
(7,310
)
 
—

Payments for purchases of treasury stock
(48,912
)
 
(2,920
)
 
—

Payments of contingent consideration
(2,078
)
 
(3,681
)
 
(3,500
)
Excess tax benefits from share-based compensation
—

 
—

 
1,506

Net cash (used in) provided by financing activities
(48,680
)
 
341

 
9,020

Effect of foreign exchange rate changes on cash
(655
)
 
(1,094
)
 
(12,858
)
Net increase (decrease) in cash, cash equivalents and restricted cash
49,181

 
(72,188
)
 
(1,652
)
Cash, cash equivalents and restricted cash at beginning of year
384,983

 
457,171

 
458,823

Cash, cash equivalents and restricted cash at end of year
$
434,164

 
$
384,983

 
$
457,171


The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that agrees to the same amounts shown in the Consolidated Statements of Cash Flows (in thousands):

 
Year Ended December 31,
 
2018
 
2017
 
2016
Cash and cash equivalents
$431,526
 
$383,824
 
$456,264
Restricted cash included in Other current assets
111

 
882

 
494

Restricted cash included in Other assets
2,527

 
277

 
413

Total cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows
$434,164
 
$384,983
 
$457,171
The accompanying notes are an integral part of these consolidated financial statements.

48


BIO-RAD LABORATORIES, INC.
Consolidated Statements of Changes in Stockholders’ Equity
(In thousands)
 
 
Common
Stock
 
Additional Paid-in Capital
 
Treasury Stock
 
Retained
Earnings
 
Accumulated Other Comprehensive Income
 
Total Stockholders' Equity
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2015
 
$
3

 
$
300,408

 
$
(101
)
 
$
1,802,581

 
$
382,138

 
$
2,485,029

Net income
 
—

 
—

 
—

 
26,000

 
—

 
26,000

Other comprehensive loss, net of tax
 
—

 
—

 
—

 
—

 
35,628

 
35,628

Issuance of common stock
 
—

 
11,280

 
—

 
—

 
—

 
11,280

Stock compensation expense
 
—

 
19,730

 
—

 
—

 
—

 
19,730

Tax benefit-exercise stock options
 
—

 
1,493

 
—

 
—

 
—

 
1,493

Balance at December 31, 2016
 
3

 
332,911

 
(101
)
 
1,828,581

 
417,766

 
2,579,160

Net income
 
—

 
—

 
—

 
122,249

 
—

 
122,249

Effect of adoption of ASU 2016-09**
 
—

 
391

 
—

 
(256
)
 
—

 
135

Other comprehensive income, net of tax
 
—

 
—

 
—

 
—

 
200,893

 
200,893

Effect of adoption of ASU 2018-02***
 
—

 
—

 
—

 
(120,135
)
 
120,135

 
—

Issuance of common stock
 
—

 
4,490

 
—

 
—

 
—

 
4,490

Stock compensation expense
 
—

 
23,439

 
—

 
—

 
—

 
23,439

Purchase of treasury stock
 
—

 
—

 
(2,920
)
 
—

 
—

 
(2,920
)
Issuance of treasury stock
 
—

 
—

 
2,804

 
 
 
 
 
2,804

Balance at December 31, 2017
 
3

 
361,231

 
(217
)
 
1,830,439

 
738,794

 
2,930,250

Effect of adoption of ASU 2016-01 and ASU 2018-03*
 
—

 
—

 
—

 
1,543,747

 
(679,257
)
 
864,490

Effect of adoption of ASU 2016-16*
 
—

 
—

 
—

 
(17,591
)
 

 
(17,591
)
Effect of adoption of ASC 606*
 
—

 
—

 
—

 
(136
)
 
—

 
(136
)
Net income
 
—

 
—

 
—

 
365,614

 
—

 
365,614

Other comprehensive loss, net of tax
 
—

 
—

 
—

 
—

 
(106,495
)
 
(106,495
)
Issuance of common stock
 
—

 
5,271

 
—

 
—

 
—

 
5,271

Stock compensation expense
 
—

 
27,840

 
—

 
—

 
—

 
27,840

Purchase of treasury stock
 
—

 
—

 
(48,912
)
 
—

 
—

 
(48,912
)
Balance at December 31, 2018
 
$
3

 
$
394,342

 
$
(49,129
)
 
$
3,722,073

 
$
(46,958
)
 
$
4,020,331


* See Note 1, "Significant Accounting Policies" under "Recent Accounting Pronouncements Adopted"
** See Note 9, "Share-Based Compensation/Equity Award and Purchase Plans" under "Share-Based Compensation"
*** See Note 8, "Accumulated Other Comprehensive Income (Loss)"

The accompanying notes are an integral part of these consolidated financial statements.

49


 
BIO-RAD LABORATORIES, INC.
Notes to Consolidated Financial Statements


1.SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair value.

Short-term Restricted Investments

Short-term restricted investments of $5.6 million at both December 31, 2018 and 2017 represent a money market fund that is renewed annually for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets.

Available-for-Sale Investments

Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities.  Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date.  Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations.  Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data.  Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect.  Effective January 1, 2018, changes in fair value for equity securities are reported in Change in fair market value of equity securities in the Consolidated Statements of Income due to the adoption of ASU 2016-01 (see Recent Accounting Pronouncement Adopted at the end of this Note and Note 3). Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary.  We review our available-for-sale debt securities for other-than-temporary losses on a quarterly basis.  Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10).

50



Concentration of Credit Risk

Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable.  Cash and cash equivalents and investments are placed with various highly rated major financial institutions located in different geographic regions.

The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements.  We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions.  In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end.  

We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral.  As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers.  Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.

Accounts Receivable

We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance.

Inventory

Inventories are valued at the lower of cost and net realizable value and include material, labor and overhead costs. The first-in, first-out method is used to relieve inventory for products sold.

Property, Plant and Equipment

Property, plant and equipment are carried at cost, less accumulated depreciation and amortization.  Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  The estimated useful lives of property, plant and equipment are generally as follows: buildings and leasehold improvements, 15-39 years or the term of the leases or life of the improvements, whichever is shorter; reagent rental equipment, 1-5 years; equipment and capitalized software, 3-12 years.

Goodwill

Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses.  Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating segments.  Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management.  Goodwill amounts are assigned to reporting units at the time of acquisition.

51



Effective January 1, 2017 in accordance with Accounting Standards Update No. 2017-04, "Simplifying the Test for Goodwill Impairment," the goodwill impairment amount will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit.  

Prior to January 1, 2017, the goodwill impairment test consisted of a two-step process.  The first step of the goodwill impairment test, used to identify potential impairment, compared the fair value of a reporting unit to its carrying value, including goodwill. We used a projected discounted cash flow model to determine the fair value of a reporting unit.  If the fair value of the reporting unit exceeded its carrying amount, goodwill of the reporting unit was considered not impaired, and the second step of the impairment test was not required.  The second step, if required, compared the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit was allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit.  If the carrying amount of the reporting unit’s goodwill exceeded its implied fair value, an impairment charge is recognized in an amount equal to that excess.

Long-Lived Assets

For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.  We assess the impairment of long-lived assets (including identifiable intangible assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors that we consider important that could trigger an impairment review include:

•
significant under-performance relative to expected, historical or projected future operating results;
•
significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;
•
a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and
•
significant negative industry, legal, regulatory or economic trends.

When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method.  Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets.  We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If this is the case, an impairment loss would be recognized.  The impairment loss recognized is the amount by which the carrying amount exceeds the fair value.

Income Taxes
 
We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

52



We record deferred tax assets to the extent we believe these assets will more likely than not be realized.  In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. To the extent we determine that we are able to realize our deferred income tax assets in the future in excess of their net recorded amount, we make an adjustment to the valuation allowance which may reduce the provision for income taxes. When we establish or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes.

On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The new legislation contains significant tax provisions that affect us, including a one-time mandatory deemed repatriation tax on certain unrepatriated foreign earnings ("Transition Tax"), a reduction of the corporate income tax rate from 35% to 21% effective January 1, 2018, and a change from a worldwide tax system to a modified territorial system.

We are required to recognize the effect of the tax law changes in the period of enactment, such as the computation of the Transition Tax, remeasurement of our U.S. federal deferred tax assets and liabilities, as well as reassessment of the net realizability of our deferred tax assets and liabilities.

Subsequent to the enactment of the Tax Act, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act ("SAB 118"), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under Accounting Standards Codification ("ASC") 740, "Income Taxes." We have completed the accounting for the income tax effects of the Tax Act, under SAB 118, as of December 31, 2018. As noted in our 2017 Annual Report, we were able to make reasonable estimates and provisionally recorded an income tax benefit of $70 million related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. The final accounting for the Tax Act resulted in an additional income tax benefit of $49 million for a final income tax benefit of $119 million. This is comprised of $169 million tax benefit related to the remeasurement of U.S. federal deferred tax assets and liabilities, offset by a $50 million tax detriment for the Transition Tax. We elected to account for the tax effect of the Global Intangible Low-Taxed Income (“GILTI”) in the period in which it is incurred.

During the fourth quarter of 2017, we early adopted ASU 2018-02, "Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income." With respect to stranded income tax effects in accumulated other comprehensive income, our policy is to use the portfolio method to reclassify such amounts.

Revenue Recognition

On January 1, 2018, we adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018.  Results for reporting periods beginning on January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under prior revenue guidance ASC 605, "Revenue Recognition."


53


We recorded a net reduction to opening retained earnings of $0.1 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. The impact to revenue as a result of applying ASC 606 as compared to ASC 605 for 2018 was not significant.

We recognize revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.
Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service.
At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced to the estimated amount that we expect to receive in exchange for transferring control for those products.
Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, transaction prices are allocated to performance obligations based on stand-alone selling prices. The method used to determine the stand-alone selling prices for service revenues is based on the observable prices when the services have been sold separately.
In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.
We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less and for contracts in which we recognize revenue at the amount to which we have the right to invoice for services performed. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.

54



Reagent Rental Agreements
Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. We concluded that the use of the instrument and related maintenance services (collectively known as “lease elements”) are not within the guidance of ASC 606 but rather ASC 840 Leases. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and requires consideration of any fixed/minimum payments as well as estimates of variable consideration. After determining what portion of the transaction price should be allocated to the lease elements, any fixed consideration would be considered the minimum lease payment to be amortized straight line over the lease term and any variable consideration would be contingent rent to be recognized monthly as earned, which coincides with the transfer of control of the non-lease elements.
For the portion of the transaction price allocated to the non-lease elements, which are principally the reagents, the related revenue will be recognized at a point in time when control transfers. Generally, the terms of the arrangements result in the transfer of control upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer.
Revenue allocated to the lease elements of these reagent rental arrangements represents approximately 5% of total revenue and are included as part of the Net sales in our Consolidated Statements of Income.
Contract costs:
As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities.
Disaggregation of Revenue:
The disaggregation of our revenue by geographic region based primarily on the location of the use of the product service, and by industry segment sources, and the disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 14).

Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are generally recognized ratably over the term of the service contract as our performance extends over the life of the arrangement. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from $36.7 million at December 31, 2017 to $37.3 million at December 31, 2018 is primarily driven by $28.0 million, net, of cash payments received or due in advance of satisfying our performance obligations, partially offset by $27.4 million of revenue recognized that were included in our deferred revenue balance as of December 31, 2017.

We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.

55



Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Consolidated Balance Sheets, were as follows (in millions):

 
 
2018
 
2017
January 1
 
$
18.7

 
$
17.6

Provision for warranty
 
25.5

 
29.9

Actual warranty costs
 
(34.1
)
 
(28.8
)
December 31
 
$
10.1

 
$
18.7



Shipping and Handling

We classify all freight costs billed to customers as Net sales.  Related freight costs are recognized upon transfer of control of the promised products to customers as a fulfillment cost and included in Cost of goods sold.

Research and Development

Internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed.

We conduct extensive research and development activities in all areas of our business, employing approximately 800 employees worldwide in these activities, including degreed scientists and technical support staff.  Research and development has played a major role in Bio-Rad’s growth and is expected to continue to do so in the future.  Our research teams are continuously developing new products and new applications for existing products.  In our development of new products and applications, we interact with scientific and medical professionals at universities, hospitals and medical schools, and within our industry.  

Foreign Currency

Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period.  Income statement items are translated at average exchange rates for the period.  The resulting translation adjustments are recorded as a separate component of stockholders’ equity.

Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income.  Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction.

Forward Foreign Exchange Contracts

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.  

56



Share-Based Compensation Plans

Share-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value.  We recognize these compensation costs net of forfeitures over the requisite service period of the award, which is generally the vesting term of the share-based payment awards.  Starting in 2017, we recognize forfeitures as they occur due to a change in accounting principle, and in prior periods we estimated the forfeiture rate based on our historical experience.  These plans are described more fully in Note 9.

Earnings Per Share

Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):
 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
Basic weighted average shares outstanding
 
29,836

 
29,655

 
29,440

Effect of potentially dilutive stock options
 
 
 
 
 
 
    and restricted stock awards
 
392

 
379

 
206

Diluted weighted average common shares
 
30,228

 
30,034

 
29,646

Anti-dilutive stock options and restricted stock awards
 
 
 
 
 
 
    excluded from the computation of diluted EPS
 
84

 
13

 
113



Fair Value of Financial Instruments

For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value.

The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3).

Recent Accounting Pronouncements Adopted

In February 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. ("ASU") 2018-03, "Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities." ASU 2018-03 amends certain items in ASU 2016-01 (see below) such as equity securities without a readily determinable fair value. ASU 2018-03 clarifies that an entity that uses the measurement alternative for equity securities without readily determinable fair values can change its measurement approach to fair value and once made the election is irrevocable. If an entity measures equity securities without readily determinable fair values at fair value, it must record a cumulative-effect adjustment to

57


Retained earnings as of the beginning of the fiscal year in which the guidance is adopted. We adopted ASU 2018-03 on January 1, 2018 and made an irrevocable election to account for our investment of the ordinary shares of Sartorius AG at fair value (see ASU 2016-01 below).

In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. Changes in fair value for equity securities will no longer be reported in other comprehensive income. For equity investments without readily determinable fair values, the cost method is also eliminated. We adopted ASU 2016-01 on January 1, 2018 and record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes and were valued at $0.6 million as of December 31, 2018. Changes in the basis of these equity investments are reported in current earnings. For equity securities that are affected by ASU 2016-01 and ASU 2018-03, see Note 3 to the consolidated financial statements, which primarily consists of our investment in Sartorius AG.

The impact of the adoption of ASU 2016-01 and ASU 2018-03 on January 1, 2018 was through a cumulative-effect adjustment of $864.5 million to Total stockholders' equity by increasing Retained earnings of $1,543.7 million and decreasing Accumulated other comprehensive income of $679.2 million, including an increase in Deferred income taxes of $232.9 million and an increase in Other investments of $1,097.4 million in our Consolidated Balance Sheet. As a result of ASU 2016-01 and ASU 2018-03 for 2018, we recorded a gain of $606.2 million for the Change in fair market value of equity securities in the Consolidated Statement of Income that resulted in a deferred tax expense of $133.9 million.

In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost," which changed how we present the net periodic benefit cost of our defined benefit pension and/or other postretirement plans. We adopted ASU 2017-07 on January 1, 2018 and applied the practical expedient to estimate amounts for comparative purposes utilizing the information disclosed in Note 12 to the consolidated financial statements in our Form 10-K for the year ended December 31, 2017. The interest costs are recorded in Interest expense, and the other costs are recorded in Other (income) expense, net in the Consolidated Statements of Income. For 2017 for interest costs and other costs, we reclassified $0.304 million, $2.152 million, and $0.144 million from Cost of goods sold (COGS), Selling, general and administrative expense (SG&A) and Research and Development expense (R&D), respectively, to Interest expense of $1.1 million and Other (income) expense, net of $1.5 million. For 2016 for interest costs and other costs, we reclassified $0.341 million, $2.027 million and $0.156 million from COGS, SG&A and R&D, respectively, to Interest expense of $1.438 million and Other (income) expense, net of $1.086 million.

In November 2016, the FASB issued ASU 2016-18, "Restricted Cash," which required us to cease to present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. We adopted ASU 2016-18 on January 1, 2018 and updated the Consolidated Statements of Cash Flows to incorporate restricted cash included in Other current assets and Other assets of $2.6 million as of December 31, 2018 and $1.2 million as of December 31, 2017.

In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory," which required immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  We adopted ASU 2016-16 on January 1, 2018 on a modified retrospective basis through a cumulative-effect adjustment by decreasing Retained earnings by $17.6 million, and decreasing Prepaid taxes by $22.8 million and increasing Deferred tax assets by $5.2 million that are both recorded in Other assets in our Consolidated Balance Sheet.

58



In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments" and adopted it on January 1, 2018, which did not have an impact to our statement of cash flows presentation.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers ("ASC 606"), an updated standard on revenue recognition. The new standard provides enhancements to the quality and consistency of how revenue is reported under the principle that revenue should be recognized in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of promised goods or services. We adopted ASC 606 as of January 1, 2018 using the cumulative effect transition method as more fully described above under the caption “Revenue Recognition.”

Recent Accounting Pronouncements to be Adopted

In November 2018, the FASB issued ASU 2018-18, "Clarifying the Interaction between Topic 808 and Topic 606." Topic 808 is Collaborative Arrangements, and Topic 606 is Revenue from Contracts with Customers. ASU 2018-18 clarifies that certain transactions between collaborative partners should be accounted for as revenue under ASC 606 when the collaborative partner is a customer. We currently do not have any customers that are collaborative partners or anticipate any in the near future. ASU 2018-18 will be effective January 1, 2020 and we will not early adopt.

In August 2018, the FASB issued ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract." ASU 2018-15 amends the definition of a hosting arrangement and requires a customer in a hosting arrangement that is a service contract to capitalize certain implementation costs as if the arrangement was an internal-use software project. The internal-use software guidance states that only qualifying costs incurred during the application development stage can be capitalized. We will prospectively adopt ASU 2018-15 effective January 1, 2019. We do not expect ASU 2018-15 to have a material impact to our consolidated financial statements.

In August 2018, the FASB issued ASU 2018-14, "Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." ASU 2018-14 eliminates and adds certain disclosures for defined benefit plans. ASU 2018-14 is effective for fiscal years ending after December 15, 2020 using a retrospective approach, with early adoption permitted. We are currently evaluating the disclosures and the timing of adoption but do not expect ASU 2018-14 to have a material impact to our disclosures for defined benefit plans.

In August 2018, the FASB issued ASU 2018-13, "Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement." ASU 2018-13 eliminates, adds and modifies certain disclosures for fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. Early adoption is permitted in interim periods, including periods for which financial statements have not yet been issued. We do not expect ASU 2018-13 to have a material impact to our fair value disclosures and we currently do not plan to early adopt.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. In November 2018, the FASB issued ASU 2018-19, "Codification Improvements to Topic 326, Financial Instruments-Credit Losses," which clarifies that receivables arising from operating leases are not within the scope of Topic 326. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.

59



In February 2016, the FASB issued ASU 2016-02, "Leases," and related accounting standard updates, which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. We will adopt ASU 2016-02 on a modified retrospective basis effective January 1, 2019 with practical expedients, and will not restate comparative prior periods. The practical expedients, include, among other items, for leases that existed prior January 1, 2019, to not reassess whether any contracts are or contain embedded leases, reassessing the classification of existing leases, and reassessing whether previously capitalized initial direct costs qualify for capitalization. Where we act as a lessee, we also elected not to separate lease and non-lease components. Where we act as a lessor in our reagent rental arrangements, we allocate the consideration in the contract to the separate lease components and the non-lease components. After the allocation, the amount of variable payments allocated to lease components will be recognized as income in accordance with the new lease accounting standard updates, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Such reagent rental arrangements are more fully described above under the caption "Reagent Rental Agreements." Where we act as a lessee, the adoption of the standard will result in material additions to the balance sheet for right-of-use assets and the associated liabilities. We will complete our review of the completeness and accuracy of the lease data, discount rate and finalize our updated controls in accordance with the new standard during the first quarter of 2019. Where we act as a lessor in reagent rental arrangements, we estimate an insignificant impact to our consolidated financial statements.



2.    ACQUISITIONS

RainDance Technologies, Inc.
In February 2017, we acquired all the issued and outstanding stock of RainDance Technologies, Inc. (RainDance) for approximately $72.7 million. Cash payments at closing were $72.9 million. In addition, we had a cash payment of $10.0 million for a preexisting condition concurrent with the acquisition that was recorded in Cost of goods sold. The acquisition was included in our Life Science segment’s results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is not deductible for income tax purposes. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented.
The final allocation for the payments of $72.9 million was $37.6 million to definite-lived intangibles, $0.2 million to acquired net assets, $26.2 million to goodwill, a deferred tax liability of $13.6 million primarily related to the purchased intangibles and a deferred tax asset of $22.5 million primarily related to the acquired net operating losses.
RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy. We believe that RainDance's droplet-based solutions will extend our reach into next-generation sequencing applications and strengthen our position in the area of Droplet Digital™ PCR, offering customers solutions for a wide range of nucleic acid detection applications.

60




3. FAIR VALUE MEASUREMENTS

We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:

•
Level 1: Quoted prices in active markets for identical instruments
•
Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)
•
Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)

Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2018 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents (a):
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
77.8

 
$
—

 
$
77.8

Time deposits
22.7

 
10.0

 
—

 
32.7

Asset-backed securities
—

 
0.3

 
—

 
0.3

Money market funds
36.9

 
—

 
—

 
36.9

Total cash equivalents
59.6

 
88.1

 
—

 
147.7

Restricted investment
5.6

 
—

 
—

 
5.6

Equity Securities (b)
2,672.9

 
—

 
—

 
2,672.9

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
215.0

 
—

 
215.0

U.S. government sponsored agencies
—

 
80.3

 
—

 
80.3

Foreign government obligations
—

 
3.6

 
—

 
3.6

Municipal obligations
—

 
11.0

 
—

 
11.0

Asset-backed securities
—

 
63.3

 
—

 
63.3

Total available-for-sale investments (c)
—

 
373.2

 
—

 
373.2

Forward foreign exchange contracts (d)
—

 
0.6

 
—

 
0.6

Total financial assets carried at fair value
$
2,738.1

 
$
461.9

 
$
—

 
$
3,200.0

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
     Forward foreign exchange contracts (e)
$
—

 
$
0.7

 
$
—

 
$
0.7

     Contingent consideration (f)
—

 
—

 
8.4

 
8.4

Total financial liabilities carried at fair value
$
—

 
$
0.7

 
$
8.4

 
$
9.1


As of first quarter 2018, our equity securities are no longer reported as Available-for-sale investments due to the implementation of ASU 2016-01. Changes in fair value of equity securities are now reported on the Consolidated Statements of Income rather than Other Comprehensive Income (see Note 1).

Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2017 are classified in the hierarchy as follows (in millions):

61



 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents (a):
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
36.0

 
—

 
$
36.0

Time deposits
43.7

 
10.0

 
—

 
53.7

U.S. government sponsored agencies
—

 
11.2

 
—

 
11.2

Money market funds
3.4

 
—

 
—

 
3.4

Total cash equivalents
47.1

 
57.2

 
—

 
104.3

Restricted investment:
5.6

 
—

 
—

 
5.6

Available-for-sale investments (c):
 
 
 
 
 
 
 
Corporate debt securities
—

 
185.7

 
—

 
185.7

U.S. government sponsored agencies
—

 
67.6

 
—

 
67.6

Foreign government obligations
—

 
3.4

 
—

 
3.4

Brokered certificates of deposit
—

 
0.7

 
—

 
0.7

Municipal obligations
—

 
15.0

 
—

 
15.0

Marketable equity securities
973.4

 
—

 
—

 
973.4

Asset-backed securities
—

 
55.6

 
—

 
55.6

Total available-for-sale investments
973.4

 
328.0

 
—

 
1,301.4

Forward foreign exchange contracts (d)
—

 
0.5

 
—

 
0.5

Total financial assets carried at fair value
$
1,026.1

 
$
385.7

 
—

 
$
1,411.8

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (e)
$
—

 
$
1.6

 
—

 
$
1.6

 Contingent consideration (f)
—

 
—

 
16.7

 
16.7

Total financial liabilities carried at fair value
$
—

 
$
1.6

 
$
16.7

 
$
18.3


(a)
Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.

(b)
Equity securities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2018
Short-term investments
$
40.2

Other investments
2,632.7

        Total
$
2,672.9



The unrealized gains on our equity securities still held as of December 31, 2018 are $607.7 million and are primarily due to our investment in Sartorius AG and is recorded in our Consolidated Statements of Income due to the adoption of ASU 2016-01 (see Note 1).

(c)
Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31,
2018
 
December 31, 2017
 
 
 
 
Short-term investments
$
373.0

 
$
371.2

Other investments
0.2

 
930.2

Total
$
373.2

 
$
1,301.4




62


In accordance with our adoption of ASU 2016-01 January 1, 2018, our investment in Sartorius AG preferred shares, which was reported within marketable equity securities as Available-for-sale as of December 31, 2017, is now reported as an Equity security as of December 31, 2018 (see Note 1 and footnote (b) above).


(d)
Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.

(e)
Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.

(f)
Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2018
 
December 31, 2017
 
 
 
 
Other current liabilities
$
3.2

 
$
2.7

Other long-term liabilities
5.2

 
14.0

   Total
$
8.4

 
$
16.7



During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount. In the first and third quarters of 2018, we paid $1.3 million and $0.8 million, respectively, per the purchase agreement. Since 2016 we have had a net decrease in the cumulative valuation of the sales milestones of $12.2 million. The contingent consideration was accrued at its estimated fair value of $8.4 million as of December 31, 2018.

The following table provides a reconciliation of the Level 3 analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value (in millions):

 
2018
 
 
January 1
$
16.7

Payment of sales milestone
(2.1
)
Net decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense
(6.2
)
December 31
$
8.4



The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of December 31, 2018. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.

63


 
Valuation Technique
Unobservable Input
Percentage
Analytical flow cytometer platform
Probability-weighted income approach
Sales milestones:
 
 
 
Discount rate
11.0
%
 
 
Cost of debt
5.1
%


To estimate the fair value of Level 2 debt securities as of December 31, 2018 and 2017, our primary pricing provider uses Securities Evaluations as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Securities Evaluations does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source.

For all commercial paper as of December 31, 2018, our primary pricing provider uses its leading pricing source in the hierarchy to determine pricing. For discount commercial paper as of December 31, 2017, pricing was determined by a straight-line calculation, starting with the purchase price on the date of purchase and increasing to par at maturity. As of December 31, 2017, interest bearing certificates of deposit and commercial paper were priced at par.

Our primary pricing provider performs daily reasonableness testing of the Securities Evaluations prices. Price changes of 5% or greater are investigated and resolved. In addition, we perform a quarterly testing of the Securities Evaluations prices to custodian reported prices. Price differences outside a tolerable variance of approximately 1% are investigated and resolved.

Available-for-sale investments consist of the following (in millions):

 
December 31, 2018
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
216.2

 
$
0.1

 
$
(1.3
)
 
$
215.0

Municipal obligations
11.1

 
—

 
(0.1
)
 
11.0

Asset-backed securities
63.5

 
—

 
(0.4
)
 
63.1

U.S. government sponsored agencies
80.9

 
0.2

 
(0.8
)
 
80.3

Foreign government obligations
3.6

 
—

 
—

 
3.6

 
375.3

 
0.3

 
(2.6
)
 
373.0

Long-term investments:
 
 
 
 
 
 
 
Asset-backed securities
0.2

 
—

 
—

 
0.2

 
0.2

 
—

 
—

 
0.2

Total
$
375.5

 
$
0.3

 
$
(2.6
)
 
$
373.2



The following is a summary of the amortized cost and estimated fair value of our debt securities at December 31, 2018 by contractual maturity date (in millions):


64


 
Amortized
Cost
 
Estimated Fair
Value
Mature in less than one year
$
155.5

 
$
155.2

Mature in one to five years
172.4

 
171.3

Mature in more than five years
47.6

 
46.7

Total
$
375.5

 
$
373.2



Available-for-sale investments consist of the following (in millions):



 
December 31, 2017
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
185.9

 
$
0.3

 
$
(0.5
)
 
$
185.7

Brokered certificates of deposit
0.7

 
—

 
—

 
$
0.7

Municipal obligations
15.1

 
—

 
(0.1
)
 
15.0

Asset-backed securities
55.6

 
—

 
(0.2
)
 
55.4

U.S. government sponsored agencies
68.3

 
—

 
(0.7
)
 
67.6

Foreign government obligations
3.4

 
—

 
—

 
3.4

Marketable equity securities
34.4

 
9.0

 
—

 
43.4

 
363.4

 
9.3

 
(1.5
)
 
371.2

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
875.5

 
—

 
930.0

Asset-backed securities
0.2

 
—

 
—

 
0.2

 
54.7

 
875.5

 
—

 
930.2

Total
$
418.1

 
$
884.8

 
$
(1.5
)
 
$
1,301.4



The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):

 
December 31,
2018
 
December 31, 2017
 
 
 
 
Fair value of investments in a loss position 12 months or more
$
117.9

 
$
43.9

Fair value of investments in a loss position less than 12 months
$
193.0

 
$
168.7

Gross unrealized losses for investments in a loss position 12 months or more
$
1.8

 
$
0.7

Gross unrealized losses for investments in a loss position less than 12 months
$
0.8

 
$
0.8



The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at December 31, 2018 or at December 31, 2017.


65


As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of December 31, 2018 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign exchange losses, net in the Consolidated Statements of Income.

The following is a summary of our forward foreign currency exchange contracts (in millions):
 
December 31,
 
2018
Contracts maturing in January through March 2019 to sell foreign currency:
 
Notional value
$
50.6

Unrealized gain
$
0.2

Contracts maturing in January through March 2019 to purchase foreign currency:
 
Notional value
$
284.5

Unrealized loss
$
(0.5
)



The estimated fair value of financial instruments that are not recognized at fair value in the Consolidated Balance Sheets and are included in Other investments, are presented in the table below. Fair value has been determined using significant observable inputs, including quoted prices in active markets for similar instruments.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value.  Other investments include financial instruments, the majority of which has fair value based on similar, actively traded stock adjusted for various discounts, including a discount for marketability.  Long-term debt, excluding leases and current maturities, has an estimated fair value based on quoted market prices for the same or similar issues.

The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):


 
December 31, 2018
 
December 31, 2017
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
Other investments
$
—

 
$
—

 
 
 
$
91.8

 
$
1,249.4

 
2
Total long-term debt, excluding leases
and current maturities
$
423.7

 
$
435.8

 
2
 
$
423.1

 
$
449.8

 
2

66



We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries.  We own over 37% of the outstanding voting shares (excluding treasury shares) of Sartorius as of December 31, 2018.  The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius’ board of directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. As of December 31, 2018, due to the adoption of
ASU 2016-01 and ASU 2018-03 as of January 1, 2018, we account for this investment at fair market value as determined at period end by a quoted price on an organized exchange (see Note 1).


4.    GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):
 
 
2018
 
 
2017
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
Balances as of January 1:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
$
234.7

 
$
324.6

 
$
559.3

 
 
$
207.1

 
$
311.7

 
$
518.8

Accumulated impairment losses and write-offs
 
(35.9
)
 
(17.3
)
 
(53.2
)
 
 
(27.2
)
 
(14.5
)
 
(41.7
)
Goodwill, net
 
198.8

 
307.3

 
506.1

 
 
179.9

 
297.2

 
477.1

Acquisitions
 
—

 
—

 
—

 
 
26.2

 
—

 
26.2

Divestiture
 
—

 
(1.4
)
 
(1.4
)
 
 
—

 
—

 
—

Impairment
 
(5.9
)
 
(276.1
)
 
(282.0
)
 
 
(8.7
)
 
(2.8
)
 
(11.5
)
Currency fluctuations
 
(0.2
)
 
(2.7
)
 
(2.9
)
 
 
1.4

 
12.9

 
14.3

Balances as of December 31:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
234.5

 
320.5

 
555.0

 
 
234.7

 
324.6

 
559.3

Accumulated impairment losses and write-offs
 
(41.8
)
 
(293.4
)
 
(335.2
)
 
 
(35.9
)
 
(17.3
)
 
(53.2
)
Goodwill, net
 
$
192.7

 
$
27.1

 
$
219.8

 
 
$
198.8

 
$
307.3

 
$
506.1



In March 2018, we wrote off $1.4 million of goodwill from our Clinical Diagnostics segment as a result of a divestiture of a product line.

In conjunction with the purchase of all the issued and outstanding stock of RainDance Technologies, Inc. in February 2017 (see Note 2, "Acquisitions"), we recorded $26.2 million of goodwill and $37.6 million of definite-lived intangible assets: $36.4 million of licenses, $1.0 million of developed product technology and $0.2 million of tradenames.

In 2018, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A., 2007 through 2012 acquisitions of DiaMed Holding AG, DiaMed Fennica Oy, DiaMed (G.B.) Limited, and DiaMed Benelux (collectively DiaMed), 2010 acquisition of Biotest AG, and 2013 acquisition of AbD Serotec in the amounts of $18.1 million, $247.2 million, $10.8 million and $5.9 million, respectively. Goodwill for DiaMed, Biotest AG and AbD Serotec was fully impaired at December 31, 2018. Impairments for the Pasteur Sanofi Diagnostics S.A., DiaMed and Biotest AG were included in our Clinical Diagnostics segment's results of operations, and the impairment for AbD Serotec was included in our Life Science segment's results of operations.

In 2017, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A. and with our 2013 acquisition of AbD Serotec in the amounts of $2.8 million and $8.7 million, respectively. Impairment for the Pasteur Sanofi Diagnostics S.A. was included in our Clinical Diagnostics segment's results of operations, and the impairment for AbD Serotec was included in our Life Science segment's results of operations.

The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows.

67



Other than goodwill, we have no intangible assets with indefinite lives. Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):
 
December 31, 2018
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-6
 
$
88.7

 
$
(68.3
)
 
$
20.4

Know how
1-7
 
190.6

 
(159.8
)
 
30.8

Developed product technology
1-10
 
130.4

 
(86.6
)
 
43.8

Licenses
7-11
 
76.3

 
(40.9
)
 
35.4

Tradenames
2-6
 
3.9

 
(3.3
)
 
0.6

Covenants not to compete
7
 
3.2

 
(1.1
)
 
2.1

     Total definite-lived intangible assets
 
 
$
493.1

 
$
(360.0
)
 
$
133.1


 
December 31, 2017
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-7
 
$
92.3

 
$
(64.4
)
 
$
27.9

Know how
1-8
 
194.9

 
(157.9
)
 
37.0

Developed product technology
1-12
 
133.3

 
(70.3
)
 
63.0

Licenses
1-12
 
76.7

 
(36.0
)
 
40.7

Tradenames
1-6
 
3.9

 
(3.0
)
 
0.9

Covenants not to compete
1-8
 
7.9

 
(3.3
)
 
4.6

     Total definite-lived intangible assets
 
 
$
509.0

 
$
(334.9
)
 
$
174.1



In 2018, we impaired developed product technology and fully impaired covenants not to compete in the amounts of $8.8 million and $1.7 million, respectively, associated with our 2012 acquisition of a cell sorting system from Propel Labs, Inc. These impairments were included in our Life Science segment's results of operations. The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows.

Amortization expense related to purchased intangible assets for the years ended December 31, 2018, 2017 and 2016 was $28.3 million, $30.8 million and $35.2 million, respectively.  Estimated future amortization expense (based on existing purchased intangible assets) for the years ending December 31, 2019, 2020, 2021, 2022, 2023 and thereafter is $21.7 million, $19.7 million, $18.9 million, $15.7 million, $14.8 million, and $42.3 million, respectively.


5.NOTES PAYABLE AND LONG-TERM DEBT


Under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had $208.2 million available for borrowing and usage as of December 31, 2018, which was reduced by $3.1 million that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations.

The principal components of long-term debt are as follows (in millions):

68


 
December 31, 2018
 
December 31, 2017
 
 
 
 
4.875% Senior Notes due 2020, net of discount
$
425.0

 
$
425.0

Less unamortized discount and debt issuance costs
(1.3
)
 
(1.9
)
Long-term debt less unamortized discount and debt issuance costs
423.7

 
423.1

Capital leases and other debt
15.7

 
11.9

 
439.4

 
435.0

Less current maturities
(0.5
)
 
(0.4
)
Long-term debt
$
438.9

 
$
434.6



Senior Notes due 2020

In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due December 2020 (4.875% Notes).  The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946%.  The 4.875% Notes pay a fixed rate of interest of 4.875% per year.  We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date.  Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness.  Certain covenants apply at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. We were in compliance with these covenants as of December 31, 2018. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios.
 
Credit Agreement

In June 2014, Bio-Rad entered into a $200.0 million unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of December 31, 2018 or 2017; however, $0.2 million and $0.5 million were utilized for domestic standby letters of credit that reduced our borrowing availability as of December 31, 2018 and 2017, respectively. The Credit Agreement matures in June 2019. If we had borrowed against our Credit Agreement, the borrowing rate would have been 3.925% at December 31, 2018.

The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of December 31, 2018.

Maturities of long-term debt at December 31, 2018 are as follows: 2019 - $0.5 million; 2020 - $426.6 million; 2021 - $1.7 million; 2022 - $1.6 million; 2023 - $0.4 million; thereafter - $9.9 million.

69




6. INCOME TAXES

The U.S. and international components of income before taxes are as follows (in millions):

 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
U.S.
 
$
363.4

 
$
72.8

 
$
(38.5
)
International
 
149.3

 
25.0

 
80.1

Income before taxes
 
$
512.7

 
$
97.8

 
$
41.6



The provision for income taxes consists of the following (in millions):

 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
Current tax expense:
 
 

 
 

 
 

U.S. Federal
 
$
8.8

 
$
6.7

 
$
16.1

State
 
2.2

 
3.4

 
3.1

International
 
30.5

 
32.0

 
30.4

Current tax expense
 
41.5

 
42.1

 
49.6

Deferred tax expense (benefit):
 
 

 
 
 
 

U.S. Federal
 
114.0

 
(69.8
)
 
(42.4
)
State
 
6.6

 
4.3

 
(2.8
)
International
 
0.3

 
(19.3
)
 
(6.0
)
Deferred tax expense (benefit)
 
120.9

 
(84.8
)
 
(51.2
)
Non-current tax (benefit) expense
 
(15.4
)
 
18.3

 
17.2

Provision for (benefit from) income taxes
 
$
147.0

 
$
(24.4
)
 
$
15.6




The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:


70


 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
U. S. statutory tax rate
 
21
 %
 
35
 %
 
35
 %
Impact of foreign operations
 
(4
)
 
6

 
(15
)
Foreign dividends, net
 
—

 
—

 
(40
)
Research tax credits
 
(1
)
 
(4
)
 
(9
)
Nontaxable subsidies
 
—

 
(2
)
 
(4
)
Tax settlements and changes to unrecognized tax benefits
 
—

 
—

 
47

Goodwill impairment
 
6

 
1

 
11

Domestic manufacturing deduction
 
—

 
—

 
(4
)
Share-based compensation
 
(1
)
 
(5
)
 
3

Nondeductible executive compensation
 
—

 
2

 
3

Fines and penalties
 
—

 
—

 
2

Prior period adjustments
 
(1
)
 
—

 
4

U.S. taxation of foreign income
 
15

 
3

 
2

Acquisition-related
 
—

 
10

 
—

U.S. tax reform
 
(10
)
 
(71
)
 
—

State taxes
 
2

 
3

 
1

Other
 
2

 
(3
)
 
1

Provision for (benefit from) income taxes
 
29
 %
 
(25
)%
 
37
 %


On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code that affect our 2017 financial statements, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities.

Subsequent to the enactment of the Tax Act, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act ("SAB 118"), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under Accounting Standards Codification ("ASC") 740, "Income Taxes." We have completed our accounting for the income tax effects of the Tax Act, under SAB 118, as of December 31, 2018. As noted in our 2017 Annual Report, we were able to make reasonable estimates and provisionally recorded an income tax benefit of $70 million related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. The final accounting for the Tax Act resulted in an additional income tax benefit of $49 million for a final income tax benefit of $119 million. This is comprised of $169 million tax benefit related to the remeasurement of U.S. federal deferred tax assets and liabilities, offset by a $50 million tax detriment for the Transition Tax. We elected to account for the tax effect of the Global Intangible Low-Taxed Income (“GILTI”) in the period in which it is incurred.

Our effective income tax rate was 29%, (25)% and 37% in 2018, 2017 and 2016, respectively. The effective tax rate for 2018 was driven by detriments due to non-deductible impairment charges and the taxation of our foreign operations, partially offset by a $49 million benefit recorded as a result of the completion of our accounting for the Tax Act under SAB 118. The effective tax rate for 2017 was driven by a $70 million benefit recorded as a provisional estimate of the accounting for the Tax Act. The effective tax rate for 2016 included additional tax liabilities for unrecognized tax benefits related to the non-deductibility of interest expense in our foreign jurisdictions.

71



Many jurisdictions in which we operate have statutory tax rates that differ from the U.S. statutory tax rate of 21%. Our effective tax rate is impacted, either favorably or unfavorably, by many factors including, but not limited to the jurisdictional mix of income before tax, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits.

Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):

 
 
December 31,
 
 
2018
 
2017
Deferred tax assets:
 
 

 
 

Bad debt, inventory and warranty accruals
 
$
21.7

 
$
28.6

Other post-employment benefits, vacation and other reserves
 
23.0

 
24.0

Tax credit and net operating loss carryforwards
 
75.3

 
73.3

Other
 
27.1

 
19.7

    Total gross deferred tax assets
 
147.1

 
145.6

Valuation allowance
 
(70.8
)
 
(66.4
)
       Total deferred tax assets
 
76.3

 
79.2

Deferred tax liabilities:
 
 
 
 
Property and equipment
 
40.1

 
33.5

Investments and intangible assets
 
540.6

 
219.1

        Total deferred tax liabilities
 
580.7

 
252.6

Net deferred tax liabilities
 
$
(504.4
)
 
$
(173.4
)


The realization of deferred tax assets is dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that our California and certain foreign deferred tax assets will not be realized as of December 31, 2018, and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our deferred tax assets in California and certain foreign jurisdictions increased by $4.4 million in 2018.

As of December 31, 2018, our foreign and California net operating loss carryforwards were approximately $205.0 million and $52.7 million, respectively. Of our foreign net operating losses, $118.8 million may be carried forward indefinitely. The majority of the remaining foreign net operating losses, if not utilized, will begin to expire in 2025. Our California net operating loss carryforwards, if not utilized, will begin to expire in 2029. As of December 31, 2018, our California research tax credit carryforwards were approximately $32.1 million and may be carried forward indefinitely.

Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2014 and forward for the U.S. and the years 2012 and forward for certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.


72


We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):
 
 
2018
 
2017
 
2016
Unrecognized tax benefits – January 1
 
$
54.9

 
$
21.1

 
$
11.9

Additions to tax positions related to prior years
 
0.6

 
1.3

 
10.4

Reductions to tax positions related to prior years
 
(20.2
)
 
(1.0
)
 
—

Additions to tax positions related to the current year
 
4.6

 
34.8

 
3.4

Settlements
 
(6.8
)
 
(0.2
)
 
(2.4
)
Lapse of statute of limitations
 
(1.1
)
 
(3.4
)
 
(2.3
)
Currency translation
 
(2.2
)
 
2.3

 
0.1

Unrecognized tax benefits – December 31
 
$
29.8

 
$
54.9

 
$
21.1



Bio-Rad recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. Related to the unrecognized tax benefits noted above, the cumulative amount of accrued interest and penalties as of December 31, 2018, 2017 and 2016, respectively was $9.5 million, $10.9 million and $11.8 million. Bio-Rad accrued interest and penalties of $(1.4) million, $(0.9) million, and $8.7 million in 2018, 2017, and 2016, respectively. The total unrecognized tax benefits and interest and penalties of $39.3 million in 2018 was partially offset by deferred tax assets of $1.6 million and prepaid taxes of $5.5 million, for a net amount of $32.2 million.

As of December 31, 2018, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $3.1 million. Substantially all such amounts will impact our effective income tax rate if recognized.

It is generally our intention to repatriate certain foreign earnings to the extent that such repatriations are not restricted by local laws or accounting rules, and there are no substantial incremental costs. During the current year, we recorded approximately $6.7 million of deferred tax liability for the earnings of certain foreign jurisdictions that we may repatriate in the future. The determination of the amount of the unrecognized deferred tax liability for foreign earnings that are indefinitely reinvested is not practicable to estimate.


7.    STOCKHOLDERS' EQUITY

Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B).  Each share of Class A and Class B participates equally in the earnings of Bio-Rad, and is identical in all respects except as follows. Class A has limited voting rights.  Each share of Class A is entitled to one tenth of a vote on most matters, and each share of Class B is entitled to one vote.  Additionally, Class A stockholders are entitled to elect 25% of the Board of Directors and Class B stockholders are entitled to elect 75% of the directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares but no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares.  Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.  The founders of Bio-Rad, the Schwartz family, collectively hold a majority of Bio-Rad’s voting stock.  As a result, the Schwartz family is able to exercise significant influence over Bio-Rad.

Changes to Bio-Rad's issued common stock shares are as follows (in thousands):

73


 
Class A Shares
 
Class B Shares
Balance at January 1, 2016
24,230

 
5,131

B to A conversions
13

 
(13
)
Issuance of common stock
211

 
6

Balance at December 31, 2016
24,454

 
5,124

B to A conversions
34

 
(34
)
Issuance of common stock
191

 
18

Balance at December 31, 2017
24,679

 
5,108

B to A conversions
30

 
(30
)
Issuance of common stock
175

 
18

Balance at December 31, 2018
24,884

 
5,096


Treasury Shares

In November, 2017, the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to $250.0 million of outstanding shares of our common stock. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. This new authorization superseded the prior authorization of up to $18.0 million of Bio-Rad's common stock and has no expiration. The share repurchase activity under the share repurchase program through open market transactions in 2017 and 2018 is summarized as follows:

 
Number of Shares Purchased
Weighted-Average Price per Share
Total Shares Repurchased To Date
Remaining Authorized Value
(in millions)
May 1, 2017 - May 31, 2017
2,500

$
220.02

3,539

$
2.7

June 1, 2017 - June 30, 2017
1,500

$
221.82

5,039

$
2.4

August 1, 2017 - August 31, 2017
9,200

$
221.45

14,239

$
0.4

November 1, 2018 - November 30, 2018
178,911

$
273.39

193,150

$
201.1


In September 2017, we used 12,740 of the repurchased shares in connection with the vesting of restricted stock units under the 2007 Incentive Award Plan in order to obtain a tax deduction in some of our foreign entities. The Credit Agreement may limit our ability to repurchase our stock.


74




8.    ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Accumulated other comprehensive income (loss) included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions):
 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains (losses) on available-for-sale investments
Total Accumulated other comprehensive income (loss)
Balances as of January 1, 2017
$
1.3

$
(18.6
)
$
435.0

$
417.7

Other comprehensive income (loss), before reclassifications
76.1

(6.5
)
203.6

273.2

Amounts reclassified from Accumulated other comprehensive income
—

2.1

(0.1
)
2.0

Income tax effects
—

0.7

(74.9
)
(74.2
)
Effect of adoption of ASU 2018-02
—

—

120.1

120.1

Other comprehensive income (loss), net of income taxes
76.1

(3.7
)
248.7

321.1

Balances as of December 31, 2017
$
77.4

$
(22.3
)
$
683.7

$
738.8

Effect of adoption of ASU 2016-01 and 2018-03**
—

—

(679.3
)
(679.3
)
Balances as of January 1, 2018
$
77.4

$
(22.3
)
$
4.4

$
59.5

Other comprehensive (loss) income, before reclassifications
(112.9
)
6.9

(1.4
)
(107.4
)
Amounts reclassified from Accumulated other comprehensive income
—

2.4

0.3

2.7

Income tax effects
—

(1.8
)
—

(1.8
)
Other comprehensive (loss) income, net of income taxes
(112.9
)
7.5

(1.1
)
(106.5
)
Balances as of December 31, 2018
$
(35.5
)
$
(14.8
)
$
3.3

$
(47.0
)


**See Note 1, "Significant Accounting Policies" under "Recent Accounting Pronouncements Adopted"

In 2017, we adopted ASU 2018-02, "Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income," which gave entities the option to reclassify to retained earnings tax effects related to items in Accumulated other comprehensive income ("OCI") that the FASB refers to as having been stranded in Accumulated OCI as a result of the Tax Act. We reclassified the income tax effects of the Tax Act on the remeasurement of our deferred tax liabilities related to our available-for-sale equity securities by increasing OCI and decreasing Retained earnings by $120.1 million.

The increase in 2017 for net unrealized holding gains on available-for-sale investments was primarily from our ownership in the preferred shares of Sartorius.


75


The amounts reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows:
 
 
 
December 31,
 
 
Components of Comprehensive income
 
2018
2017
 
Location
 
Amortization of foreign other post-employment benefit items
 
$
(2.4
)
$
(2.1
)
 
Selling, general and administrative expense
 
Net holding (losses) gains on equity securities and available for sale investments
 
$
(0.3
)
$
0.1

 
Other (income) expense, net
 

Reclassification adjustments are calculated using the specific identification method.



9. SHARE-BASED COMPENSATION/EQUITY AWARD AND PURCHASE PLANS

Description of Share-Based Compensation Plans

We believe our share-based compensation plans align the interests of our employees with those of our shareholders.

Equity Award Plans
We have three equity award plans for officers and certain other employees: the 2003 Stock Option Plan (2003 Plan), the 2007 Incentive Award Plan (2007 Plan) and the 2017 Incentive Award Plan (2017 Plan).  The 2003 Plan authorized the grant of incentive stock options and non-qualified stock options to employees. The 2007 Plan authorized the grant of stock options, restricted stock, restricted stock units, stock appreciation rights and other types of equity awards to employees.  We no longer grant equity under the 2003 Plan or 2007 Plan. From 2007 through 2016, all share-based compensation grants were from the 2007 Plan.

The 2017 Plan authorizes the grant to employees of stock options, stock appreciation rights, restricted stock, restricted stock units, and other types of equity awards. A total of 1,999,714 shares have been reserved for issuance of equity awards under the 2017 Plan and may be of either Class A or Class B common stock. At December 31, 2018, there were 1,584,834 shares available to be granted.

Under the above plans, Class A and Class B options are granted at prices not less than fair market value of the underlying common stock on the date of grant.  Generally, options granted have a maximum term of 10 years and vest in increments of 20% per year over a five-year period on the yearly anniversary date of the grant.  Stock awards issued under the 2007 Plan and 2017 Plan generally vest in increments of 20% per year over a five-year period on the yearly anniversary date of the grant.

Employee Stock Purchase Plans
Our 2011 Employee Stock Purchase Plan (2011 ESPP) provides that eligible employees may contribute up to 10% of their compensation up to $25,000 annually toward the quarterly purchase of our Class A common stock.  The employees’ purchase price is 85% of the lesser of the fair market value of the stock on the first business day or the last business day of each calendar quarter.  

The 2011 ESPP includes two components: a Code Section 423 Component that we intend to qualify as an “employee stock purchase plan” under Section 423 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and a Non-423 Component, which authorizes the grant of purchase rights that does not qualify as an “employee stock purchase plan” under Section 423 of the Code. We have authorized the sale of 1,300,000 shares of Class A common stock under the 2011 ESPP.

76



Share-Based Compensation

Included in our share-based compensation expense is the cost related to stock option grants, ESPP stock purchases and restricted stock unit awards.  Share-based compensation expense is allocated to Cost of goods sold, Research and development expense, and Selling, general and administrative expense in the Consolidated Statements of Income.

For 2018, 2017 and 2016, we recognized share-based compensation expense of $27.8 million, $23.4 million and $19.7 million, respectively.  The income tax benefit related to share-based compensation expense was $4.4 million, $5.8 million and $5.1 million for 2018, 2017 and 2016, respectively. We did not capitalize any share-based compensation expense in inventory.

The tax benefit from share-based compensation vested or exercised during 2018, 2017 and 2016 was $5.4 million, $6.3 million, and $1.5 million, respectively. The actual tax benefit realized for the tax deductions from share-based compensation vested or exercised, including excess tax benefits that were recognized in stockholders’ equity, totaled $6.0 million in 2016.

For options and awards, we amortize the fair value on a straight-line basis.  All stock compensation awards are amortized over the requisite service periods of the awards, which are generally the vesting periods. With the adoption in 2017 of ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting," we made a policy election to recognize forfeitures as they occur. Prior to 2017, we recognized compensation expense net of estimated forfeitures.

Stock Options
The following table summarizes stock option activity:

 
 
Shares
 
Weighted-
Average
Exercise Price
 
Weighted-
Average
Remaining
Contractual
Term (in years)
 
Aggregate
Intrinsic
Value
(in millions)
Outstanding, December 31, 2017
 
407,480

 
$
120.39

 
 
 
 
Granted
 
33,000

 
$
326.15

 
 
 
 
Exercised
 
(44,600
)
 
$
93.63

 
 
 
 
Forfeited/expired
 
(22,240
)
 
$
169.93

 
 
 
 
Outstanding, December 31, 2018
 
373,640

 
$
138.81

 
4.90
 
$
38.0

 
 
 
 
 
 
 
 
 
Unvested, December 31, 2018
 
99,600

 
$
223.91

 
8.32
 
$
3.9

Exercisable, December 31, 2018
 
274,040

 
$
107.88

 
3.65
 
$
34.1




Intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic value on the date of exercise of stock options exercised during 2018, 2017 and 2016 was approximately $8 million, $10 million and $1 million, respectively. The total fair value of options vested during 2018, 2017 and 2016 was $6.0 million, $4.2 million and $2.1 million, respectively.

Cash received from stock options exercised during 2018, 2017 and 2016 was $0.5 million, $1.6 million and $1.2 million, respectively.  

As of December 31, 2018, there was $6.3 million of total unrecognized compensation cost from stock options. This amount is expected to be recognized in the future over a weighted-average period of approximately 3 years.


77


The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:

 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
Expected volatility
 
22
%
 
20
%
 
21
%
Risk-free interest rate
 
2.85
%
 
1.87
%
 
1.35
%
Expected life (in years)
 
7.6

 
7.2

 
7.4

Expected dividend
 
—

 
—

 
—

Weighted-average fair value of options granted
 
$
105.94

 
$
58.65

 
$
42.40



Volatility is based on the historical volatilities of our common stock for a period equal to the stock option’s expected life.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the number of years that we estimate, based primarily on historical experience, that the options will be outstanding prior to exercise.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.

Restricted Stock Units
Restricted stock units, which are rights to receive shares of company stock, were granted from 2009 through 2016 under the 2007 Plan and since 2017 under the 2017 Plan.  The fair value of a restricted stock unit is the market value as determined by the closing price of the stock on the day of grant.

The following table summarizes restricted stock unit activity:
 
 

Restricted Stock
Units
 
Weighted-
Average
Grant-Date
Fair Value
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic Value
(in millions)
Outstanding, December 31, 2017
 
473,000

 
$
172.76

 
 
 
 
Granted
 
185,755

 
$
326.15

 
 
 
 
Vested
 
(128,294
)
 
$
158.49

 
 
 
 
Forfeited
 
(56,011
)

$
182.15

 
 
 
 
Outstanding, December 31, 2018
 
474,450

 
$
235.57

 
2.11
 
$
110.2



The total fair value of restricted stock units vested in 2018, 2017 and 2016 was $40.0 million, $27.7 million and $18.7 million, respectively. As of December 31, 2018, there was approximately $102.4 million of total unrecognized compensation cost related to restricted stock units.  This amount is expected to be recognized over a remaining weighted-average period of approximately 4 years.

Employee Stock Purchase Plans
The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions:


78


 
Year Ended December 31,
 
2018
 
 
 
2017
 
 
 
2016
Expected volatility
27
%
 
 
 
19
%
 
 
 
20
%
Risk-free interest rate
1.82
%
 
 
 
0.83
%
 
 
 
0.26
%
Expected life (in years)
0.24

 
 
 
0.24

 
 
 
0.25

Expected dividend
—

 
 
 
—

 
 
 
—

Weighted-average fair value
 
 
 
 
 
 
 
 
 
of purchase rights
$
55.04

 
 
 
$
38.86

 
 
 
$
27.36



The major assumptions are primarily based on historical data.  Volatility is based on the historical volatilities of our common stock for a period equal to the expected life of the purchase rights.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.

We sold 63,464 shares for $13.6 million, 74,409 shares for $13.0 million and 93,605 shares for $11.5 million under the 2011 ESPP to employees in 2018, 2017 and 2016, respectively.  At December 31, 2018, 658,248 shares remain authorized and available for issuance under the 2011 ESPP.

We currently issue new shares or treasury shares, if available, to satisfy stock option exercises, restricted stock issuances and ESPP stock purchases.



10. OTHER INCOME AND EXPENSE, NET

Other (income) expense, net includes the following components (in millions):
 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
 
 
 
 
 
 
 
Interest and investment income
 
$
(26.6
)
 
$
(19.1
)
 
$
(14.7
)
Net realized gains on investments
 
(1.6
)
 
(0.1
)
 
(0.8
)
Other-than-temporary impairment losses on investments
 
0.8

 
7.0

 
0.6

Gain on sale of land
 
(4.1
)
 
—

 
—

Gain on divestiture of product line
 
(5.1
)
 
—

 
—

Other expense
 
—

 
1.5

 
1.1

Other (income) expense, net
 
$
(36.6
)
 
$
(10.7
)
 
$
(13.8
)


Prior year amounts have been adjusted (see Note 1 to the consolidated financial statements in regard to ASU 2017-07) for pension and other postretirement benefits.



79


11. SUPPLEMENTAL CASH FLOW INFORMATION

The reconciliation of net income to net cash provided by operating activities is as follows (in millions):

 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
Net income
 
$
365.6

 
$
122.2

 
$
26.0

Adjustments to reconcile net income
 
 

 
 

 
 

to net cash provided by operating activities
 
 

 
 

 
 

Depreciation and amortization
 
138.1

 
148.7

 
142.9

Share-based compensation
 
27.8

 
23.4

 
19.7

Gains on dispositions of securities
 
(1.6
)
 
(0.1
)
 
(0.8
)
Other-than-temporary impairment losses on investments
 
0.8

 
7.0

 
0.6

Changes in fair market value of equity securities
 
(606.2
)
 
—

 
—

Losses on dispositions of fixed assets
 
2.0

 
8.1

 
0.6

Gain on sale of land
 
(4.1
)
 
—

 
—

Gain on divestiture of a product line
 
(5.1
)
 
—

 
—

Excess tax benefits from share-based compensation
 
—

 
—

 
(1.5
)
Changes in fair value of contingent consideration
 
(6.2
)
 
(18.1
)
 
(0.4
)
Decrease (increase) in accounts receivable, net
 
59.7

 
(64.1
)
 
12.5

Increase in inventories, net
 
(12.9
)
 
(47.7
)
 
(57.1
)
Increase in other current assets
 
(15.3
)
 
(35.7
)
 
(6.8
)
(Decrease) increase in accounts payable
 


 


 


and other current liabilities
 
(45.6
)
 
7.8

 
30.1

(Decrease) increase in income taxes payable
 
(20.9
)
 
(22.4
)
 
10.7

Increase (decrease) in deferred income taxes
 
120.9

 
(82.0
)
 
(51.4
)
Decrease in other long term assets
 
1.1

 
2.3

 
12.5

(Decrease) increase in other long term liabilities
 
(10.0
)
 
38.1

 
10.4

Impairment losses on goodwill and long-lived assets
 
292.5

 
11.5

 
62.3

Other
 
4.9

 
5.1

 
5.8

Net cash provided by operating activities
 
$
285.5

 
$
104.1

 
$
216.1

 
 
 
 
 
 
 
Non-cash investing activities:
 
 
 
 
 
 
   Purchased property, plant and equipment
 
$
5.7

 
$
—

 
$
7.2

   Purchased marketable securities and investments
 
$
0.8

 
$
2.8

 
$
0.6





80


12. COMMITMENTS AND CONTINGENT LIABILITIES

Rents and Leases

Rental expense under operating leases was $47.4 million, $43.6 million and $44.4 million in 2018, 2017 and 2016, respectively.  Leases are principally for facilities and automobiles.

Annual future minimum lease payments at December 31, 2018 under operating leases are as follows: 2019 - $44.4 million; 2020 - $37.8 million; 2021 - $27.4 million; 2022 - $19.7 million; 2023 - $13.9 million; and 2024 and beyond - $25.6 million.

The total minimum rentals to be received in the future for subleases as of December 31, 2018 were $17.8 million.

Deferred Profit Sharing Retirement Plan

We have a profit sharing plan covering substantially all U.S. employees.  Contributions are made at the discretion of the Board of Directors.  Bio-Rad has no liability other than for the current year’s contribution.  Contribution expense was $15.9 million, $16.0 million and $15.1 million in 2018, 2017 and 2016, respectively.

Other Post-Employment Benefits
In several foreign locations we are statutorily required to provide retirement benefits or a lump sum termination indemnity to our employees upon termination for virtually any reason. These plans are accounted for as defined benefit plans and the associated net benefit obligation at December 31, 2018 and 2017 of $70.4 million and $74.9 million, respectively, has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets. Most plans are not required to be funded, and as such, there is no trust or other device used to accumulate assets or settle these obligations. However, some of these plans require funding based on local laws in which there is a trust or other device administered by an external plan manager that is used to accumulate assets to assist in settling these obligations. The following disclosures include such plans, which are located in France, Switzerland, Germany, Korea, India, Thailand, Italy, Dubai and Japan.

Obligations and Funded Status
The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in the Consolidated Balance Sheets for the plans (in millions):


81


Change in benefit obligation:
2018
2017
Benefit obligation at beginning of year
$136.6
$122.7
Service cost
7.5

6.5

Interest cost
1.1

1.1

Plan participants' contributions
3.1

2.8

Actuarial (gain) loss
(5.4
)
3.3

Gross benefits paid
(3.1
)
(3.2
)
Plan amendments
(0.5
)
1.1

Special termination benefits
—

(2.0
)
Settlements
—

(5.1
)
Change attributable to foreign exchange
(2.0
)
9.4

 
 
 
Benefit obligation at end of year
137.3

136.6

 
 
 
Change in plan assets:
 
 
Fair value of plan assets at beginning year
61.7

58.8

Actual return on plan assets
0.3

0.5

Employer contributions
4.0

4.0

Plan participants' contributions
3.1

2.8

Gross benefits paid
(1.5
)
(2.3
)
Settlements
—

(5.1
)
Change attributable to foreign exchange
(0.7
)
3.0

 
 
 
Fair value of plan assets at end of year
66.9

61.7

 
 
 
Under funded status of plans
$(70.4)
$(74.9)
 
 
 
Amounts recognized in the consolidated balance sheets:
 
 
Current liabilities (Accrued payroll and employee benefits)
$(1.1)
$(1.1)
Noncurrent liabilities (Other long-term liabilities)
(69.3
)
(73.8
)
 
 
 
Net liability, end of fiscal year
$(70.4)
$(74.9)
 
 
 


Components of Net Periodic Benefit Cost
The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions):

 
2018
2017
2016
Service costs
$7.5
$6.5
$6.1
Interest costs
1.1

1.1

1.4

Expected returns on plan assets
(1.1
)
(1.1
)
(1.0
)
Amortization of actuarial losses
1.3

1.4

1.7

Amortization of prior service costs
0.1

—

—

Settlements
—

1.2

0.4

 
 
 
 
Net periodic benefit costs
$8.9
$9.1
$8.6
 
 
 
 


82



Assumptions

The weighted-average assumptions used in computing the benefit obligations are as follows:


 
2018
2017
Discount rate
1.1
%
0.8
%
Compensation rate increase
1.8
%
1.8
%
 
 
 

The weighted-average assumptions used in computing the net periodic benefit costs are as follows:

 
2018
2017
2016
Discount rate
0.8
%
0.9
%
1.1
%
Expected long-term rate of return on plan assets
1.8
%
1.9
%
1.6
%
 
 
 
 


In some foreign locations we have service award plans that are paid based upon the number of years of employment. Under these plans, the liability at December 31, 2018 and 2017 was $3.1 million and $3.7 million, respectively, and has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets.

Purchase Obligations

As of December 31, 2018, we had obligations that have been recognized on our balance sheet of $110.9 million, which include purchases of goods and services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty. These obligations also include other post-employment benefits in some of our foreign locations as indicated above.

The annual future fixed and determinable portion of our purchase obligations that have been recognized on our balance sheet as of December 31, 2018 are as follows: 2019 - $5.8 million, 2020 - $16.4 million, 2021 - $6.2 million, 2022 - $2.4 million, 2022 - $3.5 million and after 2023 - $76.6 million.

As of December 31, 2018, we had purchase obligations that have not been recognized on our balance sheet of $12.5 million, which include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty.

The annual future fixed and determinable portion of our purchase obligations that have not been recognized on our balance sheet as of December 31, 2018 are as follows: 2019 - $6.5 million, 2020 - $5.3 million, 2021 - $0.1 million, 2022 - $0.2 million, 2022 - $0.2 million and after 2023 - $0.2 million.

Letters of Credit/Guarantees

In the ordinary course of business, we are at times required to post letters of credit/guarantees.  The letters of credit/guarantees are issued by financial institutions to guarantee our obligations to various parties. We were contingently liable for $3.1 million of standby letters of credit/guarantees with financial institutions as of December 31, 2018.

83



Contingent Consideration

During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount. In the first and third quarters of 2018, we paid $1.3 million and $0.8 million, respectively, per the purchase agreement. Since 2016 we have had a net decrease in the cumulative valuation of the sales milestones of $12.2 million. The contingent consideration was accrued at its estimated fair value of $8.4 million as of December 31, 2018.

Concentrations of Labor Subject to Collective Bargaining Agreements

At December 31, 2018, approximately eight percent of Bio-Rad's approximately 3,265 U.S. employees were covered by a collective bargaining agreement, which will expire on November 7, 2019.  Many of Bio-Rad's non-U.S. full-time employees, especially in France, are covered by collective bargaining agreements.


13.    LEGAL PROCEEDINGS

On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015, we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million, plus prejudgment interest of $141,608, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We have provided for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017, we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit. Oral arguments occurred on November 14, 2018. On February 26, 2019, the United States Court of Appeals for the Ninth Circuit issued its decision, reversing in part, vacating in part, and affirming in part. Specifically, the court: (1) reversed the Dodd-Frank claim, which amounts to about $2.96 million plus interest, and directed the district court to enter judgment in Bio-Rad’s favor on that claim; (2) vacated the SOX claim due to instructional error and remanded for further proceedings, including whether a new trial is needed; and (3) affirmed the California public policy claim and the $7.96 million in damages attributable to it. On March 12, 2019 we filed a petition for panel rehearing or rehearing en banc with the United States Court of Appeals for the Ninth Circuit.

We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.

84




14. SEGMENT INFORMATION

Bio-Rad is a multinational manufacturer and worldwide distributor of its own life science research products and clinical diagnostics products.  We have two reportable segments:  Life Science and Clinical Diagnostics.  These reportable segments are strategic business lines that offer more than 9,000 different products and services and require different marketing strategies. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.

The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. These products are sold to university and medical school laboratories, pharmaceutical and biotechnology companies, food testing laboratories and government and industrial research facilities.

The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. These products are sold to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories and insurance and forensic testing laboratories.

Other Operations include the remainder of our Analytical Instruments segment.

Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. The accounting policies of the segments are the same as those described in Significant Accounting Policies (see Note 1).  Segment profit or loss includes an allocation of corporate expense based upon sales and an allocation of interest expense based upon accounts receivable and inventories.  The difference between total segment allocated interest expense, depreciation and amortization, and capital expenditures and the corresponding consolidated amounts is attributable to our corporate headquarters.  Segments are expected to manage only assets completely under their control.  Accordingly, segment assets include primarily accounts receivable, inventories and gross machinery and equipment.  Goodwill balances have been included in corporate for segment reporting purposes.

Information regarding industry segments at December 31, 2018, 2017, and 2016 and for the years then ended is as follows (in millions):


85


 
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
Segment net sales 
2018
 
$
861.7

 
$
1,411.8

 
$
15.9

 
2017
 
785.2

 
1,360.8

 
14.2

 
2016
 
730.7

 
1,323.3

 
14.2

 
 
 
 
 
 
 
 
Allocated interest expense
2018
 
$
7.2

 
$
16.7

 
$
0.1

 
2017
 
7.0

 
14.9

 
—

 
2016
 
6.9

 
16.5

 
—

 
 
 
 
 
 
 
 
Depreciation and amortization
2018
 
$
34.1

 
$
72.0

 
$
0.5

 
2017
 
36.2

 
80.2

 
—

 
2016
 
31.7

 
80.5

 
—

 
 
 
 
 
 
 
 
Segment profit (loss)
2018
 
$
28.7

 
$
(145.7
)
 
$
0.2

 
2017
 
(9.9
)
 
114.8

 
1.4

 
2016
 
(19.1
)
 
58.0

 
0.9

 
 
 
 
 
 
 
 
Segment assets
2018
 
$
450.2

 
$
949.0

 
$
5.9

 
2017
 
453.0

 
1,038.4

 
4.8

 
 
 
 
 
 
 
 
Capital expenditures
2018
 
$
36.7

 
$
60.5

 
$
0.5

 
2017
 
12.6

 
59.0

 
—




Prior year amounts have been adjusted (see Note 1 to the consolidated financial statements in regard to ASU 2017-07 for pension and other postretirement benefits). Clinical Diagnostics segment loss for 2018 was due to impairment losses taken on goodwill of $276.1 million (see Note 4 to the consolidated financial statements)

Net corporate operating expense consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. The following reconciles total segment profit to consolidated income before taxes (in millions):
 
 
 
Year Ended December 31,
 
2018
 
2017
 
2016
Total segment (loss) profit
$
(116.8
)
 
$
106.3

 
$
39.8

Foreign currency exchange losses, net
(2.9
)
 
(9.1
)
 
(4.5
)
Net corporate operating, interest and other expense not allocated to segments
(10.4
)
 
(10.1
)
 
(7.5
)
Change in fair market value of equity securities
606.2

 
—

 
—

Other income (expense), net
36.6

 
10.7

 
13.8

Consolidated income before income taxes
$
512.7

 
$
97.8

 
$
41.6



Prior year amounts have been adjusted (see Note 1 to the consolidated financial statements in regard to ASU 2017-07) for pension and other postretirement benefits.

86



The following reconciles total segment assets to consolidated total assets (in millions):

 
 
December 31,
 
 
2018
 
2017
Total segment assets
 
$
1,405.1

 
$
1,496.2

Cash and other current assets
 
1,047.2

 
965.8

Property, plant and equipment, net, excluding
 

 

  segment specific gross machinery and equipment
 
79.9

 
57.0

Goodwill, net
 
219.8

 
506.1

Other long-term assets
 
2,859.1

 
1,247.9

Total assets
 
$
5,611.1

 
$
4,273.0





The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):

 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
Europe
 
$
792.0

 
$
758.5

 
$
742.2

Pacific Rim
 
495.5

 
461.3

 
427.1

United States
 
863.6

 
800.2

 
770.6

Other (primarily Canada and Latin America)
 
138.3

 
140.2

 
128.3

Total net sales
 
$
2,289.4

 
$
2,160.2

 
$
2,068.2


The following presents Property, plant and equipment, net, Other investments and Other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):

 
 
December 31,
 
 
2018
 
2017
Europe**
 
$
1,571.9

 
$
230.6

Pacific Rim
 
20.7

 
18.4

United States  
 
1,582.1

 
1,305.2

Other (primarily Canada and Latin America)
 
11.1

 
13.1

Total Property, plant and equipment, net, Other investments and Other assets, excluding deferred income taxes
 
$
3,185.8

 
$
1,567.3


** The amounts primarily include our investment in the ordinary voting stock of Sartorius AG, of Goettingen, Germany (see Note 3). In 2017 this investment was accounted for under the cost method, and in 2018 it was accounted for at fair value in accordance with ASU 2016-01 (see Note 1).

87




15.    RESTRUCTURING COSTS

Restructuring Costs for European Reorganization

In May 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance enterprise resource planning ("ERP") platform, are expected to be incurred through 2019. We recorded approximately $(0.2) million, $0.5 million and $12.5 million in restructuring charges and adjustments related to severance and other employee benefits for the years ended December 31, 2018, 2017 and 2016, respectively. From May 2016 to December 31, 2018, total expenses were $12.8 million. The liability of $1.6 million as of December 31, 2018 was recorded in Accrued payroll and employee benefits in the Consolidated Balance Sheets. The amounts recorded were reflected in Cost of goods sold of $(0.1) million, $(0.2) million and $2.1 million, and in Selling, general and administrative expense of $(0.1) million, $0.7 million and $10.4 million in the Consolidated Statements of Income for the years ended December 31, 2018, 2017 and 2016, respectively. The amounts adjusted were primarily for additional positions identified for elimination, partially offset by employees finding other positions within Bio-Rad or leaving prematurely.

The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions):

 
 
2018
 
2017
 
 
Life Science
 
Clinical Diagnostics
 
Total
 
Life Science
 
Clinical Diagnostics
 
Total
Balance as of January 1
 
$
2.2

 
$
4.1

 
$
6.3

 
$
3.2

 
$
5.8

 
$
9.0

Adjustment to expense
 
(0.1
)
 
(0.1
)
 
(0.2
)
 
0.2

 
0.3

 
0.5

Cash payments
 
(1.5
)
 
(2.9
)
 
(4.4
)
 
(1.5
)
 
(2.7
)
 
(4.2
)
Foreign currency translation (gains) losses
 
—

 
(0.1
)
 
(0.1
)
 
0.3

 
0.7

 
1.0

Balance as of December 31
 
$
0.6

 
$
1.0

 
$
1.6

 
$
2.2

 
$
4.1

 
$
6.3




Restructuring Costs for Termination of a Diagnostics Research and Development Project and Facility Closures

In December 2017, we announced the termination of a diagnostics research and development project in Europe. From December 2017 to December 31, 2018, total expenses were $21.4 million. We recorded restructuring charges and adjustments related to severance and employee benefits of $0.4 million and $11.0 million, and asset write-offs and exit costs of $(0.1) million and $10.1 million for the years ended December 31, 2018 and 2017, respectively.

In June 2018, we announced the closure of a small manufacturing operation in Munich, Germany. We recorded $1.7 million of expense in restructuring charges related to severance and employee benefits for the year ended December 31, 2018.

In December 2018, we announced the closure of a small manufacturing facility outside Paris, France. We recorded restructuring charges related to severance and employee benefits of $3.9 million and exit costs of $0.2 million for the year ended December 31, 2018.

88



Restructuring charges for the termination of a diagnostics research and development project and the facility closures are all included in our Clinical Diagnostics segment's results of operations. The facility closures are a natural evolution from the larger consolidations that began with the 2016 European reorganization activities described above. The amounts recorded were reflected in Cost of goods sold of $5.4 million and $2.3 million, in Selling, general and administrative expense of $0.4 million and $3.3 million, and in Research and development expense of $0.3 million and $15.5 million in the Consolidated Statements of Income for the years ended December 31, 2018 and 2017, respectively. The liability of $11.5 million as of December 31, 2018 consisted of $7.3 million recorded in Accrued payroll and employee benefits, and $4.2 million recorded in Other long-term liabilities in the Consolidated Balance Sheets.

The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closures restructuring reserves for severance and exit costs (in millions):

 
 
2018
 
2017
Balance as of January 1
 
$
14.1

 
$
—

Charged to expense
 
5.8

 
14.0

Adjustment to expense
 
0.3

 
—

Cash payments
 
(8.4
)
 
—

Foreign currency translation (gains) losses
 
(0.3
)
 
0.1

Balance as of December 31
 
$
11.5

 
$
14.1



Restructuring Costs for GnuBIO, Inc.

In 2014, we acquired GnuBIO, Inc. (GnuBIO) as a business acquisition. It was included in our Clinical Diagnostics segment’s results of operations as a division, and was primarily based in Massachusetts. In September 2017, we announced that we were closing the GnuBIO research program facilities in Massachusetts. We recorded restructuring charges in September 2017 related to severance and employee benefits of $2.9 million and asset write-offs of $5.5 million. The amounts recorded were reflected in Selling, general and administrative expense of $0.8 million and in Research and development expense of $7.6 million in the Consolidated Statements of Income for the year ended December 31, 2017. The liability balance as of December 31, 2017 was $1.4 million and was recorded in Accrued payroll and employee benefits in the Consolidated Balance Sheets. The liability was paid in early 2018.


89




16. QUARTERLY FINANCIAL DATA (UNAUDITED)

Summarized quarterly financial data for 2018 and 2017 are as follows (in millions, except per share data):

 
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
2018
 
 
 
 
 
 
 
 
Net sales
 
$
551.5

 
$
575.9

 
$
545.1

 
$
616.9

Gross profit
 
302.2

 
301.7

 
286.7

 
332.6

Net income (loss)
 
656.8

 
268.0

 
269.3

 
(828.5
)
Basic earnings (loss) per share
 
$
22.05

 
$
8.99

 
$
9.02

 
$
(27.73
)
Diluted earnings (loss) per share
 
$
21.77

 
$
8.87

 
$
8.89

 
$
(27.73
)
 
 
 
 
 
 
 
 
 
2017
 
 
 
 
 
 
 
 
Net sales
 
$
500.1

 
$
504.7

 
$
534.1

 
$
621.3

Gross profit
 
270.1

 
273.4

 
299.0

 
345.2

Net income
 
12.4

 
5.0

 
22.1

 
82.7

Basic earnings per share
 
$
0.42

 
$
0.17

 
$
0.74

 
$
2.78

Diluted earnings per share
 
$
0.41

 
$
0.17

 
$
0.73

 
$
2.75



As a result of the net loss for the three months ended December 31, 2018, all potentially issuable common shares have been excluded from the diluted shares used in the computation of earnings per share as their effect was anti-dilutive. The net loss for the three months ended December 31, 2018 was primarily due to an $814.1 million decrease in fair market value of equity securities, primarily due to the adoption of ASU 2016-01 (see Note 1 to the consolidated financial statements) and mostly consisted of holding losses on our investment in Sartorius AG. The net loss for the three months ended December 31, 2018 also included impairment losses on goodwill and long-lived assets in the amount of $292.5 million (see Note 4 to the consolidated financial statements).

Prior year amounts have been adjusted (see Note 1 to the consolidated financial statements in regard to ASU 2017-07) for pension and other postretirement benefits.


17. SUBSEQUENT EVENT

On March 4, 2019, we acquired all the issued and outstanding stock of a small commercial-stage company for approximately $20 million. We believe this acquisition will complement our offerings of life science products. The acquisition will be included in our Life Science segment's results of operations from the acquisition date and will be accounted for as a business acquisition. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process.

We are presently unable to report the purchase price allocation or the evaluation of the transaction, as more time is needed to complete the information transfer from the seller and include all information into a valuation of individual assets and liabilities.

90




ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

Not applicable.



ITEM 9A.  CONTROLS AND PROCEDURES

(a)
Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures”, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Subject to the limitations noted above, our management, with the participation of our CEO and CFO, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the year covered by this Annual Report on Form 10-K. Based on that evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective to meet the objective for which they were designed and operate at the reasonable assurance level.

(b) Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company as defined in Rule 13a-15(f) or 15(d)-15(f) of the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with U.S. generally accepted accounting principles, and includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company’s assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with U.S. generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our consolidated financial statements.

91



Our management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2018 using the criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO"). Based on this assessment and those criteria, management concluded that our internal control over financial reporting was effective as of December 31, 2018. Our internal control over financial reporting has been audited by KPMG, LLP, an independent registered public accounting firm, as stated in their report, which appears in Part II, Item 8 of this Form 10-K.

(c) Remediation of Prior Material Weakness

As previously discussed in Item 9A "Controls and Procedures" of our Annual Report for the period ended December 31, 2017, and Item 4 "Controls and Procedures" of our 2018 Form 10-Q's, management identified a material weakness in our internal control over financial reporting resulting from our ERP system conversion and European reorganization leading to the internal control deficiencies described below.

We did not maintain a sufficient complement of personnel in certain European countries with appropriate training and expertise in accounting and reporting in the new ERP system following the system conversion and European reorganization including the implementation of reporting lines, appropriate authorities and responsibilities within and between our accounting and reporting function, information technology and the business operations in these European countries.

We did not conduct continuous risk assessment over changes in our European business operations, IT systems and personnel to identify and assess necessary changes in internal control over financial reporting.

As a result, we did not design effective control activities over the accounting for financial statement amounts, including inventory and revenue, reported by entities impacted by the European reorganization, including management review controls with sufficient precision to identify and investigate potential outliers.

During the fourth quarter of 2017 and throughout 2018 management conducted a global remediation plan with a focus on employees and processes in Europe as well as changes originating from system conversions to address its material weakness. The remediation plan involved enhancing the control environment in the entities impacted by the ERP system conversion and European reorganization by (i) increasing resources with sufficient accounting and reporting expertise within our reorganized business and with expertise in using our new ERP system, (ii) enhancing and monitoring reporting lines and appropriate authorities and responsibilities within the accounting and reporting function, information technology and the business operations and (iii) providing training to our control owners to effectively perform controls in the new environment including training on reconciliation review controls and certain ERP system enhancements. Testing of the operating effectiveness of the remediated controls has demonstrated the efficacy of the enhancements in Europe.

Management enhanced its risk assessment process to continuously assess the potential impact on internal control over financial reporting of changes to business operations, including changes relating to system conversions and operations reorganizations that may occur in the future.

In addition, management designed and implemented additional control activities over financial statement amounts reported by entities impacted by the European reorganization, including inventory, revenue and cost of goods sold.

Implementation of management's remediation plans described above have strengthened our internal control over financial reporting and addressed the material weakness that was identified in 2017. Based on the effectiveness of the changes to our internal controls, management concluded that the material weakness has been remediated as of December 31, 2018.

92



(d) Changes in Internal Control over Financial Reporting

Management continuously reviews disclosure controls and procedures, and internal control over financial reporting, and accordingly may, from time to time, make changes aimed at enhancing their effectiveness to ensure that its systems evolve with its business. Other than with respect to the remediation efforts described above, there were no changes in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15(d)-15(f) under the Exchange Act) during the year ended December 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

(e) Inherent Limitations on Effectiveness of Internal Controls

Because of its inherent limitations, our internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

ITEM 9B.  OTHER INFORMATION

None.


PART III.

ITEM 10.  DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Part of the information required to be furnished pursuant to this item is incorporated by reference from portions of Bio-Rad’s definitive proxy statement to be mailed to stockholders in connection with our 2019 annual meeting of stockholders (the “2019 Proxy Statement”) under “Election of Directors,” “Committees of the Board of Directors” and “Section 16(a) Beneficial Ownership Reporting Compliance.”

Bio-Rad’s Board of Directors has determined that each of Jeffrey L. Edwards, Gregory K. Hinckley and Melinda Litherland is an “audit committee financial expert,” as defined in Item 407(d)(5) of Regulation S-K.  Each of Jeffrey L. Edwards, Gregory K. Hinckley and Melinda Litherland is also an “independent” director, as determined in accordance with the independence standards set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and Section 303A.02 of the New York Stock Exchange (NYSE) Listed Company Manual.

We have adopted a code of business ethics and conduct that applies to our principal executive officer, principal financial officer, controller and all other employees and is available through the Corporate Governance section of our website (www.bio-rad.com).  We will also provide a copy of the code of ethics to any person, without charge, upon request, by writing to us at “Bio-Rad Laboratories, Inc., Investor Relations, 1000 Alfred Nobel Drive, Hercules, CA  94547.” We intend to satisfy any disclosure requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of the code of ethics by posting such information on the Corporate Governance section of our website (www.bio-rad.com).

93




ITEM 11.  EXECUTIVE COMPENSATION

The information required to be furnished pursuant to this item is incorporated by reference from portions of the 2019 Proxy Statement under “Compensation Discussion and Analysis,” “Summary Compensation Table,” “Grants of Plan-Based Awards,” “Outstanding Equity Awards at Fiscal Year-End,” “Option Exercises and Stock Vested Table,” “Pension Benefits,” “Nonqualified Deferred Compensation Plans,” “Potential Payments on Termination or Change in Control,” “Director Compensation,” “Compensation Committee Interlocks and Insider Participation” and "Pay Ratio Disclosure.”  In addition, the information from a portion of the 2019 Proxy Statement under “Compensation Committee Report” is incorporated herein by reference and furnished on this Form 10-K and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933.


ITEM 12.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Part of the information required to be furnished pursuant to this item is incorporated by reference from a portion of the 2019 Proxy Statement under “Principal and Management Stockholders.”

Equity Compensation Plan Information as of December 31, 2018
Plan category
 
Number of securities
to be issued
upon exercise of outstanding options,
warrants and rights
 
Weighted-average exercise price of
outstanding options,
warrants and rights
 
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
 
 
(a)
 
(b)(3)
 
(c)
Equity compensation plans approved by
 
 
 
 
 
 
 
 
security holders (1)
 
848,090

 
$
138.81

 
2,243,082

 
(2)
Equity compensation plans not approved by
 
 
 
 
 
 
 
 
security holders
 
—

 
—

 
—

 
 
Total
 
848,090

 
$
138.81

 
2,243,082

 
 

(1)
Consists of the Bio-Rad Laboratories, Inc. 2007 Incentive Award Plan, the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan, and the Bio-Rad Laboratories, Inc. 2011 Employee Stock Purchase Plan.
(2)
Consists of 1,584,834 shares available under the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan and 658,248 shares available under the Bio-Rad Laboratories, Inc. 2011 Employee Stock Purchase Plan.
(3)
Excludes Restricted Stock Units.


ITEM 13.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE

The information required to be furnished pursuant to this item is incorporated by reference from portions of the 2019 Proxy Statement under “Transactions with Related Persons” and “Committees of the Board of Directors.”


ITEM 14.  PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required to be furnished by this item is incorporated by reference from a portion of the 2019 Proxy Statement under “Report of the Audit Committee of the Board of Directors.”


94



PART IV.

ITEM 15.  EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
 
 
 
(a)1
Index to Financial Statements – See Item 8 of Part II of this report “Financial Statements and
 
Supplementary Data" on page 41 for a list of financial statements.
 
 
 
2
Schedule II Valuation and Qualifying Accounts
 
 
 
 
All other financial statement schedules are omitted because they are not required or the required information is included in the consolidated financial statements or the notes thereto.
 

BIO-RAD LABORATORIES, INC.
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
Years Ended December 31, 2018, 2017, and 2016
(in thousands)


Allowance for doubtful accounts receivable
 
 
Balance at
Beginning
of Year
 

Charged to Costs
and Expenses
 
Deductions
 
Balance at
End of Year
2018
 
$
25,549

 
$
11,527

 
$
(10,363
)
 
$
26,713

2017
 
$
23,367

 
$
11,174

 
$
(8,992
)
 
$
25,549

2016
 
$
24,418

 
$
3,785

 
$
(4,836
)
 
$
23,367



Valuation allowance for long-term deferred tax assets
 
 
Balance at
Beginning
of Year
 
Additions Charged
(Credited) to Income
Tax Expense
 
Deductions
 
Balance at 
End of Year 
2018
 
$
66,356

 
$
4,413

 
$
—

 
$
70,769

2017
 
$
66,403

 
$
(47
)
 
$
—

 
$
66,356

2016
 
$
58,277

 
$
8,126

 
$
—

 
$
66,403



 
 
 
3.
Index to Exhibits
 
 
 
 
The exhibits listed below in the accompanying Index to Exhibits are filed or incorporated by reference as part of this report.
 
 
 



95



 
BIO-RAD LABORATORIES, INC.
INDEX TO EXHIBITS ITEM 15(a)3
 
Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed under the Securities Exchange Act of 1934.”
 
Exhibit No.
 
 
 
3.1

 
 
3.1.1

 
 
3.2

 
 
4.1

 
 
 
10.1

 
 
10.2

 
 
10.2.1

 
 
10.3

 
 
10.4

 
 
10.4.1

 
 
10.4.2




96


 
 
10.7

 
 
10.8

 
 
10.9

 
 
 
10.10

 
 
 
 
Exhibit No.
 
 
 
21.1

 
 
23.1

 
 
31.1

 
 
31.2

 
 
32.1

 
 
 
32.2

 
 
 
101.INS
The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
101.SCH
XBRL Taxonomy Extension Schema Document
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
XBRL Taxonomy Extension Labels Linkbase Document
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
(1
)
Incorporated by reference to the Exhibits to Bio-Rad’s Form 10-K filing for the fiscal year ended
 
December 31, 2010.
 
 
(2
)
Incorporated by reference to Exhibit 3.1 to Bio-Rad’s Form 8-K filing, dated October 27, 2017.
 
 
(3
)
Incorporated by reference to Exhibit 4.1 to Bio-Rad’s Form 8-K filing, dated December 9, 2010.
 
 
(4
)
Incorporated by reference to the Exhibits to Bio-Rad’s 8-K filing, dated June 26, 2014.
 
 
(5
)
Incorporated by reference to Exhibit 10.9 to Bio-Rad's June 30, 2011 Form 10-Q filing, dated August 4, 2011.
 
 
(6
)
Incorporated by reference to Exhibit 10.2 to Bio-Rad’s Form 10-Q filing, dated May 9, 2017

97


 
 
(7
)
Incorporated by reference to Exhibit 10.6 to Bio-Rad’s September 30, 1997 Form 10-Q filing, dated
 
November 13, 1997.
 
 
(8
)
Incorporated by reference to Exhibit 10.7 to Bio-Rad’s March 31, 2003 Form 10-Q filing, dated
 
May 13, 2003.
 
 
(9
)
Incorporated by reference to Exhibit 10.7.1 to Bio-Rad’s March 31, 2007 Form 10-Q filing, dated May 4, 2007.
 
 
(10
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s June 30, 2012 Form 10-Q filing, dated August 9, 2012.
 
 
(11
)
Incorporated by reference to Exhibit 4.1 to Bio-Rad’s Form S-8 filing, dated July 30, 2007.
 
 
(12
)
Incorporated by reference to Exhibit 10.8.1 to Bio-Rad’s September 30, 2009 Form 10-Q filing, dated November 4, 2009.
 
 
(13
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s March 31, 2014 Form 10-Q filing, dated May 8, 2014.
 
 
(14
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated May 9, 2017
 
 
(15
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated November 9, 2017
 
 
(16
)
Incorporated by reference to Exhibit 10.2 to Bio-Rad’s Form 10-Q filing, dated November 9, 2017
 
 
(17
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated August 7, 2017.
 
 
(18
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated November 7, 2014.
 
 
(19
)
Incorporated by reference to the Exhibits to Bio-Rad’s Form 10-K filing for the fiscal year ended December 31, 2014.


Item 16. FORM 10-K SUMMARY

Not applicable.



98




SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIO-RAD LABORATORIES, INC.
 
 
By:
/s/ Christine A. Tsingos
 
Christine A. Tsingos
 
Executive Vice President, Chief Financial Officer
 
 
Date:
March 29, 2019

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
 
 
 
Principal Executive Officer:
Chairman of the Board, President
 
/s/ Norman Schwartz
and Chief Executive Officer
March 29, 2019
(Norman Schwartz)
 
 
 
 
 
Principal Financial Officer:
 
 
/s/ Christine A. Tsingos
Executive Vice President,
 
(Christine A. Tsingos)
Chief Financial Officer
March 29, 2019
 
 
 
Principal Accounting Officer:
 
 
/s/ James R. Stark
Vice President, Corporate Controller
March 29, 2019
(James R. Stark)
 
 
 
 
 
Other Directors:
 
 
/s/ Jeffrey L. Edwards
Director
March 29, 2019
(Jeffrey L. Edwards)
 
 
 
 
 
/s/ Gregory K. Hinckley
Director
March 29, 2019
(Gregory K. Hinckley)
 
 
 
 
 
/s/ Melinda Litherland
Director
March 29, 2019
(Melinda Litherland)
 
 
 
 
 
/s/ Arnold A. Pinkston
Director
March 29, 2019
(Arnold A. Pinkston)
 
 
 
 
 
/s/ Alice N. Schwartz
Director
March 29, 2019
(Alice N. Schwartz)
 
 


99
 EX-21.1 2 ex211123118.htm EXHIBIT 21.1 12.31.18 Exhibit


Exhibit 21.1
LISTING OF SUBSIDIARIES
 
 
 
 
 
JURISDICTION OF
SUBSIDIARY
 
ORGANIZATION
 
 
 
Bio-Rad Laboratories Pty Ltd
 
Australia
Bio-Rad Laboratories Ges.m.b.H.
 
Austria
DiaMed Österreich GmbH
 
Austria
Bio-Rad Laboratories NV
 
Belgium
Research Specialties for Laboratories NV
 
Belgium
DiaMed Benelux NV
 
Belgium
Bio-Rad Laboratórios Brasil Ltda.
 
Brazil
DiaMed Latino-América S.A.
 
Brazil
Bio-Metrics Properties Limited
 
California, USA
Bio-Rad Laboratories (Israel), Inc.
 
California, USA
Bio-Rad Pacific Limited
 
California, USA
Bio-Rad Laboratories (Canada) Limited
 
Canada
Bio-Rad Laboratories (Shanghai) Co., Ltd.
 
China
Bio-Rad (Shanghai) Life Science Research & Development Co., Ltd.
 
China
Wuxi BioCanal Nano Technology Co. Ltd.
 
China
BIO-RAD spol. s r.o.
 
Czech Republic
Bio-Rad Export LLC
 
Delaware, USA
Bio-Rad Holdings, LLC
 
Delaware, USA
Bio-Metrics, Limited
 
Delaware, USA
Bio-Rad QL, Inc.
 
Delaware, USA
GnuBIO Inc.
 
Delaware, USA
Raindance Techologies, Inc.
 
Delaware, USA
Bio-Rad Denmark ApS
 
Denmark
DiaMed Fennica Oy
 
Finland
Bio-Rad France Holding
 
France
Bio-Rad Innovations
 
France
Bio-Rad Laboratories SAS
 
France
Bio-Rad France
 
France
Bio-Rad
 
France
Bio-Rad Services France
 
France
DiaMed France SA
 
France
Bio-Rad 1
 
France
Bio-Rad Laboratories GmbH
 
Germany
Bio-Rad Germany Holding GmbH
 
Germany
DiaMed Diagnostika Deutschland GmbH
 
Germany
Bio-Rad Medical Diagnostics GmbH
 
Germany
Bio-Rad AbD Serotec GmbH
 
Germany
Bio-Rad Laboratories Logistik GmbH
 
Germany
 
 
 

1


LISTING OF SUBSIDIARIES- continued
 
 
 
 
 
JURISDICTION OF
SUBSIDIARY
 
ORGANIZATION
 
 
 
Bio-Rad Laboratories M.EPE
 
Greece
Bio-Rad China Ltd.
 
Hong Kong
Bio-Rad Hungary Trading LLC
 
Hungary
IMV Medical Information Division, Inc.
 
Illinois, USA
Bio-Rad Laboratories (India) Private Limited
 
India
Bio-Rad Haifa Ltd.
 
Israel
Bio-Rad Laboratories S.r.l.
 
Italy
Bio-Rad Laboratories K.K.
 
Japan
Bio-Rad Korea Ltd.
 
Korea
Bio-Rad Luxembourg S.à r.l.
 
Luxembourg
International Marketing Ventures, Ltd.
 
Maryland, USA
Bio-Rad, S.A.
 
Mexico
Bridger Technologies, Inc.
 
Montana, USA
Bio-Rad Laboratories B.V.
 
The Netherlands
Bio-Rad Norway AS
 
Norway
Bio-Rad Polska Sp. z o.o.
 
Poland
Bio-Rad Laboratories-Aparelhos e Reagentes para Laboratórios, Lda
 
Portugal
Bio-Rad Laboratorii OOO
 
Russia
Bio-Rad Laboratories (Singapore) Pte Ltd
 
Singapore
Bio-Rad Laboratories (Pty) Ltd
 
South Africa
Bio-Rad Laboratories, S.A.
 
Spain
Distribudora de Analítica para la Medicina Ibérica, S.A.U.
 
Spain
Bio-Rad Laboratories AB
 
Sweden
Bio-Rad Europe GmbH
 
Switzerland
Bio-Rad IHC Europe GmbH
 
Switzerland
DiaMed Holding GmbH
 
Switzerland
DiaMed (Schweiz) GmbH
 
Switzerland
DiaMed GmbH
 
Switzerland
Bio-Rad Laboratories AG
 
Switzerland
Bio-Rad Laboratories Ltd.
 
Thailand
DiaMed S.E.A. Limited
 
Thailand
Bio-Rad Middle East FZ-LLC
 
United Arab Emirates
Bio-Rad Laboratories Limited
 
United Kingdom
DiaMed (G.B.) Ltd
 
United Kingdom
Bio-Rad AbD Serotec Ltd
 
United Kingdom
Bio-Rad Services UK Limited
 
United Kingdom
Bio-Metrics (U.K.) Limited
 
United Kingdom
Raindance Technologies Limited
 
United Kingdom
Respiratory Diagnostics, Inc.
 
Washington, USA


2
 EX-23.1 3 ex231123118.htm EXHIBIT 23.1 12.31.18 Exhibit


Exhibit 23.1



Consent of Independent Registered Public Accounting Firm




The Board of Directors
Bio-Rad Laboratories, Inc.:

We consent to the incorporation by reference in the registration statement on Form S-3 (No. 333‑170981) and on Forms S-8 (Nos. 333-220219, 333-144962, 333-133507, 333-124187, 333-53335, 333-53337, 333-179876, 333-197979 and 333-206885) of Bio-Rad Laboratories, Inc. of our reports dated March 29, 2019, with respect to the consolidated balance sheets of Bio-Rad Laboratories, Inc. as of December 31, 2018 and 2017, the related consolidated statements of income, comprehensive income, changes in stockholders' equity, and cash flows for each of the years in the three-year period ended December 31, 2018, and the related notes and financial statement schedule, which report appears in the December 31, 2018 annual report on Form 10‑K of Bio-Rad Laboratories, Inc.

Our report refers to a change in the accounting method for revenue recognition in 2018 due to the adoption of Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, and a change in the accounting method for equity instruments in 2018 due to the adoption of Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities.

/s/ KPMG LLP

Santa Clara, California
March 29, 2019



EX-31.1 4 ex311123118.htm EXHIBIT 31.1 12.31.18 Exhibit


Exhibit 31.1

Certification of Chief Executive Officer Required By
Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Norman Schwartz, certify that:

1.
I have reviewed this annual report on Form 10-K of Bio-Rad Laboratories, Inc.

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:
March 29, 2019
 
/s/ Norman Schwartz
 
 
 
Norman Schwartz, Chairman of the Board, President and
 
 
 
    Chief Executive Officer



 EX-31.2 5 ex312123118.htm EXHIBIT 31.2 12.31.18 Exhibit


Exhibit 31.2

Certification of Chief Financial Officer Required By
Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Christine A. Tsingos, certify that:

1.
I have reviewed this annual report on Form 10-K of Bio-Rad Laboratories, Inc.

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date:
March 29, 2019
 
/s/ Christine A.Tsingos
 
 
 
Christine A. Tsingos, Executive Vice President,
 
 
 
   Chief Financial Officer


 EX-32.1 6 ex321123118.htm EXHIBIT 32.1 12.31.18 Exhibit


Exhibit 32.1




Certification of Periodic Report


I, Norman Schwartz, Chief Executive Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Saran's-Oxley Act of 2002, 18 U.S.C. Section 1350, that:


(1)
the Annual Report on Form 10-K of the Company for the year ended December 31, 2018 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:
March 29, 2019
 
/s/ Norman Schwartz
 
 
 
Norman Schwartz, Chairman of the Board, President and
 
 
 
    Chief Executive Officer


The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Annual Report or as a separate disclosure document.


 EX-32.2 7 ex322123118.htm EXHIBIT 32.2 12.31.18 Exhibit


Exhibit 32.2




Certification of Periodic Report


I, Christine A. Tsingos, Chief Financial Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:


(1)
the Annual Report on Form 10-K of the Company for the year ended December 31, 2018 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date:
March 29, 2019
 
/s/ Christine A. Tsingos
 
 
 
Christine A. Tsingos, Executive Vice President,
 
 
 
   Chief Financial Officer

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Annual Report or as a separate disclosure document.



 EX-101.SCH 8 bio-20181231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2114100 - Disclosure - 10. Other Income and Expenses link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - 10. Other Income and Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - 10. Other Income and Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - 11. Supplemental Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - 11. Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - 11. Supplemental Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - 12. Commitments & Contingent Liabilities link:presentationLink link:calculationLink link:definitionLink 2316303 - Disclosure - 12. Commitments & Contingent Liabilities Assumptions for Benefit Obligations and Periodic Benefit Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 2416404 - Disclosure - 12. Commitments & Contingent Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2316302 - Disclosure - 12. Commitments & Contingent Liabilities Net Periodic Benefit Cost (Tables) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - 12. Commitments & Contingent Liabilities Pension obligations and funded status (Tables) link:presentationLink link:calculationLink link:definitionLink 2416406 - Disclosure - 12. Commitments & Contingent Liabilities Pensions (Details) link:presentationLink link:calculationLink link:definitionLink 2416405 - Disclosure - 12. Commitments & Contingent Liabilities Period Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - 13. Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 2421401 - Disclosure - 13. Legal Proceedings Legal Proceedings (Details) link:presentationLink link:calculationLink link:definitionLink 2424404 - Disclosure - 14. Segment Information Segment Asset Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2424405 - Disclosure - 14. Segment Information Segment Information by Geographical Location (Details) link:presentationLink link:calculationLink link:definitionLink 2424403 - Disclosure - 14. Segment Information Segment Profit Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2124100 - Disclosure - 14. Segment Reporting link:presentationLink link:calculationLink link:definitionLink 2424402 - Disclosure - 14. Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 2324301 - Disclosure - 14. Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 2425402 - Disclosure - 15. Restructuring Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2125100 - Disclosure - 15. Restructuring Costs (Notes) link:presentationLink link:calculationLink link:definitionLink 2325301 - Disclosure - 15. Restructuring Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 2127100 - Disclosure - 16. Quarterly Financial Data link:presentationLink link:calculationLink link:definitionLink 2427402 - Disclosure - 16. Quarterly Financial Data (Details) link:presentationLink link:calculationLink link:definitionLink 2327301 - Disclosure - 16. Quarterly Financial Data (Tables) link:presentationLink link:calculationLink link:definitionLink 2429402 - Disclosure - 17. Subsequent Event (Details) link:presentationLink link:calculationLink link:definitionLink 2129100 - Disclosure - 17. Subsequent Event (Notes) link:presentationLink link:calculationLink link:definitionLink 2329301 - Disclosure - 17. Subsequent Event (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - 1. Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401407 - Disclosure - 1. Significant Accounting Policies Details (Details) link:presentationLink link:calculationLink link:definitionLink 2401406 - Disclosure - 1. Significant Accounting Policies Earnings per share (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - 1. Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2301303 - Disclosure - 1. Significant Accounting Policies Prior Year Misstatements (Tables) link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - 1. Significant Accounting Policies Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2401408 - Disclosure - 1. Significant Accounting Policies Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - 1. Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2401405 - Disclosure - 1. Significant Accounting Policies Warranty rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - 2. Acquisitions link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - 2. Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2403407 - Disclosure - 3. Fair Value Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - 3. Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - 3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2403408 - Disclosure - 3. Fair Value Measurements Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - 3. Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2403406 - Disclosure - 3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - 3. Fair Value Measurements Foreign Exchange Forward Contracts (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - 3. Fair Value Measurements Short-term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - 3. Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - 4. Intangible Assets, Goodwill and Other link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - 4. Intangible Assets, Goodwill and Other (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - 5. Notes Payable and Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - 5. Notes Payable and Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - 5. Notes Payable and Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - 6. Income Taxes link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - 6. Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - 6. Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - 6. Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - 7. Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - 7. Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - 7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - 7. Stockholders' Equity Treasury Shares (Details) link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - 7. Stockholders' Equity Treasury Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - 8. Accumulated Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - 8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - 8. Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - 9. Share-based Compensation link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - 9. Share-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - 9. Share-based Compensation Restricted Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - 9. Share-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Consolidated Balance Sheets (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2128100 - Disclosure - Schedule II - Valuation and Qualifying Accoutns link:presentationLink link:calculationLink link:definitionLink 2428402 - Disclosure - Schedule II - Valuation and Qualifying Accoutns (Details) link:presentationLink link:calculationLink link:definitionLink 2328301 - Disclosure - Schedule II - Valuation and Qualifying Accoutns Schedule II - Valuation and Qualifying Accounts (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 bio-20181231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 bio-20181231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 bio-20181231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Assumptions for Benefit Obligations and Periodic Benefit Costs [Abstract] Assumptions for Benefit Obligations and Periodic Benefit Costs [Abstract] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Retirement Plan Tax Status [Axis] Retirement Plan Tax Status [Axis] Retirement Plan Tax Status [Domain] Retirement Plan Tax Status [Domain] Retirement Plan Funding Status [Axis] Retirement Plan Funding Status [Axis] Retirement Plan Funding Status [Domain] Retirement Plan Funding Status [Domain] Retirement Plan Name [Axis] Retirement Plan Name [Axis] Retirement Plan Name [Domain] Retirement Plan Name [Domain] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Industry Sector [Axis] Industry Sector [Axis] Industry Sector [Domain] Industry Sector [Domain] Investment Objective [Axis] Investment Objective [Axis] Investment Objective [Domain] Investment Objective [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Related Party Transaction [Axis] Related Party Transaction [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Schedule of Assumptions Used [Table Text Block] Schedule of Assumptions Used [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Debt Securities, Available-for-sale [Table Text Block] Debt Securities, Available-for-sale [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Schedule of Derivative Instruments [Table Text Block] Schedule of Derivative Instruments [Table Text Block] Financial assets and liabilities carried at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of available-for-sale investments Available-for-sale Securities [Table Text Block] Summary of investments with gross unrealized losses and the associated fair value Schedule of Unrealized Loss on Investments [Table Text Block] Summary of amortized cost and estimated fair value of debt securities by contractual maturity date Investments Classified by Contractual Maturity Date [Table Text Block] Estimated fair value of financial instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Document and Entity Information -- None. No documentation exists for this element. -- Entities [Table] Entities [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Class A [Member] Common Class A [Member] Common Class B [Member] Common Class B [Member] Statement [Line Items] Statement [Line Items] Entity Registrant Name Entity Registrant Name Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Emerging Growth Company Entity Emerging Growth Company Entity Small Business Entity Small Business Entity Shell Company Entity Shell Company Entity Filer Category Entity Filer Category Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Public Float Entity Public Float Obligations and Funded Status [Abstract] Obligations and Funded Status [Abstract] Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block] Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block] Defined Contribution Plan Disclosures [Table Text Block] Defined Contribution Plan Disclosures [Table Text Block] Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Deferred Tax Asset [Domain] Deferred Tax Asset [Domain] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] RainDance Technologies, Inc. [Member] RainDance Technologies, Inc. [Member] RainDance Technologies, Inc. [Member] Analytical Flow Cytometer Platform [Member] Analytical Flow Cytometer Platform [Member] Analytical Flow Cytometer Platform Business Acquisition [Line Items] Business Combination, Consideration Transferred Business Combination, Consideration Transferred Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed Payments to Acquire Businesses, Net of Cash Acquired Payments to Acquire Businesses, Net of Cash Acquired Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Goodwill, Purchase Accounting Adjustments Goodwill, Purchase Accounting Adjustments Goodwill Goodwill Goodwill, Acquired During Period Goodwill, Acquired During Period Business Combination, Consideration Transferred, Liabilities Incurred Business Combination, Consideration Transferred, Liabilities Incurred Income Tax Disclosure [Abstract] Income Tax Contingency [Table] Income Tax Contingency [Table] Fines and penalties [Axis] Fines and penalties [Axis] Fines and penalties [Axis] Fines and penalties [Domain] Fines and penalties [Domain] [Domain] for Fines and penalties [Axis] Net of prepaid taxes [Axis] Net of prepaid taxes [Axis] Net of prepaid taxes [Axis] Net of prepaid taxes [Domain] Net of prepaid taxes [Domain] [Domain] for Net of prepaid taxes [Axis] Net of prepaid taxes [Member] Net of prepaid taxes [Member] Net of prepaid taxes [Member] Dividends [Axis] Dividends [Axis] Dividends [Domain] Dividends [Domain] Foreign Tax Authority [Member] Foreign Tax Authority [Member] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Acquisition-related Costs [Member] Acquisition-related Costs [Member] Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Foreign Tax Credit Carryforward [Member] Foreign Tax Credit Carryforward [Member] Foreign Tax Credit Carryforward [Member] Research Tax Credit Carryforward [Member] Limitations On Use Limitations On Use [Member] Limitations On Use [Member] Including accrued interest and penalties [Axis] Including accrued interest and penalties [Axis] Including accrued interest and penalties [Domain] Including accrued interest and penalties [Domain] Including accrued interest and penalties [Domain] Including accrued interest and penalties [Member] Including accrued interest and penalties [Member] Including accrued interest and penalties [Member] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Domestic Tax Authority [Member] Tax Cuts and Jobs Act [Member] Tax Cuts and Jobs Act [Member] Tax Cuts and Jobs Act [Member] State and Local Jurisdiction [Member] State and Local Jurisdiction [Member] Income Taxes [Line Items] Income Tax Contingency [Line Items] Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Prepaid Taxes Prepaid Taxes U.S. Income (Loss) from Continuing Operations before Income Taxes, Domestic International Income (Loss) from Continuing Operations before Income Taxes, Foreign Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest U.S. Federal Current Federal Tax Expense (Benefit) State Current State and Local Tax Expense (Benefit) International Current Foreign Tax Expense (Benefit) Current Income Tax Expense (Benefit) Current Income Tax Expense (Benefit) U.S. Federal Deferred Federal Income Tax Expense (Benefit) State Deferred State and Local Income Tax Expense (Benefit) International Deferred Foreign Income Tax Expense (Benefit) Deferred tax benefit Deferred Income Tax Expense (Benefit) Non-current tax expense (benefit) Non Current Income Tax Expense Non Current Income Tax Expense Provision for income taxes Income Tax Expense (Benefit) U.S. statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Impact of foreign operations Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Foreign dividends, net Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent Research tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Nontaxable subsidies Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent Tax settlements and changes to unrecognized tax benefits Effective Income Tax Rate Reconciliation, Tax Settlement, Percent Goodwill impairment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent Domestic manufacturing deduction Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent Stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent Nondeductible executive compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent Fines and penalties Effective Income Tax Rate Reconciliation, Fines and Penalties, Percent Effective Income Tax Rate Reconciliation, Fines and Penalties, Percent Prior period adjustments Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent Other reconciling items Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent U.S. tax reform Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act State taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Provision for income taxes Effective Income Tax Rate Reconciliation, Percent Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit) Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit) Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit) Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Increase Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Increase Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Increase Tax Cuts and Jobs Act, Income Tax Expense (Benefit) Composition Tax Cuts and Jobs Act, Income Tax Expense (Benefit) Composition Tax Cuts and Jobs Act, Income Tax Expense, Composition Tax Cuts and Jobs Act, Income Tax Expense, Composition Tax Cuts and Jobs Act, Income Tax Expense, Composition Aggregate Transition Tax on Foreign Earnings, 2017 Tax Act Aggregate Transition Tax on Foreign Earnings, 2017 Tax Act Aggregate Transition Tax on Foreign Earnings, 2017 Tax Act Bad debt, inventory and warranty accruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves Legal reserves Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies Other post-employment benefits, vacation and other reserves Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other Tax credit and net operating loss carryforwards Deferred Tax Assets, Tax Credit Carryforwards Other Deferred Tax Assets, Other Total gross deferred tax assets Deferred Tax Assets, Gross Valuation allowance Deferred Tax Assets, Valuation Allowance Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Investments and intangible assets Deferred Tax Liabilities, Other Finite-Lived Assets Total deferred tax liabilities Deferred Tax Liabilities, Gross Net deferred tax liabilities Deferred Tax Liabilities, Net Unrecognized tax benefits period start Unrecognized Tax Benefits Additions to tax positions related to prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Reductions to tax positions related to prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Additions to tax positions related to the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Lapse of statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation Acquisitions Unrecognized Tax Benefits, Increase Resulting from Acquisition Currency translation Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation Unrecognized tax benefits period end Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Operating Loss Carryforwards, Expiration Dates Operating Loss Carryforwards, Expiration Date Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Deferred Tax Liabilities, Undistributed Foreign Earnings Deferred Tax Liabilities, Undistributed Foreign Earnings Deferred Tax Liability Not Recognized, Cumulative Amount of Temporary Difference Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries Tax Credit Carryforward, Amount Tax Credit Carryforward, Amount Tax Credit Carryforward, Limitations on Use Tax Credit Carryforward, Limitations on Use Deferred Tax Assets, Tax Credit Carryforwards, Research Deferred Tax Assets, Tax Credit Carryforwards, Research Operating Loss Carryforward, Valuation Allowance Operating Loss Carryforwards, Valuation Allowance Operating Loss Carryforward With No Expiration Date Operating Loss Carryforward With No Expiration Date Operating Loss Carryforward With No Expiration Date Operating Loss Carryforwards Operating Loss Carryforwards Other Tax Expense (Benefit) Other Tax Expense (Benefit) Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Subsequent Events [Abstract] Subsequent Events [Text Block] Subsequent Events [Text Block] Accounting Policies [Abstract] Basis of Presentation Consolidation, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Short-term Restricted Investments [Policy Text Block] Short-term Restricted Investments [Policy Text Block] Short-term Restricted Investments [Policy Text Block] Available-for-sale Investments Marketable Securities, Policy [Policy Text Block] Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration Risk, Credit Risk, Policy [Policy Text Block] Accounts Receivable Trade and Other Accounts Receivable, Policy [Policy Text Block] Inventory Inventory, Policy [Policy Text Block] Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Warranty Standard Product Warranty, Policy [Policy Text Block] Shipping and Handling Shipping and Handling Cost, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Forward Foreign Exchange Contracts Derivatives, Policy [Policy Text Block] Share-based Compensation Plans Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Earnings Per Share Earnings Per Share, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] U.S. and international components of income before taxes [Table Text Block] Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Provision for income taxes [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Reconcilation of effective tax rate on inocme before taxes and statutory rate [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Significant components of deferred tax assets and liabilities [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Summary of income tax years currently under audit or open to examinations [Table Text Block] Summary of Income Tax Examinations [Table Text Block] Tabular reconcilation of total amounts of unrecognized tax benefits [Table Text Block] Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block] Other Income and Expenses [Abstract] Other Income and Other Expense Disclosure Other Income and Other Expense Disclosure [Text Block] Reclassification and Correction of Immaterial Errors [Abstract] Reclassification and Correction of Immaterial Errors [Abstract] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Adjustments for Error Corrections [Axis] Adjustments for Error Corrections [Axis] Adjustments for Error Correction [Domain] Adjustments for Error Correction [Domain] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Error Corrections and Prior Period Adjustments Restatement [Line Items] Error Corrections and Prior Period Adjustments Restatement [Line Items] Schedule of Quantifying Prior Year Misstatements Corrected in Current Year Financial Statements [Table Text Block] Schedule of Quantifying Prior Year Misstatements Corrected in Current Year Financial Statements [Table Text Block] Share-based Compensation [Abstract] Stock Options Activity Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Stock Options Outstanding Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Stock Options Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Resticted Stock Activity Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Employee Stock Purchase Plan, Valuation Assumptions Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Treasury Stock [Abstract] Treasury Stock [Abstract] Class of Treasury Stock [Table] Class of Treasury Stock [Table] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Treasury Stock [Text Block] Treasury Stock [Text Block] Legal Proceedings [Abstract] -- None. No documentation exists for this element. -- Legal Matters and Contingencies Legal Matters and Contingencies [Text Block] Schedule of other income (expense), net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Income Statement [Abstract] Statement [Table] Statement [Table] Net sales Revenue from Contract with Customer, Including Assessed Tax Cost of Goods and Services Sold Cost of Goods and Services Sold Gross Profit Gross Profit Selling, general and administrative expense Selling, General and Administrative Expense Research and development expense Research and Development Expense Impairment losses on goodwill and long-lived assets Asset Impairment Charges Income from operations Operating Income (Loss) Interest expense Interest Expense Foreign exchange losses, net Foreign Currency Transaction Gain (Loss), before Tax Unrealized Gain on Securities Unrealized Gain on Securities Other (income) expense, net Other Nonoperating Income (Expense) Income before income taxes Provision for income taxes Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Parent Basic earnings per share: Earnings Per Share, Basic [Abstract] Earnings Per Share, Basic Earnings Per Share, Basic Weighted average common shares - basic Weighted Average Number of Shares Outstanding, Basic Diluted earnings per share: Earnings Per Share, Diluted [Abstract] Earnings Per Share, Diluted Earnings Per Share, Diluted Weighted average common shares - diluted Weighted Average Number of Shares Outstanding, Diluted Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Estimate of Fair Value, Fair Value Disclosure [Member] Estimate of Fair Value Measurement [Member] Carrying (Reported) Amount, Fair Value Disclosure [Member] Reported Value Measurement [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Other Investments Other Investments Total long-term debt, excluding leases and current maturities Long-term Debt, Fair Value Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Short-term Investments [Member] Other Long-term Investments [Member] Other Long-term Investments [Member] Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Corporate Debt Securities [Member] Corporate Debt Securities [Member] Interest-bearing Deposits [Member] Interest-bearing Deposits [Member] Domestic Time Deposit [Member] Certificates of Deposit [Member] Municipal Obligations [Member] Municipal Bonds [Member] Asset-backed Securities [Member] Asset-backed Securities [Member] Marketable Equity Securities [Member] Equity Securities [Member] Available-for-sale Securities [Member] Available-for-sale Securities [Member] US Government Sponsored Agencies [Member] US Treasury and Government [Member] Foreign Government Obligations [Member] Debt Security, Government, Non-US [Member] Debt Securities [Member] Debt Securities [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Debt Securities, Available-for-sale, Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Debt Securities, Available-for-sale Debt Securities, Available-for-sale Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Available-for-sale Securities Available-for-sale Securities Available-for-sale Securities, Amortized Cost Basis Available-for-sale Securities, Amortized Cost Basis Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Statement, Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Foreign currency translation adjustments [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Other Postretirement Benefit Plan [Member] Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Net Unrealized Investment Gain (Loss) [Member] Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Parent [Member] Parent [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax EquitySecuritiesWithoutReadilyDeterminableFairValueFairValueElection EquitySecuritiesWithoutReadilyDeterminableFairValueFairValueElection Equity Securities Without Readily Determinable Fair Value, Fair Value Election ASU 2018-03 Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Other Comprehensive Income (Loss), Tax Other Comprehensive Income (Loss), Tax Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect Other comprehensive income, net of tax Other Comprehensive Income (Loss), Net of Tax Stockholders' Equity Attributable to Parent [Abstract] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Class of Stock [Line Items] Class of Stock [Line Items] Schedule of Stock by Class [Table Text Block] Schedule of Stock by Class [Table Text Block] Statement of Stockholders' Equity [Abstract] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-16 [Member] Accounting Standards Update 2016-16 [Member] Accounting Standards Update 2014-09 [Member] Accounting Standards Update 2014-09 [Member] Common Stock [Member] Additional Paid-in Capital [Member] Treasury Stock [Member] Treasury Stock [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Total Bio Rad [Member] Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance Stockholders' Equity Attributable to Parent Net income Other comprehensive income, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Issuance of common stock Proceeds from Issuance of Common Stock Stock compensation expense Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Tax benefit-exercise stock options Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation Cumulative Effect of New Accounting Principle in Period of Adoption Cumulative Effect of New Accounting Principle in Period of Adoption Treasury Stock, Value, Acquired, Cost Method Treasury Stock, Value, Acquired, Cost Method Stock Issued During Period, Value, Treasury Stock Reissued Stock Issued During Period, Value, Treasury Stock Reissued Balance SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Segment Reporting [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Segments [Axis] Segments [Axis] Segment [Domain] Segments [Domain] Life Science [Member] Life Sciences [Member] Clinical Diagnostics [Member] Clinical Diagnostics [Member] All Other Segments [Member] Other Segments [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Number Of Products And Services Number Of Products And Services Number Of Products And Services Net sales Revenue from Contract with Customer, Excluding Assessed Tax Depreciation and amortization Depreciation, Depletion and Amortization Segment profit Total assets Assets Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment Treasury Class-A [Member] Treasury Class-A [Member] Treasury Class A [Member] Treasury Class B [Member] Treasury Class B [Member] Treasury Class B [Member] Shares, Issued Shares, Issued Stock Issued During Period, Shares, Conversion of Convertible Securities Stock Issued During Period, Shares, Conversion of Convertible Securities Stock Issued During Period, Shares, New Issues Stock Issued During Period, Shares, New Issues Treasury Stock, Shares, Acquired Treasury Stock, Shares, Acquired Common Stock, Voting Rights Common Stock, Voting Rights Election Percentage for Board of Directors Election Percentage for Board of Directors Election Percentage for Board of Directors Retirement Benefits [Abstract] Fair Value Hierarchy and NAV [Domain] Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Defined Benefit Plan, Benefit Obligation Defined Benefit Plan, Benefit Obligation Defined Benefit Plan, Service Cost Defined Benefit Plan, Service Cost Defined Benefit Plan, Interest Cost Defined Benefit Plan, Interest Cost Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Defined Benefit Plan, Benefit Obligation, Benefits Paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Defined Benefit Plan, Plan Assets, Amount Defined Benefit Plan, Plan Assets, Amount Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Defined Benefit Plan, Plan Assets, Contributions by Employer Defined Benefit Plan, Plan Assets, Contributions by Employer Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Defined Benefit Plan, Plan Assets, Benefits Paid Defined Benefit Plan, Plan Assets, Benefits Paid Defined Benefit Plan, Plan Assets, Payment for Settlement Defined Benefit Plan, Plan Assets, Payment for Settlement Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Defined Benefit Plan, Funded (Unfunded) Status of Plan Defined Benefit Plan, Funded (Unfunded) Status of Plan Liability, Defined Benefit Plan, Current Liability, Defined Benefit Plan, Current Liability, Defined Benefit Plan, Noncurrent Liability, Defined Benefit Plan, Noncurrent Liability, Defined Benefit Plan Liability, Defined Benefit Plan Defined Benefit Plan, Expected Return (Loss) on Plan Assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Defined Benefit Plan, Amortization of Gain (Loss) Defined Benefit Plan, Amortization of Gain (Loss) Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets Quarterly Financial Data [Abstract] Quarterly Financial Data [Text Block] Quarterly Financial Information [Text Block] Scenario [Axis] Interest and investment income Investment Income, Interest and Dividend Net realized gains on investments Realized Investment Gains (Losses) Other-than-temporary impairment losses on investments Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net Gain on sale of land Gain (Loss) on Disposition of Assets Gain on divestiture of product line Gain (Loss) on Disposition of Other Assets Other Expense Other Nonoperating Expense Other (income) expense, net Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Pasteur Sanofi Diagnosics S.A. [Member] Pasteur Sanofi Diagnosics S.A. [Member] Pasteur Sanofi Diagnosics S.A. [Member] DiaMed [Member] DiaMed [Member] DiaMed [Member] Biotest AG [Member] Biotest AG [Member] Biotest AG [Member] Clinical Diagnostics [Member] Goodwill [Line Items] Goodwill [Line Items] Goodwill, Written off Related to Sale of Business Unit Goodwill, Written off Related to Sale of Business Unit Goodwill [Roll Forward] Goodwill period start Goodwill, Gross Accumulated impairment loss period start Goodwill, Impaired, Accumulated Impairment Loss Goodwill, net period start Goodwill, Purchase Accounting Adjustments Goodwill, Impairment Loss Goodwill, Impairment Loss Currency fluctuations Goodwill, Foreign Currency Translation Gain (Loss) Goodwill period end Accumulated impairment loss period end Goodwill, net period end Mature in less than one year Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost Mature in one to five years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost Mature in more than five years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Amortized Cost Total Amortized Cost Mature in less than one year Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value Mature in one to five years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value Mature in more than five years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value Estimated Fair Value Restructuring Costs [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] European Reorganization [Member] European Reorganization [Member] European Reorganization [Member] Facility Closing [Member] Facility Closing [Member] Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] Termination of a Diagnostics Research and Development Project [Member] Termination of a Diagnostics Research and Development Project [Member] Termination of a Diagnostics Research and Development Project [Member] Termination of an Diagnostics Research and Development Project [Member] Termination of an Diagnostics Research and Development Project [Member] Termination of a Diagnostics Research and Development Project [Member] GnuBIO [Member] GnuBIO [Member] GnuBIO [Member] Accounts Payable and Accrued Liabilities [Member] Accounts Payable and Accrued Liabilities [Member] Other Current Liabilities [Member] Other Current Liabilities [Member] Other Noncurrent Liabilities [Member] Other Noncurrent Liabilities [Member] Life Science [Member] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Employee Severance [Member] Employee Severance [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Other Operating Income (Expense) [Member] Other Operating Income (Expense) [Member] Cost of Goods, Total [Member] Cost of Goods, Total [Member] Selling, General and Administrative Expenses [Member] Selling, General and Administrative Expenses [Member] Research and Development Expense [Member] Research and Development Expense [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring Reserve Restructuring Reserve Restructuring Charges Restructuring Charges Restructuring Reserve, Accrual Adjustment Restructuring Reserve, Accrual Adjustment Payments for Restructuring Payments for Restructuring Restructuring Reserve, Foreign Currency Translation (Gain) Loss Restructuring Reserve, Foreign Currency Translation Gain (Loss) Restructuring Reserve, Current Restructuring Reserve, Current Segments, Geographical Areas [Abstract] Geographical [Axis] Geographical [Domain] Europe [Member] Europe [Member] Pacific Rim [Member] Asia Pacific [Member] UNITED STATES UNITED STATES Other (primarily Canada and Latin America) [Member] Americas [Member] Other assets and property, plant and equipment, net Long-Lived Assets Statement of Financial Position [Abstract] Deferred Revenue [Domain] Deferred Revenue [Domain] Common Class A [Member] Common Class B [Member] ASSETS: Assets [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Short-term investments Short-term Investments Restricted investments Restricted Investments, Current Accounts receivable, less allowance for doubtful accounts Accounts Receivable, Net, Current Inventories: Inventory, Net [Abstract] Raw materials Inventory, Raw Materials, Gross Work in process Inventory, Work in Process, Gross Finished goods Inventory, Finished Goods, Gross Total inventories Inventory, Net Prepaid expenses Prepaid Expense, Current Other current assets Other Assets, Current Total current assets Assets, Current Property, plant and equipment: Property, Plant and Equipment, Gross [Abstract] Land and improvements Land Buildings and leasehold improvements Buildings and Improvements, Gross Equipment Machinery and Equipment, Gross Total property, plant and equipment Property, Plant and Equipment, Gross Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, net Property, Plant and Equipment, Net Goodwill, net Purchased intangibles, net Intangible Assets, Net (Excluding Goodwill) Other investments Long-term Investments Long-term deferred tax assets Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Other assets Other Assets, Noncurrent Total assets LIABILITIES AND STOCKHOLDERS' EQUITY: Liabilities and Equity [Abstract] Accounts payable Accounts Payable, Current Accrued payroll and employee benefits Employee-related Liabilities, Current Current maturities of long-term debt Notes and Loans Payable, Current Income taxes payable Accrued Income Taxes, Current Other taxes payable Taxes Payable, Current Accrued royalties Accrued Royalties, Current Deferred revenue Deferred Revenue, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Long-term debt, net of current maturities Long-term Debt and Capital Lease Obligations Deferred income taxes Deferred Tax Liabilities, Net, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingent liabilities Commitments and Contingencies Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders' equity: Preferred stock Preferred Stock, Value, Issued Common stock Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Treasury Stock, Value Treasury Stock, Value Retained earnings Retained Earnings (Accumulated Deficit) Total stockholders' equity Total liabilities and stockholders' equity Liabilities and Equity Movement in Standard Product Warranty Accrual [Roll Forward] Warranty accrual, beginning of period Standard and Extended Product Warranty Accrual Provision for warranty Standard and Extended Product Warranty Accrual, Increase for Warranties Issued Actual warranty costs Standard and Extended Product Warranty Accrual, Decrease for Payments Warranty accrual, end of period Basic weighted average shares outstanding Effect of potentially dilutive stock options and restricted stock awards Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Diluted weighted average common shares Anti-dilutive shares excluded from the computation of diluted EPS Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Debt Disclosure [Abstract] Principal components of long-term debt [Table Text Block] Schedule of Long-term Debt Instruments [Table Text Block] Reconciliation of Assets from Segment to Consolidated [Table] Reconciliation of Assets from Segment to Consolidated [Table] Other Current Assets [Member] Other Current Assets [Member] Property, Plant and Equipment excluding segment specific [Member] Property, Plant and Equipment excluding segment specific [Member] Property, Plant and Equipment excluding segment specific [Member] -- excludes segment specific gross machinery and equipment Goodwill [Member] Goodwill [Member] Other Noncurrent Assets [Member] Other Noncurrent Assets [Member] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Operating Segments [Member] Operating Segments [Member] Segment Reconciling Items [Member] Segment Reconciling Items [Member] Segment Reporting, Asset Reconciling Item [Line Items] Segment Reporting, Asset Reconciling Item [Line Items] Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases, Future Minimum Payments, Due in Five Years Letters of Credit Outstanding, Amount Letters of Credit Outstanding, Amount Operating Leases, Rent Expense, Net Operating Leases, Rent Expense, Net Contribution expense Deferred Compensation Arrangement with Individual, Contributions by Employer Other Comprehensive Income Location [Axis] Other Comprehensive Income Location [Axis] Other Comprehensive Income Location [Domain] Other Comprehensive Income Location [Domain] Restructuring and Related Costs [Table Text Block] Restructuring and Related Costs [Table Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis] Award Type [Axis] Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain] Equity Award [Domain] Restricted Stock [Member] Restricted Stock Units (RSUs) [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Total unrecognized compensation cost from restricted stock Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Expected Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Nonvested shares - Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Outstanding beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Restricted Stock Units Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted Stock Units - Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Restricted Stock Units - Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Outstanding end of period Weighted Average Grant Date Fair Value - Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Restricted Stock Units Vested - Weighted-Average Grant-Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Resticted Stock Units Cancelled/forfeited - Weighted-Average Grant-Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Resticted Stock Units Outstanding Aggregate Intrinsic Value (in millions) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Notes Payable and Long-term Debt Long-term Debt [Text Block] Information regarding industry segments Schedule of Segment Reporting Information, by Segment [Table Text Block] Reconciliation of segment profit to consolidated income before taxes Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Reconciliation of Assets from Segment to Consolidated Reconciliation of Assets from Segment to Consolidated [Table Text Block] Net sales and assets to external customers by geographic area Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Equity [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Member] Reclassification out of Accumulated Other Comprehensive Income [Member] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Selling, general and administrative expense Realized Investment Gains (Losses) Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Scenario, Forecast [Member] Scenario, Forecast [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Discount rate [Member] Market Price of Risk [Member] Market Price of Risk [Member] Sales milestone percentage of annual invoices [Member] Sales milestone percentage of annual invoices [Member] Sales milestone percentage of annual invoices [Member] Sales milestone percentage of annual invoices low [Member] Sales milestone percentage of annual invoices low [Member] Sales milestone percentage of annual invoices low [Member] Sales milestone minimum amount [Member] Sales milestone minimum amount [Member] Sales milestone minimum amount [Member] Cost of debt [Member] Projected Volatility of Sales [Member] [Member] Projected Volatility of Sales [Member] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Discount Rate Discount Rate Discount Rate Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Net (decrease) increase in estimated fair value of contingent consideration included in selling, general and administrative expense Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High Business Acquisition, Contingent Consideration, Potential Percentage Payout Business Acquisition, Contingent Consideration, Potential Percentage Payout business acquisition contingent consideration percentage payout Supplemental Cash Flow Information [Abstract] Cash Flow, Supplemental Disclosures [Text Block] Cash Flow, Supplemental Disclosures [Text Block] Schedule of Quarterly Financial Data [Table Text Block] Quarterly Financial Information [Table Text Block] Disclosure of Compensation Related Costs, Share-based Payments Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Income Taxes [Text Block] Income Tax Disclosure [Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Net Periodic Benefit Cost [Abstract] Net Periodic Benefit Cost [Abstract] Schedule of Net Benefit Costs [Table Text Block] Schedule of Net Benefit Costs [Table Text Block] Schedule of Long-term Debt Instruments [Table] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Unsecured Debt [Member] Capital Lease Obligations [Member] Line of Credit [Member] Standby Letters of Credit [Member] Standby Letters of Credit [Member] Debt Instrument [Axis] Debt Instrument, Name [Domain] Senior Notes 4.875% due 2020 [Member] Senior Notes 4.875% due 2020 [Member] Senior Notes 4.875% [Member] Capital Leases and Other Debt [Member] Capital Leases and Other Debt [Member] Capital Leases and Other Debt [Member] Performance Guarantee [Member] Performance Guarantee [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Unsecured Debt Unsecured Debt Long-term debt Long-term Debt Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Long-term Debt and Capital Lease Obligations, Including Current Maturities Long-term Debt and Capital Lease Obligations, Including Current Maturities Debt and Capital Lease Obligations Debt and Capital Lease Obligations Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year Long-term Debt and Capital Lease Obligations Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Interest Rate, Effective Percentage Face amount of debt sold Debt Instrument, Face Amount Maturities of Long-term Debt [Abstract] Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months Long-term Debt, Maturities, Repayments of Principal in Year Two Long-term Debt, Maturities, Repayments of Principal in Year Two Long-term Debt, Maturities, Repayments of Principal in Year Three Long-term Debt, Maturities, Repayments of Principal in Year Three Long-term Debt, Maturities, Repayments of Principal in Year Four Long-term Debt, Maturities, Repayments of Principal in Year Four Long-term Debt, Maturities, Repayments of Principal in Year Five Long-term Debt, Maturities, Repayments of Principal in Year Five Long-term Debt, Maturities, Repayments of Principal after Year Five Long-term Debt, Maturities, Repayments of Principal after Year Five Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Long-term Line of Credit Long-term Line of Credit Line of Credit Facility, Remaining Borrowing Capacity Line of Credit Facility, Current Borrowing Capacity Line of Credit Facility, Interest Rate at Period End Line of Credit Facility, Interest Rate at Period End SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] SEC Schedule, 12-09, Allowance, Credit Loss [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease) SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease) SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Valuation Allowances and Reserves, Balance Period Start SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Deductions SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Other SEC Schedule, 12-09, Valuation Allowances and Reserves, Business Acquired Valuation Allowances and Reserves, Balance Period End Price Change Debt Security Price Change Debt Security Price Change Debt Security Tolerable variance Level 2 debt security pricing Tolerable variance Level 2 debt security pricing Tolerable variance Level 2 debt security pricing Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value Gross unrealized losses for investments in a loss position 12 months or more Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Gross unrealized losses for investments in a loss position less than 12 months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Cost Method Investment, Percentage Owned Investment ownership percentage Investment ownership percentage Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Purchase Commitment, Excluding Long-term Commitment [Table] Purchase Commitment, Excluding Long-term Commitment [Table] Employee Location [Axis] Employee Location [Axis] Employee Location [Axis] Employee Location [Domain] Employee Location [Domain] [Domain] for Employee Location [Axis] Purchase Commitment, Excluding Long-term Commitment [Line Items] Purchase Commitment, Excluding Long-term Commitment [Line Items] Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Operating leases, due next twelve months Operating Leases, Future Minimum Payments Due, Next Twelve Months Operating leases, due in two years Operating Leases, Future Minimum Payments, Due in Two Years Operating leases, due in three years Operating Leases, Future Minimum Payments, Due in Three Years Operating leases, due in four years Operating leases, due thereafter Operating Leases, Future Minimum Payments, Due Thereafter Post-Employment Benefits Liability Postemployment Benefits Liability Recorded Unconditional Purchase Obligation Recorded Unconditional Purchase Obligation Recorded Unconditional Purchase Obligation Due in Next Twelve Months Recorded Unconditional Purchase Obligation Due in Next Twelve Months Recorded Unconditional Purchase Obligation Due in Second Year Recorded Unconditional Purchase Obligation Due in Second Year Recorded Unconditional Purchase Obligation Due in Third Year Recorded Unconditional Purchase Obligation Due in Third Year Recorded Unconditional Purchase Obligation Due in Fourth Year Recorded Unconditional Purchase Obligation Due in Fourth Year Recorded Unconditional Purchase Obligation Due in Fifth Year Recorded Unconditional Purchase Obligation Due in Fifth Year Recorded Unconditional Purchase Obligation Due after Fifth Year Recorded Unconditional Purchase Obligation Due after Fifth Year Unrecorded Unconditional Purchase Obligation Unrecorded Unconditional Purchase Obligation Unrecorded Unconditional Purchase Obligation, Due in Twelve Months Unrecorded Unconditional Purchase Obligation, Due in Next Twelve Months Unrecorded Unconditional Purchase Obligation, Due within Two Years Unrecorded Unconditional Purchase Obligation, Due within Two Years Unrecorded Unconditional Purchase Obligation, Due within Three Years Unrecorded Unconditional Purchase Obligation, Due within Three Years Unrecorded Unconditional Purchase Obligation, Due within Four Years Unrecorded Unconditional Purchase Obligation, Due within Four Years Unrecorded Unconditional Purchase Obligation, Due within Five Years Unrecorded Unconditional Purchase Obligation, Due within Five Years Unrecorded Unconditional Purchase Obligation, Due after Five Years Unrecorded Unconditional Purchase Obligation, Due after Five Years Letters of Credit Outstanding Amount Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Employees Covered By Collective Bargaining Agreements U.S., Percentage Employees Covered By Collective Bargaining Agreements U.S., Percentage Employees covered by collective bargaining agreements, percentage Entity Number of Employees Entity Number of Employees Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals Derivative [Table] Derivative [Table] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Derivative, Notional Amount Derivative, Notional Amount Gain (loss) on foreign currency derivative instruments not designated as hedging instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Stock Option and Award Plans [Member] Stock Option and Award Plans [Member] Stock Option and Award Plans [Member] 2011 Employee Stock Purchase Plan [Member] 2011 Employee Stock Purchase Plan [Member] 2011 Employee Stock Purchase Plan [Member] Stock Options [Member] Employee Stock Option [Member] Employee Stock [Member] Employee Stock [Member] Stock Options [Member] Employee Stock [Member] Stock Award Plans [Member] Stock Award Plans [Member] Stock Award Plans [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Incentive Award Plan 2017 [Member] Incentive Award Plan 2017 [Member] Incentive Award Plan 2017 [Member] Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Weighted Average Remaining Contractual Term (in years) - Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (in millions) - Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Options - Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options Granted - Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options Exercised - Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options Granted Term Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award Options Forfeitured/expired - Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Options - Shares Vested and Expected to Vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Options Vested and Expected to Vest - Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Options Vested and Expected to Vest - Weighted Average Remaining Contractual Term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Options Vested and Expected to Vest - Aggregate Intrinsic Value (in millions) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Weighted Average Exercise Price - Options Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) - Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Options Exercisable Aggregate Intrinsic Value (in millions) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Options, Exercises in Period, Total Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Cash Received from Exercise of Stock Options Proceeds from Stock Options Exercised Employee Service Share-based Compensation, Tax Benefit from Exercise of Stock Options Employee Service Share-based Compensation, Tax Benefit from Exercise of Stock Options Total unrecognized compensation cost from stock options Restricted Stock Units - Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Options Number Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Stock Issued During Period, Shares, Employee Stock Purchase Plans Stock Issued During Period, Shares, Employee Stock Purchase Plans Options Vesting Period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Employee Contribution Rate - Maximum Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount Employee Purchase Price Discount from Market Price Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date Share-based Compensation Expense Allocated Share-based Compensation Expense Employee Service Share-based Compensation, Tax Benefit from Compensation Expense Employee Service Share-based Compensation, Tax Benefit from Compensation Expense Weighted average fair value of options granted, period for recognition Risk Free Interest Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected life (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected dividend Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend Weighted average fair value of options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Options - Shares Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Options - Shares Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Options - Shares Forfeitures/expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Segment Reporting Information, Profit (Loss) [Abstract] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Foreign Currency Gain (Loss) [Member] Foreign Currency Gain (Loss) [Member] Other Nonoperating Income (Expense) [Member] Other Nonoperating Income (Expense) [Member] Corporate, Non-Segment [Member] Corporate, Non-Segment [Member] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Unrealized Gain on Securities Schedule of Product Warranty Liability Schedule of Product Warranty Liability [Table Text Block] Schedule of Weighted Average Number of Shares Schedule of Weighted Average Number of Shares [Table Text Block] Schedule of Quantifying Prior Year Misstatement Corrected in Current Year Financial Statements [Table] Schedule of Quantifying Prior Year Misstatement Corrected in Current Year Financial Statements [Table] Nature of Error [Axis] Nature of Error [Axis] Nature of Error [Domain] Nature of Error [Domain] Quantifying Misstatement in Current Year Financial Statements [Line Items] Quantifying Misstatement in Current Year Financial Statements [Line Items] Operating Income (Loss) Gross profit Unrealized Loss on Securities Unrealized Loss on Securities Net Income (Loss) Attributable to Parent Income Tax Expense (Benefit) Restructuring and Related Activities Disclosure [Text Block] Restructuring and Related Activities Disclosure [Text Block] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] CellSorter [Member] CellSorter [Member] CellSorter [Member] [Member] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Acquired Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Customer Relationships [Member] Customer Relationships [Member] Know how [Member] Know How [Member] Know how [Member] Developed Technology Rights [Member] Developed Technology Rights [Member] Licensing Agreements [Member] Licensing Agreements [Member] Trade Names [Member] Trade Names [Member] Noncompete Agreements [Member] Noncompete Agreements [Member] Other Intangible Assets [Member] Other Intangible Assets [Member] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Remaining Amortization Period Finite-Lived Intangible Assets, Remaining Amortization Period Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Future Amortization Expense, Year One Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months Future Amortization Expense, Year Two Finite-Lived Intangible Assets, Amortization Expense, Year Two Future Amortization Expense, Year Three Finite-Lived Intangible Assets, Amortization Expense, Year Three Future Amortization Expense, Year Four Finite-Lived Intangible Assets, Amortization Expense, Year Four Future Amortization Expense, Year Five Finite-Lived Intangible Assets, Amortization Expense, Year Five Finite-Lived Intangible Assets, Amortization Expense, after Year Five Finite-Lived Intangible Assets, Amortization Expense, after Year Five Finite-Lived Intangible Assets, Net [Abstract] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Net Carrying Amount Finite-Lived Intangible Assets, Net Amortization [Abstract] Amortization expense Amortization of Intangible Assets Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Impairment of Intangible Assets, Finite-lived Intangible Assets, Net (Excluding Goodwill) Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Cash received from customers Proceeds from Customers Cash paid to suppliers and employees Payments to Suppliers and Employees Interest paid, net Interest Paid, Including Capitalized Interest, Operating and Investing Activities Income tax payments, net Income Taxes Paid, Net Investment proceeds and miscellaneous receipts, net Proceeds from Other Operating Activities Excess tax benefits from share-based compensation Excess Tax Benefit from Share-based Compensation, Operating Activities Proceeds from (payments for) forward foreign exchange contracts, net Proceeds from derivative instruments, operating activities Proceeds from derivative instruments, operating activities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Capital expenditures Proceeds from dispositions of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Proceeds from divestiture of a product line Proceeds from Sale of Productive Assets Proceeds from (payments for) acquisitions and long-term investment Payments for (Proceeds from) Investments Payments for (Proceeds from) Other Investing Activities Payments for (Proceeds from) Other Investing Activities Payments for purchases of intangible assets Payments to Acquire Intangible Assets Payments for purchases of restricted investment Payments to Acquire Restricted Investments Payments for purchases of marketable securities and investments Payments to Acquire Investments Proceeds from sales of marketable securities and investments Proceeds from Sale of Available-for-sale Securities Proceeds from maturities of marketable securities and investments Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net (payments) borrowings on line-of-credit arrangements and notes payable Proceeds from (Repayments of) Lines of Credit Payments on long-term borrowings Repayments of Long-term Debt Proceeds from issuance of common stock for share-based compensation Tax payments from net share settlement Payments Related to Tax Withholding for Share-based Compensation Payments for purchases of treasury stock Payments for Repurchase of Common Stock Payments of contingent consideration Payment for Contingent Consideration Liability, Financing Activities Excess tax benefits from share-based compensation Excess Tax Benefit from Share-based Compensation, Financing Activities Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of foreign exchange rate changes on cash Effect of Exchange Rate on Cash and Cash Equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Beginning Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Restricted Cash, Current Restricted Cash, Current Restricted Cash, Noncurrent Restricted Cash, Noncurrent Ending Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Balance Sheet Parenthetical [Abstract] Balance Sheet Parenthetical [Abstract] Common Stock [Member] Allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Current Preferred stock par value Preferred Stock, Par or Stated Value Per Share Preferred stock authorized Preferred Stock, Shares Authorized Preferred stock issued Preferred Stock, Shares Issued Preferred stock outstanding Preferred Stock, Shares Outstanding Common stock par value Common Stock, Par or Stated Value Per Share Common stock authorized Common Stock, Shares Authorized Common stock issued Common Stock, Shares, Issued Common stock outstanding Common Stock, Shares, Outstanding Treasury Stock, Shares Treasury Stock, Shares Business Combination Disclosure [Text Block] Business Combination Disclosure [Text Block] Loss Contingency, Damages Sought, Value Loss Contingency, Damages Sought, Value Litigation Settlement Interest Litigation Settlement Interest Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Loss Contingency Accrual, Period Increase (Decrease) Loss Contingency Accrual, Period Increase (Decrease) Loss Contingency, Damages Awarded, Value Loss Contingency, Damages Awarded, Value Changes to goodwill by segment Schedule of Goodwill [Table Text Block] Schedule of Finite-Lived Intangible Assets by Major-Class Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] 541714 Research and Development in Biotechnology (except Nanobiotechnology) [Member] 541714 Research and Development in Biotechnology (except Nanobiotechnology) [Member] Accounting Standards Update 2016-01 [Member] Accounting Standards Update 2016-01 [Member] Adjustments for New Accounting Pronouncement [Member] Adjustments for New Accounting Pronouncement [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Deferred Tax Assets, Net, Noncurrent Deferred Tax Assets, Net, Noncurrent Other assets Stockholders' Equity Attributable to Parent Prepaid Taxes Deferred Income Tax Assets, Net Deferred Income Tax Assets, Net Investments Investments Other (income) expense, net Deferred Tax Assets, Gross Deferred Income Tax Expense (Benefit) Restricted Cash Restricted Cash Statement of Comprehensive Income [Abstract] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other post-employment benefits adjustments, net of tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Net unrealized holding gains on available-for-sale investments, net of tax Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Comprehensive income attributable to Bio-Rad Comprehensive Income (Loss), Net of Tax, Attributable to Parent Other Investments [Member] Other Investments [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 3 [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Time Deposits [Member] Bank Time Deposits [Member] Money Market Funds [Member] Commercial Paper [Member] Commercial Paper [Member] Cash Equivalents [Member] Cash Equivalents [Member] Money Market Funds [Member] Equity Securities, FV-NI, Unrealized Gain Equity Securities, FV-NI, Unrealized Gain Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Restricted Investments, at Fair Value Restricted Investments, at Fair Value Equity Securities, FV-NI Equity Securities, FV-NI Forward foreign exchange contracts, Asset Foreign Currency Contract, Asset, Fair Value Disclosure Financial Assets Carried at Fair Value Assets, Fair Value Disclosure Forward foreign exchange contracts, Liability Foreign Currency Contracts, Liability, Fair Value Disclosure Liabilities, Fair Value Disclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure Other Significant Noncash Transactions [Table] Other Significant Noncash Transactions [Table] Other Significant Noncash Transaction [Axis] Other Significant Noncash Transaction [Axis] Other Significant Noncash Transaction, Name [Domain] Other Significant Noncash Transaction, Name [Domain] Other Significant Noncash Transactions [Line Items] Other Significant Noncash Transactions [Line Items] Share-based compensation Share-based Compensation Gains on disposition of securities Debt and Equity Securities, Gain (Loss) Other than Temporary Impairment Losses on Investments Other than Temporary Impairment Losses, Investments Changes in fair market value of equity securities Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss Losses on dispositions of fixed assets Gain (Loss) on Disposition of Property Plant Equipment Gain on divestiture of a product line Noncash or Part Noncash Divestiture, Amount of Consideration Received Changes in fair value of contingent consideration Decrease (increase) in accounts receivable, net Increase (Decrease) in Accounts Receivable Increase in inventories, net Increase (Decrease) in Inventories Increase in Other Current Assets Increase (Decrease) in Other Current Assets (Decrease) increase in accounts payable and other current liabilities Increase (Decrease) in Accounts Payable and Other Operating Liabilities (Decrease) increase in Income Taxes Payable Increase (Decrease) in Income Taxes Payable Increase (decrease) in deferred income taxes Increase (Decrease) in Deferred Income Taxes Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Decrease in other long term assets Increase (Decrease) in Other Noncurrent Assets (Decrease) increase in Other Long Term Liabilities Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net Noncash purchased property, plant and equipment Noncash or Part Noncash Acquisition, Fixed Assets Acquired Noncash Purchased Marketable Securities and Investments Noncash or Part Noncash Acquisition, Investments Acquired Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] accumulated other comprehensive income [Text Block] accumulated other comprehensive income [Text Block] accumulated other comprehensive income [Text Block] Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment by Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Software [Member] Computer Software, Intangible Asset [Member] Building and Building Improvements [Member] Building and Building Improvements [Member] Reagent Rental Equipment [Member] Reagent Rental Equipment [Member] Reagent Rental Equipment [Member] Equipment [Member] Equipment [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Useful Life Property, Plant and Equipment, Useful Life Restricted Cash and Cash Equivalents Restricted Cash and Cash Equivalents Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Line of Credit [Member] Segment Information Segment Reporting Disclosure [Text Block] Goodwill and Intangible Assets Disclosure Goodwill and Intangible Assets Disclosure [Text Block] Revenue from Contract with Customer [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Geographical [Axis] Geographical [Domain] Contract with Customer, Basis of Pricing [Axis] Contract with Customer, Basis of Pricing [Axis] Contract with Customer, Basis of Pricing [Domain] Contract with Customer, Basis of Pricing [Domain] Contract with Customer, Duration [Axis] Contract with Customer, Duration [Axis] Contract with Customer, Duration [Domain] Contract with Customer, Duration [Domain] Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Domain] Timing of Transfer of Good or Service [Domain] Contract with Customer, Sales Channel [Axis] Contract with Customer, Sales Channel [Axis] Contract with Customer, Sales Channel [Domain] Contract with Customer, Sales Channel [Domain] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Revenue Allocation Percent To Lease Elements Revenue Allocation Percent To Lease Elements Revenue Allocation Percent To Lease Elements Deferred Revenue Deferred Revenue Deferred Revenue, Period Increase (Decrease) Deferred Revenue, Period Increase (Decrease) Deferred Revenue, Revenue Recognized Deferred Revenue, Revenue Recognized Stock Repurchase Program, Remaining Authorized Repurchase Amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Authorized Amount Treasury Stock Acquired, Average Cost Per Share Treasury Stock Acquired, Average Cost Per Share Stock Issued During Period, Shares, Treasury Stock Reissued Stock Issued During Period, Shares, Treasury Stock Reissued Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] EX-101.PRE 12 bio-20181231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 chart-fb6cb6843e3154ef808.jpg GRAPHIC 12.31.18 begin 644 chart-fb6cb6843e3154ef808.jpg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end XML 14 a10k123118_htm.xml IDEA: XBRL DOCUMENT 0000012208 2018-01-01 2018-12-31 0000012208 2018-06-30 0000012208 us-gaap:CommonClassAMember 2019-03-26 0000012208 us-gaap:CommonClassBMember 2019-03-26 0000012208 2018-12-31 0000012208 bio:TreasuryClassBMember 2018-12-31 0000012208 2017-12-31 0000012208 us-gaap:CommonClassAMember 2017-12-31 0000012208 bio:TreasuryClassAMember 2018-12-31 0000012208 bio:TreasuryClassAMember 2017-12-31 0000012208 us-gaap:CommonClassBMember 2018-12-31 0000012208 us-gaap:CommonClassAMember 2018-12-31 0000012208 bio:TreasuryClassBMember 2017-12-31 0000012208 us-gaap:CommonClassBMember 2017-12-31 0000012208 2017-01-01 2017-12-31 0000012208 2016-01-01 2016-12-31 0000012208 2016-12-31 0000012208 2015-12-31 0000012208 us-gaap:CommonStockMember 2016-12-31 0000012208 us-gaap:TreasuryStockMember 2017-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0000012208 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000012208 us-gaap:AccountingStandardsUpdate201616Member 2018-01-01 0000012208 us-gaap:RetainedEarningsMember 2017-12-31 0000012208 us-gaap:TreasuryStockMember 2017-01-01 2017-12-31 0000012208 us-gaap:CommonStockMember 2015-12-31 0000012208 us-gaap:TreasuryStockMember 2015-12-31 0000012208 us-gaap:TreasuryStockMember 2018-01-01 2018-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000012208 us-gaap:CommonStockMember 2017-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0000012208 us-gaap:TreasuryStockMember 2016-12-31 0000012208 us-gaap:RetainedEarningsMember 2018-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 0000012208 us-gaap:RetainedEarningsMember 2015-12-31 0000012208 2018-01-01 0000012208 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 0000012208 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000012208 us-gaap:RetainedEarningsMember 2018-01-01 0000012208 us-gaap:TreasuryStockMember 2018-12-31 0000012208 us-gaap:RetainedEarningsMember 2016-12-31 0000012208 us-gaap:CommonStockMember 2018-12-31 0000012208 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2018-01-01 2018-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2018-12-31 0000012208 srt:MinimumMember us-gaap:EquipmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccountingStandardsUpdate201601Member 2018-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2017-01-01 2017-12-31 0000012208 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2018-01-01 2018-12-31 0000012208 naics:ZZ541714 2018-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2016-01-01 2016-12-31 0000012208 srt:MaximumMember us-gaap:EquipmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccountingStandardsUpdate201601Member 2018-01-01 0000012208 us-gaap:NewAccountingPronouncementMember 2018-01-01 0000012208 srt:MaximumMember bio:ReagentRentalEquipmentMember 2018-01-01 2018-12-31 0000012208 srt:MinimumMember bio:ReagentRentalEquipmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2017-12-31 0000012208 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2018-01-01 2018-12-31 0000012208 srt:MaximumMember us-gaap:ComputerSoftwareIntangibleAssetMember 2018-01-01 2018-12-31 0000012208 srt:MinimumMember us-gaap:ComputerSoftwareIntangibleAssetMember 2018-01-01 2018-12-31 0000012208 bio:RainDanceTechnologiesInc.Member 2017-01-01 2017-03-31 0000012208 bio:RainDanceTechnologiesInc.Member 2017-02-15 0000012208 us-gaap:DeferredTaxAssetDomain bio:RainDanceTechnologiesInc.Member 2017-02-15 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2018-01-01 2018-12-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2018-12-31 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2018-12-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2018-01-01 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2017-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2018-01-01 2018-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2018-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2017-12-31 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2018-07-01 2018-09-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoicesMember 2018-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoiceslowMember 2018-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestoneminimumamountMember 2018-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-12-01 2018-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2018-01-01 2018-03-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2018-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:ProjectedVolatilityOfSalesMemberMember 2018-01-01 2018-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:MarketPriceOfRiskMember 2018-01-01 2018-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0000012208 us-gaap:TradeNamesMember 2018-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2018-12-31 0000012208 us-gaap:LicensingAgreementsMember 2018-12-31 0000012208 bio:KnowHowMember 2018-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2018-12-31 0000012208 bio:ClinicalDiagnosticsMember 2018-01-01 2018-03-31 0000012208 bio:DiaMedMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 bio:CellsorterMember us-gaap:NoncompeteAgreementsMember bio:LifeScienceMember 2018-01-01 2018-12-31 0000012208 bio:RainDanceTechnologiesInc.Member us-gaap:TradeNamesMember 2017-02-15 0000012208 bio:RainDanceTechnologiesInc.Member us-gaap:LicensingAgreementsMember 2017-02-15 0000012208 bio:CellsorterMember us-gaap:DevelopedTechnologyRightsMember bio:LifeScienceMember 2018-01-01 2018-12-31 0000012208 bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:LifeScienceMember 2017-01-01 2017-12-31 0000012208 bio:LifeScienceMember 2018-01-01 2018-12-31 0000012208 bio:RainDanceTechnologiesInc.Member us-gaap:DevelopedTechnologyRightsMember 2017-02-15 0000012208 bio:PasteurSanofiDiagnosicsS.A.Member bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 bio:BiotestAGMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 us-gaap:LicensingAgreementsMember 2017-12-31 0000012208 us-gaap:TradeNamesMember 2017-12-31 0000012208 bio:KnowHowMember 2017-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2017-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2017-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2017-12-31 0000012208 bio:ClinicalDiagnosticsMember 2016-12-31 0000012208 bio:ClinicalDiagnosticsMember 2018-12-31 0000012208 bio:ClinicalDiagnosticsMember 2017-12-31 0000012208 bio:LifeScienceMember 2018-12-31 0000012208 bio:LifeScienceMember 2017-12-31 0000012208 bio:LifeScienceMember 2016-12-31 0000012208 bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 srt:MinimumMember us-gaap:LicensingAgreementsMember 2018-01-01 2018-12-31 0000012208 srt:MinimumMember us-gaap:NoncompeteAgreementsMember 2017-01-01 2017-12-31 0000012208 srt:MaximumMember us-gaap:OtherIntangibleAssetsMember 2017-01-01 2017-12-31 0000012208 srt:MaximumMember us-gaap:DevelopedTechnologyRightsMember 2018-01-01 2018-12-31 0000012208 srt:MinimumMember us-gaap:TradeNamesMember 2018-01-01 2018-12-31 0000012208 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-12-31 0000012208 srt:MinimumMember us-gaap:OtherIntangibleAssetsMember 2018-01-01 2018-12-31 0000012208 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-12-31 0000012208 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2017-01-01 2017-12-31 0000012208 srt:MaximumMember us-gaap:OtherIntangibleAssetsMember 2018-01-01 2018-12-31 0000012208 srt:MaximumMember us-gaap:NoncompeteAgreementsMember 2018-01-01 2018-12-31 0000012208 srt:MaximumMember us-gaap:TradeNamesMember 2018-01-01 2018-12-31 0000012208 srt:MaximumMember us-gaap:LicensingAgreementsMember 2017-01-01 2017-12-31 0000012208 srt:MinimumMember bio:KnowHowMember 2018-01-01 2018-12-31 0000012208 srt:MaximumMember bio:KnowHowMember 2017-01-01 2017-12-31 0000012208 srt:MinimumMember us-gaap:TradeNamesMember 2017-01-01 2017-12-31 0000012208 srt:MinimumMember us-gaap:LicensingAgreementsMember 2017-01-01 2017-12-31 0000012208 srt:MinimumMember us-gaap:NoncompeteAgreementsMember 2018-01-01 2018-12-31 0000012208 srt:MaximumMember bio:KnowHowMember 2018-01-01 2018-12-31 0000012208 srt:MinimumMember us-gaap:OtherIntangibleAssetsMember 2017-01-01 2017-12-31 0000012208 srt:MaximumMember us-gaap:NoncompeteAgreementsMember 2017-01-01 2017-12-31 0000012208 srt:MaximumMember us-gaap:LicensingAgreementsMember 2018-01-01 2018-12-31 0000012208 srt:MaximumMember us-gaap:DevelopedTechnologyRightsMember 2017-01-01 2017-12-31 0000012208 srt:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2018-01-01 2018-12-31 0000012208 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2017-01-01 2017-12-31 0000012208 srt:MaximumMember us-gaap:TradeNamesMember 2017-01-01 2017-12-31 0000012208 srt:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2017-01-01 2017-12-31 0000012208 srt:MinimumMember bio:KnowHowMember 2017-01-01 2017-12-31 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2017-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2017-12-31 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2018-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2018-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2010-12-31 0000012208 us-gaap:LineOfCreditMember 2014-06-30 0000012208 us-gaap:PerformanceGuaranteeMember 2018-12-31 0000012208 us-gaap:StandbyLettersOfCreditMember 2018-12-31 0000012208 us-gaap:StandbyLettersOfCreditMember 2017-12-31 0000012208 us-gaap:LineOfCreditMember 2018-12-31 0000012208 us-gaap:ForeignCountryMember 2018-12-31 0000012208 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2018-12-31 0000012208 bio:IncludingaccruedinterestandpenaltiesMember 2018-12-31 0000012208 us-gaap:StateAndLocalJurisdictionMember 2018-12-31 0000012208 bio:NetofprepaidtaxesMember 2018-12-31 0000012208 us-gaap:DomesticCountryMember 2018-01-01 2018-12-31 0000012208 us-gaap:DomesticCountryMember 2017-01-01 2017-12-31 0000012208 us-gaap:AcquisitionRelatedCostsMember 2018-01-01 2018-12-31 0000012208 us-gaap:DomesticCountryMember 2016-01-01 2016-12-31 0000012208 bio:TaxCutsandJobsActMember 2017-01-01 2017-12-31 0000012208 us-gaap:AcquisitionRelatedCostsMember 2017-01-01 2017-12-31 0000012208 bio:TaxCutsandJobsActMember 2016-01-01 2016-12-31 0000012208 bio:TaxCutsandJobsActMember 2018-01-01 2018-12-31 0000012208 us-gaap:AcquisitionRelatedCostsMember 2016-01-01 2016-12-31 0000012208 us-gaap:CommonClassBMember 2016-01-01 2016-12-31 0000012208 us-gaap:CommonClassAMember 2018-01-01 2018-12-31 0000012208 us-gaap:CommonClassAMember 2016-12-31 0000012208 us-gaap:CommonClassAMember 2015-12-31 0000012208 us-gaap:CommonClassAMember 2016-01-01 2016-12-31 0000012208 us-gaap:CommonClassAMember 2017-01-01 2017-12-31 0000012208 us-gaap:CommonClassBMember 2018-01-01 2018-12-31 0000012208 us-gaap:CommonClassBMember 2016-12-31 0000012208 us-gaap:CommonClassBMember 2017-01-01 2017-12-31 0000012208 us-gaap:CommonClassBMember 2015-12-31 0000012208 2018-11-30 0000012208 2017-06-30 0000012208 2017-08-01 2017-08-31 0000012208 2017-06-01 2017-06-30 0000012208 2018-11-01 2018-11-30 0000012208 2017-08-31 0000012208 2017-05-31 0000012208 2017-05-01 2017-05-31 0000012208 bio:TreasuryClassAMember 2017-01-01 2017-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-12-31 0000012208 us-gaap:ParentMember 2017-01-01 2017-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-12-31 0000012208 us-gaap:ParentMember 2018-01-01 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:ParentMember 2016-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000012208 us-gaap:ParentMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000012208 us-gaap:ParentMember 2017-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 0000012208 us-gaap:ParentMember 2018-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000012208 us-gaap:EmployeeStockMember 2018-01-01 2018-12-31 0000012208 us-gaap:EmployeeStockMember 2018-12-31 0000012208 us-gaap:EmployeeStockMember 2017-01-01 2017-12-31 0000012208 us-gaap:EmployeeStockMember 2016-01-01 2016-12-31 0000012208 us-gaap:EmployeeStockMember 2016-12-31 0000012208 us-gaap:EmployeeStockMember 2017-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2018-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2017-12-31 0000012208 bio:StockOptionAndAwardPlansMember bio:IncentiveAwardPlan2017Member 2018-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0000012208 bio:StockAwardPlansMember 2018-01-01 2018-12-31 0000012208 bio:A2011EmployeeStockPurchasePlanMember 2018-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-12-31 0000012208 bio:StockAwardPlansMember bio:IncentiveAwardPlan2017Member 2018-01-01 2018-12-31 0000012208 country:US 2018-12-31 0000012208 us-gaap:SubsequentEventMember 2019-02-26 2019-02-26 0000012208 srt:EuropeMember 2017-01-01 2017-12-31 0000012208 srt:EuropeMember 2016-01-01 2016-12-31 0000012208 country:US 2016-01-01 2016-12-31 0000012208 srt:AmericasMember 2018-01-01 2018-12-31 0000012208 srt:AmericasMember 2017-01-01 2017-12-31 0000012208 srt:AsiaPacificMember 2016-01-01 2016-12-31 0000012208 country:US 2018-01-01 2018-12-31 0000012208 srt:EuropeMember 2018-01-01 2018-12-31 0000012208 srt:AsiaPacificMember 2018-01-01 2018-12-31 0000012208 srt:AsiaPacificMember 2017-01-01 2017-12-31 0000012208 country:US 2017-01-01 2017-12-31 0000012208 srt:AmericasMember 2016-01-01 2016-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherCurrentAssetsMember 2017-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherCurrentAssetsMember 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember bio:PropertyPlantandEquipmentexcludingsegmentspecificMember 2017-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNoncurrentAssetsMember 2017-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:GoodwillMember 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember bio:PropertyPlantandEquipmentexcludingsegmentspecificMember 2018-12-31 0000012208 us-gaap:OperatingSegmentsMember 2017-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:GoodwillMember 2017-12-31 0000012208 us-gaap:OperatingSegmentsMember 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNoncurrentAssetsMember 2018-12-31 0000012208 us-gaap:OperatingSegmentsMember 2016-01-01 2016-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2016-01-01 2016-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2017-01-01 2017-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember 2018-01-01 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2017-01-01 2017-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-12-31 0000012208 us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember 2017-01-01 2017-12-31 0000012208 us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2018-01-01 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-01-01 2016-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember 2016-01-01 2016-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2016-01-01 2016-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2016-01-01 2016-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2018-01-01 2018-12-31 0000012208 bio:ClinicalDiagnosticsMember 2016-01-01 2016-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2018-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2017-01-01 2017-12-31 0000012208 bio:LifeScienceMember 2016-01-01 2016-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2017-12-31 0000012208 srt:EuropeMember 2017-12-31 0000012208 srt:AmericasMember 2017-12-31 0000012208 srt:AmericasMember 2018-12-31 0000012208 country:US 2018-12-31 0000012208 srt:AsiaPacificMember 2017-12-31 0000012208 srt:EuropeMember 2018-12-31 0000012208 country:US 2017-12-31 0000012208 srt:AsiaPacificMember 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2017-01-01 2017-12-31 0000012208 bio:EuropeanReorganizationMember 2017-01-01 2017-12-31 0000012208 bio:EuropeanReorganizationMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2016-12-31 0000012208 bio:EuropeanReorganizationMember 2018-01-01 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2018-01-01 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember 2016-12-31 0000012208 bio:EuropeanReorganizationMember 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2016-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:EuropeanReorganizationMember 2017-01-01 2017-12-31 0000012208 us-gaap:OtherOperatingIncomeExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 us-gaap:EmployeeSeveranceMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 us-gaap:OtherOperatingIncomeExpenseMember us-gaap:FacilityClosingMember bio:ClinicalDiagnosticsMember 2018-10-01 2018-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanReorganizationMember 2017-01-01 2017-12-31 0000012208 us-gaap:EmployeeSeveranceMember us-gaap:FacilityClosingMember bio:ClinicalDiagnosticsMember 2018-10-01 2018-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-12-31 0000012208 bio:GnuBIOMember us-gaap:ResearchAndDevelopmentExpenseMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanReorganizationMember 2018-01-01 2018-12-31 0000012208 bio:EuropeanReorganizationMember 2016-01-01 2016-12-31 0000012208 bio:EuropeanReorganizationMember 2016-05-01 2018-12-31 0000012208 us-gaap:EmployeeSeveranceMember bio:TerminationofanDiagnosticsResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanReorganizationMember 2016-01-01 2016-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember 2017-12-01 2018-12-31 0000012208 us-gaap:AccountsPayableAndAccruedLiabilitiesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-12-31 0000012208 us-gaap:OtherOperatingIncomeExpenseMember bio:TerminationofanDiagnosticsResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:EuropeanReorganizationMember 2018-01-01 2018-12-31 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-12-31 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2017-01-01 2017-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2017-01-01 2017-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:EuropeanReorganizationMember 2016-01-01 2016-12-31 0000012208 bio:GnuBIOMember us-gaap:OtherOperatingIncomeExpenseMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:GnuBIOMember us-gaap:EmployeeSeveranceMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:GnuBIOMember 2017-12-31 0000012208 bio:GnuBIOMember us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2017-01-01 2017-12-31 0000012208 us-gaap:EmployeeSeveranceMember us-gaap:FacilityClosingMember 2018-01-01 2018-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2017-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2017-01-01 2017-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2016-12-31 0000012208 2018-10-01 2018-12-31 0000012208 2018-04-01 2018-06-30 0000012208 2017-01-01 2017-03-31 0000012208 2017-10-01 2017-12-31 0000012208 2017-04-01 2017-06-30 0000012208 2018-07-01 2018-09-30 0000012208 2018-01-01 2018-03-31 0000012208 2017-07-01 2017-09-30 0000012208 us-gaap:SubsequentEventMember 2019-03-04 2019-03-04 0000012208 us-gaap:AllowanceForCreditLossMember 2016-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2018-01-01 2018-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2017-01-01 2017-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2015-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2016-01-01 2016-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2017-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2018-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2016-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-01-01 2018-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-01-01 2017-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2016-01-01 2016-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2015-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-12-31 iso4217:USD shares iso4217:USD pure shares false --12-31 FY 2018 2018-12-31 10-K 0000012208 24707868 5092404 Yes false Large Accelerated Filer 6181361340 BIO-RAD LABORATORIES, INC. false false No No 25549000 26713000 0.0001 0.0001 0.0001 0.0001 80000000 20000000 80000000 20000000 24679127 5107674 24884265 5096421 24678545 5106757 24704772 5095504 .10 1 P8Y P7Y P12Y P12Y P8Y P0Y P6Y P1Y P1Y P1Y P1Y P1Y P0Y P1Y P7Y P6Y P10Y P11Y P7Y P0Y P6Y P1Y P1Y P1Y P7Y P7Y P0Y P2Y 0 0.0001 0.0001 7500000 7500000 0 0 0 0 P12Y P3Y 5600000 P5Y P5Y 0 0 582 917 179493 917 431526000 383824000 413270000 371154000 5560000 5560000 392443000 464847000 108008000 113925000 145051000 142589000 330756000 338290000 583815000 594804000 187249000 146135000 9615000 10325000 2023478000 1976649000 25185000 18026000 331563000 315984000 970081000 971140000 1326829000 1305150000 818139000 811654000 508690000 493496000 219770000 506069000 133123000 174113000 2655709000 1027736000 70298000 94949000 5611068000 4273012000 122450000 135182000 143510000 171632000 493000 420000 27513000 19802000 28675000 20139000 26936000 28233000 101218000 127288000 450795000 502696000 438937000 434581000 553239000 222209000 147766000 183276000 1590737000 1342762000 0 0 2000 2000 1000 1000 394342000 361231000 49040000 128000 89000 89000 3722073000 1830439000 -46958000 738794000 4020331000 2930250000 5611068000 4273012000 2289415000 2160153000 2068172000 1066264000 972450000 929744000 1223151000 1187703000 1138428000 834783000 806790000 814697000 199196000 250157000 205708000 292513000 11506000 62305000 -103341000 119250000 55718000 23962000 23014000 23380000 -2861000 -9128000 -4542000 606230000 0 0 36593000 10697000 13764000 512659000 97805000 41560000 147045000 -24444000 15560000 365614000 122249000 26000000 12.25 4.12 0.88 29836000 29655000 29440000 12.10 4.07 0.88 30228000 30034000 29646000 365614000 122249000 26000000 -112857000 76050000 -32394000 -7549000 3767000 -2086000 -1187000 248745000 65936000 -106495000 321028000 35628000 259119000 443277000 61628000 2326310000 2093948000 2074024000 1989685000 1916119000 1808687000 22703000 22224000 22756000 62414000 52136000 38442000 26383000 18392000 14597000 0 0 1506000 7603000 -17724000 -1164000 285494000 104137000 216066000 129825000 111332000 141436000 4315000 86000 398000 6964000 0 0 -266000 76645000 14165000 3000 3795000 135000 0 1000000 350000 371019000 282656000 278071000 77029000 97523000 76859000 225295000 202247000 143020000 -186978000 -175572000 -213880000 0 -36000 37000 2961000 316000 303000 14133000 14604000 11280000 8862000 7310000 0 48912000 2920000 0 2078000 3681000 3500000 0 0 1506000 -48680000 341000 9020000 -655000 -1094000 -12858000 49181000 -72188000 -1652000 384983000 457171000 458823000 434164000 384983000 457171000 431526000 383824000 456264000 111000 882000 494000 2527000 277000 413000 434164000 384983000 457171000 3000 300408000 -101000 1802581000 382138000 2485029000 26000000 26000000 35628000 35628000 11280000 11280000 19730000 19730000 1493000 1493000 3000 332911000 -101000 1828581000 417766000 2579160000 122249000 122249000 391000 -256000 135000 200893000 200893000 -120135000 120135000 4490000 4490000 23439000 23439000 -2920000 -2920000 2804000 2804000 3000 361231000 -217000 1830439000 738794000 2930250000 1543747000 -679257000 864490000 -17591000 -17591000 0 -136000 -136000 365614000 365614000 -106495000 -106495000 5271000 5271000 27840000 27840000 -48912000 -48912000 3000 394342000 -49129000 3722073000 -46958000 4020331000 1.<span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">SIGNIFICANT ACCOUNTING POLICIES</span><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Cash and Cash Equivalents</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair value.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Short-term Restricted Investments</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term restricted investments of </span><span style="font-family:inherit;font-size:11pt;"><span>$5.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> at both </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> represent a money market fund that is renewed annually for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Available-for-Sale Investments</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities.  Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date.  Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations.  Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data.  Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect.  Effective January 1, 2018, changes in fair value for equity securities are reported in Change in fair market value of equity securities in the Consolidated Statements of Income due to the adoption of ASU 2016-01 (see Recent Accounting Pronouncement Adopted at the end of this Note and Note 3). Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary.  We review our available-for-sale debt securities for other-than-temporary losses on a quarterly basis. </span><span style="font-family:inherit;font-size:11pt;color:#007f00;"> </span><span style="font-family:inherit;font-size:11pt;">Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10).</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Concentration of Credit Risk</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable.  Cash and cash equivalents and investments are placed with various highly rated major financial institutions located in different geographic regions. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements.  We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions.  In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end.  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral.  As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers.  Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Accounts Receivable</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Inventory</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Inventories are valued at the lower of cost and net realizable value and include material, labor and overhead costs. The first-in, first-out method is used to relieve inventory for products sold.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Property, Plant and Equipment</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property, plant and equipment are carried at cost, less accumulated depreciation and amortization.  Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  The estimated useful lives of property, plant and equipment are generally as follows: buildings and leasehold improvements, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>15</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>39</span></span><span style="font-family:inherit;font-size:11pt;"> years or the term of the leases or life of the improvements, whichever is shorter; reagent rental equipment, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>1</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>5</span></span><span style="font-family:inherit;font-size:11pt;"> years; equipment and capitalized software, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>3</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>12</span></span><span style="font-family:inherit;font-size:11pt;"> years.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses.  Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating segments.  Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management.  Goodwill amounts are assigned to reporting units at the time of acquisition.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Effective January 1, 2017 in accordance with Accounting Standards Update No. 2017-04, "Simplifying the Test for Goodwill Impairment," the goodwill impairment amount will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit.  </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior to January 1, 2017, the goodwill impairment test consisted of a two-step process.  The first step of the goodwill impairment test, used to identify potential impairment, compared the fair value of a reporting unit to its carrying value, including goodwill. We used a projected discounted cash flow model to determine the fair value of a reporting unit.  If the fair value of the reporting unit exceeded its carrying amount, goodwill of the reporting unit was considered not impaired, and the second step of the impairment test was not required.  The second step, if required, compared the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit was allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit.  If the carrying amount of the reporting unit’s goodwill exceeded its implied fair value, an impairment charge is recognized in an amount equal to that excess.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Long-Lived Assets</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.  We assess the impairment of long-lived assets (including identifiable intangible assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors that we consider important that could trigger an impairment review include:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant under-performance relative to expected, historical or projected future operating results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant negative industry, legal, regulatory or economic trends.</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method.  Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets.  We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If this is the case, an impairment loss would be recognized.  The impairment loss recognized is the amount by which the carrying amount exceeds the fair value. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Income Taxes </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We record deferred tax assets to the extent we believe these assets will more likely than not be realized.  In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. To the extent we determine that we are able to realize our deferred income tax assets in the future in excess of their net recorded amount, we make an adjustment to the valuation allowance which may reduce the provision for income taxes. When we establish or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The new legislation contains significant tax provisions that affect us, including a one-time mandatory deemed repatriation tax on certain unrepatriated foreign earnings ("Transition Tax"), a reduction of the corporate income tax rate from 35% to 21% effective January 1, 2018, and a change from a worldwide tax system to a modified territorial system.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We are required to recognize the effect of the tax law changes in the period of enactment, such as the computation of the Transition Tax, remeasurement of our U.S. federal deferred tax assets and liabilities, as well as reassessment of the net realizability of our deferred tax assets and liabilities.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Subsequent to the enactment of the Tax Act, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act ("SAB 118"), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under Accounting Standards Codification ("ASC") 740, "Income Taxes." We have completed the accounting for the income tax effects of the Tax Act, under SAB 118, as of December 31, 2018. As noted in our 2017 Annual Report, we were able to make reasonable estimates and provisionally recorded an income tax benefit of </span><span style="font-family:inherit;font-size:11pt;"><span>$70 million</span></span><span style="font-family:inherit;font-size:11pt;"> related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. The final accounting for the Tax Act resulted in an additional income tax benefit of </span><span style="font-family:inherit;font-size:11pt;"><span>$49 million</span></span><span style="font-family:inherit;font-size:11pt;"> for a final income tax benefit of </span><span style="font-family:inherit;font-size:11pt;"><span>$119 million</span></span><span style="font-family:inherit;font-size:11pt;">. This is comprised of </span><span style="font-family:inherit;font-size:11pt;"><span>$169 million</span></span><span style="font-family:inherit;font-size:11pt;"> tax benefit related to the remeasurement of U.S. federal deferred tax assets and liabilities, offset by a </span><span style="font-family:inherit;font-size:11pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:11pt;"> tax detriment for the Transition Tax. We elected to account for the tax effect of the Global Intangible Low-Taxed Income (“GILTI”) in the period in which it is incurred.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">During the fourth quarter of 2017, we early adopted ASU 2018-02, "Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income." With respect to stranded income tax effects in accumulated other comprehensive income, our policy is to use the portfolio method to reclassify such amounts.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On January 1, 2018, we adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018.  Results for reporting periods beginning on January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under prior revenue guidance ASC 605, "Revenue Recognition."</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We recorded a net reduction to opening retained earnings of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. The impact to revenue as a result of applying ASC 606 as compared to ASC 605 for </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> was not significant.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We recognize revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced to the estimated amount that we expect to receive in exchange for transferring control for those products. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, transaction prices are allocated to performance obligations based on stand-alone selling prices. The method used to determine the stand-alone selling prices for service revenues is based on the observable prices when the services have been sold separately.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less and for contracts in which we recognize revenue at the amount to which we have the right to invoice for services performed. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:174%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Reagent Rental Agreements </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. We concluded that the use of the instrument and related maintenance services (collectively known as “lease elements”) are not within the guidance of ASC 606 but rather ASC 840 Leases. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and requires consideration of any fixed/minimum payments as well as estimates of variable consideration. After determining what portion of the transaction price should be allocated to the lease elements, any fixed consideration would be considered the minimum lease payment to be amortized straight line over the lease term and any variable consideration would be contingent rent to be recognized monthly as earned, which coincides with the transfer of control of the non-lease elements. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For the portion of the transaction price allocated to the non-lease elements, which are principally the reagents, the related revenue will be recognized at a point in time when control transfers. Generally, the terms of the arrangements result in the transfer of control upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Revenue allocated to the lease elements of these reagent rental arrangements represents approximately </span><span style="font-family:inherit;font-size:11pt;"><span>5%</span></span><span style="font-family:inherit;font-size:11pt;"> of total revenue and are included as part of the Net sales in our Consolidated Statements of Income.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contract costs:</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Disaggregation of Revenue:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The disaggregation of our revenue by geographic region based primarily on the location of the use of the product service, and by industry segment sources, and the disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 14).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are generally recognized ratably over the term of the service contract as our performance extends over the life of the arrangement. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from </span><span style="font-family:inherit;font-size:11pt;"><span>$36.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> to </span><span style="font-family:inherit;font-size:11pt;"><span>$37.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> is primarily driven by </span><span style="font-family:inherit;font-size:11pt;"><span>$28.0 million</span></span><span style="font-family:inherit;font-size:11pt;">, net, of cash payments received or due in advance of satisfying our performance obligations, partially offset by </span><span style="font-family:inherit;font-size:11pt;"><span>$27.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> of revenue recognized that were included in our deferred revenue balance as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Consolidated Balance Sheets, were as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:62.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for warranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Actual warranty costs</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(34.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(28.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Shipping and Handling</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We classify all freight costs billed to customers as Net sales.  Related freight costs are recognized upon transfer of control of the promised products to customers as a fulfillment cost and included in Cost of goods sold.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We conduct extensive research and development activities in all areas of our business, employing approximately </span><span style="font-family:inherit;font-size:10pt;"><span>800</span></span><span style="font-family:inherit;font-size:11pt;"> employees worldwide in these activities, including degreed scientists and technical support staff.  Research and development has played a major role in Bio-Rad’s growth and is expected to continue to do so in the future.  Our research teams are continuously developing new products and new applications for existing products.  In our development of new products and applications, we interact with scientific and medical professionals at universities, hospitals and medical schools, and within our industry.  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Foreign Currency</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period.  Income statement items are translated at average exchange rates for the period.  The resulting translation adjustments are recorded as a separate component of stockholders’ equity.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income.  Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Forward Foreign Exchange Contracts</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Share-Based Compensation Plans</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Share-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value.  We recognize these compensation costs net of forfeitures over the requisite service period of the award, which is generally the vesting term of the share-based payment awards.  Starting in 2017, we recognize forfeitures as they occur due to a change in accounting principle, and in prior periods we estimated the forfeiture rate based on our historical experience.  These plans are described more fully in Note 9.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Earnings Per Share</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic weighted average shares outstanding</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,836</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,655</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,440</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Effect of potentially dilutive stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    and restricted stock awards</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>392</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>379</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>206</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted weighted average common shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,228</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,034</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,646</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Anti-dilutive stock options and restricted stock awards </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    excluded from the computation of diluted EPS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Recent Accounting Pronouncements Adopted</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In February 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. ("ASU") 2018-03, "Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities." ASU 2018-03 amends certain items in ASU 2016-01 (see below) such as equity securities without a readily determinable fair value. ASU 2018-03 clarifies that an entity that uses the measurement alternative for equity securities without readily determinable fair values can change its measurement approach to fair value and once made the election is irrevocable. If an entity measures equity securities without readily determinable fair values at fair value, it must record a cumulative-effect adjustment to </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Retained earnings as of the beginning of the fiscal year in which the guidance is adopted. We adopted ASU 2018-03 on January 1, 2018 and made an irrevocable election to account for our investment of the ordinary shares of Sartorius AG at fair value (see ASU 2016-01 below).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:11pt;">In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. Changes in fair value for equity securities will no longer be reported in other comprehensive income. </span><span style="font-family:inherit;font-size:12pt;"> </span><span style="font-family:inherit;font-size:11pt;">For equity investments without readily determinable fair values, the cost method is also eliminated. We adopted ASU 2016-01 on January 1, 2018 and record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes and were valued at </span><span style="font-family:inherit;font-size:11pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">. Changes in the basis of these equity investments are reported in current earnings. For equity securities that are affected by ASU 2016-01 and ASU 2018-03, see Note 3 to the consolidated financial statements, which primarily consists of our investment in Sartorius AG. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The impact of the adoption of ASU 2016-01 and ASU 2018-03 on January 1, 2018 was through a cumulative-effect adjustment of </span><span style="font-family:inherit;font-size:11pt;"><span>$864.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> to Total stockholders' equity by increasing Retained earnings of </span><span style="font-family:inherit;font-size:11pt;"><span>$1,543.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> and decreasing Accumulated other comprehensive income of </span><span style="font-family:inherit;font-size:11pt;"><span>$679.2 million</span></span><span style="font-family:inherit;font-size:11pt;">, including an increase in Deferred income taxes of </span><span style="font-family:inherit;font-size:11pt;"><span>$232.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> and an increase in Other investments of </span><span style="font-family:inherit;font-size:11pt;"><span>$1,097.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> in our Consolidated Balance Sheet. As a result of ASU 2016-01 and ASU 2018-03 for </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;">, we recorded a gain of </span><span style="font-family:inherit;font-size:11pt;"><span>$606.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> for the Change in fair market value of equity securities in the Consolidated Statement of Income that resulted in a deferred tax expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$133.9 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost," which changed how we present the net periodic benefit cost of our defined benefit pension and/or other postretirement plans. We adopted ASU 2017-07 on January 1, 2018 and applied the practical expedient to estimate amounts for comparative purposes utilizing the information disclosed in Note 12 to the consolidated financial statements in our Form 10-K for the year ended December 31, 2017. The interest costs are recorded in Interest expense, and the other costs are recorded in Other (income) expense, net in the Consolidated Statements of Income. For 2017 for interest costs and other costs, we reclassified </span><span style="font-family:inherit;font-size:11pt;"><span>$0.304 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$2.152 million</span></span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.144 million</span></span><span style="font-family:inherit;font-size:11pt;"> from Cost of goods sold (COGS), Selling, general and administrative expense (SG&amp;A) and Research and Development expense (R&amp;D), respectively, to Interest expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> and Other (income) expense, net of </span><span style="font-family:inherit;font-size:11pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:11pt;">. For 2016 for interest costs and other costs, we reclassified </span><span style="font-family:inherit;font-size:11pt;"><span>$0.341 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$2.027 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.156 million</span></span><span style="font-family:inherit;font-size:11pt;"> from COGS, SG&amp;A and R&amp;D, respectively, to Interest expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$1.438 million</span></span><span style="font-family:inherit;font-size:11pt;"> and Other (income) expense, net of </span><span style="font-family:inherit;font-size:11pt;"><span>$1.086 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In November 2016, the FASB issued ASU 2016-18, "Restricted Cash," which required us to cease to present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. We adopted ASU 2016-18 on January 1, 2018 and updated the Consolidated Statements of Cash Flows to incorporate restricted cash included in Other current assets and Other assets of </span><span style="font-family:inherit;font-size:11pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of December 31, 2017. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory," which required immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  We adopted ASU 2016-16 on January 1, 2018 on a modified retrospective basis through a cumulative-effect adjustment by decreasing Retained earnings by </span><span style="font-family:inherit;font-size:11pt;"><span>$17.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, and decreasing Prepaid taxes by </span><span style="font-family:inherit;font-size:11pt;"><span>$22.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> and increasing Deferred tax assets by </span><span style="font-family:inherit;font-size:11pt;"><span>$5.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> that are both recorded in Other assets in our Consolidated Balance Sheet. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments" and adopted it on January 1, 2018, which did not have an impact to our statement of cash flows presentation.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers ("ASC 606"), an updated standard on revenue recognition. The new standard provides enhancements to the quality and consistency of how revenue is reported under the principle that revenue should be recognized in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of promised goods or services. We adopted ASC 606 as of January 1, 2018 using the cumulative effect transition method as more fully described above under the caption “Revenue Recognition.” </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Recent Accounting Pronouncements to be Adopted </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In November 2018, the FASB issued ASU 2018-18, "Clarifying the Interaction between Topic 808 and Topic 606." Topic 808 is Collaborative Arrangements, and Topic 606 is Revenue from Contracts with Customers. ASU 2018-18 clarifies that certain transactions between collaborative partners should be accounted for as revenue under ASC 606 when the collaborative partner is a customer. We currently do not have any customers that are collaborative partners or anticipate any in the near future. ASU 2018-18 will be effective January 1, 2020 and we will not early adopt.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In August 2018, the FASB issued ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract." ASU 2018-15 amends the definition of a hosting arrangement and requires a customer in a hosting arrangement that is a service contract to capitalize certain implementation costs as if the arrangement was an internal-use software project. The internal-use software guidance states that only qualifying costs incurred during the application development stage can be capitalized. We will prospectively adopt ASU 2018-15 effective January 1, 2019. We do not expect ASU 2018-15 to have a material impact to our consolidated financial statements. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In August 2018, the FASB issued ASU 2018-14, "Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." ASU 2018-14 eliminates and adds certain disclosures for defined benefit plans. ASU 2018-14 is effective for fiscal years ending after December 15, 2020 using a retrospective approach, with early adoption permitted. We are currently evaluating the disclosures and the timing of adoption but do not expect ASU 2018-14 to have a material impact to our disclosures for defined benefit plans.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In August 2018, the FASB issued ASU 2018-13, "Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement." ASU 2018-13 eliminates, adds and modifies certain disclosures for fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. Early adoption is permitted in interim periods, including periods for which financial statements have not yet been issued. We do not expect ASU 2018-13 to have a material impact to our fair value disclosures and we currently do not plan to early adopt.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. In November 2018, the FASB issued ASU 2018-19, "Codification Improvements to Topic 326, Financial Instruments-Credit Losses," which clarifies that receivables arising from operating leases are not within the scope of Topic 326. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div>In February 2016, the FASB issued ASU 2016-02, "Leases," and related accounting standard updates, which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. We will adopt ASU 2016-02 on a modified retrospective basis effective January 1, 2019 with practical expedients, and will not restate comparative prior periods. The practical expedients, include, among other items, for leases that existed prior January 1, 2019, to not reassess whether any contracts are or contain embedded leases, reassessing the classification of existing leases, and reassessing whether previously capitalized initial direct costs qualify for capitalization. Where we act as a lessee, we also elected not to separate lease and non-lease components. Where we act as a lessor in our reagent rental arrangements, we allocate the consideration in the contract to the separate lease components and the non-lease components. After the allocation, the amount of variable payments allocated to lease components will be recognized as income in accordance with the new lease accounting standard updates, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Such reagent rental arrangements are more fully described above under the caption "Reagent Rental Agreements." Where we act as a lessee, the adoption of the standard will result in material additions to the balance sheet for right-of-use assets and the associated liabilities. We will complete our review of the completeness and accuracy of the lease data, discount rate and finalize our updated controls in accordance with the new standard during the first quarter of 2019. Where we act as a lessor in reagent rental arrangements, we estimate an insignificant impact to our consolidated financial statements. Basis of Presentation<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions. Cash and Cash Equivalents<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair value. Short-term Restricted Investments<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">Short-term restricted investments of </span><span style="font-family:inherit;font-size:11pt;"><span>$5.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> at both </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span> represent a money market fund that is renewed annually for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets. 5600000 Available-for-Sale Investments<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities.  Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date.  Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations.  Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data.  Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect.  Effective January 1, 2018, changes in fair value for equity securities are reported in Change in fair market value of equity securities in the Consolidated Statements of Income due to the adoption of ASU 2016-01 (see Recent Accounting Pronouncement Adopted at the end of this Note and Note 3). Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary.  We review our available-for-sale debt securities for other-than-temporary losses on a quarterly basis. </span><span style="font-family:inherit;font-size:11pt;color:#007f00;"> </span>Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10). Concentration of Credit Risk<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable.  Cash and cash equivalents and investments are placed with various highly rated major financial institutions located in different geographic regions. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements.  We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions.  In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end.  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral.  As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers.  Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.</span></div><br/> Accounts Receivable<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance. Inventory<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Inventories are valued at the lower of cost and net realizable value and include material, labor and overhead costs. The first-in, first-out method is used to relieve inventory for products sold. Property, Plant and Equipment<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property, plant and equipment are carried at cost, less accumulated depreciation and amortization.  Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  The estimated useful lives of property, plant and equipment are generally as follows: buildings and leasehold improvements, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>15</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>39</span></span><span style="font-family:inherit;font-size:11pt;"> years or the term of the leases or life of the improvements, whichever is shorter; reagent rental equipment, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>1</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>5</span></span><span style="font-family:inherit;font-size:11pt;"> years; equipment and capitalized software, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>3</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>12</span></span> years. P15Y P39Y P1Y P5Y P3Y P12Y Goodwill<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses.  Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating segments.  Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management.  Goodwill amounts are assigned to reporting units at the time of acquisition.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Effective January 1, 2017 in accordance with Accounting Standards Update No. 2017-04, "Simplifying the Test for Goodwill Impairment," the goodwill impairment amount will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit.  </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior to January 1, 2017, the goodwill impairment test consisted of a two-step process.  The first step of the goodwill impairment test, used to identify potential impairment, compared the fair value of a reporting unit to its carrying value, including goodwill. We used a projected discounted cash flow model to determine the fair value of a reporting unit.  If the fair value of the reporting unit exceeded its carrying amount, goodwill of the reporting unit was considered not impaired, and the second step of the impairment test was not required.  The second step, if required, compared the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit was allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit.  If the carrying amount of the reporting unit’s goodwill exceeded its implied fair value, an impairment charge is recognized in an amount equal to that excess.</span></div><br/> Long-Lived Assets<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.  We assess the impairment of long-lived assets (including identifiable intangible assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors that we consider important that could trigger an impairment review include:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant under-performance relative to expected, historical or projected future operating results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant negative industry, legal, regulatory or economic trends.</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div>When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method.  Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets.  We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If this is the case, an impairment loss would be recognized.  The impairment loss recognized is the amount by which the carrying amount exceeds the fair value. Income Taxes <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We record deferred tax assets to the extent we believe these assets will more likely than not be realized.  In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. To the extent we determine that we are able to realize our deferred income tax assets in the future in excess of their net recorded amount, we make an adjustment to the valuation allowance which may reduce the provision for income taxes. When we establish or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The new legislation contains significant tax provisions that affect us, including a one-time mandatory deemed repatriation tax on certain unrepatriated foreign earnings ("Transition Tax"), a reduction of the corporate income tax rate from 35% to 21% effective January 1, 2018, and a change from a worldwide tax system to a modified territorial system.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We are required to recognize the effect of the tax law changes in the period of enactment, such as the computation of the Transition Tax, remeasurement of our U.S. federal deferred tax assets and liabilities, as well as reassessment of the net realizability of our deferred tax assets and liabilities.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Subsequent to the enactment of the Tax Act, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act ("SAB 118"), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under Accounting Standards Codification ("ASC") 740, "Income Taxes." We have completed the accounting for the income tax effects of the Tax Act, under SAB 118, as of December 31, 2018. As noted in our 2017 Annual Report, we were able to make reasonable estimates and provisionally recorded an income tax benefit of </span><span style="font-family:inherit;font-size:11pt;"><span>$70 million</span></span><span style="font-family:inherit;font-size:11pt;"> related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. The final accounting for the Tax Act resulted in an additional income tax benefit of </span><span style="font-family:inherit;font-size:11pt;"><span>$49 million</span></span><span style="font-family:inherit;font-size:11pt;"> for a final income tax benefit of </span><span style="font-family:inherit;font-size:11pt;"><span>$119 million</span></span><span style="font-family:inherit;font-size:11pt;">. This is comprised of </span><span style="font-family:inherit;font-size:11pt;"><span>$169 million</span></span><span style="font-family:inherit;font-size:11pt;"> tax benefit related to the remeasurement of U.S. federal deferred tax assets and liabilities, offset by a </span><span style="font-family:inherit;font-size:11pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:11pt;"> tax detriment for the Transition Tax. We elected to account for the tax effect of the Global Intangible Low-Taxed Income (“GILTI”) in the period in which it is incurred.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">During the fourth quarter of 2017, we early adopted ASU 2018-02, "Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income." With respect to stranded income tax effects in accumulated other comprehensive income, our policy is to use the portfolio method to reclassify such amounts.</span></div><br/> -70000000 -49000000 -119000000 -169000000 50000000 Revenue Recognition<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On January 1, 2018, we adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018.  Results for reporting periods beginning on January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under prior revenue guidance ASC 605, "Revenue Recognition."</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We recorded a net reduction to opening retained earnings of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. The impact to revenue as a result of applying ASC 606 as compared to ASC 605 for </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> was not significant.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We recognize revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced to the estimated amount that we expect to receive in exchange for transferring control for those products. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, transaction prices are allocated to performance obligations based on stand-alone selling prices. The method used to determine the stand-alone selling prices for service revenues is based on the observable prices when the services have been sold separately.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less and for contracts in which we recognize revenue at the amount to which we have the right to invoice for services performed. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:174%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Reagent Rental Agreements </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. We concluded that the use of the instrument and related maintenance services (collectively known as “lease elements”) are not within the guidance of ASC 606 but rather ASC 840 Leases. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and requires consideration of any fixed/minimum payments as well as estimates of variable consideration. After determining what portion of the transaction price should be allocated to the lease elements, any fixed consideration would be considered the minimum lease payment to be amortized straight line over the lease term and any variable consideration would be contingent rent to be recognized monthly as earned, which coincides with the transfer of control of the non-lease elements. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For the portion of the transaction price allocated to the non-lease elements, which are principally the reagents, the related revenue will be recognized at a point in time when control transfers. Generally, the terms of the arrangements result in the transfer of control upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Revenue allocated to the lease elements of these reagent rental arrangements represents approximately </span><span style="font-family:inherit;font-size:11pt;"><span>5%</span></span><span style="font-family:inherit;font-size:11pt;"> of total revenue and are included as part of the Net sales in our Consolidated Statements of Income.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contract costs:</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Disaggregation of Revenue:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The disaggregation of our revenue by geographic region based primarily on the location of the use of the product service, and by industry segment sources, and the disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 14).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are generally recognized ratably over the term of the service contract as our performance extends over the life of the arrangement. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from </span><span style="font-family:inherit;font-size:11pt;"><span>$36.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> to </span><span style="font-family:inherit;font-size:11pt;"><span>$37.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> is primarily driven by </span><span style="font-family:inherit;font-size:11pt;"><span>$28.0 million</span></span><span style="font-family:inherit;font-size:11pt;">, net, of cash payments received or due in advance of satisfying our performance obligations, partially offset by </span><span style="font-family:inherit;font-size:11pt;"><span>$27.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> of revenue recognized that were included in our deferred revenue balance as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">.</span></div><br/> 100000 0.05 36700000 37300000 28000000.0 27400000 We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Consolidated Balance Sheets, were as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:62.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for warranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Actual warranty costs</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(34.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(28.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> <br/><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:62.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for warranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Actual warranty costs</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(34.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(28.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><br/> 18700000 17600000 25500000 29900000 34100000 28800000 10100000 18700000 Shipping and Handling<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We classify all freight costs billed to customers as Net sales.  Related freight costs are recognized upon transfer of control of the promised products to customers as a fulfillment cost and included in Cost of goods sold.</span></div><br/> <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">We conduct extensive research and development activities in all areas of our business, employing approximately </span><span style="font-family:inherit;font-size:10pt;"><span>800</span></span> employees worldwide in these activities, including degreed scientists and technical support staff.  Research and development has played a major role in Bio-Rad’s growth and is expected to continue to do so in the future.  Our research teams are continuously developing new products and new applications for existing products.  In our development of new products and applications, we interact with scientific and medical professionals at universities, hospitals and medical schools, and within our industry.   800 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Foreign Currency</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period.  Income statement items are translated at average exchange rates for the period.  The resulting translation adjustments are recorded as a separate component of stockholders’ equity.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income.  Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction. <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Forward Foreign Exchange Contracts</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.   <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Share-Based Compensation Plans</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Share-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value.  We recognize these compensation costs net of forfeitures over the requisite service period of the award, which is generally the vesting term of the share-based payment awards.  Starting in 2017, we recognize forfeitures as they occur due to a change in accounting principle, and in prior periods we estimated the forfeiture rate based on our historical experience.  These plans are described more fully in Note 9. <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Earnings Per Share</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic weighted average shares outstanding</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,836</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,655</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,440</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Effect of potentially dilutive stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    and restricted stock awards</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>392</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>379</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>206</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted weighted average common shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,228</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,034</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,646</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Anti-dilutive stock options and restricted stock awards </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    excluded from the computation of diluted EPS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic weighted average shares outstanding</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,836</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,655</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,440</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Effect of potentially dilutive stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    and restricted stock awards</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>392</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>379</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>206</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted weighted average common shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,228</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,034</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,646</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Anti-dilutive stock options and restricted stock awards </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    excluded from the computation of diluted EPS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 29836000 29655000 29440000 392000 379000 206000 30228000 30034000 29646000 84000 13000 113000 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3). Recent Accounting Pronouncements Adopted<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In February 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. ("ASU") 2018-03, "Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities." ASU 2018-03 amends certain items in ASU 2016-01 (see below) such as equity securities without a readily determinable fair value. ASU 2018-03 clarifies that an entity that uses the measurement alternative for equity securities without readily determinable fair values can change its measurement approach to fair value and once made the election is irrevocable. If an entity measures equity securities without readily determinable fair values at fair value, it must record a cumulative-effect adjustment to </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Retained earnings as of the beginning of the fiscal year in which the guidance is adopted. We adopted ASU 2018-03 on January 1, 2018 and made an irrevocable election to account for our investment of the ordinary shares of Sartorius AG at fair value (see ASU 2016-01 below).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:11pt;">In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. Changes in fair value for equity securities will no longer be reported in other comprehensive income. </span><span style="font-family:inherit;font-size:12pt;"> </span><span style="font-family:inherit;font-size:11pt;">For equity investments without readily determinable fair values, the cost method is also eliminated. We adopted ASU 2016-01 on January 1, 2018 and record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes and were valued at </span><span style="font-family:inherit;font-size:11pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">. Changes in the basis of these equity investments are reported in current earnings. For equity securities that are affected by ASU 2016-01 and ASU 2018-03, see Note 3 to the consolidated financial statements, which primarily consists of our investment in Sartorius AG. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The impact of the adoption of ASU 2016-01 and ASU 2018-03 on January 1, 2018 was through a cumulative-effect adjustment of </span><span style="font-family:inherit;font-size:11pt;"><span>$864.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> to Total stockholders' equity by increasing Retained earnings of </span><span style="font-family:inherit;font-size:11pt;"><span>$1,543.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> and decreasing Accumulated other comprehensive income of </span><span style="font-family:inherit;font-size:11pt;"><span>$679.2 million</span></span><span style="font-family:inherit;font-size:11pt;">, including an increase in Deferred income taxes of </span><span style="font-family:inherit;font-size:11pt;"><span>$232.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> and an increase in Other investments of </span><span style="font-family:inherit;font-size:11pt;"><span>$1,097.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> in our Consolidated Balance Sheet. As a result of ASU 2016-01 and ASU 2018-03 for </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;">, we recorded a gain of </span><span style="font-family:inherit;font-size:11pt;"><span>$606.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> for the Change in fair market value of equity securities in the Consolidated Statement of Income that resulted in a deferred tax expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$133.9 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost," which changed how we present the net periodic benefit cost of our defined benefit pension and/or other postretirement plans. We adopted ASU 2017-07 on January 1, 2018 and applied the practical expedient to estimate amounts for comparative purposes utilizing the information disclosed in Note 12 to the consolidated financial statements in our Form 10-K for the year ended December 31, 2017. The interest costs are recorded in Interest expense, and the other costs are recorded in Other (income) expense, net in the Consolidated Statements of Income. For 2017 for interest costs and other costs, we reclassified </span><span style="font-family:inherit;font-size:11pt;"><span>$0.304 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$2.152 million</span></span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.144 million</span></span><span style="font-family:inherit;font-size:11pt;"> from Cost of goods sold (COGS), Selling, general and administrative expense (SG&amp;A) and Research and Development expense (R&amp;D), respectively, to Interest expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> and Other (income) expense, net of </span><span style="font-family:inherit;font-size:11pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:11pt;">. For 2016 for interest costs and other costs, we reclassified </span><span style="font-family:inherit;font-size:11pt;"><span>$0.341 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$2.027 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.156 million</span></span><span style="font-family:inherit;font-size:11pt;"> from COGS, SG&amp;A and R&amp;D, respectively, to Interest expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$1.438 million</span></span><span style="font-family:inherit;font-size:11pt;"> and Other (income) expense, net of </span><span style="font-family:inherit;font-size:11pt;"><span>$1.086 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In November 2016, the FASB issued ASU 2016-18, "Restricted Cash," which required us to cease to present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. We adopted ASU 2016-18 on January 1, 2018 and updated the Consolidated Statements of Cash Flows to incorporate restricted cash included in Other current assets and Other assets of </span><span style="font-family:inherit;font-size:11pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of December 31, 2017. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory," which required immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  We adopted ASU 2016-16 on January 1, 2018 on a modified retrospective basis through a cumulative-effect adjustment by decreasing Retained earnings by </span><span style="font-family:inherit;font-size:11pt;"><span>$17.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, and decreasing Prepaid taxes by </span><span style="font-family:inherit;font-size:11pt;"><span>$22.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> and increasing Deferred tax assets by </span><span style="font-family:inherit;font-size:11pt;"><span>$5.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> that are both recorded in Other assets in our Consolidated Balance Sheet. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments" and adopted it on January 1, 2018, which did not have an impact to our statement of cash flows presentation.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers ("ASC 606"), an updated standard on revenue recognition. The new standard provides enhancements to the quality and consistency of how revenue is reported under the principle that revenue should be recognized in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of promised goods or services. We adopted ASC 606 as of January 1, 2018 using the cumulative effect transition method as more fully described above under the caption “Revenue Recognition.” </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Recent Accounting Pronouncements to be Adopted </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In November 2018, the FASB issued ASU 2018-18, "Clarifying the Interaction between Topic 808 and Topic 606." Topic 808 is Collaborative Arrangements, and Topic 606 is Revenue from Contracts with Customers. ASU 2018-18 clarifies that certain transactions between collaborative partners should be accounted for as revenue under ASC 606 when the collaborative partner is a customer. We currently do not have any customers that are collaborative partners or anticipate any in the near future. ASU 2018-18 will be effective January 1, 2020 and we will not early adopt.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In August 2018, the FASB issued ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract." ASU 2018-15 amends the definition of a hosting arrangement and requires a customer in a hosting arrangement that is a service contract to capitalize certain implementation costs as if the arrangement was an internal-use software project. The internal-use software guidance states that only qualifying costs incurred during the application development stage can be capitalized. We will prospectively adopt ASU 2018-15 effective January 1, 2019. We do not expect ASU 2018-15 to have a material impact to our consolidated financial statements. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In August 2018, the FASB issued ASU 2018-14, "Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." ASU 2018-14 eliminates and adds certain disclosures for defined benefit plans. ASU 2018-14 is effective for fiscal years ending after December 15, 2020 using a retrospective approach, with early adoption permitted. We are currently evaluating the disclosures and the timing of adoption but do not expect ASU 2018-14 to have a material impact to our disclosures for defined benefit plans.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In August 2018, the FASB issued ASU 2018-13, "Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement." ASU 2018-13 eliminates, adds and modifies certain disclosures for fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. Early adoption is permitted in interim periods, including periods for which financial statements have not yet been issued. We do not expect ASU 2018-13 to have a material impact to our fair value disclosures and we currently do not plan to early adopt.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. In November 2018, the FASB issued ASU 2018-19, "Codification Improvements to Topic 326, Financial Instruments-Credit Losses," which clarifies that receivables arising from operating leases are not within the scope of Topic 326. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div>In February 2016, the FASB issued ASU 2016-02, "Leases," and related accounting standard updates, which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. We will adopt ASU 2016-02 on a modified retrospective basis effective January 1, 2019 with practical expedients, and will not restate comparative prior periods. The practical expedients, include, among other items, for leases that existed prior January 1, 2019, to not reassess whether any contracts are or contain embedded leases, reassessing the classification of existing leases, and reassessing whether previously capitalized initial direct costs qualify for capitalization. Where we act as a lessee, we also elected not to separate lease and non-lease components. Where we act as a lessor in our reagent rental arrangements, we allocate the consideration in the contract to the separate lease components and the non-lease components. After the allocation, the amount of variable payments allocated to lease components will be recognized as income in accordance with the new lease accounting standard updates, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Such reagent rental arrangements are more fully described above under the caption "Reagent Rental Agreements." Where we act as a lessee, the adoption of the standard will result in material additions to the balance sheet for right-of-use assets and the associated liabilities. We will complete our review of the completeness and accuracy of the lease data, discount rate and finalize our updated controls in accordance with the new standard during the first quarter of 2019. Where we act as a lessor in reagent rental arrangements, we estimate an insignificant impact to our consolidated financial statements. 600000 864500000 1543700000 679200000 232900000 1097400000 606200000 133900000 304000 2152000 144000 1100000 1500000 341000 2027000.000 156000 1438000 1086000.000 2600000 1200000 -17600000 22800000 5200000 2.    ACQUISITIONS<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">RainDance Technologies, Inc.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In February 2017, we acquired all the issued and outstanding stock of RainDance Technologies, Inc. (RainDance) for approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$72.7 million</span></span><span style="font-family:inherit;font-size:11pt;">. Cash payments at closing were </span><span style="font-family:inherit;font-size:11pt;"><span>$72.9 million</span></span><span style="font-family:inherit;font-size:11pt;">. In addition, we had a cash payment of </span><span style="font-family:inherit;font-size:11pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> for a preexisting condition concurrent with the acquisition that was recorded in Cost of goods sold. The acquisition was included in our Life Science segment’s results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is not deductible for income tax purposes. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The final allocation for the payments of </span><span style="font-family:inherit;font-size:11pt;"><span>$72.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;"><span>$37.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> to definite-lived intangibles, </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> to acquired net assets, </span><span style="font-family:inherit;font-size:11pt;"><span>$26.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> to goodwill, a deferred tax liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$13.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> primarily related to the purchased intangibles and a deferred tax asset of </span><span style="font-family:inherit;font-size:11pt;"><span>$22.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> primarily related to the acquired net operating losses.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy. We believe that RainDance's droplet-based solutions will extend our reach into next-generation sequencing applications and strengthen our position in the area of Droplet Digital™ PCR, offering customers solutions for a wide range of nucleic acid detection applications. </span></div><br/> 72700000 72900000 10000000.0 72900000 37600000 200000 26200000 13600000 22500000 3. FAIR VALUE MEASUREMENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1: Quoted prices in active markets for identical instruments</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Assets Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents (a):</span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>77.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>77.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>59.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>88.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>147.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Equity Securities (b)</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,672.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,672.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>215.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>215.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments (c)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (d)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,738.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>461.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,200.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Liabilities Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Forward foreign exchange contracts (e)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Contingent consideration (f)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of first quarter 2018, our equity securities are no longer reported as Available-for-sale investments due to the implementation of ASU 2016-01. Changes in fair value of equity securities are now reported on the Consolidated Statements of Income rather than Other Comprehensive Income (see Note 1).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Assets Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents (a):</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>53.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>47.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>104.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment:</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments (c):</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>973.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>973.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>973.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>328.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,301.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (d)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,026.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>385.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,411.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Liabilities Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (e)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> Contingent consideration (f)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> Equity securities are included in the following accounts in the Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,632.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">        Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,672.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The unrealized gains on our equity securities still held as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> are </span><span style="font-family:inherit;font-size:11pt;"><span>$607.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> and are primarily due to our investment in Sartorius AG and is recorded in our Consolidated Statements of Income due to the adoption of ASU 2016-01 (see Note 1).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(c)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>371.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>930.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,301.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In accordance with our adoption of ASU 2016-01 January 1, 2018, our investment in Sartorius AG preferred shares, which was reported within marketable equity securities as Available-for-sale as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, is now reported as an Equity security as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> (see Note 1 and footnote (b) above).</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(d)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(e)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(f)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from </span><span style="font-family:inherit;font-size:11pt;"><span>39%</span></span><span style="font-family:inherit;font-size:11pt;"> to </span><span style="font-family:inherit;font-size:11pt;"><span>20%</span></span><span style="font-family:inherit;font-size:11pt;"> for the calendar years 2017 through 2020. The sales milestones could potentially range from </span><span style="font-family:inherit;font-size:11pt;"><span>$0</span></span><span style="font-family:inherit;font-size:11pt;"> to an unlimited amount. In the first and third quarters of 2018, we paid </span><span style="font-family:inherit;font-size:11pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, per the purchase agreement. Since 2016 we have had a net decrease in the cumulative valuation of the sales milestones of </span><span style="font-family:inherit;font-size:11pt;"><span>$12.2 million</span></span><span style="font-family:inherit;font-size:11pt;">. The contingent consideration was accrued at its estimated fair value of </span><span style="font-family:inherit;font-size:11pt;"><span>$8.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table provides a reconciliation of the Level 3 analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Payment of sales milestone </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The following table provides q</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">ua</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">ntitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">.</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:17%;"/><td style="width:26%;"/><td style="width:41%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unobservable Input</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Percentage</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Analytical flow cytometer platform</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Probability-weighted income approach</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Sales milestones:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of debt</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">To estimate the fair value of Level 2 debt securities as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, our primary pricing provider uses Securities Evaluations as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Securities Evaluations does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source. </span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For all commercial paper as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">, our primary pricing provider uses its leading pricing source in the hierarchy to determine pricing. For discount commercial paper as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, pricing was determined by a straight-line calculation, starting with the purchase price on the date of purchase and increasing to par at maturity. As of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, interest bearing certificates of deposit and commercial paper were priced at par. </span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our primary pricing provider performs daily reasonableness testing of the Securities Evaluations prices. Price changes of </span><span style="font-family:inherit;font-size:11pt;"><span>5%</span></span><span style="font-family:inherit;font-size:11pt;"> or greater are investigated and resolved. In addition, we perform a quarterly testing of the Securities Evaluations prices to custodian reported prices. Price differences outside a tolerable variance of approximately </span><span style="font-family:inherit;font-size:11pt;"><span>1%</span></span><span style="font-family:inherit;font-size:11pt;"> are investigated and resolved.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments consist of the following (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>216.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>215.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>375.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.6</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>375.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of the amortized cost and estimated fair value of our debt securities at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> by contractual maturity date (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in less than one year</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>155.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>155.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in one to five years</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>172.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>171.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in more than five years</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>47.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>46.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>375.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments consist of the following (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>68.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>34.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>363.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>371.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>875.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>930.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>875.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>930.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>418.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>884.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,301.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>117.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>193.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>168.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> or at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign exchange losses, net in the Consolidated Statements of Income. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of our forward foreign currency exchange contracts (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in January through March 2019 to sell foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>50.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in January through March 2019 to purchase foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>284.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The estimated fair value of financial instruments that are not recognized at fair value in the Consolidated Balance Sheets and are included in Other investments, are presented in the table below. Fair value has been determined using significant observable inputs, including quoted prices in active markets for similar instruments.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value.  Other investments include financial instruments, the majority of which has fair value based on similar, actively traded stock adjusted for various discounts, including a discount for marketability.  Long-term debt, excluding leases and current maturities, has an estimated fair value based on quoted market prices for the same or similar issues. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value Hierarchy Level</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-align:center;">Carrying </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-align:center;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value Hierarchy Level</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>91.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,249.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total long-term debt, excluding leases </span></div><div style="padding-left:12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">and current maturities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>435.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>449.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries.  We own over </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>37%</span></span><span style="font-family:inherit;font-size:11pt;"> of the outstanding voting shares (excluding treasury shares) of Sartorius as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">.  The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius’ board of directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. As of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">, due to the adoption of </span></div>ASU 2016-01 and ASU 2018-03 as of January 1, 2018, we account for this investment at fair market value as determined at period end by a quoted price on an organized exchange (see Note 1). Financial assets and liabilities carried at fair value and measured on a recurring basis as of <span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Assets Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents (a):</span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>77.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>77.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>59.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>88.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>147.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Equity Securities (b)</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,672.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,672.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>215.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>215.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments (c)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (d)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,738.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>461.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,200.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Liabilities Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Forward foreign exchange contracts (e)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Contingent consideration (f)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of first quarter 2018, our equity securities are no longer reported as Available-for-sale investments due to the implementation of ASU 2016-01. Changes in fair value of equity securities are now reported on the Consolidated Statements of Income rather than Other Comprehensive Income (see Note 1).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Assets Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents (a):</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>53.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>47.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>104.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment:</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments (c):</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>973.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>973.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>973.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>328.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,301.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (d)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,026.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>385.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,411.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Liabilities Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (e)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> Contingent consideration (f)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> Equity securities are included in the following accounts in the Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,632.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">        Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,672.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The unrealized gains on our equity securities still held as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> are </span><span style="font-family:inherit;font-size:11pt;"><span>$607.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> and are primarily due to our investment in Sartorius AG and is recorded in our Consolidated Statements of Income due to the adoption of ASU 2016-01 (see Note 1).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(c)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>371.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>930.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,301.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In accordance with our adoption of ASU 2016-01 January 1, 2018, our investment in Sartorius AG preferred shares, which was reported within marketable equity securities as Available-for-sale as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, is now reported as an Equity security as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> (see Note 1 and footnote (b) above).</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(d)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(e)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(f)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div> 0 77800000 0 77800000 22700000 10000000.0 0 32700000 0 300000 0 300000 36900000 0 0 36900000 59600000 88100000 0 147700000 5600000 0 0 5600000 2672900000 0 0 2672900000 0 215000000.0 0 215000000.0 0 80300000 0 80300000 0 3600000 0 3600000 0 11000000.0 0 11000000.0 0 63300000 0 63300000 0 373200000 0 373200000 0 600000 0 600000 2738100000 461900000 0 3200000000.0 0 700000 0 700000 0 0 8400000 8400000 0 700000 8400000 9100000 0 36000000.0 0 36000000.0 43700000 10000000.0 0 53700000 0 11200000 0 11200000 3400000 0 0 3400000 47100000 57200000 0 104300000 5600000 0 0 5600000 0 185700000 0 185700000 0 67600000 0 67600000 0 3400000 0 3400000 0 700000 0 700000 0 15000000.0 0 15000000.0 973400000 0 0 973400000 0 55600000 0 55600000 973400000 328000000.0 0 1301400000 0 500000 0 500000 1026100000 385700000 0 1411800000 0 1600000 0 1600000 0 0 16700000 16700000 0 1600000 16700000 18300000 40200000 2632700000 2672900000 607700000 373000000.0 371200000 200000 930200000 373200000 1301400000 3200000 2700000 5200000 14000000.0 8400000 16700000 0.39 0.20 0 1300000 800000 -12200000 8400000 conciliation of the Level 3 analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value (in millions):<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Payment of sales milestone </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The following table provides q</span> 16700000 2100000 6200000 8400000 <span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">ntitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">.</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.</span><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:17%;"/><td style="width:26%;"/><td style="width:41%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unobservable Input</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Percentage</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Analytical flow cytometer platform</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Probability-weighted income approach</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Sales milestones:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of debt</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div> 0.110 0.051 0.05 0.01 Available-for-sale investments consist of the following (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>216.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>215.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>375.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.6</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>375.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 216200000 100000 1300000 215000000.0 11100000 0 100000 11000000.0 63500000 0 400000 63100000 80900000 200000 800000 80300000 3600000 0 0 3600000 375300000 300000 2600000 373000000.0 200000 0 0 200000 200000 0 0 200000 375500000 300000 2600000 373200000 The following is a summary of the amortized cost and estimated fair value of our debt securities at <span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> by contractual maturity date (in millions):</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in less than one year</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>155.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>155.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in one to five years</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>172.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>171.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in more than five years</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>47.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>46.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>375.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 155500000 155200000 172400000 171300000 47600000 46700000 375500000 373200000 Available-for-sale investments consist of the following (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>68.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>34.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>363.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>371.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>875.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>930.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>875.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>930.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>418.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>884.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,301.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 185900000 300000 500000 185700000 700000 0 0 700000 15100000 0 100000 15000000.0 55600000 0 200000 55400000 68300000 0 700000 67600000 3400000 0 0 3400000 34400000 9000000.0 0 43400000 363400000 9300000 1500000 371200000 54500000 875500000 0 930000000.0 200000 0 0 200000 54700000 875500000 0 930200000 418100000 884800000 1500000 1301400000 The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>117.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>193.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>168.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 117900000 43900000 193000000.0 168700000 1800000 700000 800000 800000 The following is a summary of our forward foreign currency exchange contracts (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in January through March 2019 to sell foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>50.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in January through March 2019 to purchase foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>284.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div> 50600000 200000 284500000 -500000 The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value Hierarchy Level</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-align:center;">Carrying </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-align:center;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value Hierarchy Level</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>91.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,249.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total long-term debt, excluding leases </span></div><div style="padding-left:12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">and current maturities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>435.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>449.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr></table></div></div><br/> 0 0 91800000 1249400000 423700000 435800000 423100000 449800000 0.37 4.    GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes to goodwill by segment were as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.8515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Life<br/>Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Clinical<br/>Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Life<br/>Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Clinical<br/>Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balances as of January 1:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>234.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>324.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>559.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>207.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>311.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>518.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated impairment losses and write-offs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(35.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(53.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(27.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(14.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(41.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>198.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>307.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>506.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>179.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>297.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>477.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquisitions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Divestiture</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Impairment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.9</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(276.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(282.0</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.7</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11.5</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Currency fluctuations</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balances as of December 31:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>234.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>320.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>555.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>234.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>324.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>559.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated impairment losses and write-offs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(41.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(293.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(335.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(35.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(53.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>192.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>219.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>198.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>307.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>506.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In March 2018, we wrote off </span><span style="font-family:inherit;font-size:11pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> of goodwill from our Clinical Diagnostics segment as a result of a divestiture of a product line.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In conjunction with the purchase of all the issued and outstanding stock of RainDance Technologies, Inc. in February 2017 (see Note 2, "Acquisitions"), we recorded </span><span style="font-family:inherit;font-size:11pt;"><span>$26.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> of goodwill and </span><span style="font-family:inherit;font-size:11pt;"><span>$37.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> of definite-lived intangible assets: </span><span style="font-family:inherit;font-size:11pt;"><span>$36.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> of licenses, </span><span style="font-family:inherit;font-size:11pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> of developed product technology and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> of tradenames.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In 2018, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A., 2007 through 2012 acquisitions of DiaMed Holding AG, DiaMed Fennica Oy, DiaMed (G.B.) Limited, and DiaMed Benelux (collectively DiaMed), 2010 acquisition of Biotest AG, and 2013 acquisition of AbD Serotec in the amounts of </span><span style="font-family:inherit;font-size:11pt;"><span>$18.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$247.2 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$10.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$5.9 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively. Goodwill for DiaMed, Biotest AG and AbD Serotec was fully impaired at December 31, 2018. Impairments for the Pasteur Sanofi Diagnostics S.A., DiaMed and Biotest AG were included in our Clinical Diagnostics segment's results of operations, and the impairment for AbD Serotec was included in our Life Science segment's results of operations.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In 2017, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A. and with our 2013 acquisition of AbD Serotec in the amounts of </span><span style="font-family:inherit;font-size:11pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$8.7 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively. Impairment for the Pasteur Sanofi Diagnostics S.A. was included in our Clinical Diagnostics segment's results of operations, and the impairment for AbD Serotec was included in our Life Science segment's results of operations.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other than goodwill, we have no intangible assets with indefinite lives. Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Average</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Remaining</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-6</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>88.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(68.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>190.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(159.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-10</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>130.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(86.6</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">7-11</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(40.9</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2-6</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.3</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>493.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(360.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>133.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Average</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Remaining</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-7</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>92.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(64.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>194.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(157.9</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>37.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-12</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>133.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(70.3</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-12</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(36.0</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-6</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>509.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(334.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>174.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In 2018, we impaired developed product technology and fully impaired covenants not to compete in the amounts of </span><span style="font-family:inherit;font-size:11pt;"><span>$8.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, associated with our 2012 acquisition of a cell sorting system from Propel Labs, Inc. These impairments were included in our Life Science segment's results of operations. The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">Amortization expense related to purchased intangible assets for the years ended December 31, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$28.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$30.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$35.2 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively.  Estimated future amortization expense (based on existing purchased intangible assets) for the years ending December 31, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2020</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2021</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2022</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2023</span><span style="font-family:inherit;font-size:11pt;"> and thereafter is </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$21.7 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$19.7 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$18.9 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$15.7 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$14.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;"><span>$42.3 million</span></span>, respectively. <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes to goodwill by segment were as follows (in millions):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.8515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Life<br/>Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Clinical<br/>Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Life<br/>Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Clinical<br/>Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balances as of January 1:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>234.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>324.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>559.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>207.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>311.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>518.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated impairment losses and write-offs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(35.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(53.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(27.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(14.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(41.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>198.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>307.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>506.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>179.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>297.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>477.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquisitions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Divestiture</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Impairment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.9</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(276.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(282.0</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.7</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11.5</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Currency fluctuations</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balances as of December 31:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>234.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>320.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>555.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>234.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>324.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>559.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated impairment losses and write-offs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(41.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(293.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(335.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(35.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(53.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>192.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>219.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>198.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>307.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>506.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 234700000 324600000 559300000 207100000 311700000 518800000 35900000 17300000 53200000 27200000 14500000 41700000 198800000 307300000 506100000 179900000 297200000 477100000 0 0 0 26200000 0 26200000 0 1400000 1400000 0 0 0 5900000 276100000 282000000.0 8700000 2800000 11500000 -200000 -2700000 -2900000 1400000 12900000 14300000 234500000 320500000 555000000.0 234700000 324600000 559300000 41800000 293400000 335200000 35900000 17300000 53200000 192700000 27100000 219800000 198800000 307300000 506100000 1400000 26200000 37600000 36400000 1000000.0 200000 18100000 247200000 10800000 5900000 2800000 8700000 Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):<div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Average</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Remaining</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-6</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>88.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(68.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>190.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(159.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-10</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>130.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(86.6</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">7-11</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(40.9</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2-6</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.3</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>493.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(360.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>133.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Average</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Remaining</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-7</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>92.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(64.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>194.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(157.9</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>37.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-12</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>133.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(70.3</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-12</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(36.0</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-6</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>509.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(334.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>174.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><br/> 88700000 68300000 20400000 190600000 159800000 30800000 130400000 86600000 43800000 76300000 40900000 35400000 3900000 3300000 600000 3200000 1100000 2100000 493100000 360000000.0 133100000 92300000 64400000 27900000 194900000 157900000 37000000.0 133300000 70300000 63000000.0 76700000 36000000.0 40700000 3900000 3000000.0 900000 7900000 3300000 4600000 509000000.0 334900000 174100000 8800000 1700000 28300000 30800000 35200000 21700000 19700000 18900000 15700000 14800000 42300000 5.<span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">NOTES PAYABLE AND LONG-TERM DEBT</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had </span><span style="font-family:inherit;font-size:11pt;"><span>$208.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> available for borrowing and usage as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">, which was reduced by </span><span style="font-family:inherit;font-size:11pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The principal components of long-term debt are as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4.875% Senior Notes due 2020, net of discount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.9</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Capital leases and other debt</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>439.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>435.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less current maturities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>438.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Senior Notes due 2020</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In December 2010, Bio-Rad sold </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$425.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> principal amount of Senior Notes due December 2020 (</span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes).  The sale yielded net cash proceeds of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$422.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> at an effective rate of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.946%</span></span><span style="font-family:inherit;font-size:11pt;">.  The </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes pay a fixed rate of interest of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> per year.  We have the option to redeem any or all of the </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes) and accrued and unpaid interest thereon to the redemption date.  Our obligations under the </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness.  Certain covenants apply at each year end to the </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. We were in compliance with these covenants as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Credit Agreement</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In June 2014, Bio-Rad entered into a </span><span style="font-family:inherit;font-size:11pt;color:#000000;font-style:normal;text-decoration:none;"><span>$200.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> or </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">; however, </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> were utilized for domestic standby letters of credit that reduced our borrowing availability as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, respectively. The Credit Agreement matures in </span><span style="font-family:inherit;font-size:11pt;">June 2019</span><span style="font-family:inherit;font-size:11pt;">. If we had borrowed against our Credit Agreement, the borrowing rate would have been </span><span style="font-family:inherit;font-size:11pt;"><span>3.925%</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Maturities of long-term debt at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> are as follows: </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2020</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$426.6 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2021</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2022</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2023</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">thereafter</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$9.9 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><br/> 208200000 3100000 The principal components of long-term debt are as follows (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4.875% Senior Notes due 2020, net of discount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.9</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Capital leases and other debt</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>439.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>435.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less current maturities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>438.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 425000000.0 425000000.0 1300000 1900000 423700000 423100000 15700000 11900000 439400000 435000000.0 500000 400000 438900000 434600000 425000000.0 0.04875 422600000 0.04946 0.04875 0.04875 0.04875 0.04875 0.04875 0.04875 200000000.0 200000 500000 0.03925 500000 426600000 1700000 1600000 400000 9900000 6. INCOME TAXES<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The U.S. and international components of income before taxes are as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S.</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>363.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(38.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>149.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Income before taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>512.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>97.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>41.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The provision for income taxes consists of the following (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Current tax expense:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Current tax expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>41.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax expense (benefit):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. Federal</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>114.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(69.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(42.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(19.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.0</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax expense (benefit)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>120.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(84.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(51.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Non-current tax (benefit) expense </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(15.4</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for (benefit from) income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>147.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(24.4</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U. S. statutory tax rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Impact of foreign operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign dividends, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Research tax credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Nontaxable subsidies</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tax settlements and changes to unrecognized tax benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill impairment</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Domestic manufacturing deduction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Share-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Nondeductible executive compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fines and penalties</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior period adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. taxation of foreign income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Acquisition-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. tax reform</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(71</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for (benefit from) income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(25</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>37</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code that affect our 2017 financial statements, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Subsequent to the enactment of the Tax Act, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act ("SAB 118"), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under Accounting Standards Codification ("ASC") 740, "Income Taxes." We have completed our accounting for the income tax effects of the Tax Act, under SAB 118, as of December 31, 2018. As noted in our 2017 Annual Report, we were able to make reasonable estimates and provisionally recorded an income tax benefit of </span><span style="font-family:inherit;font-size:11pt;"><span>$70 million</span></span><span style="font-family:inherit;font-size:11pt;"> related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. The final accounting for the Tax Act resulted in an additional income tax benefit of </span><span style="font-family:inherit;font-size:11pt;"><span>$49 million</span></span><span style="font-family:inherit;font-size:11pt;"> for a final income tax benefit of </span><span style="font-family:inherit;font-size:11pt;"><span>$119 million</span></span><span style="font-family:inherit;font-size:11pt;">. This is comprised of </span><span style="font-family:inherit;font-size:11pt;"><span>$169 million</span></span><span style="font-family:inherit;font-size:11pt;"> tax benefit related to the remeasurement of U.S. federal deferred tax assets and liabilities, offset by a </span><span style="font-family:inherit;font-size:11pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:11pt;"> tax detriment for the Transition Tax. We elected to account for the tax effect of the Global Intangible Low-Taxed Income (“GILTI”) in the period in which it is incurred.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our effective income tax rate was </span><span style="font-family:inherit;font-size:11pt;"><span>29%</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>(25)%</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>37%</span></span><span style="font-family:inherit;font-size:11pt;"> in </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;">, respectively. The effective tax rate for 2018 was driven by detriments due to non-deductible impairment charges and the taxation of our foreign operations, partially offset by a </span><span style="font-family:inherit;font-size:11pt;"><span>$49 million</span></span><span style="font-family:inherit;font-size:11pt;"> benefit recorded as a result of the completion of our accounting for the Tax Act under SAB 118. The effective tax rate for 2017 was driven by a </span><span style="font-family:inherit;font-size:11pt;"><span>$70 million</span></span><span style="font-family:inherit;font-size:11pt;"> benefit recorded as a provisional estimate of the accounting for the Tax Act. The effective tax rate for 2016 included additional tax liabilities for unrecognized tax benefits related to the non-deductibility of interest expense in our foreign jurisdictions. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Many jurisdictions in which we operate have statutory tax rates that differ from the U.S. statutory tax rate of 21%. Our effective tax rate is impacted, either favorably or unfavorably, by many factors including, but not limited to the jurisdictional mix of income before tax, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax assets:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bad debt, inventory and warranty accruals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other post-employment benefits, vacation and other reserves</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>24.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tax credit and net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>75.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>73.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    Total gross deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>147.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>145.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(70.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(66.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">       Total deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>79.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>33.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Investments and intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>540.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>219.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">        Total deferred tax liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>580.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>252.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net deferred tax liabilities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(504.4</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(173.4</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The realization of deferred tax assets is dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that our California and certain foreign deferred tax assets will not be realized as of December 31, 2018, and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our deferred tax assets in California and certain foreign jurisdictions increased by </span><span style="font-family:inherit;font-size:11pt;"><span>$4.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> in 2018.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of December 31, 2018, our foreign and California net operating loss carryforwards were approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$205.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$52.7 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively. Of our foreign net operating losses, </span><span style="font-family:inherit;font-size:11pt;"><span>$118.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> may be carried forward indefinitely. The majority of the remaining foreign net operating losses, if not utilized, will begin to expire in 2025. Our California net operating loss carryforwards, if not utilized, will begin to expire in 2029. As of December 31, 2018, our California research tax credit carryforwards were approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$32.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> and may be carried forward indefinitely.</span></div><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2014 and forward for the U.S. and the years 2012 and forward for certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrecognized tax benefits – January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Additions to tax positions related to prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reductions to tax positions related to prior years</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(20.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Additions to tax positions related to the current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>34.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Settlements</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Lapse of statute of limitations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.4</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Currency translation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrecognized tax benefits – December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bio-Rad recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. Related to the unrecognized tax benefits noted above, the cumulative amount of accrued interest and penalties as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;">, respectively was </span><span style="font-family:inherit;font-size:11pt;"><span>$9.5 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$10.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$11.8 million</span></span><span style="font-family:inherit;font-size:11pt;">. Bio-Rad accrued interest and penalties of </span><span style="font-family:inherit;font-size:11pt;"><span>$(1.4) million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.9) million</span></span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;"><span>$8.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> in </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;">, respectively. The total unrecognized tax benefits and interest and penalties of </span><span style="font-family:inherit;font-size:11pt;"><span>$39.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> in </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> was partially offset by deferred tax assets of </span><span style="font-family:inherit;font-size:11pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> and prepaid taxes of </span><span style="font-family:inherit;font-size:11pt;"><span>$5.5 million</span></span><span style="font-family:inherit;font-size:11pt;">, for a net amount of </span><span style="font-family:inherit;font-size:11pt;"><span>$32.2 million</span></span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:11pt;">. Substantially all such amounts will impact our effective income tax rate if recognized.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">It is generally our intention to repatriate certain foreign earnings to the extent that such repatriations are not restricted by local laws or accounting rules, and there are no substantial incremental costs. During the current year, we recorded approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$6.7 million</span></span> of deferred tax liability for the earnings of certain foreign jurisdictions that we may repatriate in the future. The determination of the amount of the unrecognized deferred tax liability for foreign earnings that are indefinitely reinvested is not practicable to estimate. The U.S. and international components of income before taxes are as follows (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S.</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>363.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(38.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>149.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Income before taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>512.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>97.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>41.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 363400000 72800000 -38500000 149300000 25000000.0 80100000 512700000 97800000 41600000 The provision for income taxes consists of the following (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Current tax expense:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Current tax expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>41.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax expense (benefit):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. Federal</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>114.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(69.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(42.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(19.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.0</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax expense (benefit)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>120.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(84.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(51.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Non-current tax (benefit) expense </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(15.4</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for (benefit from) income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>147.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(24.4</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 8800000 6700000 16100000 2200000 3400000 3100000 30500000 32000000.0 30400000 41500000 42100000 49600000 114000000.0 -69800000 -42400000 6600000 4300000 -2800000 300000 -19300000 -6000000.0 120900000 -84800000 -51200000 -15400000 18300000 17200000 147000000.0 -24400000 15600000 The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U. S. statutory tax rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Impact of foreign operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign dividends, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Research tax credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Nontaxable subsidies</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tax settlements and changes to unrecognized tax benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill impairment</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Domestic manufacturing deduction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Share-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Nondeductible executive compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fines and penalties</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior period adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. taxation of foreign income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Acquisition-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. tax reform</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(71</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for (benefit from) income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(25</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>37</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td></tr></table></div> 0.21 0.35 0.35 -0.04 0.06 -0.15 0 0 0.40 0.01 0.04 0.09 0 0.02 0.04 0 0 0.47 0.06 0.01 0.11 0 0 0.04 -0.01 -0.05 0.03 0 0.02 0.03 0 0 0.02 -0.01 0 0.04 0.15 0.03 0.02 0 0.10 0 -0.10 -0.71 0 0.02 0.03 0.01 0.02 -0.03 0.01 0.29 -0.25 0.37 -70000000 -49000000 -119000000 -169000000 50000000 0.29 -0.25 0.37 -49000000 -70000000 Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax assets:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bad debt, inventory and warranty accruals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other post-employment benefits, vacation and other reserves</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>24.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tax credit and net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>75.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>73.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    Total gross deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>147.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>145.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(70.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(66.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">       Total deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>79.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>33.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Investments and intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>540.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>219.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">        Total deferred tax liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>580.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>252.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net deferred tax liabilities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(504.4</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(173.4</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div> 21700000 28600000 23000000.0 24000000.0 75300000 73300000 27100000 19700000 147100000 145600000 70800000 66400000 76300000 79200000 40100000 33500000 540600000 219100000 580700000 252600000 504400000 173400000 4400000 205000000.0 52700000 118800000 32100000 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrecognized tax benefits – January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Additions to tax positions related to prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reductions to tax positions related to prior years</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(20.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Additions to tax positions related to the current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>34.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Settlements</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Lapse of statute of limitations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.4</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Currency translation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrecognized tax benefits – December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 54900000 21100000 11900000 600000 1300000 10400000 20200000 1000000.0 0 4600000 34800000 3400000 6800000 200000 2400000 1100000 3400000 2300000 2200000 2300000 100000 29800000 54900000 21100000 9500000 10900000 11800000 -1400000 -900000 8700000 39300000 1600000 5500000 32200000 3100000 6700000 7.    STOCKHOLDERS' EQUITY<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B).  Each share of Class A and Class B participates equally in the earnings of Bio-Rad, and is identical in all respects except as follows. Class A has limited voting rights.  Each share of Class A is entitled to one tenth of a vote on most matters, and each share of Class B is entitled to one vote.  Additionally, Class A stockholders are entitled to elect </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>25%</span></span><span style="font-family:inherit;font-size:11pt;"> of the Board of Directors and Class B stockholders are entitled to elect </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>75%</span></span><span style="font-family:inherit;font-size:11pt;"> of the directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares but no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares.  Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.  The founders of Bio-Rad, the Schwartz family, collectively hold a majority of Bio-Rad’s voting stock.  As a result, the Schwartz family is able to exercise significant influence over Bio-Rad.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes to Bio-Rad's issued common stock shares are as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:65.4296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:56%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;font-weight:bold;">Class A Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;font-weight:bold;">Class B Shares</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at January 1, 2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,230</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,131</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>211</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,454</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>191</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,679</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,108</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(30</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,884</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,096</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Treasury Shares</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In November, 2017, the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to </span><span style="font-family:inherit;font-size:11pt;"><span>$250.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> of outstanding shares of our common stock. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. This new authorization superseded the prior authorization of up to </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$18.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> of Bio-Rad's common stock and has no expiration. The share repurchase activity under the share repurchase program through open market transactions in 2017 and 2018 is summarized as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:48%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Number of Shares Purchased</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-Average Price per Share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Shares Repurchased To Date</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining Authorized Value </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 1, 2017 - May 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,500</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220.02</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,539</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 1, 2017 - June 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>221.82</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,039</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 1, 2017 - August 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,200</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>221.45</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,239</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November 1, 2018 - November 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>178,911</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>273.39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>193,150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">In September 2017, we used </span><span style="font-family:inherit;font-size:11pt;"><span>12,740</span></span> of the repurchased shares in connection with the vesting of restricted stock units under the 2007 Incentive Award Plan in order to obtain a tax deduction in some of our foreign entities. The Credit Agreement may limit our ability to repurchase our stock. 0.25 0.75 Changes to Bio-Rad's issued common stock shares are as follows (in thousands):<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:65.4296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:56%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;font-weight:bold;">Class A Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;font-weight:bold;">Class B Shares</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at January 1, 2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,230</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,131</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>211</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,454</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>191</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,679</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,108</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(30</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,884</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,096</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><br/> 24230000 5131000 13000 -13000 211000 6000 24454000 5124000 34000 -34000 191000 18000 24679000 5108000 30000 -30000 175000 18000 24884000 5096000 Treasury Shares<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In November, 2017, the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to </span><span style="font-family:inherit;font-size:11pt;"><span>$250.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> of outstanding shares of our common stock. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. This new authorization superseded the prior authorization of up to </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$18.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> of Bio-Rad's common stock and has no expiration. The share repurchase activity under the share repurchase program through open market transactions in 2017 and 2018 is summarized as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:48%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Number of Shares Purchased</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-Average Price per Share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Shares Repurchased To Date</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining Authorized Value </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 1, 2017 - May 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,500</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220.02</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,539</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 1, 2017 - June 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>221.82</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,039</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 1, 2017 - August 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,200</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>221.45</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,239</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November 1, 2018 - November 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>178,911</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>273.39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>193,150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">In September 2017, we used </span><span style="font-family:inherit;font-size:11pt;"><span>12,740</span></span> of the repurchased shares in connection with the vesting of restricted stock units under the 2007 Incentive Award Plan in order to obtain a tax deduction in some of our foreign entities. The Credit Agreement may limit our ability to repurchase our stock. 250000000.0 18000000.0 2500 220.02 3539 2700000 1500 221.82 5039 2400000 9200 221.45 14239 400000 178911 273.39 193150 201100000 12740 8.    <span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated other comprehensive income (loss) included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign other post-employment benefits adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized holding gains (losses) on available-for-sale investments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Accumulated other comprehensive income (loss)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of January 1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>435.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>417.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>203.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>273.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(74.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(74.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of adoption of ASU 2018-02</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>248.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>321.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>683.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>738.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of adoption of ASU 2016-01 and 2018-03**</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(679.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(679.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of January 1, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(112.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(107.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(112.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(106.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(35.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">*</span><span style="font-family:inherit;font-size:11pt;">*See Note 1, "Significant Accounting Policies" under "Recent Accounting Pronouncements Adopted"</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In 2017, we adopted ASU 2018-02, "Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income," which gave entities the option to reclassify to retained earnings tax effects related to items in Accumulated other comprehensive income ("OCI") that the FASB refers to as having been stranded in Accumulated OCI as a result of the Tax Act. We reclassified the income tax effects of the Tax Act on the remeasurement of our deferred tax liabilities related to our available-for-sale equity securities by increasing OCI and decreasing Retained earnings by </span><span style="font-family:inherit;font-size:11pt;"><span>$120.1 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The increase in 2017 for net unrealized holding gains on available-for-sale investments was primarily from our ownership in the preferred shares of Sartorius.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The amounts reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.65625%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:45%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:24%;"/><td style="width:5%;"/><td style="width:2%;"/></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Components of Comprehensive income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of foreign other post-employment benefit items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net holding (losses) gains on equity securities and available for sale investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Reclassification adjustments are calculated using the specific identification method. Accumulated other comprehensive income (loss) included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign other post-employment benefits adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized holding gains (losses) on available-for-sale investments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Accumulated other comprehensive income (loss)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of January 1, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>435.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>417.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>203.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>273.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(74.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(74.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of adoption of ASU 2018-02</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>248.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>321.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>683.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>738.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of adoption of ASU 2016-01 and 2018-03**</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(679.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(679.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of January 1, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(112.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(107.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(112.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(106.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(35.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div> 1300000 -18600000 435000000.0 417700000 76100000 -6500000 203600000 273200000 0 2100000 -100000 2000000.0 0 -700000 74900000 74200000 120100000 120100000 76100000 -3700000 248700000 321100000 77400000 -22300000 683700000 738800000 -679300000 -679300000 77400000 -22300000 4400000 59500000 -112900000 6900000 -1400000 -107400000 0 2400000 300000 2700000 0 1800000 0 1800000 -112900000 7500000 -1100000 -106500000 -35500000 -14800000 3300000 -47000000.0 120100000 reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.65625%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:45%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:24%;"/><td style="width:5%;"/><td style="width:2%;"/></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Components of Comprehensive income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of foreign other post-employment benefit items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net holding (losses) gains on equity securities and available for sale investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Reclassification adjustments are calculated using the specific identification method. -2400000 -2100000 -300000 100000 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">9. SHARE-BASED COMPENSATION/EQUITY AWARD AND PURCHASE PLANS</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Description of Share-Based Compensation Plans</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We believe our share-based compensation plans align the interests of our employees with those of our shareholders.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Equity Award Plans</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We have three equity award plans for officers and certain other employees: the 2003 Stock Option Plan (2003 Plan), the 2007 Incentive Award Plan (2007 Plan) and the 2017 Incentive Award Plan (2017 Plan).  The 2003 Plan authorized the grant of incentive stock options and non-qualified stock options to employees. The 2007 Plan authorized the grant of stock options, restricted stock, restricted stock units, stock appreciation rights and other types of equity awards to employees.  We no longer grant equity under the 2003 Plan or 2007 Plan. From 2007 through 2016, all share-based compensation grants were from the 2007 Plan.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The 2017 Plan authorizes the grant to employees of stock options, stock appreciation rights, restricted stock, restricted stock units, and other types of equity awards. A total of </span><span style="font-family:inherit;font-size:11pt;"><span>1,999,714</span></span><span style="font-family:inherit;font-size:11pt;"> shares have been reserved for issuance of equity awards under the 2017 Plan and may be of either Class A or Class B common stock. At </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">, there were </span><span style="font-family:inherit;font-size:11pt;"><span>1,584,834</span></span><span style="font-family:inherit;font-size:11pt;"> shares available to be granted.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Under the above plans, Class A and Class B options are granted at prices not less than fair market value of the underlying common stock on the date of grant.  Generally, options granted have a maximum term of </span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>10</span></span><span style="font-family:inherit;font-size:11pt;"> years and vest in increments of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>20%</span></span><span style="font-family:inherit;font-size:11pt;"> per year over a </span><span style="font-family:inherit;font-size:11pt;">five</span><span style="font-family:inherit;font-size:11pt;">-year period on the yearly anniversary date of the grant.  Stock awards issued under the 2007 Plan and 2017 Plan generally vest in increments of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>20%</span></span><span style="font-family:inherit;font-size:11pt;"> per year over a </span><span style="font-family:inherit;font-size:11pt;">five</span><span style="font-family:inherit;font-size:11pt;">-year period on the yearly anniversary date of the grant.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plans</span><span style="font-family:inherit;font-size:11pt;font-style:italic;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our 2011 Employee Stock Purchase Plan (2011 ESPP) provides that eligible employees may contribute up to </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>10%</span></span><span style="font-family:inherit;font-size:11pt;"> of their compensation up to </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$25,000</span></span><span style="font-family:inherit;font-size:11pt;"> annually toward the quarterly purchase of our Class A common stock.  The employees’ purchase price is </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>85%</span></span><span style="font-family:inherit;font-size:11pt;"> of the lesser of the fair market value of the stock on the first business day or the last business day of each calendar quarter.  </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The 2011 ESPP includes two components: a Code Section 423 Component that we intend to qualify as an “employee stock purchase plan” under Section 423 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and a Non-423 Component, which authorizes the grant of purchase rights that does not qualify as an “employee stock purchase plan” under Section 423 of the Code. We have authorized the sale of </span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;text-decoration:none;"><span>1,300,000</span></span><span style="font-family:inherit;font-size:11pt;"> shares of Class A common stock under the 2011 ESPP.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Share-Based Compensation</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Included in our share-based compensation expense is the cost related to stock option grants, ESPP stock purchases and restricted stock unit awards.  Share-based compensation expense is allocated to Cost of goods sold, Research and development expense, and Selling, general and administrative expense in the Consolidated Statements of Income.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;">, we recognized share-based compensation expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$27.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$23.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$19.7 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively.  The income tax benefit related to share-based compensation expense was </span><span style="font-family:inherit;font-size:11pt;"><span>$4.4 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$5.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$5.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> for </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;">, respectively. We did not capitalize any share-based compensation expense in inventory.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The tax benefit from share-based compensation vested or exercised during </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;"><span>$5.4 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$6.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively. The actual tax benefit realized for the tax deductions from share-based compensation vested or exercised, including excess tax benefits that were recognized in stockholders’ equity, totaled </span><span style="font-family:inherit;font-size:11pt;"><span>$6.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> in 2016.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For options and awards, we amortize the fair value on a straight-line basis.  All stock compensation awards are amortized over the requisite service periods of the awards, which are generally the vesting periods. With the adoption in 2017 of ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting," we made a policy election to recognize forfeitures as they occur. Prior to 2017, we recognized compensation expense net of estimated forfeitures.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Stock Options</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes stock option activity:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aggregate</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intrinsic</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Value</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>407,480</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120.39</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>326.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(44,600</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93.63</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited/expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,240</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>169.93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>373,640</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138.81</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.90</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested, December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99,600</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>223.91</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.32</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274,040</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107.88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.65</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic value on the date of exercise of stock options exercised during </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;"> was approximately </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$8 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$10 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$1 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively. The total fair value of options vested during </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$6.0 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$2.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash received from stock options exercised during </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively.  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">, there was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$6.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> of total unrecognized compensation cost from stock options. This amount is expected to be recognized in the future over a weighted-average period of approximately </span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>3</span></span><span style="font-family:inherit;font-size:11pt;"> years.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:340px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:83px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:94px;"/><td style="width:12px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.85</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.87</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.35</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected life (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected dividend</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Weighted-average fair value of options granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>105.94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>58.65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Volatility is based on the historical volatilities of our common stock for a period equal to the stock option’s expected life.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the number of years that we estimate, based primarily on historical experience, that the options will be outstanding prior to exercise.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Restricted Stock Units</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted stock units, which are rights to receive shares of company stock, were granted from 2009 through 2016 under the 2007 Plan and since 2017 under the 2017 Plan.  The fair value of a restricted stock unit is the market value as determined by the closing price of the stock on the day of grant.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes restricted stock unit activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:654px;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:186px;"/><td style="width:5px;"/><td style="width:106px;"/><td style="width:4px;"/><td style="width:10px;"/><td style="width:9px;"/><td style="width:96px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:110px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:96px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted Stock</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Grant-Date</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual Term</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aggregate</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intrinsic Value</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>473,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172.76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>185,755</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>326.15</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(128,294</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>158.49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(56,011</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182.15</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>474,450</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235.57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.11</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The total fair value of restricted stock units vested in </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;"><span>$40.0 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$27.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$18.7 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively. As of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">, there was approximately </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$102.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> of total unrecognized compensation cost related to restricted stock units.  This amount is expected to be recognized over a remaining weighted-average period of approximately </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4</span></span><span style="font-family:inherit;font-size:11pt;"> years.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plans</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:529px;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:245px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:33px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:33px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected volatility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Risk-free interest rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.82</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.83</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.26</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected life (in years)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected dividend</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Weighted-average fair value</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">of purchase rights</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The major assumptions are primarily based on historical data.  Volatility is based on the historical volatilities of our common stock for a period equal to the expected life of the purchase rights.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We sold </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>63,464</span></span><span style="font-family:inherit;font-size:11pt;"> shares for </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$13.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>74,409</span></span><span style="font-family:inherit;font-size:11pt;"> shares for </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$13.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>93,605</span></span><span style="font-family:inherit;font-size:11pt;"> shares for </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$11.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> under the 2011 ESPP to employees in </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;">, respectively.  At </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>658,248</span></span><span style="font-family:inherit;font-size:11pt;"> shares remain authorized and available for issuance under the 2011 ESPP.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>We currently issue new shares or treasury shares, if available, to satisfy stock option exercises, restricted stock issuances and ESPP stock purchases. 1999714 1584834 P10Y 0.20 0.20 0.10 25000 0.85 1300000 27800000 23400000 19700000 4400000 5800000 5100000 5400000 6300000 1500000 6000000.0 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Stock Options</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes stock option activity:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aggregate</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intrinsic</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Value</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>407,480</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120.39</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>326.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(44,600</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93.63</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited/expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,240</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>169.93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>373,640</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138.81</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.90</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested, December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99,600</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>223.91</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.32</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274,040</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107.88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.65</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 407480 120.39 33000 326.15 44600 93.63 22240 169.93 373640 138.81 P4Y10M24D 38.0 99600 223.91 P8Y3M25D 3.9 274040 107.88 P3Y7M24D 34.1 8000000 10000000 1000000 6000000.0 4200000 2100000 500000 1600000 1200000 6300000 P3Y <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:340px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:83px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:94px;"/><td style="width:12px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.85</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.87</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.35</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected life (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected dividend</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Weighted-average fair value of options granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>105.94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>58.65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 0.22 0.20 0.21 0.0285 0.0187 0.0135 P7Y7M6D P7Y2M12D P7Y4M24D 0 0 0 105.94 58.65 42.40 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes restricted stock unit activity:</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:654px;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:186px;"/><td style="width:5px;"/><td style="width:106px;"/><td style="width:4px;"/><td style="width:10px;"/><td style="width:9px;"/><td style="width:96px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:110px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:96px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted Stock</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Grant-Date</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual Term</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aggregate</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intrinsic Value</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>473,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172.76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>185,755</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>326.15</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(128,294</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>158.49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(56,011</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182.15</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>474,450</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235.57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.11</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 473000 172.76 185755 326.15 128294 158.49 56011 182.15 474450 235.57 P2Y1M9D 110.2 40000000.0 27700000 18700000 102400000 P4Y The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions:<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:529px;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:245px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:33px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:33px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected volatility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Risk-free interest rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.82</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.83</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.26</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected life (in years)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected dividend</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Weighted-average fair value</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">of purchase rights</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 0.27 0.19 0.20 0.0182 0.0083 0.0026 P0Y2M26D P0Y2M26D P0Y3M 0 0 0 55.04 38.86 27.36 63464 13600000 74409 13000000.0 93605 11500000 658248 10. OTHER INCOME AND EXPENSE, NET<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (income) expense, net includes the following components (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Interest and investment income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(26.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(19.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(14.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net realized gains on investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other-than-temporary impairment losses on investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on sale of land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on divestiture of product line</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(36.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(13.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div>Prior year amounts have been adjusted (see Note 1 to the consolidated financial statements in regard to ASU 2017-07) for pension and other postretirement benefits. Other (income) expense, net includes the following components (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Interest and investment income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(26.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(19.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(14.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net realized gains on investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other-than-temporary impairment losses on investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on sale of land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on divestiture of product line</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(36.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(13.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div> 26600000 19100000 14700000 1600000 100000 800000 800000 7000000.0 600000 4100000 0 0 5100000 0 0 0 1500000 1100000 36600000 10700000 13800000 11. SUPPLEMENTAL CASH FLOW INFORMATION<div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The reconciliation of net income to net cash provided by operating activities is as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.96956977964324%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:51%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>365.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>122.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustments to reconcile net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">to net cash provided by operating activities </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>138.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>148.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>142.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Share-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains on dispositions of securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other-than-temporary impairment losses on investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in fair market value of equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(606.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses on dispositions of fixed assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on sale of land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on divestiture of a product line</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Excess tax benefits from share-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in fair value of contingent consideration</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(18.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease (increase) in accounts receivable, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>59.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(64.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase in inventories, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(12.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(47.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(57.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase in other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(15.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(35.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Decrease) increase in accounts payable</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">and other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(45.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Decrease) increase in income taxes payable</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(20.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(22.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase (decrease) in deferred income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>120.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(82.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(51.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease in other long term assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Decrease) increase in other long term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Impairment losses on goodwill and long-lived assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>292.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net cash provided by operating activities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>285.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>104.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>216.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Non-cash investing activities:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Purchased property, plant and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Purchased marketable securities and investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 11. SUPPLEMENTAL CASH FLOW INFORMATION<div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The reconciliation of net income to net cash provided by operating activities is as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.96956977964324%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:51%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>365.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>122.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustments to reconcile net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">to net cash provided by operating activities </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>138.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>148.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>142.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Share-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains on dispositions of securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other-than-temporary impairment losses on investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in fair market value of equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(606.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses on dispositions of fixed assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on sale of land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on divestiture of a product line</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Excess tax benefits from share-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in fair value of contingent consideration</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(18.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease (increase) in accounts receivable, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>59.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(64.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase in inventories, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(12.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(47.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(57.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase in other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(15.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(35.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Decrease) increase in accounts payable</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">and other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(45.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Decrease) increase in income taxes payable</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(20.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(22.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase (decrease) in deferred income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>120.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(82.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(51.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease in other long term assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Decrease) increase in other long term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Impairment losses on goodwill and long-lived assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>292.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net cash provided by operating activities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>285.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>104.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>216.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Non-cash investing activities:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Purchased property, plant and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Purchased marketable securities and investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 365600000 122200000 26000000.0 138100000 148700000 142900000 27800000 23400000 19700000 1600000 100000 800000 800000 7000000.0 600000 606200000 0 0 -2000000.0 -8100000 -600000 4100000 0 0 5100000 0 0 0 0 1500000 -6200000 -18100000 -400000 -59700000 64100000 -12500000 12900000 47700000 57100000 15300000 35700000 6800000 -45600000 7800000 30100000 -20900000 -22400000 10700000 -120900000 82000000.0 51400000 -1100000 -2300000 -12500000 10000000.0 -38100000 -10400000 292500000 11500000 62300000 -4900000 -5100000 -5800000 285500000 104100000 216100000 5700000 0 7200000 800000 2800000 600000 12. COMMITMENTS AND CONTINGENT LIABILITIES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Rents and Leases</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Rental expense under operating leases was </span><span style="font-family:inherit;font-size:11pt;"><span>$47.4 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$43.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$44.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> in </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;">, respectively.  Leases are principally for facilities and automobiles. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Annual future minimum lease payments at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> under operating leases are as follows: </span><span style="font-family:inherit;font-size:11pt;">2019</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$44.4 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;">2020</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$37.8 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;">2021</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$27.4 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;">2022</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$19.7 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;">2023</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$13.9 million</span></span><span style="font-family:inherit;font-size:11pt;">; and </span><span style="font-family:inherit;font-size:11pt;">2024</span><span style="font-family:inherit;font-size:11pt;"> and beyond - </span><span style="font-family:inherit;font-size:11pt;"><span>$25.6 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The total minimum rentals to be received in the future for subleases as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> were </span><span style="font-family:inherit;font-size:11pt;"><span>$17.8 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Deferred Profit Sharing Retirement Plan</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We have a profit sharing plan covering substantially all U.S. employees.  Contributions are made at the discretion of the Board of Directors.  Bio-Rad has no liability other than for the current year’s contribution.  Contribution expense was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$15.9 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$16.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$15.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> in </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;">, respectively.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Other Post-Employment Benefits</span></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In several foreign locations we are statutorily required to provide retirement benefits or a lump sum termination indemnity to our employees upon termination for virtually any reason. These plans are accounted for as defined benefit plans and the associated net benefit obligation at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> of </span><span style="font-family:inherit;font-size:11pt;"><span>$70.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$74.9 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets. Most plans are not required to be funded, and as such, there is no trust or other device used to accumulate assets or settle these obligations. However, some of these plans require funding based on local laws in which there is a trust or other device administered by an external plan manager that is used to accumulate assets to assist in settling these obligations. The following disclosures include such plans, which are located in France, Switzerland, Germany, Korea, India, Thailand, Italy, Dubai and Japan.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Obligations and Funded Status</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in the Consolidated Balance Sheets for the plans (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:50%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in benefit obligation:</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit obligation at beginning of year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$136.6</span></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$122.7</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest cost</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan participants' contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actuarial (gain) loss</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross benefits paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan amendments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Special termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change attributable to foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit obligation at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>137.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Change in plan assets:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of plan assets at beginning year</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actual return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employer contributions</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan participants' contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross benefits paid</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change attributable to foreign exchange</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of plan assets at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under funded status of plans</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(70.4)</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(74.9)</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Amounts recognized in the consolidated balance sheets: </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities (Accrued payroll and employee benefits) </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(1.1)</span></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(1.1)</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent liabilities (Other long-term liabilities)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(69.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(73.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net liability, end of fiscal year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(70.4)</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(74.9)</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Components of Net Periodic Benefit Cost</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions):</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:36%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$7.5</span></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$6.5</span></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$6.1</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected returns on plan assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of actuarial losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of prior service costs </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net periodic benefit costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$8.9</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$9.1</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$8.6</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Assumptions</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The weighted-average assumptions used in computing the benefit obligations are as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:50%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation rate increase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The weighted-average assumptions used in computing the net periodic benefit costs are as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:44%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected long-term rate of return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">In some foreign locations we have service award plans that are paid based upon the number of years of employment.</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">Under these plans, the liability at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, and has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Purchase Obligations</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">, we had obligations that have been recognized on our balance sheet of </span><span style="font-family:inherit;font-size:11pt;"><span>$110.9 million</span></span><span style="font-family:inherit;font-size:11pt;">, which include purchases of goods and services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty. These obligations also include other post-employment benefits in some of our foreign locations as indicated above. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The annual future fixed and determinable portion of our purchase obligations that have been recognized on our balance sheet as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> are as follows: </span><span style="font-family:inherit;font-size:11pt;">2019</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$5.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:11pt;">2020</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$16.4 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2021</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$6.2 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2022</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$2.4 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2022</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> and after </span><span style="font-family:inherit;font-size:11pt;">2023</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$76.6 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">, we had purchase obligations that have not been recognized on our balance sheet of </span><span style="font-family:inherit;font-size:11pt;"><span>$12.5 million</span></span><span style="font-family:inherit;font-size:11pt;">, which include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The annual future fixed and determinable portion of our purchase obligations that have not been recognized on our balance sheet as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> are as follows: </span><span style="font-family:inherit;font-size:11pt;">2019</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$6.5 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$5.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:11pt;">2021</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2022</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2022</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> and after </span><span style="font-family:inherit;font-size:11pt;">2023</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Letters of Credit/Guarantees</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In the ordinary course of business, we are at times required to post letters of credit/guarantees.  The letters of credit/guarantees are issued by financial institutions to guarantee our obligations to various parties. We were contingently liable for </span><span style="font-family:inherit;font-size:11pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> of standby letters of credit/guarantees with financial institutions as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Contingent Consideration</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from </span><span style="font-family:inherit;font-size:11pt;"><span>39%</span></span><span style="font-family:inherit;font-size:11pt;"> to </span><span style="font-family:inherit;font-size:11pt;"><span>20%</span></span><span style="font-family:inherit;font-size:11pt;"> for the calendar years 2017 through 2020. The sales milestones could potentially range from </span><span style="font-family:inherit;font-size:11pt;"><span>$0</span></span><span style="font-family:inherit;font-size:11pt;"> to an unlimited amount. In the first and third quarters of 2018, we paid </span><span style="font-family:inherit;font-size:11pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, per the purchase agreement. Since 2016 we have had a net decrease in the cumulative valuation of the sales milestones of </span><span style="font-family:inherit;font-size:11pt;"><span>$12.2 million</span></span><span style="font-family:inherit;font-size:11pt;">. The contingent consideration was accrued at its estimated fair value of </span><span style="font-family:inherit;font-size:11pt;"><span>$8.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Concentrations of Labor Subject to Collective Bargaining Agreements</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">At </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">, approximately </span><span style="font-family:inherit;font-size:11pt;"><span>eight</span></span><span style="font-family:inherit;font-size:11pt;"> percent of Bio-Rad's approximately </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>3,265</span></span> U.S. employees were covered by a collective bargaining agreement, which will expire on November 7, 2019.  Many of Bio-Rad's non-U.S. full-time employees, especially in France, are covered by collective bargaining agreements. 47400000 43600000 44400000 44400000 37800000 27400000 19700000 13900000 25600000 17800000 15900000 16000000.0 15100000 70400000 74900000 Obligations and Funded Status<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in the Consolidated Balance Sheets for the plans (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:50%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in benefit obligation:</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit obligation at beginning of year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$136.6</span></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$122.7</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest cost</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan participants' contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actuarial (gain) loss</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross benefits paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan amendments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Special termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change attributable to foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit obligation at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>137.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Change in plan assets:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of plan assets at beginning year</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actual return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employer contributions</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan participants' contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross benefits paid</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change attributable to foreign exchange</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of plan assets at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under funded status of plans</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(70.4)</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(74.9)</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Amounts recognized in the consolidated balance sheets: </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities (Accrued payroll and employee benefits) </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(1.1)</span></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(1.1)</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent liabilities (Other long-term liabilities)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(69.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(73.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net liability, end of fiscal year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(70.4)</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(74.9)</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 136600000 122700000 7500000 6500000 1100000 1100000 3100000 2800000 -5400000 3300000 3100000 3200000 -500000 1100000 0 2000000.0 0 -5100000 -2000000.0 9400000 137300000 136600000 61700000 58800000 300000 500000 4000000.0 4000000.0 3100000 2800000 1500000 2300000 0 5100000 -700000 3000000.0 66900000 61700000 -70400000 -74900000 1100000 1100000 69300000 73800000 70400000 74900000 Components of Net Periodic Benefit Cost<div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions):</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:36%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$7.5</span></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$6.5</span></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$6.1</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected returns on plan assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of actuarial losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of prior service costs </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net periodic benefit costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$8.9</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$9.1</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$8.6</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 7500000 6500000 6100000 1100000 1100000 1400000 1100000 1100000 1000000.0 -1300000 -1400000 -1700000 100000 0 0 0 -1200000 -400000 8900000 9100000 8600000 Assumptions<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The weighted-average assumptions used in computing the benefit obligations are as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:50%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation rate increase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The weighted-average assumptions used in computing the net periodic benefit costs are as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:44%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected long-term rate of return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 0.011 0.008 0.018 0.018 0.008 0.009 0.011 0.018 0.019 0.016 3100000 3700000 110900000 5800000 16400000 6200000 2400000 3500000 76600000 12500000 6500000 5300000 100000 200000 200000 200000 3100000 0.39 0.20 0 1300000 800000 -12200000 8400000 0.08 3265 13.    LEGAL PROCEEDINGS<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015, we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;"><span>$10.92 million</span></span><span style="font-family:inherit;font-size:11pt;">, plus prejudgment interest of </span><span style="font-family:inherit;font-size:11pt;"><span>$141,608</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-size:11pt;">post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We have provided for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017, we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit. Oral arguments occurred on November 14, 2018. On February 26, 2019, the United States Court of Appeals for the Ninth Circuit issued its decision, reversing in part, vacating in part, and affirming in part. Specifically, the court: (1) reversed the Dodd-Frank claim, which amounts to about</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;"><span>$2.96 million</span></span><span style="font-family:inherit;font-size:11pt;"> plus interest, and directed the district court to enter judgment in Bio-Rad’s favor on that claim; (2) vacated the SOX claim due to instructional error and remanded for further proceedings, including whether a new trial is needed; and (3) affirmed the California public policy claim and the </span><span style="font-family:inherit;font-size:11pt;"><span>$7.96 million</span></span><span style="font-family:inherit;font-size:11pt;"> in damages attributable to it. On March 12, 2019 we filed a petition for panel rehearing or rehearing </span><span style="font-family:inherit;font-size:11pt;font-style:italic;">en banc</span><span style="font-family:inherit;font-size:11pt;"> with the United States Court of Appeals for the Ninth Circuit.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><br/> 10920000 141608 2960000 7960000 14. SEGMENT INFORMATION<div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bio-Rad is a multinational manufacturer and worldwide distributor of its own life science research products and clinical diagnostics products.  We have two reportable segments:  Life Science and Clinical Diagnostics.  These reportable segments are strategic business lines that offer more than </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>9,000</span></span><span style="font-family:inherit;font-size:11pt;"> different products and services and require different marketing strategies. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. These products are sold to university and medical school laboratories, pharmaceutical and biotechnology companies, food testing laboratories and government and industrial research facilities.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. These products are sold to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories and insurance and forensic testing laboratories.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other Operations include the remainder of our Analytical Instruments segment.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. The accounting policies of the segments are the same as those described in Significant Accounting Policies (see Note 1).  Segment profit or loss includes an allocation of corporate expense based upon sales and an allocation of interest expense based upon accounts receivable and inventories.  The difference between total segment allocated interest expense, depreciation and amortization, and capital expenditures and the corresponding consolidated amounts is attributable to our corporate headquarters.  Segments are expected to manage only assets completely under their control.  Accordingly, segment assets include primarily accounts receivable, inventories and gross machinery and equipment.  Goodwill balances have been included in corporate for segment reporting purposes.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Information regarding industry segments at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;"> and for the years then ended is as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:81.0546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:33%;"/><td style="width:13%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Science</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operations</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net sales </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>861.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,411.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>785.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,360.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>730.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,323.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Allocated interest expense</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation and amortization</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>34.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>31.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment profit (loss)</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(145.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.9</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>114.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(19.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>58.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment assets</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>450.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>949.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>453.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,038.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Capital expenditures</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>60.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>59.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior year amounts have been adjusted (see Note 1 to the consolidated financial statements in regard to ASU 2017-07 for pension and other postretirement benefits). Clinical Diagnostics segment loss for 2018 was due to impairment losses taken on goodwill of </span><span style="font-family:inherit;font-size:11pt;"><span>$276.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> (see Note 4 to the consolidated financial statements)</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net corporate operating expense consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. The following reconciles total segment profit to consolidated income before taxes (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:90.4296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total segment (loss) profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(116.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>106.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>39.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency exchange losses, net</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net corporate operating, interest and other expense not allocated to segments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Change in fair market value of equity securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>606.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Consolidated income before income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>512.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>97.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>41.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior year amounts have been adjusted (see Note 1 to the consolidated financial statements in regard to ASU 2017-07) for pension and other postretirement benefits.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following reconciles total segment assets to consolidated total assets (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total segment assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,405.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,496.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,047.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>965.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property, plant and equipment, net, excluding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">  segment specific gross machinery and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>79.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>219.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>506.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,859.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,247.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5,611.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4,273.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.1171875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>792.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>758.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>742.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Pacific Rim</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>495.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>461.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>427.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>863.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>800.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>770.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (primarily Canada and Latin America)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>138.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>140.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>128.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,289.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,160.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,068.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following presents Property, plant and equipment, net, Other investments and Other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.3515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Europe**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,571.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>230.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Pacific Rim</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">United States  </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,582.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,305.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (primarily Canada and Latin America)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total Property, plant and equipment, net, Other investments and Other assets, excluding deferred income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,185.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,567.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 9000 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Information regarding industry segments at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;"> and for the years then ended is as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:81.0546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:33%;"/><td style="width:13%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Science</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operations</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net sales </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>861.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,411.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>785.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,360.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>730.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,323.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Allocated interest expense</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation and amortization</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>34.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>31.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment profit (loss)</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(145.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.9</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>114.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(19.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>58.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment assets</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>450.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>949.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>453.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,038.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Capital expenditures</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>60.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>59.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><br/> 861700000 1411800000 15900000 785200000 1360800000 14200000 730700000 1323300000 14200000 7200000 16700000 100000 7000000.0 14900000 0 6900000 16500000 0 34100000 72000000.0 500000 36200000 80200000 0 31700000 80500000 0 28700000 -145700000 200000 -9900000 114800000 1400000 -19100000 58000000.0 900000 450200000 949000000.0 5900000 453000000.0 1038400000 4800000 36700000 60500000 500000 12600000 59000000.0 0 276100000 he following reconciles total segment profit to consolidated income before taxes (in millions):<div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:90.4296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total segment (loss) profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(116.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>106.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>39.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency exchange losses, net</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net corporate operating, interest and other expense not allocated to segments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Change in fair market value of equity securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>606.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Consolidated income before income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>512.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>97.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>41.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><br/> -116800000 106300000 39800000 -2900000 -9100000 -4500000 -10400000 -10100000 -7500000 606200000 0 0 36600000 10700000 13800000 512700000 97800000 41600000 The following reconciles total segment assets to consolidated total assets (in millions):<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total segment assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,405.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,496.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,047.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>965.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property, plant and equipment, net, excluding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">  segment specific gross machinery and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>79.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>219.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>506.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,859.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,247.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5,611.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4,273.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 1405100000 1496200000 1047200000 965800000 79900000 57000000.0 219800000 506100000 2859100000 1247900000 5611100000 4273000000.0 The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.1171875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>792.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>758.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>742.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Pacific Rim</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>495.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>461.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>427.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>863.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>800.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>770.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (primarily Canada and Latin America)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>138.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>140.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>128.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,289.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,160.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,068.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following presents Property, plant and equipment, net, Other investments and Other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.3515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Europe**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,571.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>230.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Pacific Rim</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">United States  </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,582.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,305.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (primarily Canada and Latin America)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total Property, plant and equipment, net, Other investments and Other assets, excluding deferred income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,185.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,567.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div>** The amounts primarily include our investment in the ordinary voting stock of Sartorius AG, of Goettingen, Germany (see Note 3). In 2017 this investment was accounted for under the cost method, and in 2018 it was accounted for at fair value in accordance with ASU 2016-01 (see Note 1). 792000000.0 758500000 742200000 495500000 461300000 427100000 863600000 800200000 770600000 138300000 140200000 128300000 2289400000 2160200000 2068200000 1571900000 230600000 20700000 18400000 1582100000 1305200000 11100000 13100000 3185800000 1567300000 RESTRUCTURING COSTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Restructuring Costs for European Reorganization</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In May 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance enterprise resource planning ("ERP") platform, are expected to be incurred through 2019. We recorded approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.2) million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$12.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> in restructuring charges and adjustments related to severance and other employee benefits for the years ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;">, respectively. From May 2016 to </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">, total expenses were </span><span style="font-family:inherit;font-size:11pt;"><span>$12.8 million</span></span><span style="font-family:inherit;font-size:11pt;">. The liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> was recorded in Accrued payroll and employee benefits in the Consolidated Balance Sheets. The amounts recorded were reflected in Cost of goods sold of </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.1) million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.2) million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$2.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, and in Selling, general and administrative expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.1) million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$10.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> in the Consolidated Statements of Income for the years ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;">, respectively. The amounts adjusted were primarily for additional positions identified for elimination, partially offset by employees finding other positions within Bio-Rad or leaving prematurely. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions): </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustment to expense</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation (gains) losses</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Restructuring Costs for Termination of a Diagnostics Research and Development Project and Facility Closures</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In December 2017, we announced the termination of a diagnostics research and development project in Europe. From December 2017 to </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">, total expenses were </span><span style="font-family:inherit;font-size:11pt;"><span>$21.4 million</span></span><span style="font-family:inherit;font-size:11pt;">. We recorded restructuring charges and adjustments related to severance and employee benefits of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$11.0 million</span></span><span style="font-family:inherit;font-size:11pt;">, and asset write-offs and exit costs of </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.1) million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$10.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> for the years ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, respectively.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In June 2018, we announced the closure of a small manufacturing operation in Munich, Germany. We recorded </span><span style="font-family:inherit;font-size:11pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> of expense in restructuring charges related to severance and employee benefits for the year ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In December 2018, we announced the closure of a small manufacturing facility outside Paris, France. We recorded restructuring charges related to severance and employee benefits of </span><span style="font-family:inherit;font-size:11pt;"><span>$3.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> and exit costs of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> for the year ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restructuring charges for the termination of a diagnostics research and development project and the facility closures are all included in our Clinical Diagnostics segment's results of operations. The facility closures are a natural evolution from the larger consolidations that began with the 2016 European reorganization activities described above. The amounts recorded were reflected in Cost of goods sold of </span><span style="font-family:inherit;font-size:11pt;"><span>$5.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$2.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, in Selling, general and administrative expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$3.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, and in Research and development expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$15.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> in the Consolidated Statements of Income for the years ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, respectively. The liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$11.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> consisted of </span><span style="font-family:inherit;font-size:11pt;"><span>$7.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> recorded in Accrued payroll and employee benefits, and </span><span style="font-family:inherit;font-size:11pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> recorded in Other long-term liabilities in the Consolidated Balance Sheets.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closures restructuring reserves for severance and exit costs (in millions): </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:50%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Charged to expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustment to expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(8.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation (gains) losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of December 31</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Restructuring Costs for GnuBIO, Inc.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">In 2014, we acquired GnuBIO, Inc. (GnuBIO) as a business acquisition. It was included in our Clinical Diagnostics segment’s results of operations as a division, and was primarily based in Massachusetts. In September 2017, we announced that we were closing the GnuBIO research program facilities in Massachusetts. We recorded restructuring charges in September 2017 related to severance and employee benefits of </span><span style="font-family:inherit;font-size:11pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> and asset write-offs of </span><span style="font-family:inherit;font-size:11pt;"><span>$5.5 million</span></span><span style="font-family:inherit;font-size:11pt;">. The amounts recorded were reflected in Selling, general and administrative expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> and in Research and development expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$7.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> in the Consolidated Statements of Income for the year ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">. The liability balance as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;"><span>$1.4 million</span></span> and was recorded in Accrued payroll and employee benefits in the Consolidated Balance Sheets. The liability was paid in early 2018. -200000 500000 12500000 12800000 1600000 -100000 -200000 2100000 -100000 700000 10400000 2200000 4100000 6300000 3200000 5800000 9000000.0 -100000 -100000 -200000 200000 300000 500000 1500000 2900000 4400000 1500000 2700000 4200000 0 100000 100000 -300000 -700000 -1000000.0 600000 1000000.0 1600000 2200000 4100000 6300000 21400000 400000 11000000.0 -100000 10100000 1700000 3900000 200000 5400000 2300000 400000 3300000 300000 15500000 11500000 7300000 4200000 The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closures restructuring reserves for severance and exit costs (in millions): <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:50%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Charged to expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustment to expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(8.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation (gains) losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of December 31</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div>The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions): <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustment to expense</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation (gains) losses</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 14100000 0 5800000 14000000.0 300000 0 8400000 0 300000 -100000 11500000 14100000 2900000 5500000 800000 7600000 1400000 16. QUARTERLY FINANCIAL DATA (UNAUDITED)<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Summarized quarterly financial data for </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> are as follows (in millions, except per share data):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">First</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Second</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Third</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fourth</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>551.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>575.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>545.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>616.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>302.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>301.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>286.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>332.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>656.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>268.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>269.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(828.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings (loss) per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.05</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.99</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.02</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(27.73</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings (loss) per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.77</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.87</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.89</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(27.73</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>500.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>504.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>534.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>621.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>270.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>273.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>299.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>345.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.17</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.74</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.78</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.73</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As a result of the net loss for the three months ended December 31, 2018, all potentially issuable common shares have been excluded from the diluted shares used in the computation of earnings per share as their effect was anti-dilutive. The net loss for the three months ended December 31, 2018 was primarily due to an </span><span style="font-family:inherit;font-size:11pt;"><span>$814.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> decrease in fair market value of equity securities, primarily due to the adoption of ASU 2016-01 (see Note 1 to the consolidated financial statements) and mostly consisted of holding losses on our investment in Sartorius AG. The net loss for the three months ended December 31, 2018 also included impairment losses on goodwill and long-lived assets in the amount of </span><span style="font-family:inherit;font-size:11pt;"><span>$292.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> (see Note 4 to the consolidated financial statements). </span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div>Prior year amounts have been adjusted (see Note 1 to the consolidated financial statements in regard to ASU 2017-07) for pension and other postretirement benefits. <div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">First</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Second</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Third</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fourth</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>551.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>575.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>545.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>616.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>302.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>301.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>286.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>332.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>656.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>268.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>269.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(828.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings (loss) per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.05</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.99</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.02</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(27.73</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings (loss) per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.77</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.87</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.89</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(27.73</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>500.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>504.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>534.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>621.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>270.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>273.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>299.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>345.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.17</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.74</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.78</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.73</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 551500000 575900000 545100000 616900000 302200000 301700000 286700000 332600000 656800000 268000000.0 269300000 -828500000 22.05 8.99 9.02 -27.73 21.77 8.87 8.89 -27.73 500100000 504700000 534100000 621300000 270100000 273400000 299000000.0 345200000 12400000 5000000.0 22100000 82700000 0.42 0.17 0.74 2.78 0.41 0.17 0.73 2.75 814100000 292500000 17. SUBSEQUENT EVENT<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On March 4, 2019, we acquired all the issued and outstanding stock of a small commercial-stage company for approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$20 million</span></span><span style="font-family:inherit;font-size:11pt;">. We believe this acquisition will complement our offerings of life science products. The acquisition will be included in our Life Science segment's results of operations from the acquisition date and will be accounted for as a business acquisition. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div>We are presently unable to report the purchase price allocation or the evaluation of the transaction, as more time is needed to complete the information transfer from the seller and include all information into a valuation of individual assets and liabilities. 20000000 BIO-RAD LABORATORIES, INC.<div style="line-height:120%;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Years Ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(in thousands)</span></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Allowance for doubtful accounts receivable</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:83.203125%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Charged to Costs</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and Expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">End of Year</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,549</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,527</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,363</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,713</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,367</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,174</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,992</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,549</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,418</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,785</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,836</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,367</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Valuation allowance for long-term deferred tax assets</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:83.203125%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions Charged</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Credited) to Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax Expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">End of Year </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,356</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,413</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,769</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,403</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,277</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,126</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,403</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 25549000 11527000 10363000 26713000 23367000 11174000 8992000 25549000 24418000 3785000 4836000 23367000 66356000 4413000 0 70769000 66403000 -47000 0 66356000 58277000 8126000 0 66403000 (a)Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets. Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets. Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions): December 31, 2018 December 31, 2017    Other current liabilities$3.2 $2.7Other long-term liabilities5.2 14.0   Total$8.4 $16.7 Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets. Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions): December 31, 2018 December 31, 2017    Short-term investments$373.0 $371.2Other investments0.2 930.2Total$373.2 $1,301.4 XML 15 R1.htm IDEA: XBRL DOCUMENT v3.19.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2018
Mar. 26, 2019
Jun. 30, 2018
Entity Registrant Name BIO-RAD LABORATORIES, INC.    
Document Type 10-K    
Document Period End Date Dec. 31, 2018    
Amendment Flag false    
Entity Central Index Key 0000012208    
Current Fiscal Year End Date --12-31    
Entity Emerging Growth Company false    
Entity Small Business false    
Entity Shell Company false    
Entity Filer Category Large Accelerated Filer    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer No    
Document Fiscal Year Focus 2018    
Document Fiscal Period Focus FY    
Entity Public Float     $ 6,181,361,340
Common Class A [Member]      
Entity Common Stock, Shares Outstanding   24,707,868  
Common Class B [Member]      
Entity Common Stock, Shares Outstanding   5,092,404  
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.19.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
ASSETS:    
Cash and cash equivalents $ 431,526 $ 383,824
Short-term investments 413,270 371,154
Restricted investments 5,560 5,560
Accounts receivable, less allowance for doubtful accounts 392,443 464,847
Inventories:    
Raw materials 108,008 113,925
Work in process 145,051 142,589
Finished goods 330,756 338,290
Total inventories 583,815 594,804
Prepaid expenses 187,249 146,135
Other current assets 9,615 10,325
Total current assets 2,023,478 1,976,649
Property, plant and equipment:    
Land and improvements 25,185 18,026
Buildings and leasehold improvements 331,563 315,984
Equipment 970,081 971,140
Total property, plant and equipment 1,326,829 1,305,150
Less: accumulated depreciation and amortization (818,139) (811,654)
Property, plant and equipment, net 508,690 493,496
Goodwill, net 219,770 506,069
Purchased intangibles, net 133,123 174,113
Other investments 2,655,709 1,027,736
Other assets 70,298 94,949
Total assets 5,611,068 4,273,012
LIABILITIES AND STOCKHOLDERS' EQUITY:    
Accounts payable 122,450 135,182
Accrued payroll and employee benefits 143,510 171,632
Current maturities of long-term debt 493 420
Income taxes payable 27,513 19,802
Other taxes payable 28,675 20,139
Deferred revenue 26,936 28,233
Other current liabilities 101,218 127,288
Total current liabilities 450,795 502,696
Long-term debt, net of current maturities 438,937 434,581
Deferred income taxes 553,239 222,209
Other long-term liabilities 147,766 183,276
Total liabilities 1,590,737 1,342,762
Commitments and contingent liabilities
Stockholders' equity:    
Preferred stock 0 0
Additional paid-in capital 394,342 361,231
Retained earnings 3,722,073 1,830,439
Accumulated other comprehensive (loss) income (46,958) 738,794
Total stockholders' equity 4,020,331 2,930,250
Total liabilities and stockholders' equity 5,611,068 4,273,012
Common Class A [Member]    
Stockholders' equity:    
Common stock 2 2
Common Class B [Member]    
Stockholders' equity:    
Common stock 1 1
Treasury Class-A [Member]    
Stockholders' equity:    
Treasury Stock, Value (49,040) (128)
Treasury Class B [Member]    
Stockholders' equity:    
Treasury Stock, Value $ (89) $ (89)
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.19.1
Consolidated Balance Sheets (Parentheticals) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Allowance for doubtful accounts $ 26,713 $ 25,549
Preferred stock par value $ 0.0001 $ 0.0001
Preferred stock authorized 7,500,000 7,500,000
Preferred stock issued 0 0
Preferred stock outstanding 0 0
Common Class A [Member]    
Common stock par value $ 0.0001 $ 0.0001
Common stock authorized 80,000,000 80,000,000
Common stock issued 24,884,265 24,679,127
Common stock outstanding 24,704,772 24,678,545
Common Class B [Member]    
Common stock par value $ 0.0001 $ 0.0001
Common stock authorized 20,000,000 20,000,000
Common stock issued 5,096,421 5,107,674
Common stock outstanding 5,095,504 5,106,757
Treasury Class-A [Member]    
Treasury Stock, Shares 179,493 582
Treasury Class B [Member]    
Treasury Stock, Shares 917 917
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.19.1
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Net sales $ 2,289,415 $ 2,160,153 $ 2,068,172
Cost of Goods and Services Sold 1,066,264 972,450 929,744
Gross Profit 1,223,151 1,187,703 1,138,428
Selling, general and administrative expense 834,783 806,790 814,697
Research and development expense 199,196 250,157 205,708
Impairment losses on goodwill and long-lived assets 292,513 11,506 62,305
Income from operations (103,341) 119,250 55,718
Interest expense 23,962 23,014 23,380
Foreign exchange losses, net 2,861 9,128 4,542
Unrealized Gain on Securities (606,230) 0 0
Other (income) expense, net (36,593) (10,697) (13,764)
Income before income taxes 512,659 97,805 41,560
Provision for income taxes (147,045) 24,444 (15,560)
Net Income (Loss) Attributable to Parent $ 365,614 $ 122,249 $ 26,000
Basic earnings per share:      
Earnings Per Share, Basic $ 12.25 $ 4.12 $ 0.88
Weighted average common shares - basic 29,836 29,655 29,440
Diluted earnings per share:      
Earnings Per Share, Diluted $ 12.10 $ 4.07 $ 0.88
Weighted average common shares - diluted 30,228 30,034 29,646
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.19.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Cash flows from operating activities:      
Cash received from customers $ 2,326,310 $ 2,093,948 $ 2,074,024
Cash paid to suppliers and employees (1,989,685) (1,916,119) (1,808,687)
Interest paid, net (22,703) (22,224) (22,756)
Income tax payments, net (62,414) (52,136) (38,442)
Investment proceeds and miscellaneous receipts, net 26,383 18,392 14,597
Excess tax benefits from share-based compensation 0 0 (1,506)
Proceeds from (payments for) forward foreign exchange contracts, net 7,603 (17,724) (1,164)
Net cash provided by operating activities 285,494 104,137 216,066
Cash flows from investing activities:      
Capital expenditures (129,825) (111,332) (141,436)
Proceeds from dispositions of property, plant and equipment 4,315 86 398
Proceeds from divestiture of a product line 6,964 0 0
Proceeds from (payments for) acquisitions and long-term investment 266 (76,645) (14,165)
Payments for purchases of intangible assets (3) (3,795) (135)
Payments for purchases of restricted investment 0 (1,000) (350)
Payments for purchases of marketable securities and investments (371,019) (282,656) (278,071)
Proceeds from sales of marketable securities and investments 77,029 97,523 76,859
Proceeds from maturities of marketable securities and investments 225,295 202,247 143,020
Net cash used in investing activities (186,978) (175,572) (213,880)
Cash flows from financing activities:      
Net (payments) borrowings on line-of-credit arrangements and notes payable 0 (36) 37
Payments on long-term borrowings (2,961) (316) (303)
Proceeds from issuance of common stock for share-based compensation 14,133 14,604 11,280
Tax payments from net share settlement (8,862) (7,310) 0
Payments for purchases of treasury stock (48,912) (2,920) 0
Payments of contingent consideration 2,078 3,681 3,500
Excess tax benefits from share-based compensation 0 0 1,506
Net cash (used in) provided by financing activities (48,680) 341 9,020
Effect of foreign exchange rate changes on cash (655) (1,094) (12,858)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 49,181 (72,188) (1,652)
Beginning Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 384,983 457,171 458,823
Cash and cash equivalents 431,526 383,824 456,264
Restricted Cash, Current 111 882 494
Restricted Cash, Noncurrent 2,527 277 413
Ending Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $ 434,164 $ 384,983 $ 457,171
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.19.1
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Treasury Stock [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total Bio Rad [Member]
Balance at Dec. 31, 2015 $ 2,485,029 $ 3 $ 300,408 $ (101) $ 1,802,581 $ 382,138  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 26,000       26,000    
Other comprehensive income, net of tax 35,628         35,628  
Issuance of common stock 11,280   11,280        
Stock compensation expense 19,730   19,730        
Tax benefit-exercise stock options 1,493   1,493        
Balance at Dec. 31, 2016 2,579,160 3 332,911 (101) 1,828,581 417,766  
Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 135   391   (256)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 122,249       122,249    
Other comprehensive income, net of tax 200,893         200,893  
Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect         (120,135) 120,135 $ 120,100
Issuance of common stock 14,604   4,490        
Stock compensation expense 23,439   23,439        
Treasury Stock, Value, Acquired, Cost Method       (2,920)      
Stock Issued During Period, Value, Treasury Stock Reissued       2,804      
Balance at Dec. 31, 2017 2,930,250 3 361,231 (217) 1,830,439 738,794  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 365,614       365,614    
Other comprehensive income, net of tax (106,495)         (106,495)  
Issuance of common stock 14,133   5,271        
Stock compensation expense 27,840   27,840        
Tax benefit-exercise stock options     0        
Treasury Stock, Value, Acquired, Cost Method       (48,912)      
Balance at Dec. 31, 2018 $ 4,020,331 $ 3 $ 394,342 $ (49,129) $ 3,722,073 $ (46,958)  
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.19.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Net Income (Loss) Attributable to Parent $ 365,614 $ 122,249 $ 26,000
Foreign currency translation adjustments (112,857) 76,050 (32,394)
Other post-employment benefits adjustments, net of tax 7,549 (3,767) 2,086
Net unrealized holding gains on available-for-sale investments, net of tax (1,187) 248,745 65,936
Other comprehensive income, net of tax (106,495) 321,028 35,628
Comprehensive income attributable to Bio-Rad $ 259,119 $ 443,277 $ 61,628
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.19.1
1. Significant Accounting Policies
 12 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies 1.SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair value.

Short-term Restricted Investments

Short-term restricted investments of $5.6 million at both December 31, 2018 and 2017 represent a money market fund that is renewed annually for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets.

Available-for-Sale Investments

Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities.  Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date.  Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations.  Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data.  Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect.  Effective January 1, 2018, changes in fair value for equity securities are reported in Change in fair market value of equity securities in the Consolidated Statements of Income due to the adoption of ASU 2016-01 (see Recent Accounting Pronouncement Adopted at the end of this Note and Note 3). Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary.  We review our available-for-sale debt securities for other-than-temporary losses on a quarterly basis.  Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10).

Concentration of Credit Risk

Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable.  Cash and cash equivalents and investments are placed with various highly rated major financial institutions located in different geographic regions.

The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements.  We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions.  In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end.  

We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral.  As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers.  Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.

Accounts Receivable

We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance.

Inventory

Inventories are valued at the lower of cost and net realizable value and include material, labor and overhead costs. The first-in, first-out method is used to relieve inventory for products sold.

Property, Plant and Equipment

Property, plant and equipment are carried at cost, less accumulated depreciation and amortization.  Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  The estimated useful lives of property, plant and equipment are generally as follows: buildings and leasehold improvements, 15-39 years or the term of the leases or life of the improvements, whichever is shorter; reagent rental equipment, 1-5 years; equipment and capitalized software, 3-12 years.

Goodwill

Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses.  Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating segments.  Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management.  Goodwill amounts are assigned to reporting units at the time of acquisition.

Effective January 1, 2017 in accordance with Accounting Standards Update No. 2017-04, "Simplifying the Test for Goodwill Impairment," the goodwill impairment amount will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit.  

Prior to January 1, 2017, the goodwill impairment test consisted of a two-step process.  The first step of the goodwill impairment test, used to identify potential impairment, compared the fair value of a reporting unit to its carrying value, including goodwill. We used a projected discounted cash flow model to determine the fair value of a reporting unit.  If the fair value of the reporting unit exceeded its carrying amount, goodwill of the reporting unit was considered not impaired, and the second step of the impairment test was not required.  The second step, if required, compared the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit was allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit.  If the carrying amount of the reporting unit’s goodwill exceeded its implied fair value, an impairment charge is recognized in an amount equal to that excess.

Long-Lived Assets

For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.  We assess the impairment of long-lived assets (including identifiable intangible assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors that we consider important that could trigger an impairment review include:

•
significant under-performance relative to expected, historical or projected future operating results;
•
significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;
•
a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and
•
significant negative industry, legal, regulatory or economic trends.

When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method.  Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets.  We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If this is the case, an impairment loss would be recognized.  The impairment loss recognized is the amount by which the carrying amount exceeds the fair value.

Income Taxes
 
We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We record deferred tax assets to the extent we believe these assets will more likely than not be realized.  In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. To the extent we determine that we are able to realize our deferred income tax assets in the future in excess of their net recorded amount, we make an adjustment to the valuation allowance which may reduce the provision for income taxes. When we establish or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes.

On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The new legislation contains significant tax provisions that affect us, including a one-time mandatory deemed repatriation tax on certain unrepatriated foreign earnings ("Transition Tax"), a reduction of the corporate income tax rate from 35% to 21% effective January 1, 2018, and a change from a worldwide tax system to a modified territorial system.

We are required to recognize the effect of the tax law changes in the period of enactment, such as the computation of the Transition Tax, remeasurement of our U.S. federal deferred tax assets and liabilities, as well as reassessment of the net realizability of our deferred tax assets and liabilities.

Subsequent to the enactment of the Tax Act, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act ("SAB 118"), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under Accounting Standards Codification ("ASC") 740, "Income Taxes." We have completed the accounting for the income tax effects of the Tax Act, under SAB 118, as of December 31, 2018. As noted in our 2017 Annual Report, we were able to make reasonable estimates and provisionally recorded an income tax benefit of $70 million related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. The final accounting for the Tax Act resulted in an additional income tax benefit of $49 million for a final income tax benefit of $119 million. This is comprised of $169 million tax benefit related to the remeasurement of U.S. federal deferred tax assets and liabilities, offset by a $50 million tax detriment for the Transition Tax. We elected to account for the tax effect of the Global Intangible Low-Taxed Income (“GILTI”) in the period in which it is incurred.

During the fourth quarter of 2017, we early adopted ASU 2018-02, "Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income." With respect to stranded income tax effects in accumulated other comprehensive income, our policy is to use the portfolio method to reclassify such amounts.

Revenue Recognition

On January 1, 2018, we adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018.  Results for reporting periods beginning on January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under prior revenue guidance ASC 605, "Revenue Recognition."

We recorded a net reduction to opening retained earnings of $0.1 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. The impact to revenue as a result of applying ASC 606 as compared to ASC 605 for 2018 was not significant.

We recognize revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.
Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service.
At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced to the estimated amount that we expect to receive in exchange for transferring control for those products.
Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, transaction prices are allocated to performance obligations based on stand-alone selling prices. The method used to determine the stand-alone selling prices for service revenues is based on the observable prices when the services have been sold separately.
In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.
We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less and for contracts in which we recognize revenue at the amount to which we have the right to invoice for services performed. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.

Reagent Rental Agreements
Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. We concluded that the use of the instrument and related maintenance services (collectively known as “lease elements”) are not within the guidance of ASC 606 but rather ASC 840 Leases. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and requires consideration of any fixed/minimum payments as well as estimates of variable consideration. After determining what portion of the transaction price should be allocated to the lease elements, any fixed consideration would be considered the minimum lease payment to be amortized straight line over the lease term and any variable consideration would be contingent rent to be recognized monthly as earned, which coincides with the transfer of control of the non-lease elements.
For the portion of the transaction price allocated to the non-lease elements, which are principally the reagents, the related revenue will be recognized at a point in time when control transfers. Generally, the terms of the arrangements result in the transfer of control upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer.
Revenue allocated to the lease elements of these reagent rental arrangements represents approximately 5% of total revenue and are included as part of the Net sales in our Consolidated Statements of Income.
Contract costs:
As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities.
Disaggregation of Revenue:
The disaggregation of our revenue by geographic region based primarily on the location of the use of the product service, and by industry segment sources, and the disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 14).

Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are generally recognized ratably over the term of the service contract as our performance extends over the life of the arrangement. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from $36.7 million at December 31, 2017 to $37.3 million at December 31, 2018 is primarily driven by $28.0 million, net, of cash payments received or due in advance of satisfying our performance obligations, partially offset by $27.4 million of revenue recognized that were included in our deferred revenue balance as of December 31, 2017.

We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.

Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Consolidated Balance Sheets, were as follows (in millions):

 
 
2018
 
2017
January 1
 
$
18.7

 
$
17.6

Provision for warranty
 
25.5

 
29.9

Actual warranty costs
 
(34.1
)
 
(28.8
)
December 31
 
$
10.1

 
$
18.7



Shipping and Handling

We classify all freight costs billed to customers as Net sales.  Related freight costs are recognized upon transfer of control of the promised products to customers as a fulfillment cost and included in Cost of goods sold.

Research and Development

Internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed.

We conduct extensive research and development activities in all areas of our business, employing approximately 800 employees worldwide in these activities, including degreed scientists and technical support staff.  Research and development has played a major role in Bio-Rad’s growth and is expected to continue to do so in the future.  Our research teams are continuously developing new products and new applications for existing products.  In our development of new products and applications, we interact with scientific and medical professionals at universities, hospitals and medical schools, and within our industry.  

Foreign Currency

Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period.  Income statement items are translated at average exchange rates for the period.  The resulting translation adjustments are recorded as a separate component of stockholders’ equity.

Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income.  Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction.

Forward Foreign Exchange Contracts

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.  

Share-Based Compensation Plans

Share-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value.  We recognize these compensation costs net of forfeitures over the requisite service period of the award, which is generally the vesting term of the share-based payment awards.  Starting in 2017, we recognize forfeitures as they occur due to a change in accounting principle, and in prior periods we estimated the forfeiture rate based on our historical experience.  These plans are described more fully in Note 9.

Earnings Per Share

Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):
 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
Basic weighted average shares outstanding
 
29,836

 
29,655

 
29,440

Effect of potentially dilutive stock options
 
 
 
 
 
 
    and restricted stock awards
 
392

 
379

 
206

Diluted weighted average common shares
 
30,228

 
30,034

 
29,646

Anti-dilutive stock options and restricted stock awards
 
 
 
 
 
 
    excluded from the computation of diluted EPS
 
84

 
13

 
113



Fair Value of Financial Instruments

For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value.

The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3).

Recent Accounting Pronouncements Adopted

In February 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. ("ASU") 2018-03, "Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities." ASU 2018-03 amends certain items in ASU 2016-01 (see below) such as equity securities without a readily determinable fair value. ASU 2018-03 clarifies that an entity that uses the measurement alternative for equity securities without readily determinable fair values can change its measurement approach to fair value and once made the election is irrevocable. If an entity measures equity securities without readily determinable fair values at fair value, it must record a cumulative-effect adjustment to
Retained earnings as of the beginning of the fiscal year in which the guidance is adopted. We adopted ASU 2018-03 on January 1, 2018 and made an irrevocable election to account for our investment of the ordinary shares of Sartorius AG at fair value (see ASU 2016-01 below).

In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. Changes in fair value for equity securities will no longer be reported in other comprehensive income. For equity investments without readily determinable fair values, the cost method is also eliminated. We adopted ASU 2016-01 on January 1, 2018 and record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes and were valued at $0.6 million as of December 31, 2018. Changes in the basis of these equity investments are reported in current earnings. For equity securities that are affected by ASU 2016-01 and ASU 2018-03, see Note 3 to the consolidated financial statements, which primarily consists of our investment in Sartorius AG.

The impact of the adoption of ASU 2016-01 and ASU 2018-03 on January 1, 2018 was through a cumulative-effect adjustment of $864.5 million to Total stockholders' equity by increasing Retained earnings of $1,543.7 million and decreasing Accumulated other comprehensive income of $679.2 million, including an increase in Deferred income taxes of $232.9 million and an increase in Other investments of $1,097.4 million in our Consolidated Balance Sheet. As a result of ASU 2016-01 and ASU 2018-03 for 2018, we recorded a gain of $606.2 million for the Change in fair market value of equity securities in the Consolidated Statement of Income that resulted in a deferred tax expense of $133.9 million.

In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost," which changed how we present the net periodic benefit cost of our defined benefit pension and/or other postretirement plans. We adopted ASU 2017-07 on January 1, 2018 and applied the practical expedient to estimate amounts for comparative purposes utilizing the information disclosed in Note 12 to the consolidated financial statements in our Form 10-K for the year ended December 31, 2017. The interest costs are recorded in Interest expense, and the other costs are recorded in Other (income) expense, net in the Consolidated Statements of Income. For 2017 for interest costs and other costs, we reclassified $0.304 million, $2.152 million, and $0.144 million from Cost of goods sold (COGS), Selling, general and administrative expense (SG&A) and Research and Development expense (R&D), respectively, to Interest expense of $1.1 million and Other (income) expense, net of $1.5 million. For 2016 for interest costs and other costs, we reclassified $0.341 million, $2.027 million and $0.156 million from COGS, SG&A and R&D, respectively, to Interest expense of $1.438 million and Other (income) expense, net of $1.086 million.

In November 2016, the FASB issued ASU 2016-18, "Restricted Cash," which required us to cease to present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. We adopted ASU 2016-18 on January 1, 2018 and updated the Consolidated Statements of Cash Flows to incorporate restricted cash included in Other current assets and Other assets of $2.6 million as of December 31, 2018 and $1.2 million as of December 31, 2017.

In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory," which required immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  We adopted ASU 2016-16 on January 1, 2018 on a modified retrospective basis through a cumulative-effect adjustment by decreasing Retained earnings by $17.6 million, and decreasing Prepaid taxes by $22.8 million and increasing Deferred tax assets by $5.2 million that are both recorded in Other assets in our Consolidated Balance Sheet.

In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments" and adopted it on January 1, 2018, which did not have an impact to our statement of cash flows presentation.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers ("ASC 606"), an updated standard on revenue recognition. The new standard provides enhancements to the quality and consistency of how revenue is reported under the principle that revenue should be recognized in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of promised goods or services. We adopted ASC 606 as of January 1, 2018 using the cumulative effect transition method as more fully described above under the caption “Revenue Recognition.”

Recent Accounting Pronouncements to be Adopted

In November 2018, the FASB issued ASU 2018-18, "Clarifying the Interaction between Topic 808 and Topic 606." Topic 808 is Collaborative Arrangements, and Topic 606 is Revenue from Contracts with Customers. ASU 2018-18 clarifies that certain transactions between collaborative partners should be accounted for as revenue under ASC 606 when the collaborative partner is a customer. We currently do not have any customers that are collaborative partners or anticipate any in the near future. ASU 2018-18 will be effective January 1, 2020 and we will not early adopt.

In August 2018, the FASB issued ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract." ASU 2018-15 amends the definition of a hosting arrangement and requires a customer in a hosting arrangement that is a service contract to capitalize certain implementation costs as if the arrangement was an internal-use software project. The internal-use software guidance states that only qualifying costs incurred during the application development stage can be capitalized. We will prospectively adopt ASU 2018-15 effective January 1, 2019. We do not expect ASU 2018-15 to have a material impact to our consolidated financial statements.

In August 2018, the FASB issued ASU 2018-14, "Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." ASU 2018-14 eliminates and adds certain disclosures for defined benefit plans. ASU 2018-14 is effective for fiscal years ending after December 15, 2020 using a retrospective approach, with early adoption permitted. We are currently evaluating the disclosures and the timing of adoption but do not expect ASU 2018-14 to have a material impact to our disclosures for defined benefit plans.

In August 2018, the FASB issued ASU 2018-13, "Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement." ASU 2018-13 eliminates, adds and modifies certain disclosures for fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. Early adoption is permitted in interim periods, including periods for which financial statements have not yet been issued. We do not expect ASU 2018-13 to have a material impact to our fair value disclosures and we currently do not plan to early adopt.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. In November 2018, the FASB issued ASU 2018-19, "Codification Improvements to Topic 326, Financial Instruments-Credit Losses," which clarifies that receivables arising from operating leases are not within the scope of Topic 326. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, "Leases," and related accounting standard updates, which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. We will adopt ASU 2016-02 on a modified retrospective basis effective January 1, 2019 with practical expedients, and will not restate comparative prior periods. The practical expedients, include, among other items, for leases that existed prior January 1, 2019, to not reassess whether any contracts are or contain embedded leases, reassessing the classification of existing leases, and reassessing whether previously capitalized initial direct costs qualify for capitalization. Where we act as a lessee, we also elected not to separate lease and non-lease components. Where we act as a lessor in our reagent rental arrangements, we allocate the consideration in the contract to the separate lease components and the non-lease components. After the allocation, the amount of variable payments allocated to lease components will be recognized as income in accordance with the new lease accounting standard updates, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Such reagent rental arrangements are more fully described above under the caption "Reagent Rental Agreements." Where we act as a lessee, the adoption of the standard will result in material additions to the balance sheet for right-of-use assets and the associated liabilities. We will complete our review of the completeness and accuracy of the lease data, discount rate and finalize our updated controls in accordance with the new standard during the first quarter of 2019. Where we act as a lessor in reagent rental arrangements, we estimate an insignificant impact to our consolidated financial statements.
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.19.1
2. Acquisitions
 12 Months Ended
Dec. 31, 2018
Business Combinations [Abstract]  
Business Combination Disclosure [Text Block] 2.    ACQUISITIONS

RainDance Technologies, Inc.
In February 2017, we acquired all the issued and outstanding stock of RainDance Technologies, Inc. (RainDance) for approximately $72.7 million. Cash payments at closing were $72.9 million. In addition, we had a cash payment of $10.0 million for a preexisting condition concurrent with the acquisition that was recorded in Cost of goods sold. The acquisition was included in our Life Science segment’s results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is not deductible for income tax purposes. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented.
The final allocation for the payments of $72.9 million was $37.6 million to definite-lived intangibles, $0.2 million to acquired net assets, $26.2 million to goodwill, a deferred tax liability of $13.6 million primarily related to the purchased intangibles and a deferred tax asset of $22.5 million primarily related to the acquired net operating losses.
RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy. We believe that RainDance's droplet-based solutions will extend our reach into next-generation sequencing applications and strengthen our position in the area of Droplet Digital™ PCR, offering customers solutions for a wide range of nucleic acid detection applications.

XML 24 R10.htm IDEA: XBRL DOCUMENT v3.19.1
3. Fair Value Measurements
 12 Months Ended
Dec. 31, 2018
Fair Value Disclosures [Abstract]  
Fair Value Measurements 3. FAIR VALUE MEASUREMENTS

We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:

•
Level 1: Quoted prices in active markets for identical instruments
•
Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)
•
Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)

Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2018 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents (a):
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
77.8

 
$
—

 
$
77.8

Time deposits
22.7

 
10.0

 
—

 
32.7

Asset-backed securities
—

 
0.3

 
—

 
0.3

Money market funds
36.9

 
—

 
—

 
36.9

Total cash equivalents
59.6

 
88.1

 
—

 
147.7

Restricted investment
5.6

 
—

 
—

 
5.6

Equity Securities (b)
2,672.9

 
—

 
—

 
2,672.9

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
215.0

 
—

 
215.0

U.S. government sponsored agencies
—

 
80.3

 
—

 
80.3

Foreign government obligations
—

 
3.6

 
—

 
3.6

Municipal obligations
—

 
11.0

 
—

 
11.0

Asset-backed securities
—

 
63.3

 
—

 
63.3

Total available-for-sale investments (c)
—

 
373.2

 
—

 
373.2

Forward foreign exchange contracts (d)
—

 
0.6

 
—

 
0.6

Total financial assets carried at fair value
$
2,738.1

 
$
461.9

 
$
—

 
$
3,200.0

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
     Forward foreign exchange contracts (e)
$
—

 
$
0.7

 
$
—

 
$
0.7

     Contingent consideration (f)
—

 
—

 
8.4

 
8.4

Total financial liabilities carried at fair value
$
—

 
$
0.7

 
$
8.4

 
$
9.1


As of first quarter 2018, our equity securities are no longer reported as Available-for-sale investments due to the implementation of ASU 2016-01. Changes in fair value of equity securities are now reported on the Consolidated Statements of Income rather than Other Comprehensive Income (see Note 1).

Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2017 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents (a):
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
36.0

 
—

 
$
36.0

Time deposits
43.7

 
10.0

 
—

 
53.7

U.S. government sponsored agencies
—

 
11.2

 
—

 
11.2

Money market funds
3.4

 
—

 
—

 
3.4

Total cash equivalents
47.1

 
57.2

 
—

 
104.3

Restricted investment:
5.6

 
—

 
—

 
5.6

Available-for-sale investments (c):
 
 
 
 
 
 
 
Corporate debt securities
—

 
185.7

 
—

 
185.7

U.S. government sponsored agencies
—

 
67.6

 
—

 
67.6

Foreign government obligations
—

 
3.4

 
—

 
3.4

Brokered certificates of deposit
—

 
0.7

 
—

 
0.7

Municipal obligations
—

 
15.0

 
—

 
15.0

Marketable equity securities
973.4

 
—

 
—

 
973.4

Asset-backed securities
—

 
55.6

 
—

 
55.6

Total available-for-sale investments
973.4

 
328.0

 
—

 
1,301.4

Forward foreign exchange contracts (d)
—

 
0.5

 
—

 
0.5

Total financial assets carried at fair value
$
1,026.1

 
$
385.7

 
—

 
$
1,411.8

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (e)
$
—

 
$
1.6

 
—

 
$
1.6

 Contingent consideration (f)
—

 
—

 
16.7

 
16.7

Total financial liabilities carried at fair value
$
—

 
$
1.6

 
$
16.7

 
$
18.3


(a)
Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.

(b)
Equity securities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2018
Short-term investments
$
40.2

Other investments
2,632.7

        Total
$
2,672.9



The unrealized gains on our equity securities still held as of December 31, 2018 are $607.7 million and are primarily due to our investment in Sartorius AG and is recorded in our Consolidated Statements of Income due to the adoption of ASU 2016-01 (see Note 1).

(c)
Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31,
2018
 
December 31, 2017
 
 
 
 
Short-term investments
$
373.0

 
$
371.2

Other investments
0.2

 
930.2

Total
$
373.2

 
$
1,301.4



In accordance with our adoption of ASU 2016-01 January 1, 2018, our investment in Sartorius AG preferred shares, which was reported within marketable equity securities as Available-for-sale as of December 31, 2017, is now reported as an Equity security as of December 31, 2018 (see Note 1 and footnote (b) above).


(d)
Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.

(e)
Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.

(f)
Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2018
 
December 31, 2017
 
 
 
 
Other current liabilities
$
3.2

 
$
2.7

Other long-term liabilities
5.2

 
14.0

   Total
$
8.4

 
$
16.7



During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount. In the first and third quarters of 2018, we paid $1.3 million and $0.8 million, respectively, per the purchase agreement. Since 2016 we have had a net decrease in the cumulative valuation of the sales milestones of $12.2 million. The contingent consideration was accrued at its estimated fair value of $8.4 million as of December 31, 2018.

The following table provides a reconciliation of the Level 3 analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value (in millions):

 
2018
 
 
January 1
$
16.7

Payment of sales milestone
(2.1
)
Net decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense
(6.2
)
December 31
$
8.4



The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of December 31, 2018. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.
 
Valuation Technique
Unobservable Input
Percentage
Analytical flow cytometer platform
Probability-weighted income approach
Sales milestones:
 
 
 
Discount rate
11.0
%
 
 
Cost of debt
5.1
%


To estimate the fair value of Level 2 debt securities as of December 31, 2018 and 2017, our primary pricing provider uses Securities Evaluations as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Securities Evaluations does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source.

For all commercial paper as of December 31, 2018, our primary pricing provider uses its leading pricing source in the hierarchy to determine pricing. For discount commercial paper as of December 31, 2017, pricing was determined by a straight-line calculation, starting with the purchase price on the date of purchase and increasing to par at maturity. As of December 31, 2017, interest bearing certificates of deposit and commercial paper were priced at par.

Our primary pricing provider performs daily reasonableness testing of the Securities Evaluations prices. Price changes of 5% or greater are investigated and resolved. In addition, we perform a quarterly testing of the Securities Evaluations prices to custodian reported prices. Price differences outside a tolerable variance of approximately 1% are investigated and resolved.

Available-for-sale investments consist of the following (in millions):

 
December 31, 2018
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
216.2

 
$
0.1

 
$
(1.3
)
 
$
215.0

Municipal obligations
11.1

 
—

 
(0.1
)
 
11.0

Asset-backed securities
63.5

 
—

 
(0.4
)
 
63.1

U.S. government sponsored agencies
80.9

 
0.2

 
(0.8
)
 
80.3

Foreign government obligations
3.6

 
—

 
—

 
3.6

 
375.3

 
0.3

 
(2.6
)
 
373.0

Long-term investments:
 
 
 
 
 
 
 
Asset-backed securities
0.2

 
—

 
—

 
0.2

 
0.2

 
—

 
—

 
0.2

Total
$
375.5

 
$
0.3

 
$
(2.6
)
 
$
373.2



The following is a summary of the amortized cost and estimated fair value of our debt securities at December 31, 2018 by contractual maturity date (in millions):

 
Amortized
Cost
 
Estimated Fair
Value
Mature in less than one year
$
155.5

 
$
155.2

Mature in one to five years
172.4

 
171.3

Mature in more than five years
47.6

 
46.7

Total
$
375.5

 
$
373.2



Available-for-sale investments consist of the following (in millions):



 
December 31, 2017
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
185.9

 
$
0.3

 
$
(0.5
)
 
$
185.7

Brokered certificates of deposit
0.7

 
—

 
—

 
$
0.7

Municipal obligations
15.1

 
—

 
(0.1
)
 
15.0

Asset-backed securities
55.6

 
—

 
(0.2
)
 
55.4

U.S. government sponsored agencies
68.3

 
—

 
(0.7
)
 
67.6

Foreign government obligations
3.4

 
—

 
—

 
3.4

Marketable equity securities
34.4

 
9.0

 
—

 
43.4

 
363.4

 
9.3

 
(1.5
)
 
371.2

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
875.5

 
—

 
930.0

Asset-backed securities
0.2

 
—

 
—

 
0.2

 
54.7

 
875.5

 
—

 
930.2

Total
$
418.1

 
$
884.8

 
$
(1.5
)
 
$
1,301.4



The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):

 
December 31,
2018
 
December 31, 2017
 
 
 
 
Fair value of investments in a loss position 12 months or more
$
117.9

 
$
43.9

Fair value of investments in a loss position less than 12 months
$
193.0

 
$
168.7

Gross unrealized losses for investments in a loss position 12 months or more
$
1.8

 
$
0.7

Gross unrealized losses for investments in a loss position less than 12 months
$
0.8

 
$
0.8



The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at December 31, 2018 or at December 31, 2017.

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of December 31, 2018 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign exchange losses, net in the Consolidated Statements of Income.

The following is a summary of our forward foreign currency exchange contracts (in millions):
 
December 31,
 
2018
Contracts maturing in January through March 2019 to sell foreign currency:
 
Notional value
$
50.6

Unrealized gain
$
0.2

Contracts maturing in January through March 2019 to purchase foreign currency:
 
Notional value
$
284.5

Unrealized loss
$
(0.5
)



The estimated fair value of financial instruments that are not recognized at fair value in the Consolidated Balance Sheets and are included in Other investments, are presented in the table below. Fair value has been determined using significant observable inputs, including quoted prices in active markets for similar instruments.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value.  Other investments include financial instruments, the majority of which has fair value based on similar, actively traded stock adjusted for various discounts, including a discount for marketability.  Long-term debt, excluding leases and current maturities, has an estimated fair value based on quoted market prices for the same or similar issues.

The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):


 
December 31, 2018
 
December 31, 2017
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
Other investments
$
—

 
$
—

 
 
 
$
91.8

 
$
1,249.4

 
2
Total long-term debt, excluding leases
and current maturities
$
423.7

 
$
435.8

 
2
 
$
423.1

 
$
449.8

 
2

We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries.  We own over 37% of the outstanding voting shares (excluding treasury shares) of Sartorius as of December 31, 2018.  The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius’ board of directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. As of December 31, 2018, due to the adoption of
ASU 2016-01 and ASU 2018-03 as of January 1, 2018, we account for this investment at fair market value as determined at period end by a quoted price on an organized exchange (see Note 1).
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.19.1
4. Intangible Assets, Goodwill and Other
 12 Months Ended
Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Disclosure 4.    GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):
 
 
2018
 
 
2017
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
Balances as of January 1:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
$
234.7

 
$
324.6

 
$
559.3

 
 
$
207.1

 
$
311.7

 
$
518.8

Accumulated impairment losses and write-offs
 
(35.9
)
 
(17.3
)
 
(53.2
)
 
 
(27.2
)
 
(14.5
)
 
(41.7
)
Goodwill, net
 
198.8

 
307.3

 
506.1

 
 
179.9

 
297.2

 
477.1

Acquisitions
 
—

 
—

 
—

 
 
26.2

 
—

 
26.2

Divestiture
 
—

 
(1.4
)
 
(1.4
)
 
 
—

 
—

 
—

Impairment
 
(5.9
)
 
(276.1
)
 
(282.0
)
 
 
(8.7
)
 
(2.8
)
 
(11.5
)
Currency fluctuations
 
(0.2
)
 
(2.7
)
 
(2.9
)
 
 
1.4

 
12.9

 
14.3

Balances as of December 31:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
234.5

 
320.5

 
555.0

 
 
234.7

 
324.6

 
559.3

Accumulated impairment losses and write-offs
 
(41.8
)
 
(293.4
)
 
(335.2
)
 
 
(35.9
)
 
(17.3
)
 
(53.2
)
Goodwill, net
 
$
192.7

 
$
27.1

 
$
219.8

 
 
$
198.8

 
$
307.3

 
$
506.1



In March 2018, we wrote off $1.4 million of goodwill from our Clinical Diagnostics segment as a result of a divestiture of a product line.

In conjunction with the purchase of all the issued and outstanding stock of RainDance Technologies, Inc. in February 2017 (see Note 2, "Acquisitions"), we recorded $26.2 million of goodwill and $37.6 million of definite-lived intangible assets: $36.4 million of licenses, $1.0 million of developed product technology and $0.2 million of tradenames.

In 2018, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A., 2007 through 2012 acquisitions of DiaMed Holding AG, DiaMed Fennica Oy, DiaMed (G.B.) Limited, and DiaMed Benelux (collectively DiaMed), 2010 acquisition of Biotest AG, and 2013 acquisition of AbD Serotec in the amounts of $18.1 million, $247.2 million, $10.8 million and $5.9 million, respectively. Goodwill for DiaMed, Biotest AG and AbD Serotec was fully impaired at December 31, 2018. Impairments for the Pasteur Sanofi Diagnostics S.A., DiaMed and Biotest AG were included in our Clinical Diagnostics segment's results of operations, and the impairment for AbD Serotec was included in our Life Science segment's results of operations.

In 2017, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A. and with our 2013 acquisition of AbD Serotec in the amounts of $2.8 million and $8.7 million, respectively. Impairment for the Pasteur Sanofi Diagnostics S.A. was included in our Clinical Diagnostics segment's results of operations, and the impairment for AbD Serotec was included in our Life Science segment's results of operations.

The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows.

Other than goodwill, we have no intangible assets with indefinite lives. Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):
 
December 31, 2018
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-6
 
$
88.7

 
$
(68.3
)
 
$
20.4

Know how
1-7
 
190.6

 
(159.8
)
 
30.8

Developed product technology
1-10
 
130.4

 
(86.6
)
 
43.8

Licenses
7-11
 
76.3

 
(40.9
)
 
35.4

Tradenames
2-6
 
3.9

 
(3.3
)
 
0.6

Covenants not to compete
7
 
3.2

 
(1.1
)
 
2.1

     Total definite-lived intangible assets
 
 
$
493.1

 
$
(360.0
)
 
$
133.1


 
December 31, 2017
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-7
 
$
92.3

 
$
(64.4
)
 
$
27.9

Know how
1-8
 
194.9

 
(157.9
)
 
37.0

Developed product technology
1-12
 
133.3

 
(70.3
)
 
63.0

Licenses
1-12
 
76.7

 
(36.0
)
 
40.7

Tradenames
1-6
 
3.9

 
(3.0
)
 
0.9

Covenants not to compete
1-8
 
7.9

 
(3.3
)
 
4.6

     Total definite-lived intangible assets
 
 
$
509.0

 
$
(334.9
)
 
$
174.1



In 2018, we impaired developed product technology and fully impaired covenants not to compete in the amounts of $8.8 million and $1.7 million, respectively, associated with our 2012 acquisition of a cell sorting system from Propel Labs, Inc. These impairments were included in our Life Science segment's results of operations. The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows.

Amortization expense related to purchased intangible assets for the years ended December 31, 2018, 2017 and 2016 was $28.3 million, $30.8 million and $35.2 million, respectively.  Estimated future amortization expense (based on existing purchased intangible assets) for the years ending December 31, 2019, 2020, 2021, 2022, 2023 and thereafter is $21.7 million, $19.7 million, $18.9 million, $15.7 million, $14.8 million, and $42.3 million, respectively.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.19.1
5. Notes Payable and Long-Term Debt
 12 Months Ended
Dec. 31, 2018
Debt Disclosure [Abstract]  
Notes Payable and Long-term Debt 5.NOTES PAYABLE AND LONG-TERM DEBT


Under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had $208.2 million available for borrowing and usage as of December 31, 2018, which was reduced by $3.1 million that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations.

The principal components of long-term debt are as follows (in millions):
 
December 31, 2018
 
December 31, 2017
 
 
 
 
4.875% Senior Notes due 2020, net of discount
$
425.0

 
$
425.0

Less unamortized discount and debt issuance costs
(1.3
)
 
(1.9
)
Long-term debt less unamortized discount and debt issuance costs
423.7

 
423.1

Capital leases and other debt
15.7

 
11.9

 
439.4

 
435.0

Less current maturities
(0.5
)
 
(0.4
)
Long-term debt
$
438.9

 
$
434.6



Senior Notes due 2020

In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due December 2020 (4.875% Notes).  The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946%.  The 4.875% Notes pay a fixed rate of interest of 4.875% per year.  We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date.  Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness.  Certain covenants apply at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. We were in compliance with these covenants as of December 31, 2018. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios.
 
Credit Agreement

In June 2014, Bio-Rad entered into a $200.0 million unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of December 31, 2018 or 2017; however, $0.2 million and $0.5 million were utilized for domestic standby letters of credit that reduced our borrowing availability as of December 31, 2018 and 2017, respectively. The Credit Agreement matures in June 2019. If we had borrowed against our Credit Agreement, the borrowing rate would have been 3.925% at December 31, 2018.

The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of December 31, 2018.

Maturities of long-term debt at December 31, 2018 are as follows: 2019 - $0.5 million; 2020 - $426.6 million; 2021 - $1.7 million; 2022 - $1.6 million; 2023 - $0.4 million; thereafter - $9.9 million.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.19.1
6. Income Taxes
 12 Months Ended
Dec. 31, 2018
Income Tax Disclosure [Abstract]  
Income Taxes [Text Block] 6. INCOME TAXES

The U.S. and international components of income before taxes are as follows (in millions):

 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
U.S.
 
$
363.4

 
$
72.8

 
$
(38.5
)
International
 
149.3

 
25.0

 
80.1

Income before taxes
 
$
512.7

 
$
97.8

 
$
41.6



The provision for income taxes consists of the following (in millions):

 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
Current tax expense:
 
 

 
 

 
 

U.S. Federal
 
$
8.8

 
$
6.7

 
$
16.1

State
 
2.2

 
3.4

 
3.1

International
 
30.5

 
32.0

 
30.4

Current tax expense
 
41.5

 
42.1

 
49.6

Deferred tax expense (benefit):
 
 

 
 
 
 

U.S. Federal
 
114.0

 
(69.8
)
 
(42.4
)
State
 
6.6

 
4.3

 
(2.8
)
International
 
0.3

 
(19.3
)
 
(6.0
)
Deferred tax expense (benefit)
 
120.9

 
(84.8
)
 
(51.2
)
Non-current tax (benefit) expense
 
(15.4
)
 
18.3

 
17.2

Provision for (benefit from) income taxes
 
$
147.0

 
$
(24.4
)
 
$
15.6




The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:

 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
U. S. statutory tax rate
 
21
 %
 
35
 %
 
35
 %
Impact of foreign operations
 
(4
)
 
6

 
(15
)
Foreign dividends, net
 
—

 
—

 
(40
)
Research tax credits
 
(1
)
 
(4
)
 
(9
)
Nontaxable subsidies
 
—

 
(2
)
 
(4
)
Tax settlements and changes to unrecognized tax benefits
 
—

 
—

 
47

Goodwill impairment
 
6

 
1

 
11

Domestic manufacturing deduction
 
—

 
—

 
(4
)
Share-based compensation
 
(1
)
 
(5
)
 
3

Nondeductible executive compensation
 
—

 
2

 
3

Fines and penalties
 
—

 
—

 
2

Prior period adjustments
 
(1
)
 
—

 
4

U.S. taxation of foreign income
 
15

 
3

 
2

Acquisition-related
 
—

 
10

 
—

U.S. tax reform
 
(10
)
 
(71
)
 
—

State taxes
 
2

 
3

 
1

Other
 
2

 
(3
)
 
1

Provision for (benefit from) income taxes
 
29
 %
 
(25
)%
 
37
 %


On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code that affect our 2017 financial statements, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities.

Subsequent to the enactment of the Tax Act, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act ("SAB 118"), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under Accounting Standards Codification ("ASC") 740, "Income Taxes." We have completed our accounting for the income tax effects of the Tax Act, under SAB 118, as of December 31, 2018. As noted in our 2017 Annual Report, we were able to make reasonable estimates and provisionally recorded an income tax benefit of $70 million related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. The final accounting for the Tax Act resulted in an additional income tax benefit of $49 million for a final income tax benefit of $119 million. This is comprised of $169 million tax benefit related to the remeasurement of U.S. federal deferred tax assets and liabilities, offset by a $50 million tax detriment for the Transition Tax. We elected to account for the tax effect of the Global Intangible Low-Taxed Income (“GILTI”) in the period in which it is incurred.

Our effective income tax rate was 29%, (25)% and 37% in 2018, 2017 and 2016, respectively. The effective tax rate for 2018 was driven by detriments due to non-deductible impairment charges and the taxation of our foreign operations, partially offset by a $49 million benefit recorded as a result of the completion of our accounting for the Tax Act under SAB 118. The effective tax rate for 2017 was driven by a $70 million benefit recorded as a provisional estimate of the accounting for the Tax Act. The effective tax rate for 2016 included additional tax liabilities for unrecognized tax benefits related to the non-deductibility of interest expense in our foreign jurisdictions.

Many jurisdictions in which we operate have statutory tax rates that differ from the U.S. statutory tax rate of 21%. Our effective tax rate is impacted, either favorably or unfavorably, by many factors including, but not limited to the jurisdictional mix of income before tax, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits.

Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):

 
 
December 31,
 
 
2018
 
2017
Deferred tax assets:
 
 

 
 

Bad debt, inventory and warranty accruals
 
$
21.7

 
$
28.6

Other post-employment benefits, vacation and other reserves
 
23.0

 
24.0

Tax credit and net operating loss carryforwards
 
75.3

 
73.3

Other
 
27.1

 
19.7

    Total gross deferred tax assets
 
147.1

 
145.6

Valuation allowance
 
(70.8
)
 
(66.4
)
       Total deferred tax assets
 
76.3

 
79.2

Deferred tax liabilities:
 
 
 
 
Property and equipment
 
40.1

 
33.5

Investments and intangible assets
 
540.6

 
219.1

        Total deferred tax liabilities
 
580.7

 
252.6

Net deferred tax liabilities
 
$
(504.4
)
 
$
(173.4
)


The realization of deferred tax assets is dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that our California and certain foreign deferred tax assets will not be realized as of December 31, 2018, and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our deferred tax assets in California and certain foreign jurisdictions increased by $4.4 million in 2018.

As of December 31, 2018, our foreign and California net operating loss carryforwards were approximately $205.0 million and $52.7 million, respectively. Of our foreign net operating losses, $118.8 million may be carried forward indefinitely. The majority of the remaining foreign net operating losses, if not utilized, will begin to expire in 2025. Our California net operating loss carryforwards, if not utilized, will begin to expire in 2029. As of December 31, 2018, our California research tax credit carryforwards were approximately $32.1 million and may be carried forward indefinitely.

Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2014 and forward for the U.S. and the years 2012 and forward for certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):
 
 
2018
 
2017
 
2016
Unrecognized tax benefits – January 1
 
$
54.9

 
$
21.1

 
$
11.9

Additions to tax positions related to prior years
 
0.6

 
1.3

 
10.4

Reductions to tax positions related to prior years
 
(20.2
)
 
(1.0
)
 
—

Additions to tax positions related to the current year
 
4.6

 
34.8

 
3.4

Settlements
 
(6.8
)
 
(0.2
)
 
(2.4
)
Lapse of statute of limitations
 
(1.1
)
 
(3.4
)
 
(2.3
)
Currency translation
 
(2.2
)
 
2.3

 
0.1

Unrecognized tax benefits – December 31
 
$
29.8

 
$
54.9

 
$
21.1



Bio-Rad recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. Related to the unrecognized tax benefits noted above, the cumulative amount of accrued interest and penalties as of December 31, 2018, 2017 and 2016, respectively was $9.5 million, $10.9 million and $11.8 million. Bio-Rad accrued interest and penalties of $(1.4) million, $(0.9) million, and $8.7 million in 2018, 2017, and 2016, respectively. The total unrecognized tax benefits and interest and penalties of $39.3 million in 2018 was partially offset by deferred tax assets of $1.6 million and prepaid taxes of $5.5 million, for a net amount of $32.2 million.

As of December 31, 2018, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $3.1 million. Substantially all such amounts will impact our effective income tax rate if recognized.

It is generally our intention to repatriate certain foreign earnings to the extent that such repatriations are not restricted by local laws or accounting rules, and there are no substantial incremental costs. During the current year, we recorded approximately $6.7 million of deferred tax liability for the earnings of certain foreign jurisdictions that we may repatriate in the future. The determination of the amount of the unrecognized deferred tax liability for foreign earnings that are indefinitely reinvested is not practicable to estimate.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.19.1
7. Stockholders' Equity
 12 Months Ended
Dec. 31, 2018
Stockholders' Equity Attributable to Parent [Abstract]  
Stockholders' Equity Note Disclosure [Text Block] 7.    STOCKHOLDERS' EQUITY

Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B).  Each share of Class A and Class B participates equally in the earnings of Bio-Rad, and is identical in all respects except as follows. Class A has limited voting rights.  Each share of Class A is entitled to one tenth of a vote on most matters, and each share of Class B is entitled to one vote.  Additionally, Class A stockholders are entitled to elect 25% of the Board of Directors and Class B stockholders are entitled to elect 75% of the directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares but no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares.  Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.  The founders of Bio-Rad, the Schwartz family, collectively hold a majority of Bio-Rad’s voting stock.  As a result, the Schwartz family is able to exercise significant influence over Bio-Rad.

Changes to Bio-Rad's issued common stock shares are as follows (in thousands):
 
Class A Shares
 
Class B Shares
Balance at January 1, 2016
24,230

 
5,131

B to A conversions
13

 
(13
)
Issuance of common stock
211

 
6

Balance at December 31, 2016
24,454

 
5,124

B to A conversions
34

 
(34
)
Issuance of common stock
191

 
18

Balance at December 31, 2017
24,679

 
5,108

B to A conversions
30

 
(30
)
Issuance of common stock
175

 
18

Balance at December 31, 2018
24,884

 
5,096


Treasury Shares

In November, 2017, the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to $250.0 million of outstanding shares of our common stock. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. This new authorization superseded the prior authorization of up to $18.0 million of Bio-Rad's common stock and has no expiration. The share repurchase activity under the share repurchase program through open market transactions in 2017 and 2018 is summarized as follows:

 
Number of Shares Purchased
Weighted-Average Price per Share
Total Shares Repurchased To Date
Remaining Authorized Value
(in millions)
May 1, 2017 - May 31, 2017
2,500

$
220.02

3,539

$
2.7

June 1, 2017 - June 30, 2017
1,500

$
221.82

5,039

$
2.4

August 1, 2017 - August 31, 2017
9,200

$
221.45

14,239

$
0.4

November 1, 2018 - November 30, 2018
178,911

$
273.39

193,150

$
201.1


In September 2017, we used 12,740 of the repurchased shares in connection with the vesting of restricted stock units under the 2007 Incentive Award Plan in order to obtain a tax deduction in some of our foreign entities. The Credit Agreement may limit our ability to repurchase our stock.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.19.1
8. Accumulated Other Comprehensive Income
 12 Months Ended
Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
accumulated other comprehensive income [Text Block] 8.    ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Accumulated other comprehensive income (loss) included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions):
 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains (losses) on available-for-sale investments
Total Accumulated other comprehensive income (loss)
Balances as of January 1, 2017
$
1.3

$
(18.6
)
$
435.0

$
417.7

Other comprehensive income (loss), before reclassifications
76.1

(6.5
)
203.6

273.2

Amounts reclassified from Accumulated other comprehensive income
—

2.1

(0.1
)
2.0

Income tax effects
—

0.7

(74.9
)
(74.2
)
Effect of adoption of ASU 2018-02
—

—

120.1

120.1

Other comprehensive income (loss), net of income taxes
76.1

(3.7
)
248.7

321.1

Balances as of December 31, 2017
$
77.4

$
(22.3
)
$
683.7

$
738.8

Effect of adoption of ASU 2016-01 and 2018-03**
—

—

(679.3
)
(679.3
)
Balances as of January 1, 2018
$
77.4

$
(22.3
)
$
4.4

$
59.5

Other comprehensive (loss) income, before reclassifications
(112.9
)
6.9

(1.4
)
(107.4
)
Amounts reclassified from Accumulated other comprehensive income
—

2.4

0.3

2.7

Income tax effects
—

(1.8
)
—

(1.8
)
Other comprehensive (loss) income, net of income taxes
(112.9
)
7.5

(1.1
)
(106.5
)
Balances as of December 31, 2018
$
(35.5
)
$
(14.8
)
$
3.3

$
(47.0
)


**See Note 1, "Significant Accounting Policies" under "Recent Accounting Pronouncements Adopted"

In 2017, we adopted ASU 2018-02, "Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income," which gave entities the option to reclassify to retained earnings tax effects related to items in Accumulated other comprehensive income ("OCI") that the FASB refers to as having been stranded in Accumulated OCI as a result of the Tax Act. We reclassified the income tax effects of the Tax Act on the remeasurement of our deferred tax liabilities related to our available-for-sale equity securities by increasing OCI and decreasing Retained earnings by $120.1 million.

The increase in 2017 for net unrealized holding gains on available-for-sale investments was primarily from our ownership in the preferred shares of Sartorius.

The amounts reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows:
 
 
 
December 31,
 
 
Components of Comprehensive income
 
2018
2017
 
Location
 
Amortization of foreign other post-employment benefit items
 
$
(2.4
)
$
(2.1
)
 
Selling, general and administrative expense
 
Net holding (losses) gains on equity securities and available for sale investments
 
$
(0.3
)
$
0.1

 
Other (income) expense, net
 

Reclassification adjustments are calculated using the specific identification method.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.19.1
9. Share-based Compensation
 12 Months Ended
Dec. 31, 2018
Share-based Compensation [Abstract]  
Disclosure of Compensation Related Costs, Share-based Payments
9. SHARE-BASED COMPENSATION/EQUITY AWARD AND PURCHASE PLANS

Description of Share-Based Compensation Plans

We believe our share-based compensation plans align the interests of our employees with those of our shareholders.

Equity Award Plans
We have three equity award plans for officers and certain other employees: the 2003 Stock Option Plan (2003 Plan), the 2007 Incentive Award Plan (2007 Plan) and the 2017 Incentive Award Plan (2017 Plan).  The 2003 Plan authorized the grant of incentive stock options and non-qualified stock options to employees. The 2007 Plan authorized the grant of stock options, restricted stock, restricted stock units, stock appreciation rights and other types of equity awards to employees.  We no longer grant equity under the 2003 Plan or 2007 Plan. From 2007 through 2016, all share-based compensation grants were from the 2007 Plan.

The 2017 Plan authorizes the grant to employees of stock options, stock appreciation rights, restricted stock, restricted stock units, and other types of equity awards. A total of 1,999,714 shares have been reserved for issuance of equity awards under the 2017 Plan and may be of either Class A or Class B common stock. At December 31, 2018, there were 1,584,834 shares available to be granted.

Under the above plans, Class A and Class B options are granted at prices not less than fair market value of the underlying common stock on the date of grant.  Generally, options granted have a maximum term of 10 years and vest in increments of 20% per year over a five-year period on the yearly anniversary date of the grant.  Stock awards issued under the 2007 Plan and 2017 Plan generally vest in increments of 20% per year over a five-year period on the yearly anniversary date of the grant.

Employee Stock Purchase Plans
Our 2011 Employee Stock Purchase Plan (2011 ESPP) provides that eligible employees may contribute up to 10% of their compensation up to $25,000 annually toward the quarterly purchase of our Class A common stock.  The employees’ purchase price is 85% of the lesser of the fair market value of the stock on the first business day or the last business day of each calendar quarter.  

The 2011 ESPP includes two components: a Code Section 423 Component that we intend to qualify as an “employee stock purchase plan” under Section 423 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and a Non-423 Component, which authorizes the grant of purchase rights that does not qualify as an “employee stock purchase plan” under Section 423 of the Code. We have authorized the sale of 1,300,000 shares of Class A common stock under the 2011 ESPP.

Share-Based Compensation

Included in our share-based compensation expense is the cost related to stock option grants, ESPP stock purchases and restricted stock unit awards.  Share-based compensation expense is allocated to Cost of goods sold, Research and development expense, and Selling, general and administrative expense in the Consolidated Statements of Income.

For 2018, 2017 and 2016, we recognized share-based compensation expense of $27.8 million, $23.4 million and $19.7 million, respectively.  The income tax benefit related to share-based compensation expense was $4.4 million, $5.8 million and $5.1 million for 2018, 2017 and 2016, respectively. We did not capitalize any share-based compensation expense in inventory.

The tax benefit from share-based compensation vested or exercised during 2018, 2017 and 2016 was $5.4 million, $6.3 million, and $1.5 million, respectively. The actual tax benefit realized for the tax deductions from share-based compensation vested or exercised, including excess tax benefits that were recognized in stockholders’ equity, totaled $6.0 million in 2016.

For options and awards, we amortize the fair value on a straight-line basis.  All stock compensation awards are amortized over the requisite service periods of the awards, which are generally the vesting periods. With the adoption in 2017 of ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting," we made a policy election to recognize forfeitures as they occur. Prior to 2017, we recognized compensation expense net of estimated forfeitures.

Stock Options
The following table summarizes stock option activity:

 
 
Shares
 
Weighted-
Average
Exercise Price
 
Weighted-
Average
Remaining
Contractual
Term (in years)
 
Aggregate
Intrinsic
Value
(in millions)
Outstanding, December 31, 2017
 
407,480

 
$
120.39

 
 
 
 
Granted
 
33,000

 
$
326.15

 
 
 
 
Exercised
 
(44,600
)
 
$
93.63

 
 
 
 
Forfeited/expired
 
(22,240
)
 
$
169.93

 
 
 
 
Outstanding, December 31, 2018
 
373,640

 
$
138.81

 
4.90
 
$
38.0

 
 
 
 
 
 
 
 
 
Unvested, December 31, 2018
 
99,600

 
$
223.91

 
8.32
 
$
3.9

Exercisable, December 31, 2018
 
274,040

 
$
107.88

 
3.65
 
$
34.1




Intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic value on the date of exercise of stock options exercised during 2018, 2017 and 2016 was approximately $8 million, $10 million and $1 million, respectively. The total fair value of options vested during 2018, 2017 and 2016 was $6.0 million, $4.2 million and $2.1 million, respectively.

Cash received from stock options exercised during 2018, 2017 and 2016 was $0.5 million, $1.6 million and $1.2 million, respectively.  

As of December 31, 2018, there was $6.3 million of total unrecognized compensation cost from stock options. This amount is expected to be recognized in the future over a weighted-average period of approximately 3 years.

The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:

 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
Expected volatility
 
22
%
 
20
%
 
21
%
Risk-free interest rate
 
2.85
%
 
1.87
%
 
1.35
%
Expected life (in years)
 
7.6

 
7.2

 
7.4

Expected dividend
 
—

 
—

 
—

Weighted-average fair value of options granted
 
$
105.94

 
$
58.65

 
$
42.40



Volatility is based on the historical volatilities of our common stock for a period equal to the stock option’s expected life.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the number of years that we estimate, based primarily on historical experience, that the options will be outstanding prior to exercise.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.

Restricted Stock Units
Restricted stock units, which are rights to receive shares of company stock, were granted from 2009 through 2016 under the 2007 Plan and since 2017 under the 2017 Plan.  The fair value of a restricted stock unit is the market value as determined by the closing price of the stock on the day of grant.

The following table summarizes restricted stock unit activity:
 
 

Restricted Stock
Units
 
Weighted-
Average
Grant-Date
Fair Value
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic Value
(in millions)
Outstanding, December 31, 2017
 
473,000

 
$
172.76

 
 
 
 
Granted
 
185,755

 
$
326.15

 
 
 
 
Vested
 
(128,294
)
 
$
158.49

 
 
 
 
Forfeited
 
(56,011
)

$
182.15

 
 
 
 
Outstanding, December 31, 2018
 
474,450

 
$
235.57

 
2.11
 
$
110.2



The total fair value of restricted stock units vested in 2018, 2017 and 2016 was $40.0 million, $27.7 million and $18.7 million, respectively. As of December 31, 2018, there was approximately $102.4 million of total unrecognized compensation cost related to restricted stock units.  This amount is expected to be recognized over a remaining weighted-average period of approximately 4 years.

Employee Stock Purchase Plans
The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions:

 
Year Ended December 31,
 
2018
 
 
 
2017
 
 
 
2016
Expected volatility
27
%
 
 
 
19
%
 
 
 
20
%
Risk-free interest rate
1.82
%
 
 
 
0.83
%
 
 
 
0.26
%
Expected life (in years)
0.24

 
 
 
0.24

 
 
 
0.25

Expected dividend
—

 
 
 
—

 
 
 
—

Weighted-average fair value
 
 
 
 
 
 
 
 
 
of purchase rights
$
55.04

 
 
 
$
38.86

 
 
 
$
27.36



The major assumptions are primarily based on historical data.  Volatility is based on the historical volatilities of our common stock for a period equal to the expected life of the purchase rights.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.

We sold 63,464 shares for $13.6 million, 74,409 shares for $13.0 million and 93,605 shares for $11.5 million under the 2011 ESPP to employees in 2018, 2017 and 2016, respectively.  At December 31, 2018, 658,248 shares remain authorized and available for issuance under the 2011 ESPP.

We currently issue new shares or treasury shares, if available, to satisfy stock option exercises, restricted stock issuances and ESPP stock purchases.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.19.1
10. Other Income and Expenses
 12 Months Ended
Dec. 31, 2018
Other Income and Expenses [Abstract]  
Other Income and Other Expense Disclosure 10. OTHER INCOME AND EXPENSE, NET

Other (income) expense, net includes the following components (in millions):
 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
 
 
 
 
 
 
 
Interest and investment income
 
$
(26.6
)
 
$
(19.1
)
 
$
(14.7
)
Net realized gains on investments
 
(1.6
)
 
(0.1
)
 
(0.8
)
Other-than-temporary impairment losses on investments
 
0.8

 
7.0

 
0.6

Gain on sale of land
 
(4.1
)
 
—

 
—

Gain on divestiture of product line
 
(5.1
)
 
—

 
—

Other expense
 
—

 
1.5

 
1.1

Other (income) expense, net
 
$
(36.6
)
 
$
(10.7
)
 
$
(13.8
)


Prior year amounts have been adjusted (see Note 1 to the consolidated financial statements in regard to ASU 2017-07) for pension and other postretirement benefits.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.19.1
11. Supplemental Cash Flow Information
 12 Months Ended
Dec. 31, 2018
Supplemental Cash Flow Information [Abstract]  
Cash Flow, Supplemental Disclosures [Text Block] 11. SUPPLEMENTAL CASH FLOW INFORMATION

The reconciliation of net income to net cash provided by operating activities is as follows (in millions):

 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
Net income
 
$
365.6

 
$
122.2

 
$
26.0

Adjustments to reconcile net income
 
 

 
 

 
 

to net cash provided by operating activities
 
 

 
 

 
 

Depreciation and amortization
 
138.1

 
148.7

 
142.9

Share-based compensation
 
27.8

 
23.4

 
19.7

Gains on dispositions of securities
 
(1.6
)
 
(0.1
)
 
(0.8
)
Other-than-temporary impairment losses on investments
 
0.8

 
7.0

 
0.6

Changes in fair market value of equity securities
 
(606.2
)
 
—

 
—

Losses on dispositions of fixed assets
 
2.0

 
8.1

 
0.6

Gain on sale of land
 
(4.1
)
 
—

 
—

Gain on divestiture of a product line
 
(5.1
)
 
—

 
—

Excess tax benefits from share-based compensation
 
—

 
—

 
(1.5
)
Changes in fair value of contingent consideration
 
(6.2
)
 
(18.1
)
 
(0.4
)
Decrease (increase) in accounts receivable, net
 
59.7

 
(64.1
)
 
12.5

Increase in inventories, net
 
(12.9
)
 
(47.7
)
 
(57.1
)
Increase in other current assets
 
(15.3
)
 
(35.7
)
 
(6.8
)
(Decrease) increase in accounts payable
 


 


 


and other current liabilities
 
(45.6
)
 
7.8

 
30.1

(Decrease) increase in income taxes payable
 
(20.9
)
 
(22.4
)
 
10.7

Increase (decrease) in deferred income taxes
 
120.9

 
(82.0
)
 
(51.4
)
Decrease in other long term assets
 
1.1

 
2.3

 
12.5

(Decrease) increase in other long term liabilities
 
(10.0
)
 
38.1

 
10.4

Impairment losses on goodwill and long-lived assets
 
292.5

 
11.5

 
62.3

Other
 
4.9

 
5.1

 
5.8

Net cash provided by operating activities
 
$
285.5

 
$
104.1

 
$
216.1

 
 
 
 
 
 
 
Non-cash investing activities:
 
 
 
 
 
 
   Purchased property, plant and equipment
 
$
5.7

 
$
—

 
$
7.2

   Purchased marketable securities and investments
 
$
0.8

 
$
2.8

 
$
0.6
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.19.1
12. Commitments & Contingent Liabilities
 12 Months Ended
Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure [Text Block] 12. COMMITMENTS AND CONTINGENT LIABILITIES

Rents and Leases

Rental expense under operating leases was $47.4 million, $43.6 million and $44.4 million in 2018, 2017 and 2016, respectively.  Leases are principally for facilities and automobiles.

Annual future minimum lease payments at December 31, 2018 under operating leases are as follows: 2019 - $44.4 million; 2020 - $37.8 million; 2021 - $27.4 million; 2022 - $19.7 million; 2023 - $13.9 million; and 2024 and beyond - $25.6 million.

The total minimum rentals to be received in the future for subleases as of December 31, 2018 were $17.8 million.

Deferred Profit Sharing Retirement Plan

We have a profit sharing plan covering substantially all U.S. employees.  Contributions are made at the discretion of the Board of Directors.  Bio-Rad has no liability other than for the current year’s contribution.  Contribution expense was $15.9 million, $16.0 million and $15.1 million in 2018, 2017 and 2016, respectively.

Other Post-Employment Benefits
In several foreign locations we are statutorily required to provide retirement benefits or a lump sum termination indemnity to our employees upon termination for virtually any reason. These plans are accounted for as defined benefit plans and the associated net benefit obligation at December 31, 2018 and 2017 of $70.4 million and $74.9 million, respectively, has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets. Most plans are not required to be funded, and as such, there is no trust or other device used to accumulate assets or settle these obligations. However, some of these plans require funding based on local laws in which there is a trust or other device administered by an external plan manager that is used to accumulate assets to assist in settling these obligations. The following disclosures include such plans, which are located in France, Switzerland, Germany, Korea, India, Thailand, Italy, Dubai and Japan.

Obligations and Funded Status
The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in the Consolidated Balance Sheets for the plans (in millions):

Change in benefit obligation:
2018
2017
Benefit obligation at beginning of year
$136.6
$122.7
Service cost
7.5

6.5

Interest cost
1.1

1.1

Plan participants' contributions
3.1

2.8

Actuarial (gain) loss
(5.4
)
3.3

Gross benefits paid
(3.1
)
(3.2
)
Plan amendments
(0.5
)
1.1

Special termination benefits
—

(2.0
)
Settlements
—

(5.1
)
Change attributable to foreign exchange
(2.0
)
9.4

 
 
 
Benefit obligation at end of year
137.3

136.6

 
 
 
Change in plan assets:
 
 
Fair value of plan assets at beginning year
61.7

58.8

Actual return on plan assets
0.3

0.5

Employer contributions
4.0

4.0

Plan participants' contributions
3.1

2.8

Gross benefits paid
(1.5
)
(2.3
)
Settlements
—

(5.1
)
Change attributable to foreign exchange
(0.7
)
3.0

 
 
 
Fair value of plan assets at end of year
66.9

61.7

 
 
 
Under funded status of plans
$(70.4)
$(74.9)
 
 
 
Amounts recognized in the consolidated balance sheets:
 
 
Current liabilities (Accrued payroll and employee benefits)
$(1.1)
$(1.1)
Noncurrent liabilities (Other long-term liabilities)
(69.3
)
(73.8
)
 
 
 
Net liability, end of fiscal year
$(70.4)
$(74.9)
 
 
 


Components of Net Periodic Benefit Cost
The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions):

 
2018
2017
2016
Service costs
$7.5
$6.5
$6.1
Interest costs
1.1

1.1

1.4

Expected returns on plan assets
(1.1
)
(1.1
)
(1.0
)
Amortization of actuarial losses
1.3

1.4

1.7

Amortization of prior service costs
0.1

—

—

Settlements
—

1.2

0.4

 
 
 
 
Net periodic benefit costs
$8.9
$9.1
$8.6
 
 
 
 


Assumptions

The weighted-average assumptions used in computing the benefit obligations are as follows:


 
2018
2017
Discount rate
1.1
%
0.8
%
Compensation rate increase
1.8
%
1.8
%
 
 
 

The weighted-average assumptions used in computing the net periodic benefit costs are as follows:

 
2018
2017
2016
Discount rate
0.8
%
0.9
%
1.1
%
Expected long-term rate of return on plan assets
1.8
%
1.9
%
1.6
%
 
 
 
 


In some foreign locations we have service award plans that are paid based upon the number of years of employment. Under these plans, the liability at December 31, 2018 and 2017 was $3.1 million and $3.7 million, respectively, and has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets.

Purchase Obligations

As of December 31, 2018, we had obligations that have been recognized on our balance sheet of $110.9 million, which include purchases of goods and services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty. These obligations also include other post-employment benefits in some of our foreign locations as indicated above.

The annual future fixed and determinable portion of our purchase obligations that have been recognized on our balance sheet as of December 31, 2018 are as follows: 2019 - $5.8 million, 2020 - $16.4 million, 2021 - $6.2 million, 2022 - $2.4 million, 2022 - $3.5 million and after 2023 - $76.6 million.

As of December 31, 2018, we had purchase obligations that have not been recognized on our balance sheet of $12.5 million, which include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty.

The annual future fixed and determinable portion of our purchase obligations that have not been recognized on our balance sheet as of December 31, 2018 are as follows: 2019 - $6.5 million, 2020 - $5.3 million, 2021 - $0.1 million, 2022 - $0.2 million, 2022 - $0.2 million and after 2023 - $0.2 million.

Letters of Credit/Guarantees

In the ordinary course of business, we are at times required to post letters of credit/guarantees.  The letters of credit/guarantees are issued by financial institutions to guarantee our obligations to various parties. We were contingently liable for $3.1 million of standby letters of credit/guarantees with financial institutions as of December 31, 2018.

Contingent Consideration

During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount. In the first and third quarters of 2018, we paid $1.3 million and $0.8 million, respectively, per the purchase agreement. Since 2016 we have had a net decrease in the cumulative valuation of the sales milestones of $12.2 million. The contingent consideration was accrued at its estimated fair value of $8.4 million as of December 31, 2018.

Concentrations of Labor Subject to Collective Bargaining Agreements

At December 31, 2018, approximately eight percent of Bio-Rad's approximately 3,265 U.S. employees were covered by a collective bargaining agreement, which will expire on November 7, 2019.  Many of Bio-Rad's non-U.S. full-time employees, especially in France, are covered by collective bargaining agreements.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.19.1
13. Legal Proceedings
 12 Months Ended
Dec. 31, 2018
Legal Proceedings [Abstract]  
Legal Matters and Contingencies 13.    LEGAL PROCEEDINGS

On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015, we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million, plus prejudgment interest of $141,608, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We have provided for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017, we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit. Oral arguments occurred on November 14, 2018. On February 26, 2019, the United States Court of Appeals for the Ninth Circuit issued its decision, reversing in part, vacating in part, and affirming in part. Specifically, the court: (1) reversed the Dodd-Frank claim, which amounts to about $2.96 million plus interest, and directed the district court to enter judgment in Bio-Rad’s favor on that claim; (2) vacated the SOX claim due to instructional error and remanded for further proceedings, including whether a new trial is needed; and (3) affirmed the California public policy claim and the $7.96 million in damages attributable to it. On March 12, 2019 we filed a petition for panel rehearing or rehearing en banc with the United States Court of Appeals for the Ninth Circuit.

We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.


XML 35 R21.htm IDEA: XBRL DOCUMENT v3.19.1
14. Segment Reporting
 12 Months Ended
Dec. 31, 2018
Segment Reporting [Abstract]  
Segment Information 14. SEGMENT INFORMATION

Bio-Rad is a multinational manufacturer and worldwide distributor of its own life science research products and clinical diagnostics products.  We have two reportable segments:  Life Science and Clinical Diagnostics.  These reportable segments are strategic business lines that offer more than 9,000 different products and services and require different marketing strategies. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.

The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. These products are sold to university and medical school laboratories, pharmaceutical and biotechnology companies, food testing laboratories and government and industrial research facilities.

The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. These products are sold to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories and insurance and forensic testing laboratories.

Other Operations include the remainder of our Analytical Instruments segment.

Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. The accounting policies of the segments are the same as those described in Significant Accounting Policies (see Note 1).  Segment profit or loss includes an allocation of corporate expense based upon sales and an allocation of interest expense based upon accounts receivable and inventories.  The difference between total segment allocated interest expense, depreciation and amortization, and capital expenditures and the corresponding consolidated amounts is attributable to our corporate headquarters.  Segments are expected to manage only assets completely under their control.  Accordingly, segment assets include primarily accounts receivable, inventories and gross machinery and equipment.  Goodwill balances have been included in corporate for segment reporting purposes.

Information regarding industry segments at December 31, 2018, 2017, and 2016 and for the years then ended is as follows (in millions):

 
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
Segment net sales 
2018
 
$
861.7

 
$
1,411.8

 
$
15.9

 
2017
 
785.2

 
1,360.8

 
14.2

 
2016
 
730.7

 
1,323.3

 
14.2

 
 
 
 
 
 
 
 
Allocated interest expense
2018
 
$
7.2

 
$
16.7

 
$
0.1

 
2017
 
7.0

 
14.9

 
—

 
2016
 
6.9

 
16.5

 
—

 
 
 
 
 
 
 
 
Depreciation and amortization
2018
 
$
34.1

 
$
72.0

 
$
0.5

 
2017
 
36.2

 
80.2

 
—

 
2016
 
31.7

 
80.5

 
—

 
 
 
 
 
 
 
 
Segment profit (loss)
2018
 
$
28.7

 
$
(145.7
)
 
$
0.2

 
2017
 
(9.9
)
 
114.8

 
1.4

 
2016
 
(19.1
)
 
58.0

 
0.9

 
 
 
 
 
 
 
 
Segment assets
2018
 
$
450.2

 
$
949.0

 
$
5.9

 
2017
 
453.0

 
1,038.4

 
4.8

 
 
 
 
 
 
 
 
Capital expenditures
2018
 
$
36.7

 
$
60.5

 
$
0.5

 
2017
 
12.6

 
59.0

 
—




Prior year amounts have been adjusted (see Note 1 to the consolidated financial statements in regard to ASU 2017-07 for pension and other postretirement benefits). Clinical Diagnostics segment loss for 2018 was due to impairment losses taken on goodwill of $276.1 million (see Note 4 to the consolidated financial statements)

Net corporate operating expense consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. The following reconciles total segment profit to consolidated income before taxes (in millions):
 
 
 
Year Ended December 31,
 
2018
 
2017
 
2016
Total segment (loss) profit
$
(116.8
)
 
$
106.3

 
$
39.8

Foreign currency exchange losses, net
(2.9
)
 
(9.1
)
 
(4.5
)
Net corporate operating, interest and other expense not allocated to segments
(10.4
)
 
(10.1
)
 
(7.5
)
Change in fair market value of equity securities
606.2

 
—

 
—

Other income (expense), net
36.6

 
10.7

 
13.8

Consolidated income before income taxes
$
512.7

 
$
97.8

 
$
41.6



Prior year amounts have been adjusted (see Note 1 to the consolidated financial statements in regard to ASU 2017-07) for pension and other postretirement benefits.

The following reconciles total segment assets to consolidated total assets (in millions):

 
 
December 31,
 
 
2018
 
2017
Total segment assets
 
$
1,405.1

 
$
1,496.2

Cash and other current assets
 
1,047.2

 
965.8

Property, plant and equipment, net, excluding
 

 

  segment specific gross machinery and equipment
 
79.9

 
57.0

Goodwill, net
 
219.8

 
506.1

Other long-term assets
 
2,859.1

 
1,247.9

Total assets
 
$
5,611.1

 
$
4,273.0





The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):

 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
Europe
 
$
792.0

 
$
758.5

 
$
742.2

Pacific Rim
 
495.5

 
461.3

 
427.1

United States
 
863.6

 
800.2

 
770.6

Other (primarily Canada and Latin America)
 
138.3

 
140.2

 
128.3

Total net sales
 
$
2,289.4

 
$
2,160.2

 
$
2,068.2


The following presents Property, plant and equipment, net, Other investments and Other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):

 
 
December 31,
 
 
2018
 
2017
Europe**
 
$
1,571.9

 
$
230.6

Pacific Rim
 
20.7

 
18.4

United States  
 
1,582.1

 
1,305.2

Other (primarily Canada and Latin America)
 
11.1

 
13.1

Total Property, plant and equipment, net, Other investments and Other assets, excluding deferred income taxes
 
$
3,185.8

 
$
1,567.3
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.19.1
15. Restructuring Costs (Notes)
 12 Months Ended
Dec. 31, 2018
Restructuring Costs [Abstract]  
Restructuring and Related Activities Disclosure [Text Block] RESTRUCTURING COSTS

Restructuring Costs for European Reorganization

In May 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance enterprise resource planning ("ERP") platform, are expected to be incurred through 2019. We recorded approximately $(0.2) million, $0.5 million and $12.5 million in restructuring charges and adjustments related to severance and other employee benefits for the years ended December 31, 2018, 2017 and 2016, respectively. From May 2016 to December 31, 2018, total expenses were $12.8 million. The liability of $1.6 million as of December 31, 2018 was recorded in Accrued payroll and employee benefits in the Consolidated Balance Sheets. The amounts recorded were reflected in Cost of goods sold of $(0.1) million, $(0.2) million and $2.1 million, and in Selling, general and administrative expense of $(0.1) million, $0.7 million and $10.4 million in the Consolidated Statements of Income for the years ended December 31, 2018, 2017 and 2016, respectively. The amounts adjusted were primarily for additional positions identified for elimination, partially offset by employees finding other positions within Bio-Rad or leaving prematurely.

The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions):

 
 
2018
 
2017
 
 
Life Science
 
Clinical Diagnostics
 
Total
 
Life Science
 
Clinical Diagnostics
 
Total
Balance as of January 1
 
$
2.2

 
$
4.1

 
$
6.3

 
$
3.2

 
$
5.8

 
$
9.0

Adjustment to expense
 
(0.1
)
 
(0.1
)
 
(0.2
)
 
0.2

 
0.3

 
0.5

Cash payments
 
(1.5
)
 
(2.9
)
 
(4.4
)
 
(1.5
)
 
(2.7
)
 
(4.2
)
Foreign currency translation (gains) losses
 
—

 
(0.1
)
 
(0.1
)
 
0.3

 
0.7

 
1.0

Balance as of December 31
 
$
0.6

 
$
1.0

 
$
1.6

 
$
2.2

 
$
4.1

 
$
6.3




Restructuring Costs for Termination of a Diagnostics Research and Development Project and Facility Closures

In December 2017, we announced the termination of a diagnostics research and development project in Europe. From December 2017 to December 31, 2018, total expenses were $21.4 million. We recorded restructuring charges and adjustments related to severance and employee benefits of $0.4 million and $11.0 million, and asset write-offs and exit costs of $(0.1) million and $10.1 million for the years ended December 31, 2018 and 2017, respectively.

In June 2018, we announced the closure of a small manufacturing operation in Munich, Germany. We recorded $1.7 million of expense in restructuring charges related to severance and employee benefits for the year ended December 31, 2018.

In December 2018, we announced the closure of a small manufacturing facility outside Paris, France. We recorded restructuring charges related to severance and employee benefits of $3.9 million and exit costs of $0.2 million for the year ended December 31, 2018.

Restructuring charges for the termination of a diagnostics research and development project and the facility closures are all included in our Clinical Diagnostics segment's results of operations. The facility closures are a natural evolution from the larger consolidations that began with the 2016 European reorganization activities described above. The amounts recorded were reflected in Cost of goods sold of $5.4 million and $2.3 million, in Selling, general and administrative expense of $0.4 million and $3.3 million, and in Research and development expense of $0.3 million and $15.5 million in the Consolidated Statements of Income for the years ended December 31, 2018 and 2017, respectively. The liability of $11.5 million as of December 31, 2018 consisted of $7.3 million recorded in Accrued payroll and employee benefits, and $4.2 million recorded in Other long-term liabilities in the Consolidated Balance Sheets.

The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closures restructuring reserves for severance and exit costs (in millions):

 
 
2018
 
2017
Balance as of January 1
 
$
14.1

 
$
—

Charged to expense
 
5.8

 
14.0

Adjustment to expense
 
0.3

 
—

Cash payments
 
(8.4
)
 
—

Foreign currency translation (gains) losses
 
(0.3
)
 
0.1

Balance as of December 31
 
$
11.5

 
$
14.1



Restructuring Costs for GnuBIO, Inc.

In 2014, we acquired GnuBIO, Inc. (GnuBIO) as a business acquisition. It was included in our Clinical Diagnostics segment’s results of operations as a division, and was primarily based in Massachusetts. In September 2017, we announced that we were closing the GnuBIO research program facilities in Massachusetts. We recorded restructuring charges in September 2017 related to severance and employee benefits of $2.9 million and asset write-offs of $5.5 million. The amounts recorded were reflected in Selling, general and administrative expense of $0.8 million and in Research and development expense of $7.6 million in the Consolidated Statements of Income for the year ended December 31, 2017. The liability balance as of December 31, 2017 was $1.4 million and was recorded in Accrued payroll and employee benefits in the Consolidated Balance Sheets. The liability was paid in early 2018.
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.19.1
16. Quarterly Financial Data
 12 Months Ended
Dec. 31, 2018
Quarterly Financial Data [Abstract]  
Quarterly Financial Data [Text Block] 16. QUARTERLY FINANCIAL DATA (UNAUDITED)

Summarized quarterly financial data for 2018 and 2017 are as follows (in millions, except per share data):

 
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
2018
 
 
 
 
 
 
 
 
Net sales
 
$
551.5

 
$
575.9

 
$
545.1

 
$
616.9

Gross profit
 
302.2

 
301.7

 
286.7

 
332.6

Net income (loss)
 
656.8

 
268.0

 
269.3

 
(828.5
)
Basic earnings (loss) per share
 
$
22.05

 
$
8.99

 
$
9.02

 
$
(27.73
)
Diluted earnings (loss) per share
 
$
21.77

 
$
8.87

 
$
8.89

 
$
(27.73
)
 
 
 
 
 
 
 
 
 
2017
 
 
 
 
 
 
 
 
Net sales
 
$
500.1

 
$
504.7

 
$
534.1

 
$
621.3

Gross profit
 
270.1

 
273.4

 
299.0

 
345.2

Net income
 
12.4

 
5.0

 
22.1

 
82.7

Basic earnings per share
 
$
0.42

 
$
0.17

 
$
0.74

 
$
2.78

Diluted earnings per share
 
$
0.41

 
$
0.17

 
$
0.73

 
$
2.75



As a result of the net loss for the three months ended December 31, 2018, all potentially issuable common shares have been excluded from the diluted shares used in the computation of earnings per share as their effect was anti-dilutive. The net loss for the three months ended December 31, 2018 was primarily due to an $814.1 million decrease in fair market value of equity securities, primarily due to the adoption of ASU 2016-01 (see Note 1 to the consolidated financial statements) and mostly consisted of holding losses on our investment in Sartorius AG. The net loss for the three months ended December 31, 2018 also included impairment losses on goodwill and long-lived assets in the amount of $292.5 million (see Note 4 to the consolidated financial statements).

Prior year amounts have been adjusted (see Note 1 to the consolidated financial statements in regard to ASU 2017-07) for pension and other postretirement benefits.
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.19.1
Schedule II - Valuation and Qualifying Accoutns
 12 Months Ended
Dec. 31, 2018
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]  
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] BIO-RAD LABORATORIES, INC.
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
Years Ended December 31, 2018, 2017, and 2016
(in thousands)


Allowance for doubtful accounts receivable
 
 
Balance at
Beginning
of Year
 

Charged to Costs
and Expenses
 
Deductions
 
Balance at
End of Year
2018
 
$
25,549

 
$
11,527

 
$
(10,363
)
 
$
26,713

2017
 
$
23,367

 
$
11,174

 
$
(8,992
)
 
$
25,549

2016
 
$
24,418

 
$
3,785

 
$
(4,836
)
 
$
23,367



Valuation allowance for long-term deferred tax assets
 
 
Balance at
Beginning
of Year
 
Additions Charged
(Credited) to Income
Tax Expense
 
Deductions
 
Balance at 
End of Year 
2018
 
$
66,356

 
$
4,413

 
$
—

 
$
70,769

2017
 
$
66,403

 
$
(47
)
 
$
—

 
$
66,356

2016
 
$
58,277

 
$
8,126

 
$
—

 
$
66,403
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.19.1
17. Subsequent Event (Notes)
 12 Months Ended
Dec. 31, 2018
Subsequent Events [Abstract]  
Subsequent Events [Text Block] 17. SUBSEQUENT EVENT

On March 4, 2019, we acquired all the issued and outstanding stock of a small commercial-stage company for approximately $20 million. We believe this acquisition will complement our offerings of life science products. The acquisition will be included in our Life Science segment's results of operations from the acquisition date and will be accounted for as a business acquisition. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process.

We are presently unable to report the purchase price allocation or the evaluation of the transaction, as more time is needed to complete the information transfer from the seller and include all information into a valuation of individual assets and liabilities.
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.19.1
1. Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
Basis of Presentation Basis of Presentation

The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions.
Cash and Cash Equivalents Cash and Cash Equivalents

Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair value.
Short-term Restricted Investments [Policy Text Block] Short-term Restricted Investments

Short-term restricted investments of $5.6 million at both December 31, 2018 and 2017 represent a money market fund that is renewed annually for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets.
Available-for-sale Investments Available-for-Sale Investments

Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities.  Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date.  Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations.  Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data.  Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect.  Effective January 1, 2018, changes in fair value for equity securities are reported in Change in fair market value of equity securities in the Consolidated Statements of Income due to the adoption of ASU 2016-01 (see Recent Accounting Pronouncement Adopted at the end of this Note and Note 3). Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary.  We review our available-for-sale debt securities for other-than-temporary losses on a quarterly basis.  Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10).
Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk

Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable.  Cash and cash equivalents and investments are placed with various highly rated major financial institutions located in different geographic regions.

The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements.  We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions.  In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end.  

We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral.  As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers.  Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.
Accounts Receivable Accounts Receivable

We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance.
Inventory Inventory

Inventories are valued at the lower of cost and net realizable value and include material, labor and overhead costs. The first-in, first-out method is used to relieve inventory for products sold.
Property, Plant and Equipment Property, Plant and Equipment

Property, plant and equipment are carried at cost, less accumulated depreciation and amortization.  Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  The estimated useful lives of property, plant and equipment are generally as follows: buildings and leasehold improvements, 15-39 years or the term of the leases or life of the improvements, whichever is shorter; reagent rental equipment, 1-5 years; equipment and capitalized software, 3-12 years.
Goodwill Goodwill

Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses.  Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating segments.  Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management.  Goodwill amounts are assigned to reporting units at the time of acquisition.

Effective January 1, 2017 in accordance with Accounting Standards Update No. 2017-04, "Simplifying the Test for Goodwill Impairment," the goodwill impairment amount will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit.  

Prior to January 1, 2017, the goodwill impairment test consisted of a two-step process.  The first step of the goodwill impairment test, used to identify potential impairment, compared the fair value of a reporting unit to its carrying value, including goodwill. We used a projected discounted cash flow model to determine the fair value of a reporting unit.  If the fair value of the reporting unit exceeded its carrying amount, goodwill of the reporting unit was considered not impaired, and the second step of the impairment test was not required.  The second step, if required, compared the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit was allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit.  If the carrying amount of the reporting unit’s goodwill exceeded its implied fair value, an impairment charge is recognized in an amount equal to that excess.
Long-Lived Assets Long-Lived Assets

For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.  We assess the impairment of long-lived assets (including identifiable intangible assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors that we consider important that could trigger an impairment review include:

•
significant under-performance relative to expected, historical or projected future operating results;
•
significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;
•
a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and
•
significant negative industry, legal, regulatory or economic trends.

When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method.  Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets.  We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If this is the case, an impairment loss would be recognized.  The impairment loss recognized is the amount by which the carrying amount exceeds the fair value.
Income Taxes Income Taxes
 
We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We record deferred tax assets to the extent we believe these assets will more likely than not be realized.  In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. To the extent we determine that we are able to realize our deferred income tax assets in the future in excess of their net recorded amount, we make an adjustment to the valuation allowance which may reduce the provision for income taxes. When we establish or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes.

On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The new legislation contains significant tax provisions that affect us, including a one-time mandatory deemed repatriation tax on certain unrepatriated foreign earnings ("Transition Tax"), a reduction of the corporate income tax rate from 35% to 21% effective January 1, 2018, and a change from a worldwide tax system to a modified territorial system.

We are required to recognize the effect of the tax law changes in the period of enactment, such as the computation of the Transition Tax, remeasurement of our U.S. federal deferred tax assets and liabilities, as well as reassessment of the net realizability of our deferred tax assets and liabilities.

Subsequent to the enactment of the Tax Act, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act ("SAB 118"), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under Accounting Standards Codification ("ASC") 740, "Income Taxes." We have completed the accounting for the income tax effects of the Tax Act, under SAB 118, as of December 31, 2018. As noted in our 2017 Annual Report, we were able to make reasonable estimates and provisionally recorded an income tax benefit of $70 million related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. The final accounting for the Tax Act resulted in an additional income tax benefit of $49 million for a final income tax benefit of $119 million. This is comprised of $169 million tax benefit related to the remeasurement of U.S. federal deferred tax assets and liabilities, offset by a $50 million tax detriment for the Transition Tax. We elected to account for the tax effect of the Global Intangible Low-Taxed Income (“GILTI”) in the period in which it is incurred.

During the fourth quarter of 2017, we early adopted ASU 2018-02, "Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income." With respect to stranded income tax effects in accumulated other comprehensive income, our policy is to use the portfolio method to reclassify such amounts.
Revenue Recognition Revenue Recognition

On January 1, 2018, we adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018.  Results for reporting periods beginning on January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under prior revenue guidance ASC 605, "Revenue Recognition."

We recorded a net reduction to opening retained earnings of $0.1 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. The impact to revenue as a result of applying ASC 606 as compared to ASC 605 for 2018 was not significant.

We recognize revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.
Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service.
At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced to the estimated amount that we expect to receive in exchange for transferring control for those products.
Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, transaction prices are allocated to performance obligations based on stand-alone selling prices. The method used to determine the stand-alone selling prices for service revenues is based on the observable prices when the services have been sold separately.
In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.
We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less and for contracts in which we recognize revenue at the amount to which we have the right to invoice for services performed. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.

Reagent Rental Agreements
Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. We concluded that the use of the instrument and related maintenance services (collectively known as “lease elements”) are not within the guidance of ASC 606 but rather ASC 840 Leases. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and requires consideration of any fixed/minimum payments as well as estimates of variable consideration. After determining what portion of the transaction price should be allocated to the lease elements, any fixed consideration would be considered the minimum lease payment to be amortized straight line over the lease term and any variable consideration would be contingent rent to be recognized monthly as earned, which coincides with the transfer of control of the non-lease elements.
For the portion of the transaction price allocated to the non-lease elements, which are principally the reagents, the related revenue will be recognized at a point in time when control transfers. Generally, the terms of the arrangements result in the transfer of control upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer.
Revenue allocated to the lease elements of these reagent rental arrangements represents approximately 5% of total revenue and are included as part of the Net sales in our Consolidated Statements of Income.
Contract costs:
As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities.
Disaggregation of Revenue:
The disaggregation of our revenue by geographic region based primarily on the location of the use of the product service, and by industry segment sources, and the disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 14).

Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are generally recognized ratably over the term of the service contract as our performance extends over the life of the arrangement. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from $36.7 million at December 31, 2017 to $37.3 million at December 31, 2018 is primarily driven by $28.0 million, net, of cash payments received or due in advance of satisfying our performance obligations, partially offset by $27.4 million of revenue recognized that were included in our deferred revenue balance as of December 31, 2017.
Warranty
 
 
2018
 
2017
January 1
 
$
18.7

 
$
17.6

Provision for warranty
 
25.5

 
29.9

Actual warranty costs
 
(34.1
)
 
(28.8
)
December 31
 
$
10.1

 
$
18.7
Shipping and Handling Shipping and Handling

We classify all freight costs billed to customers as Net sales.  Related freight costs are recognized upon transfer of control of the promised products to customers as a fulfillment cost and included in Cost of goods sold.
Research and Development Expense, Policy [Policy Text Block]
Research and Development

Internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed.

We conduct extensive research and development activities in all areas of our business, employing approximately 800 employees worldwide in these activities, including degreed scientists and technical support staff.  Research and development has played a major role in Bio-Rad’s growth and is expected to continue to do so in the future.  Our research teams are continuously developing new products and new applications for existing products.  In our development of new products and applications, we interact with scientific and medical professionals at universities, hospitals and medical schools, and within our industry.  
Foreign Currency
Foreign Currency

Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period.  Income statement items are translated at average exchange rates for the period.  The resulting translation adjustments are recorded as a separate component of stockholders’ equity.

Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income.  Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction.
Forward Foreign Exchange Contracts

Forward Foreign Exchange Contracts

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.  
Share-based Compensation Plans
Share-Based Compensation Plans

Share-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value.  We recognize these compensation costs net of forfeitures over the requisite service period of the award, which is generally the vesting term of the share-based payment awards.  Starting in 2017, we recognize forfeitures as they occur due to a change in accounting principle, and in prior periods we estimated the forfeiture rate based on our historical experience.  These plans are described more fully in Note 9.
Earnings Per Share

Earnings Per Share

Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):
 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
Basic weighted average shares outstanding
 
29,836

 
29,655

 
29,440

Effect of potentially dilutive stock options
 
 
 
 
 
 
    and restricted stock awards
 
392

 
379

 
206

Diluted weighted average common shares
 
30,228

 
30,034

 
29,646

Anti-dilutive stock options and restricted stock awards
 
 
 
 
 
 
    excluded from the computation of diluted EPS
 
84

 
13

 
113
Fair Value of Financial Instruments
Fair Value of Financial Instruments

For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value.

The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3).
New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Adopted

In February 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. ("ASU") 2018-03, "Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities." ASU 2018-03 amends certain items in ASU 2016-01 (see below) such as equity securities without a readily determinable fair value. ASU 2018-03 clarifies that an entity that uses the measurement alternative for equity securities without readily determinable fair values can change its measurement approach to fair value and once made the election is irrevocable. If an entity measures equity securities without readily determinable fair values at fair value, it must record a cumulative-effect adjustment to
Retained earnings as of the beginning of the fiscal year in which the guidance is adopted. We adopted ASU 2018-03 on January 1, 2018 and made an irrevocable election to account for our investment of the ordinary shares of Sartorius AG at fair value (see ASU 2016-01 below).

In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. Changes in fair value for equity securities will no longer be reported in other comprehensive income. For equity investments without readily determinable fair values, the cost method is also eliminated. We adopted ASU 2016-01 on January 1, 2018 and record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes and were valued at $0.6 million as of December 31, 2018. Changes in the basis of these equity investments are reported in current earnings. For equity securities that are affected by ASU 2016-01 and ASU 2018-03, see Note 3 to the consolidated financial statements, which primarily consists of our investment in Sartorius AG.

The impact of the adoption of ASU 2016-01 and ASU 2018-03 on January 1, 2018 was through a cumulative-effect adjustment of $864.5 million to Total stockholders' equity by increasing Retained earnings of $1,543.7 million and decreasing Accumulated other comprehensive income of $679.2 million, including an increase in Deferred income taxes of $232.9 million and an increase in Other investments of $1,097.4 million in our Consolidated Balance Sheet. As a result of ASU 2016-01 and ASU 2018-03 for 2018, we recorded a gain of $606.2 million for the Change in fair market value of equity securities in the Consolidated Statement of Income that resulted in a deferred tax expense of $133.9 million.

In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost," which changed how we present the net periodic benefit cost of our defined benefit pension and/or other postretirement plans. We adopted ASU 2017-07 on January 1, 2018 and applied the practical expedient to estimate amounts for comparative purposes utilizing the information disclosed in Note 12 to the consolidated financial statements in our Form 10-K for the year ended December 31, 2017. The interest costs are recorded in Interest expense, and the other costs are recorded in Other (income) expense, net in the Consolidated Statements of Income. For 2017 for interest costs and other costs, we reclassified $0.304 million, $2.152 million, and $0.144 million from Cost of goods sold (COGS), Selling, general and administrative expense (SG&A) and Research and Development expense (R&D), respectively, to Interest expense of $1.1 million and Other (income) expense, net of $1.5 million. For 2016 for interest costs and other costs, we reclassified $0.341 million, $2.027 million and $0.156 million from COGS, SG&A and R&D, respectively, to Interest expense of $1.438 million and Other (income) expense, net of $1.086 million.

In November 2016, the FASB issued ASU 2016-18, "Restricted Cash," which required us to cease to present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. We adopted ASU 2016-18 on January 1, 2018 and updated the Consolidated Statements of Cash Flows to incorporate restricted cash included in Other current assets and Other assets of $2.6 million as of December 31, 2018 and $1.2 million as of December 31, 2017.

In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory," which required immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  We adopted ASU 2016-16 on January 1, 2018 on a modified retrospective basis through a cumulative-effect adjustment by decreasing Retained earnings by $17.6 million, and decreasing Prepaid taxes by $22.8 million and increasing Deferred tax assets by $5.2 million that are both recorded in Other assets in our Consolidated Balance Sheet.

In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments" and adopted it on January 1, 2018, which did not have an impact to our statement of cash flows presentation.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers ("ASC 606"), an updated standard on revenue recognition. The new standard provides enhancements to the quality and consistency of how revenue is reported under the principle that revenue should be recognized in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of promised goods or services. We adopted ASC 606 as of January 1, 2018 using the cumulative effect transition method as more fully described above under the caption “Revenue Recognition.”

Recent Accounting Pronouncements to be Adopted

In November 2018, the FASB issued ASU 2018-18, "Clarifying the Interaction between Topic 808 and Topic 606." Topic 808 is Collaborative Arrangements, and Topic 606 is Revenue from Contracts with Customers. ASU 2018-18 clarifies that certain transactions between collaborative partners should be accounted for as revenue under ASC 606 when the collaborative partner is a customer. We currently do not have any customers that are collaborative partners or anticipate any in the near future. ASU 2018-18 will be effective January 1, 2020 and we will not early adopt.

In August 2018, the FASB issued ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract." ASU 2018-15 amends the definition of a hosting arrangement and requires a customer in a hosting arrangement that is a service contract to capitalize certain implementation costs as if the arrangement was an internal-use software project. The internal-use software guidance states that only qualifying costs incurred during the application development stage can be capitalized. We will prospectively adopt ASU 2018-15 effective January 1, 2019. We do not expect ASU 2018-15 to have a material impact to our consolidated financial statements.

In August 2018, the FASB issued ASU 2018-14, "Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." ASU 2018-14 eliminates and adds certain disclosures for defined benefit plans. ASU 2018-14 is effective for fiscal years ending after December 15, 2020 using a retrospective approach, with early adoption permitted. We are currently evaluating the disclosures and the timing of adoption but do not expect ASU 2018-14 to have a material impact to our disclosures for defined benefit plans.

In August 2018, the FASB issued ASU 2018-13, "Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement." ASU 2018-13 eliminates, adds and modifies certain disclosures for fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. Early adoption is permitted in interim periods, including periods for which financial statements have not yet been issued. We do not expect ASU 2018-13 to have a material impact to our fair value disclosures and we currently do not plan to early adopt.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. In November 2018, the FASB issued ASU 2018-19, "Codification Improvements to Topic 326, Financial Instruments-Credit Losses," which clarifies that receivables arising from operating leases are not within the scope of Topic 326. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, "Leases," and related accounting standard updates, which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. We will adopt ASU 2016-02 on a modified retrospective basis effective January 1, 2019 with practical expedients, and will not restate comparative prior periods. The practical expedients, include, among other items, for leases that existed prior January 1, 2019, to not reassess whether any contracts are or contain embedded leases, reassessing the classification of existing leases, and reassessing whether previously capitalized initial direct costs qualify for capitalization. Where we act as a lessee, we also elected not to separate lease and non-lease components. Where we act as a lessor in our reagent rental arrangements, we allocate the consideration in the contract to the separate lease components and the non-lease components. After the allocation, the amount of variable payments allocated to lease components will be recognized as income in accordance with the new lease accounting standard updates, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Such reagent rental arrangements are more fully described above under the caption "Reagent Rental Agreements." Where we act as a lessee, the adoption of the standard will result in material additions to the balance sheet for right-of-use assets and the associated liabilities. We will complete our review of the completeness and accuracy of the lease data, discount rate and finalize our updated controls in accordance with the new standard during the first quarter of 2019. Where we act as a lessor in reagent rental arrangements, we estimate an insignificant impact to our consolidated financial statements.
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.19.1
1. Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
Schedule of Product Warranty Liability We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.

Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Consolidated Balance Sheets, were as follows (in millions):

 
 
2018
 
2017
January 1
 
$
18.7

 
$
17.6

Provision for warranty
 
25.5

 
29.9

Actual warranty costs
 
(34.1
)
 
(28.8
)
December 31
 
$
10.1

 
$
18.7
Schedule of Weighted Average Number of Shares
The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):
 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
Basic weighted average shares outstanding
 
29,836

 
29,655

 
29,440

Effect of potentially dilutive stock options
 
 
 
 
 
 
    and restricted stock awards
 
392

 
379

 
206

Diluted weighted average common shares
 
30,228

 
30,034

 
29,646

Anti-dilutive stock options and restricted stock awards
 
 
 
 
 
 
    excluded from the computation of diluted EPS
 
84

 
13

 
113
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.19.1
3. Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2018
Fair Value Disclosures [Abstract]  
Debt Securities, Available-for-sale [Table Text Block] Available-for-sale investments consist of the following (in millions):

 
December 31, 2018
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
216.2

 
$
0.1

 
$
(1.3
)
 
$
215.0

Municipal obligations
11.1

 
—

 
(0.1
)
 
11.0

Asset-backed securities
63.5

 
—

 
(0.4
)
 
63.1

U.S. government sponsored agencies
80.9

 
0.2

 
(0.8
)
 
80.3

Foreign government obligations
3.6

 
—

 
—

 
3.6

 
375.3

 
0.3

 
(2.6
)
 
373.0

Long-term investments:
 
 
 
 
 
 
 
Asset-backed securities
0.2

 
—

 
—

 
0.2

 
0.2

 
—

 
—

 
0.2

Total
$
375.5

 
$
0.3

 
$
(2.6
)
 
$
373.2
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] conciliation of the Level 3 analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value (in millions):

 
2018
 
 
January 1
$
16.7

Payment of sales milestone
(2.1
)
Net decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense
(6.2
)
December 31
$
8.4



The following table provides q
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] ntitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of December 31, 2018. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.
 
Valuation Technique
Unobservable Input
Percentage
Analytical flow cytometer platform
Probability-weighted income approach
Sales milestones:
 
 
 
Discount rate
11.0
%
 
 
Cost of debt
5.1
%
Schedule of Derivative Instruments [Table Text Block] The following is a summary of our forward foreign currency exchange contracts (in millions):
 
December 31,
 
2018
Contracts maturing in January through March 2019 to sell foreign currency:
 
Notional value
$
50.6

Unrealized gain
$
0.2

Contracts maturing in January through March 2019 to purchase foreign currency:
 
Notional value
$
284.5

Unrealized loss
$
(0.5
)
Financial assets and liabilities carried at fair value on a recurring basis Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2018 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents (a):
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
77.8

 
$
—

 
$
77.8

Time deposits
22.7

 
10.0

 
—

 
32.7

Asset-backed securities
—

 
0.3

 
—

 
0.3

Money market funds
36.9

 
—

 
—

 
36.9

Total cash equivalents
59.6

 
88.1

 
—

 
147.7

Restricted investment
5.6

 
—

 
—

 
5.6

Equity Securities (b)
2,672.9

 
—

 
—

 
2,672.9

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
215.0

 
—

 
215.0

U.S. government sponsored agencies
—

 
80.3

 
—

 
80.3

Foreign government obligations
—

 
3.6

 
—

 
3.6

Municipal obligations
—

 
11.0

 
—

 
11.0

Asset-backed securities
—

 
63.3

 
—

 
63.3

Total available-for-sale investments (c)
—

 
373.2

 
—

 
373.2

Forward foreign exchange contracts (d)
—

 
0.6

 
—

 
0.6

Total financial assets carried at fair value
$
2,738.1

 
$
461.9

 
$
—

 
$
3,200.0

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
     Forward foreign exchange contracts (e)
$
—

 
$
0.7

 
$
—

 
$
0.7

     Contingent consideration (f)
—

 
—

 
8.4

 
8.4

Total financial liabilities carried at fair value
$
—

 
$
0.7

 
$
8.4

 
$
9.1


As of first quarter 2018, our equity securities are no longer reported as Available-for-sale investments due to the implementation of ASU 2016-01. Changes in fair value of equity securities are now reported on the Consolidated Statements of Income rather than Other Comprehensive Income (see Note 1).

Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2017 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents (a):
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
36.0

 
—

 
$
36.0

Time deposits
43.7

 
10.0

 
—

 
53.7

U.S. government sponsored agencies
—

 
11.2

 
—

 
11.2

Money market funds
3.4

 
—

 
—

 
3.4

Total cash equivalents
47.1

 
57.2

 
—

 
104.3

Restricted investment:
5.6

 
—

 
—

 
5.6

Available-for-sale investments (c):
 
 
 
 
 
 
 
Corporate debt securities
—

 
185.7

 
—

 
185.7

U.S. government sponsored agencies
—

 
67.6

 
—

 
67.6

Foreign government obligations
—

 
3.4

 
—

 
3.4

Brokered certificates of deposit
—

 
0.7

 
—

 
0.7

Municipal obligations
—

 
15.0

 
—

 
15.0

Marketable equity securities
973.4

 
—

 
—

 
973.4

Asset-backed securities
—

 
55.6

 
—

 
55.6

Total available-for-sale investments
973.4

 
328.0

 
—

 
1,301.4

Forward foreign exchange contracts (d)
—

 
0.5

 
—

 
0.5

Total financial assets carried at fair value
$
1,026.1

 
$
385.7

 
—

 
$
1,411.8

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (e)
$
—

 
$
1.6

 
—

 
$
1.6

 Contingent consideration (f)
—

 
—

 
16.7

 
16.7

Total financial liabilities carried at fair value
$
—

 
$
1.6

 
$
16.7

 
$
18.3


(a)
Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.

(b)
Equity securities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2018
Short-term investments
$
40.2

Other investments
2,632.7

        Total
$
2,672.9



The unrealized gains on our equity securities still held as of December 31, 2018 are $607.7 million and are primarily due to our investment in Sartorius AG and is recorded in our Consolidated Statements of Income due to the adoption of ASU 2016-01 (see Note 1).

(c)
Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31,
2018
 
December 31, 2017
 
 
 
 
Short-term investments
$
373.0

 
$
371.2

Other investments
0.2

 
930.2

Total
$
373.2

 
$
1,301.4



In accordance with our adoption of ASU 2016-01 January 1, 2018, our investment in Sartorius AG preferred shares, which was reported within marketable equity securities as Available-for-sale as of December 31, 2017, is now reported as an Equity security as of December 31, 2018 (see Note 1 and footnote (b) above).


(d)
Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.

(e)
Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.

(f)
Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2018
 
December 31, 2017
 
 
 
 
Other current liabilities
$
3.2

 
$
2.7

Other long-term liabilities
5.2

 
14.0

   Total
$
8.4

 
$
16.7
Schedule of available-for-sale investments Available-for-sale investments consist of the following (in millions):



 
December 31, 2017
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
185.9

 
$
0.3

 
$
(0.5
)
 
$
185.7

Brokered certificates of deposit
0.7

 
—

 
—

 
$
0.7

Municipal obligations
15.1

 
—

 
(0.1
)
 
15.0

Asset-backed securities
55.6

 
—

 
(0.2
)
 
55.4

U.S. government sponsored agencies
68.3

 
—

 
(0.7
)
 
67.6

Foreign government obligations
3.4

 
—

 
—

 
3.4

Marketable equity securities
34.4

 
9.0

 
—

 
43.4

 
363.4

 
9.3

 
(1.5
)
 
371.2

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
875.5

 
—

 
930.0

Asset-backed securities
0.2

 
—

 
—

 
0.2

 
54.7

 
875.5

 
—

 
930.2

Total
$
418.1

 
$
884.8

 
$
(1.5
)
 
$
1,301.4
Summary of investments with gross unrealized losses and the associated fair value The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):

 
December 31,
2018
 
December 31, 2017
 
 
 
 
Fair value of investments in a loss position 12 months or more
$
117.9

 
$
43.9

Fair value of investments in a loss position less than 12 months
$
193.0

 
$
168.7

Gross unrealized losses for investments in a loss position 12 months or more
$
1.8

 
$
0.7

Gross unrealized losses for investments in a loss position less than 12 months
$
0.8

 
$
0.8
Summary of amortized cost and estimated fair value of debt securities by contractual maturity date The following is a summary of the amortized cost and estimated fair value of our debt securities at December 31, 2018 by contractual maturity date (in millions):

 
Amortized
Cost
 
Estimated Fair
Value
Mature in less than one year
$
155.5

 
$
155.2

Mature in one to five years
172.4

 
171.3

Mature in more than five years
47.6

 
46.7

Total
$
375.5

 
$
373.2
Estimated fair value of financial instruments The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):


 
December 31, 2018
 
December 31, 2017
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
Other investments
$
—

 
$
—

 
 
 
$
91.8

 
$
1,249.4

 
2
Total long-term debt, excluding leases
and current maturities
$
423.7

 
$
435.8

 
2
 
$
423.1

 
$
449.8

 
2
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.19.1
4. Intangible Assets, Goodwill and Other (Tables)
 12 Months Ended
Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes to goodwill by segment
Changes to goodwill by segment were as follows (in millions):
 
 
2018
 
 
2017
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
Balances as of January 1:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
$
234.7

 
$
324.6

 
$
559.3

 
 
$
207.1

 
$
311.7

 
$
518.8

Accumulated impairment losses and write-offs
 
(35.9
)
 
(17.3
)
 
(53.2
)
 
 
(27.2
)
 
(14.5
)
 
(41.7
)
Goodwill, net
 
198.8

 
307.3

 
506.1

 
 
179.9

 
297.2

 
477.1

Acquisitions
 
—

 
—

 
—

 
 
26.2

 
—

 
26.2

Divestiture
 
—

 
(1.4
)
 
(1.4
)
 
 
—

 
—

 
—

Impairment
 
(5.9
)
 
(276.1
)
 
(282.0
)
 
 
(8.7
)
 
(2.8
)
 
(11.5
)
Currency fluctuations
 
(0.2
)
 
(2.7
)
 
(2.9
)
 
 
1.4

 
12.9

 
14.3

Balances as of December 31:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
234.5

 
320.5

 
555.0

 
 
234.7

 
324.6

 
559.3

Accumulated impairment losses and write-offs
 
(41.8
)
 
(293.4
)
 
(335.2
)
 
 
(35.9
)
 
(17.3
)
 
(53.2
)
Goodwill, net
 
$
192.7

 
$
27.1

 
$
219.8

 
 
$
198.8

 
$
307.3

 
$
506.1
Schedule of Finite-Lived Intangible Assets by Major-Class Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):
 
December 31, 2018
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-6
 
$
88.7

 
$
(68.3
)
 
$
20.4

Know how
1-7
 
190.6

 
(159.8
)
 
30.8

Developed product technology
1-10
 
130.4

 
(86.6
)
 
43.8

Licenses
7-11
 
76.3

 
(40.9
)
 
35.4

Tradenames
2-6
 
3.9

 
(3.3
)
 
0.6

Covenants not to compete
7
 
3.2

 
(1.1
)
 
2.1

     Total definite-lived intangible assets
 
 
$
493.1

 
$
(360.0
)
 
$
133.1


 
December 31, 2017
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-7
 
$
92.3

 
$
(64.4
)
 
$
27.9

Know how
1-8
 
194.9

 
(157.9
)
 
37.0

Developed product technology
1-12
 
133.3

 
(70.3
)
 
63.0

Licenses
1-12
 
76.7

 
(36.0
)
 
40.7

Tradenames
1-6
 
3.9

 
(3.0
)
 
0.9

Covenants not to compete
1-8
 
7.9

 
(3.3
)
 
4.6

     Total definite-lived intangible assets
 
 
$
509.0

 
$
(334.9
)
 
$
174.1
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.19.1
5. Notes Payable and Long-Term Debt (Tables)
 12 Months Ended
Dec. 31, 2018
Debt Disclosure [Abstract]  
Principal components of long-term debt [Table Text Block] The principal components of long-term debt are as follows (in millions):
 
December 31, 2018
 
December 31, 2017
 
 
 
 
4.875% Senior Notes due 2020, net of discount
$
425.0

 
$
425.0

Less unamortized discount and debt issuance costs
(1.3
)
 
(1.9
)
Long-term debt less unamortized discount and debt issuance costs
423.7

 
423.1

Capital leases and other debt
15.7

 
11.9

 
439.4

 
435.0

Less current maturities
(0.5
)
 
(0.4
)
Long-term debt
$
438.9

 
$
434.6
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.19.1
6. Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2018
Income Tax Disclosure [Abstract]  
U.S. and international components of income before taxes [Table Text Block] The U.S. and international components of income before taxes are as follows (in millions):

 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
U.S.
 
$
363.4

 
$
72.8

 
$
(38.5
)
International
 
149.3

 
25.0

 
80.1

Income before taxes
 
$
512.7

 
$
97.8

 
$
41.6
Provision for income taxes [Table Text Block] The provision for income taxes consists of the following (in millions):

 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
Current tax expense:
 
 

 
 

 
 

U.S. Federal
 
$
8.8

 
$
6.7

 
$
16.1

State
 
2.2

 
3.4

 
3.1

International
 
30.5

 
32.0

 
30.4

Current tax expense
 
41.5

 
42.1

 
49.6

Deferred tax expense (benefit):
 
 

 
 
 
 

U.S. Federal
 
114.0

 
(69.8
)
 
(42.4
)
State
 
6.6

 
4.3

 
(2.8
)
International
 
0.3

 
(19.3
)
 
(6.0
)
Deferred tax expense (benefit)
 
120.9

 
(84.8
)
 
(51.2
)
Non-current tax (benefit) expense
 
(15.4
)
 
18.3

 
17.2

Provision for (benefit from) income taxes
 
$
147.0

 
$
(24.4
)
 
$
15.6
Reconcilation of effective tax rate on inocme before taxes and statutory rate [Table Text Block] The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:

 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
U. S. statutory tax rate
 
21
 %
 
35
 %
 
35
 %
Impact of foreign operations
 
(4
)
 
6

 
(15
)
Foreign dividends, net
 
—

 
—

 
(40
)
Research tax credits
 
(1
)
 
(4
)
 
(9
)
Nontaxable subsidies
 
—

 
(2
)
 
(4
)
Tax settlements and changes to unrecognized tax benefits
 
—

 
—

 
47

Goodwill impairment
 
6

 
1

 
11

Domestic manufacturing deduction
 
—

 
—

 
(4
)
Share-based compensation
 
(1
)
 
(5
)
 
3

Nondeductible executive compensation
 
—

 
2

 
3

Fines and penalties
 
—

 
—

 
2

Prior period adjustments
 
(1
)
 
—

 
4

U.S. taxation of foreign income
 
15

 
3

 
2

Acquisition-related
 
—

 
10

 
—

U.S. tax reform
 
(10
)
 
(71
)
 
—

State taxes
 
2

 
3

 
1

Other
 
2

 
(3
)
 
1

Provision for (benefit from) income taxes
 
29
 %
 
(25
)%
 
37
 %
Significant components of deferred tax assets and liabilities [Table Text Block] Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):

 
 
December 31,
 
 
2018
 
2017
Deferred tax assets:
 
 

 
 

Bad debt, inventory and warranty accruals
 
$
21.7

 
$
28.6

Other post-employment benefits, vacation and other reserves
 
23.0

 
24.0

Tax credit and net operating loss carryforwards
 
75.3

 
73.3

Other
 
27.1

 
19.7

    Total gross deferred tax assets
 
147.1

 
145.6

Valuation allowance
 
(70.8
)
 
(66.4
)
       Total deferred tax assets
 
76.3

 
79.2

Deferred tax liabilities:
 
 
 
 
Property and equipment
 
40.1

 
33.5

Investments and intangible assets
 
540.6

 
219.1

        Total deferred tax liabilities
 
580.7

 
252.6

Net deferred tax liabilities
 
$
(504.4
)
 
$
(173.4
)
Tabular reconcilation of total amounts of unrecognized tax benefits [Table Text Block]
The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):
 
 
2018
 
2017
 
2016
Unrecognized tax benefits – January 1
 
$
54.9

 
$
21.1

 
$
11.9

Additions to tax positions related to prior years
 
0.6

 
1.3

 
10.4

Reductions to tax positions related to prior years
 
(20.2
)
 
(1.0
)
 
—

Additions to tax positions related to the current year
 
4.6

 
34.8

 
3.4

Settlements
 
(6.8
)
 
(0.2
)
 
(2.4
)
Lapse of statute of limitations
 
(1.1
)
 
(3.4
)
 
(2.3
)
Currency translation
 
(2.2
)
 
2.3

 
0.1

Unrecognized tax benefits – December 31
 
$
29.8

 
$
54.9

 
$
21.1
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.19.1
7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables)
 12 Months Ended
Dec. 31, 2018
Class of Stock [Line Items]  
Schedule of Stock by Class [Table Text Block] Changes to Bio-Rad's issued common stock shares are as follows (in thousands):
 
Class A Shares
 
Class B Shares
Balance at January 1, 2016
24,230

 
5,131

B to A conversions
13

 
(13
)
Issuance of common stock
211

 
6

Balance at December 31, 2016
24,454

 
5,124

B to A conversions
34

 
(34
)
Issuance of common stock
191

 
18

Balance at December 31, 2017
24,679

 
5,108

B to A conversions
30

 
(30
)
Issuance of common stock
175

 
18

Balance at December 31, 2018
24,884

 
5,096
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.19.1
7. Stockholders' Equity Treasury Stock (Tables)
 12 Months Ended
Dec. 31, 2018
Equity, Class of Treasury Stock [Line Items]  
Treasury Stock [Text Block] Treasury Shares

In November, 2017, the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to $250.0 million of outstanding shares of our common stock. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. This new authorization superseded the prior authorization of up to $18.0 million of Bio-Rad's common stock and has no expiration. The share repurchase activity under the share repurchase program through open market transactions in 2017 and 2018 is summarized as follows:

 
Number of Shares Purchased
Weighted-Average Price per Share
Total Shares Repurchased To Date
Remaining Authorized Value
(in millions)
May 1, 2017 - May 31, 2017
2,500

$
220.02

3,539

$
2.7

June 1, 2017 - June 30, 2017
1,500

$
221.82

5,039

$
2.4

August 1, 2017 - August 31, 2017
9,200

$
221.45

14,239

$
0.4

November 1, 2018 - November 30, 2018
178,911

$
273.39

193,150

$
201.1


In September 2017, we used 12,740 of the repurchased shares in connection with the vesting of restricted stock units under the 2007 Incentive Award Plan in order to obtain a tax deduction in some of our foreign entities. The Credit Agreement may limit our ability to repurchase our stock.
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.19.1
8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables)
 12 Months Ended
Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Accumulated other comprehensive income (loss) included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions):
 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains (losses) on available-for-sale investments
Total Accumulated other comprehensive income (loss)
Balances as of January 1, 2017
$
1.3

$
(18.6
)
$
435.0

$
417.7

Other comprehensive income (loss), before reclassifications
76.1

(6.5
)
203.6

273.2

Amounts reclassified from Accumulated other comprehensive income
—

2.1

(0.1
)
2.0

Income tax effects
—

0.7

(74.9
)
(74.2
)
Effect of adoption of ASU 2018-02
—

—

120.1

120.1

Other comprehensive income (loss), net of income taxes
76.1

(3.7
)
248.7

321.1

Balances as of December 31, 2017
$
77.4

$
(22.3
)
$
683.7

$
738.8

Effect of adoption of ASU 2016-01 and 2018-03**
—

—

(679.3
)
(679.3
)
Balances as of January 1, 2018
$
77.4

$
(22.3
)
$
4.4

$
59.5

Other comprehensive (loss) income, before reclassifications
(112.9
)
6.9

(1.4
)
(107.4
)
Amounts reclassified from Accumulated other comprehensive income
—

2.4

0.3

2.7

Income tax effects
—

(1.8
)
—

(1.8
)
Other comprehensive (loss) income, net of income taxes
(112.9
)
7.5

(1.1
)
(106.5
)
Balances as of December 31, 2018
$
(35.5
)
$
(14.8
)
$
3.3

$
(47.0
)
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.19.1
8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)
 12 Months Ended
Dec. 31, 2018
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]  
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows:
 
 
 
December 31,
 
 
Components of Comprehensive income
 
2018
2017
 
Location
 
Amortization of foreign other post-employment benefit items
 
$
(2.4
)
$
(2.1
)
 
Selling, general and administrative expense
 
Net holding (losses) gains on equity securities and available for sale investments
 
$
(0.3
)
$
0.1

 
Other (income) expense, net
 

Reclassification adjustments are calculated using the specific identification method.
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.19.1
9. Share-based Compensation (Tables)
 12 Months Ended
Dec. 31, 2018
Share-based Compensation [Abstract]  
Stock Options Activity
Stock Options
The following table summarizes stock option activity:

 
 
Shares
 
Weighted-
Average
Exercise Price
 
Weighted-
Average
Remaining
Contractual
Term (in years)
 
Aggregate
Intrinsic
Value
(in millions)
Outstanding, December 31, 2017
 
407,480

 
$
120.39

 
 
 
 
Granted
 
33,000

 
$
326.15

 
 
 
 
Exercised
 
(44,600
)
 
$
93.63

 
 
 
 
Forfeited/expired
 
(22,240
)
 
$
169.93

 
 
 
 
Outstanding, December 31, 2018
 
373,640

 
$
138.81

 
4.90
 
$
38.0

 
 
 
 
 
 
 
 
 
Unvested, December 31, 2018
 
99,600

 
$
223.91

 
8.32
 
$
3.9

Exercisable, December 31, 2018
 
274,040

 
$
107.88

 
3.65
 
$
34.1
Stock Options Valuation Assumptions
The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:

 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
Expected volatility
 
22
%
 
20
%
 
21
%
Risk-free interest rate
 
2.85
%
 
1.87
%
 
1.35
%
Expected life (in years)
 
7.6

 
7.2

 
7.4

Expected dividend
 
—

 
—

 
—

Weighted-average fair value of options granted
 
$
105.94

 
$
58.65

 
$
42.40
Resticted Stock Activity
The following table summarizes restricted stock unit activity:
 
 

Restricted Stock
Units
 
Weighted-
Average
Grant-Date
Fair Value
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic Value
(in millions)
Outstanding, December 31, 2017
 
473,000

 
$
172.76

 
 
 
 
Granted
 
185,755

 
$
326.15

 
 
 
 
Vested
 
(128,294
)
 
$
158.49

 
 
 
 
Forfeited
 
(56,011
)

$
182.15

 
 
 
 
Outstanding, December 31, 2018
 
474,450

 
$
235.57

 
2.11
 
$
110.2
Employee Stock Purchase Plan, Valuation Assumptions The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions:

 
Year Ended December 31,
 
2018
 
 
 
2017
 
 
 
2016
Expected volatility
27
%
 
 
 
19
%
 
 
 
20
%
Risk-free interest rate
1.82
%
 
 
 
0.83
%
 
 
 
0.26
%
Expected life (in years)
0.24

 
 
 
0.24

 
 
 
0.25

Expected dividend
—

 
 
 
—

 
 
 
—

Weighted-average fair value
 
 
 
 
 
 
 
 
 
of purchase rights
$
55.04

 
 
 
$
38.86

 
 
 
$
27.36
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.19.1
10. Other Income and Expenses (Tables)
 12 Months Ended
Dec. 31, 2018
Other Income and Expenses [Abstract]  
Schedule of other income (expense), net Other (income) expense, net includes the following components (in millions):
 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
 
 
 
 
 
 
 
Interest and investment income
 
$
(26.6
)
 
$
(19.1
)
 
$
(14.7
)
Net realized gains on investments
 
(1.6
)
 
(0.1
)
 
(0.8
)
Other-than-temporary impairment losses on investments
 
0.8

 
7.0

 
0.6

Gain on sale of land
 
(4.1
)
 
—

 
—

Gain on divestiture of product line
 
(5.1
)
 
—

 
—

Other expense
 
—

 
1.5

 
1.1

Other (income) expense, net
 
$
(36.6
)
 
$
(10.7
)
 
$
(13.8
)
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.19.1
11. Supplemental Cash Flow Information (Tables)
 12 Months Ended
Dec. 31, 2018
Supplemental Cash Flow Information [Abstract]  
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] 11. SUPPLEMENTAL CASH FLOW INFORMATION

The reconciliation of net income to net cash provided by operating activities is as follows (in millions):

 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
Net income
 
$
365.6

 
$
122.2

 
$
26.0

Adjustments to reconcile net income
 
 

 
 

 
 

to net cash provided by operating activities
 
 

 
 

 
 

Depreciation and amortization
 
138.1

 
148.7

 
142.9

Share-based compensation
 
27.8

 
23.4

 
19.7

Gains on dispositions of securities
 
(1.6
)
 
(0.1
)
 
(0.8
)
Other-than-temporary impairment losses on investments
 
0.8

 
7.0

 
0.6

Changes in fair market value of equity securities
 
(606.2
)
 
—

 
—

Losses on dispositions of fixed assets
 
2.0

 
8.1

 
0.6

Gain on sale of land
 
(4.1
)
 
—

 
—

Gain on divestiture of a product line
 
(5.1
)
 
—

 
—

Excess tax benefits from share-based compensation
 
—

 
—

 
(1.5
)
Changes in fair value of contingent consideration
 
(6.2
)
 
(18.1
)
 
(0.4
)
Decrease (increase) in accounts receivable, net
 
59.7

 
(64.1
)
 
12.5

Increase in inventories, net
 
(12.9
)
 
(47.7
)
 
(57.1
)
Increase in other current assets
 
(15.3
)
 
(35.7
)
 
(6.8
)
(Decrease) increase in accounts payable
 


 


 


and other current liabilities
 
(45.6
)
 
7.8

 
30.1

(Decrease) increase in income taxes payable
 
(20.9
)
 
(22.4
)
 
10.7

Increase (decrease) in deferred income taxes
 
120.9

 
(82.0
)
 
(51.4
)
Decrease in other long term assets
 
1.1

 
2.3

 
12.5

(Decrease) increase in other long term liabilities
 
(10.0
)
 
38.1

 
10.4

Impairment losses on goodwill and long-lived assets
 
292.5

 
11.5

 
62.3

Other
 
4.9

 
5.1

 
5.8

Net cash provided by operating activities
 
$
285.5

 
$
104.1

 
$
216.1

 
 
 
 
 
 
 
Non-cash investing activities:
 
 
 
 
 
 
   Purchased property, plant and equipment
 
$
5.7

 
$
—

 
$
7.2

   Purchased marketable securities and investments
 
$
0.8

 
$
2.8

 
$
0.6
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.19.1
12. Commitments & Contingent Liabilities Pension obligations and funded status (Tables)
 12 Months Ended
Dec. 31, 2018
Defined Benefit Plan Disclosure [Line Items]  
Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block] Obligations and Funded Status
The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in the Consolidated Balance Sheets for the plans (in millions):

Change in benefit obligation:
2018
2017
Benefit obligation at beginning of year
$136.6
$122.7
Service cost
7.5

6.5

Interest cost
1.1

1.1

Plan participants' contributions
3.1

2.8

Actuarial (gain) loss
(5.4
)
3.3

Gross benefits paid
(3.1
)
(3.2
)
Plan amendments
(0.5
)
1.1

Special termination benefits
—

(2.0
)
Settlements
—

(5.1
)
Change attributable to foreign exchange
(2.0
)
9.4

 
 
 
Benefit obligation at end of year
137.3

136.6

 
 
 
Change in plan assets:
 
 
Fair value of plan assets at beginning year
61.7

58.8

Actual return on plan assets
0.3

0.5

Employer contributions
4.0

4.0

Plan participants' contributions
3.1

2.8

Gross benefits paid
(1.5
)
(2.3
)
Settlements
—

(5.1
)
Change attributable to foreign exchange
(0.7
)
3.0

 
 
 
Fair value of plan assets at end of year
66.9

61.7

 
 
 
Under funded status of plans
$(70.4)
$(74.9)
 
 
 
Amounts recognized in the consolidated balance sheets:
 
 
Current liabilities (Accrued payroll and employee benefits)
$(1.1)
$(1.1)
Noncurrent liabilities (Other long-term liabilities)
(69.3
)
(73.8
)
 
 
 
Net liability, end of fiscal year
$(70.4)
$(74.9)
 
 
 
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.19.1
12. Commitments & Contingent Liabilities Net Periodic Benefit Cost (Tables)
 12 Months Ended
Dec. 31, 2018
Defined Benefit Plan Disclosure [Line Items]  
Schedule of Net Benefit Costs [Table Text Block] Components of Net Periodic Benefit Cost
The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions):

 
2018
2017
2016
Service costs
$7.5
$6.5
$6.1
Interest costs
1.1

1.1

1.4

Expected returns on plan assets
(1.1
)
(1.1
)
(1.0
)
Amortization of actuarial losses
1.3

1.4

1.7

Amortization of prior service costs
0.1

—

—

Settlements
—

1.2

0.4

 
 
 
 
Net periodic benefit costs
$8.9
$9.1
$8.6
 
 
 
 
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.19.1
12. Commitments & Contingent Liabilities Assumptions for Benefit Obligations and Periodic Benefit Costs (Tables)
 12 Months Ended
Dec. 31, 2018
Defined Benefit Plan Disclosure [Line Items]  
Schedule of Assumptions Used [Table Text Block] Assumptions

The weighted-average assumptions used in computing the benefit obligations are as follows:


 
2018
2017
Discount rate
1.1
%
0.8
%
Compensation rate increase
1.8
%
1.8
%
 
 
 

The weighted-average assumptions used in computing the net periodic benefit costs are as follows:

 
2018
2017
2016
Discount rate
0.8
%
0.9
%
1.1
%
Expected long-term rate of return on plan assets
1.8
%
1.9
%
1.6
%
 
 
 
 
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.19.1
14. Segment Reporting (Tables)
 12 Months Ended
Dec. 31, 2018
Segment Reporting [Abstract]  
Information regarding industry segments
Information regarding industry segments at December 31, 2018, 2017, and 2016 and for the years then ended is as follows (in millions):

 
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
Segment net sales 
2018
 
$
861.7

 
$
1,411.8

 
$
15.9

 
2017
 
785.2

 
1,360.8

 
14.2

 
2016
 
730.7

 
1,323.3

 
14.2

 
 
 
 
 
 
 
 
Allocated interest expense
2018
 
$
7.2

 
$
16.7

 
$
0.1

 
2017
 
7.0

 
14.9

 
—

 
2016
 
6.9

 
16.5

 
—

 
 
 
 
 
 
 
 
Depreciation and amortization
2018
 
$
34.1

 
$
72.0

 
$
0.5

 
2017
 
36.2

 
80.2

 
—

 
2016
 
31.7

 
80.5

 
—

 
 
 
 
 
 
 
 
Segment profit (loss)
2018
 
$
28.7

 
$
(145.7
)
 
$
0.2

 
2017
 
(9.9
)
 
114.8

 
1.4

 
2016
 
(19.1
)
 
58.0

 
0.9

 
 
 
 
 
 
 
 
Segment assets
2018
 
$
450.2

 
$
949.0

 
$
5.9

 
2017
 
453.0

 
1,038.4

 
4.8

 
 
 
 
 
 
 
 
Capital expenditures
2018
 
$
36.7

 
$
60.5

 
$
0.5

 
2017
 
12.6

 
59.0

 
—
Reconciliation of segment profit to consolidated income before taxes he following reconciles total segment profit to consolidated income before taxes (in millions):
 
 
 
Year Ended December 31,
 
2018
 
2017
 
2016
Total segment (loss) profit
$
(116.8
)
 
$
106.3

 
$
39.8

Foreign currency exchange losses, net
(2.9
)
 
(9.1
)
 
(4.5
)
Net corporate operating, interest and other expense not allocated to segments
(10.4
)
 
(10.1
)
 
(7.5
)
Change in fair market value of equity securities
606.2

 
—

 
—

Other income (expense), net
36.6

 
10.7

 
13.8

Consolidated income before income taxes
$
512.7

 
$
97.8

 
$
41.6
Reconciliation of Assets from Segment to Consolidated The following reconciles total segment assets to consolidated total assets (in millions):

 
 
December 31,
 
 
2018
 
2017
Total segment assets
 
$
1,405.1

 
$
1,496.2

Cash and other current assets
 
1,047.2

 
965.8

Property, plant and equipment, net, excluding
 

 

  segment specific gross machinery and equipment
 
79.9

 
57.0

Goodwill, net
 
219.8

 
506.1

Other long-term assets
 
2,859.1

 
1,247.9

Total assets
 
$
5,611.1

 
$
4,273.0
Net sales and assets to external customers by geographic area The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):

 
 
Year Ended December 31,
 
 
2018
 
2017
 
2016
Europe
 
$
792.0

 
$
758.5

 
$
742.2

Pacific Rim
 
495.5

 
461.3

 
427.1

United States
 
863.6

 
800.2

 
770.6

Other (primarily Canada and Latin America)
 
138.3

 
140.2

 
128.3

Total net sales
 
$
2,289.4

 
$
2,160.2

 
$
2,068.2


The following presents Property, plant and equipment, net, Other investments and Other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):

 
 
December 31,
 
 
2018
 
2017
Europe**
 
$
1,571.9

 
$
230.6

Pacific Rim
 
20.7

 
18.4

United States  
 
1,582.1

 
1,305.2

Other (primarily Canada and Latin America)
 
11.1

 
13.1

Total Property, plant and equipment, net, Other investments and Other assets, excluding deferred income taxes
 
$
3,185.8

 
$
1,567.3


** The amounts primarily include our investment in the ordinary voting stock of Sartorius AG, of Goettingen, Germany (see Note 3). In 2017 this investment was accounted for under the cost method, and in 2018 it was accounted for at fair value in accordance with ASU 2016-01 (see Note 1).
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.19.1
15. Restructuring Costs (Tables)
 12 Months Ended
Dec. 31, 2018
Restructuring Cost and Reserve [Line Items]  
Restructuring and Related Costs [Table Text Block] The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closures restructuring reserves for severance and exit costs (in millions):

 
 
2018
 
2017
Balance as of January 1
 
$
14.1

 
$
—

Charged to expense
 
5.8

 
14.0

Adjustment to expense
 
0.3

 
—

Cash payments
 
(8.4
)
 
—

Foreign currency translation (gains) losses
 
(0.3
)
 
0.1

Balance as of December 31
 
$
11.5

 
$
14.1

The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions):

 
 
2018
 
2017
 
 
Life Science
 
Clinical Diagnostics
 
Total
 
Life Science
 
Clinical Diagnostics
 
Total
Balance as of January 1
 
$
2.2

 
$
4.1

 
$
6.3

 
$
3.2

 
$
5.8

 
$
9.0

Adjustment to expense
 
(0.1
)
 
(0.1
)
 
(0.2
)
 
0.2

 
0.3

 
0.5

Cash payments
 
(1.5
)
 
(2.9
)
 
(4.4
)
 
(1.5
)
 
(2.7
)
 
(4.2
)
Foreign currency translation (gains) losses
 
—

 
(0.1
)
 
(0.1
)
 
0.3

 
0.7

 
1.0

Balance as of December 31
 
$
0.6

 
$
1.0

 
$
1.6

 
$
2.2

 
$
4.1

 
$
6.3
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.19.1
16. Quarterly Financial Data (Tables)
 12 Months Ended
Dec. 31, 2018
Quarterly Financial Data [Abstract]  
Schedule of Quarterly Financial Data [Table Text Block]

 
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
2018
 
 
 
 
 
 
 
 
Net sales
 
$
551.5

 
$
575.9

 
$
545.1

 
$
616.9

Gross profit
 
302.2

 
301.7

 
286.7

 
332.6

Net income (loss)
 
656.8

 
268.0

 
269.3

 
(828.5
)
Basic earnings (loss) per share
 
$
22.05

 
$
8.99

 
$
9.02

 
$
(27.73
)
Diluted earnings (loss) per share
 
$
21.77

 
$
8.87

 
$
8.89

 
$
(27.73
)
 
 
 
 
 
 
 
 
 
2017
 
 
 
 
 
 
 
 
Net sales
 
$
500.1

 
$
504.7

 
$
534.1

 
$
621.3

Gross profit
 
270.1

 
273.4

 
299.0

 
345.2

Net income
 
12.4

 
5.0

 
22.1

 
82.7

Basic earnings per share
 
$
0.42

 
$
0.17

 
$
0.74

 
$
2.78

Diluted earnings per share
 
$
0.41

 
$
0.17

 
$
0.73

 
$
2.75
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.19.1
1. Significant Accounting Policies Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Jan. 01, 2018
Property, Plant and Equipment [Line Items]        
Restricted investments $ 5,560 $ 5,560    
Retained earnings 3,722,073 1,830,439    
Other assets 70,298 94,949    
Prepaid Taxes 5,500     $ 22,800
Equipment 970,081 971,140    
Deferred income taxes 553,239 222,209    
Income Tax Expense (Benefit) $ (147,045) $ 24,444 $ (15,560)  
Minimum [Member] | Software [Member]        
Property, Plant and Equipment [Line Items]        
Property, Plant and Equipment, Useful Life 3 years      
Minimum [Member] | Building and Building Improvements [Member]        
Property, Plant and Equipment [Line Items]        
Property, Plant and Equipment, Useful Life 15 years      
Minimum [Member] | Reagent Rental Equipment [Member]        
Property, Plant and Equipment [Line Items]        
Property, Plant and Equipment, Useful Life 1 year      
Minimum [Member] | Equipment [Member]        
Property, Plant and Equipment [Line Items]        
Property, Plant and Equipment, Useful Life 3 years      
Maximum [Member] | Software [Member]        
Property, Plant and Equipment [Line Items]        
Property, Plant and Equipment, Useful Life 12 years      
Maximum [Member] | Building and Building Improvements [Member]        
Property, Plant and Equipment [Line Items]        
Property, Plant and Equipment, Useful Life 39 years      
Maximum [Member] | Reagent Rental Equipment [Member]        
Property, Plant and Equipment [Line Items]        
Property, Plant and Equipment, Useful Life 5 years      
Maximum [Member] | Equipment [Member]        
Property, Plant and Equipment [Line Items]        
Property, Plant and Equipment, Useful Life 12 years      
Adjustments for New Accounting Pronouncement [Member]        
Property, Plant and Equipment [Line Items]        
Retained earnings       $ 1,543,700
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.19.1
1. Significant Accounting Policies Warranty rollforward (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Movement in Standard Product Warranty Accrual [Roll Forward]    
Warranty accrual, beginning of period $ 18.7 $ 17.6
Provision for warranty 25.5 29.9
Actual warranty costs (34.1) (28.8)
Warranty accrual, end of period $ 10.1 $ 18.7
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.19.1
1. Significant Accounting Policies Earnings per share (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Accounting Policies [Abstract]      
Basic weighted average shares outstanding 29,836 29,655 29,440
Effect of potentially dilutive stock options and restricted stock awards 392 379 206
Diluted weighted average common shares 30,228 30,034 29,646
Anti-dilutive shares excluded from the computation of diluted EPS 84 13 113
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.19.1
1. Significant Accounting Policies Details (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Jan. 01, 2018
USD ($)
Dec. 31, 2015
USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Deferred Tax Assets, Net, Noncurrent       $ 5,200  
Interest expense $ 23,962 $ 23,014 $ 23,380    
Selling, general and administrative expense 834,783 806,790 814,697    
Research and development expense 199,196 250,157 205,708    
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit) (119,000) (70,000)      
Stockholders' Equity Attributable to Parent 4,020,331 2,930,250 2,579,160   $ 2,485,029
Restricted investments 5,560 5,560      
Retained earnings 3,722,073 1,830,439      
Prepaid Taxes (5,500)     (22,800)  
Accumulated other comprehensive (loss) income (46,958) 738,794      
Other (income) expense, net 36,593 10,697 13,764    
Deferred Tax Assets, Gross $ 147,100 145,600      
Document Fiscal Year Focus 2018        
Unrealized Gain on Securities $ 606,230 0 0    
Deferred Income Tax Expense (Benefit) 120,900 (84,800) (51,200)    
Cost of Goods and Services Sold 1,066,264 972,450 929,744    
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Increase (49,000)        
Tax Cuts and Jobs Act, Income Tax Expense (Benefit) Composition (169,000)        
Tax Cuts and Jobs Act, Income Tax Expense, Composition 50,000        
Accounting Standards Update 2016-01 [Member]          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Other assets 600        
Accumulated other comprehensive (loss) income       679,200  
Adjustments for New Accounting Pronouncement [Member]          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Interest expense   1,100 1,438    
Selling, general and administrative expense   2,152 2,027    
Research and development expense   144 156    
Stockholders' Equity Attributable to Parent       864,500  
Retained earnings       1,543,700  
Deferred Income Tax Assets, Net       232,900  
Investments       1,097,400  
Other (income) expense, net   1,500 1,086    
Deferred Income Tax Expense (Benefit) 133,900        
Cost of Goods and Services Sold   304 $ 341    
Restricted Cash $ 2,600 $ 1,200      
Accounting Standards Update 2016-16 [Member]          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Retained earnings       $ (17,600)  
541714 Research and Development in Biotechnology (except Nanobiotechnology) [Member]          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Entity Number of Employees 800        
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.19.1
1. Significant Accounting Policies Revenue Recognition (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Jan. 01, 2018
Dec. 31, 2017
Disaggregation of Revenue [Line Items]      
Retained earnings $ 3,722,073   $ 1,830,439
Revenue Allocation Percent To Lease Elements 5.00%    
Deferred Revenue $ 37,300   $ 36,700
Deferred Revenue, Period Increase (Decrease) 28,000    
Deferred Revenue, Revenue Recognized $ 27,400    
Accounting Standards Update 2014-09 [Member]      
Disaggregation of Revenue [Line Items]      
Retained earnings   $ 100  
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.19.1
2. Acquisitions (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Feb. 15, 2017
Dec. 31, 2016
Business Acquisition [Line Items]          
Goodwill, Purchase Accounting Adjustments     $ 0    
Goodwill   $ 219,770 506,069   $ 477,100
Goodwill, Acquired During Period   0 $ 26,200    
RainDance Technologies, Inc. [Member]          
Business Acquisition [Line Items]          
Business Combination, Consideration Transferred $ 72,700        
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed 10,000        
Payments to Acquire Businesses, Net of Cash Acquired 72,900        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles       $ 37,600  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net       200  
Goodwill, Acquired During Period 26,200        
Business Combination, Consideration Transferred, Liabilities Incurred $ 13,600        
Analytical Flow Cytometer Platform [Member]          
Business Acquisition [Line Items]          
Business Combination, Contingent Consideration, Liability   $ 8,400      
Deferred Tax Asset [Domain] | RainDance Technologies, Inc. [Member]          
Business Acquisition [Line Items]          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net       $ 22,500  
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.19.1
3. Fair Value Measurements (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities, FV-NI, Unrealized Gain $ 607.7  
Debt Securities, Available-for-sale 373.2  
Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value 5.6 $ 5.6
Available-for-sale Securities 373.2 1,301.4 [1]
Equity Securities, FV-NI 2,672.9  
Debt Securities, Available-for-sale 373.2  
Forward foreign exchange contracts, Asset [2] 0.6 0.5
Financial Assets Carried at Fair Value 3,200.0 1,411.8
Forward foreign exchange contracts, Liability [3] 0.7 1.6
Business Combination, Contingent Consideration, Liability [4] 8.4 16.7
Liabilities, Fair Value Disclosure 9.1 18.3
Fair Value, Measurements, Recurring [Member] | Interest-bearing Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities   0.7
Fair Value, Measurements, Recurring [Member] | Corporate Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   185.7
Debt Securities, Available-for-sale 215.0  
Fair Value, Measurements, Recurring [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   67.6
Debt Securities, Available-for-sale 80.3  
Fair Value, Measurements, Recurring [Member] | Foreign Government Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   3.4
Debt Securities, Available-for-sale 3.6  
Fair Value, Measurements, Recurring [Member] | Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   15.0
Debt Securities, Available-for-sale 11.0  
Fair Value, Measurements, Recurring [Member] | Marketable Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   973.4
Fair Value, Measurements, Recurring [Member] | Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   55.6
Debt Securities, Available-for-sale 63.3  
Fair Value, Measurements, Recurring [Member] | Time Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 32.7 53.7
Fair Value, Measurements, Recurring [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   11.2
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 36.9 3.4
Fair Value, Measurements, Recurring [Member] | Commercial Paper [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 77.8 36.0
Fair Value, Measurements, Recurring [Member] | Cash Equivalents [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 147.7 104.3
Fair Value, Measurements, Recurring [Member] | Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0.3  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value 5.6 5.6
Available-for-sale Securities [1]   973.4
Equity Securities, FV-NI 2,672.9  
Debt Securities, Available-for-sale 0.0  
Forward foreign exchange contracts, Asset [2] 0.0 0.0
Financial Assets Carried at Fair Value 2,738.1 1,026.1
Forward foreign exchange contracts, Liability [3] 0.0 0.0
Business Combination, Contingent Consideration, Liability [4] 0.0 0.0
Liabilities, Fair Value Disclosure 0.0 0.0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Interest-bearing Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities   0.0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Debt Securities, Available-for-sale 0.0  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Debt Securities, Available-for-sale 0.0  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Foreign Government Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Debt Securities, Available-for-sale 0.0  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Debt Securities, Available-for-sale 0.0  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Marketable Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   973.4
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Debt Securities, Available-for-sale 0.0  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Time Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 22.7 43.7
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   0.0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 36.9 3.4
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Commercial Paper [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 0.0 0.0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Cash Equivalents [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 59.6 47.1
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0.0  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value 0.0 0.0
Available-for-sale Securities [1]   328.0
Equity Securities, FV-NI 0.0  
Debt Securities, Available-for-sale 373.2  
Forward foreign exchange contracts, Asset [2] 0.6 0.5
Financial Assets Carried at Fair Value 461.9 385.7
Forward foreign exchange contracts, Liability [3] 0.7 1.6
Business Combination, Contingent Consideration, Liability [4] 0.0 0.0
Liabilities, Fair Value Disclosure 0.7 1.6
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Interest-bearing Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities   0.7
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   185.7
Debt Securities, Available-for-sale 215.0  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   67.6
Debt Securities, Available-for-sale 80.3  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Foreign Government Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   3.4
Debt Securities, Available-for-sale 3.6  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   15.0
Debt Securities, Available-for-sale 11.0  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Marketable Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   55.6
Debt Securities, Available-for-sale 63.3  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Time Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 10.0 10.0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   11.2
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 0.0 0.0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 77.8 36.0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Cash Equivalents [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 88.1 57.2
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0.3  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value 0.0 0.0
Available-for-sale Securities [1]   0.0
Equity Securities, FV-NI 0.0  
Debt Securities, Available-for-sale 0.0  
Forward foreign exchange contracts, Asset [2] 0.0 0.0
Financial Assets Carried at Fair Value 0.0 0.0
Forward foreign exchange contracts, Liability [3] 0.0 0.0
Business Combination, Contingent Consideration, Liability [4] 8.4 16.7
Liabilities, Fair Value Disclosure 8.4 16.7
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Interest-bearing Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities   0.0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Corporate Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Debt Securities, Available-for-sale 0.0  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Debt Securities, Available-for-sale 0.0  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Foreign Government Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Debt Securities, Available-for-sale 0.0  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Debt Securities, Available-for-sale 0.0  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Marketable Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities [1]   0.0
Debt Securities, Available-for-sale 0.0  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Time Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 0.0 0.0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents   0.0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 0.0 0.0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Commercial Paper [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 0.0 0.0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Cash Equivalents [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 0.0 0.0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0.0  
Other Current Liabilities [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability 3.2 2.7
Short-term Investments [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 373.0 371.2
Equity Securities, FV-NI 40.2  
Short-term Investments [Member] | Fair Value, Measurements, Recurring [Member] | Interest-bearing Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities   0.7
Short-term Investments [Member] | Fair Value, Measurements, Recurring [Member] | Corporate Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities   185.7
Debt Securities, Available-for-sale 215.0  
Short-term Investments [Member] | Fair Value, Measurements, Recurring [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities   67.6
Debt Securities, Available-for-sale 80.3  
Short-term Investments [Member] | Fair Value, Measurements, Recurring [Member] | Foreign Government Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities   3.4
Debt Securities, Available-for-sale 3.6  
Short-term Investments [Member] | Fair Value, Measurements, Recurring [Member] | Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities   15.0
Debt Securities, Available-for-sale 11.0  
Short-term Investments [Member] | Fair Value, Measurements, Recurring [Member] | Marketable Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities   43.4
Short-term Investments [Member] | Fair Value, Measurements, Recurring [Member] | Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities   55.4
Debt Securities, Available-for-sale 63.1  
Other Investments [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0.2 930.2
Equity Securities, FV-NI 2,632.7  
Other Noncurrent Liabilities [Member] | Fair Value, Measurements, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability $ 5.2 $ 14.0
[1] Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31,
2018
 
December 31, 2017
 
 
 
 
Short-term investments
$
373.0

 
$
371.2

Other investments
0.2

 
930.2

Total
$
373.2

 
$
1,301.4
[2] Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.
[3] Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.
[4] Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2018
 
December 31, 2017
 
 
 
 
Other current liabilities
$
3.2

 
$
2.7

Other long-term liabilities
5.2

 
14.0

   Total
$
8.4

 
$
16.7
[5]
(a)
Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.19.1
3. Fair Value Measurements Foreign Exchange Forward Contracts (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2018
USD ($)
Forward foreign exchange contract to purchase foreign currency [Member]  
Derivatives, Fair Value [Line Items]  
Derivative, Notional Amount $ 284.5
Gain (loss) on foreign currency derivative instruments not designated as hedging instruments (0.5)
Forward foreign exchange contract to sell foreign currency [Member]  
Derivatives, Fair Value [Line Items]  
Derivative, Notional Amount 50.6
Gain (loss) on foreign currency derivative instruments not designated as hedging instruments $ 0.2
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.19.1
3. Fair Value Measurements Short-term Investments (Details) - USD ($)
$ in Millions
Dec. 31, 2018
Dec. 31, 2017
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost $ 375.5  
Debt Securities, Available-for-sale 373.2  
Fair Value, Measurements, Recurring [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   $ 884.8
Debt Securities, Available-for-sale, Amortized Cost 375.5  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax 0.3  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 2.6  
Debt Securities, Available-for-sale 373.2  
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   1.5
Available-for-sale Securities 373.2 1,301.4 [1]
Available-for-sale Securities, Amortized Cost Basis   418.1
Fair Value, Measurements, Recurring [Member] | Corporate Debt Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale 215.0  
Available-for-sale Securities [1]   185.7
Fair Value, Measurements, Recurring [Member] | Interest-bearing Deposits [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities   0.7
Fair Value, Measurements, Recurring [Member] | Municipal Obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale 11.0  
Available-for-sale Securities [1]   15.0
Fair Value, Measurements, Recurring [Member] | Asset-backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale 63.3  
Available-for-sale Securities [1]   55.6
Fair Value, Measurements, Recurring [Member] | Marketable Equity Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities [1]   973.4
Fair Value, Measurements, Recurring [Member] | US Government Sponsored Agencies [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale 80.3  
Available-for-sale Securities [1]   67.6
Fair Value, Measurements, Recurring [Member] | Foreign Government Obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale 3.6  
Available-for-sale Securities [1]   3.4
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities 373.0 371.2
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Corporate Debt Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   0.3
Debt Securities, Available-for-sale, Amortized Cost 216.2  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax 0.1  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 1.3  
Debt Securities, Available-for-sale 215.0  
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   0.5
Available-for-sale Securities   185.7
Available-for-sale Securities, Amortized Cost Basis   185.9
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Interest-bearing Deposits [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   0.0
Available-for-sale Securities   0.7
Available-for-sale Securities, Amortized Cost Basis   0.7
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Municipal Obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   0.0
Debt Securities, Available-for-sale, Amortized Cost 11.1  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax 0.0  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 0.1  
Debt Securities, Available-for-sale 11.0  
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   0.1
Available-for-sale Securities   15.0
Available-for-sale Securities, Amortized Cost Basis   15.1
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Asset-backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   0.0
Debt Securities, Available-for-sale, Amortized Cost 63.5  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax 0.0  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 0.4  
Debt Securities, Available-for-sale 63.1  
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   0.2
Available-for-sale Securities   55.4
Available-for-sale Securities, Amortized Cost Basis   55.6
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Marketable Equity Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   9.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   0.0
Available-for-sale Securities   43.4
Available-for-sale Securities, Amortized Cost Basis   34.4
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Available-for-sale Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   9.3
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   1.5
Available-for-sale Securities   371.2
Available-for-sale Securities, Amortized Cost Basis   363.4
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | US Government Sponsored Agencies [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   0.0
Debt Securities, Available-for-sale, Amortized Cost 80.9  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax 0.2  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 0.8  
Debt Securities, Available-for-sale 80.3  
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   0.7
Available-for-sale Securities   67.6
Available-for-sale Securities, Amortized Cost Basis   68.3
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Foreign Government Obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   0.0
Debt Securities, Available-for-sale, Amortized Cost 3.6  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax 0.0  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 0.0  
Debt Securities, Available-for-sale 3.6  
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   0.0
Available-for-sale Securities   3.4
Available-for-sale Securities, Amortized Cost Basis   3.4
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Debt Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 375.3  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax 0.3  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 2.6  
Debt Securities, Available-for-sale 373.0  
Fair Value, Measurements, Recurring [Member] | Other Long-term Investments [Member] | Asset-backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   0.0
Debt Securities, Available-for-sale, Amortized Cost 0.2  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax 0.0  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 0.0  
Debt Securities, Available-for-sale 0.2  
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   0.0
Available-for-sale Securities   0.2
Available-for-sale Securities, Amortized Cost Basis   0.2
Fair Value, Measurements, Recurring [Member] | Other Long-term Investments [Member] | Marketable Equity Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   875.5
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   0.0
Available-for-sale Securities   930.0
Available-for-sale Securities, Amortized Cost Basis   54.5
Fair Value, Measurements, Recurring [Member] | Other Long-term Investments [Member] | Available-for-sale Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax   875.5
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax   0.0
Available-for-sale Securities   930.2
Available-for-sale Securities, Amortized Cost Basis   $ 54.7
Fair Value, Measurements, Recurring [Member] | Other Long-term Investments [Member] | Debt Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 0.2  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax 0.0  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 0.0  
Debt Securities, Available-for-sale $ 0.2  
[1] Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31,
2018
 
December 31, 2017
 
 
 
 
Short-term investments
$
373.0

 
$
371.2

Other investments
0.2

 
930.2

Total
$
373.2

 
$
1,301.4
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.19.1
3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details)
$ in Millions
Dec. 31, 2018
USD ($)
Fair Value Disclosures [Abstract]  
Mature in less than one year $ 155.5
Mature in one to five years 172.4
Mature in more than five years 47.6
Total Amortized Cost 375.5
Mature in less than one year 155.2
Mature in one to five years 171.3
Mature in more than five years 46.7
Estimated Fair Value $ 373.2
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.19.1
3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Price Change Debt Security 5.00%  
Tolerable variance Level 2 debt security pricing 1.00%  
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $ 117.9 $ 43.9
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value 193.0 168.7
Gross unrealized losses for investments in a loss position 12 months or more 1.8 0.7
Gross unrealized losses for investments in a loss position less than 12 months $ 0.8 $ 0.8
Cost Method Investment, Percentage Owned 37.00%  
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.19.1
3. Fair Value Investments (Details) - USD ($)
$ in Millions
Dec. 31, 2018
Dec. 31, 2017
Carrying (Reported) Amount, Fair Value Disclosure [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Other Investments $ 0.0 $ 91.8
Total long-term debt, excluding leases and current maturities 423.7 423.1
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Other Investments 0.0 1,249.4
Total long-term debt, excluding leases and current maturities $ 435.8 $ 449.8
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.19.1
3. Fair Value Measurements Contingent Consideration (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended 25 Months Ended
Sep. 30, 2018
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value       $ 16.7    
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability     $ (6.2) (18.1) $ (0.4)  
Fair Value, Measurements, Recurring [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Combination, Contingent Consideration, Liability [1]     8.4 $ 16.7   $ 8.4
Analytical Flow Cytometer Platform [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value     8.4     8.4
Business Combination, Contingent Consideration, Liability     8.4     8.4
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements $ (0.8) $ (1.3) (2.1)      
Net (decrease) increase in estimated fair value of contingent consideration included in selling, general and administrative expense     $ (6.2)     $ 12.2
Discount rate [Member] | Analytical Flow Cytometer Platform [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Discount Rate     11.00%      
Sales milestone percentage of annual invoices [Member] | Analytical Flow Cytometer Platform [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Acquisition, Contingent Consideration, Potential Percentage Payout     39.00%     39.00%
Sales milestone percentage of annual invoices low [Member] | Analytical Flow Cytometer Platform [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Acquisition, Contingent Consideration, Potential Percentage Payout     20.00%     20.00%
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low     $ 0.0     $ 0.0
Cost of debt [Member] | Analytical Flow Cytometer Platform [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Discount Rate     5.10%      
[1] Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2018
 
December 31, 2017
 
 
 
 
Other current liabilities
$
3.2

 
$
2.7

Other long-term liabilities
5.2

 
14.0

   Total
$
8.4

 
$
16.7
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.19.1
4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Goodwill [Line Items]        
Goodwill, Written off Related to Sale of Business Unit     $ (1,400)  
Goodwill [Roll Forward]        
Goodwill period start $ 559,300 $ 518,800 559,300 $ 518,800
Accumulated impairment loss period start (53,200) (41,700) (53,200) (41,700)
Goodwill, net period start 506,069 477,100 506,069 477,100
Goodwill, Acquired During Period     0 26,200
Goodwill, Purchase Accounting Adjustments       0
Goodwill, Impairment Loss     282,000 11,500
Currency fluctuations     (2,900) 14,300
Goodwill period end     555,000 559,300
Accumulated impairment loss period end     (335,200) (53,200)
Goodwill, net period end     219,770 506,069
Life Science [Member]        
Goodwill [Roll Forward]        
Goodwill period start 234,700 207,100 234,700 207,100
Accumulated impairment loss period start (35,900) (27,200) (35,900) (27,200)
Goodwill, net period start 198,800 179,900 198,800 179,900
Goodwill, Acquired During Period     0 26,200
Goodwill, Purchase Accounting Adjustments     0 0
Goodwill, Impairment Loss     5,900 8,700
Currency fluctuations     (200) 1,400
Goodwill period end     234,500 234,700
Accumulated impairment loss period end     (41,800) (35,900)
Goodwill, net period end     192,700 198,800
Clinical Diagnostics [Member]        
Goodwill [Line Items]        
Goodwill, Written off Related to Sale of Business Unit (1,400)   (1,400)  
Goodwill [Roll Forward]        
Goodwill period start 324,600 311,700 324,600 311,700
Accumulated impairment loss period start (17,300) (14,500) (17,300) (14,500)
Goodwill, net period start $ 307,300 297,200 307,300 297,200
Goodwill, Acquired During Period     0 0
Goodwill, Purchase Accounting Adjustments       0
Goodwill, Impairment Loss     276,100 2,800
Currency fluctuations     (2,700) 12,900
Goodwill period end     320,500 324,600
Accumulated impairment loss period end     (293,400) (17,300)
Goodwill, net period end     27,100 $ 307,300
RainDance Technologies, Inc. [Member]        
Goodwill [Roll Forward]        
Goodwill, Acquired During Period   $ 26,200    
Pasteur Sanofi Diagnosics S.A. [Member] | Clinical Diagnostics [Member]        
Goodwill [Roll Forward]        
Goodwill, Impairment Loss     18,100  
DiaMed [Member] | Clinical Diagnostics [Member]        
Goodwill [Roll Forward]        
Goodwill, Impairment Loss     247,200  
Biotest AG [Member] | Clinical Diagnostics [Member]        
Goodwill [Roll Forward]        
Goodwill, Impairment Loss     $ 10,800  
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.19.1
4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Feb. 15, 2017
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Gross $ 493,100 $ 493,100 $ 509,000    
Future Amortization Expense, Year One 21,700 21,700      
Future Amortization Expense, Year Two 19,700 19,700      
Future Amortization Expense, Year Three 18,900 18,900      
Future Amortization Expense, Year Four 15,700 15,700      
Future Amortization Expense, Year Five 14,800 14,800      
Finite-Lived Intangible Assets, Amortization Expense, after Year Five 42,300 42,300      
Finite-Lived Intangible Assets, Net [Abstract]          
Accumulated Amortization (360,000) (360,000) (334,900)    
Net Carrying Amount 133,100 133,100 174,100    
Amortization [Abstract]          
Amortization expense   28,300 30,800 $ 35,200  
Impairment losses on goodwill and long-lived assets 292,500 292,513 11,506 $ 62,305  
Intangible Assets, Net (Excluding Goodwill) 133,123 133,123 174,113    
Customer Relationships [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Gross 88,700 88,700 92,300    
Finite-Lived Intangible Assets, Net [Abstract]          
Accumulated Amortization (68,300) (68,300) (64,400)    
Net Carrying Amount 20,400 20,400 27,900    
Know how [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Gross 190,600 190,600 194,900    
Finite-Lived Intangible Assets, Net [Abstract]          
Accumulated Amortization (159,800) (159,800) (157,900)    
Net Carrying Amount 30,800 30,800 37,000    
Developed Technology Rights [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Gross 130,400 130,400 133,300    
Finite-Lived Intangible Assets, Net [Abstract]          
Accumulated Amortization (86,600) (86,600) (70,300)    
Net Carrying Amount 43,800 43,800 63,000    
Licensing Agreements [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Gross 76,300 76,300 76,700    
Finite-Lived Intangible Assets, Net [Abstract]          
Accumulated Amortization (40,900) (40,900) (36,000)    
Net Carrying Amount 35,400 35,400 40,700    
Trade Names [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Gross 3,900 3,900 3,900    
Finite-Lived Intangible Assets, Net [Abstract]          
Accumulated Amortization (3,300) (3,300) (3,000)    
Net Carrying Amount 600 600 900    
Noncompete Agreements [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Gross 3,200 3,200 7,900    
Finite-Lived Intangible Assets, Net [Abstract]          
Accumulated Amortization (1,100) (1,100) (3,300)    
Net Carrying Amount $ 2,100 $ 2,100 $ 4,600    
Minimum [Member] | Customer Relationships [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   1 year 1 year    
Minimum [Member] | Know how [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   1 year 1 year    
Minimum [Member] | Developed Technology Rights [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   1 year 1 year    
Minimum [Member] | Licensing Agreements [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   7 years 1 year    
Minimum [Member] | Trade Names [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   2 years 1 year    
Minimum [Member] | Noncompete Agreements [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   7 years 1 year    
Minimum [Member] | Other Intangible Assets [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   0 years 0 years    
Maximum [Member] | Customer Relationships [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   6 years 7 years    
Maximum [Member] | Know how [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   7 years 8 years    
Maximum [Member] | Developed Technology Rights [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   10 years 12 years    
Maximum [Member] | Licensing Agreements [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   11 years 12 years    
Maximum [Member] | Trade Names [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   6 years 6 years    
Maximum [Member] | Noncompete Agreements [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   7 years 8 years    
Maximum [Member] | Other Intangible Assets [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period   0 years 0 years    
RainDance Technologies, Inc. [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles         $ 37,600
RainDance Technologies, Inc. [Member] | Developed Technology Rights [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles         1,000
RainDance Technologies, Inc. [Member] | Licensing Agreements [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles         36,400
RainDance Technologies, Inc. [Member] | Trade Names [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles         $ 200
Life Science [Member] | CellSorter [Member] | Developed Technology Rights [Member]          
Amortization [Abstract]          
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)   $ 8,800      
Life Science [Member] | CellSorter [Member] | Noncompete Agreements [Member]          
Amortization [Abstract]          
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)   $ 1,700      
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.19.1
5. Notes Payable and Long-Term Debt (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Jun. 30, 2014
Dec. 31, 2010
Debt Instrument [Line Items]        
Debt and Capital Lease Obligations $ 439,400 $ 435,000    
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year 500 400    
Long-term Debt and Capital Lease Obligations 438,937 434,581    
Maturities of Long-term Debt [Abstract]        
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months 500      
Long-term Debt, Maturities, Repayments of Principal in Year Two 426,600      
Long-term Debt, Maturities, Repayments of Principal in Year Three 1,700      
Long-term Debt, Maturities, Repayments of Principal in Year Four 1,600      
Long-term Debt, Maturities, Repayments of Principal in Year Five 400      
Long-term Debt, Maturities, Repayments of Principal after Year Five 9,900      
Line of Credit Facility, Remaining Borrowing Capacity 208,200      
Letters of Credit Outstanding, Amount 3,100      
Performance Guarantee [Member]        
Maturities of Long-term Debt [Abstract]        
Letters of Credit Outstanding, Amount 3,100      
Unsecured Debt [Member] | Senior Notes 4.875% due 2020 [Member]        
Debt Instrument [Line Items]        
Unsecured Debt 425,000 425,000    
Long-term debt 423,700 423,100   $ 422,600
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net 1,300 1,900    
Debt Instrument, Interest Rate, Effective Percentage       4.946%
Face amount of debt sold       $ 425,000
Debt Instrument, Interest Rate, Stated Percentage       4.875%
Capital Lease Obligations [Member] | Capital Leases and Other Debt [Member]        
Debt Instrument [Line Items]        
Long-term Debt and Capital Lease Obligations, Including Current Maturities 15,700 11,900    
Line of Credit [Member]        
Maturities of Long-term Debt [Abstract]        
Line of Credit Facility, Maximum Borrowing Capacity     $ 200,000  
Long-term Line of Credit $ 0      
Line of Credit Facility, Interest Rate at Period End 3.925%      
Standby Letters of Credit [Member]        
Maturities of Long-term Debt [Abstract]        
Letters of Credit Outstanding, Amount $ 200 $ 500    
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.19.1
6. Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Jan. 01, 2018
Income Taxes [Line Items]        
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount $ 4,400      
Prepaid Taxes 5,500     $ 22,800
U.S. 363,400 $ 72,800 $ (38,500)  
International 149,300 25,000 80,100  
Income before income taxes 512,659 97,805 41,560  
U.S. Federal 8,800 6,700 16,100  
State 2,200 3,400 3,100  
International 30,500 32,000 30,400  
Current Income Tax Expense (Benefit) 41,500 42,100 49,600  
U.S. Federal 114,000 (69,800) (42,400)  
State 6,600 4,300 (2,800)  
International 300 (19,300) (6,000)  
Deferred tax benefit 120,900 (84,800) (51,200)  
Non-current tax expense (benefit) (15,400) 18,300 17,200  
Provision for income taxes $ 147,045 $ (24,444) $ 15,560  
U.S. statutory tax rate 21.00% 35.00% 35.00%  
Impact of foreign operations (4.00%) 6.00% (15.00%)  
Foreign dividends, net 0.00% 0.00% (40.00%)  
Research tax credits (1.00%) (4.00%) (9.00%)  
Nontaxable subsidies 0.00% (2.00%) (4.00%)  
Tax settlements and changes to unrecognized tax benefits 0.00% 0.00% 47.00%  
Goodwill impairment 6.00% 1.00% 11.00%  
Domestic manufacturing deduction 0.00% 0.00% (4.00%)  
Stock-based compensation (1.00%) (5.00%) 3.00%  
Nondeductible executive compensation 0.00% 2.00% 3.00%  
Fines and penalties 0.00% 0.00% 2.00%  
Prior period adjustments (1.00%) 0.00% 4.00%  
State taxes 2.00% 3.00% 1.00%  
Other 2.00% (3.00%) 1.00%  
Provision for income taxes 29.00% (25.00%) 37.00%  
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit) $ (119,000) $ (70,000)    
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Increase (49,000)      
Tax Cuts and Jobs Act, Income Tax Expense (Benefit) Composition (169,000)      
Tax Cuts and Jobs Act, Income Tax Expense, Composition 50,000      
Bad debt, inventory and warranty accruals 21,700 28,600    
Other post-employment benefits, vacation and other reserves 23,000 24,000    
Tax credit and net operating loss carryforwards 75,300 73,300    
Other 27,100 19,700    
Total gross deferred tax assets 147,100 145,600    
Valuation allowance (70,800) (66,400)    
Total deferred tax assets 76,300 79,200    
Property and equipment 40,100 33,500    
Investments and intangible assets 540,600 219,100    
Total deferred tax liabilities 580,700 252,600    
Net deferred tax liabilities (504,400) (173,400)    
Unrecognized tax benefits period start 54,900 21,100 $ 11,900  
Additions to tax positions related to prior years 600 1,300 10,400  
Reductions to tax positions related to prior years (20,200) (1,000) 0  
Additions to tax positions related to the current year 4,600 34,800 3,400  
Settlements (6,800) (200) (2,400)  
Lapse of statute of limitations (1,100) (3,400) (2,300)  
Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation   2,300 100  
Currency translation (2,200)      
Unrecognized tax benefits period end 29,800 54,900 21,100  
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued 9,500 10,900 11,800  
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense (1,400) $ (900) $ 8,700  
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit 3,100      
Deferred Tax Liabilities, Undistributed Foreign Earnings 6,700      
Foreign Tax Authority [Member]        
Income Taxes [Line Items]        
Operating Loss Carryforward With No Expiration Date 118,800      
Operating Loss Carryforwards $ 205,000      
Domestic Tax Authority [Member]        
Income Taxes [Line Items]        
Other reconciling items 15.00% 3.00% 2.00%  
Tax Cuts and Jobs Act [Member]        
Income Taxes [Line Items]        
U.S. tax reform (10.00%) (71.00%) 0.00%  
State and Local Jurisdiction [Member]        
Income Taxes [Line Items]        
Operating Loss Carryforwards $ 52,700      
Including accrued interest and penalties [Member]        
Income Taxes [Line Items]        
Other 1,600      
Unrecognized tax benefits period end 39,300      
Research Tax Credit Carryforward [Member] | State and Local Jurisdiction [Member]        
Income Taxes [Line Items]        
Deferred Tax Assets, Tax Credit Carryforwards, Research $ 32,100      
Acquisition-related Costs [Member]        
Income Taxes [Line Items]        
Other reconciling items 0.00% 10.00% 0.00%  
Net of prepaid taxes [Member]        
Income Taxes [Line Items]        
Unrecognized tax benefits period end $ 32,200      
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.19.1
7. Stockholders' Equity (Details) - shares
 1 Months Ended 12 Months Ended
Nov. 30, 2018
Aug. 31, 2017
Jun. 30, 2017
May 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Class of Stock [Line Items]                
Treasury Stock, Shares, Acquired 178,911 9,200 1,500 2,500        
Common Class A [Member]                
Class of Stock [Line Items]                
Shares, Issued         24,884,000 24,679,000 24,454,000 24,230,000
Stock Issued During Period, Shares, Conversion of Convertible Securities         30,000 34,000 13,000  
Stock Issued During Period, Shares, New Issues         175,000 191,000 211,000  
Common Stock, Voting Rights         .10      
Election Percentage for Board of Directors         25.00%      
Common Class B [Member]                
Class of Stock [Line Items]                
Shares, Issued         5,096,000 5,108,000 5,124,000 5,131,000
Stock Issued During Period, Shares, Conversion of Convertible Securities         (30,000) (34,000) (13,000)  
Stock Issued During Period, Shares, New Issues         18,000 18,000 6,000  
Common Stock, Voting Rights         1      
Election Percentage for Board of Directors         75.00%      
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.19.1
7. Stockholders' Equity Treasury Shares (Details) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended 12 Months Ended
Nov. 30, 2018
Aug. 31, 2017
Jun. 30, 2017
May 31, 2017
Dec. 31, 2017
Dec. 31, 2018
Equity, Class of Treasury Stock [Line Items]            
Treasury Stock, Shares 193,150 14,239 5,039 3,539    
Stock Repurchase Program, Remaining Authorized Repurchase Amount $ 201.1 $ 0.4 $ 2.4 $ 2.7    
Stock Repurchase Program, Authorized Amount         $ 18.0 $ 250.0
Treasury Stock, Shares, Acquired 178,911 9,200 1,500 2,500    
Treasury Stock Acquired, Average Cost Per Share $ 273.39 $ 221.45 $ 221.82 $ 220.02    
Treasury Class-A [Member]            
Equity, Class of Treasury Stock [Line Items]            
Treasury Stock, Shares         582 179,493
Stock Issued During Period, Shares, Treasury Stock Reissued         12,740  
Treasury Class B [Member]            
Equity, Class of Treasury Stock [Line Items]            
Treasury Stock, Shares         917 917
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.19.1
8. Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Jan. 01, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Accumulated other comprehensive (loss) income $ (46,958) $ 738,794    
EquitySecuritiesWithoutReadilyDeterminableFairValueFairValueElection       $ 864,490
Other comprehensive income, net of tax (106,495) 321,028 $ 35,628  
Foreign currency translation adjustments [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Accumulated other comprehensive (loss) income (35,500) 77,400 1,300 77,400
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax (112,900) 76,100    
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax 0 0    
Other Comprehensive Income (Loss), Tax 0 0    
Other comprehensive income, net of tax (112,900) 76,100    
Other Postretirement Benefit Plan [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Accumulated other comprehensive (loss) income (14,800) (22,300) (18,600) (22,300)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 6,900 (6,500)    
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax 2,400 2,100    
Other Comprehensive Income (Loss), Tax (1,800) 700    
Other comprehensive income, net of tax 7,500 (3,700)    
Net Unrealized Investment Gain (Loss) [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Accumulated other comprehensive (loss) income 3,300 683,700 435,000 4,400
EquitySecuritiesWithoutReadilyDeterminableFairValueFairValueElection       (679,300)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax (1,400) 203,600    
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax 300 (100)    
Other Comprehensive Income (Loss), Tax 0 (74,900)    
Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect   120,100    
Other comprehensive income, net of tax (1,100) 248,700    
Parent [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Accumulated other comprehensive (loss) income (47,000) 738,800 $ 417,700 59,500
EquitySecuritiesWithoutReadilyDeterminableFairValueFairValueElection       $ (679,300)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax (107,400) 273,200    
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax 2,700 2,000    
Other Comprehensive Income (Loss), Tax (1,800) (74,200)    
Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect   120,100    
Other comprehensive income, net of tax $ (106,500) $ 321,100    
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.19.1
8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Selling, general and administrative expense $ (834,783) $ (806,790) $ (814,697)
Realized Investment Gains (Losses) 1,600 100 $ 800
Other Postretirement Benefit Plan [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Selling, general and administrative expense 2,400 2,100  
Net Unrealized Investment Gain (Loss) [Member]      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect   120,100  
Net Unrealized Investment Gain (Loss) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Realized Investment Gains (Losses) $ (300) $ 100  
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.19.1
9. Share-based Compensation (Details) - USD ($)
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value $ 6,000,000.0 $ 4,200,000 $ 2,100,000
Employee Service Share-based Compensation, Tax Benefit from Exercise of Stock Options 5,400,000 6,300,000 1,500,000
Share-based Compensation Expense 27,800,000 23,400,000 19,700,000
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense $ 4,400,000 $ 5,800,000 5,100,000
2011 Employee Stock Purchase Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of Shares Authorized 1,300,000    
Stock Option and Award Plans [Member] | Incentive Award Plan 2017 [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of Shares Authorized 1,999,714    
Number of Shares Available for Grant 1,584,834    
Stock Options [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted Average Remaining Contractual Term (in years) - Outstanding 4 years 10 months 24 days    
Aggregate Intrinsic Value (in millions) - Outstanding $ 38.0    
Options - Weighted-Average Exercise Price $ 138.81 $ 120.39  
Options Granted - Weighted Average Exercise Price 326.15    
Options Exercised - Weighted Average Exercise Price $ 93.63    
Options Granted Term P10Y    
Options Forfeitured/expired - Weighted Average Exercise Price $ 169.93    
Options - Shares Vested and Expected to Vest 99,600    
Options Vested and Expected to Vest - Weighted Average Exercise Price $ 223.91    
Options Vested and Expected to Vest - Weighted Average Remaining Contractual Term (in years) 8 years 3 months 25 days    
Options Vested and Expected to Vest - Aggregate Intrinsic Value (in millions) $ 3.9    
Weighted Average Exercise Price - Options Exercisable $ 107.88    
Weighted Average Remaining Contractual Term (in years) - Exercisable 3 years 7 months 24 days    
Options Exercisable Aggregate Intrinsic Value (in millions) $ 34.1    
Options, Exercises in Period, Total Intrinsic Value 8,000,000 $ 10,000,000 1,000,000
Cash Received from Exercise of Stock Options 500,000 $ 1,600,000 1,200,000
Employee Service Share-based Compensation, Tax Benefit from Exercise of Stock Options     $ 6,000,000.0
Total unrecognized compensation cost from stock options $ 6,300,000    
Options Number Exercisable 274,040    
Options Vesting Period 5 years    
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 20.00%    
Weighted average fair value of options granted, period for recognition 3 years    
Expected Volatility 22.00% 20.00% 21.00%
Risk Free Interest Rate 2.85% 1.87% 1.35%
Expected life (in years) 7 years 7 months 6 days 7 years 2 months 12 days 7 years 4 months 24 days
Expected dividend $ 0 $ 0 $ 0
Weighted average fair value of options granted $ 105.94 $ 58.65 $ 42.40
Expected dividend yield 0.00%    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]      
Outstanding beginning of period 407,480    
Options - Shares Granted 33,000    
Options - Shares Exercised (44,600)    
Options - Shares Forfeitures/expired (22,240)    
Outstanding end of period 373,640 407,480  
Employee Stock [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of Shares Available for Grant 658,248    
Cash Received from Exercise of Stock Options $ 13,600,000 $ 13,000,000.0 $ 11,500,000
Stock Issued During Period, Shares, Employee Stock Purchase Plans 63,464 74,409 93,605
Employee Contribution Rate - Maximum 10.00%    
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount $ 25,000    
Employee Purchase Price Discount from Market Price 85.00%    
Expected Volatility 27.00% 19.00% 20.00%
Risk Free Interest Rate 1.82% 0.83% 0.26%
Expected life (in years) 2 months 26 days 2 months 26 days 3 months
Expected dividend $ 0 $ 0 $ 0
Expected dividend yield 0.00%    
Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased $ 55.04 $ 38.86 $ 27.36
Stock Award Plans [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 20.00%    
Stock Award Plans [Member] | Incentive Award Plan 2017 [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Options Vesting Period 5 years    
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.19.1
9. Share-based Compensation Restricted Stock (Details) - Restricted Stock Units (RSUs) [Member] - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value $ 40.0 $ 27.7 $ 18.7
Total unrecognized compensation cost from restricted stock $ 102.4    
Nonvested shares - Weighted Average Grant Date Fair Value $ 235.57 $ 172.76  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]      
Outstanding beginning of period 473,000    
Restricted Stock Units Granted 185,755    
Restricted Stock Units - Vested (128,294)    
Restricted Stock Units - Forfeited (56,011)    
Outstanding end of period 474,450 473,000  
Weighted Average Grant Date Fair Value - Granted $ 326.15    
Restricted Stock Units Vested - Weighted-Average Grant-Date Fair Value 158.49    
Resticted Stock Units Cancelled/forfeited - Weighted-Average Grant-Date Fair Value $ 182.15    
Weighted Average Remaining Contractual Term (in years) 2 years 1 month 9 days    
Resticted Stock Units Outstanding Aggregate Intrinsic Value (in millions) $ 110.2    
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition 4 years    
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.19.1
10. Other Income and Expenses (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Interest and investment income $ (26,600) $ (19,100) $ (14,700)
Net realized gains on investments (1,600) (100) (800)
Other-than-temporary impairment losses on investments 800 7,000 600
Gain on sale of land (4,100) 0 0
Gain on divestiture of product line (5,100) 0 0
Other Expense 0 1,500 1,100
Other (income) expense, net $ (36,593) $ (10,697) $ (13,764)
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.19.1
11. Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Other Significant Noncash Transactions [Line Items]                      
Net Income (Loss) Attributable to Parent $ (828,500) $ 269,300 $ 268,000 $ 656,800 $ 82,700 $ 22,100 $ 5,000 $ 12,400 $ 365,614 $ 122,249 $ 26,000
Depreciation and amortization                 138,100 148,700 142,900
Share-based compensation                 27,800 23,400 19,700
Gains on disposition of securities                 (1,600) (100) (800)
Other than Temporary Impairment Losses on Investments                 800 7,000 600
Changes in fair market value of equity securities                 (606,200) 0 0
Losses on dispositions of fixed assets                 2,000 8,100 600
Gain on sale of land                 (4,100) 0 0
Gain on divestiture of a product line                 (5,100) 0 0
Excess tax benefits from share-based compensation                 0 0 (1,506)
Changes in fair value of contingent consideration                 (6,200) (18,100) (400)
Decrease (increase) in accounts receivable, net                 59,700 (64,100) 12,500
Increase in inventories, net                 (12,900) (47,700) (57,100)
Increase in Other Current Assets                 (15,300) (35,700) (6,800)
(Decrease) increase in accounts payable and other current liabilities                 (45,600) 7,800 30,100
(Decrease) increase in Income Taxes Payable                 (20,900) (22,400) 10,700
Increase (decrease) in deferred income taxes                 120,900 (82,000) (51,400)
Other                 4,900 5,100 5,800
Decrease in other long term assets                 1,100 2,300 12,500
(Decrease) increase in Other Long Term Liabilities                 (10,000) 38,100 10,400
Impairment losses on goodwill and long-lived assets $ 292,500               292,513 11,506 62,305
Net cash provided by operating activities                 285,494 104,137 216,066
Noncash purchased property, plant and equipment                 5,700 0 7,200
Noncash Purchased Marketable Securities and Investments                 $ 800 $ 2,800 $ 600
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.19.1
12. Commitments & Contingent Liabilities (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended 25 Months Ended
Sep. 30, 2018
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Purchase Commitment, Excluding Long-term Commitment [Line Items]          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value         $ 16.7
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]          
Operating leases, due next twelve months     $ 44.4 $ 44.4  
Operating leases, due in two years     37.8 37.8  
Operating leases, due in three years     27.4 27.4  
Operating leases, due in four years     19.7 19.7  
Operating Leases, Future Minimum Payments, Due in Five Years     13.9 13.9  
Operating leases, due thereafter     25.6 25.6  
Post-Employment Benefits Liability     3.1 3.1 3.7
Recorded Unconditional Purchase Obligation     110.9 110.9  
Recorded Unconditional Purchase Obligation Due in Next Twelve Months     5.8 5.8  
Recorded Unconditional Purchase Obligation Due in Second Year     16.4 16.4  
Recorded Unconditional Purchase Obligation Due in Third Year     6.2 6.2  
Recorded Unconditional Purchase Obligation Due in Fourth Year     2.4 2.4  
Recorded Unconditional Purchase Obligation Due in Fifth Year     3.5 3.5  
Recorded Unconditional Purchase Obligation Due after Fifth Year     76.6 76.6  
Unrecorded Unconditional Purchase Obligation     12.5 12.5  
Unrecorded Unconditional Purchase Obligation, Due in Twelve Months     6.5 6.5  
Unrecorded Unconditional Purchase Obligation, Due within Two Years     5.3 5.3  
Unrecorded Unconditional Purchase Obligation, Due within Three Years     0.1 0.1  
Unrecorded Unconditional Purchase Obligation, Due within Four Years     0.2 0.2  
Unrecorded Unconditional Purchase Obligation, Due within Five Years     0.2 0.2  
Unrecorded Unconditional Purchase Obligation, Due after Five Years     0.2 0.2  
Letters of Credit Outstanding Amount     $ 3.1 $ 3.1  
Employees Covered By Collective Bargaining Agreements U.S., Percentage     8.00% 8.00%  
Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals     $ 17.8 $ 17.8  
Analytical Flow Cytometer Platform [Member]          
Purchase Commitment, Excluding Long-term Commitment [Line Items]          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value     8.4 8.4  
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements $ 0.8 $ 1.3 2.1    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings     6.2 (12.2)  
Business Combination, Contingent Consideration, Liability     $ 8.4 $ 8.4  
UNITED STATES          
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]          
Entity Number of Employees     3,265 3,265  
Fair Value, Measurements, Recurring [Member]          
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]          
Business Combination, Contingent Consideration, Liability [1]     $ 8.4 $ 8.4 $ 16.7
Sales milestone percentage of annual invoices [Member] | Analytical Flow Cytometer Platform [Member]          
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]          
Business Acquisition, Contingent Consideration, Potential Percentage Payout     39.00% 39.00%  
Sales milestone percentage of annual invoices low [Member] | Analytical Flow Cytometer Platform [Member]          
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]          
Business Acquisition, Contingent Consideration, Potential Percentage Payout     20.00% 20.00%  
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]          
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]          
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low     $ 0.0 $ 0.0  
[1] Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2018
 
December 31, 2017
 
 
 
 
Other current liabilities
$
3.2

 
$
2.7

Other long-term liabilities
5.2

 
14.0

   Total
$
8.4

 
$
16.7
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.19.1
12. Commitments & Contingent Liabilities Period Expense (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]      
Operating Leases, Future Minimum Payments, Due in Four Years $ 19.7    
Operating Leases, Future Minimum Payments, Due in Five Years 13.9    
Letters of Credit Outstanding, Amount 3.1    
Operating Leases, Rent Expense, Net 47.4 $ 43.6 $ 44.4
Contribution expense $ 15.9 $ 16.0 $ 15.1
XML 86 R72.htm IDEA: XBRL DOCUMENT v3.19.1
12. Commitments & Contingent Liabilities Pensions (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate 0.80% 0.90% 1.10%
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate 1.10% 0.80%  
Defined Benefit Plan, Benefit Obligation $ 137.3 $ 136.6 $ 122.7
Defined Benefit Plan, Service Cost 7.5 6.5 6.1
Defined Benefit Plan, Interest Cost 1.1 1.1 1.4
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant 3.1 2.8  
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) (5.4) 3.3  
Defined Benefit Plan, Benefit Obligation, Benefits Paid (3.1) (3.2)  
Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment (0.5) 1.1  
Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits 0.0 (2.0)  
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement 0.0 (5.1)  
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) (2.0) 9.4  
Defined Benefit Plan, Plan Assets, Amount 66.9 61.7 58.8
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) 0.3 0.5  
Defined Benefit Plan, Plan Assets, Contributions by Employer 4.0 4.0  
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant 3.1 2.8  
Defined Benefit Plan, Plan Assets, Benefits Paid (1.5) (2.3)  
Defined Benefit Plan, Plan Assets, Payment for Settlement 0.0 (5.1)  
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) (0.7) 3.0  
Defined Benefit Plan, Funded (Unfunded) Status of Plan (70.4) (74.9)  
Liability, Defined Benefit Plan, Current (1.1) (1.1)  
Liability, Defined Benefit Plan, Noncurrent (69.3) (73.8)  
Liability, Defined Benefit Plan (70.4) (74.9)  
Defined Benefit Plan, Expected Return (Loss) on Plan Assets (1.1) (1.1) (1.0)
Defined Benefit Plan, Amortization of Gain (Loss) 1.3 1.4 1.7
Defined Benefit Plan, Amortization of Prior Service Cost (Credit) 0.1 0.0 0.0
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement 0.0 1.2 0.4
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) $ 8.9 $ 9.1 $ 8.6
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase 1.80% 1.80%  
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets 1.80% 1.90% 1.60%
XML 87 R73.htm IDEA: XBRL DOCUMENT v3.19.1
13. Legal Proceedings Legal Proceedings (Details) - USD ($)
 12 Months Ended
Feb. 26, 2019
Dec. 31, 2017
Legal Proceedings [Abstract]    
Loss Contingency, Damages Sought, Value   $ 10,920,000
Litigation Settlement Interest   $ 141,608
Subsequent Event [Member]    
Subsequent Event [Line Items]    
Loss Contingency Accrual, Period Increase (Decrease) $ (2,960,000)  
Loss Contingency, Damages Awarded, Value $ 7,960,000  
XML 88 R74.htm IDEA: XBRL DOCUMENT v3.19.1
14. Segment Reporting (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Segment Reporting Information [Line Items]      
Number Of Products And Services 9,000    
Net sales $ 2,289,400 $ 2,160,200 $ 2,068,200
Interest expense 23,962 23,014 23,380
Depreciation and amortization 138,100 148,700 142,900
Segment profit (103,341) 119,250 55,718
Total assets 5,611,068 4,273,012  
Payments to Acquire Property, Plant, and Equipment 129,825 111,332 141,436
Life Science [Member]      
Segment Reporting Information [Line Items]      
Net sales 861,700 785,200 730,700
Interest expense 7,200 7,000 6,900
Depreciation and amortization 34,100 36,200 31,700
Segment profit 28,700 (9,900) (19,100)
Total assets 450,200 453,000  
Payments to Acquire Property, Plant, and Equipment 36,700 12,600  
Clinical Diagnostics [Member]      
Segment Reporting Information [Line Items]      
Net sales 1,411,800 1,360,800 1,323,300
Interest expense 16,700 14,900 16,500
Depreciation and amortization 72,000 80,200 80,500
Segment profit (145,700) 114,800 58,000
Total assets 949,000 1,038,400  
Payments to Acquire Property, Plant, and Equipment 60,500 59,000  
All Other Segments [Member]      
Segment Reporting Information [Line Items]      
Net sales 15,900 14,200 14,200
Interest expense 100 0 0
Depreciation and amortization 500 0 0
Segment profit 200 1,400 $ 900
Total assets 5,900 4,800  
Payments to Acquire Property, Plant, and Equipment $ 500 $ 0  
XML 89 R75.htm IDEA: XBRL DOCUMENT v3.19.1
14. Segment Information Segment Profit Reconciliation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Goodwill, Impairment Loss $ 282,000 $ 11,500  
Income before income taxes 512,659 97,805 $ 41,560
Unrealized Gain on Securities 606,230 0 0
Operating Segments [Member]      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Income before income taxes (116,800) 106,300 39,800
Segment Reconciling Items [Member]      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Unrealized Gain on Securities 606,200 0 0
Corporate, Non-Segment [Member]      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Income before income taxes (10,400) (10,100) (7,500)
Foreign Currency Gain (Loss) [Member] | Segment Reconciling Items [Member]      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Income before income taxes (2,900) (9,100) (4,500)
Other Nonoperating Income (Expense) [Member] | Segment Reconciling Items [Member]      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Income before income taxes 36,600 10,700 $ 13,800
Clinical Diagnostics [Member]      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Goodwill, Impairment Loss $ 276,100 $ 2,800  
XML 90 R76.htm IDEA: XBRL DOCUMENT v3.19.1
14. Segment Information Segment Asset Reconciliation (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets $ 5,611,068 $ 4,273,012
Operating Segments [Member]    
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets 1,405,100 1,496,200
Other Current Assets [Member] | Segment Reconciling Items [Member]    
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets 1,047,200 965,800
Property, Plant and Equipment excluding segment specific [Member] | Segment Reconciling Items [Member]    
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets 79,900 57,000
Goodwill [Member] | Segment Reconciling Items [Member]    
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets 219,800 506,100
Other Noncurrent Assets [Member] | Segment Reconciling Items [Member]    
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets $ 2,859,100 $ 1,247,900
XML 91 R77.htm IDEA: XBRL DOCUMENT v3.19.1
14. Segment Information Segment Information by Geographical Location (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Segment Reporting Information [Line Items]      
Net sales $ 2,289.4 $ 2,160.2 $ 2,068.2
Other assets and property, plant and equipment, net 3,185.8 1,567.3  
Europe [Member]      
Segment Reporting Information [Line Items]      
Net sales 792.0 758.5 742.2
Other assets and property, plant and equipment, net 1,571.9 230.6  
Pacific Rim [Member]      
Segment Reporting Information [Line Items]      
Net sales 495.5 461.3 427.1
Other assets and property, plant and equipment, net 20.7 18.4  
UNITED STATES      
Segment Reporting Information [Line Items]      
Net sales 863.6 800.2 770.6
Other assets and property, plant and equipment, net 1,582.1 1,305.2  
Other (primarily Canada and Latin America) [Member]      
Segment Reporting Information [Line Items]      
Net sales 138.3 140.2 $ 128.3
Other assets and property, plant and equipment, net $ 11.1 $ 13.1  
XML 92 R78.htm IDEA: XBRL DOCUMENT v3.19.1
15. Restructuring Costs (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended 13 Months Ended 32 Months Ended
Dec. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2018
Dec. 31, 2018
GnuBIO [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Reserve, Current     $ 1.4      
GnuBIO [Member] | Clinical Diagnostics [Member] | Other Operating Income (Expense) [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges     5.5      
GnuBIO [Member] | Clinical Diagnostics [Member] | Selling, General and Administrative Expenses [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges     0.8      
GnuBIO [Member] | Clinical Diagnostics [Member] | Employee Severance [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges     2.9      
GnuBIO [Member] | Clinical Diagnostics [Member] | Research and Development Expense [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges     7.6      
European Reorganization [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Reserve $ 1.6 $ 1.6 6.3 $ 9.0 $ 1.6 $ 1.6
Restructuring Charges       12.5   12.8
Restructuring Reserve, Accrual Adjustment   (0.2) 0.5      
Payments for Restructuring   (4.4) (4.2)      
Restructuring Reserve, Foreign Currency Translation (Gain) Loss   (0.1) 1.0      
European Reorganization [Member] | Cost of Goods, Total [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges       2.1    
Restructuring Reserve, Accrual Adjustment   (0.1) (0.2)      
European Reorganization [Member] | Selling, General and Administrative Expenses [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges       10.4    
Restructuring Reserve, Accrual Adjustment   (0.1) 0.7      
European Reorganization [Member] | Life Science [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Reserve 0.6 0.6 2.2 3.2 0.6 0.6
Restructuring Reserve, Accrual Adjustment   (0.1) 0.2      
Payments for Restructuring   (1.5) (1.5)      
Restructuring Reserve, Foreign Currency Translation (Gain) Loss   0.0 0.3      
European Reorganization [Member] | Clinical Diagnostics [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Reserve 1.0 1.0 4.1 5.8 1.0 1.0
Restructuring Reserve, Accrual Adjustment   (0.1) 0.3      
Payments for Restructuring   (2.9) (2.7)      
Restructuring Reserve, Foreign Currency Translation (Gain) Loss   (0.1) 0.7      
Facility Closing [Member] | Employee Severance [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges   1.7        
Facility Closing [Member] | Clinical Diagnostics [Member] | Other Operating Income (Expense) [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges 0.2          
Facility Closing [Member] | Clinical Diagnostics [Member] | Employee Severance [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges 3.9          
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Reserve 11.5 11.5 14.1 $ 0.0 11.5 11.5
Restructuring Charges   5.8 14.0      
Restructuring Reserve, Accrual Adjustment   0.3 0.0      
Payments for Restructuring   (8.4) 0.0      
Restructuring Reserve, Foreign Currency Translation (Gain) Loss   (0.3) 0.1      
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Cost of Goods, Total [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges   5.4 2.3      
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Selling, General and Administrative Expenses [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges   0.4 3.3      
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Research and Development Expense [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges   0.3 15.5      
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Accounts Payable and Accrued Liabilities [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Reserve 7.3 7.3     7.3 7.3
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Other Noncurrent Liabilities [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Reserve $ 4.2 4.2     4.2 $ 4.2
Termination of a Diagnostics Research and Development Project [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges         $ 21.4  
Termination of a Diagnostics Research and Development Project [Member] | Clinical Diagnostics [Member] | Other Operating Income (Expense) [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Reserve, Accrual Adjustment   (0.1)        
Termination of a Diagnostics Research and Development Project [Member] | Clinical Diagnostics [Member] | Employee Severance [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Reserve, Accrual Adjustment   $ 0.4        
Termination of an Diagnostics Research and Development Project [Member] | Clinical Diagnostics [Member] | Other Operating Income (Expense) [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges     10.1      
Termination of an Diagnostics Research and Development Project [Member] | Clinical Diagnostics [Member] | Employee Severance [Member]            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges     $ 11.0      
XML 93 R79.htm IDEA: XBRL DOCUMENT v3.19.1
16. Quarterly Financial Data (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Quantifying Misstatement in Current Year Financial Statements [Line Items]                      
Net sales $ 616,900 $ 545,100 $ 575,900 $ 551,500 $ 621,300 $ 534,100 $ 504,700 $ 500,100 $ 2,289,415 $ 2,160,153 $ 2,068,172
Operating Income (Loss)                 (103,341) 119,250 55,718
Cost of Goods and Services Sold                 1,066,264 972,450 929,744
Gross profit 332,600 286,700 301,700 302,200 345,200 299,000 273,400 270,100 1,223,151 1,187,703 1,138,428
Selling, general and administrative expense                 834,783 806,790 814,697
Research and development expense                 199,196 250,157 205,708
Unrealized Loss on Securities 814,100                    
Net Income (Loss) Attributable to Parent $ (828,500) $ 269,300 $ 268,000 $ 656,800 $ 82,700 $ 22,100 $ 5,000 $ 12,400 $ 365,614 $ 122,249 $ 26,000
Earnings Per Share, Basic $ (27.73) $ 9.02 $ 8.99 $ 22.05 $ 2.78 $ 0.74 $ 0.17 $ 0.42 $ 12.25 $ 4.12 $ 0.88
Earnings Per Share, Diluted $ (27.73) $ 8.89 $ 8.87 $ 21.77 $ 2.75 $ 0.73 $ 0.17 $ 0.41 $ 12.10 $ 4.07 $ 0.88
Income Tax Expense (Benefit)                 $ (147,045) $ 24,444 $ (15,560)
Impairment losses on goodwill and long-lived assets $ 292,500               $ 292,513 $ 11,506 $ 62,305
XML 94 R80.htm IDEA: XBRL DOCUMENT v3.19.1
Schedule II - Valuation and Qualifying Accoutns (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]      
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]      
SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease) $ 4,413 $ (47) $ 8,126
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Valuation Allowances and Reserves, Balance Period Start 66,356 66,403 58,277
Deductions 0 0 0
Valuation Allowances and Reserves, Balance Period End 70,769 66,356 66,403
SEC Schedule, 12-09, Allowance, Credit Loss [Member]      
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]      
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 11,527 11,174 3,785
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Valuation Allowances and Reserves, Balance Period Start 25,549 23,367 24,418
Deductions (10,363) (8,992) (4,836)
Valuation Allowances and Reserves, Balance Period End $ 26,713 $ 25,549 $ 23,367
XML 95 R81.htm IDEA: XBRL DOCUMENT v3.19.1
17. Subsequent Event (Details)
$ in Millions
Mar. 04, 2019
USD ($)
Subsequent Event [Member]  
Subsequent Event [Line Items]  
Business Combination, Consideration Transferred $ 20
XML 96 R9999.htm IDEA: XBRL DOCUMENT v3.19.1
Label Element Value
Retained Earnings [Member]  
EquitySecuritiesWithoutReadilyDeterminableFairValueFairValueElection bio_EquitySecuritiesWithoutReadilyDeterminableFairValueFairValueElection $ 1,543,747,000
AOCI Attributable to Parent [Member]  
EquitySecuritiesWithoutReadilyDeterminableFairValueFairValueElection bio_EquitySecuritiesWithoutReadilyDeterminableFairValueFairValueElection (679,257,000)
Accounting Standards Update 2014-09 [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption (136,000)
Accounting Standards Update 2016-16 [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ (17,591,000)
EXCEL 97 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

#VZ+V6!^G<^*7UZ(B!.Y_;V%_=3MPK27:2]/]%Y[?7_G MDUG9'$966N>B4D25[AET)L;VXL2;3L77MHI,!])+ML36Q$9G#:48((8P*A%7 M4E3#U=99\M*TLN3=RLAY7\P^EF)6F3X[GD[6[]F,M:%UJ UL.0?X&1TN9_0Y M^]S9*%MO,T82;27:*FF+-KU_&;-(2R\)U@H)IC""ZSQW A79E[8>.K=\"6V1 MGV'4%K^)M1)K)=8Z*=;B8&-:5\E6V%+DPG,0 :QM/='6:=3*LMB5M1XZT'P) M:X&?1=0! HFU3H:U>M>Y_#^KF'9Q.2?BX">FYL T\I)G@_>+'WFJ%4* MV[B\:]4(VQA,-G:7<\%7Y!PY:!S 4EHA96UW!09KN8OUZJOEXO]^=W-1S-Y= M5WF"_R27G;.[N1RVW;+UM#9@*S8_):9^GKU%GJ<-@\+6A*"#:@28CW M3-N 3$D=HHBL72*KH8H-S9:K]#)H,GK4\$Z"YLE!\\34ID1-2R\B7%"/%'IE M )1$4\U)C4V@J(^-S99#\#)L$G+4),>$S=IKT\T7OM]?V=;2;CY4H5I5S&=+S^1)0- M 4F;*!NQRFK@C.2."RBU8K*)@+NMQ^LK\^B"L15R N M")O64 1Y 1B"F@OO>5 ;$PUXF!K-N/CQ!4_GQ$<;K!9XJW$6XFWNLY;N.D: M13B$*AA6"DC"%+%:6KCF+>=:(QEWYZV4T9AX*V4T[IG1N/*=4W+&$RQ&&^L+ M*NX!"33FL1, FWD>GJ3\7[7G,85F;5R- Z\&8XC4X$1 MU^CEX(R9UQC "?!1.^LF<)X<.$]-=MP(":BCCGF"M7%2TE49IB>:_UX M]7/C>L:C2?%FE1H"$?CS@=9[QV_<%Z.?KHM!/@PF?WCCM[#\@\ET$:S^\I0L M?-(HP.7S+!\/;O/98C"]&BRNBWGI(4RJ5J%YZ39KG]:S^D-O 86\N9D7^CS?Y M5;BD7_+Q'_FW>?BJOUS/5G>35_PYMSI0H[7$,0*HH"@8+UA(YB4#7%M-RO?D MWRW#\5=_ZQZTKJ.]*1&N3+]]]^:#LH/?E'[W07UZ]^&M^Y@-WOYN?MY=/ ]R M868311_7V"EA9@(>9\5U,9F/OA2#U?CS5[[<']]. ORG=_.@3.<_O?+%/),H M.W\-*_K>>/]W*K2,'E7O'TV"ZEO^O?D%D](J&7^G92%8:M!*B0V&Q7B\>K:* M;99_APL?UG\_<-^?1C=!$?Q>_#'X,+W)6_KV)I]]'DV6EY??+:;U TOU73WR MQ^AR;=']5Y'/ M!B[PQ.7 %L.B=(D&&&9GD&_LKWO)TU[V9B_O^WG=+98\ M:.;M 29U1DWZ./5Q/7L,,CW9,3X$,U%PR-+\PV?L^FF.]^EMZD@BOT1^+R _ M3--\Q41^B?P2^9TA^6TDV)WK_,:3Y[Z^Q1O?+<(39;KLQEG=C^,@9#^M'. N MMCGH$N?WX/[27O;G_LYF+\^G#8"?SHKP>8/AW6Q63(;?!HM9/IF/\\K$R"__ M[]U\425=O#1#,Z;5?BR+Z\>G3:[-L3X>:"0EA-HRY'6PMP1;I4T;JKAJ-8.M M-.-W22R-!;;:$K/:D4_EABPO0$TN/S7;H]:[$PRX=U>?\J\OCMK-P_>&QY[V M8"'*!(U:E;I-.!H\O$0Z8D'FI^2UGA$);.$ VG" )$P;H014"GK!)0,4UAP M,6@E9Q^- Z(%KWCPWVA4_RV5;28@=T2;\V;J@G4. .,!=U1 A!QP#*V1K$"K MSOIH2'Y>)&87;8Y1AF74L[C35^:]JV"NC?QI%8^YGZ@-TF1RV<(-L"B2I@1([*P(E>"LA$E1ML6/-)<:F7B_]^'(B@30'OI[.*&Q:+V>CBKLI4_C1]GPMJGHX,38$\#L%OPNA$BHPQ10T1X'"LBG$".FA5>A3"PE8]V1+S& M-ZM1!D3,2N?N'TF>?"2\3,N]F\R*\*G_+"X'U]-Q>07+\\IB_M/@1"+P8_*?RS/-+\43]G/@WQR.2BNKHIA]51^.;VM,!-^ M5Q__/B@MN#< _6MRSML\0AL#7!"&*7#",FH!E<)+4X?9N,# [,HC?U_O]?]: M;O5?PP:7'ON[R<=B>!6- MGD:>>PX%Y8X%%!O."12U'Z^](ZU4[2-B.5KB(Z.9C#L*N7-0/KO,62L*:&ZIM[;.HR$*\5B:/)J9CFG& M$HS/IQ/']UT$(_7D./0DEE,OS8P\IN4D.)&+QK;QQ'DIC+>8.^0D ]*NPQV" MMCCQ 3J,YM0\%7VD,H/P<'7JSY&";K)DI\BQ2X5NB0X3'3Y-AY(W65S::<.9 ME@*P8'MQ 06HZ1!*V$JG?!X=1O/P",$9XMT8Q9?H,-%AHL/^T"'<:-K&##.& M"$J]YYQHZ1@C=9(R'R, U# OWXLBL'OTT4Q M$-G@!S4KW:MQ' M$-KAZE;NRD/D$D =7MB\^:987$\O]YN@$.N.#C2Z),H]Q1YB MLAK[ 3!F' 3^Q!A3Z:PREDOF7.!0JS$6X0.^&_NQRZ6W.M_*YUZ[?/+2.S1_ MY7Z/Y>HC*GI?UU B5?'X]\,%(GL>YPN=OZ?(2'QZ; MLG$5W]G')SWH _W,!))H]0,??-P'(WL-Q=AS2,A^3X$C?MEN-[;]^"-(U;&/ M.%YWTD?43,-X X9B3O+HVYX^VJ*KO-%#'$X_8R'B24":\7$^&YT&@)S)1A]C M.LB!ZA"_^Q(H'C!6(RQ19;F7$C@?7,VF-X/I;3'+%Z6#7\;AOE2)[B_MK'K@ M[Q1Y%!<52,+/@48V^E$'@4L<,[^;A@HK9 M(Q4NQ_,>8]WC/D>54>OK]HZ /GVF*#A$!>?-*!2Y3*4 R"C*&*+2.;DZ4L0" MM_ODO)]-AT5Q.?=AVTV]ZP=--KQI0!G@) ,H9O?9WM3, M=-PYN,V#Y[68#N9WM[?C41"496^KJJEL\?(R^-?I>/$R9#Y>XKZ$)I*-2>XX M)P9AXSWWS&@CO5^9Y(@RW:H!>9]7G7KGGZ8?Z_56DTM7K_8AC7.822$S)H[2 MAZ8MS5W0&*D)58)Q V/2P-@)P+E5&"(GF#=&>UAWKO$0H+:&?3:,XXT=S21D ML0NZ$HP3C$\5QJR!,87(6J6!$(Q ISS@BJP;23O7:D#U?!A',YEA)H (VK@' M+2%CPKAW ?BWY6EZ,5]4=G;5:*K3+:0/"U79#&9!'AJB(8%,0R\P!9K6C6&, M=+0UF*5>Q_=A&0\:PD89!_AD&K4?4X6>DZ8\891)V*",(!:<4@D!,9AQ)#42 M;HDRHC11K4[M6U 6+SB,,A0U6I10EE!V7)3A!F6<$J T,IA(J:"&4OKZ7-9; MT1X9N@5E\<*R09?1F+U*3P=EYQ/$?;ON61I,S&_-R(+D*K8QNS%[@$B !;4" M<(@Q!))!5&/6,D1\&[/E,G\J.\.6L/V]>/G8KJ>JLE%&8 ]F^:4(3XKPO!RV M&^,"$";.:$[#?]P29CCCJ[0'!B1$K9$A.\$VFEE+40:/TQP\P3;!MNNPW1BU MJ;F37G&+#:MT+E62U'XHM:;5!G@GV,9K%BHR0E"";<\#L?5(K\'M*C^FRG2X M&"R#(N8$=R4==@!#7G*8,)-VBXF% NN.528*&4) MLF+5,]9"K57[A'(_,,7+-A 9EC%58P)3 M.+P+01P]&"8XT5!IH8C@7U *^; MTAN/6AU']P13O#-_DE$9\\ _Y<@>? 77%9S98J)O.J7]PY>H+;,,L;!6@0 D@+Z)DI*]B$X$*NK$F(B*;W,;M<_^ ) MKJ9$E]C]6"Z]+E?>;"S\HP;HFQ0@B;&4T.4*Z,UA8[ M#BQ60F"_*A/3PJA62EULM$;,C:4@G:+T.QQ;^V)+8_K'.G6A%(N?RA]_Y+/+ M\O]%^-)!\75XG4\^5RV-%Z4\Q$EQ.$"CK8XH<;@1JDM (@"@3S6A-9* MW'EAUI7B%Z/IVD,N-R6LS>A+0/V78C29+V9WU?ZL&U3E1XGE\HQ%3<;=MN6= MU>!GI:A/&)=;]?5F"I+A#GD)E=><*\LX '7MJ+* J , \WD&]4Z3DGG&HV;R M'F10X+IC?PD5^;_>B&4TL()*+&@<(5I:KWT!\#T\\SNG3"=098@ M?=YIQ;\7B\&PZ@\QFWX9E7VY+[X]V)[TP,1PDE[[-L*0=,,Z)PQH:JS4'AJ@ M"1!U'9QDP3:X[[2'?2G;=KQ?[8K^]O?@J[\]>/#[?HZ%H!F1Q^2(%'3KI=[O M([P1)!N-)2@7W$EB#48DV :.JU5,3CKK6BT;7P3O>%D?@&00'VY&9H)W@O?S M%RG2!,C#8A\WOH ASBJ$E$!<&4P,I>OT%"D-:L7C7X3]>$6#D&6 10V_[RLD M'1X(^?Q0?&WDJ]WH^\1B3WXX6 M^7A0?+TM)I>CQ=TL]>9\R ##D*\-,&&U 89(!!0%F.)5B.X/8/2XU:-=],. M3 W_YVXT*X(I%HROQ;?WXWRR*#N#A4=ORY<5H7@YFM].YZ-RGZN9Z[#%U2BO&-:9(4&TID;S6U@+ )\=5?0PP?'?U*O8W MR3",:7UW]@3CG#3I*4-*BC6D ".(P5 M&PH]<@P[+JEGED,2$,D!%0I*^.0$X9T1N;_%>UZ([%;T]!4,WGL5X'D9WJ_# MK65L=3PM;[&8U?EIYQUF)9)OA%DM!8#Q &:&+!%,:HN\T9 CYRUM=52JSU#\ M=+8)Z:8_ZLO-W5V*S%#4'-/.JM)STIA=!M2V4TD*&\THC>88<2&0Y (A!!Q; M(8HH+7UK:M)>B(H67.4L8R3F@<7IG#DF\/4$?+@!'Q008XNI,T00P*#F B[! M1[& &D0!7\R6GI"=)_A.)'@;PU+=,$T'MW>SX74^+ZHL@-%DD4\^CR[&Q2"O M7*!S]#FWHILVL5F$%)?$$Q44*0S/0LSJJ5:/?.WP/&\:QLG$#$/Z[6-&?T] MUBE.BOEV0%-V&4K;]"'#3;(Z(4AZXCUAQ&**"6*P=DPQ@&I[:=FN6(I75I8! M ,XR\I3PUQ/\4;F1V0ZU$ QI:Z#SWD"C7*W+N%;M1-Q]\1>)_I2W/=J M<)//_E$L\C+N.R^&=[.J24Z5I]#8J"D6_!#D!6Q.>A F3!I3/D>#FF7$*&B\ METQ9P_3V]@R',EKO YT'50ME\D!3&"E!N( <-!"VG$HCG?6888@UEM:O(*PQ M%>C13(D=(1S-5D8"98RFBNT$X03A$L*H@3"77B"C%64*4JNQUT2L(,P8V:%) MTI',;<1%!CA,$.YW'/B[I.!YD(NCV=M=!O0V/).FZVQ G152 ,2E!L90:N2J M1Y)A%(FV2FZE]:LO^6A/Y:]BA"-$/'21[LK%)-$:"^(G.EBF!2*AZ3 G'C+7&E!P* MN?&"O0!EB$2=7I20FY#;$>22)O\/X.",$J"D5U@088BNAXLQI(,*/A9R(U;3 MX0R@F&D5W4-N[T*VZTFA=_,J1_?! 4('GC.V#Z [,4YLVTF-8(VB#CAWI.R< M!#7&5DA'N%V[RQRT(KN/S!-[6V]/Q%&A.TT5%BR3/&;?PH/,%7[=H6,IW3$1 MP<-$L!$W6[T0$G&:41YV'D8@@ M$<&9$('<2+\BWF+LN0PXM=Y! BBJB_BX ;(5='L1$3S/RM^I!13$F1!1S?WS M((+88?O.^A;W9Y->C2;Y9#B*.IOTU-=H[T&79Q$C2KO?A1M/NW_D1>AEE&G= M(_2G0=#)L^D?X1KF@V BE4WQWTROW@QGQ>5H,1//@5+\ M2$S4&8:GDS6?0'@:(-R&0=1@$"@.E+2,8L4EDY15(X&K!%V-#'@R_>@Y&(Q7 M/1XS/Z'[AYFGGS]8UX*7YN:Z%WUCAIYCJL)6)4D:>Y,3)A2FDA@C! TJDM6C MNXUCPK?:^GX'RK#>G\)RV^+BH),_4299*C!+480$WA*\K &OXEQXI(GAB$KC M%+6 UN4O7+0;C3T#O/%:?<)4WIV@FZ!;0G+8P2)VV^QV]_;[Z9C2?W^63X;+X9CB]N9F6GS8=_J-JM#2_SF?% MFXN\S"8,3]X6DWE>BL3Y.KH0;+3?-MQ[A3$B#%$#2 M_-MJT3^6:WY(@[JT I7I$)S%#4I+,4?3WX"GS*OPZ: :&E#3DI%DM+<3 O%HMQ$:$K?"]]0<@: MC8< QLH PY!UAD K"'7&*1)>8XE_O%_\AV*<+XK+3].P#?\Y6EQ?3\?E[9:E M8>4.Z-)4-QN6^B%-2I$)%C5U_/2]Q13H.5MP"[Y9%"(H0!9[ICR3#@*H2G!C MQK%S\M$QP!' '6^4:8;A4:H_$[@3N%\;W%NPC4"#;>$($\!9 RCD"#MB/2ZQ M32Q72#T^"+UY\HDU%[G"3L)>P=US1E#?0\ MH!PY3*!T@'CN-6_R"Y"$[<3;?:#732.T^[;FR<=]FZS;JTHJPM>'/\M?YZ/+ M8A8C+^ D?<>MRE$TD]6$YL!RX(P!*/ 6-%"M,V\%Y8\A- #4K%?<;"[X;Z/\ M8C0>+;[YNAH[8B>A)_4FB-L^*$6'SD+3]A+A�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

AGZN'Q!7 M!!D[.D!:9PFL!EL\_$L$D5K;)Y=KP-NF4PZ>K#?I0]EQMY)ZYQVSB]LJ=+1@ M?BFO"NUB6!9D.!;4ZQN38PWOIX8;G:Q#T93S\88YUQ9'-1*V'24T+:8+YMHE MWTTT'04]B2&VYK_RP#/A\63N'WPJ@A+=HK76:%%9G7W+1THWI;K@*?&4;]\4 MXZM.EI,R4A"GV#R=OQP7C!O88^%FF-U@LI=R"WQ$Q]$( X"SDEJND1W9%H$* M&%UXZ->Z8G2U/ @N0F8\:9Q\%8LCQ*:SMZV9#P,2TYWE?Q03MIYW-]589F:+ M.%B[!L>G.GTG4WV"^]=ZI^3XA2P\/$M4L#9/XN]0_ V/ZZ'W4=8F1CKHHT8< M6KYC@AD:A78H1)N3.=XV=K$4:)]&F#AP16Y(5KDHMC253J# M1J$>QK$3IWX:>E%J !=@/$"/DWYOO9^YW!=;FI"RP+H$'#OO-I>U-MGG7@JE M:+#8<$0$"NX/+ZA=7?H8@R".@R0S8RN+,\\W/>#R0E";J;4-@U_EBU#.L2A- M./;M-ZQ#\G)5I58T8FH5,;S)FRYS9\&?+I$PT),G(! )AQG$)H(,A4:D.P$H M=:$="2>TGKF1_;Q\GX7EJ-+_%Z[Y=E!$%K$2DNH6B.A(J,TT#]FX.29:RA)-JAL2) M5I0LW*$+QVC(-]R0KU4,^B&\FS^8?Z*.K8<#=O0IIZ[^>E).#SV./80M MS78Z_?3,5<'Y%(PIS_/]S+1=!_Z+*-.):7JZ&[I6F.J/",[6QM\'KC>WHQ>0NSW\4_6?CIF_9_PE]^2[5?T_#BMV_IK^GG[SM' MY+<9U2Z3>D!$_J5DEKS[V^],>->W\&R6*R4KI=#=/A&Z>JU8=DQD\@3?''7< M*<\R0R'+FUMB\3U5W%,&'L$$S%G_7-#HAJW;O?]T!E."<0LLOE+0"%HP@F5O MR%GS/:5BC@(.YQI+_:#J:*ZURT34_H,ZTVEA6W*>Z\OJ*]ERL3Q5+/N>3.?< M;<^@,>8-#VN(B9(&T9^I&%NH+OI-"=H%:#KW&EA2K 8.TX-!#6INX+$L@?L: ME!URY0^+$6ES\.(598.@>(V'O*$Y*WBM+K%&G7(H^="K'Y2DB)4Q[)+YI'?1 M.2B$L )R>)1#7&)E5<,; M*S2%&:W=0%J%YUE6-:\(]B3(GBH/)B"O;'Y\XK MF]&TAJ"&\L#&?[S3W]%GN&HH/B]YR??R%B;[N;C3OH']-?E)ZQ_@&:@Q9M7T84E (DZ# 9F/ILW> M^N 5(^ ;]Z<%?8:-??5('Z )/G8K?T%*THR/6$10\33V8<&S0>9G5-V MVH=DA+7E;4LF1?OP5Z*)$VF\;-(P@308K**:C]OG=^]E8?+_;$%)30DOSSL5 MIA].A/2:"]TP2QTPHUQN0+D66,/K*T,WO:=G0,EB M[17E=EAO7K**=X7>"'!"%,-3+5LMEH2KM*(!P7+;:XNZQBVFLLM*F \GKV$U MKNJ/_Z+3/RQ1982)4#0%G&7QTP$Z)]2RTHWE3N'1E^JRU'^1/-!:L-] M?\NV9?"S&;[*U1T)I8M4I7*"^B!]5A\WP;#&N)5J(&1P2"34 M]B;"%V;+!+:APSPNR0*,JT:J?>9J>^A55^=$WW;."EC_6 M17^\*4=P/O9QE!E#7:[9M<1KO5L_5WXP1,+A]$^-BN@TP=2WF/J[#9&+_1FD M#]%B3WMYU'MIGO;RU>RE==K+5["7WZM9/EYE'S^7V#Q \KLT\'C_J5@:=!)M M\.-C]QR])R]D)=81]^GPGC;RE6SDZYGK:Y_?VSB46PO4RWSXQW6-68YGW-,V MO?Y-:_@45XLQ-_XP?_ MD7:U?K0SC:O;VZ(FRWJ:3XOZB738@\_K7W>8R&/&35NVE]A_&UI>4KEE&:ZI M>X4?2 B:-#.2++0S-W5-P_4C*PAX?!)#[W:OTS/5V$^H0WPJM;PER=1+^L?[ M2O_XY<_IE&5)VOJ*I,4JJMI?VU=&]^V?_RD"PN2C[#RLO>83)9C0!<;J1RH@ M_%G-"E'NES]/N;)I,R(>7_WUSZ*N1K H+(O','_JU7XMU'P]@$"W/C7[+-5X M(V;LB<4=%8L+# E*X"=F$-EI&@21;YM!B#B7C,6Y<9K9/9B1U\3BS"-D<8M( M*-Z2;NXG)G=B*'8)_ZO%F,9P=I:KX$%G=2NO;+ MD?8=5SM>3QOF/<-.$]3%LDH[U;EJ/IES]4BXA"N!R'S?CD+#U,,D<;,,3#TW M#CB7B*(PC)Z12T3YY _G%FZ@X[TR/?<./7]-.4!;TUMQ!)P9T8D!'P8!,R8!B/XD\ MQP1>8YJ>[^NA([J=Z'Z0.CWP@:-D0,>BL%BOW61Z=6E15&5TA@N-Z*=($(0C M\5B.<0CW_%S\@; M:-\BVK:+=M?>AIOF%+!ZK?K&X;B'BOT1P.5/IFFX,H$Q,-/,B9),CT,SRJS M!HL'N$ED)D;D1WJO3^+KXR8OP.6BGULG=G)B)\>BC/@R.="R=#NUC=@,@M3+ M?-VQ#!/91VR$B>_$;T 9>6ONDA/W>&[GQPOV<1BZDE>LNVD66K:C6WIF9!:H M&PFPCMB(DB0(L^?,1WD@ZSBI":>DE$>=F5^K27$O@-ZO8!Z[9:9LP,QYC4Y3 MPY0,),[ ,6WTK[3/&6[SV_")+/IAW24] M6W?PPSZ6W(]6@SG%==XD"[-ECFZ6)%D(IE,6.+Z9I:$9V0EG88&?!/JK9F'' MZ(@Y:.#YQ,!.#.PU,#!7(L_'NN.Z26#8<>IGB9FY\ 4O%LT,J]_)]%4QL+?F M"CHQL!,#>Q4,S)<,S+%T,]4]US&<-(M3,W0#0QB1<6P\9^K?]@SL9/$=";]Y M7&:.Y1ZMQXH0C[7A DKACK&P;<&>7R!K,77)6E(SRAPOBQT_LK,$_O1<7MB@ M>VGL/6N->?>W-^F>5X+Y[%\F1\49YGI9;Z=!9D+ M"H^GQ[P3H6GKT;,F*Q^<\YS<02>^<^([3\AW',EWG"AT(\L'M4>W0M.W=#\- M!&AA$J4OPM8Z%O7$L+W]%E =*Y]X,UTFOA7-K"Z',^H%*SH]'TT])JZ M/7$\,:_Q%%[CZ%G@N;;O)+:;A88=.:)8T_,= MC.LW8>#I/8_.\_.<8_3#/ NLQ(GEG%C.2V$Y\-^6Y;B.[1B1E<598&619=N! M'8O4'EL/>LB S\]RWIP#YL1R7@_+>:TP-Y8E64HQ>DU6!VOO+#V^TF--RY$DV#=WP@C"V MLL36O<#.3-/6G1B^B7W#BGHGF:VC7,;LQ^?RY/= ?-^!ZYE[S9H[6OG^9L3X M2S[CG@3F=4P_M@(0RX87!Y:99'Z4PAD/;0M8@17V_)S/<\;?FI_A=+R/P#'P M@M% )#TPS]M*^B?\\)_RMF?6G$WX2X(\6 MX+8ACW<2FFZ4^8GOV8[N&Z:5DI(>)HFO)Y;70US9[7B?-.I3@L*C 6!_Y.4X MOQP79["Q9PWLLI*HT'Q\;'/T-^!8?+,3/^W^:?=/N_\V)W[:_5<' 1]7];2J M\QDV[;N<[0$$_H7K\8[A*8ZXQ$G\P#.=.#;=%+1Y5P"=N8'C&(MZ?*M-955] M ;J4U.@36%OYZ>4[X.7%Y22?8$/13Y-F5L_QVH6.HYR\NBMP<@"<' "OC7$H M\?;4#FW7BQS@%Z8=QUE@!KP"W8U27>\A)!X/XSBT5__Y&,>BM\)P]MI>[\0[ M3KSC\;S#D=$_.\@R.PP2RXY OL6>8?D<&,+$#FPO#2,O$B7@B9_T@HK[9QPO_)2_5@WA[>"\_W9^ M<:Y=(Y.9(+EHS;2:-%5=C+3\&HAQ1Z_&:\P2=@+)0/3(=+PD#E(S0UQ1RW== M7LOM^4%H]?*.CD?S.!IWQV\7WVMZS'TX&?W<$N)Q:A['E\5\\JV_11[D*JD3 M?I;:ENF%;F*$F>Y'2>8+'A3:NG[$+M>C\9SLG0C$@TX\Z*$\R)$\ MR,LR9#V)J0>FF_AAFGEMERU3MWH='EZZ.^>DMCQ/">CQ>G. D MXGNK0J2[A M#3ENW5O-3W$]R2)L,W"!9:21[SMZG,1.FG U1?SDZ02FKON>ZSEQ&GM>$NM>(!#U,M=.CY>!'(VWY6 ,9+'% MRUX!+$X/E($?C*3FI M("<&\L88B"49B&NY;A9F1FI'9A:FL9&$NLBQ!^7D"5205W+:7Z>^\'9R5WZ% M+1^6TWR\+R?':W20>H[".?1 S_S,L&W=]!,G03=(JWKX::_*_GA4CZ/Q?K0T M%U5MG\MCTS2.S]%ZBLV\2=;C*=VW0S!SG#2.HTR/X\!/XU3@:0;''1\^&K_) MOEC/8@\58Z\YNR?F<6,^)]6S'>GQ=83VVF7E6G%J)Y6:)$82!)[R];F*;3U";^/^S]^[- MC=MHPN]7875MZF2JVA[<+\G9J<(UF[2>X>[Z<_ M $6*M&5;MDQ9E(2=VHYM420!//CAP8/GA<4=1\7BS.8D<7PY0C M1: &"8@ 8KRU7!CG(1/&X/H(F6J*?'^UD=Y884KATJ5LI6.?=.QSO-@@HN6Z MIK@"6A# C#2(4L":+ 9Z\/S8>Z"@,=^HNF\"Q;W <<4%JP9J<;198KA7Q M&B#.O/92&UA73Y,0]#B(N3?6D0/21WI;XCIAYPCT%=%@!5*.I#+( !P^I\0I M ^J,;M!#>6R6CZ1<[,$[!;/>&D ^3Q?Y.,N?31>??3_8ND3;"WG>Q\*P.V60 M! V#-(H9X*!&UA#"C7'2BCK!DX#P'1(\]=74T1:3D+7$^A"K%7P M"B,?%2H/'7= 8*MTI3Y9S&6/=V5]+'/WT-67XW.4Z)7HE>C5(;U(DQB/.8T\ M5]QHKC0%&(0?*WJY\&N/S[A.K81?0E="5T(7:R4%EL)Y"!$@1CNII)%53L^P M9V1 X0.Q6R4MJ3>FK%V@93?)8[[ELV&4B#*)3/&OP54^^5*48>4 K$:@TP#Q=!"?T+$_=* F)YX!Q"/IO#?>*N84HQ#4Z(BA"[U'1S+9 M)'(D81Q&>#B]O1@7;[.(O#FX M;=O>^K===,%&&3H 9K(FC -#+SC$3G(B)'58:ES9?SAQZI& T%+BDJ7GB8IS M'SD6YW!GT'V-//96[3KF,Z\>X;4;0^#1L/< #/,(M/S5@794&$,\I09BJ*E% MM (S--JL.USM#\P'8"LC#)[+7F#Y,.WSB=F)V8G9CS$;@L9)EBM@E0#&4XB0 ME=MOU\\XHUR&OTT^GT;_5[9BHZXX?T<_?><^\<6$+=LZ%/_OB1'W'V^0X['5/_1N%-+Q0$)4HB//1,*R$ MY;SX_O+-J];]J=OP)&,A2E(K$G<6C2JY25/6$- 4VJ!<>X$5H'_A@M+ :8 MLCIL6 $$U$&PIH]FGE[FUDTL2BSJ&8L06K%(,:R#TD,$%=(":04@];:(2J_7 MMD6]9%$?;3@/-EKBG"08)1@E&*W!B#0PPDX)"9"5SH:/*02.HU69.8K6RLSM M%$:)'/T@QW:>2 >4AVK<0ZEC= MH5)+#3)V+3/)OHG:1]/<3L\=$U(34GOM,M$%-7L"1@J:^C?"&LF4$I![CA$& MF)NZ4 7DU*QY@.T;C"=N)WQ$[A+[CHE]29WLJSI)44--(Y63A'D!@2"6ZW") M;HH2RC57DZZHV1?$R7?.\=Q+W:^T:OYU$6M-KOY>_MMZG?%H4IS5>2$0^*X3 M:5U_GQT_4]5'7142"@A$& U79X<14P5X=5M,2@!N%SQ,?P8Q8EO^<0/?ROE M:C .W3"ZC T>+:7JJE9H8XLNI^.@K8/2#BH73_W7E<^Z.MRV?\<^O13,2[*E>U, M"(TL 5(A"ZS48;E$,U>+57R4\0 MU8+:*K10*&8$.D//OL7&K^/=B\V;:=6Z^IYR#8(.6TI M>[CJG8@5Y"C'$J6Q[&0L=Q1MU?5PXS3<1S!U2[^KK1S,8AG0 PD0;';8RW3K M'2>\/*">Z'66V[W/W#201S*0Q]/68V_?:4S*EZVFZV[F@\'EY6!P*,TW^?RJ M/"SXFH]+L__W^9IE]E7#?N@=TF$:V1TVO) M>EQ%[4Y-AO$_KM'Q7N9\Q5O.5X_?YY[/52-<_XBR];2#:@JOZGD.LA/8P2;& M]8QQM$EUCP/D#)->"\L4=TPX!RK&">X).&;&'4# $V:=E@M-E.M!NHY.B;=& MCJU'[D7D8*W4AQ1!0(#V'!+%,6<*U.&-BC.X5L?WF,C1QXB@I!T=)C>2=M0S M[4BT2FM R0RACBL-"<,4"%8EQ6#8,'$0VE%29=X[L= KC'3]-5]%5^,PS#?3 M^6@QWU;CZ=Q MAIGH 7<([C9IQ%/BW%L=Z21.3$X/0:C)#&V@QI J09DQ06-!1&-1(0A08M%1 M(^@ K#@0=*KZ) 0E!/4"0:T%0(.C5S M4 )0 E O ,0: DE@08V8(=QR0UCR,L*0$)ZLI8>I9< ZHO"0H]]SW1GSU*?C>"G)J=)/$CJ1_;JQ^D@8<7"GFJK=-**.,)P,I4Q@W" M)=ZG=?75\$BZ0O)'V6+._'TZ*>ZRZWSV9['(+D,[WN:4\NIZ9@=O+0VT:("" M)'">:429DY8[@A'T-5"(QFLI^-\1*.5 _[T<9Q^'^32L( ^=Y?9..:BPTT2C%D!;( 6T@)7[K=.:(,LO:H"=9'4TR_JJ@G@/4>8,<( M*"E6@ )!I6+ &4TY!SRH6X+5T>.2\+U&5NX>4*=FZ4D .D G: &!:%H'8A+ M33Q15 @#/& $RMIECVA-U\JF]Q)0:.B+S3@_I M-@EUPLXQ8N<@]"3.&CV)&2^148AI;23$ADA69YVP'.SSM'_G3#HYPU'2DA*N M^JDER89("% ,N&*$2(HU8PQQ4A&),H/H(1"I+RH-!.0>L_<#!= 0=R0K1WA$-KI29&:ERE M,>7*V7759O_ Z:/99B]GZXDWA\>;771"1\C9:2@8HDW&0(\UL9XI+2VE'F*% M(VN6&0,]P6LVY_TCY^2L,@DYQX.,,;"IQW FG,C+("2:YM;;T1P*P[ M^G3'F[0!Z@$=CJI0M?J:C\;YQ;@X"\-]-@]CWS*[S+/O!V^KIWD@O9#JX::! M/(&!/)ZV'GO[3F-2GDBHM9G.;J:S?!'S_U\LLGE4QT:+-V:1.T9O>MQRVN!* M"28<0Y9;3P"2&M3Y)[DP<$W)7BDR?CK[%-283ZM>/OPCB^;BT22?Q!HE/T_" MEN(V7ON@B$DE:38(6M,#!V842/O^T]CW]X4ZLCF]<$0ZCBUU'@K))(#$UC$\ ME#NP%F2X3^KL^MQB?]1YZ.$AZ)&GSTW@.47P$-C8%!5T%CN/C=!0 "\$M[6Z M@XP4O5)W=GUZD=2=1)U$G9U1!Y-6M ZE1%"E&#<:(F4$K$].,95T)^K.@2/B MY'23E-K_)-)C$MK:!1GB(25:6P5]C)!A&%8^7,0)L%;_+-E>-B7N[)LRTEN= MXV14BT-&1^]-8JTR=4],9@TCDJ'B@EC'?JGY%@ MD6"Q/2QD4U>5AS\+QS@3&!!LK>"X3@Z@A2.X3[#HC9$CZ14)%:>!"@H;5# ! MJ3<:.".D8<8(8FM42&W4FD_WX5DFDA*PA[#7_AHF@MP6X7YMV\3T(CPAC^.6 M/$4>H@(WJ"#6<:T(X,P1CPGFP%7I/:@%!O5J"](;:T4E;@UWTA%*.D))1R@O MI ]MRJ!J@P1S&%J ,:Q9K*K;:642-LK^O3& +(S^NPVBVS"3\)/'_##FT*J M# =E1P+"N-9&$TL9Q76^1>KD6@[89%))RD^B3Z+/&^@C82N/&3*( "H5148R MYB&%==$@X.Q:=J'#L](D325YD:Q_0\^F?Q;1:600VW 96K$HYMGT,HS\S70^ M6IRH 9?!!@U&6(>,YL1)!@522AM1HX%+1_JDF/3&*O-S:.>LF"]TD<=OVZ4T M]50AZ:W><3+JQ2&C C?%4PG3"DJ!L!1:.$>%XZK:PS!"F>@3*GIC0ND<%0\4 M$M"I6VMB10^2A.T6%SM-]\5(4ZD44$VL$3":80DAWD-=6URY"Q_U"1>],7DD MS2+1XD0T"]8J:AS((!#"#&G- %(2.U.A A+$W>';)Y(:D)Q(FF_\/8SW8'23 MCY/OR#. $+*U]7#>$P$H#*H#4L024.D2S%K8K[#;WE@I5E*FIZM:HGU3(?IG M 4VG):<(&PY$RZ>5,$:\\\H9A(&G;G56&WZ2O=JX],;.T15L'L;MTG.0<)-P M^4 M)PQP8K&Q1I@J)SI54N"=P.8PR7!JBLAQ>7[\/9_]62RBX&9!XD:+NX[2N1XR M!EB# 4$%E$Q)91VR2%D=J5"G,?,N90YYC"RN%*0=.)5)WJU;66_UBY-1(PX9 M$X*U,&$A-()X @A&2G)!ZB-<09U.03.[Q40ZNTV,Z"4C!&B2D&E/-$! :VD( M$19JPX$1<.]1\7BS.8C.*85Q MU)QZ4IU^4^-??8CI= MQ-=\Q ">QAZA4T^8WAHB@DQ^RV?#..9EP9SB7X.K?/*E*"4SCNX\^W[XEV3Y M?!4N" MG0(#K;TFB!/MC>3:K+SJI*5@S2^FRI%LPLR-L]Q4XU":%U>SW([F M@_$T3O33-%RDXY=T_-);"%4/BU>\8CU[9T*A)F.LPE K*+B#5'."-42HK@[H M.6*Z]X0Z ),).*=]0-1VHIGXM7=^':.2A)O,<=P2[#@$F'@AL"2 BU5^>^GM M6FK)WB'HY*PQ20DZ/(BRXR_,\@D MI:0?R-C"IP3VUY2S]"FYK-V4LCS*Z3P;Y$%HBF&6+[++(%;9URA7;QY>'(9W M.+V-F5MV8M[MJE/^;9 H,IH %_4%IBO*AM\%R: M]8B)_:'O &Q96-!.ZQ@D\/5ZZ[A+"'9D*M]EM20"82LCGS36.6\AH,A)2AGE M==)QPA3A/0+)R5FD-LGG8=J^CP Q2;^E^*$-RE.)](AJ1.25"2I M2%*1I"))Q18=\F(%XU \JU<'<;^,\HO1N/3XSTQS&A>5U*S44G]XHWP<2(]L M#80CV .GL4QC>8AM/?;VG*LY4[8NH68H=6M%49YP]IO7RMM= M1"1-F2@(#(-&6,[R^PG MF&*GGC"8-4&C@E@O(*>8*DJ #5H6MQ5-J.%L+?5>/VER MOQ*M$GM,.0*<\8IS805B/E:^*^L@U#1LF<0Y*BQ& +# MH5>Q9E.=DTM+^+XZ2)KO?31KO,PX>T Y<\8M5]U>)\XY,$OOQMCC7L2*]\[.G,[)$EY/&:\4-"'G MP$$E)8XI?1"@!$H.;5V!0PNZ5J9GWWCMHR%LM\=TB:^)K[OEZ[;]<,!\W:GQ MD**F9(GCAEO'-=!. *"L"+IM[3L?]OYKB7+WS==3MQ,FP"; )@6V[PHL:0"K M)-?>_3^)I7B\7-#W_]Z[=OW\[_=3$;GT]G M7_Z* ,!_G86/_UI?^R'[U_7XAW$^^?+O'XK)V1^?ED(^FMP60[5X]6O#U4BT MVO]@7,(GU2/RU?Q]]6/>])8HO&4I$MF@&(\KE/W[!_"A_#V\ZZ#^_9$A_SRZ M+N;9K\6W[/?I=3[Y,5L?^_OV_&^CX>+J!R*6B*PFVFO,_Q]>+*T1D_=7,;)\ MZJM1^WW^JNC=>$CQNM?EPT,@*O._/)8XY][<>*ZEK=5^$.9B,7ND[:WOWQLP$,:K_/YH$K8/ MR]_;#YA$W6=\3SN%8#G&G4GT X&^SF=?1I/EZ^6WBVG]A^46J/S+4L0%/&<$ M,$2_JQ6GH!.-\YMY\4/]PX\/-:%FMJR\),B'IR=']2#T76LJW?\,/O,1>]'7 M]IHOJJ]92G;AFO**8_GU>;1M;]AB4&XVEKV"X< LNJSGN^V6U$RIM_[[*"%+[(F M,-Q8$PQVQ@CMG+#"*LV(Q (P&*-P"00"/K0F+)?GI@R]__KKZ!$;@FC9$*I% MN%R#?YD.2DWMGN&@E,[/03A_;F2S_U99 L[13J/37C1+]NK&=5CIK7X+ZN%L M,_]>[,JY U?-O1&AE>K#2T*UP88RC 4%C!)"2B)(PRC3X#V(4 [50=$ ?608 M=7I,T_]Y?^A:T5(_?/F_I<-G?P]IJLY_0ZF2OJATO5H+WAF3<* MFU6(:1^T-4YHT,\0=H@ :I2U EC,40=X[B=>.3J7^SWW>?L$>]]#H2[NO;41 MK,/V[=CD^/FJ" (Z*T)+_K<89E_RT62>A4DXO9V5YO;[ULCY8C0>9U?%>)CE MX;++K'[75S_W>3/%ZRVGT4ZZ];>7'/JW32 238@/-1PRQI7WW"&FI*8. &JY MY4Y([=9"?!X#T1^K;O\I]/H#+-DEEO[KL^T ( SP1[2SVAK\ "-;]/UD6/;_ MS2P\;A:NS8:W1;:8ED+4;#FBD?I3/EM,9Z/;>:9^*K\WFF>S8A"A4IJWXS?N M&;$_+<)_2JY&%_7MH\4['TYORL$*GZI/?T0I8F< 9M_/BR+[-9[5 MPK^F0.I[.8Y\]B!CT\B]EPW@^9C-6ZPD:1>">HH8"Z^IR.* ,?G/=O MNOR]SOLWOC;\\#?U-1^-H\2>!:2UA\+KSJ6W.75_2,8=T MJ%6=^@#PMK,JL?&LBO'MSJKP5E_;\F",='0PMIZ12NQ\@[^?8[$R2/4U9V([ MB%5]\G"Y VVS7*6?.!E+YZ(G( #1U[-O=O\G*D@A>-.?DEI'UNY3:NM)CO%I ME&_IF8]#KT,F#C\B0K1"SICVR I*I32*4!HT/1DPQ^?@J!/MIOBQQ+H#9AUIL@,;@<+_,%-0-<^6T>L=U0DDW!"RJ:> L91>*H81!\X; M3(V4M3)%K%XKR+*U,M5#[$73T.ZP=Q#9-I+M**'PE%$H8>/SR0G07+"8>H@R MIBB6=5IW1(!WOC,-LHY9?AE7[(Q]_RNWET]KJ: M5:W90T?7S[W7E9O]$S6#R$"EL/.>(*H%M55A/*&8$>@,/^OWN?'KY$5>DD)H M9 F0"EE@I1;6U)70A>:0ZG";Y]YBX]?I[OUZ?YZ4/JJS8>F)^FVTN"J=SI_R M(_\_>>B-V5U6!2A\W.33?C,K+HO9K CTN\IGQ?QC]NUJ-+C*ON71T?UF.HM^ ML/&IT?$$*%%)IA/!. M"H.1Y=0C73NU6Z? @R"%39>_5Y#"QM>&'_X6=.IO^2S.W;(6=%;\:W 5;E^4 M]RVK04?$+<\MU%:UP3SS+2=&1 M8&Q8RU_2RRG37 ?@* X/'$H"0'10#1V@@!K $:RC811"Q#\ QZ;+NP3'2V?^ MJB+5W4LG?[N$546 @T9 6N)?.U.?JM+>XYG*& 2<&**XD Q9;;1#]=3S5CQ< MXC==_EY+_,;7#HM/4P,QWJDI@GAOHO8C&G'S:ON"!K^IO] &23S5G)U2G /" M!']CSLX7Q$'* XB#?-G7>A4#]5YN,@>7(+334+@4!GG*HY\"(;<0B2-K]RFU M]23'^ V9#0\K%O+)77T*$3K*$"$*<>.OIAR"1B.I.22&6NPP-2NNLD*L LQ;-5GZK_;L =>\/USK^C M5V#LD[-;HN A4) VKFK$".040AAR8B%B"O&J3!Y'W,H=4?#U41"'2,%N$UWW MCX+'F?E^/(TO%O-C;%0(]YD#_]U@P7&30<)@JHGQ7AD.L*;>(E*K3-+*M7C) M?:E,OTXG@P/D!>U4:^JM;G+Z'TWHT5N*9+P7IA'D38BF M4T("9*6SX6,*@>.5;P#3D"*Y>_VMAW 5/0E6ZF>]C%Z1N$^6K@3>!-[GP8N; M8G&:$>2H"=0%AD.O+*T#0HG2$JZE(^M>/^XA>"'KUCYV9.1]+(9T8\#/#B;_ M^U<:VC[J=-?NM6]UW43=Q$[&X,<7](B]C?-UZ>@ZFLT7V3]O\]FBF,40NQBU M^#'[5I0U=;Y,1K&D4U[YE3[C2'N7W=Y4-9_RP3]O1Y6[?+AAGEV%[LYNP@H= MIWQTE\TG^?BNG*E97+6SP5V8F45\@9MQOHB799>SZ77VC]GTIAB?9YE:+"OU MM.X<'7 _+O]Z'1UTXZ.>?,L8.CF,#[@.XS_,+O)Y^#=Z\V,2W??NF#0X&I4?"WI%Y\:HRKGT>^WF"^FDQBO.5?BG_D=]/;Q2:+[/H3RL4D//V_U4H ?!A_4P__ M/ZK1?V!X>>+%]-WGNYMB=<^8'V&^&H6;U>F;&?X>U)L 8000 M"#B-%?L>4BL,S.UXF-W4(S>^*S%6= *Q#77Q@D32UED2XY9!2#&!"&IDF)45 MQ2AAPFVO$JM9V:*EUAI_^NWRM]M%1/V\U&I_F7[KM7R&Q6MT?7N]7.]>H6V# MY_-U;E*UMR)8^,KM9#RZ'I4A_>4;!\'[>=)2.F+<_.)J-!O6ZL>\TC]$J7_< MY$'9WKG<-6Y?R$!N >-,S MKU$__WER[9=T/A_-5]NT3\5B,5[*YJ-U'.'__6R[D\,N M=FGG>+?U('<]]J(YOQ; "R2-TH)P']1T9N,B:#DT2%I+Z)[''O=M[,&YV-G8 M!_6YF-_$'<_78GSW,6X<2FC;U#63RV'+XEV\A+!;"5&$QA M)G0@D,:48X*,\35\H/=^S0[4L0#&ZK&_3.?SGZLPR)\G+I]-PF4/Y-%VO1Z^ M5!;GHR^3\+?G@80><9/H2BHKK>G9'68^&,QNXW*WR$:+>18D*;Q87/\NPVB5 M(E>\AUBUCM_#WQ11AA"#H RZ'W* 56)%K'3O<*[3!UH]=I#3W4K5J\1$>Z]3 MO.,G?KX7F[T,#;Z93;\&N0SS+ZP3X]?8ZW&#P=$'L)W!ZS_NC).OPMP?0 M7$/L?<)&BYT>3P=_?GC$@(C?7>^!SX(>!ID-]$RW5@UH>_M9M0KXF_%&$%SO!+S'4; M[8,QT/ZZZM$(R$?A^$C\?#.6#P1ML[7T)9WPEC[<%"___A/L5"/T&3OG\NT1 M^F1CA#[?KE(Q>BZ@/@7-[]-%O+NPZ"="X/OINO94!"GH4>3LCCOD%8>[^^JM M8XNC6&5"?2?G\%[ZOQR.(S=N6<@8=80*ARBQS !"*'=BJ0T!:H1:B_#8UD Q M?\)"4=[K<5>6_GF<)#_I74^\?^1W3QR_9QM6G8V!&5WVS'M-Y.\WS60I6A4P M*9.&>&J!X]0Y25F5:3'L+25?LPF]LZT[;L][93U"Y_ ]@C77)U$?%KC'LAD> MFU;RZX.C@J?LMD_:.-K) S^%76^XZ&,6K@N?C\N3K'P8CV[GB]GR\*'XUTTQ MF1=''#JZB4<$-N>NW!JN);)*(HPHHI J7FL62"/6DZ./ON*)=1H;>H04.G15 MISXAR/ VVZ84C9"B$9Y',6EH8-C+O3ZIJQ+W&7Y?YM.8/^Y:OQ;BIIM>(/;O'[* MV\YZ55FI0TV&SQ_ZA@M^G4YF]XCU_]7N0Y^+P=5D],_;8OXY]L2SA[_4*:EV_I\/'G+ZK<*WR40PXHS7;8G"GK1M;_(,ZT[W_*6H5^V=X;Y%/ _ MN@SC759%6^[(P^#-5MOS.@M_N5$OA2C\/@KKWG+,ER[LLV)^.UXL*WC,FSN. M[[(@0S'(:59&)!5/2=]Y&V+W_ ^>)GJOJAKB5-7P7EG"-U4UI"]:A%_"W+<@ M.]5F>-SS0]!SVD%M!KK1\P,^X_F!V-.?D>=EV1MN4D)6VA!XF7MN+OU$36GG*UE&U<8O0]]PUNS@=?T%0^\EU MR\,-56A&,8MZ3MQX/(C^^:%/3@1]6H)/R44UM:_O4_K#W^QH7I;GR\*DWD9+ MVNTA^M;;XY<M$0=44:4QP=02"K6I[(7"&:/:61SJ+OL]7SP\:]G% M$?&91J MRGCT?V4(FYK_*09A)_/_E>;^N+GY[;)4W)>WZW*AH,?@\]GY O+:,_W=G*CW M_0Q_%YD6.SB B"<(:PWY/%UYNRX3\]QS>%V>UZ(2K=D\'H!7!;-[%?+^MEPQ M[=*EK_[RQ_*4^F86.G!V%_\;CSQJ;XA9=AL/+#\U_>9664?*/BR3FCSX[CS< M<%"<9]EORQO7-QP$T&9Y]+J8A]O&!$OS:S@-?YA,%^6-BG#W6@:JF]R%M\X79:Z5Z7A8YE^W(Q'Q7#UI:HSYM%);/AH=V0O9\#^,YWN MX U\&,YSK/#V-1 )TD=K&CIF%I,N!,Z7 MDSAF5.U9)XWBL4A8B[*+(B^3TPZB*A4]-Q;+9$S#XF8:M,RR<6M#_BU\=]DI M97*)T-SS4R?&;\]-Q"H9;^!]/HJ)'H.D3"=1N8L*?;:(.D&XO$H#\L1247;W M_#PK;359D+R@P7>1-FO#YH:1)G1$1)S*B['/7"G2KD8!O\UHQU9TJSCLS E9XMJ'6]$83BZO SS M<1*OG]XNXH8N/' Q'0>JQU/!KUKU(!#:^R8\FA33@S$@@ MQCV4AL?T6)YH5*=*-E2QMN1\KM^\?O%2)T)1*ZZUHFJ"[5B8UO>D;Q>FYR5H MWSNO=\C<_GH'XA8^PBQ17P-"HW0$I21:(S;[ 7.GN1* < >1-L@83@Q@$$)C M())$M/R F5?,-66LR"%9S&PNI*- M,EQWZ6"[M+8M[GF!=YNWZ27O_99FOR)O4Y?^C3L/!'AMP_ON!%@YP@'P-M\^ MR#8Z]SWKI/?,1VB[KZ6';?.PS6=802C?^]1BIPF2('W*S22V]%TKB';GMO:\ MQ>%$74U>GA.K%]Z+CTAC%ZY\UV$W$7X?/JD#OM>;Q#/%GOC,)$%\_^'_8Q*V MU^->2&+,3O%$C?DDBDD4W_-58I*4(LGBZO>2;:?[,"=MWRK#&UO2,#V98DZ()U>&& M>8\HPPI2S;$0D"]#=3QCDAK\\+3QX?GB@]/'VF86359E:J)-Z=/R<3S"_G15 M%(M?IH-\Y;9=7U!J?)^#PO=SH^\]\-?NNF1\<_%H$EYNE(]_GLP7L]MX[;V; MK2;._4[H+M4O[#:;YMLG6M>YV7H5#=*G,)C$T?YSE '0N$90*HG@E!#MC>#> M.TZJ@@3,.H/(*SDZJ(I#%L.?9M/YO+&[10NL+@(TBL_YOQ)8/3:X_CV,^&!TDX^SZ<4XQCE$1_5M4WQM:VCO"ULH M;>EY$L> <1Y+30-H/.:TVD,[1]$S_^MYA-A_G\*LJJ0!#] MF.B1Z-$/BY)LXFTQ(YAP1L.NQ2%E.*2^*E+#I81JK;)4LBCM1_WHR$C?%MW# M-Q8EVO2 -AM@ V&CJU@L#'% :^\I541Y;WRMJU",73*9O.=VIDM#2<_M(0?O MF5:61#N+S2B&&_W27L:4@ZRGO@DVN($-]DISQ+PBU'*EM*,KV&B!,4\VE*>A M4XJ;+J5M!U9:AL_7T^\)1+^P\D*,5D!0'C -)G.*><.&P@:X"$C&,@&3GZ96* M!+HI9/XBT3Y\.U#BUT'R:Q.^6F9JA)ADFCJ,D<&"&TDLK#9S0F*CD^5H#YNX MXW8;/RY/FS_./YUG7R*[)F4A]_G-=#(/J_0PR[\$,7RC+>F *8-@0QFBD-+* M HPL9QHHBP&NE"3ED$\A@,_0YH]/GV?E;>[49/C32M ZXXT Y_(8#-;I3.L( MF(&;C95#QAL&,,:>"VRIEH#79UK$R.1_TS>0@$XCB1-'$D>VM] @VN0?0)!* M B *FH<7$@F+H%H=CE--DX6F=R 1R24G8:>'V-E$G99=F%'NN).,(TJ)XA@K M3JHM#W:8B618V-R?,A"+F]T+=3KZ%$OD2^4R ? M;E)H"$JEY1@BY1R"C$EFW"I5'),I^"R1+Y$OD>]8R$<;\ED/L0* >,B!(I8' M$-:GA@)QOS$XY13-;FE'VR>SW2Y0M:]ZCF]"U2$3B8.6AZ4CDG&*/(%62R.9 MJM.9">O<1@_+4[:U[0I$G':;/G*#)/=6GTIJT1&P1C1I;+%3T'D*I:-<*DV( M [0^=-2 FV3QZ@> NCV'3/A)^-F?JQ4!H@F&LUIP1BUSCCI@(&"HMK@+PT%* MH]T3_J!N=F*O$>WD@95HM7]EB:!&6:)" F0 TLI#C85#0./:"<(QME%9.D53 MTL%)G&BDH4]#GX8^#?TI M#/UQ1;_O(GWB\>X^*&Z<$[WFVBJ,F624< 6AIG5^:$(OI M3F37:8(ZK8K;U^W(6U_\F):CDX52RWN&(.29 I0@2+'BCABKZ_,CJEEG]MM. MSX].C%3[]!A,H$J@VA^H6&.[=4I09HV2%&)$"<$:UMH3X,BC7AXT)5 E4"50 MG0"H6AXYT&!/J//6$8W"YURR.OF($ YMU*AV=W=89TV]9=%QQ@T MP6"S[?-!M1*8 $&$5MIR+$!5T8,CA/C&7"6G;HO:F9?@>U*J?_$2Z90D@>L1 M<+5<>(20'BK-.09:8FR,(U4U$*8@42S9J_9(LQ3:FF"68+8!9J1QGN;$$F:D M@8X;#KVSIH89!U)[DFQ:"68)9@EF_849$ZV31&:<8](XRI'S0$%4GR12[/<7 MAW\JO$I;R?Z'WF\[&3]/%_GXS<.&P[ -I[=ARNW&YMY5:_]MERT] *BVBC49 MP;0%R##DN8=>.N1,M=WE%D&X8SM=UU#L*)*_TY*WFP2GMRK7$6A6"5['!B\. M6_5OM=?A\<%_$ M[5+$_^OS6E7+EHG:C//Y?'0Y*H;ZSH1O1S&[S<=_SQ=QWMS9H#I\CN/R.=Q6 MCZ>#/S^4DS?^^JD8%Z5,GD$D.=5(8@DXMMP@#05@$)&@P!B"[%GC%08D!"KN MVHACBC@$*,7Q4FZ(5L*QY30-HUX,U>+5SX$?LB+,K9LHOK/;XL/?/E\588J- MP^(49F8VFF=Y-K^]OLYG=]GT,EN$3_/:8!4>/%]D^608;K$(,S#H3-EEF.G9 MUSC5X^73VUF8QQ>+5DQJEB^R>HI6@[ 2@ <2O$V_P;=U!]I&I&PQ* FV7((Q M_)A%.:H;]>K;91=W91LJP:Q-OF7DZF# M'D5OZU'\81\0>:0_UOY27KC\ZD/PM$@^"'.^F/VX^U8P\J )Y;]7L_HF-_F7 MXNPB[$;^/,LOPRO]D(^_Y7?S\*B_7LVJUNRAH^OGWNO*S6*G@XP8J!1VWA-$ MM:"V\G45BAF!XIK_C-AM_#K;,&#K(_SH2O'6R?- ^N^ITB"HD^5KC"9A#[#\ MO?V>DZCHC.\II1 L5=!RX<\&Q7A&]O/H.B#XU^); M]OOT.E_;> 3,?QE-EJ^7WRZF]1^6^YCR+]]&P\55N#KT8:4>#<)JD=_,BQ_J M'WY\J A]6!WZK4[MQ8>GCP27CV#\NQ\_K"EJU>.?^8AL][5=/FSSL>?Q[#4W MYQ798PC6^JQ_Y/BY R5S=:;WI&K[7F\2#Q5/T^B1!#%\PZT4\[@%W[LTEC: M@X^0VK;UY1:QR(("/R[F\["7"M^?3HKLKLAGKYFCV_K(O-T?Z%VL=2\:ZOZ; MZ$3+IU@ [Y4QC& .&#(&6"&6ZFK8Q[\@(?Q]$UUE:@B__>=H<36:_#8I_BN( MT#U'DL>-=QW8V"#MV-6C=TYJI^Q5FX!SP,!AO)680T*OI12.4VD5@-17^V.( M.:?= &=EU=\I;#HUZ/<.-D?E$=LH.%&M64RSR]'7I7KSIE2$!^R++T1S3@>< MH199A[3 FB(*$*.U$B (V5@-]*DYJ:(U,$S)SU=!LK]<^=#G<7;.WTD?X.B< M=#A%>[OL'\'J?O3338+&+TA;@QBB-OP_1$HJI 2IIQOF+;[ <3%.D8E!CYVKM%H8%Z4U3 M.T[H:FY_+B;ON)(2?N*%64]YXYTF_I,3G[3*2A/@J*.:**%5G//>UVLZ5MB_ MTM5M\\3?_9I.V#D_Z4E_7(GX7QT3NCZKC](#]U7-/ F,=H4>^5 2$2U1E+) M< %&3-=,LD#ZW42#IJ#-M+5/=#E2N@C2Q)ISKY" 4@B'/7 !+1#75@R$ .W6 MN3_YX"LN=JO&G06YM/9/#2I7:@Q/BLL_XO:[;YQRG_H M OZX,_U+/7%?\MYO:3;:BP/X*3SQ49?V5\S;#F3CP>#VW;^Y(^=ER#9Z+Y,M M'8K1>WHOG_K#>GGXOE/K(J2]*0;Q9-A%-_%7?"M;T_%L")/[\X_)#S\)8D\$ ML4DCLG=)C(F9GCA]3J*81/$]7R6FU'FJ2G&2Q1.0Q55XTMY%\0C"HP[$+>K3 M5=#)SD(G7K>M73]L.TL.J.5;IV@Z"=RE@4P#F08R#62W ]FEJW&/_8[,='8S MG<7\0 _2+;V3;!](I-]+'4E[[R/ ,6CRT4, +"886L&8@,P;V&1 A1AMS$?_ MA/?1(RX"_#4U/DI%KZ?U/5;S94>%/J"@Y_*H Q=/V5D[X?/@\8E:<9E<,8,% M8= +;J""7BX/N1U6AI!7N%AMGPT_@74_>?D35A-6$U9?CM4-B?DY)DV4'A>: M2"&X4)K3H)=B!F'%5:$1?D7MN>V3\B>NOIBK[Y+49YTX?7 VWZ8L0 )Q G&/ M]5O6Z+>2.\.9]99Q)V+N VIMK=\B9C8&*#T;-) ^PJ+0*>1GKU378\KDE// MIG\6LYCD/K;A,K1B49-D3!C'I3% ,DPJ=@=?X[> ^&E=)'';]NE+'6IQG7)F-[N@H] QSI^4DC6JM'& MM=!&0\T%) )3H$Q-"LUQ,K'ME2'_6\RFPWQ^%056((A^3 A)".D#0@ALTBP M8)S@&A@D-;72.8E=C1"BL4[6I(20A)"]6WIZ:= Y(.*1=C0ZA9 S[@ +Z,%( M0H,KNPTQDB2[3=I1=6V<.7@_N+^'\1Z,;O)Q-KT(-RY%^6VI-H\OHQXGM%&K ME/)AN?9<4^$$ML9PJY:0L1!ZG7S'UHFSDC$]G0P[-!#380] M"]LIR#UB%"@"N!&5R@-0^$^R).U?&0+=Z$(ODN?DBW38T-J]UTX[BYD,E[^7 M[D1AHSLI(#@#S&@L@/8:2ZUYK3MAA66R!NUV;P:.6BTZ+M\=-9\7B[/8R\5P M8RSDT9^B4=Q0!&KN@9>",D.D!9S[VMR#%GMONHD-)%#!P7%+5,-HI82XZF&4$ED'*^#XA@BKI/@C9,QU72,D'38G@#2 M3S,+Y4W8@<7<$,5BP7.O )1",;4R]G)!DIFE-TH(Z*9B0UMZ#]^HPI_Q+$\(U&DX,\2MH ' 8;X$@%N)!",ZR@%=9JJEGSK+S-G9H,?UH)7F?\82(E"#GALZ"CI0Y&+9<]R[FG3&AB M,%5AG\5$31V%,4BFF7WR*+G3)!H=/(TVV7D8;=+\,(0 @Y*P0"5DG,!.^'K7 MQ>2KLD\F.\^NU:..HAF27\T)T.MX_6I8VTQ-! 5 .:$DY8PQA"&M\"4!1Z\X MZ$I<>L.VC7=Z#-X_1>FX'&R"[!?A?FW+44?Q5GW6BC911;:HPBT$A$B@I+' M0NU9K11))BU*EJ$UQ%0RU$3@\-F&X6XTQ9B1I7GU#@C M$%G9DHE#*45.+UB27&\22OJ)$MPDCN $6L&=Y<@8 X #U-6)EY7TJA.4G(Q% M)J$DH>34G&HX;6 B@6848 ,-5< 81;2CM5X"!'N%&U^B1-J\G)9WS=_SV9_% M(DZ&+$C@:''743#2II+ !WGFM(E)O&&2I0$\D#H2-!T#N>/*K(Z<@N;S&@7G M5*PKKI2_71")=(JDK46[MRK/:1\BG2RNA&SV8T!K+KWA7FN#$!*$\CJ1GY3& M)=-.'T FNPWQ3AQ+'#L"C@D@&HYY8:DA@5O<,>6,M'ZU%81&IH)>^^'83CT. M$\:."F-O'=;#M6D)U(#,0&+"UM$QK\,%DAM)JW(4F N+DTUKMYH6Z=:*=7B, MVL(9:/=&KO[J58>L/I&&.@PX"+$(.T"GM*: 85!O Q5F/EFM'HE5K;L@T&1^ MKPNZLU^Q]Z51;Q6CD]!_CATWK*G.9X&7Q%B#A.9: R(L9*O=&B I@T_/0"2[ M#5Q-&$H8VEM\F!!-[3\/F9 <4H"I5(QPZ$F=E4.%3=@K$I6>"TMJ#P-O88H*>[?M&8?=)"?K MNU[4I4M4?SVB?IG&5PK2G(T:!('&6GHT]"GH4]# M?PI#?UPAXKOR?3[<#88 L%71CTVR(T M,"II/=UQ[.Q,FI)NS![[CJQ(AHHCX 1J?()9XMI-A/5SS%B0-T1B#,M8GQE)A M+(WRELM:0Z-T)5VDNFL/ 4:K"1/JRA#R9>*D69<$)ZPXR&KDY&01U" MKRGG=U)FK=W''E#23;6LOH<>I .[$R".H(V^$SCC*' 2664T]QA17!G2 994 M)8M4_UC4M7=1@E&"T=Y@A !I3O4(IQ H0H1%A "D,(#UYLL@V;_RH:<(HWW: ME!*)$HEV1R+4D,AP8"V@7'&*N #4,N!7!W6L]L./A]K4$]-_H<>M#; MY^DB'[]YV' 8MN'T-L:4O84];[?\;=L-_[:++MBA=?[=,$Q:V?*QQY @'OXK MM1;$:[^RQDMN=I0FL6N6=I$F%8ISN#,$OD:0>JN"'?/I7>)BXB)J.>%#K@AR MT'AF@9,$>$E5[7?AC'_-.4$G5KL>$E,(^Q,P@X_%60B;"+L01-V V!Q MNR)4#,42#'!'*&.*8FGTRF3JG>_,9-I')Y+__$Y=B\^OM=?A\<%_Z;9!^ M\7_)?WU>.W/X-+@JAK?CXK?+^QK(;Y/6,<'G.!R?P]WT>#KX\T,Y@>.OGXIQ M44D:%$)Q;!J&72I3SU@M-'%)G3:*J,.TY(V'J$RJMCE63;%6UQ!%" M%5M.W##8Q5 M7OT<^"$KPFR[B5([NRT^_.WS51$FW3@L:6&N9J-YEF?SV^OK M?':732_;24.S;Z/%5?8E*F-A+M=]D8W#[T7XUF28+<*M\OE\.AA%M2V[#%C( MOD8N9-^/)ED8G7%XQ?E??JAG<#44#\3@@31OTYGP;7V$/NQ#_->G\>O>H8-^ M>]#P>^H#" MBVW<\_MY^JTD$]_C>L@K!F_?P ?RM]#^P?U M[X]TW^?1=1"M7XMOV>_3ZWQ-V?HV&BZNPH^A.RJ2!TB/\YMY\4/]PX\/T?QA M=?:S.HH5'YX^&5H^@L/O?ORPMJ94CW_F([3=UW;YL,VG7T=XV/YD>LL7GE7N M^,QO$.93,>L"*[88E-K6LE1>+(VGU*;3W),3X-QQ;?["H>[$_"'B,OMR/9S70^*G5@B++K<(.K>3:= MA9]F1;*R)2O;XU8V0E%C9;-.&&0 <@9CAV'TCUYNE"#0#K\B5[19[LBFMP\. M,/Y12>CG;\7X:_'W4D9_*ST0B]G*G/:(B4[\7]*%)0WR,4C=SQ,,NZNV>^,1]G@$1!#E1("*DT(E$P!46N#D"C[BM*$F_#X M2Q#6ST%6VYA\!VU0XDXSW6[F8S>"G\+/#D#S.UJ,]014M%7B2 @#A>9,>*4 M%8H2!FM04<1>47>@:U!UH\=!)G:8'Z1/*#H-4]Y/3_@2!!%(AKU^@/ (=KH4 MMXK :6 \,T(A8[ 1 #LF:T(R)=92 ]OB8M'R27[ RTV4A.C^3K?ETQPOVYU" MEV(RDG$O(>^$D=>*[E5>>J(89YI0 $G&(/5[I5!N6_D=:,:@O=5#/N'O*.R M\+U!,>RQO>\P<7A U&,-]3!G%$L$*,'$0B^$IW2EZ#FPEN3J;=2KM\,U_=Y+ MT0/OJ^CU5I]+:EO"4?]PU*JDI94/*(HY5KQ5'@HFJ5^=L&JW9IE[;QQUI82= M!H[Z%H/58?MV'/82@XW6U;HP=Q97Q;QHE>W+\EF1#6^+;#$-*EZ0LXMB%D][ M+X-836?SCT'U&XQOX\S/!D'2OQ2E,CB*3M1!.\QF0=;#1:V/BC ZT^MEW->P MG"7+F*76)=?Y[,]BD4UO%^/I],]2V?R:ST9AFH5/A[?SQ6P4;YH'K?)+-HT9 MX^;GV9+INACDMZ$!>C0]^ST?9E?Y?!D-=3$:CQ9WY9/BRTT6L4%7T_&P:O%: M?-5Z[]P&J1J'3IB%)H29CP2@^?GEIC)X?Y/,8I?74;;]=C097H4_NLHLB_&<1!^8N_#D,RS2; M3!>Q(^>C,$,?:4EH8_A2V45G41<_6Q37-]-9Z,SQ73:ZO@F/"4_.%UDM?*\4 MI&K/57&@G/D!0N$!<5PC?HJG'.'%ED_\\+?8S_MX8[[U&Y_O&R:/1K35%SY\ MI_5@B)='X6W[SHP^>.'RWZM9?9.;_$MQ=A'FU9]G^65XI1_R\;?\;AYCJ:YF M56OVT*WU<^]UY>;P/\T@,E I[+PG0>T0U%9*B%#,"'3V?&CIQJ_SW8=-JK#3 MSV>+R*KA* +YXG81UX#I[2R[F4V'MX/%O&34K/@2%)Y9P$TI2Q&^T^7R,)@& M_DSNLL4LG\R72LH*X_]9M"\/D/R6SX8E+(-89L6_EHM%V4E1ORE!=YU/@I2L M7S0;S?\LF7H;T!D(&B"[,EJL7QS7JVBV6&3YY67H\-4E,8@^!MP'?2RN7Y,R MLO9>0P+ B]'7B/WEBG:3WY6_M!I5$3NN4 '8X>+%Z&MXY3KI:+A?G75T:6.9 MWX2%>+R\*OP:&ENNM#>WLYOI_+$[SXOBS^RJ&(:FY(/!-"Y9X?I%F#GEBE#> M=+E,K/JNOHF:ETO7_':\^/CPFH_9EV)2S/)Q&,=R=:S7H6Q8=ECH7@G"SW?E M,6!I^HD]T.ZJFUG039?KSJHS1\NOUHMZZ(#RE:OE?5:4:V)0/LLE*KQ26!1; MLEL:+95+9;!ZSRI8O5#$,:D\0BV7&A'*E#M]J"67V=3H.0Q+5D?DBM"IV:%Z^]R$MFN5P+&5D5MR$ M82Y5H*@9E9T1FU/I3/_//$R'(%ZQ-\*TBLK/>9;%K@QJ11C#!Q'ERPYK"TOV M+71/*=[ARMMY*8#AV_.;::4/9I>SZ77V>W$;)D^M=&;CH 5E%_'R*#U!E.JA M^.=M $U 01W8?C,=M09OF%W<+:6FF$4BC9I9$5]Y*<_Q%;[D87*5TEGINI>7 M\R NJYF_]OGRM69%N5U[-8/NC3(OQG28!PTY\G@2Y!GE-*B&=30M@53)N\S?-G\T!(*JUG MBD"D8_4/I A6]2)* $"M/!#$>$&%MXX*@1E5QEA5YX$ 6C^?XV#C/;Q_;HTDF\$3BB*,:;K-:M):[B[CZ3;+_DX<%)JQ]BZO9]/;+5?;W?!;4 MK- ?,FJG\P#UM77PAQ[C8.=SHTN/5=C?]O]:;^O*7<@['54>F(/5X?M/<=0< MW2G@/.!* *<)L5X)#ZJ,BR1\!'"].UC:OW]HM@2UJ*ARI_NX#\ JA>)C.XG? M1_,_RSR+%Z/I?_NE\ETQI]:X:X5[,8U$JCZL>=1=64YPSKH\V#L&YZD>,ZHY M%"ZM"^\$J5ZRZ("00UI)7IF04#+*"+6:A)VL@J!&3L#/FD$B%A%8YJ2LS#ZF M(L"C]HG )5O,PU71[J/F_U$,OX0N:5WPX2E#R&'0JMLR5CUGTJ&' &VC?-_< MAM_R>=&M G[H/?E&S?Q0%K>]*.!I;7O;VB8:QURHK(#^).ETS9E>+%!*DTSH01[%,]1@[?]QWRTH;_P/=^&\J9B- @RIO);=4 &X0 M9H9*+-T*51Z!M6#1PU/#.Z%<;$/XVP:=O-.B-X=?TR:Y$!^6T_)3/BB/^U M M';EF1>7W,IA^F91+1_AKZ^N/N6%4E:JSLE3UTN7CH6M'6:NZ[6Z[]%FJG&N6 MUY2^1.5Q]$4QGGX[S[)6TJSHG'Q1%),PHQ?%[#KT6.TO$Z?RZ#),N.B9WBGL_U/V^GE7/58.D['>?TUZ)RH:Z9\ MU4F3(MQH7CMJ#4>#ROGLLN4L5/7K8'H['D;_XM6*7(8!+N&UJ+VX5SX)H;&U MIW+9F/^Y'7XI?=)&\RQ6LRE=D6O?\=")I==.=9,P)GGTFAO&;>>P^!KZ\F8E M"O/['M-M]Y_H:%>Z*%Y>%NV7RN?SV^N;I?-YZ*'J3G$96A2#J\GHG[?%O&K? M51Z:G\==<5%ZJ!5+M\#*/>@Q<:Q?8$T^:NEY7%A+I[OPG/^9EHYU*X^B*"4M M8;W(8S>$QU?#^K$:\G'I21E%<[Z8#O[,\N'_W)9^Y6WW^>%H7OI*W9.A?/7G M\MIE%U4.\W5;8A#Q6132T/L7BX]Q5*MOCXN\+CO2C/RBBA[X6+Y]F.:/3MM5 M4RHIK@:G$N;*53&;Y]>E\^-*C,/812>O(X?==BY1K6I1%<%*@/T4%NF;,%K/ MND0IJ#CS0B(!@-1!OQ)HY:Y#.6 MERBOE/22((2Q=<8)09VM7:*H4/99EZB- MSWG4)>H9Y\,GX!^E^G8>12R_F,9)7#D0CB,_5E]MX7@4R!3TL*6+:R#1#=_U62?M3BC?V^6LE:=S_8;[\#S,4B&C) 6'4=!H M[S[&CT;1[\L5]1%1[>+P.)_-[L*+/-91>WB=Y"4)\@!3(H.>J"T-9=CG?W'RKCQ2S1_G.:H)RS^N/Z4GBW?C[U@ M6M"3Y*8%?7<+^CZ$)BWX^U[P3\.Q>>T4-KF,':C+V/,>8Q*BQF,,8".@(9I+ MK+WQQ I9I6PPGCJ^EFN[%)*?&QG9X-7:.F7]>W,W=6?^WF$V'^?PJTD\@B'X\ZOBP5$\@$>J "=4* M+?/<0JIC64]C,#1>*TF6A++ +;FV+$]H58_KC2"4B&X!ZK5-3^7'F;E!6@) MI5=#K];2?[M3C;+PI;N?) MDZM[S2H#PCMXJ<>CA%+RB$-8-5&K?*^G3FIB&5;2.$Z<08=FIU2%0Z("KU1F=.@Y>6E/=>4GBSI$B+/5<8 M&^4!P(AR G"EF$+C%-YV23D,NW-43&%: A)%$D5>3Q'9>EKF8+D;3YM./V4UXD>M\4-R6P(JEQHOK^%.9 M[NER.AV6/UR$]7(6R\,V!<1;Q5-C@R)H=UK1\T5:",:D*7CBF;#>8@$1!5$' M0;IR$74"("%J+21TR _-B71H2S&;7XUN;HI9!%)H].,FLM;*OBSKWE[,<[KX5Q#4T;RXE_1R-+D,RFA,P%G.R_*U@T#GY=N6,WN5 M\NUF.A[5E817KW.>9>HM0]_YN'[,AK=%C;!\."V33[9?\)E*[;O$>1?K;UA MU:<_8O^P,P#+X:E^%V< 5W.P+B51=619'+PJ45VE>AS-6V%:JQ2M55+(JN3S MO)TK-5P29&(4$%],RCK ^;U\J%$^0V],9U_R9=;752K2[^=!>G\-5V;P+^?K M?7[TU78??>+?_M^\'/RY@<02Y!30T%+&G$;48\^AY,Y!YWQ4(_-W>=7EK_'R M'T:+H&,/EG_YMGS&14!=)<&O3Y3Y4] ,OHW&8S49_AS8-ODR"AL#-9\7BWFS M!7XV729FWENOG2< &@>)D9)5TT)[)T4K72;B3%/'C8WOHY7F9'70)2R&]%G] M=>-SUM)EDO,EM-;__>FWW^Q__OS++YGZU6:_??X/]WOVCS]^-_^A/CF;_?SK M9_7K3S_K7UR8OI_( 8O>>Q; MWOH58K!U@JMRW9C']?M+-:)QO9D7RPS6WXKG,[]VLL*_>"?YV@Z[9];I;6)3 MR<]%:!!#](WY3=F'I]W[JORFM.M\F>*@DWT^_=&6=;IC?- M_EY'OXP82_I9DO2CE_2TNIWBJ*?5[91'_ZG5[;BL9U71O_G#0_>'AQ!)R ]P M<).*DD8RC60:R;1K2H)\;(*<1C*-9!K)EX[DBSL&7[:^^YOF<*$V959I@*PF'I"*/LU+MF#RU*;YEA>^,0!B1 ME,ISG.BQ M.WH:5*[ M1.1$GD2>;L@3%+H5>:C"BBG#K:'4 T6"3F=K6Y9$,G[CJ,^A3-V2EUOM^$'=+" M#L,.$:.L$IP;:JD 59X:(A$73Z8>^KD4KF+8$KB?5_+V2U\/^# ]EUW2[(4B MTHC^6V2D&T+\)4W[4YWVK)GV6F,.O2$(..*)1M2P^NS>:L'T_J;]+O="D'=K M'D_3/TW_PYG^HIG^PFID/1*""B,)YM9I74U_*IE5'4__+C8B^!REJ9L<]1.Y M3H]<"**&7(XBP9 5SED>Z.*$KUQ_*/8<^2[)U8/C(YZHEZ;]J4Y[W$Q[QUV< MXM 1HCA02BBTVJ\ SO8X[7>Z7R'G-$W_-/U/<_K3QMV.*:F)E!I*8YE7&!-1 M._PJCI7I>/IW43>LXU/7(YFZ)Q;[]3&;%(MT9+TEVKKLA%Z<][:+O88_6,HL MLU@"J7PD&JT]3HQP:\5>:Y'JY;D*E,=^3)QF[&G.V%9A58Z<"WTD@D''9R)IYI[\S*V4U;*\Q@9C\9ZF=?BW,2U0#JSVD"EM M&?50--,:>:&>/ K=W5$'8._C,[[=.!WY?#W8LX[$L:/40#!IK* 84PRD%(8X M[;P&3+&JS"XE +HGS2"]/-N 7';KC)4TCS1C>S%C&6Q*W@E$D,)6 *(8@-AX MOHIH4X#O;L;N> MC/#?W8D"/_90TF,+Q?CG[6@^BJ.40BVZ;VLO@$%:(:2020(<$MI*2I#3[/]G M[TV;VT:RM<&_@O!TQ5L58:MS7US3-R*12[V^4V77:[NGIS_=@$C(0A=%JKE8 MI?[UDXF%@$11I"A0 DGTO>$2-R"1>9XGSSEY%LI\)?H]$ZF:]+ZVS_R>=3H;)[#(LM$ 0_=PB 75V=^^A=PC00[2VBYE" M ,C.9>"$*8YM"7TB,6Q?&GHM:I\]Q#L(=A1")*Z&"CS2*'" Q )Y#1A'H>5 M%QU" =>JRT^"8 ^?/NR_9X]C80]6!\/$!CE@(--&FQ@0@!"357P?$&YM,,R6 M[,%?17>^[S5CK3K-CIQ[>O#M%WRBCFNA,710"(J=QQQGL76L\G0Q"8!]:?#U MVG,/P1. ( 4U!!'T,R&- 2"FEL=,8@"J@UW*X-KB/T^"8+^'G5H8NLF^IYX_ MYXOI+EUB3_N0RS_+$9YP45PGU2#,M(,QUR V7#.HL2V5;A9+:M=ZS7Y?3 >7 MR2Q5@X&?FKE_3#7\UV(VSW?QD_!<=^_HK,?R$6)Y4X8$J]YBXA@2CF M' I 6.D"YXC&;FWIY'_XV\_3\:>+B\]IGA_W=?+%P^G3187.OWOD=ZMQ*3K&78]$YPB$_":"9"FQMOM1$@!*/&6O4)ED"@'&*Q/+'L>$_0H M/B84'ZSGOV>W V2W3>36R,$3G'# ((BY-UH<8LC&I9K#7!PCT9;-\CHG!KW- MTF/YN+',&HEWC) 80.>,IDI+#I4$94T?)CV:USH]]X[E@SF Z#'=8[H#F,8U MIC6Q3!J L<+.<@Z4566^"S.(FK7Y+KMANL?C:874U[6;^D/1]0S372+9Y,9@ MK%'Q#SIAB:$,:>N443B&G,38(@H0A69#A?(U];U>[SCB?HY_.ZFOS>4^=)=& MC\_NXU/4^"102@P]1*UE#C,14U1U3!/Y(Y*))!C>)X MF&(EB.).6Q2'YF%E77ZKN>>?W=6!3L3NBW:*^?;TU./S)?%):GP:( 7 %B(7 M8P1E++ #)3YC!<3:_+SV\;E7=;V=*K0]3GN2Q= M3&**J_I,6D+8KOK5B1.?EI+1GBL]?2!W3PJ=(@4!ZMX&'!(9DM!9C* 5$A!; M]60FW+_YNJ2PUWSSCFA>/3OT[- E=I"@9@=');.6&"L-(336RHFX9 <+D5I[ MD/4,=FBGXWJKW1 /#MG'E3 2)Z/$:X6S*)E%DXO(I(-\"X@P?'_B1^EX#V7U M7GQY^^#"?B7[E>Q7\AB\;+T@]X+LC7%<51$73J^M_/?+=-6K\J$XL7[MGAF8M!-LW-D" M'3UL3Q.VO$[-D811@ %E'&.*H(X=(:6GU$EFR7YAN\]S$HQ #]\>OD<(7UF7 MO!*QY!:HF,3 4( 40XR7\#68&;H#?-LH,$-I.RGU/?2.S-'44])14A)$C68 MG"&H$-78$*"<1597D1D8"[JVXL'[]'!MQ$D+3%P#E/*L08,:\Z%+(.D M*;/ K2VQ\0A\6S$$9+LA39V#WG&%+*G!8'&UR!NP1-FRJ$,T\C(2XIC&P^C& M_RQ]-[FXV"4U_Y3HIKNLLB%)#4'!&LJ\L!P[S04"FK$X9KJJ"**Y4>;QBB#I ML"%0CQ8)Z8;'G\!V2OC<$X%#STWK87L(L$6@AJV,&=3:<"LQQ=)8R[FN8*N4 MVU!U2W!*.&5!FJH *RD'HFX:%7C?WW7 M/FZI%T;/6CUL7QZVC<:[<8PY=)H@8(DC,:*:5:=N)A;K\Z'W#]N]YD+S5MV+ M/7Q[^+X@?"6N_6PF1L8A(:C0DF!N;%PE+%-O!*PM6+DC?-MP[>.3U/=/+-;_ M;31.=^EW=\PGCH\_^)VD>^Q-M>%D<3Y*E[;:+A.P=C;+NX6?;K(*6Q>1O^QC M=C;*S6.SM--DO.2!+49DR?@4,PN4Y5Y58T8R[ 1%50LS@N.UD9N=/#B!)(+1*R]+"KJW/T,EC6RA% MOXUT=QOIZ;*GRP.D2]*(H.7(:N:4 QA (RV&3E9]Z[$S>FT83*>/RS%H][R\ MI\V>-GO:/'G:; 0N6\J!B1UD*C:,.BAJVD1.J+5A2/L+4P"L][$^0GEY/,-? MYXE_A.7[?K+":F3CH@EO.W=K/)[?X=)WEVGA9$#@A^;OX9.?#^YRQT=F>-<1 M?!A'OR73P644G&5OHYLTNIE.YFDTN;B(JH$]_;'RW_UE$P))C4!L$+!<0^.T M%%PP;RIQQZG0%!KAO[\.@?_P]Y^GXT\7%Y_3/([HZ^2+Q]>GBTI3^;N'XH.= MY>#_Z4YOE ?R?R(_PR/_QSW,/WDI0@W_;^5D11?3R54T64RCZFFBQN-$L^*9 M0^'_))JFL\5H'GZ=1%XD4_^5^6*:%F]<3R?#Q6 >!0$]>U7Q[02 O'3]:S$N M9/PFFU]&\\LTNEYX5"6S8L;\W(?WLMELD0[SC.3)8CZ;^S_\ONEO-QG\$;[W M.9+,L[S_^YJ<%[&NBAH#AS'4"H?H'N97E*BR/ANECO(5,[):!CVY.L_&^?;[V MM[$?Q?"#-P/FV446-FLUFZ7S6;76:CS\U;^=C?S"I3/_V>+*?WWL8?$M\U^^ M%P5::%>P(VN/^0/56=I<^V%ZX3EZGKX;>?8=>O17T^+Y.4SB^[T+1.-$3F!M M('>$:XQB :5_581]62V=5BOU-@]-();7;7;)"._:V_J6_3--;($]JT3S M,.2P9+,G&!XO;VBT8U@L;?*L3)AI:(2SV620Y26/R&64U#(4YNOW M9#9/_6=?DO'D(KMC[WTY4V=O_3T ]\;)=++XECL!4/,*10NX+/G-W^9_3T:Y MM:)^>5N]Y=)Q,".C3[?+MW[\Y2P^^RGZ-;ORTCA\F\.]_"A.Q^EH\6?TXV R M&J5>-#Q+W)8?_A0& L']T<>9-V]F\_R>X4K^._C^=]2YB;ZDP6DQ"#92L+.2 MJ\G"[\+ATWU33:.Y*\" >TKA%D,;QY193"VQFDN#$&3(/IX-M2;UJ7!6W&GD M^AA;E,M=K':YV'ZMPU+?XXM7=GF(!_R;;?'$_G4946=$8"N1Y!I:H_R^8JTR M#A'K90!2A!C;4+2FG54O,-2I!?:;\!YW@A=8X;K9@/ * R6$"H%I+"P$L35A MA1' 3DFR-ARQS14NB5#]TJE%AN"!>);6=ON7T!1EG8MNH1.6&,J0MDX9A6/( M28PMH@!1:#;DHF^_S*\3>_10Q8CVT#A-9]?5CGX61;\L'/_:U9ZQ7/%PMLWT]P\F!6J2>[?K8M/AL'=?\3[-POK')4+ MO>DFIZ'M\OUJNT4MT.H"G5,F/=$LV<@ *0"V$+D8(RAC@1VH7"0*B+4'8AO9 MB#^5C?:J)1SX_D&;L5>88B6(XDY;%(>Z0XZ4*\:51!NJG[6Y8OO8/\0#F;)[ MVS\^W.71+4C^07[MR?R5R/SKG>F;%5OM>3+SL[6X]B@*Q\O?/>L6G)O/7G 9 M1CCZGHR*\ T_K=>+N5^.["SU6WCZ9Y /__N+17X,/4AFEU&(,[L_EZMA(/G; MQ136QN=@UI8?S>@/-_+Z?51:Z3;^F[\VF:_/$NN?!# M>I^,;I+;F;_57R^GY=/L>8@/1=U4][TSE??F.F?'KWY.OZ2Y?V9<\;% MUA$ M85$2UG691.QLU*\0P7A^4ND0S5_\L_Q]@MV./#YY.DGL)[_V;=E11.O M%UTFW]-H/%D]"RQTFFQ/)H,_GCSD"@(1+GCRD (,)4:LQA6:\D@T.]J3QJTF B_F6(0 MG"M (J#CG]:S]9@^KU \CZFEWY^?^8WD2?)U?)2A#R33:<7_H__7.4X8W!(YU< MS]+WU1\KD4)OEO63EC6^('FSOKQ2<0\"?_BY^M+]SR!YY+/=/D*M7_&P;K9] MF:L[\;"K@:U'$!E?B^FF-N;;3L8N)N6?SVO%:W6PO=STILET=NHU--OBK?W*][VQ M^6NW(0:_E[KF$X1O3P/QVFG:"^+)"F*C1.NKRZ*ZFOC+_B>WB7J1/%F1_'B_ MMNLKC$$GT^GMTY2#O6%B,7ZHUNUF-3B,H"/U?G=?A\7,WSV=1M.0_A5\*Y?9 M]>ROHVPV?U*KOQ>8B]TR*=O3+.$[UB>/[W>W>'ZCSUT7=Z<$\&?D=V^=PKV[ MV[UXGL?/7SFNDPHT%I91ZYB(A0,*QA 72=S6Q!B8E4"\1WS:Z]K+-FMP[A)O M7;'5YR99M7=$^] 9[3-RQCO7M;;GJIZK.LQ5FSIG<-JH.,$$!C$T $F1*PD MXF5:BM$.RY5@PT?8IF&A-0VD@Z,O)EZFZ?8JL)\C0VV!8A=G7\]W/=]U6#?C MM6Z&H3!< R6)$, I2IDPE6X&(5[)PGN$G;SU?W#4AD"K'7Z[IYEMYVPX$)_" M_S.>W$27DYNG^@\.YCP-OKL?@W9J[M.U[=EV7<>.<*YH1)!#SATFTC',"5!4 M&AB+2L5D!JW4;'A!>S@$*0>4_>_)38O%=<$#%3EV)]G.6KD]#CN PTVVGD"- M$@3(*02113!FCOC_"56FH_V<(J_@[!WIAVE,TTVG&E<:T59*, FE9 $ NNML9)XH6&J M Z;8/NMZ<]9JL%-G3:T>EAV Y2;#2;+:<***QX!CZ$+7528(H!J7N)06Z)4B MMITPG/:)5 (>J)S8GUWUN'Y]7&^"M6@$@UBH8V48,IQ:@%4,D:L"\#@3KQ^ MM]O=5 5]8]!P4TE'H ,.B-A1CHPR M%-)**XL9>\U8OCWV$L'M:%Z==4SUN#Y*7&\PMS# M;D%%8MC:RP5 H0P06-- MV5C-"(7(2KO$3IA;>X%Z*^Z0_ERJ)X;N$L,F7J#UAD]BX@ Q3E/ '#$$2Z%* M7G!2N:>X8?9CK^VE=5B;\?O=V^Z/ZAQ*>UH8)Z&X]W@RC^83+V%7U^G\2:7" M#NM2':.7#(.&EPQA3[B:*>2$LT("Q%7E_+86F"[$!WZ[,] MC4.I K/K_OTZF2>C9?N/=Z']QP--0GI'3__@3RS:CZ__C(:319"AYU3N73N; MN]4D?=7"2)OFYSF5DW:;CA?>0&FCY"4GCAMMK6 "&T@P9KC*I;;C>&#@#G6#(G?P!KXN<_@RUI]2>4EO3,&53P[32,<$-L,HZI %$LBHB M1[AHI>9-*S4->OURHY/FKWD_S>7[P]?I)+SE'?NNHGU7T8[<;$L/Y^MV7&J+ M09[94K0#,['GEJ,/Q8'T+4.G[EJ,G>>IZRFWU^I:CO2!V0A#[EJ.] M2'9,)/N6HW)&0*FY+:N,.FD(?$I5C77Q%[S3C:TD>IF>?7U@1L]5/5<]/3B"X$9RDY". M<$.=),8R21039;"8XPARO9?@B&[3%R,O4PG]>%(L>K[K^:[#NAFM=3.%)1;( ML9@8! 157E,Y19=.?0,M1<>+NTV--Z"-< MU&V>)1),.HT$IYIJQ: LJY8X1>*XC3)EN[+N?EJ.DE9)MK-6;H_##N!PHZW7 M"-L4@F/(M(J!QG;8#41]C M(4=*:@8WBC,NM0 TML1K998O32+&%80=.")\B9:C+=5W[:PWJ@?Z40)]D\U% M66US66LU=EI82H#!)#80FA+IE"FYG^3C[F.?@[ZT_6!J_YS <+NU#CJG#AS5X=31MQS=T7@[&48^8.)E M#6=:Z&4(K+0 QM !B@0AK%+0N)1/<:;MRQ3;<\M1?@SNM1Z6!P#+3883PPW# M"1L"@8R1=0(:$GM@5H&),:#N*35&7LYPVFN_0M:.>M2?7?6X?N'MEM;;+=(P M=@PH8)5Q-(8$0U!Y/H%A3_&'[,?.V7/7X*/8;$_C+.N46X["ON5H[Z:JZ+OA MIA)4LQC&_@,N8P&\DF;9,G[:Q&W4%GXN@?HMV9D]>=2/3%TDQ@V\0*J-WP&G82<^,T= M6$*Y,%C"REYSL7E^-YX.<@ X\NW^J,ZA3J[E:)\T]3@A[Z'@5%=XN>%'@]IJ M0A&),152,Q!+4L4+,,31:R95O4B?M)8363<(36Z#+N-\%>UMNY ML];;5IP:;VFYF%K#:-GTU!$-,'AU,VNO$"=GK#\6.Q2#ZZ6;GG9ISOJ.IWT_ MJH[493KU?E0"UU6=$(9* X*U1)0"3 SD<578P'*"VC&&6]CH*) =Z>?7S8Y4 M/1WV=-C3X4Y.!$'KHI[0:FPXTYAIX@A2@+$JO5@Z*=2^G AM6/NXW>I)?(B\ -)V(&@7Z'EH^R,OIGM&9]\J-\&(?^B>)M=)-&V=5UDDW3 MH1?]]66$HF0\C"X6H]%M_?W!FB" *!M'\\LT2O+F-+-HOH#BR5Y:^HH3+[7K*+9[Z?SV^4M_PL M9R^:%5/[OV9AA(M109[^RM.B+'EQU=5KGBO8V2O\,4Y$&>I\O_,4&R>PR"O;"[.Q%]Z0];/%; M;-C,.>-BZPB VD*BI635ANVL%.]P 59_"6^+SY_\<[++3#1M_GQYQEZ0\A9G M?I7\/GM=M@=]X(PG0"K??/,>LE$Z#I)6-4^.0M_D'5%3*IJE+IEKCQZKDT(P M TI3/_! 9,] Y9Z'QE]EW]EV=&SWT=TDL[V.;KN-4T)9*V%&4B,$<$H@Q1$G MU)4!S)IYA*S4=VA*_.K6N7:_;*,Y@W@@TJ6]C:8#RX)JW=@82&/L=6*O(6,< M"VF0JY:%8;&2WO_D9>%M+0L&!ZY&RD8XOV54:,-"?7Y)(%0. E)..U% KGB& MGSSMK+5IIV?HA=2NLZAP(MK9W-^[H7\D#^U^/Q8J3OY.-LO5KT=VP9]6M\'P MBY?S:^W+V)_<5)'YA#*;1P[B:B$0/@7#%^\U*[+J-MW+6><6OL][)M\KGWH^X&'>\HXM'HGG_R3Y?,ZD MI@+&U@*K,84Q5M R (CDE@+--/,7^&NRS5#O1,V (@+HB=-3O Q??Y_-DU$V M*-ZY*>YR/AD-[P4:$5'D_=78C].AE_^YI.KTQZ/@]B%8\F M@S_>/"!ET'C-'RK I;8QDL:KDKJ2,N$-@'>@H7=:J*%P$#C&!9 J%F4U%:R0 M=>913_[&^WB62#U2KT/LQ'21OODO>E;AL7SVY4)OQLXV=WO.8-%>UO_-?WW\ M]-5^B7Y7_U3QKS92'TWTZZ>/O[S[:C__%AD;?UW/0(4,MS SZ'DS@]^\$NB[ M26R[WO'OXV$ZC8:3JW0V]Z@/&WH6:BV,\W5-1E&X:7YZ.9BFPVS^UE_=?^G\ M-AJE<_^]QD?YC[\MDFGB+Y!&R=3_\:TXB<[C4RZ3_2D+C F(4\IK$A'$&,>, M !9!*KBAJ#JYP(H0O>*K_=4_YZ<+G3^)OT VRN:W>C&=AO/RR70ZN?&$J9-K M_\G\=G_N!2#VZ+>-DN])-@KA6[E;];QZK'SA%K/D6W"[/BO*IW+,%A[AX)U] MYDGBS64VN,S/Q?S"+ ;I,/*2MV\A:M1;=_X/9WFI+]4$&LQ M27PU[+$UH9M?)O-\!1=S#ZK_A/,!+WR[L$B4S6:+0@1"/,1Y,OYC%H[19XOK M:Z_-YV].SD?9MS+(XLBI>S>%[J 5:(^(<0P8[YZTS M(:OMF%- &MJ;T]((@F-I.=0!.U2[)688C!_=]C?>9T5["W$TU]-L/,BN_6X5 M8J"\J5]&*XXF(8[::Z<>%.=>LJ8YP5U,1B$H)OHQ&U="/OOI_3H=\)$ EFK- M[R_V:N&B_>LJ['Y9H_S?RVEUD6O/[N_.IVGRQ[O\A.!],KI);F?!,+FPM1/O.35=,P5RL,J^OC8O7S5&- [F/ M[N0.P-)\S..U\X"W\M._O0%O\M>SH,V4KQ]8R*^95PJCC^E-]'GB-Y[["WJ3 M#>>7[R4[(Q[MG/Y0!:T//+R2ZUGZOOKCY_LAZF^6>?[+*A7BS?HJ ,6-./SA MY^I+]S][[".TV\_V>;/-E0Z.L X)7E>'9,LB4@=38>YQ'?A$J]"<]NKS!V:G M4R10[B+(3WQG1.+(GON4GO4DU_@TZA>1,^%UO>A+.LZ\%?]Q,O, U9;^X@* K2Q&C$E ML"%>/ IK'Q$N]$K@R=_'LW2PF*;#X'UXNCLL9"D5LI>+7BZ-7OR"]-W+=@H' M4_/J8.KV.KWC3;LSBO8*L2%ZY#U8^W((/6T=+FTAVHSDE]H!S9VA@'D&XQI7 MM*606@E'W41;O*>M#M/6497L_S6=S?RBE]D5(=V_U+;RDY/L]L*\QW4V3_Z7,_).E$%93"&5:*RHI @Q3 M 8$ TE44@N)X1:-HGT(.60>![92M.RX*.0V/TJ]W#^E'+ZK>'%/_L9*31)T5 MI$S(M\.:6B%EC&-*P%*M8>"!&+A&,.^1Z2@$X5:[1W?/R#EEW\S)HET T&A" M"@ W#ECL8D0(09"P"NU$LY4JBQO0?LCJ1$![JY4<.X?VHW)IZ.0ZI"KXO3^9 MI;-\HY^$9/9\NS]5VV,#\%$#^,19ITD,)+7:((D9TQ7P8^A6O!=-X'OSHIS] M7\/D?ZK#9S_D]CBS5C M;<\.>2BWM:T*L!TJY=I[)XZ?(7"=Q>SU *T@%9(I:""1DJBRD@.F%,*5?I=[ M8(@MU(G#8(B67!5=9XC#GR(2&[F(.L9 2(FM%8@+I:F)EP<,V*Z&+#P9B>TT M42"XCR8X(-,[CR88%/I;=+54X$Y5I=YPX"<:36>1)) I([F*B04&2H#A,H0H MKU*QBTY=Z]"?T^OD-L_,_'3Q>Y7@^#F]2D(*V/33AE\>CB74#2*3HD8"0 9C#%D6GE\+]WJ*C8K1:=>%.?M[-F@'=WYN'!^6 9P M.Z?OSW9@](W@^D9P]ZB4U/7[F"0\CH'" @$B,<(,Q165.LE6BBEN1Z5[="H\ M5)6T+5_?X?>#.V671,^)/2?NSHFL+HRN'5*4Y76F! - ,2Z7ZB44;L>CF3VZ M=\@9ZSGQ*3TRGU7%]50J$18OP]>KJI5O_NO!)..CGH6\H>>RNXD'+7@;Q=GD MW>=D& 1\O[VKMJJ.)T5M&0M$I&5<(>H,P4@!!9;5\0@R^O&0=W^)=&U5/'#0 MP6JV"F.Q.-^@!C:R]FK$A M\2)*+RZ*XN^17[CT9<3A<6F H!'Z3(FF!E$*M<,4$P=!%0&)PX'IREG,>DZQ MU8,>-ZU(LBHRSZ:5)I]T0#Q(O^5T;;\-A9Z0D^M\!>>34!P\3:_\1G4;>34X&8V"+,T[ M04,0]_+4(7DJ:"A7:FZC>7:5YG_G G15B).WKP8Y+WDN^*&2HQ6CZ\?KT<)? M)PI-<;*+S-/95?)'^N[FNR"GOY;1KW@:739'"9ZP*A#70E\1T08-H+<.<$.*M2DZ)1=I7- M2]Z;%)MPT0#"?_@^\A^GX]G;POT5)#5/00UG3M'<"_RL&);_PE4Z_99._1]^ M'?*CINJ2T_RWN8>LZ%G>2%]="O%9%'G%]<8O;Y3+]M7U*,LK6.2H\=^=I4V) MW[N_K>4^/?[QOH:-J.2-T"MP[K6HW%]4/]8T'24Y(P3H3N8YC]0$\+;>U,)/ MIE[H0Z^IB5^):5JUB)^%/H2#XLBS;-[HWQIFWS.O5@V+J1]FX>;GBV)]0GN8 M2S\LKY<-\SXSTV6TS+*"@09^0.=>VYFEN9H2#,/@Q_#[4-!ZDL&_ M%]DL*[DK],*ZF4S_"%N+)L-A5 M0EL]S[F3NM=8W=GM\6.=6;95%;ZU969@;E?M/LQ*"9// ML3,^7%2M9(N%#1OJMR0;SXKVC_<'_C;?^FH9R/?/F\EB-"R.$<[3]!E/M)V# M@#=.E R01G-/!3'B1@(+S+(WHA*0;:/%-=T$:OZ[']ED:,?#YY#[HTK4L.G(3ZT'.F*9>T0VD49E<7A?.71^WA=MC4+KZ M+K)Q,AYD7L4M+/)"AZ[MU\E!9^ MA.)[T3SX%G*'^GC5UY!_^C9L"S?I:!3E#8=+)T;I.0KT4NT>_DF\T(QR*V": M'VHO?1#!C^&-BSR=ZFVCD6WQ.K%G9%-O[NQUFTQ\WG89H&BLO=6HTSTW6NI_JH=-UT'IR5U#$>*\E[_N]COU9JD?T[O4#(*'_WU*5B)4D3$*'E+;>/,28TS)O! L( MU:J5T8B W)!\_&'\T8_RJR?"[^EO_F$N]Y=BMT\#XN<]2U.=BW"HTE0KIB3F M))2-C4,XK8FI(J9R-0@-Q:-92!NE*>2N?[V9["]/$[$]1L#N78S@@8L1:F2$ M, () E@H;_;$3%%']9*4F%[U6#U9C"Z]=KDW08(/%/\\&#%"NXM1-^0(UZ<= MB@&(8H:!119)Q#DBR\RB.-;VV7+DO#:_1S$Z8#;"!\Y&S7(#F,4Q8%X9LDY* MAR!>5CWEQ+ 6I"C[OC\R>J@HRV%(41Z4EEQXH^3 98G6L;MQC 62$@D&"*)^ MF].VSFM+G*=?$O?G7L9_N-=+L;OD]%-FBAUAEHD@E0FKQ1+E+]S4]SC?#(:EM/D.>;CXLI?8G"7S4S!9O_\ MNI*0]V$\F%RE7Y,_0_>ST62VF*9A:N/19/#'FP=F6@H!$07>>-(&(2.5*;=V M/].&&_BNS@W4GK%=3+53L:%*4ZT%*KZ*G$08/RK\&^\#WT2IY]_KP&331>JY MY2PJ_O?AH_[TFXV^JO_/?JF8MYR5>ZN]6;"V&<9SG@*]"H1? +!/E\0O@\MT MN!BEGRX*F8Q3OZFFM7R61]!J/'3^?;]M?0VU/AX55F.8<=9R; T$P&#(#"BG M7SL'>4-8C?+:AS->4F,54P6,@X57SV&$@42/+O/&^ZP(:SBW^?O9E[/@]^I1 6N_RPTYB)-*7_='%49U-@LP@1!48DK MKW@3#=+1J/ST;V_ F_SU+ 09EJ\?F+ZOF0=4]#&]B3Y/KI*5NETWV7!^^3ZD M8E4%?[R"/TJN9^G[ZH^?[Y?W>;.LV[@L9 KQF_5E'8M[4/'#S]67[G\&=_MH MQY\=S@K<2Z R4)B* I;^3S2>J0P=*;Y98(9[R] MCI>1X%*IE:X2A0/JU\ELYJ:3*UTX ?Q3?KI.BZ.MV3U'53JK7%5OUKN^GGVJ MA!GN^Z[U7',R!LA2K"UI8HR&,#16",&$ILK%:IK)YDEKI_M@N M2_&V6(JC,_$2)-7-DN0]@_7:4B>UI;5-N$HB$C4102RU932&%GC-"3.O/>&* MB"!3>+]$Q)Y$1#,_5?Z]Q_4FT6)KO4U+?2R]M@[$:/W0/$<]<3?-HPT$N]P@ M\'%J$J"VY& L%(?4&6,)Y)A!ID%%38[3E0'EP]N%X!7(T$ M"644P#&1F&@&*:6$BN76%4NF]@JNIRG5CX!+@#-X#. ZC2.=#ZN1A+W/8EM+ MK^\K^8S).7*_K>"UUN2@<8;$-$9Q3*T62&M9$3N2:"7S;0=B_RT;3Z:-@]LN:4/:OVK-JSZM-85=;J MLH8, D:5T;$2"%@08[JT13E8*9+QNJS:FO$J>;NG9SVI]J3:D^HIDZJ$#5(E M4L9(<46A18YSH.HBQ\KJ-AQ\+9)J:TX+\E"1D)Y4N]I&O<7GZWC6JU[F?589 ML!Y#]L_K=#Q+XW2<7F3S+3)> >4*2VV0(,Y9!T LJBQ$8JUI9+QR_V:,L%!$ M>--4^N_),F$10RBA>#S-<]-]'LQXO9Y.OF>S0$NAJ'29VEKDM(9JF]FLR'F] MTRJF[?36+0;^G.<^VO36)S[X'2WCM--;>>M)H*A[&:=]>FN?WMJGM_;IK:B(+?;I9K;IL0.E-SB@M+.OWO6-YARBL M5F?@E?VF.ZLS!^;9ZZ6ZE^I>JGNI[J6Z^U)]5/Z"O,ZE2X>AF>YIVA@OY-EZ MM6/U@XG!AU#4C9RX5C@FSF'%,=9$A98%Q0$X41+(E=36TGHH)7GE<&Z?\96B MU4"@SF[6/=1WA?JNC_*Z4-]9OK:!.@+U67?L00X=0HQ2H9RRAMJX@CI5L 6H MMQ;TQUH-I.ZA?G10[W?U5:BC&NH(8>0LLPY8)ICAG$-709T(N]()[>E0;RT4 M#;(^?^YPG,=?YLD\[3T0K^V!Z KED)IRO *A&522X1@J&%LM@"TH1W/$N%Q# M.;E J?'PU\G@AT@>(21YW:+8,8TDIX1"R@!A% *W=+)(_JD*&O_7;T!70@!G7V&H;2J]H""T&<8LRYF- EF\06K#/SJ]9Q+ZAM M8]!.R+;0Z@][1CU9=QZ M"'4$0@35.BV.20R%MG'L#)2.P;AL=*\)T:%KZ',AU)XV^U!;^P.$T&DXFQ^( M5.Z-ZEV,Z@UQ^\<4'+<=>[':(M=<,02 0T9C"6/)B5@>E4&T6MN]%,HUR>G[ M5*$);%6%WEDJNADMV-- 3P-/I0'!:U\YM()IKVK(6"-)8RF)KHZO (Q72E8\ MF09:,P,(:M%[(V$^[)&^>#-EUT\6R(FO_@01($P(QL=HPJQ"R2"W] M!VZUHW:ETY4R]0KN1 A)J^>)W8OMZ5%YE*C%^RE1#8G6'Y-/?>-DU:F6PGWW6K=>Y^D]8>S*<)9ER#F9 X!IIJI2UE M4+.PXU:!!D#PE0X8.X.Y_8[+!+43>' D8#XJ]]RN.7$G0TQ=YI]-],/J4$%C MM29" D])3#J+K".FI!_*%%_I%5'1SYW@_5=0]%FK!P6=U>9[.!T G$0=-FB\ MK>R,H)!3&1-I!1=5PBB)+5LY<7\FG-H[?^\[E?=PZHAVS$!=R#'HR>(@,6$T&B&!) M@?.VO+?>F8!"H2J"GOIM=ZU[[,EDT+[EP=HY"#\1+C@JY_WCL;6]WZ3=!3Z$ M= F:1W5$R.,X]@P3FQ,C)(6FTK!<0RNI#97TO0:X3P(G,GV$P(Z%M??H^_0 MT;=)I>"-[NPQE\#H&,>.XQ@0&$NX= H@IM=&[[RF82'(*[LQVP'N2QH//6@/ M'K2X!JU5"A CH,)8"L>Y13"N4N@H5N+YH&W? *"PG6*P1P3:TSB8^#@9OQLT MRHPL-?^E+= [0[KN##D,AF3U22W37K'1 AD0"ZV =H_:TT=/&$WT1O-&IRU%.N4.&*<@1 [%T$E2L M$0-N=V:-UB*CH&CW2/2X2A+T\._A_T3XBT;W+F@9H9X0!+&&4P@(LV5XET:< M ;@S_-OKY,/;[:AQ7/ _JE.3WZ>3[]DL2*R7AZ71%%U,)U<_15DN<\&<2F>G MZ0W:EN*P%\_A9'$^2I?R^7)4]FHMU;:>@T-G;UPK;Y *Z8P!EM(82XE97'5' M(HJ >*6NU&L<(!'>;C[XIF7N)D_W]-33TW'0TR:7E*"U=FDU%)IQS"F57K,$ MVLEE;UC T4HRSFN>L"&R+Y_4(XM]Y+ZGGM5Z5CL,5MM$:APV2 U#&PN#$ .A MD*=&:AF>#*A8Z8+["E4\(=UC%<^#T;ERV_BO\\2/=/F^GY,P[=EXD123TL;= M&H\WRL;IN\LTYRZ(P ][>K[.WG%G%!;"^G%QY3\?K+='[D+KR^ R'2Y&Z:<+ M>W&1>C'_GB[1]CF9IY]3?Z%!-LKRQ?X:).&KOVP\F@S^>)-C/+S\DH[2'"+O MJ(888FIIXK2;S9/Y8CZ9WM:_R/RG,T\K([^[SMY7_%$N MR3UQN(>C7>82/F^*T)O7@,$J@:R^DW^Q^.E]Z#38;Y"&[,6?]_\4'-Q[A/S? MRVEUD>OD6_KN?)HF?[Q++OR0WB>CF^1VYF_UU\MI^32O,-'5?>],Y6:QDT) M1 % 4/L=VDAERMW9RXWA!GJY>4SL-OX<;[]@-;,]%RKW9/V.8@F\"I6+53;V MZG#QNCFJ<5 31G<4,0@*K3K?&J-!.AJ5G_[M#7B3O_8K,:A>/["07[,K3R4? MTYOH\^0J6='!;[+A_-+_Z:>CU P&GE22ZUGZOOKCY_MZP)NE&WMYJ@/!F_5> M[N(>E/[P\YL5+::\_R,?X=U^UL$K;CX V*,MUI<8WL]YIEAWGOF,9UV[.O4_.RQ.Z72BCO?'F;J(7Q(BBA31\Z6KK0 M@R?@L?/ 5MKAM5]9]W5/B IH_-"30D\*:TB!UB=E)B2A6(250")6CE"+BHP4 M1X3!=B71=C^DL!(J\ Q2P*VTRNU)H2>%TR(%5FL*#D+E%0442RFD4AQP"DM2 M(%B E9C%_9#"RE%[3PHO1@I=W;3SLAZMKO_+1Y"+(2:@[%4VN MO3P&6>B#U??LOW[9^$8$&NV].1%.DUA(Y*"W@-FFZ=%WV^CA]:H;'VPTP(MC!F,KN64QH7'LN*;EQH<%,_2E M\/5D+7Z[XA0GN?-MK96_UD%'B^IZ*6J1OU'F*6$X>QN-TWGOOWBE!^^* H%K MS9[&2F KA*5,4DT-E&BX'5-:\1 )PP V4<& 0;'CVH7)(4QHK:I7#,=+6H=*SKYP@*\WW M6H-@F\IYFQUK#@>"I^3!_^C?2/[,\Y=GB_-9-LQVJ@K9^QL.R=^PB<8:_OM8 M.L@@X9!"*;AG,L=YI4G$@*ZT"]F2QNR?Z=5U6?ZV]]CWGL >F5MJ& V7/7%8 M ^0U"V X\U@$!%>5<[S!+79RV6^&9IL:?JOUJ _?]==#^:2@W(CE!YH#BR72 M(HY=S!2PL:Q<9A*(7>WU#5!NU8W?0_G(O?A>GJ)9.I^/TJMT/"\*H TND_&W M=!;-)UZ(0EFU;V/_BZ);;UEUOO?T'Y:/8Q-K-:+V*<'6:< ,X$ Q$V,L1*F M2*/,KK;!EUK(#LDTZ*P%T*.ILVC"39\] \ZKUP13:; 6$AEC*H>A,'I7=?YQ M-'4VY*9'4X^F)Z,)UF$R3E',D&14""XLY!:@ROT>.\EWU:@?1U.K"C4_!C2= MDBO]E\ED>).-1E%V=9UDTR DKVWK'A+Q'*21OXF1<,U($"!#"=!6E]/TZF:ER[EP*4+^)$.!PF["%_4I GM>V@ MO4I#9>PPX0! +16FJBJ=P72\DT[S;,@_V838!O)M5M[K(=]#OE.0WX1X5F_R M#F#CS1;'8(":MJ\[<&8SE3C7RGXWX5DOF]P<$AW5 <$=ZHO3/=+#(VXT_ MTTXY=J(Z9#YJ'!((1RRP%!AAL>&6.U%Z5;P&0@0$;?'1I_EE()3^6*#W5QXQ ML!K' CI4S[8&"<&QHU0*Q6$57(>=V^GT[2G ZFI6;(^K'E=/Q15M' , A9"+ M0ZE)02#0"DI<';G3W;/@>GJ<$3U+GNS" B!88."H1DDS@O&!UJ3H0$N\1GIT-R^GAV%) MZP07;0%RC%.B'46&(!K+JGH4$XC3/<*S3:7^14I(=5_;/QRE_O=I-IEZA=[_ M9Q@EPW#E/)VZ]R$XKD;&=U]E/@(' M^=_/OIR%6HNYP$23B["X>3_6+)>9U[9Z#XF)CM'<9ZBF*(A#]'MLI/&T!! 1 M0%8ZN$&:[!0)EQ_:+=\:?_LP3Z\V.LW_I[S#_RPOK!;SRXE_REOU9S9;?EQE M4FN_)O/I[6]I06NMI-6_2'AL9Y6*'N/'A'&"&KV6J<."$J.8!!0 RLVR-:3% M<*>:-4_$..\*QH\[,+:'^"E!G-:%XA66SC(":"RI9M!"PLN =@(1!3N5M7PB MQ%E7(-Z[_@_,]:\&_UYDLRPLU;MI.O*"..Q](D?E$^$U4TGHF#*4 V08I@H0 M(JO(0:ZYH"]O<,2+63BCG#7$\ Y5-=[_7$AG2."9/8NR>J]EC]!.(52".@( M6$H8E &E7JE@D,>V,A>@LR^!4/[Z"+WO&VBS'7V/T!ZA3T4H!_59G>#BI88BA1?9B'@(1_WMR[FEJ]X,(?\?_6;G: MDXELJWBB-G6.OEQ'SP:'Q098-A0>%D,AM(:02&)#XRM;%>4R2.%]L,%V1Q8O MQP:\K]?5L\'1LL$F,J"U:@ =418"2I!")E:2L!@OR8#%8A]DL-WA1CMD<+I) M1T=XMO%E[N4M&#D[Y2@?.U4=,B/Q1NQT["S@0BH#N9%&0P>JAK<6&K23QS07 M'#4>_CKQL]9R,D-?9*2'55=A)>K81"F0(Y92;"0#U@D#(*XZWV+"=HI-? *L MVJS=TB<H4\P-2J7<6A\XJ#3VRCPG9FYSZ K-F#4$!8DDM M1H0*B1A:JO>Q5'4AH):AO9?"^JVF%3Q7,'K??4\*72*%39Q Z]I]#L,82F.9 M(<(J1XU"O#KV!XCM5(5@"T[HJDUR>-O]9F/&"^2^#9:VJ.OWZ>1[-@LBZ]<[ M^O$\':<7V3RZF$ZN?BISJ7O7_D/K>U=NL9?;X601&AM4@KO+TY<7#=]814)7 MN(S77,:\7F.1T(Q*!R 64M&R]C@RR#*]'9=I/XYLO/!S\>DZG>:$MG>#1;9! M84^2@R>I++L)0END4"#BAQ[RIP+YC3:-:-@TF%!EE*".$"P!E=*9 O-48@S: MQ?Q>+!G42A&$8P7_3SWN3P;W&V O0;W5*P(YD@@I"R"D AJ@RJ*I- 8*;NG* MV!+VK?8^X#W:=]GJ;#";^Z_/+9!XE.42CR6*:#S&ZR,;)>) E M(_^T'JNY)^%M, )'BR"T^66RJ^M)D>04BFXET<1/WSSS1N*5OWQR,DW]%C\>I!&4@N7/&T8UK=JKAT&%-P:3Z?5D6L:E1?D?P:2- M,/TA3 B"/^3V[K**6$!Q8>V^]1>;+4;S\,!^*(TGG/K'2F:+:3XQX4;YKR]2 MCUX_90W3&:S=%[T[QAER7DVRKN[GQVYW']9G,_2?R_"[)1"EXMZ M-5WS6F8+-'RQ.DC:Q464S68+/W5?\A=J, @5,\("Q(O1*/5_11\G9Q&$XFU4 M[";E=9;?^^!%WI-UOITT;Q7"5/-5"(&J.5A^?/-%Q>%2;WYZ&]U<9H/+Z#JX M0(8>*=\6V3 )LN7E**DO'@0E7# L;)I#9G;O<3P@RZO6%TNBIK2419]SV'DI M7HR&T7@RCSR?IWYTY^GMQ/_'2UITZV6_$-7&]1OS.,Q%V8\HP#P99P7 "\P' M:?<_:@Q],?;"V9PH/\,>IM/A+-*38791SIF?%?5%O_DIX@2\C=[4<^QE]DT4 M_2.-+I.R46.XRS"GC =FJ/87K9FHM^6(RMEZZX$2OK%D2PQSMA1^0M4LS)"_ MEU_])4.IL=]Y1M'GU(/;7^PF]?_O&2&'KY^&J^2/ --D-AGG;X7R*UXMJ#KI M5*ZN9#2Z]5\;A(TW<&9SW)4#S(^JPLZ.NM5?-BE7B#=3P91!ECC&C*:8418# M#( PV"I-+6_&>Z]$7^NXNDB_P"D$'N7DR21>;:]@+1P_)> 7)8I4PL>M+2M[GFCRPUW>.F')9HF'HS+U_)Y1YY9V\^ MRS7(=)0.2A$H=]4'%.M*7?QE-#GWDO!A[-75;WF[\%\G-^^"0CJL+(#*FOSE MPZ]?/RR-2+\9A]^7ZK9_5:CX7@0#98P'BR!8QVZ'??)J3UJYWYJ[6FX'WWB= M^YF(V008BH[RA/"'Y\+E[7,G?M,YC:1'?D[ST[/7(-]*]BS_#!REV_SY<^\) M>>Q/UNA"FT6UIUM;;0NT7G>3.%9%O#,.I_VP< MU*KEKN[?7.3>%2\*[^KNU<$3G&33?-\?7";3;Z67I=S0EWT9@@U>]6:8+(7W M;72=3.=9[HEY256.\]Y*WD&*:SV^;^Y<3 7O?W+/EH^%P7;IB*VE9+QL;I8&51U+A-K77+3\_JRW$_,N+<1C0 MM[$?ZK!IC\[N&Z1-:@L7"*3D[S)/O8@'+WV^6)4GNF*S?RVFV6R8Y5,Y.XON MJOBK1Z7YVX4M<-\(:)SKAEJ$Z?3>N>]C1L*NH1"AULZ= >?_7DZKBUPGW])W MYYZ^_GB77/@AO4]&-\GMS-_JKY?3\FGV/,2' G"K^]Z9RGMSG:/YJY_3+[G1 M&6IN2R%"D7B H#8(&>D5X[(CLX@--_ =+C#H+Y$.U?S)/R?;+]CAV)&_)>/; MNU)>6]0W:;F;EV=#X<1XD1__5G"=%:==P\P#N7&DE;MZ5K\= (?@#Q[\=ZW7 MY>?!?O<:1_ AO(W2+ 2\1Q?)]\DT.0\Z1 #[\N7;L$E+:_^S$?5>7MXXYOGJ>E2A.4QM#X(!R1&M5]K,36CF'W]6F'0%:2F9B*C!S4!!,5.7:L+$#_%%& MV7@?^,;OF8/D.FP/TT7ZYK_,9K=HJ#(:;O#05^I0*6SW!'WSGK+-$CY' M#^E8"'=MB'%);OWX'>B*\'UGS_GZE+F+8AQ\;HYJG%0@$=WXNX@*$)+\U"V:)".1N6G?WL# MWN2O_?,/JM5^]-XDPWGE_Y//QUE+-_ RUMR/4O? M5W_\?#]R[\TR@\A_)4S_W][(-^OSBXI;<'^'ZDOW/X.[?81:O^*S;]:5"FEM MI9&]:"V6CL54+X6;OVG_6=>N7&E#M:".- .3.ES,K]U@X!,75;Q!5#\!R>M]7;'@8$6@=(EH7A%=.@&J_ M]G0[B3Q]<:)>JGNIWD\9;=C=/2I.AM$P/9^'?*OO?ML/3N7@S;I)IM-D/+\- M!V;313+JZW#LV7AL:T'_\HP'Z7Q!(PP;@13("2NH1$@;:A@VSM+2GP> H#&\ M[ZU?\='[/ZKWRG/QS^DLG7Y/@_=>E7+_CQ((U4?WSLP_%(<#CQR8TRW#91$\ M:R5C^+5KKO:LT+/"2[."K,-/L592F)@Q2!5U3AK#65'FS#EF"'\Q5N#ML((X M8\? "BU78NZP1I77Q(NN)[/YN_3J>C2YS4,5JPB@M]'WI$Q^#6K6)/_RM)2B MWHQZHAEUO&V9,((UIUFL.7 Q!9!Y1D..(5MQFG40N1TX+>0 ^?_FDNAYK0P( MG.7"NS\5!Y^]2-_%SNH^/5J/%:V-;%K&D<+46E 1.S_J63CV4.@,E7A=@ M $ 1'1LJH'96]LSMZ#\)C!2'"C?1MQ(G6 MA&(;2Z,8=QQ6OCC-R&;K?K]&.Y2MGB)V#X1'9[07J%O]]^MDGHPB/_G>;'\@ MYZBW.%I_U@,HC8XQJ9LX.TFE%BY6UFAIG3/,E(F !,H5AHXKE#1+T&X]J8/ M0-*R0M#)B+ >="< .E9''0G) $'20AM3_P5.D8=&#;B^TL.NM4\.7"#:3X7O5_\(5O_HSJU_GX;8\GE1+B#]]R*[#HEN MO?)VK(&P%-6!L%[[(EX'@PAK1&)M",:\\B(QBQ[3OQI5<2L)^GV4C.=J/+25 M$.W-F"*@U1/IWA[J(?4L2#6".6(! >/28:BD 5((R:IJ%HAPR]J'5#O6#L9G MJ^V2#A!2IW.D_&'\/9W-BQ8[8>_.ZFYW.[M,3T)W/<705\H;H:^6"LZ<8;$. M6S^'M"RX8YTA1-OM*"J/?W69YYWTU^Q[.BP<,GO;\JG?\UL-B.E<1&R/S5/% M9B.V0SKD(2FXL( ZB*%0@%1G&$K1Q\K>[(+-EC+,H3SRE)'3/9!=>RS;\)'V MEDU_TO, KS%8G_1@"@5#0#H!F%"Q0Y;$U4F/%0ROX[5EQ[L&N^U/QQ"@W:R; M@SSRZ:';0Y?ANFH5(QS&SCFA'4*4J!@MZ^ 1,A:)^&6T&U)!:%H'_'R!P;= MDSFM_9C.V]1&CMFT>OC!\\+E=V0<>S$>3A;!??0L=GNV[OXBM5&W>OZ-8M$! MVW)3T#!C-9,K!&(F,5 @MD+3F %=%1Y 6*''@H9?1/T"I)U X786M_MAPCVM MO3ZMM:,(' ?G=4*SW4B(HB9$[I!Q& #B^0][X]0HM"1$H/5CE5A>0JF%'!\L M(;XN+M8F5?PU[^*Y?'^E66D;JGCCT5ZHZ>J6=]RY'N5E&DU3OT+_6?:4?JA[ M;A8*7%RG>6/5:'$]*3H W^U%/5M<7&2#+'S#_S+OJ%IV[PV-JD-SW^OKZ>1Z MFH6>W8/+) A]&CK\1A>+^6*:1M=^B)/A["R*_I&63;&GH]M\"+-9-%E,HP*7 MMZ'!=C'H-'][7;_?=!9$(IM=1DGT?35+-\HNHFP>GNTJM/ >97^D_G;S2S^% MH0MXWJ-\%L:?MRN>C-^&9MW^UV_# ZV[[TTV&N4_/Z\F-AWZ)_HP+I_#8RF? MC'+2RP=:?\&WH9_Z35CT<.LH^9YDHWQNKR>S+.^#7M01_9;D+]+OV3"T:O:W M-(NTZF">_WZ>W^7\7T7[=/^DGDFRBRR_V,KO\]N>IZ,L#9W6PTQLFJDP?NV? MR9/>.$OR40T\525A??V// 5L/5^A,;,?:[/%9A14T:(S==Y4_BH)9^(>$,,U M:^M?S!:#RX?NZ>: 6$5AECX_Z=:\!5S8#5E\'X\OLY[UW\8 MJ[Q#][U]L=E__?D18 ]LC%5O[GL;Y)-G,BQ@&.O9BY+LR].Z6@>@(-B5J ;Q M;4CSIEK$GA&F)8G_Z5=J'BA@WR+=J+ /XAA("ZDW_"3&I+^,."[WO%$&B$H'H:XL QZUD(:6)7XC_;O!S:XM'T0.'2VUQUMO0?.2ZVK7]YO7IX@Z,5W&;>JUA[^M< M%[UTW,3<22@X$%)+"I@MZ^V@6%FP+')UGDW6K_$_LOGEQXG]\SHK-$KCUZR3 M0(5^]UBM>]':!G65W 95*#!OYM6&!H+]<)?_*'[I2KZ=I M4(J"##PN&5[K#?K68I[ERM;;0@4[3[_YO='KBVE8@K38*!$-XG97L=NT33SM M!M+?X-'-JG'GT(,GF7J=;EX7T7_U'0K5\<& $-I#5$8/1!BU!J@PJ:W#:BVT\\X^>'GESGUV[.& M&%!=FN8$D"@!9^^0N3Y>]G7\ZBBW3HX>[-WEF0H7Q"*X;)3:-2 MWK*T--W#-08++]GCN0?@PD_RU(/>CV= M1G,+^9=T&I[CK3?NAZ4U^.4FF_\GG8[\W\533(OI&&87'NOAQUGHVW[MISLI M+ALF(1QR)C>%SZ+P>^2?%>:NMX5SZEN,YGX%_+B\S3Y(QG-_S=GU8I[.\WT8?G-/2.G8R^YR.8S1;IK-HUYME5>#._4V[:%2Z@X:)\[/P#;Q0. MZO&68N._[G_XW=]YLICE][LS884LI(657?AI//-/9@O_+,&F\V26S78SWMH\D%_Q+>9O%U^\/Z8& M6PS2L/CW7*3[&#-']P:<_WLYK2YRG7Q+WYU/T^2/=\F%']+[9'23W,[\K?YZ M.2V?YA6FM;KOG:F\-]?Y!OS5S^F7=)3FDO9."@$1!0!!;1 R4AE5IKJ)V' # MWY%BZ_272(=J_N2?T^T7;%@XDGHD:T0TY*BW'XP*/^/Z4GJFI3Z'\P MR@'DB7$QKK@K?&.)G@*"PTGI7RN<>8%Y:W8./MV N#57*%2WW..61$&CFF;) M*$J&W].IYYC4D]I@'C :\.NG.#\*R ?EMU5/DN'+^::1I[)X/AMY0EH$5^9X M>1%/!Y/1HG(B3\9I\++F;L;E_K!N<-DX?YK";YS3X/V19E?723'"0D,.+)IS M6*G!AJL4VT0R+Z_SPJZA0NWYN+CRGP_6>]7N:HY?%E=7R?3VT\7OU5QX8^N[\W),AK=U5GL@]>L4QFDW%R/KKUEYF%[*( C-AS_1]O'H 9 M#!JMUW1*%_XK%;KC.]T3))W[HK[7$9E961[- MM26-I+;?^311!(HBID& 1@%BT[_^S:P%521 K(6][+!, +5FGO.<_9Q(,7Q= M&V@D=<@(HAH2IB#%1)8#C6@8FF@Q/RZ]#WP7)$ZQ?/3@.IHD4RQYL92OL&4Y MBJQRVVV>&NT>1;S6=#?T'MQW/HR2H8OC1XZZS][+X5?:Y_E0#;YKT M7T0^(B4Q-?R M[ZG7'=^[/]UR%-'4CMNW^#%-WI=_S)@9[Z;Y?],<5XC?O9T>F-^#LC_\4A[T M^C>XV4^@\2LN^ GO\V9HI=,.6C%R%+DXY_-^JW<]63%=?)-$LL(N:$ ">(VA MW;N1Y;"3;*)T_2^PZ\5S^7]]4)__W_Q((PE^"_XB=TC=Z#F"; [MB MLM]%I[B>>@;KDFB2J$TQ@= RJC"U1D'(3:B H'E992A02&=&![UAYN\L@Y62 M&[F/PO#C+,=JL:G%I@O#IEIR/8Q"HXU4F%C(J&'$$E-BDS&S8\U6QR;64->* M_32M:+&IQ:86FPZ/31)4V(28 ,;PD)-08LL<;($2FQ@E;";U>75LHLU4_L!+ MUIM6LWM/Q+Q5[HYY#-'76;P(3=:"LX^CWG"4YYUWHK-%X8C/_IOT?:IE-!H^?/:D]#D+4[MC MI\'?759C--N:[VAUHI;-3H#-"*T:77)+D('$A!$/"1,R!+BT0 "4,S->=\1F MO"DV@XV.$&K9K&6SS=F,U4H[ XQEXPB9CDQD:_P*-A,*1[-)";MB,U88VP& M&IU7>.1J]*F'C[Y4:]DEH./T8.)P!6'(XC12",3 091Y!I MR53)X3H,Q4QO[1UQ>(/FP&PM>,O@+8.?%8,OXV]<\3=4$.'(("R@50@0!*PM MS7U+Z*KF_K;\O;D=\L]D-.S&Z;W?;($@^N7">^J?G9??EU,49569*=(Z1\[1 M.4( K44:J:14 6@HUUH3;N34.1("35S MBM,=,S..I2 ,D(A+ :@J;0Y%413MF],;,SU0@Q,^3I_3SRHF\!??H2<;>C&. MQY-Q]F>_]] KNCJVGI+3])0LA2U1U6<3S0C' $# L&30R,H4"4,+5U50JARW M%[B5$=BG._7XV'?K=]M/ON:$]NGN+Q69[=(@::B"LK[CQX]1+9.> 9.BVAP4 MP2A6"DK@+ C C#4(E+J%9 0TV+2RXA7Y!&MSG,P'L6#-&_;WCHY6B=' M@7&T"JQ*'2&#%5@.)WYFP^LNT&NU?3N=[F[K+L-I-WHCN#9V5"N*N!42 M2JXA(HH;&I5QXQ!LTX12--.$4C::X[UTBX^SX5L+4"U 71) $7RQ';Q;@&H! MJ@6H8P[]CKHWO/X2=X,I MU:9!W.F,)DDW'\.)C?!EY?- M -X^?S#TA\6W3@I<%7T#'K*9SS^2V@SF)4\:9_,:R^5<>VE*KT(N-C"\"NJC MP]:^W-7F3U*?=+7VR=FB;'-KML4KNUUY]/,I?R3]Y^#);L M2J(-)A$'$="&B% H$0D BPFKVGVQ:L[$AXR.?2UF25AJT/U04)S**7!G!K*\ MH3/H7LX8?87R^R3(53=#5EEFD50F1% 1)RBHIHP5P=T(A<(BL]O-:,88@&". M,=#4;FS'IJMM" &5:P@@Z%L%15 :88T ".MB_C F"!&\VPUI1OF!<([[J*D- MN0F"4C@ND3/;")EBXY;E21 @ICL76HA(:"(=A180K#@WQ:!?%(52KQ%$?7OG M;"ZQM\Z-2)WVY[Y;DD8]FZ'Y_^*RWD$G,C"[D3 M.69;H^?-)ONS7F![E?V9AWI-[\\^P ]6;8D,-"'42D&&(AY%7 $L2Q:2D5UU M ,J&6]18&%/<\)F=:71C'.)MI3J>GK:\)2DVJ"X[^?-M.G]^@:4UV*5<6L93 MN/*4"$HUQA)#(*(P,E8:1 N% E,8H:UB3?]]VQO^MV.W_L0[E IY7+ZV>^OI M2ZO?>^G*!_\UL^^:*#*0<[* &M,,#\:$F<7V&(_&O;CO[+?AW5V:C(/;9[=$ M=\EH5)!BG+IO]T)M!%9=]SF67$ 50AYJI[L2H'DI9)7!,P@>%D_L*$UES_MI M?.^W_@2)#<[I0-XUZVP_N!DMKD$J.)Y$XR"QE%-K):4H0*\6RD M ?KUYG[.G_6;?]2=F>)TIZ:XNW$0!P/'7I5[:]Y=RQ_N(AY-QYF=VC]I)1N/8"M05ZU%'B^/)\IK_,QGUTFXO+YZZ"IX2IX'U>\D/IZ#= MQ^/@J3>^[^5/-G#D'XR?DK[[[<&]Q7T:],9!SSO.XW0XB&^=)'T3D8?;'[WA)'4_OJWK=8:3?MU1"F>+-;XZ0[-WU^O$@[&YCP??DP^#MXRJ],MTH3X7 MZZ0R3/QTEY\RZB;=XNB=H3V>$U9KT+/T=7+KM8-"L7+_!.FDWAT-\ZH([F[R\V">E3%T:_[?%>%;KHWAT:DV:#;>ACUZO2, +^YW?V:])-L M#ZZE$!!1 )"SX!$*I0I5H?<)'?(0^@TN+I%TU7CMT]DF2/DAX^_OCB1'N:+L MMLRK@(/L)<;#P NW\:CG-ZP$E+L\\3E(XM' *8YI&1-SC^O[8V? D-'$]-P, MSN)1XH-C'L[[3L>3D;MJ,)KTDS2W:;V^FQ3GNRM/ MZ<^3U"AK_^+^[@S3<>KH,W1PYTY_W;$[ [Z2!?<,/KSRL#'A+$^GJ$###>4. M<)!3^;G[#T* \9 M4/[_THMO>_VLK\VO@V[/+^*M@_YND8=NB]W8&:ZP.2Z; M-W!EJPAV=,1F9D6Y)Q30Z7)/Y"=A;RTLG&^+G.%X7T MO)N,)Z.D\'UT$V=&E:*\%-V5?CP30E[PC+/LYA_#_=YI3O,\4J+&0\[O]V[*R2CU/YCXHCKXW"?HS.:)._^Q&]R)7WVWZ_?/IG_]^^?_A+:+U__-;#_^>N';_]5 MXE>Q=J]H8CGBK/)\V[P>>G>&QE@1BLPJ7O@OSJ1(4Q^1](+=64"9I\D+[-03 MJ%^]U(FV#(Q-/T[30 5F^."LD2"CX."GXMN?LPOD'_3<0_3/-T%."C9VRDAZ M[R&S=MGZ^9FGL--SD.Y,J>0?DTP7*G"]+A^*=\G5$@>SO:[7E#J9*I+IPH4; MW%WD]T[R./8&W-VPWQ\^>=6DO/.]^S8SUMPR_!CFVHY?\G3Q [O[^;N-^WD: MTG#@8-U]<9_E$_D+)=[$?'!ZD)-08R=_"O4IF7,U/>]J_A+E(ZAN/A?%K\35 M]!'2&HID(JA^B8S.-U6FBO*S(ATO2\#K>FTM8T7/L\G2'$@F,.$)K0TX50 ) M$&H318R@,$(*\+R().(*6S[5MFY[P_>VX-+/R:CC-=3_=A3TG MJL?#T=L]N?Z[P-G_]OU',I4T6[)/=QE)9@ZC\HB<5K.?U8R_R.E5?H:F MZIF#AX7YE+-.OC]L[4\M=)5L'?R'Z4J\8)^3((LJ#0$)&5%FK=&&*DTE5+AP M&7)-HE =FBQTDV3!=T@6W7(!;@(3I_?N\P^/B-TT4Y%ODR#SP[N]F.*'1Z$T M\SDY['<_/WOPBX-._>SJ!%V>X P=;_N]/&SN/::G3 ;.?G34. [Z29P%&'-@ M?W617OK&0Y9 ^.JRGKK=9FK]K MZ?P>PY/1+[O7LSE^]<#9O_>C\B*/3I)6L@'#"&UG&.&5'$*KD.PV%+_,/)NEL]DUKYW_HO0*//Z>G^^= M.H/\<_T& R_A^R_JE"#(2\^RXI&@D_3[Q:__]QUXEWUV6]LI/\^AC&].:*7! MQ^0I^#)\B&<*U1[BT??>('^\>#(>EE_D=6_9-T^][OC^/:,W!$DF./U#667C M)9%OS?>^_*.^.%E-S;MIFX=IKQ+OP7ZK"41^)\K^\$MYT.O?_ Z\]1M<<-K6 M5US>LN)\B@V7]Y79X;NNPE]KONUKBR+3M#S?S?.\E:K=UTQ^76:U:4L SA9X MDP!6AH)CZ8VYV:+-61H=]V.O\SO#YC]B)Z)'ST&>-\$VX),#]:7:6)%:P?_ M<-42ET%+,0.2<1IR:J!6(M?+;824%#-!P)S[G\@5PHW,M3_:WE1'Q=1'U67@#/F55AF[E&EG"G!(E:)6 Z(1R /- MUAK'?C,%9[OBUUF_X!;\2J\@OO16F\NU^ M33J3)7.DCD#NPB:;N!ZM:#UW"7K,7/EF!6G!EJ+R./N$MM )2*8PTE@CAD4A M*2.JN9[-K3TFMEQ?O*Y4(]PD?^ZV8_JF9++9B(BU=,?#/3U^'Y.G[*>C%MX( M[JX%UAKD<[1B_W(MZLM# @YK6:22@.8&KA3!GE09"@ M47-\MC#VDG#@H"&T/;O':RW?-W:0GS"7(UIK-\. (L1 "Z1!4%" 2"'O,5)T MELL7^]78L?C!"6UD<&-KD[-U@ MT\9,UK3S&IT%CUV.F=R(\_H&"8LF8HDP;%4%6&L!A*,3.W6?\ M6 QCW"1W'Y^^V]J]Y\3@2QSDO%9Z8G04,4%,!)42(E12%$ 0F>U' MN+'WZVC$/93[](,?K=@_>^E^ONPK*QFO_>PZ1@@4OO08<40,*RWN",QQ:QV" M?1LUQ^'N1N$=$?>VR=USO-?\4I3\Q?PO8-5@SD(=G9V\H6G=PM2:Y,8&:.1\J78RFC.J"+3/%+$PIE! M)(V[R9KMZK.-([S)DJJC%:WG+D&/F2N7>*\%K1(T::2(YLZVA1P@)RMA5!9" M14!*-"LICXDM=^2];I(_S]!)??)QZR:]UV>H1]=Z&T>2,X, U7XN'P2$*E"D M<]D0DW ]=%CD]SH:X0SG-%<[)Q6[M8@OB)-%)>>!E@(H30BD42@T"QG1)23N:JE.AK\S@?_'K#/D]/MN$W..UGC" ME0>YK-1X,W_1 TXNR3_ZP\OA'.\V[/K[S0]!FXR>,ZY8V.S70)F-NA>4 07" M"%JH*66,<:FT6[)ZLU^MF$74(,?0$$,D0B0IY0@*2V#(PH6M3Y?>9Z;9;_D. MTUYXVTW66.4!MGG^LYRL\6$0?'1"U8-GGHMQ]6:S_LGX?CCJ^4E#?E3G4S$. M8I0\3D:=>S^1[W$T_#Z*'ZX"]V\^@*OHX5R>.WXNQH$59USEK<1"6S2Z%D2364GF&>_+ M]%4^Y^^NIHN4#^V#.QNEA2BXF?4;-S9UV6W]B\DJ12?ZNVRZ6]V'>1,$U2I, MF_8_Q-W,D'J(!_'W3(K_:UK;Y^!N-'S(&][[P6_^_XO)EL/'9.#.&OV6C(-L MN):S@;_?.]+J_<@'K0V2[\.QGYG5#<:.S-+\Q=-L9I8?6N4(LZ34'"C2R6,R M2A,_LLW?P%W)#XE[<8A[K:W(;8T)$\LHLA; )-A8A\(@BBQW<@U@=T1)D=JP M^0',C2B2-T*14.R8(*N.\"]:P?LI(GXO7O8$GK']7(-T\N .S6%RVIC^_3%/+KC4EN,0@.UZ MC4/X[FW?6'X/(A:T_U[0-GQ!L_%%/VUXVJ$>I.UZOJ<$]S7W[08%!I?<'?XOXD"=Y4!W;R('X. M3Z'XI7M(_3C6(-.[/_TU+GO8\^ Z\)_:FH>ZO0,!KIS)!BL481I1;AG#$B!M MO/N)*F&E5GRF\^<+'UB.#JKSCTEO]-JWG!I MWRBP<;"W_)==L-H)-[HR26\AL -0!?-;&>)^K1RO'(D0@PQ$T P*%1H M.4"4"JXE$Q+"FI8J)BDAG%BB9 BXL0QH\8< 6U7,WG/+5#*C.D.F:N&WHNSVX<&KGA M^^#7(X[:GTV:WKL__<=DD-1,J.PC!AO;4*J8^?%U3R2]S(](3-FPLG960/$IQ=SH, 6N9IB0D@HC0$!-QI8VQ M$7-".:M'$N@T?V3&NUSO(JQ)(+K(QFCN:4 M0<;A,!5.2Y*"4;R8UN99+$40'C6"N/0*-&JO7 8UM8B[$A>@JL,Z&9G'Q95L=&;K68.41UF&$*0, *T11Q)0DB&;6!@T!#LWZ<9&\ M6A8ZTFH&>26^@K2-1K?(NQ-.0%5.8T2P,M1;"9PIH&PH",ML!!UAS<#\*?0- MV0@S#+-Q= 3 F[-04]YL9++_.MPYS4>V;*;20%\,M%U?#+S24_ ( ALICK7B MVCINL.5 *F$,!\1WYUGP%$M/)YOLT(=!\#5Y'.=V5-[]XBD))KZT;,O.$\O MHCY=-T+O$Y+:\W]N>T-_[N\ MZ,J]U%:6R.B*D^4">06F67^;&B!9T@S_X;R]@>]%,*H5-Q8]-WH#OWN#_&+! M4V]\GQWY(TFS%BON1'?4>-3K^)88>4<$OS-IK<,! H ''P:^OJ_W(PG4DV_N M\KGO5LQ=/,MB]OUW#N+]6 M/.77RZLHW^W\"3EY)5NR?^]'Y44>G=EV?>M8][?K^,X]TONX_Q0_I^Y6?[P? M%6^S_T51S(G(-ZK3F?R,.G[KCR?'.",S/#A<93<)X/4X8T#'H9 MN,F;.LS^^U:[LE4$PO*GV.8ET(94D!U>-J:;0Q?*F%__^NM?U#<;!I^^_;O] M$IA/?_W\Q?Z[_?CUP]]L\.&C^VR#G_[RZ>O7GQ<([^ZJ_=R6ON=6RX1W#]'[ M[^>V63?!KYU[)^_[R:>[%3CY+\,T_>:-J84L#;%CU$A *DTD*4%*TJGR9&TH M:RPM*+*:&^UL9A8:;2%2NF1I:B5=N,U+[S/#TK57#(;^'7T[J>HEG<+CWS+X MJ>_>\V?_J3_QS<.\JN3T%3,<9)4^V>EER^BO]TGB-"[?!^K%[U.U.FN=9N[C MP?=/,HK>?X!AX/L.B]:*[Q? MW#-Q$:VMTO=A.8^NL/KGV3Q*RAL!"!.<;ME#RJ/0XAY2F&W6@XDTWM7I?*YX MD9VG+J8/3E38J)W):)0,.L]YU[Y^#F)Q]W\FZ3@#Y7:]7JY7+@T?A^GX.GEX M[ ^?,TO^-ADD=]ZAT*[<;%Y&,@XF V=C][->2UZB>WG]/>X-TER#2)P.X:GN M1]SK>Z%U?3<<7:=QW^L9WH?3+F?MC+S1UUH*VB770Q3J9^H[C3J=\3]BIZB- MI@VGMNY4WPPA'6G]_$:9C$N6YVP[17"&($M8/0O2$BP0,(Q8"$.+-5(T5_Q] MWI6<&=2VHEWI\/33W;?X]SDE7VS>;(C<:HY (B"**I4#&EHXB LU, M.<.!02=T:O,@Z>IF#8H$P0@9%H<"<&F-@J$&98.:PZ2C4IL_Q MJ$F+C$#>;!/ \\*6HRJ/>W$/B%X%!:^S;QI8BT_+/(E7P6WBL]N"4=+QB8Z] M.[<>V:"?+>[L ))(240@!08Z.,' J@)%I"1B!D4608?.%OK+ MZW5^ U$6Y:L>AP.(L_/(E#\7JE[B4^"UUN@0:6H4%)1B""TED> R]RF$$18& M'C=9[]G%P&Z:[!>RD:/@4+Z L^"+)6S!JEH^"VG(>.1;9Y)00@.T*6Q62#D, M9_S[Q\46^S)A$<"-^MS.%OA/P6+B5?T>%5P )C@BCO2EI0(;8RWVL\T95'!F M7L814'_#!I0OOFYT[L9IVT$'S138DX&45Y2F-?,GZ>:#>E=+R-AV6MTY]>(J M($56>B:.B#0TQ H2RJV"3K06Z>B0N^-F>I2\!HS(;<0*CAF3I;R-\Y+ T[&G M_IF,AMTXO?>9C )!],M9=R>Z<+80L.J@"(3/_H>4,1R:2%@A(2K8@K$HFNDB M?.1LT: ]MK!O<9/>AI8_CLT_X?Y_RB!A2&@(02BQYMQ(##@HY09#(0 GQB"- M6F:KN"S ?GCE/'T9)\E<2WB+5.U1C7#ZF(4AY@9&B(:< IN;>:%3R?!,*\=C MY*VF[;YF0_)')UHN,?*54V'6UB&YNTLZ2^L-SM?%*5A-]>1.D'(D4"2H)(C[ M^%;N^;<@$FIFAM;B>M@+-[).0E<\8;KEO.:^TV]QN\^EM\RJ6G:258A#9,(R C8#3#HS6+-(DLA9;'KKO>#5:QK?< MDC]RK3^;#>/@E\8T]DZZ-1[Z;M-<9 M<#J.J7/A@&4,4"M]EB&6E!*H-44&4PH)UF6LS(K9-E4'8H"]U:L0T<;*3HF4 M<561A:$?W\<0H)++4"!&:%&HB)6&>JVHP9$G(6%T3I.GVE# W&Z58=(IYM>V M_2I76+VV!\H&\,GJ0P8$)AHA&D$.J=0FU&6A@30&\.:;H/#C;5C)>;/SO\^K M.TJ+.BWJ;&6!L"@&L9;HFJ7)E89WL2C"4U$13"*J1)6:Z,L)SQ'!X8M_;E0&&B6>=A MJSFU -0"4 E $%2*DU*6$>"T)\D0,H(@QF@1NE"AVD73RO4!J.F,62QN1 LN M;?!^Q?19=@U@-G,P3Z7%__9O.TX3.L'.3SO,M#Q*)FFWN]WNR]GNU?PQD%3% MDT1&T@!%B.;!(#$A%6-=H^+\S91\0_!56?" M-6W _.V ^Y%]7M%SGD<:D!1BH]!D8A))A&3G$A(9)41F@Z^ L0 M,^/X:7;TD3A\*?PJ9AB$J&W7>-(LL8PC:GVBL2;2(*"4XX4HE *%MIS @"6! M:_6)WC]'[&*8J7LIX-?:20M$(DPT-RPB2#*F#=1%A8K$&NUX MUMVVY+WW= C8J#W; O_1L8:L4A8($C*"4I,(<"HB1JRF!?(;!O$QLL:N\A4@ M:#8$=CJ$WZ8DU,YH9T0VKFIB6/5KHA@BJA@-J1\_!",?="\ 1TDK9@!GQP.) MCL ::X=$7BQ?H"H;14(KE*5 26DY$:%A#!>C>B"@6D9 MY-@8A%0^"F2X1$! K(,HR7&BJ5"*HT8DQR+Z"DZ#9;(J618Z-16CEYU"A M\',="0)<0\)#'LI"MZ)<$*5/@44:'_;8:"W[T9'_)4; VF&/-?;G55S+($ND MLD9#2A5D.-*B'#6&E2#1]D.7+LA:.@F!=LR$N\P+B6M>2(LQ-51B;:)(8,)U M)$1!N80HWL"T5HH+6P?,0DO@VV"8*W2'$,,B<*&68FI%CHJ?%8A4T;/=/[;$PTW M/5/F0D&YC0JMEW77_(B9O$.1%,4J(T9H"$(IJVV8S"F:S] ['I M?@P\WF;S-^3*OSB66RH:>>5/@:$,J28 J#"TG$BE35B.7X] -!,K.Q#/'2"S M\2B&0[8BLN572$3E#(+84&NEC9"QPDC&0\2+Y \6,KJ6__,8 G*KI5NRXQ"& M9\*-EQ@)7#)O:?L&4MCM;7TG!^@A>3QUQPN6X=1AF,*J(;>D,D2&)XW )-"S0O@*:6[$LB M+!FA%FLI%00$25Y4(%.&))IQ71X8:/;< 0J2'$,JQ08: M"A2&U(HPBIA51J*B #:4#,N9Q- #X\V^8)'A "V= Q"?"JO5K?::?7]TFV^D_J[KV[/LQJ/P=C7,/OR9D=&P6='+)U>DGJF M<404O/N2=))7AXR& _=W)^/"-%!^0%/2?;?1LC0HMW:\]1\&V;#VJ^ IR6=2 M)=UR'I6X!N@J6ZD7A3/>^6@@%+ 8Y+EZ]"Y[N M>YW[X'OLOG/+G4V%"-SQ03$5:SRL:M*?\T_^ANZJ23P:N.U*ZR41[M?\EN[ MGH/1-'#/MEH%>_#3NT_FP[N?WGP7W\PQ/(;9+X MM1W%CH*ZK^_@+N(/C=V9Z:2?)4?YB_D%4IWQ31#\/7E99>]_[_/?$CB=#+*:-,?,YR,'."[9QSY2[F#^[WXMM?/U[&V&OZX^$?F_E6SMQETO4PIO_HRLP'NE(V9-A?/_[), M/ M:2ZT(P\@+:(*XT9I%FD368LM#]QTWHCYOQ*V>F8Q3]P;_,;Q-W3J^IF%/ MJ\J]Y'A8OI8MWLJ=FA/TG) 2/Z80\"*? @)S8K^!VY&^^^.56%][ZV[.6C2] M^].WG#$]W?L_,GCTJYWE/$ZF^Q?<.\'E&>.[V[[4,^H5Y_')5\G=X[=2^#A*_Q:#P<]2;I9HO?I!DU MH]]D7^<'OGZFFAKFI6TR>J6F[>*9.7WUP-F_]Z/R(H_Q]^3ZUNWB;]?QG7ND M]W'_*7Y.W:W^>#\JWN8 RUK>]\52OEKK#!Z_N37]FA1#D:X-U%@3HD7D -%R M0+4NFMD) YC"USC',7>)I*O&:Y].5M^P;?@M+OK0%/+@X^3!'=MY*ZB_K+3W MT\297"N89]\\L_H%T?UAY[=W$1:&P,G<[$25Q:!;NP]+[..LS<=C_Z)EJ-$G>_>F%+C&<9$K!BAI/ M;^ 4 X\T9CC(C*CLA*DTRP"GT-."I][XWB-2ZG[(:= M5?:'UQA'B==Y[H;] M_O I?5]*G&+WIA2^G(I7>?UM5@^]I.(73ASP*E[O/]?)?.#E;/^%?0I!GA.0 M&7Y!)^GWBU__[SOP+OOL7KQ3?I[#"]]Z#P[7/R9/P9?A0SQXC1!/O>[X_KWD M-XPR1/]0&KX=M\[Q8YJ\+__XY;69^VZ:%#'-58+^W=_*F_X;? M_@F^_1/?Z*S&+[C@X1%Y^[<%RX&JG^K+65_M_>>C#-VM[AP'OK_O=1T)_U+B MLV@F[^1__R_(P+P1K =-PGG]TKM\T0MXORD%LWV6\Q5*80/O5L^&NO =Q$< M04,M" M)U #<0#P_4MA!E^@LG%4R?<-O*AZ&+JG_^[OK%RZ4QV$ZODX>'OO# MYRSXNU$ M@N+9-):O2;_O7NO/CJQ'<5\-NJK[T!OT?)QS[#1)^_NC4RF3Y056FSIA7P3+ M-KU('CH[F:3?9EOY;I1,8L?FV-%D6?=E8\>1Z54[[:EV ,6Z@(>KX'L.$%E*4?P"(H(DQX@+ MW/#3:#G6P I\3,;39)FLC5B2_EQESU>=/8V8N&R]K,6?/==/REJS9@U,)#1B1ENF(A$144Q)]$:@H7-FSZP'/^=D M^^UOL$VCO;R.;K+')6MOAYGH

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Ŵ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o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end </TEXT> </DOCUMENT> </SEC-DOCUMENT>

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 99 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 100 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 491 533 1 true 126 0 false 4 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.bio-rad.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Consolidated Balance Sheets Sheet http://www.bio-rad.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 1002000 - Statement - Consolidated Statements of Income Sheet http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome Consolidated Statements of Income Statements 4 false false R5.htm 1003000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 5 false false R6.htm 1005000 - Statement - Consolidated Statements of Changes in Stockholders' Equity Sheet http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity Consolidated Statements of Changes in Stockholders' Equity Statements 6 false false R7.htm 1005000 - Statement - Consolidated Statements of Comprehensive Income Sheet http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 7 false false R8.htm 2101100 - Disclosure - 1. Significant Accounting Policies Sheet http://www.bio-rad.com/role/A1SignificantAccountingPolicies 1. Significant Accounting Policies Notes 8 false false R9.htm 2102100 - Disclosure - 2. Acquisitions Sheet http://www.bio-rad.com/role/A2Acquisitions 2. Acquisitions Notes 9 false false R10.htm 2103100 - Disclosure - 3. Fair Value Measurements Sheet http://www.bio-rad.com/role/A3FairValueMeasurements 3. Fair Value Measurements Notes 10 false false R11.htm 2104100 - Disclosure - 4. Intangible Assets, Goodwill and Other Sheet http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOther 4. Intangible Assets, Goodwill and Other Notes 11 false false R12.htm 2106100 - Disclosure - 5. Notes Payable and Long-Term Debt Notes http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebt 5. Notes Payable and Long-Term Debt Notes 12 false false R13.htm 2108100 - Disclosure - 6. Income Taxes Sheet http://www.bio-rad.com/role/A6IncomeTaxes 6. Income Taxes Notes 13 false false R14.htm 2109100 - Disclosure - 7. Stockholders' Equity Sheet http://www.bio-rad.com/role/A7StockholdersEquity 7. Stockholders' Equity Notes 14 false false R15.htm 2111100 - Disclosure - 8. Accumulated Other Comprehensive Income Sheet http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncome 8. Accumulated Other Comprehensive Income Notes 15 false false R16.htm 2112100 - Disclosure - 9. Share-based Compensation Sheet http://www.bio-rad.com/role/A9ShareBasedCompensation 9. Share-based Compensation Notes 16 false false R17.htm 2114100 - Disclosure - 10. Other Income and Expenses Sheet http://www.bio-rad.com/role/A10OtherIncomeAndExpenses 10. Other Income and Expenses Notes 17 false false R18.htm 2115100 - Disclosure - 11. Supplemental Cash Flow Information Sheet http://www.bio-rad.com/role/A11SupplementalCashFlowInformation 11. Supplemental Cash Flow Information Notes 18 false false R19.htm 2116100 - Disclosure - 12. Commitments & Contingent Liabilities Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilities 12. Commitments & Contingent Liabilities Notes 19 false false R20.htm 2121100 - Disclosure - 13. Legal Proceedings Sheet http://www.bio-rad.com/role/A13LegalProceedings 13. Legal Proceedings Notes 20 false false R21.htm 2124100 - Disclosure - 14. Segment Reporting Sheet http://www.bio-rad.com/role/A14SegmentReporting 14. Segment Reporting Notes 21 false false R22.htm 2125100 - Disclosure - 15. Restructuring Costs (Notes) Notes http://www.bio-rad.com/role/A15RestructuringCostsNotes 15. Restructuring Costs (Notes) Notes 22 false false R23.htm 2127100 - Disclosure - 16. Quarterly Financial Data Sheet http://www.bio-rad.com/role/A16QuarterlyFinancialData 16. Quarterly Financial Data Notes 23 false false R24.htm 2128100 - Disclosure - Schedule II - Valuation and Qualifying Accoutns Sheet http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns Schedule II - Valuation and Qualifying Accoutns Notes 24 false false R25.htm 2129100 - Disclosure - 17. Subsequent Event (Notes) Notes http://www.bio-rad.com/role/A17SubsequentEventNotes 17. Subsequent Event (Notes) Notes 25 false false R26.htm 2201201 - Disclosure - 1. Significant Accounting Policies (Policies) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies 1. Significant Accounting Policies (Policies) Policies http://www.bio-rad.com/role/A1SignificantAccountingPolicies 26 false false R27.htm 2301302 - Disclosure - 1. Significant Accounting Policies (Tables) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesTables 1. Significant Accounting Policies (Tables) Tables http://www.bio-rad.com/role/A1SignificantAccountingPolicies 27 false false R28.htm 2303301 - Disclosure - 3. Fair Value Measurements (Tables) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsTables 3. Fair Value Measurements (Tables) Tables http://www.bio-rad.com/role/A3FairValueMeasurements 28 false false R29.htm 2304301 - Disclosure - 4. Intangible Assets, Goodwill and Other (Tables) Sheet http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables 4. Intangible Assets, Goodwill and Other (Tables) Tables http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOther 29 false false R30.htm 2306301 - Disclosure - 5. Notes Payable and Long-Term Debt (Tables) Notes http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtTables 5. Notes Payable and Long-Term Debt (Tables) Tables http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebt 30 false false R31.htm 2308301 - Disclosure - 6. Income Taxes (Tables) Sheet http://www.bio-rad.com/role/A6IncomeTaxesTables 6. Income Taxes (Tables) Tables http://www.bio-rad.com/role/A6IncomeTaxes 31 false false R32.htm 2309301 - Disclosure - 7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables) Sheet http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables 7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables) Tables 32 false false R33.htm 2309302 - Disclosure - 7. Stockholders' Equity Treasury Stock (Tables) Sheet http://www.bio-rad.com/role/A7StockholdersEquityTreasuryStockTables 7. Stockholders' Equity Treasury Stock (Tables) Tables 33 false false R34.htm 2311301 - Disclosure - 8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables) Sheet http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables 8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables) Tables 34 false false R35.htm 2311302 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables) Sheet http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables) Tables 35 false false R36.htm 2312301 - Disclosure - 9. Share-based Compensation (Tables) Sheet http://www.bio-rad.com/role/A9ShareBasedCompensationTables 9. Share-based Compensation (Tables) Tables http://www.bio-rad.com/role/A9ShareBasedCompensation 36 false false R37.htm 2314301 - Disclosure - 10. Other Income and Expenses (Tables) Sheet http://www.bio-rad.com/role/A10OtherIncomeAndExpensesTables 10. Other Income and Expenses (Tables) Tables http://www.bio-rad.com/role/A10OtherIncomeAndExpenses 37 false false R38.htm 2315301 - Disclosure - 11. Supplemental Cash Flow Information (Tables) Sheet http://www.bio-rad.com/role/A11SupplementalCashFlowInformationTables 11. Supplemental Cash Flow Information (Tables) Tables http://www.bio-rad.com/role/A11SupplementalCashFlowInformation 38 false false R39.htm 2316301 - Disclosure - 12. Commitments & Contingent Liabilities Pension obligations and funded status (Tables) Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables 12. Commitments & Contingent Liabilities Pension obligations and funded status (Tables) Tables 39 false false R40.htm 2316302 - Disclosure - 12. Commitments & Contingent Liabilities Net Periodic Benefit Cost (Tables) Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables 12. Commitments & Contingent Liabilities Net Periodic Benefit Cost (Tables) Tables 40 false false R41.htm 2316303 - Disclosure - 12. Commitments & Contingent Liabilities Assumptions for Benefit Obligations and Periodic Benefit Costs (Tables) Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables 12. Commitments & Contingent Liabilities Assumptions for Benefit Obligations and Periodic Benefit Costs (Tables) Tables 41 false false R42.htm 2324301 - Disclosure - 14. Segment Reporting (Tables) Sheet http://www.bio-rad.com/role/A14SegmentReportingTables 14. Segment Reporting (Tables) Tables http://www.bio-rad.com/role/A14SegmentReporting 42 false false R43.htm 2325301 - Disclosure - 15. Restructuring Costs (Tables) Sheet http://www.bio-rad.com/role/A15RestructuringCostsTables 15. Restructuring Costs (Tables) Tables http://www.bio-rad.com/role/A15RestructuringCostsNotes 43 false false R44.htm 2327301 - Disclosure - 16. Quarterly Financial Data (Tables) Sheet http://www.bio-rad.com/role/A16QuarterlyFinancialDataTables 16. Quarterly Financial Data (Tables) Tables http://www.bio-rad.com/role/A16QuarterlyFinancialData 44 false false R45.htm 2401404 - Disclosure - 1. Significant Accounting Policies Property, Plant and Equipment (Details) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails 1. Significant Accounting Policies Property, Plant and Equipment (Details) Details 45 false false R46.htm 2401405 - Disclosure - 1. Significant Accounting Policies Warranty rollforward (Details) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails 1. Significant Accounting Policies Warranty rollforward (Details) Details 46 false false R47.htm 2401406 - Disclosure - 1. Significant Accounting Policies Earnings per share (Details) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails 1. Significant Accounting Policies Earnings per share (Details) Details 47 false false R48.htm 2401407 - Disclosure - 1. Significant Accounting Policies Details (Details) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails 1. Significant Accounting Policies Details (Details) Details http://www.bio-rad.com/role/A1SignificantAccountingPoliciesTables 48 false false R49.htm 2401408 - Disclosure - 1. Significant Accounting Policies Revenue Recognition (Details) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails 1. Significant Accounting Policies Revenue Recognition (Details) Details 49 false false R50.htm 2402401 - Disclosure - 2. Acquisitions (Details) Sheet http://www.bio-rad.com/role/A2AcquisitionsDetails 2. Acquisitions (Details) Details http://www.bio-rad.com/role/A2Acquisitions 50 false false R51.htm 2403402 - Disclosure - 3. Fair Value Measurements (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsDetails 3. Fair Value Measurements (Details) Details http://www.bio-rad.com/role/A3FairValueMeasurementsTables 51 false false R52.htm 2403403 - Disclosure - 3. Fair Value Measurements Foreign Exchange Forward Contracts (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails 3. Fair Value Measurements Foreign Exchange Forward Contracts (Details) Details 52 false false R53.htm 2403404 - Disclosure - 3. Fair Value Measurements Short-term Investments (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails 3. Fair Value Measurements Short-term Investments (Details) Details 53 false false R54.htm 2403405 - Disclosure - 3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails 3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details) Details 54 false false R55.htm 2403406 - Disclosure - 3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails 3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) Details 55 false false R56.htm 2403407 - Disclosure - 3. Fair Value Investments (Details) Sheet http://www.bio-rad.com/role/A3FairValueInvestmentsDetails 3. Fair Value Investments (Details) Details 56 false false R57.htm 2403408 - Disclosure - 3. Fair Value Measurements Contingent Consideration (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails 3. Fair Value Measurements Contingent Consideration (Details) Details 57 false false R58.htm 2404402 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details) Sheet http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details) Details 58 false false R59.htm 2404403 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details) Sheet http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details) Details 59 false false R60.htm 2406402 - Disclosure - 5. Notes Payable and Long-Term Debt (Details) Notes http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails 5. Notes Payable and Long-Term Debt (Details) Details http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtTables 60 false false R61.htm 2408402 - Disclosure - 6. Income Taxes (Details) Sheet http://www.bio-rad.com/role/A6IncomeTaxesDetails 6. Income Taxes (Details) Details http://www.bio-rad.com/role/A6IncomeTaxesTables 61 false false R62.htm 2409403 - Disclosure - 7. Stockholders' Equity (Details) Sheet http://www.bio-rad.com/role/A7StockholdersEquityDetails 7. Stockholders' Equity (Details) Details http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables 62 false false R63.htm 2409404 - Disclosure - 7. Stockholders' Equity Treasury Shares (Details) Sheet http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails 7. Stockholders' Equity Treasury Shares (Details) Details http://www.bio-rad.com/role/A7StockholdersEquityTreasuryStockTables 63 false false R64.htm 2411403 - Disclosure - 8. Accumulated Other Comprehensive Income (Details) Sheet http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails 8. Accumulated Other Comprehensive Income (Details) Details http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables 64 false false R65.htm 2411404 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) Sheet http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) Details http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables 65 false false R66.htm 2412402 - Disclosure - 9. Share-based Compensation (Details) Sheet http://www.bio-rad.com/role/A9ShareBasedCompensationDetails 9. Share-based Compensation (Details) Details http://www.bio-rad.com/role/A9ShareBasedCompensationTables 66 false false R67.htm 2412403 - Disclosure - 9. Share-based Compensation Restricted Stock (Details) Sheet http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails 9. Share-based Compensation Restricted Stock (Details) Details 67 false false R68.htm 2414402 - Disclosure - 10. Other Income and Expenses (Details) Sheet http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails 10. Other Income and Expenses (Details) Details http://www.bio-rad.com/role/A10OtherIncomeAndExpensesTables 68 false false R69.htm 2415402 - Disclosure - 11. Supplemental Cash Flow Information (Details) Sheet http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails 11. Supplemental Cash Flow Information (Details) Details http://www.bio-rad.com/role/A11SupplementalCashFlowInformationTables 69 false false R70.htm 2416404 - Disclosure - 12. Commitments & Contingent Liabilities (Details) Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails 12. Commitments & Contingent Liabilities (Details) Details http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables 70 false false R71.htm 2416405 - Disclosure - 12. Commitments & Contingent Liabilities Period Expense (Details) Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPeriodExpenseDetails 12. Commitments & Contingent Liabilities Period Expense (Details) Details 71 false false R72.htm 2416406 - Disclosure - 12. Commitments & Contingent Liabilities Pensions (Details) Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails 12. Commitments & Contingent Liabilities Pensions (Details) Details http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables 72 false false R73.htm 2421401 - Disclosure - 13. Legal Proceedings Legal Proceedings (Details) Sheet http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails 13. Legal Proceedings Legal Proceedings (Details) Details 73 false false R74.htm 2424402 - Disclosure - 14. Segment Reporting (Details) Sheet http://www.bio-rad.com/role/A14SegmentReportingDetails 14. Segment Reporting (Details) Details http://www.bio-rad.com/role/A14SegmentReportingTables 74 false false R75.htm 2424403 - Disclosure - 14. Segment Information Segment Profit Reconciliation (Details) Sheet http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails 14. Segment Information Segment Profit Reconciliation (Details) Details 75 false false R76.htm 2424404 - Disclosure - 14. Segment Information Segment Asset Reconciliation (Details) Sheet http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails 14. Segment Information Segment Asset Reconciliation (Details) Details 76 false false R77.htm 2424405 - Disclosure - 14. Segment Information Segment Information by Geographical Location (Details) Sheet http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails 14. Segment Information Segment Information by Geographical Location (Details) Details 77 false false R78.htm 2425402 - Disclosure - 15. Restructuring Costs (Details) Sheet http://www.bio-rad.com/role/A15RestructuringCostsDetails 15. Restructuring Costs (Details) Details http://www.bio-rad.com/role/A15RestructuringCostsTables 78 false false R79.htm 2427402 - Disclosure - 16. Quarterly Financial Data (Details) Sheet http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails 16. Quarterly Financial Data (Details) Details http://www.bio-rad.com/role/A16QuarterlyFinancialDataTables 79 false false R80.htm 2428402 - Disclosure - Schedule II - Valuation and Qualifying Accoutns (Details) Sheet http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails Schedule II - Valuation and Qualifying Accoutns (Details) Details http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns 80 false false R81.htm 2429402 - Disclosure - 17. Subsequent Event (Details) Sheet http://www.bio-rad.com/role/A17SubsequentEventDetails 17. Subsequent Event (Details) Details http://www.bio-rad.com/role/A17SubsequentEventNotes 81 false false R9999.htm Uncategorized Items - a10k123118.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - a10k123118.htm Cover 82 false false All Reports Book All Reports a10k123118.htm bio-20181231.xsd bio-20181231_cal.xml bio-20181231_def.xml bio-20181231_lab.xml bio-20181231_pre.xml ex211123118.htm ex231123118.htm ex311123118.htm ex312123118.htm ex321123118.htm ex322123118.htm chart-fb6cb6843e3154ef808.jpg http://xbrl.sec.gov/naics/2017-01-31 http://xbrl.sec.gov/country/2017-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true JSON 103 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a10k123118.htm": { "axisCustom": 3, "axisStandard": 29, "contextCount": 491, "dts": { "calculationLink": { "local": [ "bio-20181231_cal.xml" ] }, "definitionLink": { "local": [ "bio-20181231_def.xml" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml" ] }, "inline": { "local": [ "a10k123118.htm" ] }, "labelLink": { "local": [ "bio-20181231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-doc-2018-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-doc-2013-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-doc-2018-01-31.xml" ] }, "presentationLink": { "local": [ "bio-20181231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-ref-2018-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-ref-2013-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-ref-2018-01-31.xml" ] }, "schema": { "local": [ "bio-20181231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd", "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" ] } }, "elementCount": 918, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 68, "http://xbrl.sec.gov/dei/2018-01-31": 18, "total": 86 }, "keyCustom": 23, "keyStandard": 510, "memberCustom": 34, "memberStandard": 89, "nsprefix": "bio", "nsuri": "http://www.bio-rad.com/20181231", "report": { "R1": { "firstAnchor": null, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information", "role": "http://www.bio-rad.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": null }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - 3. Fair Value Measurements", "role": "http://www.bio-rad.com/role/A3FairValueMeasurements", "shortName": "3. Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - 4. Intangible Assets, Goodwill and Other", "role": "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOther", "shortName": "4. Intangible Assets, Goodwill and Other", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - 5. Notes Payable and Long-Term Debt", "role": "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebt", "shortName": "5. Notes Payable and Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - 6. Income Taxes", "role": "http://www.bio-rad.com/role/A6IncomeTaxes", "shortName": "6. Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - 7. Stockholders' Equity", "role": "http://www.bio-rad.com/role/A7StockholdersEquity", "shortName": "7. Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bio:AccumulatedOtherComprehensiveIncomeTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - 8. Accumulated Other Comprehensive Income", "role": "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncome", "shortName": "8. Accumulated Other Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bio:AccumulatedOtherComprehensiveIncomeTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - 9. Share-based Compensation", "role": "http://www.bio-rad.com/role/A9ShareBasedCompensation", "shortName": "9. Share-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - 10. Other Income and Expenses", "role": "http://www.bio-rad.com/role/A10OtherIncomeAndExpenses", "shortName": "10. Other Income and Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - 11. Supplemental Cash Flow Information", "role": "http://www.bio-rad.com/role/A11SupplementalCashFlowInformation", "shortName": "11. Supplemental Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - 12. Commitments & Contingent Liabilities", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilities", "shortName": "12. Commitments & Contingent Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Consolidated Balance Sheets", "role": "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2018Q4", "decimals": "-3", "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121100 - Disclosure - 13. Legal Proceedings", "role": "http://www.bio-rad.com/role/A13LegalProceedings", "shortName": "13. Legal Proceedings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124100 - Disclosure - 14. Segment Reporting", "role": "http://www.bio-rad.com/role/A14SegmentReporting", "shortName": "14. Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125100 - Disclosure - 15. Restructuring Costs (Notes)", "role": "http://www.bio-rad.com/role/A15RestructuringCostsNotes", "shortName": "15. Restructuring Costs (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127100 - Disclosure - 16. Quarterly Financial Data", "role": "http://www.bio-rad.com/role/A16QuarterlyFinancialData", "shortName": "16. Quarterly Financial Data", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128100 - Disclosure - Schedule II - Valuation and Qualifying Accoutns", "role": "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns", "shortName": "Schedule II - Valuation and Qualifying Accoutns", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129100 - Disclosure - 17. Subsequent Event (Notes)", "role": "http://www.bio-rad.com/role/A17SubsequentEventNotes", "shortName": "17. Subsequent Event (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - 1. Significant Accounting Policies (Policies)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies", "shortName": "1. Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2301302 - Disclosure - 1. Significant Accounting Policies (Tables)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesTables", "shortName": "1. Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - 3. Fair Value Measurements (Tables)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsTables", "shortName": "3. Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - 4. Intangible Assets, Goodwill and Other (Tables)", "role": "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables", "shortName": "4. Intangible Assets, Goodwill and Other (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - Consolidated Balance Sheets (Parentheticals)", "role": "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - 5. Notes Payable and Long-Term Debt (Tables)", "role": "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtTables", "shortName": "5. Notes Payable and Long-Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - 6. Income Taxes (Tables)", "role": "http://www.bio-rad.com/role/A6IncomeTaxesTables", "shortName": "6. Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - 7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables)", "role": "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables", "shortName": "7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - 7. Stockholders' Equity Treasury Stock (Tables)", "role": "http://www.bio-rad.com/role/A7StockholdersEquityTreasuryStockTables", "shortName": "7. Stockholders' Equity Treasury Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - 8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables)", "role": "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables", "shortName": "8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)", "role": "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables", "shortName": "8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - 9. Share-based Compensation (Tables)", "role": "http://www.bio-rad.com/role/A9ShareBasedCompensationTables", "shortName": "9. Share-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - 10. Other Income and Expenses (Tables)", "role": "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesTables", "shortName": "10. Other Income and Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - 11. Supplemental Cash Flow Information (Tables)", "role": "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationTables", "shortName": "11. Supplemental Cash Flow Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316301 - Disclosure - 12. Commitments & Contingent Liabilities Pension obligations and funded status (Tables)", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "shortName": "12. Commitments & Contingent Liabilities Pension obligations and funded status (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Consolidated Statements of Income", "role": "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome", "shortName": "Consolidated Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316302 - Disclosure - 12. Commitments & Contingent Liabilities Net Periodic Benefit Cost (Tables)", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "shortName": "12. Commitments & Contingent Liabilities Net Periodic Benefit Cost (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316303 - Disclosure - 12. Commitments & Contingent Liabilities Assumptions for Benefit Obligations and Periodic Benefit Costs (Tables)", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "shortName": "12. Commitments & Contingent Liabilities Assumptions for Benefit Obligations and Periodic Benefit Costs (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324301 - Disclosure - 14. Segment Reporting (Tables)", "role": "http://www.bio-rad.com/role/A14SegmentReportingTables", "shortName": "14. Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325301 - Disclosure - 15. Restructuring Costs (Tables)", "role": "http://www.bio-rad.com/role/A15RestructuringCostsTables", "shortName": "15. Restructuring Costs (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327301 - Disclosure - 16. Quarterly Financial Data (Tables)", "role": "http://www.bio-rad.com/role/A16QuarterlyFinancialDataTables", "shortName": "16. Quarterly Financial Data (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestrictedInvestmentsCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401404 - Disclosure - 1. Significant Accounting Policies Property, Plant and Equipment (Details)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "shortName": "1. Significant Accounting Policies Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember", "decimals": null, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2017Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401405 - Disclosure - 1. Significant Accounting Policies Warranty rollforward (Details)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails", "shortName": "1. Significant Accounting Policies Warranty rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2016Q4", "decimals": "-5", "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401406 - Disclosure - 1. Significant Accounting Policies Earnings per share (Details)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails", "shortName": "1. Significant Accounting Policies Earnings per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "I2018Q1SD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401407 - Disclosure - 1. Significant Accounting Policies Details (Details)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "shortName": "1. Significant Accounting Policies Details (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "I2018Q1SD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401408 - Disclosure - 1. Significant Accounting Policies Revenue Recognition (Details)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails", "shortName": "1. Significant Accounting Policies Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "2", "lang": null, "name": "bio:RevenueAllocationPercentToLeaseElements", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2017Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GoodwillPurchaseAccountingAdjustments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - 2. Acquisitions (Details)", "role": "http://www.bio-rad.com/role/A2AcquisitionsDetails", "shortName": "2. Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2017Q1QTD_us-gaap_BusinessAcquisitionAxis_bio_RainDanceTechnologiesInc.Member", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGain", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - 3. Fair Value Measurements (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "shortName": "3. Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGain", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_bio_ForwardforeignexchangecontracttopurchaseforeigncurrencyMember", "decimals": "-5", "first": true, "lang": null, "name": "invest:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - 3. Fair Value Measurements Foreign Exchange Forward Contracts (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails", "shortName": "3. Fair Value Measurements Foreign Exchange Forward Contracts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_bio_ForwardforeignexchangecontracttopurchaseforeigncurrencyMember", "decimals": "-5", "first": true, "lang": null, "name": "invest:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403404 - Disclosure - 3. Fair Value Measurements Short-term Investments (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails", "shortName": "3. Fair Value Measurements Short-term Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-5", "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403405 - Disclosure - 3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails", "shortName": "3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "2", "first": true, "lang": null, "name": "bio:PriceChangeDebtSecurity", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403406 - Disclosure - 3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "shortName": "3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "2", "first": true, "lang": null, "name": "bio:PriceChangeDebtSecurity", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403407 - Disclosure - 3. Fair Value Investments (Details)", "role": "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails", "shortName": "3. Fair Value Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2017Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403408 - Disclosure - 3. Fair Value Measurements Contingent Consideration (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "shortName": "3. Fair Value Measurements Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_bio_AnalyticalFlowCytometerPlatformMember_us-gaap_ContingentConsiderationByTypeAxis_bio_MarketPriceOfRiskMember", "decimals": "3", "lang": null, "name": "bio:DiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details)", "role": "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "shortName": "4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details)", "role": "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "shortName": "4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2017Q4", "decimals": "-5", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2015Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Consolidated Statements of Changes in Stockholders' Equity", "role": "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "shortName": "Consolidated Statements of Changes in Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - 5. Notes Payable and Long-Term Debt (Details)", "role": "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails", "shortName": "5. Notes Payable and Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - 6. Income Taxes (Details)", "role": "http://www.bio-rad.com/role/A6IncomeTaxesDetails", "shortName": "6. Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "D2018Q4November", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TreasuryStockSharesAcquired", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - 7. Stockholders' Equity (Details)", "role": "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "shortName": "7. Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember", "decimals": "-3", "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "I2018Q1Nov", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TreasuryStockShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - 7. Stockholders' Equity Treasury Shares (Details)", "role": "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "shortName": "7. Stockholders' Equity Treasury Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "I2018Q1Nov", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TreasuryStockShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - 8. Accumulated Other Comprehensive Income (Details)", "role": "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "shortName": "8. Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "I2018Q1SD", "decimals": "-3", "lang": null, "name": "bio:EquitySecuritiesWithoutReadilyDeterminableFairValueFairValueElection", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details)", "role": "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "shortName": "8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember", "decimals": "-5", "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - 9. Share-based Compensation (Details)", "role": "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "shortName": "9. Share-based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412403 - Disclosure - 9. Share-based Compensation Restricted Stock (Details)", "role": "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails", "shortName": "9. Share-based Compensation Restricted Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - 10. Other Income and Expenses (Details)", "role": "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "shortName": "10. Other Income and Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - 11. Supplemental Cash Flow Information (Details)", "role": "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "shortName": "11. Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Consolidated Statements of Comprehensive Income", "role": "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2017Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416404 - Disclosure - 12. Commitments & Contingent Liabilities (Details)", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "shortName": "12. Commitments & Contingent Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2017Q4", "decimals": "-5", "lang": null, "name": "us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416405 - Disclosure - 12. Commitments & Contingent Liabilities Period Expense (Details)", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPeriodExpenseDetails", "shortName": "12. Commitments & Contingent Liabilities Period Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416406 - Disclosure - 12. Commitments & Contingent Liabilities Pensions (Details)", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails", "shortName": "12. Commitments & Contingent Liabilities Pensions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2017Q4YTD", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LossContingencyDamagesSoughtValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421401 - Disclosure - 13. Legal Proceedings Legal Proceedings (Details)", "role": "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails", "shortName": "13. Legal Proceedings Legal Proceedings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2017Q4YTD", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LossContingencyDamagesSoughtValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "0", "first": true, "lang": null, "name": "bio:NumberOfProductsAndServices", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424402 - Disclosure - 14. Segment Reporting (Details)", "role": "http://www.bio-rad.com/role/A14SegmentReportingDetails", "shortName": "14. Segment Reporting (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "0", "first": true, "lang": null, "name": "bio:NumberOfProductsAndServices", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424403 - Disclosure - 14. Segment Information Segment Profit Reconciliation (Details)", "role": "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "shortName": "14. Segment Information Segment Profit Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember", "decimals": "-5", "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424404 - Disclosure - 14. Segment Information Segment Asset Reconciliation (Details)", "role": "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "shortName": "14. Segment Information Segment Asset Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2018Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember", "decimals": "-5", "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424405 - Disclosure - 14. Segment Information Segment Information by Geographical Location (Details)", "role": "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails", "shortName": "14. Segment Information Segment Information by Geographical Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2018Q4", "decimals": "-5", "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2017Q4_us-gaap_BusinessAcquisitionAxis_bio_GnuBIOMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringReserveCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425402 - Disclosure - 15. Restructuring Costs (Details)", "role": "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "shortName": "15. Restructuring Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FI2017Q4_us-gaap_BusinessAcquisitionAxis_bio_GnuBIOMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringReserveCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427402 - Disclosure - 16. Quarterly Financial Data (Details)", "role": "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "shortName": "16. Quarterly Financial Data (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - 1. Significant Accounting Policies", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPolicies", "shortName": "1. Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428402 - Disclosure - Schedule II - Valuation and Qualifying Accoutns (Details)", "role": "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails", "shortName": "Schedule II - Valuation and Qualifying Accoutns (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "D2019Q1SubsequentEvent_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429402 - Disclosure - 17. Subsequent Event (Details)", "role": "http://www.bio-rad.com/role/A17SubsequentEventDetails", "shortName": "17. Subsequent Event (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "D2019Q1SubsequentEvent_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - 2. Acquisitions", "role": "http://www.bio-rad.com/role/A2Acquisitions", "shortName": "2. Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10k123118.htm", "contextRef": "I2018Q1SD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember", "decimals": "-3", "first": true, "lang": null, "name": "bio:EquitySecuritiesWithoutReadilyDeterminableFairValueFairValueElection", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - a10k123118.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - a10k123118.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 126, "tag": { "bio_A2011EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2011 Employee Stock Purchase Plan [Member]", "label": "2011 Employee Stock Purchase Plan [Member]", "terseLabel": "2011 Employee Stock Purchase Plan [Member]" } } }, "localname": "A2011EmployeeStockPurchasePlanMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_AccumulatedOtherComprehensiveIncomeTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "accumulated other comprehensive income [Text Block]", "label": "accumulated other comprehensive income [Text Block]", "terseLabel": "accumulated other comprehensive income [Text Block]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeTextBlock", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncome" ], "xbrltype": "textBlockItemType" }, "bio_AggregateTransitionTaxonForeignEarnings2017TaxAct": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate Transition Tax on Foreign Earnings, 2017 Tax Act", "label": "Aggregate Transition Tax on Foreign Earnings, 2017 Tax Act", "terseLabel": "Aggregate Transition Tax on Foreign Earnings, 2017 Tax Act" } } }, "localname": "AggregateTransitionTaxonForeignEarnings2017TaxAct", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_AnalyticalFlowCytometerPlatformMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Analytical Flow Cytometer Platform", "label": "Analytical Flow Cytometer Platform [Member]", "terseLabel": "Analytical Flow Cytometer Platform [Member]" } } }, "localname": "AnalyticalFlowCytometerPlatformMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bio_AssumptionsforBenefitObligationsandPeriodicBenefitCostsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assumptions for Benefit Obligations and Periodic Benefit Costs [Abstract]", "label": "Assumptions for Benefit Obligations and Periodic Benefit Costs [Abstract]" } } }, "localname": "AssumptionsforBenefitObligationsandPeriodicBenefitCostsAbstract", "nsuri": "http://www.bio-rad.com/20181231", "xbrltype": "stringItemType" }, "bio_BalanceSheetParentheticalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Balance Sheet Parenthetical [Abstract]", "label": "Balance Sheet Parenthetical [Abstract]" } } }, "localname": "BalanceSheetParentheticalAbstract", "nsuri": "http://www.bio-rad.com/20181231", "xbrltype": "stringItemType" }, "bio_BiotestAGMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Biotest AG [Member]", "label": "Biotest AG [Member]", "terseLabel": "Biotest AG [Member]" } } }, "localname": "BiotestAGMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "domainItemType" }, "bio_BusinessAcquisitionContingentConsiderationPotentialPercentagePayout": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "business acquisition contingent consideration percentage payout", "label": "Business Acquisition, Contingent Consideration, Potential Percentage Payout", "terseLabel": "Business Acquisition, Contingent Consideration, Potential Percentage Payout" } } }, "localname": "BusinessAcquisitionContingentConsiderationPotentialPercentagePayout", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "bio_CapitalLeasesandOtherDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Capital Leases and Other Debt [Member]", "label": "Capital Leases and Other Debt [Member]", "terseLabel": "Capital Leases and Other Debt [Member]" } } }, "localname": "CapitalLeasesandOtherDebtMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "bio_CellsorterMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CellSorter [Member] [Member]", "label": "CellSorter [Member]", "terseLabel": "CellSorter [Member]" } } }, "localname": "CellsorterMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bio_ClinicalDiagnosticsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Clinical Diagnostics [Member]", "label": "Clinical Diagnostics [Member]", "terseLabel": "Clinical Diagnostics [Member]" } } }, "localname": "ClinicalDiagnosticsMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "domainItemType" }, "bio_DiaMedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "DiaMed [Member]", "label": "DiaMed [Member]", "terseLabel": "DiaMed [Member]" } } }, "localname": "DiaMedMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "domainItemType" }, "bio_DiscountRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Discount Rate", "label": "Discount Rate", "terseLabel": "Discount Rate" } } }, "localname": "DiscountRate", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "bio_DocumentAndEntityInformation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Document and Entity Information" } } }, "localname": "DocumentAndEntityInformation", "nsuri": "http://www.bio-rad.com/20181231", "xbrltype": "stringItemType" }, "bio_EffectiveIncomeTaxRateReconciliationFinesandPenaltiesPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Fines and Penalties, Percent", "label": "Effective Income Tax Rate Reconciliation, Fines and Penalties, Percent", "terseLabel": "Fines and penalties" } } }, "localname": "EffectiveIncomeTaxRateReconciliationFinesandPenaltiesPercent", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "bio_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsAct": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act", "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act", "terseLabel": "U.S. tax reform" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsandJobsAct", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "bio_ElectionPercentageForBoardOfDirectors": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Election Percentage for Board of Directors", "label": "Election Percentage for Board of Directors", "terseLabel": "Election Percentage for Board of Directors" } } }, "localname": "ElectionPercentageForBoardOfDirectors", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "bio_EmployeeLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee Location [Axis]", "label": "Employee Location [Axis]", "terseLabel": "Employee Location [Axis]" } } }, "localname": "EmployeeLocationAxis", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "stringItemType" }, "bio_EmployeeLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Employee Location [Axis]", "label": "Employee Location [Domain]", "terseLabel": "Employee Location [Domain]" } } }, "localname": "EmployeeLocationDomain", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "domainItemType" }, "bio_EmployeesCoveredByCollectiveBargainingAgreementsUSPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employees covered by collective bargaining agreements, percentage", "label": "Employees Covered By Collective Bargaining Agreements U.S., Percentage", "terseLabel": "Employees Covered By Collective Bargaining Agreements U.S., Percentage" } } }, "localname": "EmployeesCoveredByCollectiveBargainingAgreementsUSPercentage", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "bio_EquitySecuritiesWithoutReadilyDeterminableFairValueFairValueElection": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity Securities Without Readily Determinable Fair Value, Fair Value Election ASU 2018-03", "label": "EquitySecuritiesWithoutReadilyDeterminableFairValueFairValueElection", "terseLabel": "EquitySecuritiesWithoutReadilyDeterminableFairValueFairValueElection" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueFairValueElection", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "bio_EuropeanReorganizationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "European Reorganization [Member]", "label": "European Reorganization [Member]", "terseLabel": "European Reorganization [Member]" } } }, "localname": "EuropeanReorganizationMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "bio_FinesandpenaltiesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fines and penalties [Axis]", "label": "Fines and penalties [Axis]", "terseLabel": "Fines and penalties [Axis]" } } }, "localname": "FinesandpenaltiesAxis", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "bio_FinesandpenaltiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Fines and penalties [Axis]", "label": "Fines and penalties [Domain]", "terseLabel": "Fines and penalties [Domain]" } } }, "localname": "FinesandpenaltiesDomain", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_ForeignTaxCreditCarryforwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign Tax Credit Carryforward [Member]", "label": "Foreign Tax Credit Carryforward [Member]", "terseLabel": "Foreign Tax Credit Carryforward [Member]" } } }, "localname": "ForeignTaxCreditCarryforwardMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_ForwardforeignexchangecontracttopurchaseforeigncurrencyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forward foreign exchange contract to purchase foreign currency [Member]", "label": "Forward foreign exchange contract to purchase foreign currency [Member]", "terseLabel": "Forward foreign exchange contract to purchase foreign currency [Member]" } } }, "localname": "ForwardforeignexchangecontracttopurchaseforeigncurrencyMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "bio_ForwardforeignexchangecontracttosellforeigncurrencyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forward foreign exchange contract to sell foreign currency [Member]", "label": "Forward foreign exchange contract to sell foreign currency [Member]", "terseLabel": "Forward foreign exchange contract to sell foreign currency [Member]" } } }, "localname": "ForwardforeignexchangecontracttosellforeigncurrencyMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "bio_GnuBIOMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "GnuBIO [Member]", "label": "GnuBIO [Member]", "terseLabel": "GnuBIO [Member]" } } }, "localname": "GnuBIOMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_IncentiveAwardPlan2017Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Incentive Award Plan 2017 [Member]", "label": "Incentive Award Plan 2017 [Member]", "terseLabel": "Incentive Award Plan 2017 [Member]" } } }, "localname": "IncentiveAwardPlan2017Member", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_IncludingaccruedinterestandpenaltiesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Including accrued interest and penalties [Axis]", "label": "Including accrued interest and penalties [Axis]" } } }, "localname": "IncludingaccruedinterestandpenaltiesAxis", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "bio_IncludingaccruedinterestandpenaltiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Including accrued interest and penalties [Domain]", "label": "Including accrued interest and penalties [Domain]", "terseLabel": "Including accrued interest and penalties [Domain]" } } }, "localname": "IncludingaccruedinterestandpenaltiesDomain", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_IncludingaccruedinterestandpenaltiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Including accrued interest and penalties [Member]", "label": "Including accrued interest and penalties [Member]", "terseLabel": "Including accrued interest and penalties [Member]" } } }, "localname": "IncludingaccruedinterestandpenaltiesMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_Investmentownershippercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Investment ownership percentage", "label": "Investment ownership percentage", "terseLabel": "Cost Method Investment, Percentage Owned" } } }, "localname": "Investmentownershippercentage", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "percentItemType" }, "bio_KnowHowMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Know how [Member]", "label": "Know How [Member]", "terseLabel": "Know how [Member]" } } }, "localname": "KnowHowMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bio_LegalProceedingsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Legal Proceedings [Abstract]" } } }, "localname": "LegalProceedingsAbstract", "nsuri": "http://www.bio-rad.com/20181231", "xbrltype": "stringItemType" }, "bio_LifeScienceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Life Sciences [Member]", "label": "Life Science [Member]", "terseLabel": "Life Science [Member]" } } }, "localname": "LifeScienceMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bio_LimitationsOnUseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Limitations On Use [Member]", "label": "Limitations On Use [Member]", "terseLabel": "Limitations On Use" } } }, "localname": "LimitationsOnUseMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_MarketPriceOfRiskMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Market Price of Risk [Member]", "label": "Market Price of Risk [Member]", "terseLabel": "Discount rate [Member]" } } }, "localname": "MarketPriceOfRiskMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_NetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net Periodic Benefit Cost [Abstract]", "label": "Net Periodic Benefit Cost [Abstract]" } } }, "localname": "NetPeriodicBenefitCostAbstract", "nsuri": "http://www.bio-rad.com/20181231", "xbrltype": "stringItemType" }, "bio_NetofprepaidtaxesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net of prepaid taxes [Axis]", "label": "Net of prepaid taxes [Axis]", "terseLabel": "Net of prepaid taxes [Axis]" } } }, "localname": "NetofprepaidtaxesAxis", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "bio_NetofprepaidtaxesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Net of prepaid taxes [Axis]", "label": "Net of prepaid taxes [Domain]", "terseLabel": "Net of prepaid taxes [Domain]" } } }, "localname": "NetofprepaidtaxesDomain", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_NetofprepaidtaxesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net of prepaid taxes [Member]", "label": "Net of prepaid taxes [Member]", "terseLabel": "Net of prepaid taxes [Member]" } } }, "localname": "NetofprepaidtaxesMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_NonCurrentIncomeTaxExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Non Current Income Tax Expense", "label": "Non Current Income Tax Expense", "terseLabel": "Non-current tax expense (benefit)" } } }, "localname": "NonCurrentIncomeTaxExpense", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_NumberOfProductsAndServices": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Products And Services", "label": "Number Of Products And Services", "terseLabel": "Number Of Products And Services" } } }, "localname": "NumberOfProductsAndServices", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "integerItemType" }, "bio_ObligationsandFundedStatusAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Obligations and Funded Status [Abstract]", "label": "Obligations and Funded Status [Abstract]" } } }, "localname": "ObligationsandFundedStatusAbstract", "nsuri": "http://www.bio-rad.com/20181231", "xbrltype": "stringItemType" }, "bio_OperatingLossCarryforwardWithNoExpirationDate": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Loss Carryforward With No Expiration Date", "label": "Operating Loss Carryforward With No Expiration Date", "terseLabel": "Operating Loss Carryforward With No Expiration Date" } } }, "localname": "OperatingLossCarryforwardWithNoExpirationDate", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_PasteurSanofiDiagnosicsS.A.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pasteur Sanofi Diagnosics S.A. [Member]", "label": "Pasteur Sanofi Diagnosics S.A. [Member]", "terseLabel": "Pasteur Sanofi Diagnosics S.A. [Member]" } } }, "localname": "PasteurSanofiDiagnosicsS.A.Member", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "domainItemType" }, "bio_PriceChangeDebtSecurity": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price Change Debt Security", "label": "Price Change Debt Security", "terseLabel": "Price Change Debt Security" } } }, "localname": "PriceChangeDebtSecurity", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "percentItemType" }, "bio_Proceedsfromderivativeinstrumentsoperatingactivities": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from derivative instruments, operating activities", "label": "Proceeds from derivative instruments, operating activities", "terseLabel": "Proceeds from (payments for) forward foreign exchange contracts, net" } } }, "localname": "Proceedsfromderivativeinstrumentsoperatingactivities", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bio_ProjectedVolatilityOfSalesMemberMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Projected Volatility of Sales [Member]", "label": "Projected Volatility of Sales [Member] [Member]", "terseLabel": "Cost of debt [Member]" } } }, "localname": "ProjectedVolatilityOfSalesMemberMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_PropertyPlantandEquipmentexcludingsegmentspecificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Property, Plant and Equipment excluding segment specific [Member] -- excludes segment specific gross machinery and equipment", "label": "Property, Plant and Equipment excluding segment specific [Member]", "terseLabel": "Property, Plant and Equipment excluding segment specific [Member]" } } }, "localname": "PropertyPlantandEquipmentexcludingsegmentspecificMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "domainItemType" }, "bio_RainDanceTechnologiesInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "RainDance Technologies, Inc. [Member]", "label": "RainDance Technologies, Inc. [Member]", "terseLabel": "RainDance Technologies, Inc. [Member]" } } }, "localname": "RainDanceTechnologiesInc.Member", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bio_ReagentRentalEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reagent Rental Equipment [Member]", "label": "Reagent Rental Equipment [Member]", "terseLabel": "Reagent Rental Equipment [Member]" } } }, "localname": "ReagentRentalEquipmentMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "bio_ReclassificationandCorrectionofImmaterialErrorsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reclassification and Correction of Immaterial Errors [Abstract]", "label": "Reclassification and Correction of Immaterial Errors [Abstract]" } } }, "localname": "ReclassificationandCorrectionofImmaterialErrorsAbstract", "nsuri": "http://www.bio-rad.com/20181231", "xbrltype": "stringItemType" }, "bio_RevenueAllocationPercentToLeaseElements": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue Allocation Percent To Lease Elements", "label": "Revenue Allocation Percent To Lease Elements", "terseLabel": "Revenue Allocation Percent To Lease Elements" } } }, "localname": "RevenueAllocationPercentToLeaseElements", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "percentItemType" }, "bio_SalesmilestoneminimumamountMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales milestone minimum amount [Member]", "label": "Sales milestone minimum amount [Member]", "terseLabel": "Sales milestone minimum amount [Member]" } } }, "localname": "SalesmilestoneminimumamountMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_SalesmilestonepercentageofannualinvoicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales milestone percentage of annual invoices [Member]", "label": "Sales milestone percentage of annual invoices [Member]", "terseLabel": "Sales milestone percentage of annual invoices [Member]" } } }, "localname": "SalesmilestonepercentageofannualinvoicesMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_SalesmilestonepercentageofannualinvoiceslowMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales milestone percentage of annual invoices low [Member]", "label": "Sales milestone percentage of annual invoices low [Member]", "terseLabel": "Sales milestone percentage of annual invoices low [Member]" } } }, "localname": "SalesmilestonepercentageofannualinvoiceslowMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_SeniorNotes4.875due2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes 4.875% [Member]", "label": "Senior Notes 4.875% due 2020 [Member]", "terseLabel": "Senior Notes 4.875% due 2020 [Member]" } } }, "localname": "SeniorNotes4.875due2020Member", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "bio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeContributionAmount", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "bio_ShorttermRestrictedInvestmentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Short-term Restricted Investments [Policy Text Block]", "label": "Short-term Restricted Investments [Policy Text Block]", "terseLabel": "Short-term Restricted Investments [Policy Text Block]" } } }, "localname": "ShorttermRestrictedInvestmentsPolicyTextBlock", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bio_StockAwardPlansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Award Plans [Member]", "label": "Stock Award Plans [Member]", "terseLabel": "Stock Award Plans [Member]" } } }, "localname": "StockAwardPlansMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_StockOptionAndAwardPlansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Option and Award Plans [Member]", "label": "Stock Option and Award Plans [Member]", "terseLabel": "Stock Option and Award Plans [Member]" } } }, "localname": "StockOptionAndAwardPlansMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_TaxCutsandJobsActChangeinTaxRateIncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)", "label": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)", "terseLabel": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)" } } }, "localname": "TaxCutsandJobsActChangeinTaxRateIncomeTaxExpenseBenefit", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_TaxCutsandJobsActChangeinTaxRateIncomeTaxExpenseBenefitIncrease": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Increase", "label": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Increase", "terseLabel": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Increase" } } }, "localname": "TaxCutsandJobsActChangeinTaxRateIncomeTaxExpenseBenefitIncrease", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_TaxCutsandJobsActIncomeTaxExpenseBenefitComposition": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "", "label": "Tax Cuts and Jobs Act, Income Tax Expense (Benefit) Composition", "terseLabel": "Tax Cuts and Jobs Act, Income Tax Expense (Benefit) Composition" } } }, "localname": "TaxCutsandJobsActIncomeTaxExpenseBenefitComposition", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_TaxCutsandJobsActIncomeTaxExpenseComposition": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act, Income Tax Expense, Composition", "label": "Tax Cuts and Jobs Act, Income Tax Expense, Composition", "terseLabel": "Tax Cuts and Jobs Act, Income Tax Expense, Composition" } } }, "localname": "TaxCutsandJobsActIncomeTaxExpenseComposition", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_TaxCutsandJobsActMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act [Member]", "label": "Tax Cuts and Jobs Act [Member]", "terseLabel": "Tax Cuts and Jobs Act [Member]" } } }, "localname": "TaxCutsandJobsActMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_TaxCutsandJobsActReclassificationfromAOCItoRetainedEarningsTaxEffect": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect", "label": "Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect", "terseLabel": "Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect" } } }, "localname": "TaxCutsandJobsActReclassificationfromAOCItoRetainedEarningsTaxEffect", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "bio_TerminationofaDiagnosticsResearchandDevelopmentProjectMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of a Diagnostics Research and Development Project [Member]", "label": "Termination of a Diagnostics Research and Development Project [Member]", "terseLabel": "Termination of a Diagnostics Research and Development Project [Member]" } } }, "localname": "TerminationofaDiagnosticsResearchandDevelopmentProjectMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "bio_TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of a Diagnostics Research and Development Project and a Facility Closure [Member]", "label": "Termination of a Diagnostics Research and Development Project and a Facility Closure [Member]", "terseLabel": "Termination of a Diagnostics Research and Development Project and a Facility Closure [Member]" } } }, "localname": "TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "bio_TerminationofanDiagnosticsResearchandDevelopmentProjectMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of a Diagnostics Research and Development Project [Member]", "label": "Termination of an Diagnostics Research and Development Project [Member]", "terseLabel": "Termination of an Diagnostics Research and Development Project [Member]" } } }, "localname": "TerminationofanDiagnosticsResearchandDevelopmentProjectMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "bio_TolerablevarianceLevel2debtsecuritypricing": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tolerable variance Level 2 debt security pricing", "label": "Tolerable variance Level 2 debt security pricing", "terseLabel": "Tolerable variance Level 2 debt security pricing" } } }, "localname": "TolerablevarianceLevel2debtsecuritypricing", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "percentItemType" }, "bio_TreasuryClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Treasury Class A [Member]", "label": "Treasury Class-A [Member]", "terseLabel": "Treasury Class-A [Member]" } } }, "localname": "TreasuryClassAMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "domainItemType" }, "bio_TreasuryClassBMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Treasury Class B [Member]", "label": "Treasury Class B [Member]", "terseLabel": "Treasury Class B [Member]" } } }, "localname": "TreasuryClassBMember", "nsuri": "http://www.bio-rad.com/20181231", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "domainItemType" }, "bio_TreasuryStockAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Treasury Stock [Abstract]", "label": "Treasury Stock [Abstract]" } } }, "localname": "TreasuryStockAbstract", "nsuri": "http://www.bio-rad.com/20181231", "xbrltype": "stringItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r665" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r665" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r665" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityNumberOfEmployees": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of persons employed by the Entity", "label": "Entity Number of Employees", "terseLabel": "Entity Number of Employees" } } }, "localname": "EntityNumberOfEmployees", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "decimalItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r665" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r665" ], "lang": { "en-US": { "role": { "documentation": "Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r665" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "invest_DerivativeNotionalAmount": { "auth_ref": [ "r666" ], "lang": { "en-US": { "role": { "documentation": "Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "monetaryItemType" }, "naics_ZZ541714": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "541714 Research and Development in Biotechnology (except Nanobiotechnology) [Member]", "terseLabel": "541714 Research and Development in Biotechnology (except Nanobiotechnology) [Member]" } } }, "localname": "ZZ541714", "nsuri": "http://xbrl.sec.gov/naics/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "domainItemType" }, "srt_AmericasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Continents of North and South America.", "label": "Americas [Member]", "terseLabel": "Other (primarily Canada and Latin America) [Member]" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region of Asia Pacific.", "label": "Asia Pacific [Member]", "terseLabel": "Pacific Rim [Member]" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r180", "r190" ], "lang": { "en-US": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Continent of Europe.", "label": "Europe [Member]", "terseLabel": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r195", "r321", "r325" ], "lang": { "en-US": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r192", "r321", "r323", "r653" ], "lang": { "en-US": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by range, including, but not limited to, upper and lower bounds.", "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extent of variation, for example, but not limited to, upper and lower bounds.", "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r147", "r669" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "terseLabel": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r194", "r321", "r324", "r660", "r663", "r667", "r668" ], "lang": { "en-US": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/srt/2018-01-31", "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsScheduleIiValuationAndQualifyingAccountsTables" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r147", "r669" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsScheduleIiValuationAndQualifyingAccountsTables" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "Accounting Standards Update 2014-09 [Member]" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201601Member": { "auth_ref": [ "r557" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.", "label": "Accounting Standards Update 2016-01 [Member]", "terseLabel": "Accounting Standards Update 2016-01 [Member]" } } }, "localname": "AccountingStandardsUpdate201601Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201616Member": { "auth_ref": [ "r475", "r476" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-16 Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory.", "label": "Accounting Standards Update 2016-16 [Member]", "terseLabel": "Accounting Standards Update 2016-16 [Member]" } } }, "localname": "AccountingStandardsUpdate201616Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts Payable and Accrued Liabilities [Member]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r33", "r322" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable, less allowance for doubtful accounts" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r24", "r601", "r636" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r13", "r15", "r50" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r73", "r79", "r80", "r367", "r514" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Other Postretirement Benefit Plan [Member]" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r44", "r259" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r70", "r71", "r72", "r79", "r80" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]", "terseLabel": "Net Unrealized Investment Gain (Loss) [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r76", "r78", "r79" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r75", "r79", "r80", "r514" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r69", "r79", "r80", "r514" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation adjustments [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcquisitionRelatedCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Category of acquisition-related costs allocated to (included in) reported pro forma earnings (supplemental pro forma information).", "label": "Acquisition-related Costs [Member]", "terseLabel": "Acquisition-related Costs [Member]" } } }, "localname": "AcquisitionRelatedCostsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortizationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Amortization [Abstract]" } } }, "localname": "AdjustmentForAmortizationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from a tax benefit (deficiency) associated with an share-based compensation plan other than an employee stock ownership plan (ESOP).", "label": "Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net", "terseLabel": "Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsForErrorCorrectionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the types error corrections made to the financial statements.", "label": "Adjustments for Error Correction [Domain]", "terseLabel": "Adjustments for Error Correction [Domain]" } } }, "localname": "AdjustmentsForErrorCorrectionDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPriorYearMisstatementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r389", "r391", "r427", "r428" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation": { "auth_ref": [ "r304", "r311", "r430" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit.", "label": "Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation", "terseLabel": "Tax benefit-exercise stock options" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllOtherSegmentsMember": { "auth_ref": [ "r173", "r174", "r175", "r176", "r177", "r178" ], "lang": { "en-US": { "role": { "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.", "label": "Other Segments [Member]", "terseLabel": "All Other Segments [Member]" } } }, "localname": "AllOtherSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r391", "r421", "r426" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Share-based Compensation Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForCreditLossMember": { "auth_ref": [ "r146" ], "lang": { "en-US": { "role": { "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]" } } }, "localname": "AllowanceForCreditLossMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r60", "r200" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.", "label": "Allowance for Doubtful Accounts Receivable, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r121", "r245", "r251" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive shares excluded from the computation of diluted EPS" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r217", "r358" ], "lang": { "en-US": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset-backed Securities [Member]" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r121", "r257" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairment losses on goodwill and long-lived assets" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r184", "r599", "r635" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r8", "r67" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r538" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Financial Assets Carried at Fair Value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r209" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r210" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "terseLabel": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r207" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "terseLabel": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Total Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities", "terseLabel": "Available-for-sale Securities" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r209" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax", "terseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Securities, Amortized Cost Basis", "terseLabel": "Available-for-sale Securities, Amortized Cost Basis" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for less than twelve months.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value", "terseLabel": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for twelve months or longer.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value", "terseLabel": "Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "auth_ref": [ "r215" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth fiscal year through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Amortized Cost", "terseLabel": "Mature in more than five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "auth_ref": [ "r211", "r215", "r624" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value", "terseLabel": "Mature in more than five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "auth_ref": [ "r214" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost", "terseLabel": "Mature in one to five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r211", "r214", "r623" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value", "terseLabel": "Mature in one to five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r213" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost", "terseLabel": "Mature in less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r211", "r213", "r622" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value", "terseLabel": "Mature in less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r204", "r208" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Debt Securities, Available-for-sale", "totalLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available-for-sale Securities [Table Text Block]", "terseLabel": "Schedule of available-for-sale investments" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AvailableforsaleSecuritiesMember": { "auth_ref": [ "r221" ], "lang": { "en-US": { "role": { "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Securities [Member]", "terseLabel": "Available-for-sale Securities [Member]" } } }, "localname": "AvailableforsaleSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r392", "r423" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r523", "r526" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "domainItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r620" ], "lang": { "en-US": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]", "terseLabel": "Time Deposits [Member]" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Building and Building Improvements [Member]" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r11", "r258" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and Improvements, Gross", "terseLabel": "Buildings and leasehold improvements" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables", "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r487", "r488" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables", "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r499", "r500", "r502" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Business Combination, Consideration Transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r497", "r499", "r500", "r503" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "terseLabel": "Business Combination, Consideration Transferred, Liabilities Incurred" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r120", "r506" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "verboseLabel": "Changes in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh": { "auth_ref": [ "r507" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r505" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow": { "auth_ref": [ "r505" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r498", "r501", "r504" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Business Combination, Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r508" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combination Disclosure [Text Block]" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r489", "r490" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r489", "r490" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed": { "auth_ref": [ "r486" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.", "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed", "terseLabel": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalLeaseObligationsMember": { "auth_ref": [ "r573" ], "lang": { "en-US": { "role": { "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.", "label": "Capital Lease Obligations [Member]" } } }, "localname": "CapitalLeaseObligationsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r555", "r556" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying (Reported) Amount, Fair Value Disclosure [Member]" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r40", "r123" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r17", "r124", "r132", "r197" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r115", "r123", "r129" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Ending Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodStartLabel": "Beginning Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r115", "r561" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash Equivalents [Member]" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "terseLabel": "Cash Flow, Supplemental Disclosures [Text Block]" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r627" ], "lang": { "en-US": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Domestic Time Deposit [Member]" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.", "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]", "terseLabel": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]" } } }, "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables", "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/A7StockholdersEquityTreasuryStockTables", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r312", "r313", "r314", "r315" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/A7StockholdersEquityTreasuryStockTables" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r293" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r55", "r280", "r616", "r645" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingent liabilities" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r279", "r283" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common Class A [Member]", "verboseLabel": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Common Class B [Member]", "verboseLabel": "Common Class B [Member]" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r32", "r304" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r32" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r305" ], "lang": { "en-US": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock, Voting Rights", "terseLabel": "Common Stock, Voting Rights" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r83", "r85", "r86" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income attributable to Bio-Rad" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r495" ], "lang": { "en-US": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Software [Member]" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r171", "r629" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration Risk, Credit Risk, Policy [Policy Text Block]" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r132", "r512", "r515", "r516" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerBasisOfPricingAxis": { "auth_ref": [ "r321", "r326" ], "lang": { "en-US": { "role": { "documentation": "Information by basis of pricing for contract representing right to consideration in exchange for good or service transferred to customer.", "label": "Contract with Customer, Basis of Pricing [Axis]", "terseLabel": "Contract with Customer, Basis of Pricing [Axis]" } } }, "localname": "ContractWithCustomerBasisOfPricingAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerBasisOfPricingDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Basis of pricing for contract with customer. Includes, but is not limited to, fixed-price and time-and-materials contracts.", "label": "Contract with Customer, Basis of Pricing [Domain]", "terseLabel": "Contract with Customer, Basis of Pricing [Domain]" } } }, "localname": "ContractWithCustomerBasisOfPricingDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerDurationAxis": { "auth_ref": [ "r321", "r327" ], "lang": { "en-US": { "role": { "documentation": "Information by duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.", "label": "Contract with Customer, Duration [Axis]", "terseLabel": "Contract with Customer, Duration [Axis]" } } }, "localname": "ContractWithCustomerDurationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerDurationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.", "label": "Contract with Customer, Duration [Domain]", "terseLabel": "Contract with Customer, Duration [Domain]" } } }, "localname": "ContractWithCustomerDurationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerSalesChannelAxis": { "auth_ref": [ "r321", "r329" ], "lang": { "en-US": { "role": { "documentation": "Information by sales channel for delivery of good or service in contract with customer.", "label": "Contract with Customer, Sales Channel [Axis]", "terseLabel": "Contract with Customer, Sales Channel [Axis]" } } }, "localname": "ContractWithCustomerSalesChannelAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerSalesChannelDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.", "label": "Contract with Customer, Sales Channel [Domain]", "terseLabel": "Contract with Customer, Sales Channel [Domain]" } } }, "localname": "ContractWithCustomerSalesChannelDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r358", "r385" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate, Non-Segment [Member]" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r95" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of Goods and Services Sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsTotalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Consolidated cost of goods (such as cost of goods sold, or purchases) for the period after providing for returns, allowances and discounts, when it serves as a benchmark in a concentration of risk calculation.", "label": "Cost of Goods, Total [Member]", "terseLabel": "Cost of Goods, Total [Member]" } } }, "localname": "CostOfGoodsTotalMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Cumulative Effect of New Accounting Principle in Period of Adoption" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r135", "r471", "r478" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "U.S. Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r141", "r473" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "International" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r135", "r471", "r478" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Current Income Tax Expense (Benefit)" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r135", "r471", "r478" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r493" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndCapitalLeaseObligations": { "auth_ref": [ "r613", "r649" ], "calculation": { "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.", "label": "Debt and Capital Lease Obligations", "totalLabel": "Debt and Capital Lease Obligations" } } }, "localname": "DebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtAndEquitySecuritiesGainLoss": { "auth_ref": [ "r91", "r92" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in debt and equity securities.", "label": "Debt and Equity Securities, Gain (Loss)", "negatedLabel": "Gains on disposition of securities" } } }, "localname": "DebtAndEquitySecuritiesGainLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r22", "r24", "r25", "r600", "r604", "r631" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r566", "r568" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount of debt sold" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r52", "r298", "r566" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r53" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r53", "r137", "r305", "r308", "r309", "r310", "r565", "r566", "r568", "r628" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r296", "r567" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r219" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "terseLabel": "Gross unrealized losses for investments in a loss position 12 months or more" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r219" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "terseLabel": "Gross unrealized losses for investments in a loss position less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Debt Securities, Available-for-sale [Table Text Block]" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesMember": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.", "label": "Debt Securities [Member]", "terseLabel": "Debt Securities [Member]" } } }, "localname": "DebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of contributions made by employer into fund established for purposes of making future disbursement to individual in accordance with deferred compensation arrangement.", "label": "Deferred Compensation Arrangement with Individual, Contributions by Employer", "terseLabel": "Contribution expense" } } }, "localname": "DeferredCompensationArrangementWithIndividualContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPeriodExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r135", "r472", "r478" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "verboseLabel": "U.S. Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r135", "r472", "r478" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "verboseLabel": "International" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r464" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred Income Tax Assets, Net" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r121", "r135", "r472", "r478" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Deferred tax benefit" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r28", "r29", "r460", "r602", "r630" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "verboseLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.", "label": "Deferred Revenue", "terseLabel": "Deferred Revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueArrangementTypeDomain": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.", "label": "Deferred Revenue [Domain]", "terseLabel": "Deferred Revenue [Domain]" } } }, "localname": "DeferredRevenueArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenuePeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in deferred revenue.", "label": "Deferred Revenue, Period Increase (Decrease)", "terseLabel": "Deferred Revenue, Period Increase (Decrease)" } } }, "localname": "DeferredRevenuePeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueRevenueRecognized1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue, Revenue Recognized", "terseLabel": "Deferred Revenue, Revenue Recognized" } } }, "localname": "DeferredRevenueRevenueRecognized1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r135", "r472", "r478" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "verboseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetDomain": { "auth_ref": [ "r463" ], "lang": { "en-US": { "role": { "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.", "label": "Deferred Tax Asset [Domain]", "terseLabel": "Deferred Tax Asset [Domain]" } } }, "localname": "DeferredTaxAssetDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r461" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "terseLabel": "Deferred Tax Assets, Gross", "totalLabel": "Total gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent": { "auth_ref": [ "r441", "r443", "r464" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Assets, Net, Noncurrent", "terseLabel": "Deferred Tax Assets, Net, Noncurrent" } } }, "localname": "DeferredTaxAssetsLiabilitiesNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r462" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "verboseLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetNoncurrent": { "auth_ref": [ "r441", "r442", "r443", "r444", "r461" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as noncurrent.", "label": "Deferred Tax Assets, Net of Valuation Allowance, Noncurrent", "terseLabel": "Long-term deferred tax assets" } } }, "localname": "DeferredTaxAssetsNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r435", "r469", "r470" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r466", "r469", "r470" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit and net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r466", "r469", "r470" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Research" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther": { "auth_ref": [ "r434", "r469", "r470" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other", "terseLabel": "Other post-employment benefits, vacation and other reserves" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": { "auth_ref": [ "r434", "r469", "r470" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies", "terseLabel": "Legal reserves" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves": { "auth_ref": [ "r434", "r469", "r470" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warranty reserves.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves", "terseLabel": "Bad debt, inventory and warranty accruals" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r463" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r443", "r464" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNoncurrent": { "auth_ref": [ "r441", "r443", "r444" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Liabilities, Net, Noncurrent", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets": { "auth_ref": [ "r435", "r469", "r470" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from long-lived assets other than property, plant, and equipment.", "label": "Deferred Tax Liabilities, Other Finite-Lived Assets", "terseLabel": "Investments and intangible assets" } } }, "localname": "DeferredTaxLiabilitiesOtherFiniteLivedAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r435", "r469", "r470" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "auth_ref": [ "r435", "r469", "r470" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiaries and other recognized entities not within the country of domicile of the entity.", "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings", "verboseLabel": "Deferred Tax Liabilities, Undistributed Foreign Earnings" } } }, "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries": { "auth_ref": [ "r483" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability not recognized because of the exceptions to comprehensive recognition of deferred taxes related to undistributed earnings of foreign subsidiaries.", "label": "Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries", "terseLabel": "Deferred Tax Liability Not Recognized, Cumulative Amount of Temporary Difference" } } }, "localname": "DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "auth_ref": [ "r350", "r385" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "terseLabel": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r344" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "terseLabel": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r364", "r381", "r385" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedTerseLabel": "Defined Benefit Plan, Amortization of Gain (Loss)" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r365", "r382", "r385" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "terseLabel": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "auth_ref": [ "r369" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "terseLabel": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "auth_ref": [ "r370" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "terseLabel": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "auth_ref": [ "r369" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "terseLabel": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "auth_ref": [ "r371" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets", "terseLabel": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r339" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation", "terseLabel": "Defined Benefit Plan, Benefit Obligation" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "auth_ref": [ "r346", "r386" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "negatedTerseLabel": "Defined Benefit Plan, Benefit Obligation, Benefits Paid" } } }, "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": { "auth_ref": [ "r343" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation.", "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant", "terseLabel": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant" } } }, "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "auth_ref": [ "r358", "r359", "r372", "r385" ], "lang": { "en-US": { "role": { "documentation": "Information by defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]" } } }, "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r352", "r358", "r359", "r384", "r385" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Defined Benefit Plan, Plan Assets, Contributions by Employer" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r363", "r380", "r385" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedTerseLabel": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "auth_ref": [ "r349", "r358", "r359", "r385" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.", "label": "Defined Benefit Plan, Plan Assets, Amount", "terseLabel": "Defined Benefit Plan, Plan Assets, Amount" } } }, "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "auth_ref": [ "r345" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "terseLabel": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)" } } }, "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "auth_ref": [ "r337", "r356" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "terseLabel": "Defined Benefit Plan, Funded (Unfunded) Status of Plan" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlan", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r342", "r362", "r379", "r385" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Defined Benefit Plan, Interest Cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r360", "r377", "r385" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAmendments": { "auth_ref": [ "r347" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment", "terseLabel": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment" } } }, "localname": "DefinedBenefitPlanPlanAmendments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "auth_ref": [ "r354", "r386" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "negatedTerseLabel": "Defined Benefit Plan, Plan Assets, Benefits Paid" } } }, "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": { "auth_ref": [ "r353" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "terseLabel": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant" } } }, "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r351" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)" } } }, "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "auth_ref": [ "r366", "r383" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "negatedTerseLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r340", "r361", "r378", "r385" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Defined Benefit Plan, Service Cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": { "auth_ref": [ "r341" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement", "terseLabel": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement" } } }, "localname": "DefinedBenefitPlanSettlementsBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "auth_ref": [ "r355" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "negatedTerseLabel": "Defined Benefit Plan, Plan Assets, Payment for Settlement" } } }, "localname": "DefinedBenefitPlanSettlementsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSpecialTerminationBenefits": { "auth_ref": [ "r341" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in benefit obligation for benefits provided to employees payable from defined benefit plan or payable upon retirement.", "label": "Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits", "negatedTerseLabel": "Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits" } } }, "localname": "DefinedBenefitPlanSpecialTerminationBenefits", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanDisclosuresTableTextBlock": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.", "label": "Defined Contribution Plan Disclosures [Table Text Block]", "terseLabel": "Defined Contribution Plan Disclosures [Table Text Block]" } } }, "localname": "DefinedContributionPlanDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r121", "r182" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r524", "r525", "r529", "r531" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r142", "r518", "r519", "r520", "r521", "r522", "r527", "r529", "r532", "r534", "r536" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r132", "r143", "r518", "r519", "r521", "r522", "r533" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Forward Foreign Exchange Contracts" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r496" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed Technology Rights [Member]" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r317", "r431" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock.", "label": "Dividends [Axis]", "terseLabel": "Dividends [Axis]" } } }, "localname": "DividendsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock.", "label": "Dividends [Domain]", "terseLabel": "Dividends [Domain]" } } }, "localname": "DividendsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r90", "r150", "r159", "r161", "r162", "r163", "r167", "r618", "r651" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Earnings Per Share, Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic earnings per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r90", "r150", "r159", "r161", "r162", "r163", "r167", "r618", "r651" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Earnings Per Share, Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted earnings per share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r132", "r164", "r165", "r166" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r561" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of foreign exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r140", "r446", "r447" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Provision for income taxes" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r446", "r447", "r477" ], "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "U.S. statutory tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r446", "r447", "r477" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities": { "auth_ref": [ "r446", "r447", "r477" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for qualified production activity.", "label": "Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent", "negatedTerseLabel": "Domestic manufacturing deduction" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r446", "r447", "r477" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Impact of foreign operations" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": { "auth_ref": [ "r446", "r447", "r477" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent", "terseLabel": "Goodwill impairment" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r446", "r447", "r477" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent", "terseLabel": "Nondeductible executive compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r446", "r447", "r477" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent", "terseLabel": "Stock-based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r446", "r447", "r477" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent", "terseLabel": "Other reconciling items" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": { "auth_ref": [ "r446", "r447", "r477" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.", "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent", "terseLabel": "Prior period adjustments" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r446", "r447", "r477" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent", "negatedTerseLabel": "Foreign dividends, net" } } }, "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r446", "r447", "r477" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State taxes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r446", "r447", "r477" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "negatedTerseLabel": "Research tax credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome": { "auth_ref": [ "r446", "r447", "r477" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.", "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent", "negatedTerseLabel": "Nontaxable subsidies" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxExemptIncome", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": { "auth_ref": [ "r446", "r447", "r477" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.", "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent", "terseLabel": "Tax settlements and changes to unrecognized tax benefits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll and employee benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r422" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized cost of unvested share-based compensation awards.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized", "terseLabel": "Total unrecognized compensation cost from stock options", "verboseLabel": "Total unrecognized compensation cost from restricted stock" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r422" ], "lang": { "en-US": { "role": { "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition", "verboseLabel": "Weighted average fair value of options granted, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r421" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.", "label": "Employee Service Share-based Compensation, Tax Benefit from Compensation Expense", "terseLabel": "Employee Service Share-based Compensation, Tax Benefit from Compensation Expense" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": { "auth_ref": [ "r424" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax benefit from exercise of stock options granted under share-based compensation arrangement.", "label": "Employee Service Share-based Compensation, Tax Benefit from Exercise of Stock Options", "terseLabel": "Employee Service Share-based Compensation, Tax Benefit from Exercise of Stock Options" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Employee Severance [Member]" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock [Member]", "verboseLabel": "Employee Stock [Member]" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options [Member]", "verboseLabel": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/A7StockholdersEquityTreasuryStockTables" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesByIndustryAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.", "label": "Industry Sector [Axis]", "terseLabel": "Industry Sector [Axis]" } } }, "localname": "EquitySecuritiesByIndustryAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesByInvestmentObjectiveAxis": { "auth_ref": [ "r357", "r385" ], "lang": { "en-US": { "role": { "documentation": "Information by investment objective.", "label": "Investment Objective [Axis]", "terseLabel": "Investment Objective [Axis]" } } }, "localname": "EquitySecuritiesByInvestmentObjectiveAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r551" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Equity Securities, FV-NI" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGain": { "auth_ref": [ "r224" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain", "terseLabel": "Equity Securities, FV-NI, Unrealized Gain" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesIndustryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.", "label": "Industry Sector [Domain]", "terseLabel": "Industry Sector [Domain]" } } }, "localname": "EquitySecuritiesIndustryMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesInvestmentObjectiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Objective of investment.", "label": "Investment Objective [Domain]", "terseLabel": "Investment Objective [Domain]" } } }, "localname": "EquitySecuritiesInvestmentObjectiveMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r18", "r23", "r223", "r611", "r632", "r659" ], "lang": { "en-US": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Marketable Equity Securities [Member]" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis": { "auth_ref": [ "r153", "r154", "r155" ], "lang": { "en-US": { "role": { "documentation": "Information by type of error correction.", "label": "Adjustments for Error Corrections [Axis]", "terseLabel": "Adjustments for Error Corrections [Axis]" } } }, "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPriorYearMisstatementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]", "terseLabel": "Error Corrections and Prior Period Adjustments Restatement [Line Items]" } } }, "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPriorYearMisstatementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r554" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Estimate of Fair Value, Fair Value Disclosure [Member]" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities": { "auth_ref": [ "r429" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.", "label": "Excess Tax Benefit from Share-based Compensation, Financing Activities", "terseLabel": "Excess tax benefits from share-based compensation" } } }, "localname": "ExcessTaxBenefitFromShareBasedCompensationFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": { "auth_ref": [ "r429" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.", "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities", "negatedTerseLabel": "Excess tax benefits from share-based compensation" } } }, "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FacilityClosingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Facility Closing [Member]", "terseLabel": "Facility Closing [Member]" } } }, "localname": "FacilityClosingMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r537", "r538", "r539", "r540", "r546", "r547" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r541" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r538", "r555", "r556" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r538", "r555" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Estimated fair value of financial instruments" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r358", "r359", "r385", "r539", "r579" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails", "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r538", "r548" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r537" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r550" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r358", "r359", "r385", "r539", "r580" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r358", "r359", "r385", "r539", "r581" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r358", "r359", "r385", "r539", "r582" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r542", "r547" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [ "r537", "r545" ], "lang": { "en-US": { "role": { "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).", "label": "Fair Value, Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r543" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "negatedTerseLabel": "Net (decrease) increase in estimated fair value of contingent consideration included in selling, general and administrative expense", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r544" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r544" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedTerseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r542" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "verboseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails", "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r537", "r545" ], "lang": { "en-US": { "role": { "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.", "label": "Fair Value, Measurements, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r132", "r549", "r553" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r250" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "Future Amortization Expense, Year One" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "Future Amortization Expense, Year Five" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "Future Amortization Expense, Year Four" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "Future Amortization Expense, Year Three" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "Future Amortization Expense, Year Two" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r246", "r247", "r250", "r253", "r584" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Acquired Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r250", "r584" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-Lived Intangible Assets, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r246", "r249" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r250" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "verboseLabel": "Net Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Finite-Lived Intangible Assets, Remaining Amortization Period" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authority [Member]" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "terseLabel": "Forward foreign exchange contracts, Asset" } } }, "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "terseLabel": "Forward foreign exchange contracts, Liability" } } }, "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyGainLossMember": { "auth_ref": [ "r530" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing foreign currency gain (loss).", "label": "Foreign Currency Gain (Loss) [Member]", "terseLabel": "Foreign Currency Gain (Loss) [Member]" } } }, "localname": "ForeignCurrencyGainLossMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r558", "r559", "r560" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Foreign exchange losses, net" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r132", "r560", "r563" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "Debt security issued by government not domiciled in United States of America (US).", "label": "Debt Security, Government, Non-US [Member]", "terseLabel": "Foreign Government Obligations [Member]" } } }, "localname": "ForeignGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r121" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 }, "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedTerseLabel": "Gain on sale of land" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "auth_ref": [ "r524", "r528" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "terseLabel": "Gain (loss) on foreign currency derivative instruments not designated as hedging instruments" } } }, "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfOtherAssets": { "auth_ref": [ "r121" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of other assets.", "label": "Gain (Loss) on Disposition of Other Assets", "negatedTerseLabel": "Gain on divestiture of product line" } } }, "localname": "GainLossOnSaleOfOtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r121" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedTerseLabel": "Losses on dispositions of fixed assets" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r231", "r233" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, net period end", "periodStartLabel": "Goodwill, net period start", "terseLabel": "Goodwill, net", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r235" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill, Acquired During Period" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets Disclosure" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOther" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r132", "r241" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r238" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Currency fluctuations" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r234", "r240" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Gross", "periodEndLabel": "Goodwill period end", "periodStartLabel": "Goodwill period start" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r234", "r240" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "negatedPeriodEndLabel": "Accumulated impairment loss period end", "negatedPeriodStartLabel": "Accumulated impairment loss period start" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r121", "r232", "r237", "r242" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill, Impairment Loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill [Member]", "terseLabel": "Goodwill [Member]" } } }, "localname": "GoodwillMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r239", "r485" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "negatedTerseLabel": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Goodwill, Purchase Accounting Adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "auth_ref": [ "r236" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Written off Related to Sale of Business Unit", "negatedTerseLabel": "Goodwill, Written off Related to Sale of Business Unit" } } }, "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r94" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Gross profit", "totalLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r121", "r254" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfInvestments": { "auth_ref": [ "r206" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Other than Temporary Impairment Losses, Investments", "terseLabel": "Other than Temporary Impairment Losses on Investments" } } }, "localname": "ImpairmentOfInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r132", "r256", "r263" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r138" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "U.S." } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r138" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "International" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r138" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "terseLabel": "Income before income taxes", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r450" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Taxes [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r451", "r457", "r459", "r474" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r484" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r135", "r183", "r480" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for income taxes", "negatedTerseLabel": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r132", "r439", "r440", "r458", "r459", "r465", "r482", "r662" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r125" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "negatedTerseLabel": "Income tax payments, net" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": { "auth_ref": [ "r120" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.", "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities", "terseLabel": "(Decrease) increase in accounts payable and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r120" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Decrease (increase) in accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r120" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "(Decrease) increase in Income Taxes Payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r120" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedTerseLabel": "Increase (decrease) in deferred income taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r120" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Increase in inventories, net" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r120" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Increase in Other Current Assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r120" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Decrease in other long term assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net", "negatedTerseLabel": "(Decrease) increase in Other Long Term Liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r120" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r160", "r165" ], "calculation": { "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Effect of potentially dilutive stock options and restricted stock awards" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r244", "r248" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible Assets, Net (Excluding Goodwill)", "verboseLabel": "Purchased intangibles, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestBearingDepositsMember": { "auth_ref": [ "r597", "r606" ], "lang": { "en-US": { "role": { "documentation": "Cash on deposit with financial institutions that earns interest, either at a fixed or market rate.", "label": "Interest-bearing Deposits [Member]", "terseLabel": "Interest-bearing Deposits [Member]" } } }, "localname": "InterestBearingDepositsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r88", "r181", "r564", "r567", "r619" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r125" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "negatedTerseLabel": "Interest paid, net" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r61" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r64", "r226" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventories:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r16", "r65", "r132", "r168", "r227", "r228" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r63" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r62" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r97" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "negatedTerseLabel": "Interest and investment income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Investments": { "auth_ref": [ "r647" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Investments" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Summary of amortized cost and estimated fair value of debt securities by contractual maturity date" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_Land": { "auth_ref": [ "r10", "r43" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land and improvements" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Legal Matters and Contingencies" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedings" ], "xbrltype": "textBlockItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of Credit Outstanding, Amount", "verboseLabel": "Letters of Credit Outstanding Amount" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPeriodExpenseDetails", "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r49" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r38", "r607", "r642" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY:" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r538" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "terseLabel": "Liabilities, Fair Value Disclosure" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r494" ], "lang": { "en-US": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Agreements [Member]" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r25", "r604", "r631" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Long-term Line of Credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r47" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Current Borrowing Capacity", "terseLabel": "Line of Credit Facility, Remaining Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Line of Credit Facility, Interest Rate at Period End" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r47" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit [Member]" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails", "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Interest expense (income) directly attributable to an award in settlement of litigation.", "label": "Litigation Settlement Interest", "terseLabel": "Litigation Settlement Interest" } } }, "localname": "LitigationSettlementInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r25", "r297", "r604", "r638" ], "calculation": { "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r25" ], "calculation": { "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital lease obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Long-term Debt and Capital Lease Obligations", "terseLabel": "Long-term Debt and Capital Lease Obligations", "verboseLabel": "Long-term debt, net of current maturities" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital lease obligations including current maturities.", "label": "Long-term Debt and Capital Lease Obligations, Including Current Maturities", "terseLabel": "Long-term Debt and Capital Lease Obligations, Including Current Maturities" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital lease obligation maturing in the remainder of the fiscal year following the latest fiscal year ended.", "label": "Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year", "terseLabel": "Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Total long-term debt, excluding leases and current maturities" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r145", "r294" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal after Year Five", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal after Year Five" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r145", "r294" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r145", "r294" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Year Five" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r145", "r294" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Year Four" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r145", "r294" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Year Three" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r145", "r294" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Year Two" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r299" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Notes Payable and Long-term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r41" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Other investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r53" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails", "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r53", "r295" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails", "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in loss contingency liability.", "label": "Loss Contingency Accrual, Period Increase (Decrease)", "negatedTerseLabel": "Loss Contingency Accrual, Period Increase (Decrease)" } } }, "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesAwardedValue": { "auth_ref": [ "r280", "r281", "r282" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of damages awarded to the plaintiff in the legal matter.", "label": "Loss Contingency, Damages Awarded, Value", "terseLabel": "Loss Contingency, Damages Awarded, Value" } } }, "localname": "LossContingencyDamagesAwardedValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r280", "r281", "r282" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Loss Contingency, Damages Sought, Value" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r11", "r258" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment, Gross", "verboseLabel": "Equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r626" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Available-for-sale Investments" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security, excluding other-than-temporary impairment (OTTI).", "label": "Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss", "negatedTerseLabel": "Changes in fair market value of equity securities" } } }, "localname": "MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r188", "r189" ], "lang": { "en-US": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Segment Reconciling Items [Member]" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaturitiesOfLongTermDebtAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maturities of Long-term Debt [Abstract]" } } }, "localname": "MaturitiesOfLongTermDebtAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Standard Product Warranty Accrual [Roll Forward]" } } }, "localname": "MovementInStandardProductWarrantyAccrualRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds [Member]", "terseLabel": "Municipal Obligations [Member]" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfErrorDomain": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of the error being corrected including when and how the error arose and the fact that the error had previously been considered immaterial.", "label": "Nature of Error [Domain]", "terseLabel": "Nature of Error [Domain]" } } }, "localname": "NatureOfErrorDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r115" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r115" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r115", "r119", "r122" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r81", "r84", "r89", "r122", "r165", "r617", "r650" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net Income (Loss) Attributable to Parent", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues \"Accounting Standards Updates\" to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Adjustments for New Accounting Pronouncement [Member]", "terseLabel": "Adjustments for New Accounting Pronouncement [Member]" } } }, "localname": "NewAccountingPronouncementMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r149", "r151", "r152" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "auth_ref": [ "r126", "r127", "r128" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "terseLabel": "Noncash purchased property, plant and equipment" } } }, "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1": { "auth_ref": [ "r126", "r127", "r128" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of investments that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Investments Acquired", "terseLabel": "Noncash Purchased Marketable Securities and Investments" } } }, "localname": "NoncashOrPartNoncashAcquisitionInvestmentsAcquired1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1": { "auth_ref": [ "r126", "r127", "r128" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.", "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received", "negatedTerseLabel": "Gain on divestiture of a product line" } } }, "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r492" ], "lang": { "en-US": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "terseLabel": "Noncompete Agreements [Member]" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r193" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Other assets and property, plant and equipment, net" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansPayableCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.", "label": "Notes and Loans Payable, Current", "terseLabel": "Current maturities of long-term debt" } } }, "localname": "NotesAndLoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating Income (Loss)", "totalLabel": "Income from operations", "verboseLabel": "Segment profit" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r569", "r571" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "Operating leases, due next twelve months" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals": { "auth_ref": [ "r572" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contractually required future rental payments receivable on noncancelable subleasing arrangements.", "label": "Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals", "terseLabel": "Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r569", "r571" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Five Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPeriodExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r569", "r571" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Four Years", "verboseLabel": "Operating leases, due in four years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPeriodExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r569", "r571" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "Operating leases, due in three years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r569", "r571" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "Operating leases, due in two years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r569", "r571" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "verboseLabel": "Operating leases, due thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r570" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Operating Leases, Rent Expense, Net", "terseLabel": "Operating Leases, Rent Expense, Net" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPeriodExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r466" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating Loss Carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsExpirationDate": { "auth_ref": [ "r466" ], "lang": { "en-US": { "role": { "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYY-MM-DD format.", "label": "Operating Loss Carryforwards, Expiration Date", "terseLabel": "Operating Loss Carryforwards, Expiration Dates" } } }, "localname": "OperatingLossCarryforwardsExpirationDate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "dateItemType" }, "us-gaap_OperatingLossCarryforwardsValuationAllowance": { "auth_ref": [ "r436", "r463", "r467" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.", "label": "Operating Loss Carryforwards, Valuation Allowance", "terseLabel": "Operating Loss Carryforward, Valuation Allowance" } } }, "localname": "OperatingLossCarryforwardsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r180", "r190" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r1", "r148", "r172", "r517" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r66" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r74", "r76", "r510", "r513" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedTerseLabel": "Other post-employment benefits adjustments, net of tax" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location in other comprehensive income.", "label": "Other Comprehensive Income Location [Axis]", "terseLabel": "Other Comprehensive Income Location [Axis]" } } }, "localname": "OtherComprehensiveIncomeLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in other comprehensive income.", "label": "Other Comprehensive Income Location [Domain]", "terseLabel": "Other Comprehensive Income Location [Domain]" } } }, "localname": "OtherComprehensiveIncomeLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r79", "r87" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r68", "r562" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r82", "r85", "r87", "r304" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r82", "r85", "r510", "r511", "r513" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r77", "r479", "r481" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "negatedTerseLabel": "Other Comprehensive Income (Loss), Tax" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r70", "r76" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax", "terseLabel": "Net unrealized holding gains on available-for-sale investments, net of tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r523", "r535" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other Current Assets [Member]" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other Current Liabilities [Member]" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r332", "r432" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other Income and Other Expense Disclosure" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other Intangible Assets [Member]" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherInvestments": { "auth_ref": [ "r41", "r646" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments classified as other.", "label": "Other Investments", "terseLabel": "Other Investments", "verboseLabel": "Other assets" } } }, "localname": "OtherInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other investments.", "label": "Other Investments [Member]", "terseLabel": "Other Investments [Member]" } } }, "localname": "OtherInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r12", "r13", "r50" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r54" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermInvestmentsMember": { "auth_ref": [ "r633", "r655" ], "lang": { "en-US": { "role": { "documentation": "Long-term investments classified as other.", "label": "Other Long-term Investments [Member]", "terseLabel": "Other Long-term Investments [Member]" } } }, "localname": "OtherLongTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Noncurrent Assets [Member]" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities [Member]" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r98" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": 6.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "Other Nonoperating Expense", "terseLabel": "Other Expense" } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r98" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income) expense, net", "negatedTotalLabel": "Other (income) expense, net", "verboseLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other Nonoperating Income (Expense) [Member]" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherOperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other operating income (expense).", "label": "Other Operating Income (Expense) [Member]", "terseLabel": "Other Operating Income (Expense) [Member]" } } }, "localname": "OtherOperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherSignificantNoncashTransactionNameDomain": { "auth_ref": [ "r126", "r127", "r128" ], "lang": { "en-US": { "role": { "documentation": "The name of other significant noncash (or part noncash) investing and financing activities required to be supplementally disclosed to enable users of the financial information to fully understand the period cash flows of the Entity in relation to the statements of financial position, income statement, and statement of changes in shareholders' equity. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.", "label": "Other Significant Noncash Transaction, Name [Domain]", "terseLabel": "Other Significant Noncash Transaction, Name [Domain]" } } }, "localname": "OtherSignificantNoncashTransactionNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherSignificantNoncashTransactionsByUniqueDescriptionAxis": { "auth_ref": [ "r126", "r127", "r128" ], "lang": { "en-US": { "role": { "documentation": "Information by other significant noncash transactions.", "label": "Other Significant Noncash Transaction [Axis]", "terseLabel": "Other Significant Noncash Transaction [Axis]" } } }, "localname": "OtherSignificantNoncashTransactionsByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherSignificantNoncashTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Significant Noncash Transactions [Line Items]", "terseLabel": "Other Significant Noncash Transactions [Line Items]" } } }, "localname": "OtherSignificantNoncashTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherSignificantNoncashTransactionsTable": { "auth_ref": [ "r126", "r127", "r128" ], "lang": { "en-US": { "role": { "documentation": "This table may contain information related to other significant noncash investing and financing activities that occurred during the accounting period and are not otherwise listed in the existing taxonomy. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.", "label": "Other Significant Noncash Transactions [Table]", "terseLabel": "Other Significant Noncash Transactions [Table]" } } }, "localname": "OtherSignificantNoncashTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherTaxExpenseBenefit": { "auth_ref": [ "r139", "r445", "r473" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other income tax expense (benefit).", "label": "Other Tax Expense (Benefit)", "terseLabel": "Other Tax Expense (Benefit)" } } }, "localname": "OtherTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of other than temporary impairment (OTTI) losses on equity securities, OTTI related to credit losses on debt securities, and OTTI losses on debt securities when the entity intends to sell the securities or it is more likely than not that the entity will be required to sell the securities before recovery of its amortized cost basis. Additionally, this item includes OTTI losses recognized during the period on investments accounted for under the cost method of accounting.", "label": "Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net", "terseLabel": "Other-than-temporary impairment losses on investments" } } }, "localname": "OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Total Bio Rad [Member]", "verboseLabel": "Parent [Member]" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r111" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "terseLabel": "Payments of contingent consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromInvestments": { "auth_ref": [ "r144" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.", "label": "Payments for (Proceeds from) Investments", "negatedTerseLabel": "Proceeds from (payments for) acquisitions and long-term investment" } } }, "localname": "PaymentsForProceedsFromInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r104", "r107", "r144" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedTerseLabel": "Payments for (Proceeds from) Other Investing Activities" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r109" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Payments for purchases of treasury stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r114", "r265" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Payments for Restructuring" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r109", "r388" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.", "label": "Payments Related to Tax Withholding for Share-based Compensation", "negatedTerseLabel": "Tax payments from net share settlement" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r105" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r106" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Payments for purchases of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r107" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Payments for purchases of marketable securities and investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r106" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Capital expenditures", "terseLabel": "Payments to Acquire Property, Plant, and Equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireRestrictedInvestments": { "auth_ref": [ "r107" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.", "label": "Payments to Acquire Restricted Investments", "negatedTerseLabel": "Payments for purchases of restricted investment" } } }, "localname": "PaymentsToAcquireRestrictedInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToSuppliersAndEmployees": { "auth_ref": [ "r112", "r113", "r118" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash payments to suppliers for goods and services provided and to employees for services provided.", "label": "Payments to Suppliers and Employees", "negatedTerseLabel": "Cash paid to suppliers and employees" } } }, "localname": "PaymentsToSuppliersAndEmployees", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "auth_ref": [ "r24", "r337", "r338", "r356" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.", "label": "Liability, Defined Benefit Plan, Current", "negatedTerseLabel": "Liability, Defined Benefit Plan, Current" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r337", "r356", "r603", "r637" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans.", "label": "Liability, Defined Benefit Plan", "negatedTerseLabel": "Liability, Defined Benefit Plan" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r26", "r337", "r338", "r356" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "negatedTerseLabel": "Liability, Defined Benefit Plan, Noncurrent" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceGuaranteeMember": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "An agreement (contract) that requires the guarantor to make payments to a guaranteed party based on another entity's failure to perform under an obligating agreement. This may include the issuance of a performance standby letter of credit which requires the guarantor to make payments if a specified party fails to perform under a nonfinancial contractual obligation.", "label": "Performance Guarantee [Member]", "terseLabel": "Performance Guarantee [Member]" } } }, "localname": "PerformanceGuaranteeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanAssetCategoriesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]" } } }, "localname": "PlanAssetCategoriesDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r392", "r423" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r552" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent": { "auth_ref": [ "r335", "r336", "r615", "r648" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount as of the balance sheet date of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.", "label": "Postemployment Benefits Liability", "terseLabel": "Post-Employment Benefits Liability" } } }, "localname": "PostemploymentBenefitsLiabilityCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r31" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r7", "r230" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r5", "r7", "r229", "r230" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Taxes", "negatedTerseLabel": "Prepaid Taxes", "terseLabel": "Prepaid Taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromCustomers": { "auth_ref": [ "r116" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services.", "label": "Proceeds from Customers", "terseLabel": "Cash received from customers" } } }, "localname": "ProceedsFromCustomers", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r108" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock for share-based compensation", "verboseLabel": "Issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r100", "r101", "r205" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from maturities of marketable securities and investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromOtherOperatingActivities": { "auth_ref": [ "r117" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from operating activities classified as other.", "label": "Proceeds from Other Operating Activities", "terseLabel": "Investment proceeds and miscellaneous receipts, net" } } }, "localname": "ProceedsFromOtherOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [ "r144" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "terseLabel": "Net (payments) borrowings on line-of-credit arrangements and notes payable" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities": { "auth_ref": [ "r102", "r205" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.", "label": "Proceeds from Sale of Available-for-sale Securities", "terseLabel": "Proceeds from sales of marketable securities and investments" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "auth_ref": [ "r103" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Proceeds from Sale of Productive Assets", "terseLabel": "Proceeds from divestiture of a product line" } } }, "localname": "ProceedsFromSaleOfProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r103" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from dispositions of property, plant and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r108", "r424" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Cash Received from Exercise of Stock Options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrual": { "auth_ref": [ "r289", "r290", "r614" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.", "label": "Standard and Extended Product Warranty Accrual", "periodEndLabel": "Warranty accrual, end of period", "periodStartLabel": "Warranty accrual, beginning of period" } } }, "localname": "ProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualPayments": { "auth_ref": [ "r286" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.", "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments", "negatedTerseLabel": "Actual warranty costs" } } }, "localname": "ProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r287" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued.", "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued", "terseLabel": "Provision for warranty" } } }, "localname": "ProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r44", "r260" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment by Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r43", "r258" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Total property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGrossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment, Gross [Abstract]", "terseLabel": "Property, plant and equipment:" } } }, "localname": "PropertyPlantAndEquipmentGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r19", "r20", "r260", "r644" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r42", "r132", "r260" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r19", "r258" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Purchase Commitment, Excluding Long-term Commitment [Line Items]", "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Line Items]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable": { "auth_ref": [ "r27", "r605", "r639" ], "lang": { "en-US": { "role": { "documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers. Such disclosure may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing for failing to reach minimum quantities required to be purchased (such as penalties), cancellation rights, and termination provisions.", "label": "Purchase Commitment, Excluding Long-term Commitment [Table]", "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Table]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_QuantifyingMisstatementInCurrentYearFinancialStatementsByNatureOfErrorAxis": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Information by type of error in the financial statements.", "label": "Nature of Error [Axis]", "terseLabel": "Nature of Error [Axis]" } } }, "localname": "QuantifyingMisstatementInCurrentYearFinancialStatementsByNatureOfErrorAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails" ], "xbrltype": "stringItemType" }, "us-gaap_QuantifyingMisstatementInCurrentYearFinancialStatementsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Quantifying Misstatement in Current Year Financial Statements [Line Items]", "terseLabel": "Quantifying Misstatement in Current Year Financial Statements [Line Items]" } } }, "localname": "QuantifyingMisstatementInCurrentYearFinancialStatementsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails" ], "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialDataAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Quarterly Financial Data [Abstract]" } } }, "localname": "QuarterlyFinancialDataAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r170" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Quarterly Financial Data [Text Block]" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialData" ], "xbrltype": "textBlockItemType" }, "us-gaap_RealizedInvestmentGainsLosses": { "auth_ref": [ "r652" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.", "label": "Realized Investment Gains (Losses)", "negatedTerseLabel": "Net realized gains on investments", "terseLabel": "Realized Investment Gains (Losses)" } } }, "localname": "RealizedInvestmentGainsLosses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r79", "r80", "r87" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "terseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Member]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable": { "auth_ref": [ "r187", "r189" ], "lang": { "en-US": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table]", "terseLabel": "Reconciliation of Assets from Segment to Consolidated [Table]" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "auth_ref": [ "r187", "r189" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Assets from Segment to Consolidated" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "auth_ref": [ "r186", "r189" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r186", "r189" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of segment profit to consolidated income before taxes" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligation": { "auth_ref": [ "r278" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).", "label": "Recorded Unconditional Purchase Obligation", "terseLabel": "Recorded Unconditional Purchase Obligation" } } }, "localname": "RecordedUnconditionalPurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueAfterFifthYear": { "auth_ref": [ "r278" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due after Fifth Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due after Fifth Year" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueAfterFifthYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInFifthYear": { "auth_ref": [ "r278" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Fifth Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Fifth Year" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInFifthYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear": { "auth_ref": [ "r278" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Fourth Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Fourth Year" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInFourthYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear": { "auth_ref": [ "r278" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Second Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Second Year" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear": { "auth_ref": [ "r278" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Third Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Third Year" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear": { "auth_ref": [ "r278" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Next Twelve Months", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Next Twelve Months" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueWithinOneYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r576" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r372", "r574", "r575" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r372", "r574", "r575", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r110" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Payments on long-term borrowings" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r433", "r664" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r132", "r433" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r468" ], "lang": { "en-US": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r129", "r598", "r640" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted Cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r17", "r123", "r129", "r598", "r640" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r2", "r17", "r129" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted Cash, Current" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r9", "r21", "r129", "r661" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted Cash, Noncurrent" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsAtFairValue": { "auth_ref": [ "r657", "r658" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate value of all restricted investments.", "label": "Restricted Investments, at Fair Value", "terseLabel": "Restricted Investments, at Fair Value" } } }, "localname": "RestrictedInvestmentsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsCurrent": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.", "label": "Restricted Investments, Current", "terseLabel": "Restricted investments" } } }, "localname": "RestrictedInvestmentsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r276" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring and Related Activities Disclosure [Text Block]" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r121", "r264", "r269", "r274" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring Charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring Costs [Abstract]" } } }, "localname": "RestructuringCostsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r265", "r271" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "terseLabel": "Restructuring Reserve" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "auth_ref": [ "r264", "r270" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.", "label": "Restructuring Reserve, Accrual Adjustment", "terseLabel": "Restructuring Reserve, Accrual Adjustment" } } }, "localname": "RestructuringReserveAccrualAdjustment1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveCurrent": { "auth_ref": [ "r264", "r273" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.", "label": "Restructuring Reserve, Current", "terseLabel": "Restructuring Reserve, Current" } } }, "localname": "RestructuringReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveTranslationAdjustment": { "auth_ref": [ "r265", "r273" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve.", "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)", "negatedTerseLabel": "Restructuring Reserve, Foreign Currency Translation (Gain) Loss" } } }, "localname": "RestructuringReserveTranslationAdjustment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r35", "r311", "r641" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanFundingStatusAxis": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "Information by status of funding for defined benefit plan designed to provide retirement benefits.", "label": "Retirement Plan Funding Status [Axis]", "terseLabel": "Retirement Plan Funding Status [Axis]" } } }, "localname": "RetirementPlanFundingStatusAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanFundingStatusDomain": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "Status of funding for defined benefit plan designed to provide retirement benefits.", "label": "Retirement Plan Funding Status [Domain]", "terseLabel": "Retirement Plan Funding Status [Domain]" } } }, "localname": "RetirementPlanFundingStatusDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanNameAxis": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Axis]", "terseLabel": "Retirement Plan Name [Axis]" } } }, "localname": "RetirementPlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanNameDomain": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Domain]", "terseLabel": "Retirement Plan Name [Domain]" } } }, "localname": "RetirementPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r374", "r376" ], "lang": { "en-US": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r374", "r376" ], "lang": { "en-US": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTaxStatusAxis": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "Information by tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Tax Status [Axis]", "terseLabel": "Retirement Plan Tax Status [Axis]" } } }, "localname": "RetirementPlanTaxStatusAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTaxStatusDomain": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "Tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Tax Status [Domain]", "terseLabel": "Retirement Plan Tax Status [Domain]" } } }, "localname": "RetirementPlanTaxStatusDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r333", "r334", "r373", "r374", "r387" ], "lang": { "en-US": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r333", "r334", "r373", "r374", "r387" ], "lang": { "en-US": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r319", "r320", "r321" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r319", "r320", "r321" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r133", "r331" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The reporting scenario used to indicate financial results forecast for a future period.", "label": "Scenario, Forecast [Member]", "terseLabel": "Scenario, Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario, Unspecified [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPriorYearMisstatementsTables", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r79" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets by Major-Class" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r368" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the assumptions used to determine for pension plans and/or other employee benefit plans the benefit obligation and net benefit cost, including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets.", "label": "Schedule of Assumptions Used [Table Text Block]", "terseLabel": "Schedule of Assumptions Used [Table Text Block]" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r212", "r216", "r218", "r219", "r220", "r222", "r621", "r625" ], "lang": { "en-US": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r487", "r488" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r473" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Provision for income taxes [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r53", "r137", "r305", "r308", "r309", "r310", "r565", "r566", "r568", "r628" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Principal components of long-term debt [Table Text Block]" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r464" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Significant components of deferred tax assets and liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r373", "r374", "r375", "r376", "r385" ], "lang": { "en-US": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r142", "r518", "r519", "r520", "r521", "r522", "r527", "r529", "r532", "r534" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments [Table Text Block]" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r446" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Reconcilation of effective tax rate on inocme before taxes and statutory rate [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": { "auth_ref": [ "r153", "r154", "r155" ], "lang": { "en-US": { "role": { "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.", "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]", "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPriorYearMisstatementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r537" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Financial assets and liabilities carried at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r241", "r243" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r241", "r243" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Changes to goodwill by segment" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r138" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "U.S. and international components of income before taxes [Table Text Block]" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r360" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of Net Benefit Costs [Table Text Block]" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Schedule of other income (expense), net" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Schedule of Product Warranty Liability" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r44", "r260" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule of Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuantifyingPriorYearMisstatementCorrectedInCurrentYearFinancialStatementsTable": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Disclose the nature of each individual error being corrected in the correcting adjustment. This disclosure would also generally include when and how each error being corrected arose and assert that the errors were immaterial to the prior amounts reported.", "label": "Schedule of Quantifying Prior Year Misstatement Corrected in Current Year Financial Statements [Table]", "terseLabel": "Schedule of Quantifying Prior Year Misstatement Corrected in Current Year Financial Statements [Table]" } } }, "localname": "ScheduleOfQuantifyingPriorYearMisstatementCorrectedInCurrentYearFinancialStatementsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuantifyingPriorYearMisstatementsCorrectedInCurrentYearFinancialStatementsTextBlock": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the nature and amount of prior period errors that had previously been considered immaterial and which are being corrected in the current fiscal year. This disclosure would also generally include when and how each error being corrected arose and assert that the errors were immaterial to the prior amounts reported.", "label": "Schedule of Quantifying Prior Year Misstatements Corrected in Current Year Financial Statements [Table Text Block]", "terseLabel": "Schedule of Quantifying Prior Year Misstatements Corrected in Current Year Financial Statements [Table Text Block]" } } }, "localname": "ScheduleOfQuantifyingPriorYearMisstatementsCorrectedInCurrentYearFinancialStatementsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPriorYearMisstatementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r169" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Schedule of Quarterly Financial Data [Table Text Block]" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r267", "r268", "r272" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r267", "r268", "r272" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Restructuring and Related Costs [Table Text Block]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r93", "r194" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Net sales and assets to external customers by geographic area" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r179", "r184", "r185", "r188", "r241" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r179", "r184", "r185", "r188", "r241" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Information regarding industry segments" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r392", "r423" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r423" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]", "terseLabel": "Stock Options Outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r415" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "terseLabel": "Employee Stock Purchase Plan, Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r415" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Stock Options Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Resticted Stock Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r56", "r136", "r300", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r310", "r311" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r30", "r31", "r32", "r134", "r301", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r310", "r311" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule of Stock by Class [Table Text Block]", "terseLabel": "Schedule of Stock by Class [Table Text Block]" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).", "label": "Schedule of Unrealized Loss on Investments [Table Text Block]", "terseLabel": "Summary of investments with gross unrealized losses and the associated fair value" } } }, "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Schedule of Weighted Average Number of Shares" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segment [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingAssetReconcilingItemLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Asset Reconciling Item [Line Items]", "terseLabel": "Segment Reporting, Asset Reconciling Item [Line Items]" } } }, "localname": "SegmentReportingAssetReconcilingItemLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r196" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationProfitLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting Information, Profit (Loss) [Abstract]" } } }, "localname": "SegmentReportingInformationProfitLossAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]" } } }, "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentsGeographicalAreasAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segments, Geographical Areas [Abstract]" } } }, "localname": "SegmentsGeographicalAreasAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r96", "r225" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "negatedTerseLabel": "Selling, general and administrative expense", "terseLabel": "Selling, general and administrative expense" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r99" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r120" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation [Abstract]" } } }, "localname": "ShareBasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r394" ], "lang": { "en-US": { "role": { "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Options Vesting Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "auth_ref": [ "r423" ], "lang": { "en-US": { "role": { "documentation": "Discount rate from fair value on purchase date that participants pay for shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date", "terseLabel": "Employee Purchase Price Discount from Market Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r404" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Restricted Stock Units - Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r409" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Resticted Stock Units Cancelled/forfeited - Weighted-Average Grant-Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r407" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Restricted Stock Units Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r407" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value - Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": { "auth_ref": [ "r406" ], "lang": { "en-US": { "role": { "documentation": "Per share weighted average intrinsic value of equity-based compensation awards not vested. Excludes stock and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value", "terseLabel": "Resticted Stock Units Outstanding Aggregate Intrinsic Value (in millions)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r406" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "Nonvested shares - Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r413" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted Average Remaining Contractual Term (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r408" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Restricted Stock Units - Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r411" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r408" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Restricted Stock Units Vested - Weighted-Average Grant-Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r418" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r417" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r419" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "verboseLabel": "Risk Free Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": { "auth_ref": [ "r418" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend", "terseLabel": "Expected dividend" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r423" ], "lang": { "en-US": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Employee Contribution Rate - Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r395" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "verboseLabel": "Number of Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r423" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Number of Shares Available for Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r401" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Options Number Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r401" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price - Options Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r411" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Options, Exercises in Period, Total Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r405" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Options - Shares Forfeitures/expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r405" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Options Forfeitured/expired - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r404" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "terseLabel": "Restricted Stock Units - Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r402" ], "lang": { "en-US": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Options - Shares Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r410" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average fair value of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "auth_ref": [ "r410" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]", "terseLabel": "Stock Options Activity" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r423" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value (in millions) - Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r400", "r423" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding end of period", "periodStartLabel": "Outstanding beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r399" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "terseLabel": "Options - Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r412" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Options Vested and Expected to Vest - Aggregate Intrinsic Value (in millions)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r413" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Options - Shares Vested and Expected to Vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r413" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Options Vested and Expected to Vest - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": { "auth_ref": [ "r390", "r423" ], "lang": { "en-US": { "role": { "documentation": "The weighted average of per share prices paid for shares purchased on the open market for issuance to employees under the plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "auth_ref": [ "r393" ], "lang": { "en-US": { "role": { "documentation": "Description of pertinent provisions of equity-based compensation awards that have actual or potential impact upon the company's financial statements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award", "terseLabel": "Options Granted Term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r390", "r396" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options Exercised - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options Granted - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r132", "r392", "r397" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.", "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Share-based Compensation Plans" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r414" ], "lang": { "en-US": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r420" ], "lang": { "en-US": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasuryStockTables" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasuryStockTables" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r394" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of share-based compensation awards.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r416", "r425" ], "lang": { "en-US": { "role": { "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r423" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Options Exercisable Aggregate Intrinsic Value (in millions)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r423" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (in years) - Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r413" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (in years) - Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r413" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options Vested and Expected to Vest - Weighted Average Remaining Contractual Term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r398" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Shares, Issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShippingAndHandlingCostPolicyTextBlock": { "auth_ref": [ "r131", "r132" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.", "label": "Shipping and Handling Cost, Policy [Policy Text Block]", "terseLabel": "Shipping and Handling" } } }, "localname": "ShippingAndHandlingCostPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r23", "r608", "r609", "r611", "r634" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r608", "r609", "r634", "r654" ], "lang": { "en-US": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-term Investments [Member]" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": { "auth_ref": [ "r449" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.", "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit", "terseLabel": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit" } } }, "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r132", "r288" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Standard Product Warranty, Policy [Policy Text Block]", "terseLabel": "Warranty" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandbyLettersOfCreditMember": { "auth_ref": [ "r285", "r292", "r509", "r656" ], "lang": { "en-US": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.", "label": "Standby Letters of Credit [Member]", "terseLabel": "Standby Letters of Credit [Member]" } } }, "localname": "StandbyLettersOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r184", "r241", "r262", "r266", "r275", "r653" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r30", "r31", "r32", "r304" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables", "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/A7StockholdersEquityTreasuryStockTables", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r59", "r304" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Statement, Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]", "verboseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPriorYearMisstatementsTables", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r58", "r304", "r305", "r311" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Stock Issued During Period, Shares, Conversion of Convertible Securities" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r31", "r32", "r304", "r311" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Stock Issued During Period, Shares, Employee Stock Purchase Plans" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r31", "r32", "r304", "r311" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r31", "r32", "r304", "r311", "r403" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Options - Shares Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": { "auth_ref": [ "r32", "r304", "r311" ], "lang": { "en-US": { "role": { "documentation": "Number of treasury shares (units) reissued during the period, excluding reissuance of shares (units) held in treasury used to satisfy equity-based compensation obligations exercised by the holders of such rights. Upon reissuance of shares (units) from treasury, either the common or preferred stock (unit) reissued is outstanding.", "label": "Stock Issued During Period, Shares, Treasury Stock Reissued", "terseLabel": "Stock Issued During Period, Shares, Treasury Stock Reissued" } } }, "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": { "auth_ref": [ "r31", "r32", "r304", "r311", "r312" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of treasury stock (units) reissued during the period, excluding reissuance of shares (units) held in treasury used to satisfy equity-based compensation obligations exercised by the holders of such rights. Upon reissuance of shares (units) from treasury, either the common or preferred stock (unit) reissued is outstanding.", "label": "Stock Issued During Period, Value, Treasury Stock Reissued", "terseLabel": "Stock Issued During Period, Value, Treasury Stock Reissued" } } }, "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock Repurchase Program, Authorized Amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Stock Repurchase Program, Remaining Authorized Repurchase Amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r32", "r36", "r37", "r202" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r318" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails", "http://www.bio-rad.com/role/A17SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails", "http://www.bio-rad.com/role/A17SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r577" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails", "http://www.bio-rad.com/role/A17SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r577" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails", "http://www.bio-rad.com/role/A17SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r577" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails", "http://www.bio-rad.com/role/A17SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r578" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_SummaryOfIncomeTaxExaminationsTextBlock": { "auth_ref": [ "r451", "r474" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the increase or decrease in the liability from the prior period, and any penalties and interest that have been recorded.", "label": "Summary of Income Tax Examinations [Table Text Block]", "terseLabel": "Summary of income tax years currently under audit or open to examinations [Table Text Block]" } } }, "localname": "SummaryOfIncomeTaxExaminationsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock": { "auth_ref": [ "r449" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.", "label": "Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]", "terseLabel": "Tabular reconcilation of total amounts of unrecognized tax benefits [Table Text Block]" } } }, "localname": "SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r466" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax Credit Carryforward, Amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r468" ], "lang": { "en-US": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardLimitationsOnUse": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of the limitation related to use of the tax credit carryforward.", "label": "Tax Credit Carryforward, Limitations on Use", "terseLabel": "Tax Credit Carryforward, Limitations on Use" } } }, "localname": "TaxCreditCarryforwardLimitationsOnUse", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r468" ], "lang": { "en-US": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Other taxes payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "auth_ref": [ "r321", "r328" ], "lang": { "en-US": { "role": { "documentation": "Information by timing of transfer of good or service to customer.", "label": "Timing of Transfer of Good or Service [Axis]", "terseLabel": "Timing of Transfer of Good or Service [Axis]" } } }, "localname": "TimingOfTransferOfGoodOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.", "label": "Timing of Transfer of Good or Service [Domain]", "terseLabel": "Timing of Transfer of Good or Service [Domain]" } } }, "localname": "TimingOfTransferOfGoodOrServiceDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r33", "r39", "r132", "r198", "r199", "r201", "r203", "r612", "r643" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables. If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.", "label": "Trade and Other Accounts Receivable, Policy [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r491" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r583" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r312" ], "lang": { "en-US": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Treasury Stock Acquired, Average Cost Per Share" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r57", "r312" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r57", "r312" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury Stock, Shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r32", "r304", "r311" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Treasury Stock, Shares, Acquired" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockTextBlock": { "auth_ref": [ "r316" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Treasury Stock [Text Block]", "terseLabel": "Treasury Stock [Text Block]" } } }, "localname": "TreasuryStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasuryStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r57", "r312", "r315" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury Stock, Value" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r304", "r311", "r312" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "terseLabel": "Treasury Stock, Value, Acquired, Cost Method" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r358", "r610" ], "lang": { "en-US": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "US Government Sponsored Agencies [Member]" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainOnSecurities": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease), resulting in a gain, in the difference between the fair value and the carrying value, or in the comparative fair values, of securities held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain on Securities", "negatedTerseLabel": "Unrealized Gain on Securities", "terseLabel": "Unrealized Gain on Securities" } } }, "localname": "UnrealizedGainOnSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedLossOnSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease), resulting in a loss, in the difference between the fair value and the carrying value, or in the comparative fair values, of securities held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Loss on Securities", "terseLabel": "Unrealized Loss on Securities" } } }, "localname": "UnrealizedLossOnSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r437", "r452" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized tax benefits period end", "periodStartLabel": "Unrecognized tax benefits period start" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation": { "auth_ref": [ "r452" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from foreign currency translation.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation", "negatedTerseLabel": "Currency translation" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r453" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedTerseLabel": "Reductions to tax positions related to prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r455" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedTerseLabel": "Settlements" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r448" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r448" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions.", "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition", "terseLabel": "Acquisitions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r454" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions to tax positions related to the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation": { "auth_ref": [ "r452" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from foreign currency translation.", "label": "Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation", "terseLabel": "Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r453" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Additions to tax positions related to prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r456" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedTerseLabel": "Lapse of statute of limitations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary": { "auth_ref": [ "r277" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due within Five Years", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due within Five Years" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary": { "auth_ref": [ "r277" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due in Next Twelve Months", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due in Twelve Months" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary": { "auth_ref": [ "r277" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due within Four Years", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due within Four Years" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary": { "auth_ref": [ "r277" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due within Two Years", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due within Two Years" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary": { "auth_ref": [ "r277" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due within Three Years", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due within Three Years" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": { "auth_ref": [ "r277" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).", "label": "Unrecorded Unconditional Purchase Obligation", "terseLabel": "Unrecorded Unconditional Purchase Obligation" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationDueAfterFiveYears": { "auth_ref": [ "r277" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due after Five Years", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due after Five Years" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationDueAfterFiveYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebt": { "auth_ref": [ "r25", "r604", "r638" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Unsecured Debt", "terseLabel": "Unsecured Debt" } } }, "localname": "UnsecuredDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": { "auth_ref": [ "r146" ], "lang": { "en-US": { "role": { "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.", "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]" } } }, "localname": "ValuationAllowanceOfDeferredTaxAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r147" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Valuation Allowances and Reserves, Balance Period End", "periodStartLabel": "Valuation Allowances and Reserves, Balance Period Start" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r147" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r147" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedTerseLabel": "Deductions" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsScheduleIiValuationAndQualifyingAccountsTables" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)" } } }, "localname": "ValuationAllowancesAndReservesPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired": { "auth_ref": [ "r147" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from business combination.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Business Acquired", "terseLabel": "Other" } } }, "localname": "ValuationAllowancesAndReservesReservesOfBusinessesAcquired", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsScheduleIiValuationAndQualifyingAccountsTables" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r158", "r163" ], "calculation": { "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares - diluted", "totalLabel": "Diluted weighted average common shares" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r157", "r163" ], "calculation": { "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares - basic", "verboseLabel": "Basic weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "http://asc.fasb.org/topic&trid=2134446" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(ColumnA))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 1.N)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e30840-122693" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1500-109256" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e543-108305" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=109225645&loc=d3e1280-108306" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r172": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8615-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8654-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8657-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8660-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8663-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8672-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8475-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "305", "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=SL6953423-111524" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5212-111524" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5074-111524" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5093-111524" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=SL6284422-111562" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27232-111563" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27340-111563" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "8B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=SL6284393-111563" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563" }, "r223": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=84241550&loc=SL75117546-209714" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r255": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r276": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=77896938&loc=d3e25336-109308" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=77896938&loc=d3e25383-109308" }, "r279": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349" }, "r283": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=99404985&loc=d3e10037-110241" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12021-110248" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=82913499&loc=d3e12803-110250" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r299": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r316": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/subtopic&trid=2208821" }, "r317": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/subtopic&trid=2208855" }, "r318": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r332": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "http://asc.fasb.org/topic&trid=49130413" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79691-111665" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79708-111665" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(b)(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2410-114920" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2417-114920" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2439-114920" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2709-114920" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2709-114920" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2709-114920" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2709-114920" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2709-114920" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2709-114920" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2709-114920" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2709-114920" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "19A", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=107668666&loc=SL79513924-113897" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11374-113907" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "740", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109245112&loc=d3e23524-113945" }, "r431": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r432": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "http://asc.fasb.org/topic&trid=2122503" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238119&loc=d3e30536-109315" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=SL37586934-109318" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32123-109318" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31917-109318" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31928-109318" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31958-109318" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238393&loc=d3e36027-109320" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928189&loc=SL96870463-158277" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928189&loc=SL96870463-158277" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r484": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84229725&loc=d3e961-128460" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=108330185&loc=d3e2207-128464" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r508": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=66022390&loc=d3e923-111674" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828" }, "r517": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109975725&loc=SL5629052-113961" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL6742756-110258" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75026489&loc=d3e13220-108610" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13279-108611" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13433-108611" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13467-108611" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13476-108611" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75032774&loc=SL75039408-165497" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32211-110900" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r576": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r578": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=73530178&loc=d3e59706-112781" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(9))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13,16)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6477933&loc=d3e60009-112784" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62652-112803" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=50488274&loc=d3e64164-112818" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(f))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f,g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.3(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6484115&loc=d3e19393-158473" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6484115&loc=d3e19393-158473" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12.6(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C.9(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "305", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=84242212&loc=d3e2352-115587" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r665": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r666": { "Article": "12", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "13", "Sentence": "Column B" }, "r667": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r668": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r669": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e640-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" } }, "version": "2.1" } ZIP 104 0000012208-19-000014-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000012208-19-000014-xbrl.zip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